Genes regulated by NF-kB in response to TNF [GeneID=7124].
Genes up-regulated in response to low oxygen levels (hypoxia).
Genes involved in cholesterol homeostasis.
Genes important for mitotic spindle assembly.
Genes up-regulated by activation of WNT signaling through accumulation of beta catenin CTNNB1 [GeneID=1499].
Genes up-regulated in response to TGFB1 [GeneID=7040].
Genes up-regulated by IL6 [GeneID=3569] via STAT3 [GeneID=6774], e.g., during acute phase response.
Genes involved in DNA repair.
Genes involved in the G2/M checkpoint, as in progression through the cell division cycle.
Genes mediating programmed cell death (apoptosis) by activation of caspases.
Genes up-regulated by activation of Notch signaling.
Genes up-regulated during adipocyte differentiation (adipogenesis).
Genes defining early response to estrogen.
Genes defining late response to estrogen.
Genes defining response to androgens.
Genes involved in development of skeletal muscle (myogenesis).
Genes involved in protein secretion pathway.
Genes up-regulated in response to alpha interferon proteins.
Genes up-regulated in response to IFNG [GeneID=3458].
Genes encoding components of apical junction complex.
Genes encoding proteins over-represented on the apical surface of epithelial cells, e.g., important for cell polarity (apical area).
Genes up-regulated by activation of hedgehog signaling.
Genes encoding components of the complement system, which is part of the innate immune system.
Genes up-regulated during unfolded protein response, a cellular stress response related to the endoplasmic reticulum.
Genes up-regulated by activation of the PI3K/AKT/mTOR pathway.
Genes up-regulated through activation of mTORC1 complex.
Genes encoding cell cycle related targets of E2F transcription factors.
A subgroup of genes regulated by MYC - version 1 (v1).
A subgroup of genes regulated by MYC - version 2 (v2).
Genes defining epithelial-mesenchymal transition, as in wound healing, fibrosis and metastasis.
Genes defining inflammatory response.
Genes encoding proteins involved in processing of drugs and other xenobiotics.
Genes encoding proteins involved in metabolism of fatty acids.
Genes encoding proteins involved in oxidative phosphorylation.
Genes encoding proteins involved in glycolysis and gluconeogenesis.
Genes up-regulated by reactive oxigen species (ROS).
Genes involved in p53 pathways and networks.
Genes up-regulated in response to ultraviolet (UV) radiation.
Genes down-regulated in response to ultraviolet (UV) radiation.
Genes up-regulated during formation of blood vessels (angiogenesis).
Genes involved in metabolism of heme (a cofactor consisting of iron and porphyrin) and erythroblast differentiation.
Genes encoding components of blood coagulation system; also up-regulated in platelets.
Genes up-regulated by STAT5 in response to IL2 stimulation.
Genes involve in metabolism of bile acids and salts.
Genes encoding components of peroxisome.
Genes up-regulated during transplant rejection.
Genes up-regulated during production of male gametes (sperm), as in spermatogenesis.
Genes up-regulated by KRAS activation.
Genes down-regulated by KRAS activation.
Genes specifically up-regulated in pancreatic beta cells.
Genes in cytogenetic band chr5q23
Genes in cytogenetic band chr16q24
Genes in cytogenetic band chr8q24
Genes in cytogenetic band chr13q11
Genes in cytogenetic band chr7p21
Genes in cytogenetic band chr10q23
Genes in cytogenetic band chr13q13
Genes in cytogenetic band chr10q21
Genes in cytogenetic band chr1p13
Genes in cytogenetic band chrxp21
Genes in cytogenetic band chr4q12
Genes in cytogenetic band chr6q13
Genes in cytogenetic band chr2p22
Genes in cytogenetic band chr18q23
Genes in cytogenetic band chr8p11
Genes in cytogenetic band chr1p11
Genes in cytogenetic band chr9p12
Genes in cytogenetic band chr20p12
Genes in cytogenetic band chr7p13
Genes in cytogenetic band chr4p16
Genes in cytogenetic band chr8q22
Genes in cytogenetic band chr14q11
Genes in cytogenetic band chryp11
Genes in cytogenetic band chr10q25
Genes in cytogenetic band chr11q
Genes in cytogenetic band chr4p14
Genes in cytogenetic band chr15q26
Genes in cytogenetic band chr12q15
Genes in cytogenetic band chr4p12
Genes in cytogenetic band chr9q12
Genes in cytogenetic band chr2q22
Genes in cytogenetic band chr9q33
Genes in cytogenetic band chr18p
Genes in cytogenetic band chr3q28
Genes in cytogenetic band chr12q14
Genes in cytogenetic band chr2q36
Genes in cytogenetic band chr9q22
Genes in cytogenetic band chr3p22
Genes in cytogenetic band chrxq
Genes in cytogenetic band chr6p11
Genes in cytogenetic band chr12q24
Genes in cytogenetic band chr2q32
Genes in cytogenetic band chr4q35
Genes in cytogenetic band chr3p14
Genes in cytogenetic band chr22q
Genes in cytogenetic band chr15q24
Genes in cytogenetic band chr2p
Genes in cytogenetic band chr13q31
Genes in cytogenetic band chr19p13
Genes in cytogenetic band chr12q22
Genes in cytogenetic band chr7p
Genes in cytogenetic band chr11q22
Genes in cytogenetic band chrxq28
Genes in cytogenetic band chr16q22
Genes in cytogenetic band chr11q24
Genes in cytogenetic band chr5q12
Genes in cytogenetic band chr10p11
Genes in cytogenetic band chr5q21
Genes in cytogenetic band chr14q21
Genes in cytogenetic band chrxq12
Genes in cytogenetic band chr1p35
Genes in cytogenetic band chr3p12
Genes in cytogenetic band chr4q21
Genes in cytogenetic band chr10p15
Genes in cytogenetic band chr18q21
Genes in cytogenetic band chr1p33
Genes in cytogenetic band chr11q12
Genes in cytogenetic band chr17q22
Genes in cytogenetic band chr1p31
Genes in cytogenetic band chr10p13
Genes in cytogenetic band chr14q13
Genes in cytogenetic band chr2q24
Genes in cytogenetic band chr22q13
Genes in cytogenetic band chr15q11
Genes in cytogenetic band chr1q43
Genes in cytogenetic band chr19p
Genes in cytogenetic band chr3q24
Genes in cytogenetic band chr22q11
Genes in cytogenetic band chr7p11
Genes in cytogenetic band chr16q13
Genes in cytogenetic band chr1p22
Genes in cytogenetic band chr12p
Genes in cytogenetic band chr2q11
Genes in cytogenetic band chr9p21
Genes in cytogenetic band chr4q33
Genes in cytogenetic band chr2p11
Genes in cytogenetic band chr2q34
Genes in cytogenetic band chr17q23
Genes in cytogenetic band chr14q23
Genes in cytogenetic band chr5q33
Genes in cytogenetic band chr6q27
Genes in cytogenetic band chr3q26
Genes in cytogenetic band chr10q11
Genes in cytogenetic band chr5p12
Genes in cytogenetic band chr1q21
Genes in cytogenetic band chr4q24
Genes in cytogenetic band chr7q31
Genes in cytogenetic band chr6p21
Genes in cytogenetic band chr17q
Genes in cytogenetic band chr5q15
Genes in cytogenetic band chr2q13
Genes in cytogenetic band chr1q23
Genes in cytogenetic band chr6q23
Genes in cytogenetic band chr11q14
Genes in cytogenetic band chr5p14
Genes in cytogenetic band chr5q31
Genes in cytogenetic band chr2p24
Genes in cytogenetic band chr9p11
Genes in cytogenetic band chr4q26
Genes in cytogenetic band chr1q25
Genes in cytogenetic band chrxq11
Genes in cytogenetic band chr5q14
Genes in cytogenetic band chr4q28
Genes in cytogenetic band chr1q42
Genes in cytogenetic band chr6p25
Genes in cytogenetic band chr13q34
Genes in cytogenetic band chr8q12
Genes in cytogenetic band chr4q22
Genes in cytogenetic band chr7q22
Genes in cytogenetic band chr6p23
Genes in cytogenetic band chr8p21
Genes in cytogenetic band chr5q35
Genes in cytogenetic band chr13q32
Genes in cytogenetic band chr12q12
Genes in cytogenetic band chr3p24
Genes in cytogenetic band chr7q33
Genes in cytogenetic band chr12p12
Genes in cytogenetic band chr9p23
Genes in cytogenetic band chr7p14
Genes in cytogenetic band chr6q21
Genes in cytogenetic band chryq11
Genes in cytogenetic band chr15q13
Genes in cytogenetic band chr3q22
Genes in cytogenetic band chr6q15
Genes in cytogenetic band chr4q31
Genes in cytogenetic band chr3q12
Genes in cytogenetic band chr13q22
Genes in cytogenetic band chr15q15
Genes in cytogenetic band chr3p26
Genes in cytogenetic band chr17q12
Genes in cytogenetic band chr11p12
Genes in cytogenetic band chr7p12
Genes in cytogenetic band chr6q
Genes in cytogenetic band chrxq21
Genes in cytogenetic band chr19q13
Genes in cytogenetic band chr16p12
Genes in cytogenetic band chr1q32
Genes in cytogenetic band chr8p23
Genes in cytogenetic band chrxq23
Genes in cytogenetic band chr2p15
Genes in cytogenetic band chr18q12
Genes in cytogenetic band chr17p13
Genes in cytogenetic band chr14q
Genes in cytogenetic band chr11p14
Genes in cytogenetic band chr1q
Genes in cytogenetic band chr9q32
Genes in cytogenetic band chr20q12
Genes in cytogenetic band chr14q32
Genes in cytogenetic band chr7p22
Genes in cytogenetic band chr5q
Genes in cytogenetic band chr21q21
Genes in cytogenetic band chr2p13
Genes in cytogenetic band chr16q12
Genes in cytogenetic band chr3p
Genes in cytogenetic band chr10q22
Genes in cytogenetic band chr17p11
Genes in cytogenetic band chr15q22
Genes in cytogenetic band chr10q
Genes in cytogenetic band chr1q31
Genes in cytogenetic band chr10q24
Genes in cytogenetic band chr13q14
Genes in cytogenetic band chr11p
Genes in cytogenetic band chr14q12
Genes in cytogenetic band chr4q
Genes in cytogenetic band chr1p34
Genes in cytogenetic band chr2q23
Genes in cytogenetic band chr6q16
Genes in cytogenetic band chr16q21
Genes in cytogenetic band chr9q13
Genes in cytogenetic band chr15q25
Genes in cytogenetic band chr18q22
Genes in cytogenetic band chr2q21
Genes in cytogenetic band chr3p25
Genes in cytogenetic band chr20p13
Genes in cytogenetic band chr8q21
Genes in cytogenetic band chr4p15
Genes in cytogenetic band chr12p11
Genes in cytogenetic band chr9p13
Genes in cytogenetic band chr2q37
Genes in cytogenetic band chr3q29
Genes in cytogenetic band chr16p
Genes in cytogenetic band chr13q12
Genes in cytogenetic band chr3p21
Genes in cytogenetic band chr1p12
Genes in cytogenetic band chr4p11
Genes in cytogenetic band chr10q26
Genes in cytogenetic band chr13q21
Genes in cytogenetic band chr15q23
Genes in cytogenetic band chr2p21
Genes in cytogenetic band chr19q12
Genes in cytogenetic band chr20p11
Genes in cytogenetic band chr5q22
Genes in cytogenetic band chr4p13
Genes in cytogenetic band chr8q23
Genes in cytogenetic band chr19p12
Genes in cytogenetic band chr21q22
Genes in cytogenetic band chrxq25
Genes in cytogenetic band chr4q34
Genes in cytogenetic band chr11q23
Genes in cytogenetic band chr10p14
Genes in cytogenetic band chr9q34
Genes in cytogenetic band chr15q
Genes in cytogenetic band chr7q
Genes in cytogenetic band chr2q33
Genes in cytogenetic band chr8q
Genes in cytogenetic band chr22q12
Genes in cytogenetic band chr6p12
Genes in cytogenetic band chr7q21
Genes in cytogenetic band chr16q23
Genes in cytogenetic band chr11q25
Genes in cytogenetic band chr5q11
Genes in cytogenetic band chr21q11
Genes in cytogenetic band chr11q13
Genes in cytogenetic band chr9p
Genes in cytogenetic band chr17q25
Genes in cytogenetic band chr6q25
Genes in cytogenetic band chr10p12
Genes in cytogenetic band chr7q36
Genes in cytogenetic band chrxp11
Genes in cytogenetic band chr9q21
Genes in cytogenetic band chrxp22
Genes in cytogenetic band chr1p32
Genes in cytogenetic band chr12q21
Genes in cytogenetic band chr8p12
Genes in cytogenetic band chr11q11
Genes in cytogenetic band chr12q23
Genes in cytogenetic band chrxq13
Genes in cytogenetic band chr1p36
Genes in cytogenetic band chr2p23
Genes in cytogenetic band chr2q31
Genes in cytogenetic band chr3p13
Genes in cytogenetic band chr2q
Genes in cytogenetic band chrxq27
Genes in cytogenetic band chr3p11
Genes in cytogenetic band chr17q21
Genes in cytogenetic band chr13q33
Genes in cytogenetic band chr11p15
Genes in cytogenetic band chr1p21
Genes in cytogenetic band chr3q25
Genes in cytogenetic band chr3q13
Genes in cytogenetic band chr5p13
Genes in cytogenetic band chr14q22
Genes in cytogenetic band chr9p22
Genes in cytogenetic band chr4q27
Genes in cytogenetic band chr2p25
Genes in cytogenetic band chr6p24
Genes in cytogenetic band chr1p
Genes in cytogenetic band chr2q12
Genes in cytogenetic band chr8q13
Genes in cytogenetic band chr2p16
Genes in cytogenetic band chr12q
Genes in cytogenetic band chr4q25
Genes in cytogenetic band chr20q13
Genes in cytogenetic band chr5q34
Genes in cytogenetic band chr17q24
Genes in cytogenetic band chr2q14
Genes in cytogenetic band chr7q35
Genes in cytogenetic band chr5q13
Genes in cytogenetic band chr19q
Genes in cytogenetic band chr5q32
Genes in cytogenetic band chr20q11
Genes in cytogenetic band chr6q24
Genes in cytogenetic band chr5p15
Genes in cytogenetic band chr1q22
Genes in cytogenetic band chr6q26
Genes in cytogenetic band chr6p22
Genes in cytogenetic band chr11q21
Genes in cytogenetic band chr1q41
Genes in cytogenetic band chr15q14
Genes in cytogenetic band chr8q11
Genes in cytogenetic band chr1q24
Genes in cytogenetic band chr4q23
Genes in cytogenetic band chrxq26
Genes in cytogenetic band chr3q23
Genes in cytogenetic band chr3p23
Genes in cytogenetic band chr12q13
Genes in cytogenetic band chr9q31
Genes in cytogenetic band chr2p12
Genes in cytogenetic band chr1q44
Genes in cytogenetic band chr7q34
Genes in cytogenetic band chr2q35
Genes in cytogenetic band chr6q14
Genes in cytogenetic band chr16p13
Genes in cytogenetic band chr18q11
Genes in cytogenetic band chr3q27
Genes in cytogenetic band chr7q11
Genes in cytogenetic band chr3q21
Genes in cytogenetic band chr16p11
Genes in cytogenetic band chr12p13
Genes in cytogenetic band chr7p15
Genes in cytogenetic band chr3q11
Genes in cytogenetic band chr6q22
Genes in cytogenetic band chr7q32
Genes in cytogenetic band chr12q11
Genes in cytogenetic band chr18p11
Genes in cytogenetic band chr17q11
Genes in cytogenetic band chrxq24
Genes in cytogenetic band chr6q12
Genes in cytogenetic band chr3q
Genes in cytogenetic band chr6p
Genes in cytogenetic band chr21p11
Genes in cytogenetic band chrxq22
Genes in cytogenetic band chr9p24
Genes in cytogenetic band chr11p11
Genes in cytogenetic band chr4q13
Genes in cytogenetic band chr16q11
Genes in cytogenetic band chr8p22
Genes in cytogenetic band chr14q24
Genes in cytogenetic band chr1q12
Genes in cytogenetic band chr15q21
Genes in cytogenetic band chr11p13
Genes in cytogenetic band chr17p12
Genes in cytogenetic band chr4q32
Genes in cytogenetic band chr4q11
Genes in cytogenetic band chr14q31
Genes in cytogenetic band chr2p14
Glycolysis / Gluconeogenesis
Citrate cycle (TCA cycle)
Pentose phosphate pathway
Pentose and glucuronate interconversions
Fructose and mannose metabolism
Galactose metabolism
Ascorbate and aldarate metabolism
Fatty acid metabolism
Steroid biosynthesis
Primary bile acid biosynthesis
Steroid hormone biosynthesis
Oxidative phosphorylation
Purine metabolism
Pyrimidine metabolism
Alanine, aspartate and glutamate metabolism
Glycine, serine and threonine metabolism
Cysteine and methionine metabolism
Valine, leucine and isoleucine degradation
Valine, leucine and isoleucine biosynthesis
Lysine degradation
Arginine and proline metabolism
Histidine metabolism
Tyrosine metabolism
Phenylalanine metabolism
Tryptophan metabolism
beta-Alanine metabolism
Taurine and hypotaurine metabolism
Selenoamino acid metabolism
Glutathione metabolism
Starch and sucrose metabolism
N-Glycan biosynthesis
Other glycan degradation
O-Glycan biosynthesis
Amino sugar and nucleotide sugar metabolism
Glycosaminoglycan degradation
Glycosaminoglycan biosynthesis - chondroitin sulfate
Glycosaminoglycan biosynthesis - keratan sulfate
Glycosaminoglycan biosynthesis - heparan sulfate
Glycerolipid metabolism
Inositol phosphate metabolism
Glycosylphosphatidylinositol(GPI)-anchor biosynthesis
Glycerophospholipid metabolism
Ether lipid metabolism
Arachidonic acid metabolism
Linoleic acid metabolism
alpha-Linolenic acid metabolism
Sphingolipid metabolism
Glycosphingolipid biosynthesis - lacto and neolacto series
Glycosphingolipid biosynthesis - globo series
Glycosphingolipid biosynthesis - ganglio series
Pyruvate metabolism
Glyoxylate and dicarboxylate metabolism
Propanoate metabolism
Butanoate metabolism
One carbon pool by folate
Riboflavin metabolism
Nicotinate and nicotinamide metabolism
Pantothenate and CoA biosynthesis
Folate biosynthesis
Retinol metabolism
Porphyrin and chlorophyll metabolism
Terpenoid backbone biosynthesis
Limonene and pinene degradation
Nitrogen metabolism
Sulfur metabolism
Aminoacyl-tRNA biosynthesis
Metabolism of xenobiotics by cytochrome P450
Drug metabolism - cytochrome P450
Drug metabolism - other enzymes
Biosynthesis of unsaturated fatty acids
ABC transporters
Ribosome
RNA degradation
RNA polymerase
Basal transcription factors
DNA replication
Spliceosome
Proteasome
Protein export
PPAR signaling pathway
Base excision repair
Nucleotide excision repair
Mismatch repair
Homologous recombination
Non-homologous end-joining
MAPK signaling pathway
ErbB signaling pathway
Calcium signaling pathway
Cytokine-cytokine receptor interaction
Chemokine signaling pathway
Phosphatidylinositol signaling system
Neuroactive ligand-receptor interaction
Cell cycle
Oocyte meiosis
p53 signaling pathway
Ubiquitin mediated proteolysis
SNARE interactions in vesicular transport
Regulation of autophagy
Lysosome
Endocytosis
Peroxisome
mTOR signaling pathway
Apoptosis
Cardiac muscle contraction
Vascular smooth muscle contraction
Wnt signaling pathway
Dorso-ventral axis formation
Notch signaling pathway
Hedgehog signaling pathway
TGF-beta signaling pathway
Axon guidance
VEGF signaling pathway
Focal adhesion
ECM-receptor interaction
Cell adhesion molecules (CAMs)
Adherens junction
Tight junction
Gap junction
Complement and coagulation cascades
Antigen processing and presentation
Renin-angiotensin system
Toll-like receptor signaling pathway
NOD-like receptor signaling pathway
RIG-I-like receptor signaling pathway
Cytosolic DNA-sensing pathway
Jak-STAT signaling pathway
Hematopoietic cell lineage
Natural killer cell mediated cytotoxicity
T cell receptor signaling pathway
B cell receptor signaling pathway
Fc epsilon RI signaling pathway
Fc gamma R-mediated phagocytosis
Leukocyte transendothelial migration
Intestinal immune network for IgA production
Circadian rhythm - mammal
Long-term potentiation
Neurotrophin signaling pathway
Long-term depression
Olfactory transduction
Taste transduction
Regulation of actin cytoskeleton
Insulin signaling pathway
GnRH signaling pathway
Progesterone-mediated oocyte maturation
Melanogenesis
Adipocytokine signaling pathway
Type II diabetes mellitus
Type I diabetes mellitus
Maturity onset diabetes of the young
Aldosterone-regulated sodium reabsorption
Vasopressin-regulated water reabsorption
Proximal tubule bicarbonate reclamation
Alzheimer's disease
Parkinson's disease
Amyotrophic lateral sclerosis (ALS)
Huntington's disease
Prion diseases
Vibrio cholerae infection
Epithelial cell signaling in Helicobacter pylori infection
Pathogenic Escherichia coli infection
Leishmania infection
Pathways in cancer
Colorectal cancer
Renal cell carcinoma
Pancreatic cancer
Endometrial cancer
Glioma
Prostate cancer
Thyroid cancer
Basal cell carcinoma
Melanoma
Bladder cancer
Chronic myeloid leukemia
Acute myeloid leukemia
Small cell lung cancer
Non-small cell lung cancer
Asthma
Autoimmune thyroid disease
Systemic lupus erythematosus
Allograft rejection
Graft-versus-host disease
Primary immunodeficiency
Hypertrophic cardiomyopathy (HCM)
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
Dilated cardiomyopathy
Viral myocarditis
Acetylation and Deacetylation of RelA in The Nucleus
Actions of Nitric Oxide in the Heart
Activation of Csk by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor
Activation of Src by Protein-tyrosine phosphatase alpha
Acute Myocardial Infarction
Adhesion and Diapedesis of Granulocytes
Adhesion and Diapedesis of Lymphocytes
ADP-Ribosylation Factor
Agrin in Postsynaptic Differentiation
AKAP95 role in mitosis and chromosome dynamics
AKT Signaling Pathway
ALK in cardiac myocytes
Angiotensin II mediated activation of JNK Pathway via Pyk2 dependent signaling
Angiotensin-converting enzyme 2 regulates heart function
Antigen Dependent B Cell Activation
Apoptotic DNA fragmentation and tissue homeostasis
Apoptotic Signaling in Response to DNA Damage
Aspirin Blocks Signaling Pathway Involved in Platelet Activation
ATM Signaling Pathway
Attenuation of GPCR Signaling
B Cell Survival Pathway
B Lymphocyte Cell Surface Molecules
BCR Signaling Pathway
Bioactive Peptide Induced Signaling Pathway
Biosynthesis of neurotransmitters
Bone Remodelling
Ca++/ Calmodulin-dependent Protein Kinase Activation
Cadmium induces DNA synthesis and proliferation in macrophages
CARM1 and Regulation of the Estrogen Receptor
Caspase Cascade in Apoptosis
CBL mediated ligand-induced downregulation of EGF receptors
CCR3 signaling in Eosinophils
CD40L Signaling Pathway
CDK Regulation of DNA Replication
Cell Cycle: G1/S Check Point
Cell Cycle: G2/M Checkpoint
Cell to Cell Adhesion Signaling
Cells and Molecules involved in local acute inflammatory response
Ceramide Signaling Pathway
Chaperones modulate interferon Signaling Pathway
Classical Complement Pathway
Complement Pathway
Control of Gene Expression by Vitamin D Receptor
Control of skeletal myogenesis by HDAC and calcium/calmodulin-dependent kinase (CaMK)
Corticosteroids and cardioprotection
CTCF: First Multivalent Nuclear Factor
CTL mediated immune response against target cells
CXCR4 Signaling Pathway
Cyclins and Cell Cycle Regulation
Cystic Fibrosis Transmembrane Conductance Regulator And Beta 2 Adrenergic Receptor Pathway
Cytokine Network
Cytokines and Inflammatory Response
D4-GDI Signaling Pathway
Dendritic cells in regulating TH1 and TH2 Development
Deregulation of CDK5 in Alzheimers Disease
Double Stranded RNA Induced Gene Expression
Downregulated of MTA-3 in ER-negative Breast Tumors
E2F1 Destruction Pathway
Effects of calcineurin in Keratinocyte Differentiation
EGF Signaling Pathway
Electron Transport Reaction in Mitochondria
Endocytotic role of NDK, Phosphins and Dynamin
Eph Kinases and ephrins support platelet aggregation
EPO Signaling Pathway
Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia
Erk1/Erk2 Mapk Signaling pathway
Erythrocyte Differentiation Pathway
Erythropoietin mediated neuroprotection through NF-kB
Eukaryotic protein translation
Extrinsic Prothrombin Activation Pathway
FAS signaling pathway ( CD95 )
Fc Epsilon Receptor I Signaling in Mast Cells
Feeder Pathways for Glycolysis
Fibrinolysis Pathway
fMLP induced chemokine gene expression in HMC-1 cells
Free Radical Induced Apoptosis
Gamma-aminobutyric Acid Receptor Life Cycle
GATA3 participate in activating the Th2 cytokine genes expression
Glycolysis Pathway
Granzyme A mediated Apoptosis Pathway
Growth Hormone Signaling Pathway
Hemoglobin's Chaperone
HIV Induced T Cell Apoptosis
HIV-I Nef: negative effector of Fas and TNF
How does salmonella hijack a cell
How Progesterone Initiates Oocyte Membrane
Human Cytomegalovirus and Map Kinase Pathways
Hypoxia and p53 in the Cardiovascular system
Hypoxia-Inducible Factor in the Cardiovascular System
IGF-1 Signaling Pathway
IL 17 Signaling Pathway
IL 2 signaling pathway
IL 3 signaling pathway
IL 4 signaling pathway
IL 5 Signaling Pathway
IL 6 signaling pathway
IL-10 Anti-inflammatory Signaling Pathway
IL12 and Stat4 Dependent Signaling Pathway in Th1 Development
IL-2 Receptor Beta Chain in T cell Activation
IL22 Soluble Receptor Signaling Pathway
IL-7 Signal Transduction
Inactivation of Gsk3 by AKT causes accumulation of b-catenin in Alveolar Macrophages
Induction of apoptosis through DR3 and DR4/5 Death Receptors
Influence of Ras and Rho proteins on G1 to S Transition
Inhibition of Cellular Proliferation by Gleevec
Insulin Signaling Pathway
Integrin Signaling Pathway
Intrinsic Prothrombin Activation Pathway
Keratinocyte Differentiation
Lck and Fyn tyrosine kinases in initiation of TCR Activation
Lectin Induced Complement Pathway
Links between Pyk2 and Map Kinases
Map Kinase Inactivation of SMRT Corepressor
MAPKinase Signaling Pathway
mCalpain and friends in Cell motility
Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha)
METS affect on Macrophage Differentiation
Monocyte and its Surface Molecules
mTOR Signaling Pathway
Multiple antiapoptotic pathways from IGF-1R signaling lead to BAD phosphorylation
Multi-step Regulation of Transcription by Pitx2
Nerve growth factor pathway (NGF)
Neuropeptides VIP and PACAP inhibit the apoptosis of activated T cells
NFAT and Hypertrophy of the heart (Transcription in the broken heart)
NFkB activation by Nontypeable Hemophilus influenzae
NF-kB Signaling Pathway
Nitric Oxide Signaling Pathway
NO2-dependent IL 12 Pathway in NK cells
Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription in carcinoma cells
Nuclear Receptors in Lipid Metabolism and Toxicity
Oxidative Stress Induced Gene Expression Via Nrf2
p38 MAPK Signaling Pathway
p53 Signaling Pathway
PDGF Signaling Pathway
Pertussis toxin-insensitive CCR5 Signaling in Macrophage
Phosphoinositides and their downstream targets.
Phospholipase C-epsilon pathway
Phospholipids as signalling intermediaries
Phosphorylation of MEK1 by cdk5/p35 down regulates the MAP kinase pathway
PKC-catalyzed phosphorylation of inhibitory phosphoprotein of myosin phosphatase
Platelet Amyloid Precursor Protein Pathway
Presenilin action in Notch and Wnt signaling
Proteasome Complex
Protein Kinase A at the Centrosome
PTEN dependent cell cycle arrest and apoptosis
Rab GTPases Mark Targets In The Endocytotic Machinery
Rac 1 cell motility signaling pathway
Ras Signaling Pathway
Ras-Independent pathway in NK cell-mediated cytotoxicity
RB Tumor Suppressor/Checkpoint Signaling in response to DNA damage
Regulation And Function Of ChREBP in Liver
Regulation of BAD phosphorylation
Regulation of ck1/cdk5 by type 1 glutamate receptors
Regulation of eIF2
Regulation of eIF4e and p70 S6 Kinase
Regulation of hematopoiesis by cytokines
Regulation of p27 Phosphorylation during Cell Cycle Progression
Regulation of PGC-1a
Regulation of transcriptional activity by PML
Repression of Pain Sensation by the Transcriptional Regulator DREAM
Reversal of Insulin Resistance by Leptin
Rho cell motility signaling pathway
Rho-Selective Guanine Exchange Factor AKAP13 Mediates Stress Fiber Formation
Role of BRCA1, BRCA2 and ATR in Cancer Susceptibility
Role of EGF Receptor Transactivation by GPCRs in Cardiac Hypertrophy
Role of ERBB2 in Signal Transduction and Oncology
Role of Erk5 in Neuronal Survival
Role of MAL in Rho-Mediated Activation of SRF
Role of MEF2D in T-cell Apoptosis
Role of Mitochondria in Apoptotic Signaling
Role of nicotinic acetylcholine receptors in the regulation of apoptosis
Role of Parkin in the Ubiquitin-Proteasomal Pathway
Role of PI3K subunit p85 in regulation of Actin Organization and Cell Migration
Role of Ran in mitotic spindle regulation
Role of fl-arrestins in the activation and targeting of MAP kinases
Role of Tob in T-cell activation
Roles of fl-arrestin-dependent Recruitment of Src Kinases in GPCR Signaling
Selective expression of chemokine receptors during T-cell polarization
Signal transduction through IL1R
Signaling of Hepatocyte Growth Factor Receptor
Signaling Pathway from G-Protein Families
Skeletal muscle hypertrophy is regulated via AKT/mTOR pathway
SODD/TNFR1 Signaling Pathway
Sonic Hedgehog (Shh) Pathway
Sonic Hedgehog (SHH) Receptor Ptc1 Regulates cell cycle
Sprouty regulation of tyrosine kinase signals
fl-arrestins in GPCR Desensitization
Stathmin and breast cancer resistance to antimicrotubule agents
Stress Induction of HSP Regulation
T Cell Receptor Signaling Pathway
T Cytotoxic Cell Surface Molecules
T Helper Cell Surface Molecules
TACI and BCMA stimulation of B cell immune responses.
Telomeres, Telomerase, Cellular Aging, and Immortality
TGF beta signaling pathway
Th1/Th2 Differentiation
The 4-1BB-dependent immune response
The Citric Acid Cycle
The Co-Stimulatory Signal During T-cell Activation
The IGF-1 Receptor and Longevity
The SARS-coronavirus Life Cycle
Thrombin signaling and protease-activated receptors
TNF/Stress Related Signaling
TNFR1 Signaling Pathway
TNFR2 Signaling Pathway
Toll-Like Receptor Pathway
TPO Signaling Pathway
Transcription factor CREB and its extracellular signals
Transcription Regulation by Methyltransferase of CARM1
Trefoil Factors Initiate Mucosal Healing
Trka Receptor Signaling Pathway
Tumor Suppressor Arf Inhibits Ribosomal Biogenesis
uCalpain and friends in Cell spread
VEGF, Hypoxia, and Angiogenesis
Vitamin C in the Brain
WNT Signaling Pathway
Y branching of actin filaments
Interferon gamma pathway.
Wnt/Ca2+/cyclic GMP signaling.
Differentiation Pathway in PC12 Cells; this is a specific case of PAC1 Receptor Pathway.
Tumor Necrosis Factor Pathway.
Antigen binding to B cell receptors activates protein tyrosine kinases, such as the Src family, which ultimate activate MAP kinases.
ERK1/ERK2 MAPK Pathway
Genes related to CD40 signaling
Genes related to PIP3 signaling in cardiac myocytes
Apoptosis is mediated by caspases, cysteine proteases arranged in a proteolytic cascade.
G alpha 12 Pathway
G alpha s Pathway
G alpha i Pathway
Genes related to chemotaxis
Interleukin 13 (IL-13) Pathway
p38 MAPK Pathway
Genes related to IL4 rceptor signaling in B lymphocytes
Genes related to Wnt-mediated signal transduction
Jak-STAT Pathway
Genes related to regulation of the actin cytoskeleton
Granule Cell Survival Pathway is a specific case of more general PAC1 Receptor Pathway.
Adrenergic Pathway
Integrin Signaling Pathway
G alpha q Pathway
G alpha 13 Pathway
STAT3 Pathway
The TNF-type receptor Fas induces apoptosis on ligand binding.
Cdk2, 4, and 6 bind cyclin D in G1, while cdk2/cyclin E promotes the G1/S transition.
Genes related to the insulin receptor pathway
T Cell Signal Transduction
Type I Interferon (alpha/beta IFN) Pathway
PAC1 Receptor Pathway
Genes related to PIP3 signaling in B lymphocytes
Members of the BCR signaling pathway
Cdc25 activates the cdc2/cyclin B complex to induce the G2/M transition.
B Cell Antigen Receptor
Interleukin 4 (IL-4) Pathway
Wnt/beta-catenin Pathway
Cytokines can induce activation of matrix metalloproteinases, which degrade extracellular matrix.
JNK MAPK Pathway
Programmed cell death, or apoptosis, eliminates damaged or unneeded cells.
Fas Signaling Pathway
Myocyte Adrenergic Pathway is a specific case of the generalized Adrenergic Pathway.
PTEN is a tumor suppressor that dephosphorylates the lipid messenger phosphatidylinositol triphosphate.
Expression of cyclins regulates progression through the cell cycle by activating cyclin-dependent kinases.
The TrkA receptor binds nerve growth factor to activate MAP kinase pathways and promote cell growth.
PI3K Pathway
Fanconi anemia pathway
Regulation of nuclear SMAD2/3 signaling
Fc-epsilon receptor I signaling in mast cells
Endothelins
BCR signaling pathway
Signaling events mediated by PRL
RhoA signaling pathway
ErbB4 signaling events
Aurora B signaling
LPA receptor mediated events
Insulin Pathway
Notch signaling pathway
Beta1 integrin cell surface interactions
p73 transcription factor network
p38 MAPK signaling pathway
GMCSF-mediated signaling events
Noncanonical Wnt signaling pathway
Atypical NF-kappaB pathway
IL4-mediated signaling events
Signaling events mediated by HDAC Class II
Degradation of beta catenin
Signaling events mediated by HDAC Class III
Glypican 1 network
TCR signaling in na&#xef;ve CD4+ T cells
IL27-mediated signaling events
Canonical NF-kappaB pathway
E2F transcription factor network
Plasma membrane estrogen receptor signaling
DNA-PK pathway in nonhomologous end joining
HIF-2-alpha transcription factor network
CD40/CD40L signaling
ATR signaling pathway
Integrin family cell surface interactions
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
Signaling events mediated by PTP1B
Beta3 integrin cell surface interactions
IL12-mediated signaling events
S1P3 pathway
LPA4-mediated signaling events
Coregulation of Androgen receptor activity
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
EPHB forward signaling
Osteopontin-mediated events
S1P4 pathway
Validated transcriptional targets of AP1 family members Fra1 and Fra2
Validated targets of C-MYC transcriptional activation
Arf6 trafficking events
Regulation of RhoA activity
Reelin signaling pathway
Presenilin action in Notch and Wnt signaling
Integrin-linked kinase signaling
Nectin adhesion pathway
Regulation of p38-alpha and p38-beta
Wnt signaling network
TRAIL signaling pathway
CDC42 signaling events
Signaling events regulated by Ret tyrosine kinase
Regulation of CDC42 activity
ATM pathway
Arf6 signaling events
LKB1 signaling events
TCR signaling in na&#xef;ve CD8+ T cells
Canonical Wnt signaling pathway
Signaling events mediated by TCPTP
Angiopoietin receptor Tie2-mediated signaling
FAS (CD95) signaling pathway
Circadian rhythm pathway
Thromboxane A2 receptor signaling
SHP2 signaling
Signaling events mediated by HDAC Class I
S1P1 pathway
Regulation of Telomerase
FOXA2 and FOXA3 transcription factor networks
Netrin-mediated signaling events
IL1-mediated signaling events
Role of Calcineurin-dependent NFAT signaling in lymphocytes
Glucocorticoid receptor regulatory network
Visual signal transduction: Cones
Alpha9 beta1 integrin signaling events
Validated nuclear estrogen receptor beta network
Arf6 downstream pathway
mTOR signaling pathway
IL2-mediated signaling events
CXCR4-mediated signaling events
IGF1 pathway
EGF receptor (ErbB1) signaling pathway
TNF receptor signaling pathway
PLK1 signaling events
Ras signaling in the CD4+ TCR pathway
IL5-mediated signaling events
FoxO family signaling
VEGF and VEGFR signaling network
PAR4-mediated thrombin signaling events
C-MYC pathway
Sumoylation by RanBP2 regulates transcriptional repression
Class I PI3K signaling events
Posttranslational regulation of adherens junction stability and dissassembly
IL2 signaling events mediated by PI3K
Ceramide signaling pathway
Direct p53 effectors
Regulation of Androgen receptor activity
p75(NTR)-mediated signaling
Sphingosine 1-phosphate (S1P) pathway
E-cadherin signaling in the nascent adherens junction
Alpha6 beta4 integrin-ligand interactions
amb2 Integrin signaling
Integrins in angiogenesis
IFN-gamma pathway
RXR and RAR heterodimerization with other nuclear receptor
Lissencephaly gene (LIS1) in neuronal migration and development
ErbB1 downstream signaling
Syndecan-4-mediated signaling events
ATF-2 transcription factor network
AP-1 transcription factor network
Beta2 integrin cell surface interactions
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
ErbB2/ErbB3 signaling events
FOXM1 transcription factor network
EPHA forward signaling
Hypoxic and oxygen homeostasis regulation of HIF-1-alpha
BMP receptor signaling
IL3-mediated signaling events
IL6-mediated signaling events
E-cadherin signaling in keratinocytes
ALK1 signaling events
PDGFR-beta signaling pathway
Neurotrophic factor-mediated Trk receptor signaling
JNK signaling in the CD4+ TCR pathway
Nephrin/Neph1 signaling in the kidney podocyte
C-MYB transcription factor network
IL23-mediated signaling events
HIV-1 Nef: Negative effector of Fas and TNF-alpha
Syndecan-1-mediated signaling events
p38 signaling mediated by MAPKAP kinases
Validated nuclear estrogen receptor alpha network
ErbB receptor signaling network
ALK2 signaling events
Visual signal transduction: Rods
PDGFR-alpha signaling pathway
Retinoic acid receptors-mediated signaling
Signaling mediated by p38-gamma and p38-delta
IL8- and CXCR2-mediated signaling events
Signaling events mediated by the Hedgehog family
Beta5 beta6 beta7 and beta8 integrin cell surface interactions
Nongenotropic Androgen signaling
Internalization of ErbB1
Hedgehog signaling events mediated by Gli proteins
Caspase cascade in apoptosis
CXCR3-mediated signaling events
Regulation of nuclear beta catenin signaling and target gene transcription
VEGFR1 specific signals
Regulation of cytoplasmic and nuclear SMAD2/3 signaling
Signaling mediated by p38-alpha and p38-beta
Signaling events mediated by Stem cell factor receptor (c-Kit)
Stabilization and expansion of the E-cadherin adherens junction
EPO signaling pathway
IL2 signaling events mediated by STAT5
Calcium signaling in the CD4+ TCR pathway
Validated transcriptional targets of deltaNp63 isoforms
Signaling events mediated by VEGFR1 and VEGFR2
PAR1-mediated thrombin signaling events
a6b1 and a6b4 Integrin signaling
Syndecan-2-mediated signaling events
Regulation of RAC1 activity
Aurora A signaling
Arf1 pathway
Insulin-mediated glucose transport
Class I PI3K signaling events mediated by Akt
Syndecan-3-mediated signaling events
IL8- and CXCR1-mediated signaling events
Validated targets of C-MYC transcriptional repression
HIF-1-alpha transcription factor network
Validated transcriptional targets of TAp63 isoforms
Ephrin B reverse signaling
BARD1 signaling events
p53 pathway
Endogenous TLR signaling
N-cadherin signaling events
Cellular roles of Anthrax toxin
S1P2 pathway
Regulation of Ras family activation
Trk receptor signaling mediated by the MAPK pathway
Trk receptor signaling mediated by PI3K and PLC-gamma
Downstream signaling in na&#xef;ve CD8+ T cells
EPHA2 forward signaling
VEGFR3 signaling in lymphatic endothelium
Alpha-synuclein signaling
FGF signaling pathway
Alpha4 beta1 integrin signaling events
RAC1 signaling pathway
Regulation of retinoblastoma protein
Signaling events mediated by focal adhesion kinase
FOXA1 transcription factor network
TGF-beta receptor signaling
Notch-mediated HES/HEY network
IL12 signaling mediated by STAT4
Genes involved in Glycogen breakdown (glycogenolysis)
Genes involved in Translation
Genes involved in Pyrimidine catabolism
Genes involved in RNA Polymerase III Transcription Initiation From Type 2 Promoter
Genes involved in Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components
Genes involved in Pyruvate metabolism and Citric Acid (TCA) cycle
Genes involved in Extrinsic Pathway for Apoptosis
Genes involved in PTM: gamma carboxylation, hypusine formation and arylsulfatase activation
Genes involved in Apoptotic cleavage of cellular proteins
Genes involved in RNA Polymerase I Transcription Termination
Genes involved in Formation of the ternary complex, and subsequently, the 43S complex
Genes involved in Activation of the pre-replicative complex
Genes involved in Processing of Intronless Pre-mRNAs
Genes involved in Gap junction degradation
Genes involved in Base Excision Repair
Genes involved in Bile acid and bile salt metabolism
Genes involved in Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol
Genes involved in Recycling of bile acids and salts
Genes involved in Signaling by Rho GTPases
Genes involved in Signaling by Wnt
Genes involved in Metabolism of non-coding RNA
Genes involved in Synthesis of bile acids and bile salts via 24-hydroxycholesterol
Genes involved in Synthesis of bile acids and bile salts
Genes involved in Metabolism of steroid hormones and vitamins A and D
Genes involved in Androgen biosynthesis
Genes involved in Signalling by NGF
Genes involved in Beta-catenin phosphorylation cascade
Genes involved in Insulin receptor recycling
Genes involved in COPI Mediated Transport
Genes involved in Nef mediated downregulation of MHC class I complex cell surface expression
Genes involved in Signaling by SCF-KIT
Genes involved in Developmental Biology
Genes involved in Cross-presentation of soluble exogenous antigens (endosomes)
Genes involved in Signaling by NODAL
Genes involved in DAG and IP3 signaling
Genes involved in Spry regulation of FGF signaling
Genes involved in The citric acid (TCA) cycle and respiratory electron transport
Genes involved in BMAL1:CLOCK/NPAS2 Activates Circadian Expression
Genes involved in Antigen processing-Cross presentation
Genes involved in Growth hormone receptor signaling
Genes involved in TRIF mediated TLR3 signaling
Genes involved in Cell-Cell communication
Genes involved in ABCA transporters in lipid homeostasis
Genes involved in Endosomal/Vacuolar pathway
Genes involved in Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
Genes involved in ER-Phagosome pathway
Genes involved in Meiosis
Genes involved in Negative regulation of FGFR signaling
Genes involved in G0 and Early G1
Genes involved in Regulation of KIT signaling
Genes involved in Membrane Trafficking
Genes involved in Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
Genes involved in Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Genes involved in Activated AMPK stimulates fatty-acid oxidation in muscle
Genes involved in Vitamin B5 (pantothenate) metabolism
Genes involved in Botulinum neurotoxicity
Genes involved in Metabolism of vitamins and cofactors
Genes involved in trans-Golgi Network Vesicle Budding
Genes involved in Proteolytic cleavage of SNARE complex proteins
Genes involved in Resolution of AP sites via the multiple-nucleotide patch replacement pathway
Genes involved in Gamma-carboxylation, transport, and amino-terminal cleavage of proteins
Genes involved in Interleukin-7 signaling
Genes involved in Cell Cycle
Genes involved in Signaling by ERBB4
Genes involved in Orc1 removal from chromatin
Genes involved in O-linked glycosylation of mucins
Genes involved in Sulfur amino acid metabolism
Genes involved in Downregulation of ERBB2:ERBB3 signaling
Genes involved in Antiviral mechanism by IFN-stimulated genes
Genes involved in Prolactin receptor signaling
Genes involved in Signaling by ERBB2
Genes involved in Sphingolipid de novo biosynthesis
Genes involved in Termination of O-glycan biosynthesis
Genes involved in Defensins
Genes involved in Signaling by constitutively active EGFR
Genes involved in GRB2 events in ERBB2 signaling
Genes involved in Signaling by EGFR in Cancer
Genes involved in Membrane binding and targetting of GAG proteins
Genes involved in Beta defensins
Genes involved in SRP-dependent cotranslational protein targeting to membrane
Genes involved in PI3K events in ERBB4 signaling
Genes involved in SHC1 events in ERBB4 signaling
Genes involved in PI3K events in ERBB2 signaling
Genes involved in Nuclear signaling by ERBB4
Genes involved in Glycosphingolipid metabolism
Genes involved in PPARA Activates Gene Expression
Genes involved in Association of licensing factors with the pre-replicative complex
Genes involved in RIP-mediated NFkB activation via DAI
Genes involved in Pre-NOTCH Transcription and Translation
Genes involved in Degradation of the extracellular matrix
Genes involved in Mitochondrial Protein Import
Genes involved in Signaling by Hippo
Genes involved in Activated NOTCH1 Transmits Signal to the Nucleus
Genes involved in Trafficking and processing of endosomal TLR
Genes involved in Signaling by NOTCH4
Genes involved in Downstream Signaling Events Of B Cell Receptor (BCR)
Genes involved in Activation of NF-kappaB in B Cells
Genes involved in RORA Activates Circadian Expression
Genes involved in Antigen Activates B Cell Receptor Leading to Generation of Second Messengers
Genes involved in Regulation of Complement cascade
Genes involved in YAP1- and WWTR1 (TAZ)-stimulated gene expression
Genes involved in Signaling by NOTCH2
Genes involved in Pre-NOTCH Expression and Processing
Genes involved in Signaling by the B Cell Receptor (BCR)
Genes involved in Extracellular matrix organization
Genes involved in NOTCH1 Intracellular Domain Regulates Transcription
Genes involved in Circadian Repression of Expression by REV-ERBA
Genes involved in Pre-NOTCH Processing in Golgi
Genes involved in Signaling by NOTCH1
Genes involved in Signaling by NOTCH3
Genes involved in Triglyceride Biosynthesis
Genes involved in Insulin receptor signalling cascade
Genes involved in ARMS-mediated activation
Genes involved in Prolonged ERK activation events
Genes involved in Signalling to RAS
Genes involved in Signaling by BMP
Genes involved in Cell surface interactions at the vascular wall
Genes involved in NGF signalling via TRKA from the plasma membrane
Genes involved in Signalling to ERKs
Genes involved in p38MAPK events
Genes involved in Acyl chain remodelling of PI
Genes involved in TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
Genes involved in Downregulation of TGF-beta receptor signaling
Genes involved in Collagen formation
Genes involved in SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
Genes involved in Signaling by FGFR in disease
Genes involved in HS-GAG degradation
Genes involved in Synthesis of PIPs at the early endosome membrane
Genes involved in Signalling to p38 via RIT and RIN
Genes involved in p53-Independent G1/S DNA damage checkpoint
Genes involved in Regulation of Hypoxia-inducible Factor (HIF) by Oxygen
Genes involved in Acyl chain remodelling of PC
Genes involved in Synthesis of PIPs at the Golgi membrane
Genes involved in TGF-beta receptor signaling activates SMADs
Genes involved in Activated point mutants of FGFR2
Genes involved in Phospholipid metabolism
Genes involved in CS/DS degradation
Genes involved in Synthesis of PA
Genes involved in Oxygen-dependent Proline Hydroxylation of Hypoxia-inducible Factor Alpha
Genes involved in Synthesis of PIPs at the late endosome membrane
Genes involved in Synthesis of PE
Genes involved in Gastrin-CREB signalling pathway via PKC and MAPK
Genes involved in Chondroitin sulfate biosynthesis
Genes involved in Hyaluronan uptake and degradation
Genes involved in Signaling by FGFR1 mutants
Genes involved in Synthesis of PIPs at the plasma membrane
Genes involved in The activation of arylsulfatases
Genes involved in Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
Genes involved in Hyaluronan metabolism
Genes involved in Downregulation of SMAD2/3:SMAD4 transcriptional activity
Genes involved in Keratan sulfate biosynthesis
Genes involved in Reversible Hydration of Carbon Dioxide
Genes involved in Signaling by FGFR1 fusion mutants
Genes involved in alpha-linolenic acid (ALA) metabolism
Genes involved in Signaling by activated point mutants of FGFR1
Genes involved in PI Metabolism
Genes involved in Abacavir transport and metabolism
Genes involved in Chondroitin sulfate/dermatan sulfate metabolism
Genes involved in Latent infection of Homo sapiens with Mycobacterium tuberculosis
Genes involved in Synthesis of PC
Genes involved in HS-GAG biosynthesis
Genes involved in Signaling by FGFR3 mutants
Genes involved in Keratan sulfate/keratin metabolism
Genes involved in Apoptosis induced DNA fragmentation
Genes involved in Keratan sulfate degradation
Genes involved in Heparan sulfate/heparin (HS-GAG) metabolism
Genes involved in Glycosaminoglycan metabolism
Genes involved in Acyl chain remodelling of PG
Genes involved in Acyl chain remodelling of PE
Genes involved in Acyl chain remodelling of PS
Genes involved in Signaling by FGFR mutants
Genes involved in MHC class II antigen presentation
Genes involved in Glycerophospholipid biosynthesis
Genes involved in A tetrasaccharide linker sequence is required for GAG synthesis
Genes involved in CDK-mediated phosphorylation and removal of Cdc6
Genes involved in Platelet Adhesion to exposed collagen
Genes involved in VEGF ligand-receptor interactions
Genes involved in eNOS activation and regulation
Genes involved in MicroRNA (miRNA) Biogenesis
Genes involved in Nuclear Events (kinase and transcription factor activation)
Genes involved in Retrograde neurotrophin signalling
Genes involved in ERKs are inactivated
Genes involved in Negative regulation of the PI3K/AKT network
Genes involved in PI3K/AKT activation
Genes involved in Regulatory RNA pathways
Genes involved in EGFR downregulation
Genes involved in Processing of Capped Intron-Containing Pre-mRNA
Genes involved in PECAM1 interactions
Genes involved in TCR signaling
Genes involved in Regulation of pyruvate dehydrogenase (PDH) complex
Genes involved in Downstream TCR signaling
Genes involved in Basigin interactions
Genes involved in AKT phosphorylates targets in the cytosol
Genes involved in GAB1 signalosome
Genes involved in SHC1 events in EGFR signaling
Genes involved in Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S
Genes involved in Phosphorylation of CD3 and TCR zeta chains
Genes involved in Glutamate Neurotransmitter Release Cycle
Genes involved in Translocation of ZAP-70 to Immunological synapse
Genes involved in ERK/MAPK targets
Genes involved in Tie2 Signaling
Genes involved in Generation of second messenger molecules
Genes involved in Generic Transcription Pathway
Genes involved in Response to elevated platelet cytosolic Ca2+
Genes involved in Transport of Mature Transcript to Cytoplasm
Genes involved in Metabolism of amino acids and derivatives
Genes involved in RNA Polymerase I Transcription
Genes involved in Fatty Acyl-CoA Biosynthesis
Genes involved in E2F-enabled inhibition of pre-replication complex formation
Genes involved in p75NTR recruits signalling complexes
Genes involved in Biological oxidations
Genes involved in Regulated proteolysis of p75NTR
Genes involved in Transmission across Chemical Synapses
Genes involved in p75NTR signals via NF-kB
Genes involved in Caspase-mediated cleavage of cytoskeletal proteins
Genes involved in Xenobiotics
Genes involved in Integrin cell surface interactions
Genes involved in Regulation of ornithine decarboxylase (ODC)
Genes involved in Cytochrome P450 - arranged by substrate type
Genes involved in Base-free sugar-phosphate removal via the single-nucleotide replacement pathway
Genes involved in Apoptotic cleavage of cell adhesion  proteins
Genes involved in HDL-mediated lipid transport
Genes involved in NRAGE signals death through JNK
Genes involved in SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs
Genes involved in NRIF signals cell death from the nucleus
Genes involved in Regulation of Apoptosis
Genes involved in RNA Polymerase II Transcription
Genes involved in Neuronal System
Genes involved in NF-kB is activated and signals survival
Genes involved in Regulation of beta-cell development
Genes involved in Phase 1 - Functionalization of compounds
Genes involved in RNA Polymerase III Transcription
Genes involved in Cell death signalling via NRAGE, NRIF and NADE
Genes involved in Neurotransmitter Release Cycle
Genes involved in p75 NTR receptor-mediated signalling
Genes involved in Amino acid transport across the plasma membrane
Genes involved in Endogenous sterols
Genes involved in Regulation of gene expression in beta cells
Genes involved in Glycolysis
Genes involved in Processive synthesis on the lagging strand
Genes involved in Peptide chain elongation
Genes involved in Common Pathway
Genes involved in mRNA Capping
Genes involved in Mitochondrial Fatty Acid Beta-Oxidation
Genes involved in Signaling by GPCR
Genes involved in Peptide ligand-binding receptors
Genes involved in Metabolism of polyamines
Genes involved in Class A/1 (Rhodopsin-like receptors)
Genes involved in Notch-HLH transcription pathway
Genes involved in Integration of energy metabolism
Genes involved in Cell Cycle, Mitotic
Genes involved in Gluconeogenesis
Genes involved in Dopamine Neurotransmitter Release Cycle
Genes involved in Opioid Signalling
Genes involved in Recruitment of mitotic centrosome proteins and complexes
Genes involved in Mitochondrial tRNA aminoacylation
Genes involved in Cytosolic tRNA aminoacylation
Genes involved in Ca-dependent events
Genes involved in Acetylcholine Neurotransmitter Release Cycle
Genes involved in Adenylate cyclase activating pathway
Genes involved in Adenylate cyclase inhibitory pathway
Genes involved in DARPP-32 events
Genes involved in Chemokine receptors bind chemokines
Genes involved in Loss of Nlp from mitotic centrosomes
Genes involved in Neurotransmitter Receptor Binding And Downstream Transmission In The  Postsynaptic Cell
Genes involved in Cell Cycle Checkpoints
Genes involved in Diabetes pathways
Genes involved in p130Cas linkage to MAPK signaling for integrins
Genes involved in Glycoprotein hormones
Genes involved in Norepinephrine Neurotransmitter Release Cycle
Genes involved in PLC beta mediated events
Genes involved in Regulation of Insulin-like Growth Factor (IGF) Activity by Insulin-like Growth Factor Binding Proteins (IGFBPs)
Genes involved in GRB2:SOS provides linkage to MAPK signaling for Intergrins
Genes involved in Peptide hormone biosynthesis
Genes involved in G-protein activation
Genes involved in Acetylcholine Binding And Downstream Events
Genes involved in ABC-family proteins mediated transport
Genes involved in tRNA Aminoacylation
Genes involved in Olfactory Signaling Pathway
Genes involved in Steroid hormones
Genes involved in PKA-mediated phosphorylation of CREB
Genes involved in Recruitment of NuMA to mitotic centrosomes
Genes involved in Amine-derived hormones
Genes involved in Transmembrane transport of small molecules
Genes involved in Integrin alphaIIb beta3 signaling
Genes involved in Nuclear Receptor transcription pathway
Genes involved in Insulin Synthesis and Processing
Genes involved in Cyclin E associated events during G1/S transition
Genes involved in Homologous recombination repair of replication-independent double-strand breaks
Genes involved in G1 Phase
Genes involved in Elevation of cytosolic Ca2+ levels
Genes involved in p53-Dependent G1 DNA Damage Response
Genes involved in Transcription-coupled NER (TC-NER)
Genes involved in RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
Genes involved in Glucagon signaling in metabolic regulation
Genes involved in mRNA Processing
Genes involved in Signaling by PDGF
Genes involved in Association of TriC/CCT with target proteins during biosynthesis
Genes involved in Prefoldin mediated transfer of substrate  to CCT/TriC
Genes involved in Hormone ligand-binding receptors
Genes involved in GPVI-mediated activation cascade
Genes involved in Protein folding
Genes involved in Formation of tubulin folding intermediates by CCT/TriC
Genes involved in Peroxisomal lipid metabolism
Genes involved in Post-chaperonin tubulin folding pathway
Genes involved in Striated Muscle Contraction
Genes involved in Metabolism of nucleotides
Genes involved in Amine ligand-binding receptors
Genes involved in Metabolism of proteins
Genes involved in Downstream signal transduction
Genes involved in Muscle contraction
Genes involved in Serotonin receptors
Genes involved in CDC6 association with the ORC:origin complex
Genes involved in M/G1 Transition
Genes involved in mRNA Splicing
Genes involved in mRNA Splicing - Minor Pathway
Genes involved in 3' -UTR-mediated translational regulation
Genes involved in Processing of Capped Intronless Pre-mRNA
Genes involved in Purine ribonucleoside monophosphate biosynthesis
Genes involved in G1/S Transition
Genes involved in Citric acid cycle (TCA cycle)
Genes involved in Transcription
Genes involved in Polymerase switching
Genes involved in Nucleotide Excision Repair
Genes involved in Regulation of the Fanconi anemia pathway
Genes involved in Axon guidance
Genes involved in Activation of Chaperone Genes by XBP1(S)
Genes involved in Regulation of Insulin Secretion by Glucagon-like Peptide-1
Genes involved in PERK regulated gene expression
Genes involved in G alpha (q) signalling events
Genes involved in P2Y receptors
Genes involved in Trafficking of AMPA receptors
Genes involved in NCAM1 interactions
Genes involved in Class C/3 (Metabotropic glutamate/pheromone receptors)
Genes involved in Regulation of Insulin Secretion
Genes involved in NCAM signaling for neurite out-growth
Genes involved in Inhibition of Insulin Secretion by Adrenaline/Noradrenaline
Genes involved in Nucleotide-like (purinergic) receptors
Genes involved in Activation of Chaperones by ATF6-alpha
Genes involved in Transport of Mature mRNA Derived from an Intronless Transcript
Genes involved in Eicosanoid ligand-binding receptors
Genes involved in Activation of Genes by ATF4
Genes involved in Unfolded Protein Response
Genes involved in Class B/2 (Secretin family receptors)
Genes involved in Glucagon-type ligand receptors
Genes involved in Regulation of Insulin Secretion by Acetylcholine
Genes involved in G alpha (12/13) signalling events
Genes involved in Fanconi Anemia pathway
Genes involved in Trafficking of GluR2-containing AMPA receptors
Genes involved in Activation of Chaperone Genes by ATF6-alpha
Genes involved in Prostanoid ligand receptors
Genes involved in Opsins
Genes involved in Formation of RNA Pol II elongation complex
Genes involved in mRNA 3'-end processing
Genes involved in Post-translational modification: synthesis of GPI-anchored proteins
Genes involved in Cyclin A/B1 associated events during G2/M transition
Genes involved in Elongation arrest and recovery
Genes involved in SLC-mediated transmembrane transport
Genes involved in ADP signalling through P2Y purinoceptor 1
Genes involved in G beta:gamma signalling through PLC beta
Genes involved in CD28 co-stimulation
Genes involved in GPCR downstream signaling
Genes involved in Synthesis, Secretion, and Deacylation of Ghrelin
Genes involved in Adherens junctions interactions
Genes involved in CRMPs in Sema3A signaling
Genes involved in Other semaphorin interactions
Genes involved in Activation of Rac
Genes involved in Purine salvage
Genes involved in G alpha (i) signalling events
Genes involved in Sema3A PAK dependent Axon repulsion
Genes involved in CD28 dependent Vav1 pathway
Genes involved in Sema4D in semaphorin signaling
Genes involved in Semaphorin interactions
Genes involved in Sema4D induced cell migration and growth-cone collapse
Genes involved in SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
Genes involved in Lysosome Vesicle Biogenesis
Genes involved in G beta:gamma signalling through PI3Kgamma
Genes involved in Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
Genes involved in Sphingolipid metabolism
Genes involved in PD-1 signaling
Genes involved in G alpha (s) signalling events
Genes involved in Cell-cell junction organization
Genes involved in G alpha (z) signalling events
Genes involved in Facilitative Na+-independent glucose transporters
Genes involved in Costimulation by the CD28 family
Genes involved in Signaling by Robo receptor
Genes involved in CD28 dependent PI3K/Akt signaling
Genes involved in Tight junction interactions
Genes involved in G-protein beta:gamma signalling
Genes involved in Transport of inorganic cations/anions and amino acids/oligopeptides
Genes involved in Golgi Associated Vesicle Biogenesis
Genes involved in CTLA4 inhibitory signaling
Genes involved in Formation of transcription-coupled NER (TC-NER) repair complex
Genes involved in Amino acid and oligopeptide SLC transporters
Genes involved in CDT1 association with the CDC6:ORC:origin complex
Genes involved in Branched-chain amino acid catabolism
Genes involved in Repair synthesis for gap-filling by DNA polymerase in TC-NER
Genes involved in Receptor-ligand binding initiates the second proteolytic cleavage of Notch receptor
Genes involved in Synthesis of DNA
Genes involved in Na+/Cl- dependent neurotransmitter transporters
Genes involved in Formation of Fibrin Clot (Clotting Cascade)
Genes involved in Deadenylation of mRNA
Genes involved in mRNA Decay by 5' to 3' Exoribonuclease
Genes involved in Signal amplification
Genes involved in Zinc transporters
Genes involved in Double-Strand Break Repair
Genes involved in Ras activation uopn Ca2+ infux through NMDA receptor
Genes involved in Metal ion SLC transporters
Genes involved in Autodegradation of the E3 ubiquitin ligase COP1
Genes involved in Smooth Muscle Contraction
Genes involved in Activation of NMDA receptor upon glutamate binding and postsynaptic events
Genes involved in CREB phosphorylation through the activation of Ras
Genes involved in Post NMDA receptor activation events
Genes involved in Unblocking of NMDA receptor, glutamate binding and activation
Genes involved in Metabolism of mRNA
Genes involved in mRNA Decay by 3' to 5' Exoribonuclease
Genes involved in Bile salt and organic anion SLC transporters
Genes involved in Deadenylation-dependent mRNA decay
Genes involved in CREB phosphorylation through the activation of CaMKII
Genes involved in Thromboxane signalling through TP receptor
Genes involved in Cell-extracellular matrix interactions
Genes involved in ADP signalling through P2Y purinoceptor 12
Genes involved in Cell junction organization
Genes involved in Amine compound SLC transporters
Genes involved in Pyruvate metabolism
Genes involved in Purine catabolism
Genes involved in Glucose transport
Genes involved in FRS2-mediated cascade
Genes involved in Metabolism of RNA
Genes involved in Mitotic G1-G1/S phases
Genes involved in PI-3K cascade
Genes involved in Downstream signaling of activated FGFR
Genes involved in Regulation of mitotic cell cycle
Genes involved in TAK1 activates NFkB by phosphorylation and activation of IKKs complex
Genes involved in Regulation of AMPK activity via LKB1
Genes involved in Mitotic M-M/G1 phases
Genes involved in Myogenesis
Genes involved in MAP kinase activation in TLR cascade
Genes involved in Phospholipase C-mediated cascade
Genes involved in Activation of Kainate Receptors upon glutamate binding
Genes involved in Ionotropic activity of Kainate Receptors
Genes involved in Activation of the AP-1 family of transcription factors
Genes involved in MAPK targets/ Nuclear events mediated by MAP kinases
Genes involved in Synthesis and interconversion of nucleotide di- and triphosphates
Genes involved in GPCR ligand binding
Genes involved in RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
Genes involved in JNK (c-Jun kinases) phosphorylation and  activation mediated by activated human TAK1
Genes involved in SHC-mediated cascade
Genes involved in Thrombin signalling through proteinase activated receptors (PARs)
Genes involved in Energy dependent regulation of mTOR by LKB1-AMPK
Genes involved in Mitotic G2-G2/M phases
Genes involved in Regulation of Rheb GTPase activity by AMPK
Genes involved in activated TAK1 mediates p38 MAPK activation
Genes involved in DNA Repair
Genes involved in Effects of PIP2 hydrolysis
Genes involved in RNA Polymerase II Pre-transcription Events
Genes involved in Role of DCC in regulating apoptosis
Genes involved in Post-translational protein modification
Genes involved in Chromosome Maintenance
Genes involved in Deposition of New CENPA-containing Nucleosomes at the Centromere
Genes involved in L1CAM interactions
Genes involved in Role of second messengers in netrin-1 signaling
Genes involved in Signaling by Interleukins
Genes involved in Netrin-1 signaling
Genes involved in Metabolism of lipids and lipoproteins
Genes involved in Interaction between L1 and Ankyrins
Genes involved in Signal transduction by L1
Genes involved in Fatty acid, triacylglycerol, and ketone body metabolism
Genes involved in Transport of vitamins, nucleosides, and related molecules
Genes involved in Highly calcium permeable postsynaptic nicotinic acetylcholine receptors
Genes involved in RNA Polymerase I Promoter Opening
Genes involved in Presynaptic nicotinic acetylcholine receptors
Genes involved in Organic cation/anion/zwitterion transport
Genes involved in DCC mediated attractive signaling
Genes involved in Recycling pathway of L1
Genes involved in Synthesis of substrates in N-glycan biosythesis
Genes involved in Respiratory electron transport
Genes involved in Asparagine N-linked glycosylation
Genes involved in Assembly of the pre-replicative complex
Genes involved in Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
Genes involved in Interleukin-1 signaling
Genes involved in Global Genomic NER (GG-NER)
Genes involved in cGMP effects
Genes involved in Regulation of signaling by CBL
Genes involved in Amino acid synthesis and interconversion (transamination)
Genes involved in Calnexin/calreticulin cycle
Genes involved in Synthesis, Secretion, and Inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)
Genes involved in Passive Transport by Aquaporins
Genes involved in Nephrin interactions
Genes involved in Interleukin-3, 5 and GM-CSF signaling
Genes involved in Nitric oxide stimulates guanylate cyclase
Genes involved in Platelet homeostasis
Genes involved in N-glycan trimming in the ER and Calnexin/Calreticulin cycle
Genes involved in Platelet sensitization by LDL
Genes involved in Aquaporin-mediated transport
Genes involved in Interleukin receptor SHC signaling
Genes involved in Rap1 signalling
Genes involved in Platelet calcium homeostasis
Genes involved in Signal regulatory protein (SIRP) family interactions
Genes involved in Prostacyclin signalling through prostacyclin receptor
Genes involved in GABA synthesis, release, reuptake and degradation
Genes involved in Incretin Synthesis, Secretion, and Inactivation
Genes involved in Transport of organic anions
Genes involved in Synthesis, Secretion, and Inactivation of Glucagon-like Peptide-1 (GLP-1)
Genes involved in Regulation of Water Balance by Renal Aquaporins
Genes involved in Destabilization of mRNA by Butyrate Response Factor 1 (BRF1)
Genes involved in IRAK1 recruits IKK complex
Genes involved in TRAF6 mediated IRF7 activation
Genes involved in Circadian Clock
Genes involved in TRAF6 mediated NF-kB activation
Genes involved in Factors involved in megakaryocyte development and platelet production
Genes involved in Regulation of IFNG signaling
Genes involved in GABA A receptor activation
Genes involved in Regulation of mRNA Stability by Proteins that Bind AU-rich Elements
Genes involved in Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits
Genes involved in IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation
Genes involved in TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
Genes involved in TRAF3-dependent IRF activation pathway
Genes involved in GABA B receptor activation
Genes involved in NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
Genes involved in Destabilization of mRNA by KSRP
Genes involved in Transport to the Golgi and subsequent modification
Genes involved in Iron uptake and transport
Genes involved in Destabilization of mRNA by Tristetraprolin (TTP)
Genes involved in Interferon gamma signaling
Genes involved in N-Glycan antennae elongation
Genes involved in TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling
Genes involved in Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
Genes involved in Ion transport by P-type ATPases
Genes involved in Interferon alpha/beta signaling
Genes involved in Advanced glycosylation endproduct receptor signaling
Genes involved in GABA receptor activation
Genes involved in Kinesins
Genes involved in N-glycan antennae elongation in the medial/trans-Golgi
Genes involved in Regulation of IFNA signaling
Genes involved in Interferon Signaling
Genes involved in Negative regulators of RIG-I/MDA5 signaling
Genes involved in NFkB and MAP kinases activation mediated by TLR4 signaling repertoire
Genes involved in Transferrin endocytosis and recycling
Genes involved in DSCAM interactions
Genes involved in Ion channel transport
Genes involved in Destabilization of mRNA by AUF1 (hnRNP D0)
Genes involved in TRAF6 mediated induction of TAK1 complex
Genes involved in RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
Genes involved in IKK complex recruitment mediated by RIP1
Genes involved in Ligand-gated ion channel transport
Genes involved in Formation of incision complex in GG-NER
Genes involved in Transcriptional Regulation of White Adipocyte Differentiation
Genes involved in Endosomal Sorting Complex Required For Transport (ESCRT)
Genes involved in Meiotic Recombination
Genes involved in Interleukin-2 signaling
Genes involved in Interleukin-6 signaling
Genes involved in Platelet Aggregation (Plug Formation)
Genes involved in Signaling by NOTCH
Genes involved in Lagging Strand Synthesis
Genes involved in Intrinsic Pathway
Genes involved in Inhibition of replication initiation of damaged DNA by RB1/E2F1
Genes involved in Ethanol oxidation
Genes involved in Synthesis of very long-chain fatty acyl-CoAs
Genes involved in DNA Replication
Genes involved in Cleavage of Growing Transcript in the Termination Region
Genes involved in PKB-mediated events
Genes involved in E2F mediated regulation of DNA replication
Genes involved in Metabolism of carbohydrates
Genes involved in Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis
Genes involved in Signaling by Insulin receptor
Genes involved in Signal attenuation
Genes involved in Purine metabolism
Genes involved in SOS-mediated signalling
Genes involved in RNA Polymerase III Transcription Initiation From Type 3 Promoter
Genes involved in Apoptosis
Genes involved in Lipid digestion, mobilization, and transport
Genes involved in Hemostasis
Genes involved in Influenza Life Cycle
Genes involved in Influenza Viral RNA Transcription and Replication
Genes involved in NEP/NS2 Interacts with the Cellular Export Machinery
Genes involved in HIV Infection
Genes involved in Transport of Ribonucleoproteins into the Host Nucleus
Genes involved in HIV Life Cycle
Genes involved in Abortive elongation of HIV-1 transcript in the absence of Tat
Genes involved in Early Phase of HIV Life Cycle
Genes involved in Host Interactions of HIV factors
Genes involved in RNA Polymerase III Transcription Termination
Genes involved in Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.
Genes involved in Formation of the HIV-1 Early Elongation Complex
Genes involved in RAF/MAP kinase cascade
Genes involved in Viral Messenger RNA Synthesis
Genes involved in Late Phase of HIV Life Cycle
Genes involved in SHC-mediated signalling
Genes involved in Interactions of Vpr with host cellular proteins
Genes involved in Formation of ATP by chemiosmotic coupling
Genes involved in APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
Genes involved in Activation of ATR in response to replication stress
Genes involved in Unwinding of DNA
Genes involved in APC/C:Cdc20 mediated degradation of mitotic proteins
Genes involved in Glucuronidation
Genes involved in Autodegradation of Cdh1 by Cdh1:APC/C
Genes involved in MyD88:Mal cascade initiated on plasma membrane
Genes involved in Innate Immune System
Genes involved in Regulation of Glucokinase by Glucokinase Regulatory Protein
Genes involved in Mitotic Prometaphase
Genes involved in APC/C:Cdc20 mediated degradation of Cyclin B
Genes involved in SCF-beta-TrCP mediated degradation of Emi1
Genes involved in Lipoprotein metabolism
Genes involved in G1/S-Specific Transcription
Genes involved in The role of Nef in HIV-1 replication and disease pathogenesis
Genes involved in Chylomicron-mediated lipid transport
Genes involved in Signaling by TGF-beta Receptor Complex
Genes involved in Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase
Genes involved in Activated TLR4 signalling
Genes involved in Immune System
Genes involved in Binding and entry of HIV virion
Genes involved in Phosphorylation of the APC/C
Genes involved in Cytosolic sulfonation of small molecules
Genes involved in Integration of provirus
Genes involved in Glutathione conjugation
Genes involved in Complement cascade
Genes involved in Phase II conjugation
Genes involved in mTORC1-mediated signalling
Genes involved in Toll Receptor Cascades
Genes involved in Activation of BH3-only proteins
Genes involved in Glucose metabolism
Genes involved in RNA Polymerase III Chain Elongation
Genes involved in Voltage gated Potassium channels
Genes involved in Adaptive Immune System
Genes involved in NOD1/2 Signaling Pathway
Genes involved in Cytokine Signaling in Immune system
Genes involved in Meiotic Synapsis
Genes involved in Antigen Presentation: Folding, assembly and peptide loading of class I MHC
Genes involved in The NLRP3 inflammasome
Genes involved in Class I MHC mediated antigen processing & presentation
Genes involved in Nonsense Mediated Decay Enhanced by the Exon Junction Complex
Genes involved in PIP3 activates AKT signaling
Genes involved in Antigen processing: Ubiquitination & Proteasome degradation
Genes involved in Tandem pore domain potassium channels
Genes involved in Inflammasomes
Genes involved in Potassium Channels
Genes involved in Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
Genes involved in Inwardly rectifying K+ channels
Genes involved in Amyloids
Genes involved in Packaging Of Telomere Ends
Genes involved in Telomere Maintenance
Genes involved in Platelet activation, signaling and aggregation
Genes involved in Removal of the Flap Intermediate from the C-strand
Genes involved in Creation of C4 and C2 activators
Genes involved in APC-Cdc20 mediated degradation of Nek2A
Genes involved in Initial triggering of complement
Genes involved in Extension of Telomeres
Genes involved in G2/M Checkpoints
Genes involved in G2/M DNA damage checkpoint
Genes involved in S Phase
Genes involved in SCF(Skp2)-mediated degradation of p27/p21
Genes involved in Tryptophan catabolism
Genes involved in DNA strand elongation
Genes involved in Resolution of AP sites via the single-nucleotide replacement pathway
Genes involved in FGFR ligand binding and activation
Genes involved in Cholesterol biosynthesis
Genes involved in APOBEC3G mediated resistance to HIV-1 infection
Genes involved in Gap junction trafficking
Genes involved in FGFR2c ligand binding and activation
Genes involved in Metabolism of porphyrins
Genes involved in FGFR4 ligand binding and activation
Genes involved in Vif-mediated degradation of APOBEC3G
Genes involved in Signaling by FGFR
Genes involved in Digestion of dietary carbohydrate
Genes involved in FGFR1 ligand binding and activation
Genes involved in Gap junction assembly
Genes involved in Synthesis of glycosylphosphatidylinositol (GPI)
Genes involved in RNA Polymerase I Transcription Initiation
Genes involved in Pyrimidine metabolism
Genes involved in Intrinsic Pathway for Apoptosis
Genes involved in PI3K Cascade
Genes involved in Apoptotic execution  phase
Genes involved in SHC-related events
Genes up-regulated in pancreatic cancer cells grown in orthotopic xenograft tumors compared to those grown in vitro.
Genes down-regulated in pancreatic cancer cells grown in orthotopic xenograft tumors compared to those grown in vitro.
Top up-regulated genes in pediatric adrenocortical tumors (ACT) compared to the normal tissue.
Top down-regulated genes in pediatric adrenocortical tumors (ACT) compared to the normal tissue.
Genes up-regulated in head and neck tumor samples which clustered around known hypoxia genes.
Genes down-regulated in head and neck tumor samples which clustered around known hypoxia genes.
Genes up-regulated in HepaRG cells (liver cancer) expressing constituvely active form of MTOR [GeneID=2475].
Genes down-regulated in HepaRG cells (liver cancer) expressing constituvely active form of MTOR [GeneID=2475].
Up-regulated genes in cervical carcinoma and head and neck tumors positive for human papilloma virus (HPV) compared to those negative for HPV.
Down-regulated genes in cervical carcinoma and head and neck tumors positive for human papilloma virus (HPV) compared to those negative for HPV.
Up-regulated genes in peripheral zone of human pancreatic cancer growing in the pancreas of nude mice compared to that of the tumor from the central zone.
Down-regulated genes in peripheral zone of human pancreatic cancer growing in the pancreas of nude mice compared to that of the tumor from the central zone.
Up-regulated genes in angioimmunoblastic lymphoma (AILT) compared to normal T lymphocytes.
Down-regulated genes in angioimmunoblastic lymphoma (AILT) compared to normal T lymphocytes.
Genes up-regulated in endothelial cells derived from invasive ovarian cancer tissue.
Genes down-regulated in endothelial cells derived from invasive ovarian cancer tissue.
Genes from the 12p region that were up-regulated in embryonic carcinoma tumors compared to normal testis.
Genes from the 12p region that were down-regulated in embryonic carcinoma tumors compared to normal tissue.
Genes from the 12p region that up-regulated in teratoma cells compared to normal testis.
Genes from the 12p region that were up-regulated in yolk sac tumor cells compared to normal testis.
Genes from the 12p region that were up-regulated in choriocarcinoma cells compared to normal testis.
Genes from the 12p region that were down-regulated in choriocarcinoma cells compared to normal testis.
Genes from the 12p region that were up-regulated in seminoma tumors compared to normal testis.
Genes from the 12p region that were down-regulated in seminoma tumors compared to normal testis.
Genes up-regulated in rectal cancer patients resistant to radiotherapy (non-responders) relative to the sensitive ones (responders).
Genes down-regulated in rectal cancer patients resistant to radiotherapy (non-responders) relative to the sensitive ones (responders).
Genes up-regulated in DLBCL (diffuse large B-cell lymphoma) cell lines sensitive to stimulation of CD40 [GeneID=958] relative to the resistant ones.
Genes down-regulated in DLBCL (diffuse large B-cell lymphoma) cell lines sensitive to stimulation of CD40 [GeneID=958] relative to the resistant ones.
Genes up-regulated in prostate cancer samples.
Genes down-regulated in prostate cancer samples.
Genes up-regulated in LNCaP cells (prostate cancer) by overexpression of SOX4 [GeneID=6659] and down-regulated by its RNAi knockdown.
Genes down-regulated in LNCaP cells (prostate cancer) by overexpression of SOX4 [GeneID=6659] and up-regulated by its RNAi knockdown.
Genes up-regulated in uveal melanoma: class 2 vs class 1 tumors.
Genes down-regulated in uveal melanoma: class 2 vs class 1 tumors.
Genes up-regulated in medullary breast cancer (MBC) relative to ductal breast cancer (DBD).
Genes down-regulated in medullary breast cancer (MBC) relative to ductal breast cancer (DBD).
Genes up-regulated in invasive ductal carcinoma (IDC) relative to ductal carcinoma in situ (DCIS, non-invasive).
Genes down-regulated in invasive ductal carcinoma (IDC) relative to ductal carcinoma in situ (DCIS, non-invasive).
'PAX-FKHR signature':  genes up-regulated by PAX3- or PAX7-FOXO1 [GeneID=5081;5077;2308] fusion in primary alveolar rhabdomyosarcoma(ARMS) tumors.
'PAX-FKHR signature':  genes down-regulated by PAX3- or PAX7-FOXO1 [GeneID=5081;5077;2308] fusion in primary alveolar rhabdomyosarcoma(ARMS) tumors.
Genes up-regulated early in HMEC cells (mammary epithelium) during acinar development in vitro.
Genes down-regulated early in HMEC cells (mammary epithelium) during acinar development in vitro.
Genes up-regulated late in HMEC cells (mammary epithelium) during acinar development in vitro.
Genes down-regulated late in HMEC cells (mammary epithelium) during acinar development in vitro.
Genes down-regulated in MDA-MB-231 cells (breast cancer) after knockdown of FXYD5 [GeneID=53827] by RNAi.
Genes preferentially up-regulated in MCF-7 cells (breast cancer) by tamoxifen [PubChem=5376] but not by estradiol or fulvestrant (ICI 182780) [PubChem=5757;3478439].
Genes preferentially down-regulated in MCF-7 cells (breast cancer) by tamoxifen [PubChem=5376] but not by estradiol or fulvestrant (ICI 182780) [PubChem=5757;3478439].
Genes up-regulated in glioma cell lines treated with both decitabine [PubChem=451668] and TSA [PubChem=5562].
Genes down-regulated in glioma cell lines treated with both decitabine [PubChem=451668] and TSA [PubChem=5562].
Genes up-regulated in nsopharyngeal carcinoma relative to the normal tissue.
Genes down-regulated in nsopharyngeal carcinoma relative to the normal tissue.
Up-regulated genes discriminating between MSI (microsatellite instability) and MSS (microsatellite stability) colon cancers.
Down-regulated genes discriminating between MSI (microsatellite instability) and MSS (microsatellite stability) colon cancers.
Genes up-regulated in H1975 cells (non-small cell lung cancer, NSCLC) resistant to gefitinib [PubChem=123631] after treatment with EGFR inhibitor CL-387785 [PubChem=2776] for 6h.
Genes down-regulated in H1975 cells (non-small cell lung cancer, NSCLC) resistant to gefitinib [PubChem=123631] after treatment with EGFR inhibitor CL-387785 [PubChem=2776] for 6h.
Up-regulated genes whose expression correlated with histologic grade of invasive breast cancer tumors: comparison of grade 1 vs grade 3.
Down-regulated genes whose expression correlated with histologic grade of invasive breast cancer tumors: comparison of grade 1 vs grade 3.
Genes up-regulated in erythroid progenitor cells isolated from bone marrow of patients with Diamond-Blackfan anemia (DBA) and mutated RPS19 [GeneID=6223].
Genes down-regulated in erythroid progenitor cells isolated from bone marrow of patients with Diamond-Blackfan anemia (DBA) and mutated RPS19 [GeneID=6223].
Genes up-regulated in myeloid progenitor cells isolated from bone marrow of patients with Diamond-Blackfan anemia (DBA) and mutated RPS19 [GeneID=6223].
Genes down-regulated in myeloid progenitor cells isolated from bone marrow of patients with Diamond-Blackfan anemia (DBA) and mutated RPS19 [GeneID=6223].
Genes up-regulated in common hematopoietic progenitor cells isolated from bone marrow of patients with Diamond-Blackfan anemia (DBA) and mutated RPS19 [GeneID=6223].
Genes down-regulated in common hematopoietic progenitor cells isolated from bone marrow of patients with Diamond-Blackfan anemia (DBA) and mutated RPS19 [GeneID=6223].
Genes up-regulated in CD4+ [GeneID=920] T lymphocytes after stimulation with prostaglandin E2 [PubChem=5280360].
Genes down-regulated in CD4+ [GeneID=920] T lymphocytes after stimulation with prostaglandin E2 [PubChem=5280360].
Selected genes up-regulated in DU145 and PC-3 cells (prostate cancer) after treatment with the NSAID (non-steroid anti-inflammatory drug) sulindac [PubChem=5352].
Selected genes down-regulated in DU145 and PC-3 cells (prostate cancer) after treatment with the NSAID (non-steroid anti-inflammatory drug) sulindac [PubChem=5352].
Genes up-regulated in A549 cells (lung cancer) after knockdown of ATF4 [GeneID=468] by RNAi.
Genes down-regulated in A549 cells (lung cancer) after knockdown of ATF4 [GeneID=468] by RNAi.
Genes up-regulated in 3 out of 4 NSCLC cell lines (non-small cell lung cancer) after treatment with azacitidine [PubChem=9444] and TSA [PubChem=5562].
Genes down-regulated in 3 out of 4 NSCLC cell lines (non-small cell lung cancer) after treatment with azacitidine [PubChem=9444] and TSA [PubChem=5562].
Genes up-regulated in mARMS (molecular ARMS) compared to the mERMS (molecular ERMS) class of rhabdomyosarcoma tumors.
Genes down-regulated in mARMS (molecular ARMS) compared to the mERMS (molecular ERMS) class of rhabdomyosarcoma tumors.
Genes up-regulated in RD cells (embryonal rhabdomyosarcoma, ERMS) by expression of PAX3- or PAX7-FOXO1 [GeneID=5077;5081;2308] fusions off retroviral vectors.
Genes down-regulated in RD cells (embryonal rhabdomyosarcoma, ERMS) by expression of PAX3- or PAX7-FOXO1 [GeneID=5077;5081;2308] fusions off retroviral vectors.
Genes up-regulated in RMS cells (rhabdomyosarcoma) expressing PAX3 or PAX7 fusions with FOXO1 [GeneID=5077;5081;2308] compared to the fusion negative cell lines.
Genes down-regulated in RMS cells (rhabdomyosarcoma) expressing PAX3 or PAX7 fusions with FOXO1 [GeneID=5077;5081;2308] compared to the fusion negative cell lines.
Genes up-regulated in nasopharyngeal carcinoma (NPC) positive for LMP1 [GeneID=9260], a latent gene of Epstein-Barr virus (EBV).
Genes down-regulated in nasopharyngeal carcinoma (NPC) positive for LMP1 [GeneID=9260], a latent gene of Epstein-Barr virus (EBV).
Genes up-regulated in normal ductal and normal lobular breast cells.
Genes down-regulated in normal ductal and normal lobular breast cells.
Genes up-regulated in ductal carcinoma vs normal ductal breast cells.
Genes down-regulated in ductal carcinoma vs normal ductal breast cells.
Genes up-regulated in ductal carcinoma vs normal lobular breast cells.
Genes down-regulated in ductal carcinoma vs normal lobular breast cells.
Genes up-regulated in ductal vs lobular carcinoma breast tumor cells.
Genes down-regulated in ductal vs lobular carcinoma breast tumor cells.
Genes up-regulated in lobular carcinoma vs normal ductal breast cells.
Genes down-regulated in lobular carcinoma vs normal ductal breast cells.
Genes up-regulated in lobular carcinoma vs normal lobular breast cells.
Genes down-regulated in lobular carcinoma vs normal lobular breast cells.
Top 50 genes up-regulated in metastatic vs primary prostate cancer  tumors.
Top 50 genes down-regulated in metastatic vs primary prostate cancer  tumors.
Genes up-regulated in primary cultures of ovarian surface epithlium cells exposed to progesterone [PubChem=5994] for 5 days.
Genes down-regulated in primary cultures of ovarian surface epithlium cells exposed to progesterone [PubChem=5994] for 5 days.
Genes up-regulated in monocyte-derived dendritic cells (MDDC) after stimulation with galecin-1 (lectin, LGALS1) [GeneID=3956] compared to that with bacterial lipopolysaccharide (LPS).
Genes down-regulated in monocyte-derived dendritic cells (MDDC) after stimulation with galecin-1 (lectin, LGALS1) [GeneID=3956] compared to that with bacterial lipopolysaccharide (LPS).
Genes up-regulated in Daudi cells (B lymphocytes) stably expressing CD5 [GeneID=921] off a plasmid vector.
Genes down-regulated in Daudi cells (B lymphocytes) stably expressing CD5 [GeneID=921] off a plasmid vector.
Genes up-regulated in macrophage by live P.gingivalis.
Genes down-regulated in macrophage by live P.gingivalis.
Genes up-regulated in 293 cells (embryonic kidney) upon expression of KHSV (Kaposi sarcoma-associated herpesvirus) microRNAs.
Genes down-regulated in 293 cells (embryonic kidney) upon expression of KHSV (Kaposi sarcoma-associated herpesvirus) microRNAs.
Genes up-regulated in PC-3 cells (prostate cancer) stably expressing ST7 [GeneID=7982] off a plasmid vector.
Genes down-regulated in PC-3 cells (prostate cancer) stably expressing ST7 [GeneID=7982] off a plasmid vector.
Genes up-regulated in ACC3 cells (adenoid cystic carcinoma) after knockdown of SOX4 [GeneID=6659] by RNAi.
Genes down-regulated in ACC3 cells (adenoid cystic carcinoma) after knockdown of SOX4 [GeneID=6659] by RNAi.
Genes up-regulated in OV-90 cells (ovarian cancer) exposed to ascites which inhibited invasion.
Genes down-regulated in OV-90 cells (ovarian cancer) exposed to ascites which inhibited invasion.
Up-regulated genes in U87 cells (glioblastoma multiforme, GBM) engineered to stably express LGI1 [GeneID=9211].
Down-regulated genes in U87 cells (glioblastoma multiforme, GBM) engineered to stably express LGI1 [GeneID=9211].
Genes up-regulated in samples with systolic heart failure compared to normal hearts.
Genes down-regulated in samples with systolic heart failure compared to normal hearts.
Genes up-regulated in APL (acute promyeolocytic leukemia) blasts expressing PML-RARA fusion [GeneID=5371;5914] compared to normal promyeloblasts.
Genes down-regulated in APL (acute promyeolocytic leukemia) blasts expressing PML-RARA fusion [GeneID=5371;5914] compared to normal promyeloblasts.
Genes up-regulated in multiple myeloma (MM) bone marrow mesenchymal stem cells.
Genes down-regulated in multiple myeloma (MM) bone marrow mesenchymal stem cells.
Up-regulated genes in B-CLL (B-cell chronic leukemia) patients expressing high levels of ZAP70 and CD38 [GeneID=7535;952], which are associated with poor survival.
Down-regulated genes in B-CLL (B-cell chronic leukemia) patients expressing high levels of ZAP70 and CD38 [GeneID=7535;952], which are associated with poor survival.
Genes up-regulated in CD34+ [GeneID=947] cells isolated from bone marrow of CML (chronic myelogenous leukemia) patients, compared to those from normal donors.
Genes down-regulated in CD34+ [GeneID=947] cells isolated from bone marrow of CML (chronic myelogenous leukemia) patients, compared to those from normal donors.
Genes up-regulated in secondary APL (acute promyelocytic leukemia) compared to the de novo tumors.
Genes down-regulated in secondary APL (acute promyelocytic leukemia) compared to the de novo tumors.
Genes up-regulated in T-PLL cells (T-cell prolymphocytic leukemia) bearing the inv(14)/t(14:14) chromosomal aberration.
Genes down-regulated in T-PLL cells (T-cell prolymphocytic leukemia) bearing the inv(14)/t(14:14) chromosomal aberration.
Genes up-regulated in MCF-7 cells (breast cancer) by overexpression of CMYB [GeneID=4602] off adenovirus vector.
Genes down-regulated in MCF-7 cells (breast cancer) by overexpression of CMYB [GeneID=4602] off adenovirus vector.
Genes up-regulated in MCF-7 cells (breast cancer) by overexpression of v-MYB oncogenic varian of CMYB [GeneID=4602] off adenovirus vector.
Genes regulated in the opposite directions by v-MYB (UP) and c-MYB  (DN) variants of CMYB [GeneID=4602] overexpressed in primary monocyte cultures off adenoviral vectors.
Gene regulated in the opposite directions by v-MYB (DN) and c-MYB  (UP) variants of CMYB [GeneID=4602] overexpressed in primary monocyte cultures off adenoviral vectors.
Genes up-regulated in luminal-like breast cancer cell lines compared to the basal-like ones.
Genes down-regulated in luminal-like breast cancer cell lines compared to the basal-like ones.
Genes up-regulated in luminal-like breast cancer cell lines compared to the mesenchymal-like ones.
Genes down-regulated in luminal-like breast cancer cell lines compared to the mesenchymal-like ones.
Genes up-regulated in basal-like breast cancer cell lines as compared to the mesenchymal-like ones.
Genes down-regulated in basal-like breast cancer cell lines as compared to the mesenchymal-like ones.
Genes up-regulated in ER(-) / PR(-) breast tumors (do not express ESR1 and PGR [GeneID=2099;5241]) with molecular similarity to ER(+) (class A) relative to the rest of the ER(-) / PR(-) samples (class B).
Genes down-regulated in ER(-) / PR(-) breast tumors (do not express ESR1 and PGR [GeneID=2099;5241]) with molecular similarity to ER(+) (class A) relative to the rest of the ER(-) / PR(-) samples (class B).
Genes up-regulated in MDA-MB-453 cells (class A ER(-) [GeneID=2099] breast cancer) after exposure to the androgen R1881 [PubChem=13766].
Genes down-regulated in MDA-MB-453 cells (class A ER(-) [GeneID=2099] breast cancer) after exposure to the androgen R1881 [PubChem=13766].
Genes up-regulated in breast cancer samples positive for ESR1 [GeneID=2099] compared to the ESR1 negative tumors.
Genes down-regulated in breast cancer samples positive for ESR1 [GeneID=2099] compared to the ESR1 negative tumors.
Genes up-regulated in LNCaP cells (prostate cancer) treated with synthetic androgen R1881 [PubChem=13766].
Genes up-regulated in LNCaP cells (prostate cancer) treated with forskolin [PubChem=47936], an activator of PKA pathway.
Genes down-regulated in LNCaP cells (prostate cancer) treated with forskolin [PubChem=47936], an activator of PKA pathway.
Genes down-regulated in SK-NEP-1 cells (Wilm's tumor ) stably expressing inactivated forms of STAT1 [GeneID=6772] under growth stress (hypoxia or nutritional deprivation).
Genes up-regulated in serrated vs conventional colorectal carcinoma (CRC) samples.
Genes down-regulated in serrated vs conventional colorectal carcinoma (CRC) samples.
Genes up-regulated in biphasic (mixed) vs epithelial subtypes of malignant peritoneal mesothelioma.
Genes down-regulated in biphasic (mixed) vs epithelial subtypes of malignant peritoneal mesothelioma.
Genes up-regulated in blood vessel cells from wound site.
Genes down-regulated in blood vessel cells from wound site.
Genes up-regulated in Jurkat cells (transformed T lymphocytes) after knockdown of BCL11B [GeneID=64919] by RNAi.
Genes down-regulated in Jurkat cells (transformed T lymphocytes) after knockdown of BCL11B [GeneID=64919] by RNAi.
Genes up-regulated in Cockayne syndrome fibroblasts rescued by expression of ERCC6 [GeneID=2074] off a plasmid vector.
Genes down-regulated in Cockayne syndrome fibroblasts rescued by expression of ERCC6 [GeneID=2074] off a plasmid vector.
Genes up-regulated in primary endothelial cells (HUVEC) after knockdown of WTAP [GeneID=9589] by RNAi.
Genes down-regulated in primary endothelial cells (HUVEC) after knockdown of WTAP [GeneID=9589] by RNAi.
Genes up-regulated in leukemic stem cells (LSC), defined as CD34+CD38- [GeneID=947;952] cells from AML (acute myeloid leukemia patients) compared to the CD34+CD38+ cells.
Genes down-regulated in leukemic stem cells (LSC), defined as CD34+CD38- [GeneID=947;952] cells from AML (acute myeloid leukemia patients) compared to the CD34+CD38+ cells.
Genes down-regulated in adult T-cell leukemia (ATL), chronic vs acute clinical condition.
Genes up-regulated in SKOC-3 cells (ovarian cancer) after YB-1 (YBX1) [GeneID=4904] knockdown by RNAi.
Genes down-regulated in SKOC-3 cells (ovarian cancer) after YB-1 (YBX1) [GeneID=4904] knockdown by RNAi.
Cellular proliferation, growth, apoptosis and Wnt signaling genes up-regulated in SNU638 cells (gastric cancer) by overexpression of SFRP2 [GeneID=6423] off a plasmid vector.
Cellular proliferation, growth, apoptosis and Wnt signaling genes down-regulated in SNU638 cells (gastric cancer) by overexpression of SFRP2 [GeneID=6423] off a plasmid vector.
Genes positively correlated with the asbestos exposure of lung cancer patients.
Genes negatively correlated with the asbestos exposure of lung cancer patients.
Genes up-regulated in HCT8/S1 cells (colon cancer) which normally lack DCC [GeneID=9423] compared to those stably expressing wild type DCC off a plasmid vector.
Genes down-regulated in HCT8/S1 cells (colon cancer) which normally lack DCC [GeneID=9423] compared to those stably expressing wild type DCC off a plasmid vector.
Genes up-regulated in HCT8/S11 cells (colon cancer) engineered to stably express NTN1 [GeneID=1630] off a plasmid vector.
Genes down-regulated in HCT8/S11 cells (colon cancer) engineered to stably express NTN1 [GeneID=1630] off a plasmid vector.
Genes up-regulated in MCF7 cells (breast cancer) engineered to conditionally express LMO4 [GeneID=8543] by a Tet Off system.
Genes down-regulated in MCF7 cells (breast cancer) engineered to conditionally express LMO4 [GeneID=8543] by a Tet Off system.
Genes up-regulated in MCF7 cells (breast cancer) engineered to conditionally express a dominant negative form of CLIM2 [GeneID=8861] by a Tet Off system.
Genes down-regulated in MCF7 cells (breast cancer) engineered to conditionally express a dominant negative form of CLIM2 [GeneID=8861] by a Tet Off system.
Up-regulated genes distinguishing between two subtypes of gastric cancer: advanced (AGC) and early (EGC).
Down-regulated genes distinguishing between two subtypes of gastric cancer: advanced (AGC) and early (EGC).
Up-regulated genes distinguishing between early gastric cancer (EGC) and normal tissue samples.
Down-regulated genes distinguishing between early gastric cancer (EGC) and normal tissue samples.
Up-regulated genes from the 70-gene prognosis predictor for stage 2 colon cancer, based on non-neoplastic mucosa gene expression profiles.
Down-regulated genes from the 70-gene prognosis predictor for stage 2 colon cancer, based on non-neoplastic mucosa gene expression profiles.
Genes up-regulated in circulating endothelial cells (CEC) from cancer patients compared to those from healthy donors.
Genes down-regulated in circulating endothelial cells (CEC) from cancer patients compared to those from healthy donors.
Genes up-regulated in head and neck squamous cell carcinoma (HNSCC) samples positive for HPV compared to the HPV-negative tumors.
Genes up-regulated in metastases from malignant melanoma compared to the primary tumors.
Genes down-regulated in metastases from malignant melanoma compared to the primary tumors.
Genes up-regulated in blood samples from bladder cancer patients.
Genes down-regulated in blood samples from bladder cancer patients.
Genes up-regulated in non-metastatic breast cancer tumors having type 1 amplification in the 20q13 region; involves ZNF217 [GeneID=7764] locus only.
Genes down-regulated in non-metastatic breast cancer tumors having type 1 amplification in the 20q13 region; involves ZNF217 [GeneID=7764] locus only.
Genes up-regulated in metastatic breast cancer tumors having  type 2 amplification in the 20q13 region; involves MYBL2, STK6 and ZNF217 [GeneID=4605;6790;7764]
Genes down-regulated in metastatic breast cancer tumors having  type 2 amplification in the 20q13 region; involves MYBL2, STK6 and ZNF217 [GeneID=4605;6790;7764]
Genes up-regulated in hematopoietic stem cells (HSC, CD34+ [GeneID=947]) cultured in a three-dimentional collagen gel compared to the cells grown in suspension.
Genes down-regulated in hematopoietic stem cells (HSC, CD34+ [GeneID=947]) cultured in a three-dimentional collagen gel compared to the cells grown in suspension.
Genes from the yellow module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).
Genes from the yellow module which are down-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).
Genes from the turquoise module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphocholine (oxPAPC).
Genes from the turquoise module which are down-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphocholine (oxPAPC).
Genes from the red module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).
Genes from the red module which are down-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).
Genes from the magenta module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).
Genes from the magenta module which are down-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).
Genes from the lightyellow module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).
Genes from the lightyellow module which are down-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).
Genes from the green module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).
Genes from the green module which are down-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).
Genes from the blue module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).
Genes from the blue module which are down-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).
Genes from the black module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).
Genes from the black module which are down-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).
Genes from the grey module which are up-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).
Genes from the grey module which are down-regulated in HAEC cells (primary aortic endothelium) after exposure to the oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycerophosphorylcholine (oxPAPC).
Up-regulated genes detecting gender effects in global expression profiling studies.
Genes up-rgulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 6h.
Genes down-rgulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 6h.
Genes up-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 3 days after transduction.
Genes down-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 3 days after transduction.
Genes up-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 8 days after transduction.
Genes down-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 8 days after transduction.
Genes up-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 10 days after transduction.
Genes down-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 10 days after transduction.
Genes up-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 16 days after transduction.
Genes down-regulated in CD34+ [GeneID=947] hematopoetic cells by expression of NUP98-HOXA9 fusion [GeneID=4928;3205] off a retroviral vector at 16 days after transduction.
Top genes higher expressed in short term mesothelioma survivors.
Top genes higher expressed in long term mesothelioma survivors.
Genes up-regulated in ALL (acute lymphoblastic leukemia) patients who developed t-ML (treatment related myeloid leukemia).
Genes down-regulated in ALL (acute lymphoblastic leukemia) patients who developed t-ML (treatment related myeloid leukemia).
Genes up-regulated in B-CLL (B-cell chronic leukemia) samples expressing high levels of LPL [GeneID=4023] compared with those expressing low levels of the gene.
Genes down-regulated in B-CLL (B-cell chronic leukemia) samples expressing high levels of LPL [GeneID=4023] compared with those expressing low levels of the gene.
Genes up-regulated in the common lymphoid progenitor (CLP, defined as CD34+CD38-CD7+ [GeneID=947;952;924]) compared to a multipotent cord blood cell (defined as CD34+CD38+CD7-).
Genes down-regulated in the common lymphoid progenitor (CLP, defined as CD34+CD38-CD7+ [GeneID=947;952;924]) compared to a multipotent cord blood cell (defined as CD34+CD38+CD7-).
Genes up-regulated in CD38+ [GeneID=952] CLL (chronic lymphocytic leukemia) cells.
Genes down-regulated in CD38+ [GeneID=952] CLL (chronic lymphocytic leukemia) cells.
Genes up-regulated in WE17/10 cells (CD4+ [GeneID=920] T lymphocytes) infected by HTLV1 (and thus displaying low CD7 [GeneID=924]) compared to the uninfected (i.e., CD7+) cells.
Genes down-regulated in WE17/10 cells (CD4+ [GeneID=920] T lymphocytes) infected by HTLV1 (and thus displaying low CD7 [GeneID=924]) compared to the uninfected (i.e., CD7+) cells.
Genes up-regulated in ALL (acute lymphoblastic leukemia) blasts after 1 week of treatment with glucocorticoids.
Genes down-regulated in ALL (acute lymphoblastic leukemia) blasts after 1 week of treatment with glucocorticoids.
The 'NPM1-mutated signature 1': genes up-regulated in pediatric AML (acute myeloid leukemia) samples with mutated NPM1 [GeneID=4869] compared to all AML cases with the intact gene.
The 'NPM1-mutated signature 1': genes down-regulated in pediatric AML (acute myeloid leukemia) samples with mutated NPM1 [GeneID=4869] compared to all AML cases with the intact gene.
The 'NPM1-mutated signature 2': genes up-regulated in pediatric AML (acute myeloid leukemia) samples with mutated NPM1 [GeneID=4869] compared to the AML cases with the intact gene and without recurring cytogenetic anomalities or M7 phenotype.
The 'NPM1-mutated signature 2': genes down-regulated in pediatric AML (acute myeloid leukemia) samples with mutated NPM1 [GeneID=4869] compared to the AML cases with the intact gene and without recurring cytogenetic anomalities or M7 phenotype.
The 'MLL signature 1': genes up-regulated in pediatric AML (acute myeloid leukemia) with rearranged MLL [GeneID=4297] compared to all AML cases with the intact gene.
The 'MLL signature 1': genes down-regulated in pediatric AML (acute myeloid leukemia) with rearranged MLL [GeneID=4297] compared to all AML cases with the intact gene.
The 'MLL signature 2': genes up-regulated in pediatric AML (acute myeloid leukemia) with rearranged MLL [GeneID=4297] compared to the AML cases with intact MLL and NPM1 [GeneID=4869].
The 'MLL signature 2': genes down-regulated in pediatric AML (acute myeloid leukemia) with rearranged MLL [GeneID=4297] compared to the AML cases with intact MLL and NPM1 [GeneID=4869].
The 'NPM1 signature 3': genes up-regulated in pediatric AML (acute myeloid leukemia) with mutated NPM1 [GeneID=4869] compared to the AML cases with intact NPM1 and MLL [GeneID=4297].
The 'NPM1 signature 3': genes down-regulated in pediatric AML (acute myeloid leukemia) with mutated NPM1 [GeneID=4869] compared to the AML cases with intact NPM1 and MLL [GeneID=4297].
Genes up-regulated by RUNX1-RUNX1T1 [GeneID=861;862] fusion protein in normal hematopoietic progenitors; their expression was sustained in subsequently developing granulocytes.
Genes down-regulated by RUNX1-RUNX1T1 [GeneID=861;862] fusion protein in normal hematopoietic progenitors; their expression was sustained in subsequently developing granulocytes.
Genes up-regulated in normal hematopoietic progenitors by RUNX1-RUNX1T1 [GeneID=861;862] fusion.
Genes down-regulated in normal hematopoietic progenitors by RUNX1-RUNX1T1 [GeneID=861;862] fusion.
Genes up-regulated in granulocytes by RUNX1-RUNX1T1 [GeneID=861;862] fusion.
Genes down-regulated in granulocytes by RUNX1-RUNX1T1 [GeneID=861;862] fusion.
Genes up-regulated in monocytes by RUNX1-RUNX1T1 [GeneID=861;862] fusion.
Genes down-regulated in monocytes by RUNX1-RUNX1T1 [GeneID=861;862] fusion.
Genes up-regulated in erythroid lineage cells by RUNX1-RUNX1T1 [GeneID=861;862] fusion .
Genes down-regulated in erythroid lineage cells by RUNX1-RUNX1T1 [GeneID=861;862] fusion .
Genes up-regulated by RUNX1-RUNX1T1 [GeneID=861;862] fusion protein in normal hematopoietic progenitors; their expression was sustained in subsequently developing monocytes.
Genes down-regulated by RUNX1-RUNX1T1 [GeneID=861;862] fusion protein in normal hematopoietic progenitors; their expression was sustained in subsequently developing monocytes.
Genes up-regulated by RUNX1-RUNX1T1 [GeneID=861;862] fusion protein in normal hematopoietic progenitors; their expression was sustained in subsequently developing erythroid lineage.
Genes higher expressed in the worst 25 mesothelioma survivors compared to the 25 best ones.
Genes higher expressed in the best 25 mesothelioma survivors compared to the 25 worst ones.
Genes up-regulated in unstable ateroslerotic plaques compared to the stable ones.
Genes down-regulated in unstable ateroslerotic plaques compared to the stable ones.
Genes up-regulated in MDA-MB-231 cells (breast cancer) after knockdown of PTHLH [GeneID=5744] by RNAi.
Genes down-regulated in MDA-MB-231 cells (breast cancer) after knockdown of PTHLH [GeneID=5744] by RNAi.
Genes up-regulated in HeLa cells after knockdown of MED1 [GeneID=5469] by RNAi.
Genes down-regulated in HeLa cells after knockdown of MED1 [GeneID=5469] by RNAi.
Genes up-regulated in P493-6 cells (B lymphocyte, Burkitt's lymphoma model) upon knockdown of TFRC [GeneID=7037] by RNAi.
Genes down-regulated in P493-6 cells (B lymphocyte, Burkitt's lymphoma model) upon knockdown of TFRC [GeneID=7037] by RNAi.
Genes down-regulated in P493-6 cells (B lymphocyte, Burkitt's lymphoma model) by MYC [GeneID=4609] and up-regulated by RNAi knockdown of TFRC [GeneID=7037].
Genes up-regulated in P493-6 cells (B lymphocyte, Burkitt's lymphoma model) by MYC [GeneID=4609] and down-regulated by RNAi knockdown of TFRC [GeneID=7037].
Genes up-regulated in U2OS cells (osteosarcoma) upon knockdown of HDAC1 [GeneID=3065] by RNAi.
Genes down-regulated in U2OS cells (osteosarcoma) upon knockdown of HDAC1 [GeneID=3065] by RNAi.
Genes up-regulated in U2OS cells (osteosarcoma) upon knockdown of both HDAC1 and HDAC2 [GeneID=3065;3066] by RNAi.
Genes down-regulated in U2OS cells (osteosarcoma) upon knockdown of both HDAC1 and HDAC2 [GeneID=3065;3066] by RNAi.
Genes up-regulated in U2OS cells (osteosarcoma) upon knockdown of HDAC2 [GeneID=3066] by RNAi.
Genes down-regulated in U2OS cells (osteosarcoma) upon knockdown of HDAC2 [GeneID=3066] by RNAi.
Genes up-regulated in U2OS cells (osteosarcoma) upon knockdown of HDAC3 [GeneID=8841] by RNAi.
Genes down-regulated in U2OS cells (osteosarcoma) upon knockdown of HDAC3 [GeneID=8841] by RNAi.
Genes up-regulated in the neural crest stem cells (NCS), defined as p75+/HNK1+ [GeneID=4804;27087].
Genes down-regulated in the neural crest stem cells (NCS), defined as p75+/HNK1+ [GeneID=4804;27087].
Up-regulated genes constituting the molecular signature of Burkitt 's lymphoma.
Down-regulated genes constituting the molecular signature of Burkitt 's lymphoma.
Genes up-regulated in Caco-2 cells (intestinal epithelium) after coculture with the probiotic bacteria L. casei for 2h.
Genes down-regulated in Caco-2 cells (intestinal epithelium) after coculture with the probiotic bacteria L. casei for 2h.
Genes up-regulated in Caco-2 cells (intestinal epithelium) after coculture with the probiotic bacteria L. casei for 6h.
Genes down-regulated in Caco-2 cells (intestinal epithelium) after coculture with the probiotic bacteria L. casei for 6h.
Genes up-regulated in Caco-2 cells (intestinal epithelium) after coculture with the probiotic bacteria L. casei for 24h.
Genes down-regulated in Caco-2 cells (intestinal epithelium) after coculture with the probiotic bacteria L. casei for 24h.
Genes up-regulated in macrophages by P.gingivalis FimA pathogen.
Genes down-regulated in macrophages by P.gingivalis FimA pathogen.
Genes up-regulated in macrophages by P.gingivalis LPS (lipopolysaccharide).
Genes up-regulated in TC71 and EWS502 cells (Ewing's sarcoma) by EWSR1-FLI1  [GeneID=2130;2314] as inferred from RNAi knockdown of this fusion protein.
Genes down-regulated in TC71 and EWS502 cells (Ewing's sarcoma) by EWSR1-FLI1  [GeneID=2130;2314] as inferred from RNAi knockdown of this fusion protein.
A selection of genes whose expression displayed significant positive correlation with size of colorectal adenoma.
A selection of genes whose expression displayed significant negative correlation with size of colorectal adenoma.
Genes up-regulated in colorectal adenoma compared to normal mucosa samples.
Genes down-regulated in colorectal adenoma compared to normal mucosa samples.
Genes up-regulated in HB2 cells (mammary epithelium) upon expression of KDM5B [GeneID=10765] off an adenoviral vector.
Genes down-regulated in HB2 cells (mammary epithelium) upon expression of KDM5B [GeneID=10765] off an adenoviral vector.
Genes up-regulated in MCF7 cells (breast cancer) after stimulation with NRG1 [GeneID=3084].
Genes down-regulated in MCF7 cells (breast cancer) after stimulation with NRG1 [GeneID=3084].
Genes up-regulated in MCF7 cells (breast cancer) after stimulation with EGF [GeneID=1950].
Genes up-regulated in UB27 cells (osteosarcoma) at any time point after inducing the expression of a mutant form of WT1 [GeneID=7490].
Genes down-regulated in UB27 cells (osteosarcoma) at any time point after inducing the expression of a mutant form of WT1 [GeneID=7490].
Genes up-regulated in UB27 cells (osteosarcoma) at 8 hr after inducing the expression of a mutant form of WT1 [GeneID=7490].
Genes down-regulated in UB27 cells (osteosarcoma) at 8 hr after inducing the expression of a mutant form of WT1 [GeneID=7490].
Genes up-regulated in UB27 cells (osteosarcoma) at 12 hr after inducing the expression of a mutated form of WT1 [GeneID=7490].
Genes down-regulated in UB27 cells (osteosarcoma) at 12 hr after inducing the expression of a mutated form of WT1 [GeneID=7490].
Genes up-regulated in MCF7 cells (breast cancer) under hypoxia conditions.
Genes down-regulated in MCF7 cells (breast cancer) under hypoxia conditions.
Genes up-regulated in MCF7 cells (breast cancer) treated with hypoxia mimetic DMOG [PubChem=3080614].
Genes down-regulated in MCF7 cells (breast cancer) treated with hypoxia mimetic DMOG [PubChem=3080614].
Genes up-regulated in MCF7 cells (breast cancer) after knockdown of HIF1A [GeneID=3091] by RNAi.
Genes down-regulated in MCF7 cells (breast cancer) after knockdown of HIF1A [GeneID=3091] by RNAi.
Genes up-regulated in MCF7 cells (breast cancer) after knockdown of HIF2A [GeneID=2034] by RNAi.
Genes up-regulated in MCF7 cells (breast cancer) after knockdown of both HIF1A and HIF2A [GeneID=3091;2034] by RNAi.
Genes down-regulated in MCF7 cells (breast cancer) after knockdown of both HIF1A and HIF2A [GeneID=3091;2034] by RNAi.
Genes up-regulated in CD133+ [GeneID=8842] cells (hematopoietic stem cells, HSC) compared to the CD133- cells.
Genes down-regulated in CD133+ [GeneID=8842] cells (hematopoietic stem cells, HSC) compared to the CD133- cells.
Genes up-regulated in FSHD (facioscapulohumeral muscular dystrophy) mesoangioblasts.
Genes down-regulated in FSHD (facioscapulohumeral muscular dystrophy) mesoangioblasts.
Genes up-regulated in quiescent (G0) vs dividing (M) CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloid leukemia) patients.
Genes down-regulated in quiescent (G0) vs dividing (M) CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloid leukemia) patients.
Genes up-regulated in quiescent (G0) CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloid leukemia) patients compared to the quiescent cells from normal donors.
Genes down-regulated in quiescent (G0) CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloid leukemia) patients compared to the quiescent cells from normal donors.
Genes up-regulated in quescent CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloblastic leukemia) patients compared to the dividing cells from normal donors.
Genes down-regulated in quescent CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloblastic leukemia) patients compared to the dividing cells from normal donors.
Genes up-regulated in dividing CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloid leukemia) patients compared to the dividing cells from normal donors.
Genes down-regulated in dividing CD34+ [GeneID=8842] cells isolated from peripheral blood of CML (chronic myeloid leukemia) patients compared to the dividing cells from normal donors.
Genes up-regulated in quiescent CD34+ [GeneID=8842] cells isolated from peripheral blood of normal donors compared to the dividing cells from CML (chronic myeloid leukemia) patients.
Genes down-regulated in quiescent CD34+ [GeneID=8842] cells isolated from peripheral blood of normal donors compared to the dividing cells from CML (chronic myeloid leukemia) patients.
Genes up-regulated in quiescent vs dividing CD34+ [GeneID=8842] cells isolated from peripheral blood of normal donors.
Genes down-regulated in quiescent vs dividing CD34+ [GeneID=8842] cells isolated from peripheral blood of normal donors.
Genes up-regulated in endometroid endometrial tumors from patients with lymph node metastases compared to those without the metastases.
Genes down-regulated in endometroid endometrial tumors from patients with lymph node metastases compared to those without the metastases.
Genes up-regulated in mucinous ovarian carcinoma tumors of low malignant potential (LMP) compared to normal ovarian surface epithelium tissue.
Genes down-regulated in mucinous ovarian carcinoma tumors of low malignant potential (LMP) compared to normal ovarian surface epithelium tissue.
Genes up-regulated in mucinous ovarian carcinoma tumors of grades 1 and 2 compared to the normal ovarian survace epithelium tissue.
Genes down-regulated in mucinous ovarian carcinoma tumors of grades 1 and 2 compared to the normal ovarian survace epithelium tissue.
Genes up-regulated in H720 cells (lung cancer) after treatment with L663536 (MK886) [PubChem=105049], an inhibitor of leukotriene biosynthesis.
Genes down-regulated in H720 cells (lung cancer) after treatment with L663536 (MK886) [PubChem=105049], an inhibitor of leukotriene biosynthesis.
Genes up-regulated in non-neoplastic rectal mucosa samples from patients having cancer associated with ulcerative collitis, compared to those who did not have the cancer.
Genes down-regulated in non-neoplastic rectal mucosa samples from patients having cancer associated with ulcerative collitis, compared to those who did not have the cancer.
Genes up-regulated in nasopharyngeal carcinoma (NPC) compared to the normal tissue.
Genes down-regulated in nasopharyngeal carcinoma (NPC) compared to the normal tissue.
Genes up-regulated in poorly differentiated thyroid carcinoma (PDTC) compared to normal thyroid tissue.
Genes down-regulated in poorly differentiated thyroid carcinoma (PDTC) compared to normal thyroid tissue.
Genes up-regulated in anaplastic thyroid carcinoma (ATC) compared to normal thyroid tissue.
Genes down-regulated in anaplastic thyroid carcinoma (ATC) compared to normal thyroid tissue.
Genes up-regulated in poorly differentiated thyroid carcinoma (PDTC) compared to anaplastic thyroid carcinoma (ATC).
Genes down-regulated in poorly differentiated thyroid carcinoma (PDTC) compared to anaplastic thyroid carcinoma (ATC).
Genes up-regulated in TMX2-28 cells (breast cancer) which do not express ESR1 [GeneID=2099]) compared to the parental MCF7 cells which do.
Genes down-regulated in TMX2-28 cells (breast cancer) which do not express ESR1 [GeneID=2099]) compared to the parental MCF7 cells which do.
Genes up-regulated in monocytes isolated from peripheral blood samples of Sezary syndrom patients compared to those from healthy normal donors.
Genes down-regulated in monocytes isolated from peripheral blood samples of Sezary syndrom patients compared to those from healthy normal donors.
Genes up-regulated in lesional skin biopsies from mycosis fundoides patients compared to the normal skin samples.
Genes down-regulated in lesional skin biopsies from mycosis fundoides patients compared to the normal skin samples.
Genes up-regulated in T helper cells (defines as CD4+) isolated from patients with mucosis fungoides compared to those from normal control donors.
Genes down-regulated in T helper cells (defines as CD4+) isolated from patients with mucosis fungoides compared to those from normal control donors.
Genes up-regulated in monocytes isolated from peripheral blood samples of patients with mucosis fungoides compared to those from normal healthy donors.
Genes down-regulated in monocytes isolated from peripheral blood samples of patients with mucosis fungoides compared to those from normal healthy donors.
Genes up-regulated in polysomal and total RNA samples from SW480 cells (primary colorectal carcinoma, CRC) compared to the SW620 cells (lymph node metastasis from the same individual).
Genes down-regulated in polysomal and total RNA samples from SW480 cells (primary colorectal carcinoma, CRC) compared to the SW620 cells (lymph node metastasis from the same individual).
Genes up-regulated in MCF7 cells (breast cancer) by IGF1 and IGF2 [GeneID=3479;3481].
Genes up-regulated in HET1A cells (esophagus epithelium) engineered to stably express CDX2 [GeneID=1045].
Genes down-regulated in HET1A cells (esophagus epithelium) engineered to stably express CDX2 [GeneID=1045].
Genes up-regulated in NSCLC (non-small cell lung carcinoma) cell lines resistant to gefitinib [PubChem=123631] compared to the sensitive ones.
Genes down-regulated in NSCLC (non-small cell lung carcinoma) cell lines resistant to gefitinib [PubChem=123631] compared to the sensitive ones.
Genes up-regulated in MEWO cells (melanoma) after 48h of methionine [PubChem=876] deprivation.
Genes down-regulated in MEWO cells (melanoma) after 48h of methionine [PubChem=876] deprivation.
Genes up-regulated in MEWO cells (melanoma) after 96 h of methionine [PubChem=876] deprivation.
Genes down-regulated in MEWO cells (melanoma) after 96 h of methionine [PubChem=876] deprivation.
Genes up-regulated in K562 (chronic myelogenous leukemia, CML) cells engineered to stably express RIZ1 [GeneID=7799].
Genes down-regulated in K562 (chronic myelogenous leukemia, CML) cells engineered to stably express RIZ1 [GeneID=7799].
Genes up-regulated in C666-1 cells (nasopharyngeal carcinoma) by stable expression of RASSF1 [GeneID=11186].
Genes down-regulated in C666-1 cells (nasopharyngeal carcinoma) by stable expression of RASSF1 [GeneID=11186].
Genes up-regulated in epidermis after to UVB irradiation.
Genes down-regulated in epidermis after to UVB irradiation.
Genes up-regulated in NHEK cells (normal epidermal keratinocytes) after UVB irradiation.
Genes down-regulated in NHEK cells (normal epidermal keratinocytes) after UVB irradiation.
Genes up-regulated in preneoplastic mammary tissues and whose expression is maintained in tumors.
Genes down-regulated in preneoplastic mammary tissues and whose expression is maintained in tumors.
Genes down-regulated in MEF cells (embryonic fibroblasts) with TERT [GeneID=7015] knockout, after expression of the gene off a retroviral vector.
Transcription factors down-regulated in LNCaP cells (prostate cancer) by expression of GR [GeneID=2908] off a lentiviral vector.
Genes up-regulated by UV-irradiation in cervical cancer cells after knockdown of CDKN2A [GeneID=1029].
Genes down-regulated by UV-irradiation in cervical cancer cells after knockdown of CDKN2A [GeneID=1029].
Genes up-regulated in papillary thyroid carcinoma (PTC) compared to normal tissue.
Genes down-regulated in papillary thyroid carcinoma (PTC) compared to normal tissue.
Genes up-regulated in NIH3T3 cells (fibroblasts) transformed by activated KRAS [GeneID=3845] vs those reverted to normal cells upon over-expression of a dominant negative form of CDC25 [GeneID=5923].
Genes down-regulated in NIH3T3 cells (fibroblasts) transformed by activated KRAS [GeneID=3845] vs those reverted to normal cells upon over-expression of a dominant negative form of CDC25 [GeneID=5923].
Genes up-regulated in transformed NIH3T3 cells (fibroblasts transformed by activated KRAS [GeneID=3845]) vs normal cells.
Genes down-regulated in transformed NIH3T3 cells (fibroblasts transformed by activated KRAS [GeneID=3845]) vs normal cells.
Genes up-regulated in reverted NIH3T3 cells (fibroblasts transformed by activated KRAS [GeneID=3845] which then reverted to normal cells upon stable over-expression of a dominant negative form of CDC25 [GeneID=5923]) vs normal fibroblasts.
Genes down-regulated in reverted NIH3T3 cells (fibroblasts transformed by activated KRAS [GeneID=3845] which then reverted to normal cells upon stable over-expression of a dominant negative form of CDC25 [GeneID=5923]) vs normal fibroblasts.
Genes up-regulated in MEF cells (embryonic fibroblast) isolated from HRAS [GeneID=3265] knockout mice.
Genes down-regulated in MEF cells (embryonic fibroblast) isolated from HRAS [GeneID=3265] knockout mice.
Genes up-regulated in MEF cells (embryonic fibroblasts) isolated from HRAS and NRAS [GeneID=3265;4893] double knockout mice.
Genes down-regulated in MEF cells (embryonic fibroblasts) isolated from HRAS and NRAS [GeneID=3265;4893] double knockout mice.
Genes up-regulated in MEF cells (embryonic fibroblast) isolated from NRAS [GeneID=4893] knockout mice.
Genes down-regulated in MEF cells (embryonic fibroblast) isolated from NRAS [GeneID=4893] knockout mice.
Genes up-regulated in follicular epithelial stem cells after transgenic expression of GR [GeneID=2908] under control of the keratin5 (K5) [GeneID=3852] promoter.
Genes down-regulated in follicular epithelial stem cells after transgenic expression of GR [GeneID=2908] under control of the keratin5 (K5) [GeneID=3852] promoter.
Genes up-regulated in NIH3T3 cells (fibroblasts) after treatment with Y27632 [PubChem=123862], an inhibitor of ROCK proteins; the changes did not depend on expression of constitutively active (Q63L) form of RHOA [GeneID=387].
Genes down-regulated in NIH3T3 cells (fibroblasts) after treatment with Y27632 [PubChem=123862], an inhibitor of ROCK proteins; the changes did not depend on expression of constitutively active (Q63L) form of RHOA [GeneID=387].
Genes up-regulated in NIH3T3 cells (fibroblasts) transformed by  expression of contitutively active (Q63L) form of RHOA [GeneID=387] off plasmid vector; their expression reverted completely after treatment with Y27632 [PubChem=123862], an inhibitor of ROCK proteins.
Genes down-regulated in NIH3T3 cells (fibroblasts) transformed by  expression of contitutively active (Q63L) form of RHOA [GeneID=387] off plasmid vector; their expression reverted completely after treatment with Y27632 [PubChem=123862], an inhibitor of ROCK proteins.
Up-regulated genes whose expression profile is specific to Custer I of urothelial cell carcinoma (UCC) tumors.
Down-regulated genes whose expression profile is specific to Custer I of urothelial cell carcinoma (UCC) tumors.
Genes whose expression profile is specific to Cluster IIa of urothelial cell carcinoma (UCC) tumors.
Genes whose expression profile is specific to Cluster IIa of urothelial cell carcinoma (UCC) tumors.
Genes whose expression profile is specific to Cluster III of urothelial cell carcinoma (UCC) tumors.
Genes whose expression profile is specific to Cluster III of urothelial cell carcinoma (UCC) tumors.
Genes up-regulated in colorectal carcinoma samples positive for MSI (microsatellite instability) compared to the MSI negative ones.
Genes down-regulated in colorectal carcinoma samples positive for MSI (microsatellite instability) compared to the MSI negative ones.
Genes in the AKT1 [GeneID=207] pathway which are independent of MTOR [GeneID=2475], insensitive to RAD001 (everolimus) [PubChem=6442177].
Genes in the AKT1 [GeneID=207] pathway which depend on MTOR [GeneID=2475], sensitive to RAD001 (everolimus) [PubChem=6442177].
Up-regulated genes in the breast cancer prognostic signature of 70 genes that significantly correlated with survival.
Down-regulated genes in the breast cancer prognostic signature of 70 genes that significantly correlated with survival.
Genes up-regulated in MEF cells (embryonic fibroblasts) isolated from RB1 [GeneID=5925] knockout mice: chronic loss of function (LOF) of RB1.
Genes down-regulated in MEF cells (embryonic fibroblasts) isolated from RB1 [GeneID=5925] knockout mice: chronic loss of function (LOF) of RB1.
Genes up-regulated in adult fibroblasts with inactivated RB1 [GeneID=5925] by Cre-lox: acute loss of function (LOF) of RB1.
Genes down-regulated in adult fibroblasts with inactivated RB1 [GeneID=5925] by Cre-lox: acute loss of function (LOF) of RB1.
Genes from common regions of gains observed in more than 15% of 148 primary breast cancer tumors.
Genes from common regions of losses observed in more than 15% of 148 primary breast cancer tumors.
Genes up-regulated in ME-A cells (breast cancer) undergoing apoptosis upon serum starvation (5% to 0% FCS) for 22 hr.
Genes down-regulated in ME-A cells (breast cancer) undergoing apoptosis upon serum starvation (5% to 0% FCS) for 22 hr.
Genes up-regulated in uterine fibroids vs normal myometrium samples.
Genes down-regulated in uterine fibroids vs normal myometrium samples.
Genes up-regulated in uterine fibroids with deletions in the 7q region vs those without the deletion.
Genes down-regulated in uterine fibroids with deletions in the 7q region vs those without the deletion.
Up-regulated genes from the 65 most significantly changed (p<0.01) genes identified by two analytical methods in the mammary tumors induced by transgenic expression of ERBB2 [GeneID=2064].
Down-regulated genes from the 65 most significantly changed (p<0.01) genes identified by two analytical methods in the mammary tumors induced by transgenic expression of ERBB2 [GeneID=2064].
Up-regulated genes from top 82 genes out of the 324-gene signature identified in the pre-neoplastic tissue adjacent to the mammary tumors induced by transgenic expression of ERBB2 [GeneID=2064].
Down-regulated genes from top 82 genes out of the 324-gene signature identified in the pre-neoplastic tissue adjacent to the mammary tumors induced by transgenic expression of ERBB2 [GeneID=2064].
Genes up-regulated in SH-SY5Y cells (neuroblastoma) after treatment with epoxomicin [PubChem=3035402], a protease inhibitor causing apoptosis.
Genes down-regulated in SH-SY5Y cells (neuroblastoma) after treatment with epoxomicin [PubChem=3035402], a protease inhibitor causing apoptosis.
Up-regulated genes in the signature set for lymph node metastasis in head and neck squamous cell carcinoma (HNSCC).
Down-regulated genes in the signature set for lymph node metastasis in head and neck squamous cell carcinoma (HNSCC).
Genes up-regulated in ME-A cells (breast cancer, sensitive to apoptotic stimuli) upon serum deprivation for 22 hr in the presence of medium concentrate (MC) from ME-C cells (breast cancer, resistant to apoptotic stimuli).
Genes down-regulated in ME-A cells (breast cancer, sensitive to apoptotic stimuli) upon serum deprivation for 22 hr in the presence of medium concentrate (MC) from ME-C cells (breast cancer, resistant to apoptotic stimuli).
Genes up-regulated in ME-A cells (breast cancer) undergoing apoptosis in response to doxorubicin [PubChem=31703].
Genes down-regulated in ME-A cells (breast cancer) undergoing apoptosis in response to doxorubicin [PubChem=31703].
Genes up-regulated in ME-A cells (breast cancer, sensitive to apoptotic stimuli) exposed to doxorubicin [PubChem=31703] in the presence of medium concentrate (MC) from ME-C cells (breast cancer, resistant to apoptotic stimuli).
Genes down-regulated in ME-A cells (breast cancer, sensitive to apoptotic stimuli) exposed to doxorubicin [PubChem=31703] in the presence of medium concentrate (MC) from ME-C cells (breast cancer, resistant to apoptotic stimuli).
Up-regulated genes from the set A (Fig. 5a): specific to cells expressing MLL-AF4 [GeneID=4297;4299] fusion protein alone.
Down-regulated genes from the set A (Fig. 5a): specific to cells expressing MLL-AF4 [GeneID=4297;4299] fusion protein alone.
Up-regulated genes from the set B (Fig. 5a): specific signature shared by cells expressing either AF4-MLL or MLL-AF4 [GeneID=4299;4297] fusion proteins.
Down-regulated genes from the set B (Fig. 5a): specific signature shared by cells expressing either AF4-MLL or MLL-AF4 [GeneID=4299;4297] fusion proteins.
Up-regulated genes from the set C (Fig. 5a): specific to cells expressing AF4-MLL [GeneID=4299;4297] fusion protein alone.
Down-regulated genes from the set C (Fig. 5a): specific to cells expressing AF4-MLL [GeneID=4299;4297] fusion protein alone.
Up-regulated genes from the set D (Fig. 5a): specific signature shared by cells expressing MLL-AF4 [GeneID=4297;4299] alone and those expressing both MLL-AF4 and AF4-MLL fusion proteins.
Down-regulated genes from the set D (Fig. 5a): specific signature shared by cells expressing MLL-AF4 [GeneID=4297;4299] alone and those expressing both MLL-AF4 and AF4-MLL fusion proteins.
Up-regulated genes from the set E (Fig. 5a): specific signature shared by cells expressing either MLL-AF4 [GeneID=4297;4299] or AF4-MLL fusion proteins alone, and those expressing both fusion proteins.
Down-regulated genes from the set E (Fig. 5a): specific signature shared by cells expressing either MLL-AF4 [GeneID=4297;4299] or AF4-MLL fusion proteins alone, and those expressing both fusion proteins.
Up-regualted genes from the set F (Fig. 5a): specific signature shared by cells expressing AF4-MLL [GeneID=4299;4297] alone and those expressing both AF4-MLL and MLL-AF4 fusion proteins.
Down-regualted genes from the set F (Fig. 5a): specific signature shared by cells expressing AF4-MLL [GeneID=4299;4297] alone and those expressing both AF4-MLL and MLL-AF4 fusion proteins.
Up-regulated genes from the set G (Fig. 5a): specific to cells expressing both MLL-AF4 [GeneID=4297;4299] and AF4-MLL fusion proteins.
Down-regulated genes from the set G (Fig. 5a): specific to cells expressing both MLL-AF4 [GeneID=4297;4299] and AF4-MLL fusion proteins.
Genes up-regulated in NIH3T3 cells (fibroblasts) transfrormed by expression of constitutively active (Q63L) form of RHOA [GeneID=387] off plasmid vector; their expression did NOT reverted completely after treatment with Y27632 [PubChem=123862], an inhibitor of ROCK proteins.
Genes down-regulated in NIH3T3 cells (fibroblasts) transfrormed by expression of constitutively active (Q63L) form of RHOA [GeneID=387] off plasmid vector; their expression did NOT reverted completely after treatment with Y27632 [PubChem=123862], an inhibitor of ROCK proteins.
Genes up-regulated in MEF cells (embryonic fibroblasts) after knockout of PML [GeneID=5371] and whose promoters were bound by MYC [GeneID=4609].
Genes down-regulated in MEF cells (embryonic fibroblasts) after knockout of PML [GeneID=5371] and whose promoters were bound by MYC [GeneID=4609].
Genes up-regulated in epithelial ovarian cancer (EOC) biopsies: invasive (TOV) vs low malignant potential (LMP) tumors.
Genes down-regulated in epithelial ovarian cancer (EOC) biopsies: invasive (TOV) vs low malignant potential (LMP) tumors.
Up-regulated genes from the 324 genes identified by two analytical methods as changed in the mammary tumors induced by transgenic expression of ERBB2 [GeneID=2064].
Down-regulated genes from the 324 genes identified by two analytical methods as changed in the mammary tumors induced by transgenic expression of ERBB2 [GeneID=2064].
Up-regulated genes in non-neoplastic mucosa samples from colon cancer patients who developed recurrence of the disease.
Down-regulated genes in non-neoplastic mucosa samples from colon cancer patients who developed recurrence of the disease.
Up-regulated genes in tumor samples from colon cancer patients who developed recurrence of the disease.
Down-regulated genes in tumor samples from colon cancer patients who developed recurrence of the disease.
Genes up-regulated in oncocytic follicular carcinoma (FTC) vs mitochondrial-rich papillary carcinoma (PTC) types of thyroid cancer.
Genes down-regulated in oncocytic follicular carcinoma (FTC) vs mitochondrial-rich papillary carcinoma (PTC) types of thyroid cancer.
Genes up-regulated in NIH3T3 cells (fibroblasts) transformed by  expression of contitutively active (Q63L) form of RHOA [GeneID=387] off plasmid vector.
Genes down-regulated in NIH3T3 cells (fibroblasts) transformed by  expression of contitutively active (Q63L) form of RHOA [GeneID=387] off plasmid vector.
Candidate genes in the regions of copy number gain in gastric cancer cell lines.
Candidate genes in the regions of copy number loss in gastric cancer cell lines.
Genes up-regulated in esophageal adenocarcinoma (EAC) and Barret's esophagus (BE) relative to normal esophagi.
Genes down-regulated in esophageal adenocarcinoma (EAC) and Barret's esophagus (BE) relative to normal esophagi.
Genes genes up-regulated in NT2/D1 cells (embryonal carcinoma) in response to treatment with cisplatin [PubChem=2767].
Genes genes down-regulated in NT2/D1 cells (embryonal carcinoma) in response to treatment with cisplatin [PubChem=2767].
Genes up-regulated in PaCa44 and CFPAC1 cells (pancreatic cancer) after treatment with decitabine [PubChem=451668], a DNA hypomethylating agent similar to azacitidine [PubChem=9444].
Genes down-regulated in PaCa44 and CFPAC1 cells (pancreatic cancer) after treatment with decitabine [PubChem=451668], a DNA hypomethylating agent similar to azacitidine [PubChem=9444].
Genes up-regulated in WI-38 cells (senescent primary fibroblasts) after inactivation of TP53 [GeneID=7157] by GSE56 polypeptide.
Genes down-regulated in WI-38 cells (senescent primary fibroblasts) after inactivation of TP53 [GeneID=7157] by GSE56 polypeptide.
Genes up-regulated in Barrett's esophagus compared to the normal tissue.
Genes down-regulated in Barrett's esophagus compared to the normal tissue.
Up-regulated genes specific to esophageal adenocarcinoma (EAC) relative to normal tissue.
Down-regulated genes specific to esophageal adenocarcinoma (EAC) relative to normal tissue.
Candidate progression biomarkers up-regulated in transition from non-tumor-risk associated to tumor-risk associated Barrett's esophagus and then to esophageal adenocarcinoma (EAC).
Genes bound by EWSR1-FLT1 [GeneID=2130;2321] fusion and up-regulated in STA-ET-7.2 cells (Ewing's sarcoma) after knockdown of EWSR1-FLT1 by RNAi.
Genes bound by EWSR1-FLT1 [GeneID=2130;2321] fusion and down-regulated in STA-ET-7.2 cells (Ewing's sarcoma) after knockdown of EWSR1-FLT1 by RNAi.
Genes in discrete regions of gain within 16q region detected in individual invasive breast cancer tumors.
Genes in discrete regions of loss within 16q region detected in individual invasive breast cancer tumors.
Genes up-regulated in brain tumors induced by retroviral delivery of PDGFB [GeneID=5155].
Genes down-regulated in brain tumors induced by retroviral delivery of PDGFB [GeneID=5155].
Genes up-regulated during pubertal mammary gland development between weeks 3 and 4.
Genes down-regulated during pubertal mammary gland development between weeks 3 and 4.
Genes up-regulated during pubertal mammary gland development between week 4 and 5.
Genes down-regulated during pubertal mammary gland development between week 4 and 5.
Genes up-regulated during pubertal mammary gland development between week 5 and 6.
Genes down-regulated during pubertal mammary gland development between week 5 and 6.
Genes up-regulated during pubertal mammary gland development between week 6 and 7.
Genes down-regulated during pubertal mammary gland development between week 6 and 7.
Genes up-regulated in MDA-MB-231 cells (breast cancer) after knockdown of PRKCA and ETS1 [GeneID=5578;2113] by RNAi.
Genes down-regulated in MDA-MB-231 cells (breast cancer) after knockdown of PRKCA and ETS1 [GeneID=5578;2113] by RNAi.
Genes up-regulated in Kasumi-1 cells (acute myeloid leukaemia (AML) with the t(8;21) translocation) after knockdown of the AML1 MTG8 fusion [GeneID=861;862] by RNAi.
Genes down-regulated in Kasumi-1 cells (acute myeloid leukaemia (AML) with the t(8;21) translocation) after knockdown of the AML1 MTG8 fusion [GeneID=861;862] by RNAi.
Top up-regulated genes distinguishing between follicular thyroid carcinoma (FTC) samples by the presence or absence of the PAX8-PPARG [GeneID=7849;5468] fusion protein.
Top down-regulated genes distinguishing between follicular thyroid carcinoma (FTC) samples by the presence or absence of the PAX8-PPARG [GeneID=7849;5468] fusion protein.
Genes up-regulated in T1 cells (primary melanoma, sensitive to TRAIL [GeneID=8743]) compared to G1 cells (metastatic melanoma, resistant to TRAIL).
Genes down-regulated in T1 cells (primary melanoma, sensitive to TRAIL [GeneID=8743]) compared to G1 cells (metastatic melanoma, resistant to TRAIL).
Genes up-regulated in pirmary cultures of epithelial ovarian cancer (EOC): invasive (TOV) vs low malignant potential (LMP) tumors.
Genes down-regulated in pirmary cultures of epithelial ovarian cancer (EOC): invasive (TOV) vs low malignant potential (LMP) tumors.
Genes up-regulated in benign skin tumors (papilloma) induced by treatment with DMBA and TPA [PubChem=6001;4792] chemicals in the two stage skin carcinogenesis model.
Genes down-regulated in benign skin tumors (papilloma) induced by treatment with DMBA and TPA [PubChem=6001;4792] chemicals in the two stage skin carcinogenesis model.
Pubertal genes up-regulated by TGFB1 [GeneID=7040].
Pubertal genes down-regulated by TGFB1 [GeneID=7040].
Genes up-regulated in malignant skin tumors (squamous cell carcinoma, SCC) formed by treatment with DMBA and TPA [PubChem=6001;4792] in the two stage skin carcinogenesis model.
Genes down-regulated in malignant skin tumors (squamous cell carcinoma, SCC) formed by treatment with DMBA and TPA [PubChem=6001;4792] in the two stage skin carcinogenesis model.
Genes up-regulated in Tet-On HEK293 cells (embryonic kidney) by expression of HNF4A [GeneID=3172].
Genes down-regulated in Tet-On HEK293 cells (embryonic kidney) by expression of HNF4A [GeneID=3172].
Genes up-regulated in MZ128 cells (Wilms tumor with mutated WT1 [GeneID=7490]) after treatment with 10 microM tretinoin (ATRA) [PubChem=444795] for 24 h.
Genes down-regulated in MZ128 cells (Wilms tumor with mutated WT1 [GeneID=7490]) after treatment with 10 microM tretinoin (ATRA) [PubChem=444795] for 24 h.
Genes up-regulated in MS427 cells (Wilms tumor with normal WT1 [GeneID=7490]) after treatment with 10 microM tretinoin (ATRA) [PubChem=444795] for 24 h.
Genes down-regulated in MS427 cells (Wilms tumor with normal WT1 [GeneID=7490]) after treatment with 10 microM tretinoin (ATRA) [PubChem=444795] for 24 h.
Genes up-regulated in MCF10A cells (breast cancer) by expression of LSM1 [GeneID=27257] off a letiviral vector.
Genes down-regulated in MCF10A cells (breast cancer) by expression of LSM1 [GeneID=27257] off a letiviral vector.
Genes up-regulated in LNCaP cells (prostate cancer) after knockdown of SAM68 [GeneID=10657] by RNAi.
Genes down-regulated in LNCaP cells (prostate cancer) after knockdown of SAM68 [GeneID=10657] by RNAi.
Genes changed in U373-MG cells (malignant glioma) upon treatment with arsenic trioxide [PubChem=14888], a chemical that can cause autophagic cell death.
Myb family target genes.
The 'TEB profile genes': up-regulated during pubertal mammary gland development specifically in the TEB (terminal end bud) structures.
The 'TEB profile genes': down-regulated during pubertal mammary gland development specifically in the TEB (terminal end bud) structures.
Genes up-regulated in K562 cells (bone marrow) after treatment with dasatinib [PubChem=3062316] or imatinib [PubChem=5291].
Genes down-regulated in K562 cells (bone marrow) after treatment with dasatinib [PubChem=3062316] or imatinib [PubChem=5291].
Genes up-regulated during skin tumor progression: epidermis treated with the carcinogen DMBA [PubChem=6001] followed by 20 weekly applications of the tumor promoter TPA [PubChem=4792], compared to the untreated skin.
Genes down-regulated during skin tumor progression: epidermis treated with the carcinogen DMBA [PubChem=6001] followed by 20 weekly applications of the tumor promoter TPA [PubChem=4792], compared to the untreated skin.
Genes up-regulated during skin tumor progression from low risk papilloma vs normal skin.
Genes down-regulated during skin tumor progression from low risk papilloma vs normal skin.
Genes up-regulated during skin tumor progression from normal skin to high risk papilloma.
Genes down-regulated during skin tumor progression from normal skin to high risk papilloma.
Genes up-regulated in squamous cell carcinoma (SCC) compared to normal skin.
Genes down-regulated in squamous cell carcinoma (SCC) compared to normal skin.
Top genes up-regulated in the GIST (gastrointestinal stromal tumor) cell line resistant to imatinib [PubChem=5291] compared to the parental cell line sensitive to the drug.
Top genes down-regulated in the GIST (gastrointestinal stromal tumor) cell line resistant to imatinib [PubChem=5291] compared to the parental cell line sensitive to the drug.
Up-regulated genes associated with the acquision of metastatic potential in LNM35 cells (large cell lung cancer).
Down-regulated genes associated with the acquision of metastatic potential in LNM35 cells (large cell lung cancer).
Detoxification pathway genes down-regulated in enterocytes of transgenic mice expressing SV40 T antigen.
Cancer motility and invasion genes up-regulated by the AP-1 transcription factor.
Cancer motility and invasion genes down-regulated by the AP-1 transcription factor.
Proteins implicated in prostate carcinogenesis.
Major antagonists linked to the mTOR [GeneID=2475] signaling network.
Up-regulated genes that separate angiogenic from non-angiogenic non-small cell lung carcinoma (NSCLC) samples.
Down-regulated genes that separate angiogenic from non-angiogenic non-small cell lung carcinoma (NSCLC) samples.
Genes up-regulated in SaOS-2 cells (osteosarcoma) upon expression of PAX3-FOXO1 [GeneID=5077;2308] fusion protein off an adenoviral vector.
Genes down-regulated in SaOS-2 cells (osteosarcoma) upon expression of PAX3-FOXO1 [GeneID=5077;2308] fusion protein off an adenoviral vector.
Genes that classify progression risk of benign papilloma samples: low vs high risk.
Genes up-regulated in A375 and 397 cells (melanoma) by forced expression of PLZF [GeneID=7704] off adenovirus vector.
Genes down-regulated in A375 and 397 cells (melanoma) by forced expression of PLZF [GeneID=7704] off adenovirus vector.
Genes up-regulated in ovarian epithelial cells in response to dihydrotestosterone (DHT) [PubChem=10635].
Genes down-regulated in ovarian epithelial cells in response to dihydrotestosterone (DHT) [PubChem=10635].
Apoptotic genes dependent on SMAD4 [GeneID=4089] and up-regulated in AML12 cells (hepatocytes) after stimulation with TGFB1 [GeneID=7040].
Apoptotic genes dependent on SMAD4 [GeneID=4089] and down-regulated in AML12 cells (hepatocytes) after stimulation with TGFB1 [GeneID=7040].
Apoptotic genes dependent on MAPK1 [GeneID=5594] and up-regulated in AML12 cells (hepatocytes) after stimulation with TGFB1 [GeneID=7040].
Apoptotic genes dependent on MAPK1 [GeneID=5594] and down-regulated in AML12 cells (hepatocytes) after stimulation with TGFB1 [GeneID=7040].
Genes up-regulated in the 5637 cell line (bladder cancer) after knockdown of E2F3 [GeneID=1871] by RNAi.
Genes down-regulated in the 5637 cell line (bladder cancer) after knockdown of E2F3 [GeneID=1871] by RNAi.
Genes whose transcription is up-regulated by histone deacetylase inhibitors.
Genes whose transcription is down-regulated by histone deacetylase inhibitors.
Acute stage-specific genes for adult T cell leukemia (ATL).
Genes used to predict the clinical stages of acute T-cell leukemia (ATL): chronic vs acute.
Genes up-regulated in cancer endometrium samples compared to the normal endometrium.
Genes down-regulated in cancer endometrium samples compared to the normal endometrium.
Genes down-regulated in late stage (stage 3) endometrial cancers compared to the earlier stages (stage 1 and 2).
Genes up-regulated in the RCC4 cells (renal cell carcinoma, RCC) expressing VHL [GeneID=7428] mutants Type 1 and 2B (associated with RCC) but not those of Type 2A and 2C (not associated with RCC).
Genes down-regulated in the RCC4 cells (renal cell carcinoma, RCC) expressing VHL [GeneID=7428] mutants Type 1 and 2B (associated with RCC) but not those of Type 2A and 2C (not associated with RCC).
Genes up-regulated in MEF cells (embryonic fibroblast) at 16 h after serum stimulation and knockdown of E2F1 [GeneID=1869] by RNAi.
Genes up-regulated in MEF cells (embryonic fibroblasts) at 16 hr after serum stimulation and knockdown of E2F3 [GeneID=1871] by RNAi.
Genes with hypermethylated DNA in all four esophageal squamous cell carcinoma (ESCC) lines analyzed.
RB1 [GeneID=5925] target genes involved in cell cycle regulation: genes down-regulated by doxorubicin [PubChem=31703] only in cells expressing RB1.
Putative E2F4 [GeneID=1874] target genes identified as mitotic genes down-regulated in the LNCaP C4-2 cells (prostate cancer) at both 6 and 24 h following irradiation.
Non-histone proteins that are acetylated.
Genes mutated in colon cancer cell lines, identified using the GINI method described in the paper.
Genes whose promoters bound AR [GeneID=367] in LNCaP cells (prostate cancer) after exposure to the synthetic androgen R1881 [PubChem=13766], based on ChIP-chip analysis.
Selected gradually up-regulated genes in the TLX1 [GeneID=3195] Tet On iEBHX15-4 cells (pro-erythroblasts).
Selected gradually up-regulated genes whose expression profile follows that of CCNE1 [GeneID=898] in the TLX1 [GeneID=3195] Tet On iEBHX15-4 cells (pro-erythroblasts).
Selected gradually up-regulated genes whose expression profile follows that of HBZ [GeneID=3050] in the TLX1 [GeneID=3195] Tet On iEBHX15-4 cells (pro-erythroblasts).
List of the transcription factors up-regulated 1 hr after wounding HDF cells (dermal fibroblasts).
Genes with copy number gains in primary neuroblastoma tumors.
Genes with copy number losses in primary neuroblastoma tumors.
Genes up-regulated in short-term cultured glioblastomas after azacitidine [PubChem=9444] treatment.
Selected gradually up-regulated genes whose expression profile follows that of HEMGN [GeneID=55363] in the TLX1 [GeneID=3195] Tet On iEBHX15-4 cells (pro-erythroblasts).
Selected genes whose expression profile follows that of APOBEC2 [GeneID=10930] in the TLX1 [GeneID=3195] Tet On iEBHX15-4 cells (pro-erythroblasts).
Selected genes down-regulated in the TLX1 [GeneID=3195] Tet On iEBHX15-4 cells (pro-erythroblasts) at 6 h time point.
Selected genes down-regulated in the TLX1 [GeneID=3195] Tet On iEBHX15-4 cells (pro-erythroblasts) at 12 h time point.
Genes up-regulated in Rh4 cells (alveolar rhabdomyosarcoma, ARMS) after knockdown of the PAX3-FOXO1 [GeneiD=5077;2308] fusion protein by RNAi for 72 hr.
Genes up-regulated in the HMEC cells (primary mammary epithelium) upon expression of TP53 [GeneID=7157] off adenoviral vector.
Genes up-regulated in the HMEC cells (primary mammary epithelium) upon expression of the transcriptionally active isoform of TP63 [GeneID=8626] off adenoviral vector.
Genes up-regulated in HMEC cells (primary mammary epithelium) upon expression of both of TP53 [GeneID=7157] and the transcriptionally active isoform of TP63 [GeneID=8626] off adenoviral vectors.
DNA repair genes whose promoters contain putative ZNF143 [GeneID=7702] binding sites.
Genes down-regulated in HCT8/S11 cells (colon cancer) which lack DCC [GeneID=9423] and stably express NTN1 [GeneID=1630].
Genes exclusively up-regulated in fibroblasts expressing the XP/CS mutant form of ERCC3 [GeneID=2071] after high dose UVC irradiation.
Genes exclusively down-regulated in fibroblasts expressing the XP/CS mutant form of ERCC3 [GeneID=2071] after high dose UVC irradiation.
Genes exclusively up-regulated in fibroblasts expressing the TTD mutant form of ERCC3 [GeneID=2071], after UVC irradiation.
Genes exclusively down-regulated in fibroblasts expressing the TTD mutant form of ERCC3 [GeneID=2071], after UVC irradiation.
Examples of transcription factors whose activities are regulated by MAPK1 and MAPK3 [GeneID=5594;5595] phosphorylation.
Examples of transcription factors whose activities are regulated by MAPK8 and MAPK9 [GeneID=5599;5601].
Examples of transcription factors whose activities are regulated by MAPK7 [GeneID=5598] phosphorylation.
Examples of transcription factors whose activities are regulated by MAPK11 [GeneID=5600] phosphorylation.
Examples of transcription factors whose activities are regulated by MAPK14 [GeneID=1432] phosphorylation.
Genes up-regulated in the GIST (gastrointestinal stromal tumor) cell line resistant to imatinib [PubChem=5291] that may correlate with the morphological switch in these cells.
Bottom genes down-regulated in the GIST (gastrointestinal stromal tumor) cell line sensitive to imatinib [PubChem=5291] after treatment with MP470, a protein kinase inhibitor.
Top genes up-regulated in the GIST (gastrointestinal stromal tumor) cell line resistant to imatinib [PubChem=5291] after treatment with MP470, a protein kinase inhibitor.
Genes up-regulated in A2780 cells (ovarian carcinoma) exposed to fenretinide [PubChem=1744].
Genes down-regulated in A2780 cells (ovarian carcinoma) exposed to fenretinide [PubChem=1744].
Composition of the 2 MDa human TFTC complex containing KAT2A [GeneID=2648].
Composition of the 2 MDa human STAGA complex containing KAT2A [GeneID=2648].
Composition of the 2 MDa human PCAF complex.
STAT1 [GeneID=6772] targets in hematopoetic signaling.
STAT3 [GeneID=6774] targets in hematopoietic signaling.
STAT5 [GeneID=6777] targets in hematopoietic signaling.
Genes down-regulated both in vivo and in vitro upon activation of MET [GeneID=4233] signaling.
Selected genes specifically expressed in gastric cancer.
Genes up-regulated in BJ cells (forskin fibroblasts) upon overexpression of the most abundant alternative splicing forms of MDM2 [GeneID=4193], HDM2-A and HDM2-B, off a retroviral vector.
Growth factor signaling components up-regulated  in hepatocellular carcinoma (HCC).
Genes up-regulated in lung adenocarcinoma cell lines and not expressed in non-cancerous lung epithelial cells.
Proteins that permeabilize mitochondria.
Genes with the highest differential expression in primary tissue cultures of high grade glioma: responders vs non-responders to imatinib [PubChem=5291] treatment.
Genes identified with the Fanconi anemia (FA) and the FA pathway.
Candidate genes in genomic amplification regions in hepatocellular carcinoma (HCC) samples.
Genes encoding the NF-kB core signaling proteins.
Genes encoding substrates of IkappaB kinase (IKK) complex.
NF-kB target genes involved in the regulation of programmed cell death.
NF-kB-driven pro-inflammatory genes that are  negatively regulated by glucocorticoids.
Genes in the most frequently homozygous deleted loci in a panel of glioma cell lines.
Genes changed in xenograft tumors formed by DLD-1 or DKO-4 cells (colon cancer) overexpressing MET [GeneID=4233].
Selected genes up-regulated during progression through benign to malignant skin tumors formed by treatment with DMBA and TPA [PubChem=6001;4792] chemicals in the two stage skin carcinogenesis model.
Selected genes down-regulated during progression through benign to malignant skin tumors formed by treatment with DMBA and TPA [PubChem=6001;4792] chemicals in the two stage skin carcinogenesis model.
Genes identified by subtractive hybridization comparing malignant and benign components of a hepatocellular carcinoma (HCC) in a pre-existing liver adenoma in a morphologically normal liver.
Genes changed in pre-B lymphoblastic leukemia cells with BCR-ABL1 fusion [GeneID=613, 25] vs normal pre-B lymphocytes.
Genes in the most frequently heterozygous deleted loci of a panel of glioma cell lines.
Genes in the most frequently gained loci in a panel of glioma cell lines.
Cluster 1: ATM [GeneID=472] dependent genes induced at 30 min after ionizing radiation treatment.
Cluster 2: late ATM [GeneID=472] dependent genes induced by ionizing radiation treatment.
Cluster 3: genes activated by ionizing radiation regardless of ATM [GeneID=472] status.
Cluster 4: genes repressed by ionizing radiation regardless of ATM [GeneID=472] status.
Cluster 5: early responding genes activated in ATM [GeneID=472] deficient but not in the wild type tissues.
Cluster 6: late responding genes activated in ATM [GeneID=472] deficient but not in the wild type tissues.
Known and putative targets of NFKB1 [GeneID=4790] identified among the ATM [GeneID=472] dependent, late responders to ionizing radiation.
Genes up-regulated in REF52 cells (embryonic fibroblast) by expression of E2F1 [GeneID=1869] that were also induced at 16 hr after serum stimulation.
Genes up-regulated in MDA-MB-231 cells (breast cancer) after knockdown of ZEB1 [GeneID=6935] by RNAi.
High-level amplifications detected in oral squamous cell carcinoma (OSCC) lines by array-CGH analysis.
Genes in the tumor suppressor cluster of the 3p21.3 region.
Interaction partners of class IIa histone deacetylases (HDAC).
Genes co-amplified within MYCN [GeneID=4613] in primary neuroblastoma tumors.
Genes up-regulated in REF52 cells (embryonic fibroblast) by expression of E2F1 [GeneID=1869] that were not induced at all at 16 hr after serum stimulation.
Proteins showing significant overexpression in lung cancer cell lines  relative to normal bronchial epithelial cell lines.
Genes with increased copy number that correlates with increased expression across six different lung adenocarcinoma cell lines.
Genes specifically up-regulated in Cluster IIb of urothelial cell carcinom (UCC) tumors.
Genes up-regulated among the high recurrence rate urothelial cell carcinoma (UCC) tumors.
Genes down-regulated in urothelial cell carcinoma (UCC) tumors with LOH on 9q as compared to the tumors showing retention.
Differentiation markers for normal alveolar epithelium cells.
Differentiation markers for normal bronchiolar and bronchial epithelial cells.
14 candidate differentiation markers in lung adenocarcinoma cells, noncancerous lung cells and peripheral blood cells.
Proteins acting on mitochondria to prevent membrane permeabilization.
Amplification hot spot 17: colocalized fragile sites and cancer genes in the 1q11-q44 region.
Amplification hot spot 24: colocalized fragile sites and cancer genes in the 1q21-q24 region.
Amplification hot spot 25: colocalized fragile sites and cancer genes in the 2q13-q36 region.
Amplification hot spot 7: colocalized fragile sites and cancer genes in the 3q26.3-q29 region.
Amplification hot spot 27: colocalized fragile sites and cancer genes in the 5p15.3-p15.1; 5p12-q35 region.
Amplification hot spot 15: colocalized fragile sites and cancer genes in the 6p25-p11.1 region.
Amplification hot spot 29: colocolized fragile sites and cancer genes in the 7p22-p13 region.
Amplification hot spot 9: colocolized fragile sites and cancer genes in the 8p23-q12; 8q23 region.
Amplification hot spot 16: colocolized fragile sites and cancer genes in the 8q11.1-q24.3 region.
Amplification hot spot 14: colocolized fragile sites and cancer genes in the 8q24.1-q24.3 region.
Genes down-regulated in Rh4 cells (alveolar rhabdomyosarcoma, ARMS) after knockdown of the PAX3-FOXO1 [GeneiD=5077;2308] fusion protein by RNAi for 72 hr.
Muscle development genes up-regulated in Rh4 cells (alveolar rhabdomyosarcoma, ARMS) but not in the RD cells (embryonal rhabdomyosarcoma, ERMS) after knockdown of PAX3-FOXO1 [GeneID=5077;2308] fusion by RNAi for 72 hr.
Genes up-regulated by TP53 [GeneID=7157]  and down-regulated by an isoform of TP63 [GeneID=8626] in primary HEK cells (epidermal keratinocytes).
Amplification hot spot 8: colocolized fragile sites and cancer genes in the 9q11-34 region.
Amplification hot spot 23: colocolized fragile sites and cancer genes in the 11q12-q25 region.
Amplification hot spot 11: colocolized fragile sites and cancer genes in the 11q3 region.
Amplification hot spot 2: colocolized fragile sites and cancer genes in the 12p13-p11.1 region.
Amplification hot spot 21: colocolized fragile sites and cancer genes in the 12q13-q21 region.
Amplification hot spot 30: colocolized fragile sites and cancer genes in the 12q21-q24.3 region.
Amplification hot spot 3: colocolized fragile sites and cancer genes in the 15q21-q26 region.
Amplification hot spot 6: colocolized fragile sites and cancer genes in the 17p13-p11.1 region.
Amplification hot spot 12: colocolized fragile sites and cancer genes in the 17q11.1-q21; 17q25 region.
Genes changed in MGUS (monoclonal gammopathy of undetermined significance) compared to PCL (plasma cell leukemia) samples.
Genes distinguishing between MGUS (monoclonal gammopathy of undetermined significance) and multiple myeloma (MM) samples.
Genes which best discriminate between two groups of breast cancer according to the status of ESR1 and AR [GeneID=2099;367]: apocrine (ESR1- AR+) and luminal (ESR1+ AR+).
Genes which best discriminate between two groups of breast cancer according the status of ESR1 and AR [GeneID=2099;367]: apocrine (ESR1- AR+) vs basal (ESR1- AR-).
Genes which best discriminated between two groups of breast cancer according to the status of ESR1 and AR [GeneID=2099;367]: basal (ESR1- AR-) and luminal (ESR1+ AR+).
Amplification hot spot 5: colocolized fragile sites and cancer genes in the 17q22-q25 region.
Amplification hot spot 18: colocolized fragile sites and cancer genes in the 18q11.2-q23 region.
Cluster 1: genes with similar expression profiles across follicular thyrorid carcinoma (FTC) samples.
Cluster 2: genes with similar expression profiles across follicular thyroid carcinoma (FTC) samples.
Cluster 3: genes with similar expression profiles across follicular thyrorid carcinoma (FTC) samples; genes in this cluster correlated well with the presence of PAX8-PPARG [GeneID=7849;5468] fusion protein.
Cluster 4: genes with similar expression profiles across follicular thyroid carcinoma (FTC) samples.
Cluster 5: genes with similar expression profiles across follicular thyroid carcinoma (FTC) samples.
Amplification hot spot 22: colocolized fragile sites and cancer genes in the 22q11.1-q13s region.
Amplification hot spot 1: colocolized fragile sites and cancer genes in the Xp22.3-p11.1 region.
Amplification hot spot 13: colocolized fragile sites and cancer genes in the Xq12-q28 region.
Genes changed in retinoblastoma tumors with respect to chromosome 6p amplifications.
Genes down-regulated in follicular thyroid carcinoma (FTC) samples that bear PAX8-PPARG [GeneID=7849;5468] fusion protein.
Cluster 1: genes up-regulated in B493-6 cells (B lymphocytes) upon serum stimulation but not by affected by MYC [GeneID=4609].
Cluster 2: genes up-regulated in B493-6 cells (B lymphocytes) by serum alone or in combination with MYC [GeneID=4609] but not by MYC alone.
Cluster 3: genes strongly up-regulated in B493-6 cells (B lymphocytes) by a combination of MYC [GeneID=4609] and serum but not by each of them alone.
Cluster 7: genes up-regulated in B493-6 cells (B lymphocytes) by MYC [GeneID=4609] and down-regulated by the combination of MYC and serum.
Cluster 6: genes down-regulated in B493-6 cells (B lymphocytes) by MYC [GeneID=4609] in combination with serum but not affected by serum alone; they are also up-regulated by MYC alone.
Cluster 5: genes up-regulated in B493-6 cells (B lymphocytes) by MYC [GeneID=4609] alone or in combination with serum but not by serum alone.
Cluster 4: genes down-regulated in B493-6 cells (B lymphocytes) upon serum stimulation but not affected by MYC [GeneID=4609].
Genes differentially expressed in multiple myeloma (MM) patients: comparison of MGUS-like vs PCL-like samples; MGUS=monoclonal gammopathy of undetermined significance, PCL=plasma cell leukemia.
Genes expressed in multiple myeloma (MM) patients carrying specific translocations involving the immunoglobulin heavy chain (IGH) locus at 14q32.
Cluster 1: interferon, T and B lymphocyte genes clustered together across breast cancer samples.
Cluster 8: selected ERBB2 [GeneID=2064] amplicon genes clustered together across breast cancer samples.
Cluster 7: selected apocrine and luminal genes clustered together across breast cancer samples.
Cluster 2: selected proliferation and 8q amplicon genes clustered together across breast cancer samples.
The 'Cervical Cancer Proliferation Cluster' (CCPC): genes whose expression in cervical carcinoma positively correlates with that of the HPV E6 and E7 oncogenes; they are also differentially expressed according to disease outcome.
Genes encoding IkappaB kinase (IKK) interacting proteins.
Genes whose expression was increased due to copy number gain in laryngeal cancer tumors (both in primary cultures and cell lines).
Genes from selected recurrently amplified regions in soft tissue tumors with supernumerary  ring chromosomes.
Genes from selected recurrently amplified regions in bone tissue tumors with supernumerary  ring chromosomes.
Candidate substrate proteins of AURKA [GeneID=6790].
Candidate substrate proteins of AURKB [GeneID=9212].
Genes up-regulated in MM-LH cells (malignant melanoma) after treatment with the HDAC inhibitor romidepsin (FK228) [PubChem=5352062].
Genes up-regulated in cells expressing MEN1 [GeneID=4221].
Genes changed in H1299 cells (non-small cell lung cancer, NSCLC) transiently transfected to express the TP63 [GeneID=8626] gamma splice variant.
Genes up-regulated in FE-8 cells (fibroblasts) upon treatment with azacitidine [PubChem=9444].
Genes distinguishing between breast cancer tumors bearing mutations in BRCA1 [GeneID=672] and those with mutated BRCA2 [GeneID=675].
Genes up-regulated in DU145-RD cells (prostate cancer) resistant to docetaxel [PubChem=148124] vs the parental, docetaxel-sensitive cells.
Genes up-regulated by growing HMEC-E6 cells (mammary epithelial cells damaged by expression of HPV-16 E6 [GeneID=1489078]) in extracellular matrix (ECM).
Genes up-regulated  by tamoxifen [PubChem=5376] in HMEC-E6 cells (mammary epithelial cells damaged by expression of HPV-16 E6 [GeneID=1489078]).
Genes up-regulated in T47D cells (breast cancer) after COBRA1 [GeneID=25920] knockdown by RNAi.
Genes down-regulated in T47D cells (breast cancer) after COBRA1 [GeneID=25920] knockdown by RNAi.
Genes consistently down-regulated in ACRP cells (ovarian cancer, resistant to cisplatin [PubChem=2767]) compared to the parental sensitive A2780 cells, regardless of cisplatin exposure.
Genes consistently up-regulated in ACRP cells (ovarian cancer, resistant to cisplatin [PubChem=2767]) compared to the parental sensitive A2780 cells, regardless of cisplatin exposure.
Genes up-regulated in MCF7 cells (breast cancer, normal TP53 [GeneID=7157]) undergoing aberrant mitosis and necrosis after treatment wiht 4 nM docetaxel [PubChem=148124].
Genes down-regulated in MCF7 cells (breast cancer, normal TP53 [GeneID=7157]) undergoing aberrant mitosis and necrosis after treatment wiht 4 nM docetaxel [PubChem=148124].
Genes up-regulated in MCF7 cells (breast cancer, normal TP53 [GeneID=7157]) undergoing mitotic arrest and apoptosis after treatment with 100 nM docetaxel [PubChem=148124].
Genes down-regulated in MCF7 cells (breast cancer, normal TP53 [GeneID=7157]) undergoing mitotic arrest and apoptosis after treatment with 100 nM docetaxel [PubChem=148124].
Genes up-regulated in MDA-MB-231 cells (breast cancer, mutated TP53 [GeneID=7157]) undergoing aberrant mitosis and necrosis after treatment with 2 nM docetaxel [PubChem=148124].
Genes down-regulated in MDA-MB-231 cells (breast cancer, mutated TP53 [GeneID=7157]) undergoing aberrant mitosis and necrosis after treatment with 2 nM docetaxel [PubChem=148124].
Genes up-regulated in MDA-MB-231 cells (breast cancer, mutated TP53 [GeneID=7157]) undergoing mitotic arrest and apoptosis after treatment with 100 nM docetaxel [PubChem=148124].
Genes down-regulated in MDA-MB-231 cells (breast cancer, mutated TP53 [GeneID=7157]) undergoing mitotic arrest and apoptosis after treatment with 100 nM docetaxel [PubChem=148124].
Genes changed similarly in DU-145 cells (prostate cancer) in the absence and presence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 6 h.
Genes changed in DU-145 cells (prostate cancer) in the absence but not presence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 6 h.
Genes up-regulated in DU-145 cells (prostate cancer) in the absence and presence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 48 h.
Genes down-regulated in DU-145 cells (prostate cancer) in the absence and presence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 48 h.
Genes up-regulated in DU-145 cells (prostate cancer) in the absence but not in the presence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 48 h.
Genes down-regulated in DU-145 cells (prostate cancer) in the absence but not in the presence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 48 h.
Genes up-regulated in DU-145 cells (prostate cancer) in the presence but not in the absence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 48 h.
Genes down-regulated in DU-145 cells (prostate cancer) in the presence but not in the absence of a dominant negative form of AKT1 [GeneID=207] upon exposure to HGF [GeneID=3082] for 48 h.
Genes up-regulated in DU-145 cells (prostate cancer) expressing a dominant negative form of AKT1 [GeneID=207] upon sham-treatment for 6 h (as a control for the HGF [GeneID=3082] experiments).
Genes up-regulated in DU-145 cells (prostate cancer) expressing a dominant negative form of AKT1 [GeneID=207] upon sham-treatment for 48 h (as a control for the HGF [GeneID=3082] experiments).
Genes up-regulated in glioma cell lines after knockdown of SPARC [GeneID=6678] by RNAi.
Genes down-regulated in glioma cell lines after knockdown of SPARC [GeneID=6678] by RNAi.
Subunits of the anaphase promoting complex (APC).
Angiogenic and metastatic genes changed in RKO cells (colorectal cancer) upon perturbation of key components of AKT pathway.
Genes up-regulated in acute myeloid leukemia (AML) samples with constitutively activated FLT3 [GeneID=2322] or with activating point mutations within NRAS [GeneID=4893].
Genes down-regulated in acute myeloid leukemia (AML) samples with constitutively activated FLT3 [GeneID=2322] or with activating point mutations within NRAS [GeneID=4893].
Clusters 1 and 2: genes up-regulated in B2264-19/3 cells (primary B lymphocytes) within 30-60 min after activation of LMP1 (an oncogene encoded by Epstein-Barr virus, EBV).
A gene expression signature found in a subset of cancer patients suggestive of a deregulated immune or inflammatory response.
Genes discriminating TP53 [GeneID=7157] status across various genotoxic stress agents.
Genes from the recurrent amplicons in 89 samples of oral squamous cell carcinoma (SCC).
Genes regulated by CTNNB1 [GeneID=1499] and whose promoters contain binding sites for LEF1 [GeneID=51176].
Genes within the smallest region of consistend deletion (SRD) within 1p36.3 area across a large collection of neuroblastoma cell lines and biopsy samples.
Genes up-regulated in SaOS-2 cells (osteosarcoma) upon expression of PAX3-FOXO1 [GeneID=5077;2308] but down-regulated by PAX3 expression off adenoviral vectors.
Genes bound by EWSR1-FLT1 [GeneID=2130;2321] fusion but whose expression did not change in STA-ET-7.2 cells (Ewing's sarcoma) after knockdown of EWSR1-FLT1 by RNAi.
Top 50 genes up-regulated in A549 cells (lung cancer) expressing STAT3 [GeneID=6774] off an adenovirus vector.
Top 50 genes down-regulated in A549 cells (lung cancer) expressing STAT3 [GeneID=6774] off an adenovirus vector.
Genes up-regulated in hepatocellular carcinoma (HCC) compared to normal liver samples.
Genes predicting the embryonic carcinoma (EC) subtype of nonseminomatous male germ cell tumors (NSGCT).
Genes predicting the teratoma (T) subtype of nonseminomatous male germ cell tumors (NSGCT).
Genes predicting the yolk sac tumor (YS) subtype of nonseminomatous male germ cell tumors (NSGCT).
Genes predicting the choriocarcinoma (CC) of nonseminomatous male germ cell tumors (NSGCT).
Genes up-regulated in MDA468 cells (breast cancer) vs DU99 cells (normal breast) after treatment with azacytidine [PubChem=9444].
Genes amplified and up-regulated more than twofold in at least two out of 10 pancreatic cancer cell lines studied.
Cluster 1: genes whose up-regulation peaked one day after knockdown of OPN [GeneID=6696] by RNAi in the NIH3T3 cells (fibroblasts) transformed by activated HRAS [GeneID=3265].
Cluster 3: genes whose up-regulation peaked 3 days after knockdown of OPN [GeneID=6696] by RNAi in the NIH3T3 cells (fibroblasts) transformed by activated HRAS [GeneID=3265].
Cluster 4: genes whose up-regulation peaked 4 days after knockdown of OPN [GeneID=6696] by RNAi in the NIH3T3 cells (fibroblasts) transformed by activated HRAS [GeneID=3265].
Cluster 5: genes whose up-regulation peaked 5 days after knockdown of OPN [GeneID=6696] by RNAi in the NIH3T3 cells (fibroblasts) transformed by activated HRAS [GeneID=3265].
Cluster 6:  genes exhibiting prolonged up-regulation (>72 h) after knockdown of OPN [GeneID=6696] by RNAi in the NIH3T3 cells (fibroblasts) transformed by activated HRAS [GeneID=3265].
Cluster 7: genes down-regulated early (within 24 h) after knockdown of OPN [GeneID=6696] by RNAi in the NIH3T3 cells (fibroblasts) transformed by activated HRAS [GeneID=3265].
Cluster 8: genes showing sustained pattern of down-regulation after knockdown of OPN [GeneID=6696] by RNAi in the NIH3T3 cells (fibroblasts) transformed by activated HRAS [GeneID=3265].
Genes up-regulated in Kelly cells (neuroblastoma) by overexpressing INHBA [GeneID=3624] off a plasmid vector.
Genes down-regulated in Kelly cells (neuroblastoma) by overexpressing INHBA [GeneID=3624] off a plasmid vector.
Genes up-regulated in CT60/4 cells (breast cancer reverted to normal by transfer of chromosome 8p region) vs parental MDA-MB-231 cells (deleted chromosome 8p).
Genes down-regulated in CT60/4 cells (breast cancer reverted to normal by transfer of chromosome 8p region) vs parental MDA-MB-231 cells (deleted chromosome 8p).
Genes down-regulated in HUVEC cells (endothelium) by ETS1 [GeneID=2113] which were up-regulated by SP100 [GeneID=6672].
Genes up-regulated in HUVEC cells (endothelium) by ETS1 [GeneID=2113] which were down-regulated by SP100 [GeneID=6672].
Genes up-regulated in gastrointestinal stromal tumors (GIST) with PDGFRA [GeneID=5156] mutations.
Genes down-regulated in gastrointestinal stromal tumors (GIST) with PDGFRA [GeneID=5156] mutations.
Genes up-regulated in low grade (LMP and G1) serous ovarian carcinomas vs the higher grade invasive tumors (G2 and G3).
Genes down-regulated in low grade (LMP and G1) serous ovarian carcinomas vs the higher grade invasive tumors (G2 and G3).
Genes up-regulated in fibroblasts expressing different mutant forms of ERCC3 [GeneID=2071]: XP/CS (xeroderma pigmentosum (XP) and Cockraine's syndrome (CS)) vs TTD (trichothiodystrophy).
Genes down-regulated in fibroblasts expressing different mutant forms of ERCC3 [GeneID=2071]: XP/CS (xeroderma pigmentosum (XP) and Cockraine's syndrome (CS)) vs TTD (trichothiodystrophy).
Genes up-regulated in fibroblasts expressing the XP/CS mutant form of ERCC3 [GeneID=2071], after low dose UVC irradiation.
Genes down-regulated in fibroblasts expressing the XP/CS mutant form of ERCC3 [GeneID=2071], after low dose UVC irradiation.
Genes up-regulated in fibroblasts expressing mutant forms of ERCC3 [GeneID=2071] after UV irradiation.
Genes down-regulated in fibroblasts expressing mutant forms of ERCC3 [GeneID=2071] after UV irradiation.
Common down-regulated transcripts in fibroblasts expressing either XP/CS or TDD mutant forms of ERCC3 [GeneID=2071], after UVC irradiation.
Cluster 3: genes up-regulated in B2264-19/3 cells (primary B lymphocytes) within 60-180 min after activation of LMP1 (an oncogene encoded by Epstein-Barr virus, EBV).
Cluster 4: genes down-regulated in B2264-19/3 cells (primary B lymphocytes) within 60-180 min after activation of LMP1 (an oncogene encoded by Epstein-Barr virus, EBV).
Up-regulated genes whose expression is associated with amplification of the 8q24 chromosome region in pancreatic cancer cell lines.
Down-regulated genes whose expression is associated with amplification of the 8q24 chromosome region in pancreatic cancer cell lines.
Up-regulated genes whose expression is associated with amplification of the 12p11-12 chromosome in pancreatic cancer cell lines.
Down-regulated genes whose expression is associated with amplification of the 12p11-12 chromosome in pancreatic cancer cell lines.
Genes discriminating genotoxic (DNA damaging) agents from other kinds of stresses.
Genes discriminating responses to sodium arsenite [PubChem=26435] from other stresses.
Genes up-regulated by IL2 [GeneID=3558] in T1 cells (primary thymocytes immortalized by Tax, an HTLV-1 encoded gene).
Genes up-regulated by IL2 [GeneID=3558] in both primary thymocytes and T1 cells (primary thymocytes immortalized by Tax, an HTLV-1 encoded gene).
Genes with putative STAT5 [GeneID=6777] binding sites; up-regulated by IL2 [GeneID=3558] only in T1 cells (primary thymocytes immortalized by Tax, an HTLV-1 encoded gene).
Genes with putative STAT5 [GeneID=6777] binding sites; up-regulated by IL2 [Gene D=3558] in both primary thymocytes and T1 cells (primary thymocytes immortalized by Tax, an HTLV-1 encoded gene).
Genes up-regulated in DLD1 cells (colon cancer) by p73 beta [GeneID=7161] or by and p63 gamma [GeneID=8626] but not by p53 [GeneID=7157].
Genes down-regulated in U2-OS Tet-On cells (osteosarcoma) after induction of ESX1 [GeneID=80712] expression.
Genes most up-regulated in hypoxia tolerant NCI H460 cells (lung cancer).
Genes most down-regulated in hypoxia tolerant NCI H460 cells (lung cancer).
Genes up-regulated in bladder cancer cells resistant to cisplatin [PubChem=2767] compared to the parental cells sensitive to the drug.
Genes down-regulated in bladder cancer cells resistant to cisplatin [PubChem=2767] compared to the parental cells sensitive to the drug.
Genes up-regulated by hypoxia in RCC4 cells (renal cell carcinoma) engineered to stably express VHL [GeneID=7428] off a plasmid vector.
Genes up-regulated in apoptotic tissues (neuroepithelium) after MDM4 [GeneID=4194] knockout.
Genes down-regulated in apoptotic tissues (neuroepithelium) after MDM4 [GeneID=4194] knockout.
Genes up-regulated in non-apoptotic tissues (fetal liver) after MDM4 [GeneID=4194] knockout.
Genes down-regulated in non-apoptotic tissues (fetal liver) after MDM4 [GeneID=4194] knockout.
Selected up-regulated genes distinguishing between Wilms tumors of different histological types: anaplastic vs favorable histology.
Selected down-regulated genes distinguishing between Wilms tumors of different histological types: anaplastic vs favorable histology.
Genes up-regulated in hepatocellular carcinoma (HCC) developed by transgenic mice overexpressing a secretable form of EGF [GeneID=1950] in liver.
Genes up-regulated in HCT116 cells (colon cancer) after treatment with amifostine [PubChem=2141] depending on the presence of TP53 [GeneID=7157]: TP53-positive vs TP53-null cells.
Genes down-regulated in HCT116 cells (colon cancer) after treatment with amifostine [PubChem=2141] depending on the presence of TP53 [GeneID=7157]: TP53-positive vs TP53-null cells.
Genes up-regulated in IEC-18 cells (intestinal epithelial cells) which avoided anoikis (a form of apoptosis) after detachment.
Genes that classify skin lesions into high risk papilloma.
Genes that classify skin lesions into low risk papilloma.
Genes up-regulated in the UMUC-3 cells (bladder cancer) after knockdown of RALA [GeneID=5898] by RNAi.
Genes down-regulated in the UMUC-3 cells (bladder cancer) after knockdown of RALA [GeneID=5898] by RNAi.
Genes down-regulated in the UMUC-3 cells (bladder cancer) after knockdown of RALB [GeneID=5899] by RNAi.
Genes up-regulated in the UMUC-3 cells (bladder cancer) after knockdown of RALB [GeneID=5899] by RNAi.
Genes up-regulated in the UMUC-3 cells (bladder cancer) after knockdown of both RALA and RALB [GeneID=5898;5899] by RNAi.
Genes down-regulated in the UMUC-3 cells (bladder cancer) after knockdown of both RALA and RALB [GeneID=5898;5899] by RNAi.
Genes up-regulated after knockdown of RALA or RALB [GeneiD=5898;5899], which were also differentially expressed in bladder cancer compared to normal bladder urothelium tissue.
Genes down-regulated after knockdown of RALA or RALB [GeneiD=5898;5899], which were also differentially expressed in bladder cancer compared to normal bladder urothelium tissue.
Genes up-regulated between two breast carcinoma subtypes: metaplastic (MCB) and ductal (DCB).
Genes down-regulated between two breast carcinoma subtypes: metaplastic (MCB) and ductal (DCB).
Genes up-regulated in the Ad/AH cells (adenocarcinoma) engineered to stably express the Epstein-Barr virus (EBV) gene EBNA1.
Genes down-regulated in the Ad/AH cells (adenocarcinoma) engineered to stably express the Epstein-Barr virus (EBV) gene EBNA1.
Up-regulated in MCF7 cells (breast cancer) by HOXA1 [GeneID=3198].
Down-regulated in MCF7 cells (breast cancer) by HOXA1 [GeneID=3198].
Genes up-regulated in non-spontaneously immortalizing (NSI) primary breast cancer tumor cultures upon expression of TERT [GeneID=7015] off a retroviral vector.
Genes down-regulated in non-spontaneously immortalizing (NSI) primary breast cancer tumor cultures upon expression of TERT [GeneID=7015] off a retroviral vector.
Genes hypermethylated in at least one of the lymphoma tumors of transgenic mice overexpressing TCL1 [GeneID=8115] in germinal center B lymphocytes.
Selected genes up-regulated in WT-A10 cells (gastric epithelium) expressing the H. pilori virulence gene CagA.
Genes with the high-CpG-density promoters (HCP) that were up-regulated in 1542-CP3TX cells (prostate cancer) compared to 1542-NPTX (normal prostate).
Genes up-regulated in early vs late brain tumors induced by retroviral delivery of PDGFB [GeneID=5155].
Genes down-regulated in early vs late brain tumors induced by retroviral delivery of PDGFB [GeneID=5155].
Genes up-regulated by telomere shortening due to the knockout of TERC [GeneID=7012] in the presence of chronic liver damage.
Genes down-regulated by telomere shortening due to the knockout of TERC [GeneID=7012] in the presence of chronic liver damage.
Genes up-regulated in RCC4 cells (renal cell carcinoma) engineered to stably express VHL [GeneID=7428] off a plasmid vector.
Genes down-regulated in RCC4 cells (renal cell carcinoma) engineered to stably express VHL [GeneID=7428] off a plasmid vector.
Genes up-regulated in pancreatic ductal adenocarcinoma (PDAC) identified in a meta analysis across four independent studies.
Genes down-regulated in pancreatic ductal adenocarcinoma (PDAC) identified in a meta analysis across four independent studies.
Genes up-regulated in PANC-1-puro cells (pancreatic cancer) stimulated by TGF1B [GeneID=7040] for 2 h.
Genes down-regulated in PANC-1-puro cells (pancreatic cancer) stimulated by TGF1B [GeneID=7040] for 2 h.
Genes up-regulated in PANC-1-S4KD cells (pancreatic cancer; SMAD4 [GeneID=4089] knocked down by RNAi) after stimulation by TGF1B [GeneID=7040] for 2 h.
Genes down-regulated in PANC-1-S4KD cells (pancreatic cancer; SMAD4 [GeneID=4089] knocked down by RNAi) after stimulation by TGF1B [GeneID=7040] for 2 h.
Genes up-regulated in Wilm's tumor vs fetal kidney.
Genes down-regulated in Wilm's tumor vs fetal kidney.
Genes up-regulated in HFK cells (primary keratinocytes) in response to UVB irradiation.
Genes down-regulated in HFK cells (primary keratinocytes) in response to UVB irradiation.
Genes down-regulated in response to UVB radiation in HFK cells (keratinocytes) immortalized by overexpression of HPV E6 and E7 viral oncogenes.
Genes up-regulated in K562 cells (chronic myelogenous leukemia, CML) expressing TP53 and MYC [GeneID=7157;4609].
Genes down-regulated in K562 cells (chronic myelogenous leukemia, CML) expressing TP53 and MYC [GeneID=7157;4609].
Up-regulated genes characteristic to the squamous cell carcinoma (SCC) type of non-small cell lung cancer (NSCLC).
Down-regulated genes characteristic to the squamous cell carcinoma (SCC) type of non-small cell lung cancer (NSCLC).
Up-regulated genes discriminating between two subtypes of squamous cell carcinoma (SCC) type of non-small cell lung cancer: SSC-A vs SSC-B.
Down-regulated genes discriminating between two subtypes of squamous cell carcinoma (SCC) type of non-small cell lung cancer: SSC-A vs SSC-B.
Up-regulated genes characteristic for autonomous thyroid adenoma.
Down-regulated genes characteristic for autonomous thyroid adenoma.
Genes down-regulated in MEF and REF cells (mouse and rat fibroblasts) but not in TIG3/T cells (human lung fibroblasts expressing TERT [GeneID=7015]) by co-expression of the SV40 early region and the activated HRAS (H-RasV12) [GeneID=3265].
Genes positively correlated with amplifications of MYC [GeneID=4609] in SCLC (small cell lung cancer) cell lines.
Genes negatively correlated with amplifications of MYC [GeneID=4609] in SCLC (small cell lung cancer) cell lines.
Genes positively  correlated with amplifications of MYCN  [GeneID=4613] in the SCLC (small cell lung cancer) cell lines.
Genes negatively  correlated with amplifications of MYCN  [GeneID=4613] in the SCLC (small cell lung cancer) cell lines.
Genes positively correlated with amplifications of MYCL1 [GeneID=4610] in SCLC (small cell lung cancer) cell lines.
Genes negatively correlated with amplifications of MYCL1 [GeneID=4610] in SCLC (small cell lung cancer) cell lines.
Genes up-regulated in TK6, WTK1, and NH32 cell lines (lymphoblast) in response to ionizing radiation.
Genes up-regulated in early primary breast tumors expressing ESR1 [GeneID=2099] vs the ESR1 negative ones.
Genes down-regulated in early primary breast tumors expressing ESR1 [GeneID=2099] vs the ESR1 negative ones.
Genes up-regulated in laser microdissected (LCM) samples of early primary breast tumors expressing ESR1 [GeneID=2099] vs the ESR1 negative ones.
Genes down-regulated in laser microdissected (LCM) samples of early primary breast tumors expressing ESR1 [GeneID=2099] vs the ESR1 negative ones.
Genes up-regulated in bulk samples from early primary breast tumors expressing ESR1 [GeneID=2099] vs the ESR1 negative samples.
Genes down-regulated in bulk samples from early primary breast tumors expressing ESR1 [GeneID=2099] vs the ESR1 negative samples.
Genes up-regulated in the mouse lung cancer model and which reverted to normal levels upon treatment with bexarotene [PubChem=82146].
Genes down-regulated in the mouse lung cancer model and which reverted to normal levels upon treatment with bexarotene [PubChem=82146].
Selected genes up-regulated in Rat1Ras cells (fibroblasts) which were transformed by expression of an oncogenic activated form of HRAS [GeneID=3265] compared to the parental Rat1 cells.
Genes down-regulated in SK-N-DZ cells (neuroblastoma) after knockdown of MIF [GeneID=4282] by antisense RNA.
Genes up-regulated in H1299 cells (non-small cell lung cancer, NSCLC) expressing the Y144F mutant form of FHIT [GeneID=2272].
Genes down-regulated in H1299 cells (non-small cell lung cancer, NSCLC) expressing the Y144F mutant form of FHIT [GeneID=2272].
Genes down-regulated in preleukemic thymocytes from transgenic mice which overexpress TAL1 [GeneID=6886] in thymus.
Genes up-regulated in SiHa cells (cervical carcinoma) by stable expression of NOL7 [GeneID=51406] off a plasmid vector.
Genes down-regulated in SiHa cells (cervical carcinoma) by stable expression of NOL7 [GeneID=51406] off a plasmid vector.
Genes up-regulated in HSC-2/8 cells (chondrosarcoma) under hypoxic conditions.
Genes up-regulated in pubertal mammary glands compared to mammary glands from other developmental stages.
Genes up-regulated in ESFT cells (Ewing's sarcoma family of tumors) after knockdown of CD99 [GeneID=4267] by RNAi.
Genes down-regulated in ESFT cells (Ewing's sarcoma family of tumors) after knockdown of CD99 [GeneID=4267] by RNAi.
Genes with hypermethylated DNA in lung cancer samples.
Genes with unmethylated DNA in lung cancer samples.
Genes up-regulated in neuroblastoma xenografts: sensitive vs resistant to the topoisomerase inhibitor irinotecan [GeneID=3750].
Genes down-regulated in neuroblastoma xenografts: sensitive vs resistant to the topoisomerase inhibitor irinotecan [GeneID=3750].
Genes up-regulated in neuroblastoma xenografts: resistant vs those that reverted to be sensitive to the topoisomerase inhibitor irinotecan [PubChem=3750].
Genes down-regulated in neuroblastoma xenografts: resistant vs those that reverted to be sensitive to the topoisomerase inhibitor irinotecan [PubChem=3750].
Genes up-regulated in PCI-35 cells (pancreatic cancer, lack endogenous DUSP6 [GeneID=1848]) upon expression of DUSP6 off an adenoviral vector.
Genes down-regulated in PCI-35 cells (pancreatic cancer, lack endogenous DUSP6 [GeneID=1848]) upon expression of DUSP6 off an adenoviral vector.
Genes specifically up-regulated via JNK (MAPK8) [GeneID=5599] signaling pathway activated by paclitaxel [PubChem=4666] in BR cells (ovarian cancer).
Genes specifically down-regulated via JNK (MAPK8) [GeneID=5599] signaling pathway activated by paclitaxel [PubChem=4666] in BR cells (ovarian cancer).
Genes up-regulated by TGFB1 [GeneID=7040] in MCF10A cells (breast cancer): both wild-type and those lacking p21 [GeneID=1026].
Cluster PAM1: genes up-regulated in hepatocellular carcinoma (HCC) vs normal liver tissue from mice deficient for TXNIP [GeneID=10628].
Cluster PAM2: genes up-regulated in hepatocellular carcinoma (HCC) vs normal liver tissue from mice deficient for TXNIP [GeneID=10628].
Cluster PAM3: genes most highly up-regulated in hepatocellular carcinoma (HCC) vs normal liver tissue from mice deficient for TXNIP [GeneID=10628].
Cluster PAM4: genes down-regulated in hepatocellular carcinoma (HCC) vs normal liver tissue from mice deficient for TXNIP [GeneID=10628].
Cluster PAM5: genes changed exclusively in hepatocellular carcinoma (HCC) samples from 27 month old mice deficient for TXNIP [GeneID=10628].
Cluster PAM6: genes changed exclusively in normal liver tissue adjacent to hepatocellular carcinoma (HCC) from mice deficient for TXNIP [GeneID=10628].
Genes up-regulated in metaplastic carcinoma of the breast (MCB) subclass 2 compared to the MCB subclass 1.
These genes form a a network that controls specific processes downstream of PDGF signaling.
Genes up-regulated in prostate cancer vs benign prostate tissue, based on a meta-analysis of five gene expression profiling studies.
Genes down-regulated in prostate cancer vs benign prostate tissue, based on a meta-analysis of five gene expression profiling studies.
Top genes up-regulated in hormone refractory metastatic prostate cancer compared to localized prostate cancer.
Top genes down-regulated in hormone refractory metastatic prostate cancer compared to localized prostate cancer.
Genes up-regulated in LSK cells (bone marrow) as a function of a QTL for the size of hematopoietic stem cell (HSC) population: comparison of congenic B.D. chr3 (BD, large HSC size) vs parental B6 strain (tiny HSC size).
Genes down-regulated in LSK cells (bone marrow) as a function of a QTL for the size of hematopoietic stem cell (HSC) population: comparison of congenic B.D. chr3 (BD, large HSC size) vs parental B6 strain (tiny HSC size).
Genes up-regulated in LSK cells (bone marrow) as a function of a QTL for the size of hematopoietic stem cell (HSC) population: comparison of congenic D.B. Chr 3 (DB, small HSC population) vs parental D2 strain (huge HSC population).
Genes down-regulated in LSK cells (bone marrow) as a function of a QTL for the size of hematopoietic stem cell (HSC) population: comparison of congenic D.B. Chr 3 (DB, small HSC population) vs parental D2 strain (huge HSC population).
Genes up-regulated more than two-fold in lymphoblastoid cell lines from European population compared to those from Asian population.
Genes down-regulated more than two-fold in lymphoblastoid cell lines from European population compared to those from Asian population.
Genes up-regulated in lymphoblastoid cells from the European population compared to those from the Asian population.
Genes down-regulated in lymphoblastoid cells from the European population compared to those from the Asian population.
Genes up-regulated in fetal liver (days E13.5 and E15.5) samples from embryo-specific Cre-lox knockout of MAPK14 [GeneID=1432].
Genes involved in serotonin [PubChem=5202] function, orthologs computed from D. melanogaster genes using InsParanoid resource.
Candidate mammary tumorigenesis genes from the common insertion sites (CIS) of MMTV virus that induced breast tumors in mice.
Candidate genes in the pericentromeric microdeletion in 16p11.2-p12.2 associated with developmental disabilities.
Genes expressed in normal colon; they undergo down-regulation in tumors through DNA methylation.
Genes mapped to core duplicons - elements shared by a majority of segmental duplication blocks.
Genes constituting the LIT-Int network of proteins interacting with breast cancer reference proteins BRCA1, BRCA2, ATM, and CHEK2 [GeneID=672;675;472;11200]; the interactions were manually curated from the literature.
Genes constituting the XPRSS-Int network: intersection of genes whose expression correlates with BRCA1, BRCA2, ATM, and CHEK2 [GeneID=672;675;472;11200] in a compendium of normal tissues.
Genes constituting the BRCA1-PCC network of transcripts whose expression positively correlated (Pearson correlation coefficient, PCC >= 0.4) with that of BRCA1 [GeneID=672] across a compendium of normal tissues.
Genes constituting the BRCA2-PCC network of transcripts whose expression positively correlated (Pearson correlation coefficient, PCC >= 0.4) with that of BRCA2 [GeneID=675] across a compendium of normal tissues.
Genes constituting the ATM-PCC network of transcripts whose expression positively correlated (Pearson correlation coefficient, PCC >= 0.4) with that of ATM [GeneID=472] across a compendium of normal tissues.
Genes constituting the CHEK2-PCC network of transcripts whose expression positively correlates (Pearson correlation coefficient, PCC >= 0.4) with that of CHEK2 [GeneID=11200].
Genes constituting the BRCA-centered network (BCN).
Genes bearing the H3K27me3 mark in normal cells; their DNA is methylated in cancer cells.
Genes bearing H3K27me3 mark or whose promoters are bound by the polycomb proteins SUZ12 or EED [GeneID=23512;8726]; their DNA is methylated de novo in cancer.
Top scoring cis-regulated QTL (quantitative trait loci) influencing blood levels of high-density lipoprotein (HDL) cholesterol.
Top scoring trans-regulated expression quantitative trait loci (eQTL) influencing blood levels of high-density lipoprotein (HDL) cholesterol.
Retinoic acid-responsive genes up-regulated in hepatocellular carcinoma (HCC) samples of TRIM24 [GeneID=8805] knockout mice.
Retinoic acid-responsive genes down-regulated in hepatocellular carcinoma (HCC) samples of TRIM24 [GeneID=8805] knockout mice.
Genes showing frequent DNA methylation and which are silenced in adult cancers but remain unmethylated in embryonic carcinoma and embryonic stem (ES) cells.
Genes with a high basal transcription state in undifferentiated embryonic carcinoma cells.
Genes with low to medium basal transcription state in undifferentiated embryonic carcinoma cells.
Genes able to induce cell death in an expression cDNA library screen.
Genes in the smallest region of deletion (SRD) in 1p36.3 area in neuroblastoma samples.
Genes down-regulated by MYCN [GeneID=4613] but not by its transactivation-defficient, trunkated form N-Myc-delta-73.
Genes uniquely up-regulated in SEND cells (skin endothelium) at hypoxia after knockdown of HIF1A [GeneID=3091] by RNAi.
Genes that distinguish normal from cancer (lung adenocarcinoma) samples and smokers from non-smoking subjects.
Potential targets of MIR125B1 [GeneID=406911] microRNA which are up-regulated in prostate cancer.
Angiogenic genes up-regulated in A17 carcinomas (high vascularization) compared to the syngeneic BB1 and spontaneous tumors (little vascularization).
Stemness-related genes changed in A17 carcinomas (MTC, mesenchymal tumor cells) compared with the mesenchymal stem cells (MSC).
DNA repair and replication genes up-regulated in melanoma patients who will relapse vs patients who will not.
DNA repair and replication genes down-regulated in melanoma patients who will relapse vs patients who will not.
The 'ER-alpha profile': genes up-regulated in T47D cells (breast cancer, ESR2 [GeneID=2100] Tet-Off) upon activation of ESR1 [GeneID=2099] by estradiol (E2) [PubChem=5757].
The 'ER-alpha profile': genes down-regulated in T47D cells (breast cancer, ESR2 [GeneID=2100] Tet-Off) upon activation of ESR1 [GeneID=2099] by estradiol (E2) [PubChem=5757].
Genes uniquely up-regulated in T47D cells (breast cancer) by induction of ESR2 [GeneID=2100] expression in the Tet-Off system.
Genes uniquely down-regulated in T47D cells (breast cancer) by induction of ESR2 [GeneID=2100] expression in the Tet-Off system.
Genes up-regulated in SEND cells (skin endothelium) at normal oxygen (normoxia) conditions after knockdown of ELK3 [GeneID=2004] by RNAi.
Genes down-regulated in SEND cells (skin endothelium) at normal oxygen (normoxia) conditions after knockdown of ELK3 [GeneID=2004] by RNAi.
Genes up-regulated in SEND cells (skin endothelium) at hypoxia with ELK3 [GeneID=2004] knockdown by RNAi.
Genes down-regulated in SEND cells (skin endothelium) at hypoxia with ELK3 [GeneID=2004] knockdown by RNAi.
Genes up-regulated in SEND cells (skin endothelium) at normal oxygen (normoxia) conditions after knockdown of HIF1A [GeneID=3091] by RNAi.
Genes down-regulated in SEND cells (skin endothelium) at normal oxygen (normoxia) conditions after knockdown of HIF1A [GeneID=3091] by RNAi.
Genes up-regulated in SEND cells (skin endothelium) at hypoxia after knockdown of HIF1A [GeneID=3091] by RNAi.
Genes down-regulated in SEND cells (skin endothelium) at hypoxia after knockdown of HIF1A [GeneID=3091] by RNAi.
Genes specifically up-regulated in SEND cells (skin endothelium) at hypoxia after knockdown of ELK3 [GeneID=2004] by RNAi.
Genes specifically down-regulated in SEND cells (skin endothelium) at hypoxia after knockdown of ELK3 [GeneID=2004] by RNAi.
Genes up-regulated in SEND cells (skin endothelium) at hypoxia after knockdown of ELK3 [GeneID=2004] and HIF1A [GeneID=3091] by RNAi.
Genes down-regulated in SEND cells (skin endothelium) at hypoxia after knockdown of ELK3 [GeneID=2004] and HIF1A [GeneID=3091] by RNAi.
Genes up-regulated in PC3 cells (prostate cancer) after knockdown of NIPP1 [GeneID=5511] by RNAi.
Genes down-regulated in PC3 cells (prostate cancer) after knockdown of NIPP1 [GeneID=5511] by RNAi.
Genes up-regulated in PC3 cells (prostate cancer) after knockdown of EZH2 [GeneID=2146] by RNAi.
Genes down-regulated in PC3 cells (prostate cancer) after knockdown of EZH2 [GeneID=2146] by RNAi.
Genes up-regulated in 10T1/2 cells (multipotent mesoderma) by expression of SHH [GeneID=6469].
Genes down-regulated in 10T1/2 cells (multipotent mesoderma) by expression of SHH [GeneID=6469].
NF-kB-controlled genes up-regulated in endothelial cells in response to viral GPCR protein.
NF-kB-controlled genes down-regulated in endothelial cells in response to viral GPCR protein.
Up-regulated genes in the expression signature of direct and paracrine viral GPCR signaling in endothelial cells.
Down-regulated genes in the expression signature of direct and paracrine viral GPCR signaling in endothelial cells.
Genes up-regulated in T24 (bladder cancer) cells in response to the photodynamic therapy (PDT) stress.
Genes down-regulated in T24 (bladder cancer) cells in response to the photodynamic therapy (PDT) stress.
Genes up-regulated in genomically unstable Ewing's sarcoma tumors compared to the stable ones.
Genes down-regulated in genomically unstable Ewing's sarcoma tumors compared to the stable ones.
Genes down-regulated in ST1 cells (adult T-cell leukemia, ATL) after knockdown of FRA2 [GeneID=2355] by RNAi.
Genes up-regulated in HeLa cells (cervical cancer) after simultaneus knockdown of all three MBD (methyl-CpG binding domain) proteins MeCP2, MBD1 and MBD2 [GeneID=4204;4152;8932] by RNAi.
X chromosome and imprinted genes up-regulated in HeLa cells (cervical cancer) after knockdown of the MBD (methyl-CpG binding domain) proteins by RNAi.
Genes up-regulated genes in cell lines with HDAC2 [GeneID=3066] loss of function (LOS).
Genes up-regulated in constitutively invasive HT-29 5M21 cells (colon cancer) vs the parental non-invasive cells.
Low abundance transcripts specific to hepatocellular carcinoma (HCC).
Low abundance transcripts specific for breast cancer.
Low abundance transcripts specific to nasopharyngeal carcinoma (NPC).
Low abundance transcripts common to nasopharyngeal carcinoma (NPC), breast and liver tumors.
Overexpressed genes with amplified copy number across 27 non-small cell lung cancer (NSCLC) cell lines.
Genes down-regulated in H1703 cells (non-small cell lung cancer, NSCLC) after knockdown of PRKCI [GeneID=5584] by RNAi.
Proteins phosporylated in HCT116 cells (colon cancer) upon p53 [GeneID=7157] activation.
Potential direct target genes for MIR34A [GeneID=407040] microRNA in IMR32 cells (neuroblastoma).
Genes whose promoters contain E-box motifs and whose expression changed in MYCN-3 cells (neuroblastoma) upon induction of MYCN [GeneID=4613].
Genes up-regulated in the samples with intrahepatic metastatic hepatocellular carcinoma (HCC) vs primary HCC that also have putative binding sites for SOX4 [GeneID=6659].
Genes up-regulated in the samples with intrahepatic metastatic hepatocellular carcinoma (HCC) vs primary HCC.
Genes up-regulated in salivary, thyroid and mammary gland carcinomas developed in transgenic mice carrying RET [GeneID=5979] allele with the MEN2A mutation (C634R).
Proteins that interact with PTTG1 [GeneID=9232], based on protein array.
Cell cycle genes up-regulated in H1299 cells (lung cancer) after overexpression of either P53 or P73 [GeneID=7157;7161].
Cell cycle genes down-regulated in H1299 cells (lung cancer) after overexpression of either P53 or P73 [GeneID=7157;7161].
Genes that were inversely correlated in H1299 cells (lung cancer): up-regulated by P53 [GeneID=7157] and down-regulated by P73 [GeneID=7161].
Genes that were inversely correlated in H1299 cells (lung cancer): down-regulated by P53 [GeneID=7157] and up-regulated by P73 [GeneID=7161].
Genes up-regulated in glioblastoma cell lines displaying spherical growth (cluster-1) compared to those displaying semiadherent or adherent growth phenotype (cluster-2).
Genes down-regulated in glioblastoma cell lines displaying spherical growth (cluster-1) compared to those displaying semiadherent or adherent growth phenotype (cluster-2).
Genes up-regulated in 293 cells (embryonic kidney) expressing  polymorphic variants S427G (SNP ID=rs2070235) or I624M (SNP ID=rs11556379) of BMYB [GeneID=4605].
Genes down-regulated in 293 cells (embryonic kidney) expressing  polymorphic variants S427G (SNP ID=rs2070235) or I624M (SNP ID=rs11556379) of BMYB [GeneID=4605].
Genes up-regulated in constitutively invasive HT-29 5M21 cells (colon cancer) vs those expressing functionally inactive TATI [GeneID=6690].
Genes down-regulated in constitutively invasive HT-29 5M21 cells (colon cancer) vs those expressing functionally inactive TATI [GeneID=6690].
Genes up-regulated in EVSA-T cells (breast cancer) treated THC (delta-9-tetrahydrocannabinol) [PubChem=6610319].
Genes down-regulated in EVSA-T cells (breast cancer) treated THC (delta-9-tetrahydrocannabinol) [PubChem=6610319].
Genes up-regulated in EVSA-T cells (breast cancer) treated with 5 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 8 h.
Genes down-regulated in EVSA-T cells (breast cancer) treated with 5 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 8 h.
Genes up-regulated in EVSA-T cells (breast cancer) treated with 3 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 8 h.
Genes down-regulated in EVSA-T cells (breast cancer) treated with 3 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 8 h.
Genes up-regulated in EVSA-T cells (breast cancer) after treatment with 3 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 24 h.
Genes down-regulated in EVSA-T cells (breast cancer) after treatment with 3 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 24 h.
Genes up-regulated in EVSA-T cells (breast cancer) treated with 5 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 24 h.
Genes down-regulated in EVSA-T cells (breast cancer) treated with 5 micromolar THC (delta-9-tetrahydrocannabinol) [PubChem=6610319] for 24 h.
Angiogenic genes up-regulated in hepatocytes after knockout of VHL and HIF2A [GeneID=7428;2034].
Angiogenic genes down-regulated in hepatocytes after knockout of VHL and HIF2A [GeneID=7428;2034].
Genes up-regulated in the invasive ductal carcinoma (IDC) compared to the invasive lobular carcinoma (ILC), the two major pathological types of breast cancer.
Genes down-regulated in the invasive ductal carcinoma (IDC) compared to the invasive lobular carcinoma (ILC), the two major pathological types of breast cancer.
Genes whose expression positively correlates with that of both ID1 and ID2 [GeneID=3397;3398] genes in a cohort of 285 patients with primaly AML (acule myelogenous leukemia) [PMID=15084694].
Common target genes up-regulated by all three Runx family members (RUNX1, RUNX2, and RUNX3 [GeneID=861;860;864]) in MEF cells (embryonic fibroblasts).
Common target genes down-regulated by all three Runx family members (RUNX1, RUNX2, and RUNX3 [GeneID=861;860;864]) in MEF cells (embryonic fibroblasts).
Genes commonly up-regulated in both non-tumorous and tumorous liver tissues of PARK2 [GeneID=5071] knockout mice.
Genes commonly down-regulated in both non-tumorous and tumorous liver tissues of PARK2 [GeneID=5071] knockout mice.
Genes up-regulated in tumorous  liver tissues from PARK2 [GeneID=5071] knockout mice compared to the normal, non-tumorous tissue from wild type mice.
Genes down-regulated in tumorous  liver tissues from PARK2 [GeneID=5071] knockout mice compared to the normal, non-tumorous tissue from wild type mice.
Genes up-regulated in the A673 cells (Ewing sarcoma) after double knockdown of both FLI1 and DAX1 [GeneID=2313;190] by RNAi.
Genes down-regulated in the A673 cells (Ewing sarcoma) after double knockdown of both FLI1 and DAX1 [GeneID=2313;190] by RNAi.
Up-regulated genes that vary between HNSCC (head and neck squamous cell carcinoma) groups formed on the basis of their level of pathological differentiation: well vs poorly differentiated tumors.
Down-regulated genes that vary between HNSCC (head and neck squamous cell carcinoma) groups formed on the basis of their level of pathological differentiation: well vs poorly differentiated tumors.
Up-regulated genes that vary between HNSCC (head and neck squamous cell carcinoma) groups formed on the basis of their level of pathological differentiation: well vs moderately differentiated tumors.
Down-regulated genes that vary between HNSCC (head and neck squamous cell carcinoma) groups formed on the basis of their level of pathological differentiation: well vs moderately differentiated tumors.
Up-regulated genes that vary between HNSCC (head and neck squamous cell carcinoma) groups formed on the basis of their level of pathological differentiation: moderately vs poorly differentiated tumors.
Down-regulated genes that vary between HNSCC (head and neck squamous cell carcinoma) groups formed on the basis of their level of pathological differentiation: moderately vs poorly differentiated tumors.
Genes up-regulated in metastatic vs non-metastatic HNSCC (head and neck squamous cell carcinoma) samples.
Genes down-regulated in metastatic vs non-metastatic HNSCC (head and neck squamous cell carcinoma) samples.
Genes up-regulated in senescent cells.
Genes down-regulated in senescent cells.
Genes down-regulated in immortalized cell lines.
Genes up-regulated in the urogenital sinus (UGS) of day E16 females exposed to the androgen dihydrotestosterone [PubChem=10635] for 6 h.
Genes down-regulated in the urogenital sinus (UGS) of day E16 females exposed to the androgen dihydrotestosterone [PubChem=10635] for 6 h.
Genes up-regulated in the urogenital sinus (UGS) of day E16 females exposed to the androgen dihydrotestosterone [PubChem=10635] for 12 h.
Genes down-regulated in the urogenital sinus (UGS) of day E16 females exposed to the androgen dihydrotestosterone [PubChem=10635] for 12 h.
Genes up-regulated in the urogenital sinus (UGS) of day E16 females exposed to the androgen dihydrotestosterone [PubChem=10635] for 48 h.
Genes down-regulated in the urogenital sinus (UGS) of day E16 females exposed to the androgen dihydrotestosterone [PubChem=10635] for 48 h.
Early prostate development genes (up-regulated at 6 h dihydrotestosterone [PubChem=10635]) which are also up-regulated in normal epithelium vs high grade prostatic intraepithelial neoplasia (PIN).
Early prostate development genes (down-regulated at 6 h dihydrotestosterone [PubChem=10635]) which are also down-regulated in normal epithelium vs high grade prostatic intraepithelial neoplasia (PIN).
Early prostate development genes (up-regulated at 6 hr dihydrotestosterone [PubChem=10635]) which are also up-regulated in high grade prostatic intraepithelial neoplasia (PIN) vs invasive cancer.
Early prostate development genes (down-regulated at 6 hr dihydrotestosterone [PubChem=10635]) which are also down-regulated in high grade prostatic intraepithelial neoplasia (PIN) vs invasive cancer.
Early prostate development genes (up-regulated at 6 hr dihydrotestosterone [PubChem=10635]) which are also up-regulated in localized vs metastatic prostate cancers.
Early prostate development genes (down-regulated at 6 hr dihydrotestosterone [PubChem=10635]) which are also down-regulated in localized vs metastatic prostate cancers.
Early prostate development genes (up-regulated at 12 hr dihydrotestosterone [PubChem=10635]) which are also up-regulated in high grade prostatic intraepithelial neoplasia (PIN) vs invasive cancer.
Early prostate development genes (down-regulated at 12 hr dihydrotestosterone [PubChem=10635]) which are also down-regulated in high grade prostatic intraepithelial neoplasia (PIN) vs invasive cancer.
Early prostate development genes (up-regulated at 48 hr dihydrotestosterone [PubChem=10635]) which are also up-regulated in high grade prostatic intraepithelial neoplasia (PIN) vs invasive cancer.
Early prostate development genes (down-regulated at 48 hr dihydrotestosterone [PubChem=10635]) which are also down-regulated in high grade prostatic intraepithelial neoplasia (PIN) vs invasive cancer.
Predicted targets of SOX9 [GeneID=6662] that are up-regulated during early prostate development.
Predicted targets of SOX9 [GeneID=6662] that are down-regulated during early prostate development.
Genes up-regulated in NCI-H1299 cells (large cell neuroendocrine carcinoma) stably expressing SEMA3B [GeneID=7869].
Genes down-regulated in NCI-H1299 cells (large cell neuroendocrine carcinoma) stably expressing SEMA3B [GeneID=7869].
Genes that trigger senescence in vitro and in vivo.
Cluster a: genes identifying an intrinsic group in head and neck squamous cell carcinoma (HNSCC).
Early prostate development genes (up-regulated at 6 hr dihydrotestosterone [PubChem=10635]) which are also up-regulated in lower grade vs higher grade locally invasive prostate cancers.
Cluster b: genes identifying an intrinsic group in head and neck squamous cell carcinoma (HNSCC).
Cluster c: genes identifying an intrinsic group in head and neck squamous cell carcinoma (HNSCC).
Cluster d: genes identifying an intrinsic group in head and neck squamous cell carcinoma (HNSCC).
Cluster e: genes identifying an intrinsic group in head and neck squamous cell carcinoma (HNSCC).
Cluster f: genes identifying an intrinsic group in head and neck squamous cell carcinoma (HNSCC).
Genes associated with migration rate of 40 human bladder cancer cells.
Genes that cooperate with MYC and TBX2 [GeneID=4609;6909] to transform MEF cells (embryo fibroblasts).
Genes up-regulated in pilocytic astrocytoma compared to glioblastoma samples.
Genes down-regulated in pilocytic astrocytoma compared to glioblastoma samples.
Genes up-regulated in U87MG cells (glioblastoma multiforme) after knockdown of PRKCI [GeneID=5584] by RNAi.
Genes up-regulated in MMH-RT cells (hepatocytes displaying an invasive, metastatic phenotype) during epithelial to mesenchymal transition (EMT).
Genes down-regulated in MMH-RT cells (hepatocytes displaying an invasive, metastatic phenotype) during epithelial to mesenchymal transition (EMT).
Genes up-regulated in the intestine after the tissue specific knockout of PTEN [GeneID=5728] by Cre-lox.
Genes down-regulated in the intestine after the tissue specific knockout of PTEN [GeneID=5728] by Cre-lox.
Delayed early genes (DEG) which are coordinately down-regulated in multiple epithelial tumor types.
Proteins shown to interact with LCA5 [GeneID=167691] in vivo.
Genes up-regulated in post-GC, BCL6 [GeneID=604] dependent B cell non-Hodgkin's lymphoma (B-NHL) vs MYC [GeneID=4609] driven pre-GC lymphoma.
Genes down-regulated in post-GC, BCL6 [GeneID=604] dependent B cell non-Hodgkin's lymphoma (B-NHL) vs MYC [GeneID=4609] driven pre-GC lymphoma.
Set 'ES exp1': genes overexpressed in human embryonic stem cells according to 5 or more out of 20 profiling studies.
Set 'Set 'ES exp2': genes overexpressed in human embryonic stem cells according to a meta-analysis of 8 profiling studies.
Set 'Nanog targets': genes upregulated and identified by ChIP on chip as Nanog [GeneID=79923] transcription factor targets in human embryonic stem cells.
Set 'Oct4 targets': genes upregulated and identified by ChIP on chip as OCT4 [GeneID=5460] transcription factor targets in human embryonic stem cells.
Set 'Sox2 targets': genes upregulated and identified by ChIP on chip as SOX2 [GeneID=6657] transcription factor targets in human embryonic stem cells.
Set 'NOS targets': genes upregulated and identified by ChIP on chip as targets of the transcription factors NANOG , OCT4, and Sox2 [GeneID=79923;5460;6657] (NOS) in human embryonic stem cells.
Set 'Suz12 targets': genes identified by ChIP on chip as targets of the Polycomb protein SUZ12 [GeneID=23512] in human embryonic stem cells.
Set 'Eed targets': genes identified by ChIP on chip as targets of the Polycomb protein EED [GeneID=8726] in human embryonic stem cells.
Set 'H3K27 bound': genes posessing the trimethylated H3K27 (H3K27me3) mark in their promoters in human embryonic stem cells, as identified by ChIP on chip.
Set 'PRC2 targets': Polycomb Repression Complex 2 (PRC) targets; identified by ChIP on chip on human embryonic stem cells as genes that: posess the trimethylated H3K27 mark in their promoters and are bound by SUZ12 [GeneID=23512] and EED [GeneID=8726] Polycomb proteins.
Set 'Myc targets1': targets of c-Myc [GeneID=4609] identified by ChIP on chip in cultured cell lines, focusing on E-box-containing genes; high affinity bound subset
Set 'Myc targets2': targets of c-Myc [GeneID=4609] and Max [GeneID=4149] identified by ChIP on chip in a Burkitt's lymphoma cell line; overlap set.
Genes showing cell-cycle stage-specific expression [PMID=12058064].
Set 'Proliferation Cluster': genes defined in human breast tumor expression data.
Genes that correlated most highly with left ventricular mass (LVM) index.
Genes up-regulated in prefrontal cortex (PFC) of mice carrying a hemizygotic microdeletion in the 22q11.2 region.
Genes down-regulated in prefrontal cortex (PFC) of mice carrying a hemizygotic microdeletion in the 22q11.2 region.
Genes up-regulated in hyppocampus of mice carrying a hemizygotic microdeletion in the 22q11.2 region.
Genes down-regulated in hyppocampus of mice carrying a hemizygotic microdeletion in the 22q11.2 region.
Genes located outside the microdeletion region in 22q11 which were differentially expressed in the same manner both in hyppocampus and prefrontal cortex.
Set 'Core 9': 'embryonic stem cell' transcription regulators that are preferentially and coordinately overexpressed in the high-grade, ER-negative breast cancer tumors.
Breast cancer compendium: 100 transcription regulators showing most correlated expression with the 9 'embryonic stem cell' transcription factors that are preferentially and coordinately overexpressed in the high-grade, ER-negative breast cancer tumors.
Genes that are most strongly positively correlated with systolic blood pressure (SBP).
Genes that are most strongly negatively correlated with systolic blood pressure (SBP).
Up-regulated cis-regulated expression quantitative loci (cis-eQTL) in the heart that colocalize with previously mapped cardiac mass QTLs.
Down-regulated cis-regulated expression quantitative loci (cis-eQTL) in the heart that colocalize with previously mapped cardiac mass QTLs.
Up-regulated cis-regulated expression quantitative loci (cis-eQTL) in the heart that were identified as candidate genes for the regulation of left ventricle mass (LVM).
Down-regulated cis-regulated expression quantitative loci (cis-eQTL) in the heart that were identified as candidate genes for the regulation of left ventricle mass (LVM).
Genes whose expression peaked at 20 min after stimulation of HeLa cells with EGF [GeneID=1950].
Genes whose expression peaked at 40 min after stimulation of HeLa cells with EGF [GeneID=1950].
Genes whose expression peaked at 60 min after stimulation of HeLa cells with EGF [GeneID=1950].
Genes whose expression peaked at 120 min after stimulation of HeLa cells with EGF [GeneID=1950].
Genes whose expression peaked at 240 min after stimulation of HeLa cells with EGF [GeneID=1950].
Genes whose expression peaked at 480 min after stimulation of HeLa cells with EGF [GeneID=1950].
Genes whose expression peaked at 20 min after stimulation of MCF10A cells with EGF [GeneID=1950].
Genes whose expression peaked at 40 min after stimulation of MCF10A cells with EGF [GeneID=1950].
Genes whose expression peaked at 60 min after stimulation of MCF10A cells with EGF [GeneID=1950].
Genes whose expression peaked at 120 min after stimulation of MCF10A cells with EGF [GeneID=1950].
Genes whose expression peaked at 240 min after stimulation of MCF10A cells with EGF [GeneID=1950].
Genes whose expression peaked at 480 min after stimulation of MCF10A cells with EGF [GeneID=1950].
Genes whose expression peaked at 20 min after stimulation of MCF10A cells with serum.
Genes whose expression peaked at 40 min after stimulation of MCF10A cells with serum.
Genes whose expression peaked at 60 min after stimulation of MCF10A cells with serum.
Genes whose expression peaked at 120 min after stimulation of MCF10A cells with serum.
Genes whose expression peaked at 240 min after stimulation of MCF10A cells with serum.
Genes whose expression peaked at 480 min after stimulation of MCF10A cells with serum.
Experimentally validated direct targets of MIR192 [GeneID=406967] microRNA; MIR192 caused cell cycle arrest in HCT116 cells (colon cancer).
Genes down-regulated in HCT116 cells (colon cancer) by expression of MIR192 or MIR215 [GeneID=406967;406997] at 24 h.
Genes whose expression positively correlated with that of SMARCA2 [GeneID=6595] in prostate cancer samples.
Genes whose expression negatively correlated with that of SMARCA2 [GeneID=6595] in prostate cancer samples.
Genes downregulated in MCF10A cells (breast cancer) co-cultured with cancer-associated fibroblasts (CAF).
Selected genes down-regulated in inflammatory monocytes infiltrating hepatocellular carcinoma (HCC).
Selected genes up-regulated in inflammatory monocytes infiltrating hepatocellular carcinoma (HCC).
Selected genes down-regulated in peripheral blood monocytes (PBMC) of patients with hepatocellular carcinoma (HCC) compared to those with chronic hepatitis.
Genes up-regulated in H1299 cells (lung cancer) upon knockdown of SMAD6 [GeneID=4091] by RNAi.
Genes down-regulated in H1299 cells (lung cancer) upon knockdown of SMAD6 [GeneID=4091] by RNAi.
Genes changed in prostate cancer: androgen independent vs androgen dependent samples.
Genes up-regulated in metastatic vs non-metastatic stromal cells originated from either bone or prostate tissues.
Genes down-regulated in metastatic vs non-metastatic stromal cells originated from either bone or prostate tissues.
Cluster 1 of genes distinguishing among different B lymphocyte neoplasms.
Cluster 2 of genes distinguishing among different B lymphocyte neoplasms.
Cluster 3 of genes distinguishing  among different B lymphocyte neoplasms.
Cluster 5 of genes distinguishing among different B lymphocyte neoplasms.
Cluster 6 of genes distinguishing among different B lymphocyte neoplasms.
Cluster 7 of genes distinguishing among different B lymphocyte neoplasms.
Cluster 8 of genes distinguishing among different B lymphocyte neoplasms.
Cluster 9 of genes distinguishing among different B lymphocyte neoplasms.
Genes up-regulated in BxPC3 cells (pancreatic cancer) after treatment with TNF [GeneID=7124] or IKI-1, an inhibitor of IkappaB kinase (IKK).
Genes down-regulated in BxPC3 cells (pancreatic cancer) after treatment with TNF [GeneID=7124] or IKI-1, an inhibitor of IkappaB kinase (IKK).
Up-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the Pre-BI stage.
Down-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the Pre-BI stage.
Up-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the  Large Pre-BII stage.
Down-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the  Large Pre-BII stage.
Up-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the Small Pre-BII stage.
Down-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the Small Pre-BII stage.
Up-regulated genes in the B lymphocyte developmental signature based on expression profiling of lymphomas from the Emu-myc transgenic mice: the immature B stage.
Down-regulated genes in the B lymphocyte developmental signature based on expression profiling of lymphomas from the Emu-myc transgenic mice: the immature B stage.
Up-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the  mature B
Down-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: the  mature B
Up-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: plasma cell.
Down-regulated genes in the B lymphocyte developmental signature, based on expression profiling of lymphomas from the Emu-myc transgenic mice: plasma cell.
Genes correlated with the early tumor onset in the Emu-myc transgenic mouse lymphoma model.
Genes correlated with the late tumor onset in the Emu-myc transgenic mouse lymphoma model.
Substrates of PRKDC [GeneID=5591].
Proteins that regulate activity of PRKDC [GeneID=5591].
Metastatic signature genes that best distinguished between favorable and unfavorable prognosis for the non-small cell lung cancer (NSCLC) patients.
Genes up-regulated in medulloblastoma tumors from animals with  inactivating mutations of one copy of PTCH1 or SUFU [GeneID=5727;51684] in conjunction with TP53 [GeneID=7157] loss.
Genes down-regulated in medulloblastoma tumors from animals with  inactivating mutations of one copy of PTCH1 or SUFU [GeneID=5727;51684] in conjunction with TP53 [GeneID=7157] loss.
Genes involved in DNA repair, compiled manually by the authors.
Genes involved in DNA replication, compiled manually by the authors.
Genes within amplicon 1q21 identified in a copy number alterations study of 191 breast tumor samples.
Genes within amplicon 1q32 identified in a copy number alterations study of 191 breast tumor samples.
Genes within amplicon 5p15 identified in a copy number alterations study of 191 breast tumor samples.
Genes within amplicon 6p24-p22 identified in a copy number alterations study of 191 breast tumor samples.
Genes within amplicon 7p22 identified in a copy number alterations study of 191 breast tumor samples.
Genes within amplicon 7p15 identified in a copy number alterations study of 191 breast tumor samples.
Genes within amplicon 7q21-q22 identified in a copy number alterations study of 191 breast tumor samples.
Genes within amplicon 8p12-p11 identified in a copy number alterations study of 191 breast tumor samples.
Genes within amplicon 8q12-q22 identified in a copy number alterations study of 191 breast tumor samples.
Genes within amplicon 8q23-q24 identified in a copy number alterations study of 191 breast tumor samples.
Genes within amplicon 10q22 identified in a copy number alterations study of 191 breast tumor samples.
Genes within amplicon  11q12-q14 identified in a copy number alterations study of 191 breast tumor samples.
Genes within amplicon 12q13-q21 identified in a copy number alterations study of 191 breast tumor samples.
Genes within amplicon  12q24 identified in a copy number alterations study of 191 breast tumor samples.
Genes within amplicon 14q22 identified in a copy number alterations study of 191 breast tumor samples.
Genes within amplicon 15q26 identified in a copy number alterations study of 191 breast tumor samples.
Genes within amplicon 16p13 identified in a study of 191 breast tumor samples.
Genes within amplicon 16q24 identified in a copy number alterations study of 191 breast tumor samples.
Genes within amplicon 17p11 identified in a copy number alterations study of 191 breast tumor samples.
Genes within amplicon 17q11-q21 identified in a copy number alterations study of 191 breast tumor samples.
Genes within amplicon 17q21-q25 identified in a copy number alterations study of 191 breast tumor samples.
Genes within amplicon 19p13 identified in a copy number alterations study of 191 breast tumor samples.
Genes within amplicon 19q13.1 identified in a copy number alterations study of 191 breast tumor samples.
Genes within amplicon 19q13.4 identified in a copy number alterations study of 191 breast tumor samples.
Genes within amplicon 20p13 identified in a copy number alterations study of 191 breast tumor samples.
Genes within amplicon 20q11 identified in a copy number alterations study of 191 breast tumor samples.
Genes within amplicon 20q12-q13 identified in a copy number alterations study of 191 breast tumor samples.
Genes within amplicon 21q22 identified in a copy alterations study of 191 breast tumor samples.
Genes within amplicon 22q13 identified in a copy number alterations study of 191 breast tumor samples.
Genes both mutated and amplified in a panel of 191 breast tumor samples.
Genes that reduced viability of NCI-H1155 cells (non-small-cell lung cancer, NSCLC) in the presence of otherwise sublethal concentrations of paclitaxel [PubChem=4666], based on RNAi synthetic lethal screen.
Pre-mitotic cell cycle regulators (CDC) identified in an shRNA screen of the ubiquitin pathway components.
Genes down-regulated in hES cells (human embryonic stem cells) after treatment with the ALK [GeneID=238] inhibitor SB-431542 [PubChem=16079008].
Genes up-regulated in hES cells (human embryonic stem cells) after treatment with the ALK [GeneID=238] inhibitor SB-431542 [PubChem=4521392].
Genes down-regulated in hES cells (human embryonic stem cells) after treatment with the ALK [GeneID=238] inhibitor SB-431542 [PubChem=4521392].
Adenocarcinoma metastatic program genes up-regulated in A549 and H2126 cells (lung cancer) lacking functional STK11 [GeneID=6794] but down-regulated by the normal gene.
Genes down-regulated in BJAB cell line (B lymphocyte) after expression of the viral microRNA miR-K12-11 which functions as an ortholog of cellular MIR155 [GeneID=406947].
High-grade amplification (copy number, CN >= 5) detected in primary neuroblastoma samples.
Genes up-regulated and displaying increased copy number in glioblastoma samples.
Genes down-regulated and displaying decreased copy number in glioblastoma samples.
The lung adenocarcinoma TSP (tumor sequencing project) genes that were found significantly mutated by at least one method.
The lung adenocarcinoma TSP (tumor sequencing project) genes with significantly higher frequencies of nonsense, splice site, and frame-shift mutations.
The lung adenocarcinoma TSP (tumor sequencing project) genes showing strong correlation between DNA copy number variation and gene expression.
Genes up-regulated in HMLE cells (immortalized nontransformed mammary epithelium) after E-cadhedrin (CDH1) [GeneID=999] knockdown by RNAi.
Genes down-regulated in HMLE cells (immortalized nontransformed mammary epithelium) after E-cadhedrin (CDH1) [GeneID=999] knockdown by RNAi.
Genes up-regulated in HMLE cells (mmortalized nontransformed mammary epithelial) by expression of a dominant-negative form of E-cadhedrin (CDH1) [GeneID=999].
Genes down-regulated in HMLE cells (mmortalized nontransformed mammary epithelial) by expression of a dominant-negative form of E-cadhedrin (CDH1) [GeneID=999].
Genes up-regulated in HMLE cells (immortalized nontransformed mammary epithelial) cells after loss of function of E-cadhedrin (CDH1) [GeneID=999], which was achieved either by RNAi knockdown or by expression of a dominan-negative form of CDH1.
Genes down-regulated in HMLE cells (immortalized nontransformed mammary epithelial) cells after loss of function of E-cadhedrin (CDH1) [GeneID=999], which was achieved either by RNAi knockdown or by expression of a dominan-negative form of CDH1.
Genes changed in HMLE cells (mmortalized nontransformed mammary epithelium) after RNAi knockdown of both CDH1 and CTNNB1 [GeneID=999;1499], compared to the knockdown of CDH1 alone.
Genes implicated in apoptosis that were up-regulated in duodenum of CD44 [GeneID=960] knockout mice.
Genes implicated in apoptosis that were down-regulated in duodenum of CD44 [GeneID=960] knockout mice.
Genes present but differentially expressed between Hep3B cells (hepatocellular carcinoma, HCC) with RNAi knockdown of SDHB [GeneID=6390] and control cells.
Genes linked to the ECM maintenance and angiogenesis that were changed in HT1080 cells (fibrosarcoma) over-expressing MMP14 [GeneID=4323] compared to those with knockdown of the gene by RNAi.
Genes whose expression most uniformly correlated with that of MMP14 [GeneID=4323] both in HT1080 cells (fibrosarcoma) and in 190 human tumors.
Genes up-regulated in HT1080 cells (fibrosarcoma) over-expressing MMP14 [GeneID=4323] compared to those with knockdown of the gene by RNAi.
Genes down-regulated in HT1080 cells (fibrosarcoma) over-expressing MMP14 [GeneID=4323] compared to those with knockdown of the gene by RNAi.
Genes associated with metastasis of breast cancer in the lung compared to the non-lung metastasis.
Genes turned on in Hep3B cells (hepatocellular carcinoma, HCC) upon knockdown of SDHB [GeneID=6390] by RNAi.
Genes turned off in Hep3B cells (hepatocellular carcinoma, HCC) upon knockdown of SDHB [GeneID=6390] by RNAi.
Genes down-regulated in P14 nerves of transgenic mice having hypomorhic (reduced function) allele of EGR2 [GeneID=1959].
Top 100 probe sets for core-binding factor (CBF) acute myeloid leukemia (AML): contains CBFB MYH11 [GeneID=865;4629] or AML1 ETO [GeneID=861;862] fusions.
Genes that physically map to the hematopoietic stem cell (HSC) proliferation QTL (quantitative trait locus) Scp2.
Genes up-regulated in HC11 cells (mammary epithelium) by expression of constantly active CTNNB1 [GeneID=1499].
Genes specifically down-regulated in pediadric acute lymphoblastic leukemia (ALL) patients by mercaptopurine [PubChem=667490].
Genes down-regulated in LNCaP cells (prostate cancer) in response to synthetic androgen R1881 [PubChem=13766].
Genes up-regulated in plasma cells compared with B lymphocytes.
Genes whose expression in bone marrow samples correlated inversely with increased levels of serum IL5 [GeneID=3567].
Genes upregulated in control vs KRAS [GeneID=3845] knockdown in a human cell line.
Human orthologs of genes up-regulated in the crb ('crash and burn') zebrafish mutant that represents a loss-of-function mutation in BMYB [GeneID=4605].
Top 100 probe sets for pediatric acute myeloid leukemia (AML) subtype t(15;17): has PML RARA fusion [GeneID=5371;5914].
The 50 most down-regulated genes in primary invasive breast dutcal carcinoma (IDC) or lymph node metastases,  compared to normal mammary epithelium.
Genes up-regulated in MEF cells (embryonic fibroblasts) by overexpression of HOXC8 [GeneID=3224].
Genes down-regulated in long term hematopoietic stem cells (LT-HSC) compared to multipotent progenitor (MPP) cells.
Genes down-regulated in hepatocellular carcinoma (HCC) induced by ciprofibrate [PubChem=2763].
Genes down-regulated in the temporal cortex samples from patients with major depressive disorder.
Genes up-regulated by induction of E2F1 expression in Saos2 (osteosarcoma) cells.
Cis-regulatory QTLs (quantitative trait loci) found at the D6Mit150 region.
Top 50 down-regulated markers for the diffused large B-cell lymphoma (DLBCL) that distinguished between cured and fatal/refractory clinical outcomes.
Genes up-regulated in Jurkat cells (T lymphocyte) by IFN1@, and IFNB1 [GeneID=3438;3456] but not by overexpression of a constitutively active form of IRF3 [GeneID=3661].
Molecular timetable composed of 96 time-indicating genes (103 probes) in the central (suprachiasmatic nucleus (SCN)) clock.
Genes whose expression is coregulated with that of FGF3 [GeneID=2248] in hematopoietic stem cells (HSC).
Up-regulated genes highly correlated with acute lymphoblastic leukemia (ALL) vs acute myeloid leukemia (AML).
Genes known to modulate ROS or whose expression changes in response to ROS
Genes which comprise the top 1% of highly interconnected genes (major hubs) that account for most of gene interactions in the reconstructed regulatory networks from expression profiles in B lymphocytes.
Transcripts in hematopoietic stem cells (HSC) which are cis-regulated (i.e., modulated by a QTL (quantitative trait locus) in close proximity to the gene).
Genes down-regulated in P493-6 cells (Burkitt's lymphoma) induced to express MYC [GeneID=4609].
Genes down-regulated in MEF cells (embryonic fibroblasts) by overexpression of HOXC8 [GeneID=3224].
Best cis-regulated quantitative trait loci (QTLs) in the mouse genome which modulate transcription in brain tissue.
Top 63 probe sets for pediatric acute myeloid leukemia (AML) subtype inv(16); has a CBFB-MYH11 fusion [GeneID=865;4629].
Genes up-regulated during transition from L0 (non-tumor, not infected with HCV) to L1 (non-tumor, infected with HCV) in the development of hepatocellular carcinoma.
Genes down-regulated during transition from L1 (non-tumor, infected with HCV) to G1 (well differentiated tumor, infected with HCV) in the development of hepatocellular carcinoma.
Nearest neighbors of TAL1 [GeneID=6886], based on the close agreement of their expression profiles with that of TAL1 in pediatric T cell acute lymphoblastic leukemia (T-ALL)
Genes trans-regulated by the same QTL (quantitative trait loci) in brain and hematopoietic stem cells (HSC).
Genes up-regulated in BJAB cells (B-lymphoma) after leucine [PubChem=857] deprivation.
Genes down-regulated in hepatocellular carcinoma (HCC) tissue of MYC and TGFA [GeneID=4609;7039] double transgenic mice.
Genes down-regulated during transition from G1 (well differentiated tumor, infected with HCV) to G2 (moderately differentiated tumor, infected with HCV) in the development of hepatocellular carcinoma.
Up-regulated in CD8+ [GeneID=925] T lymphocytes undergoing homeostatic proliferation (HP) versus the naive cells; these genes are not up-regulated versus effector or memory cell population.
The cyclin D1 signature: genes whose expression correlated with the levels of CCND1 [GeneID=595].
Top 50 most up-regulated genes in human platelet cells.
Genes up-regulated in germinal center T helper cells compared to other CD4+ [GeneID=920] T lymphocyte types.
Human orthologs of genes down-regulated in zebra fish after knockdown of BMYB [GeneID=4605] by morpholino.
Genes associated with the same cis-regulatory QTL (quantitative trait loci) in both brain and hematopoietic stem cells (HSC).
Genes down-regulated in hepatocellular carcinoma of ACOX1 [GeneID=51] knockout mice.
Genes up-regulated in BJAB cells (B-lymphoma) after glucose [PubChem=206] deprivation.
Genes consistently up-regulated in HMEC cells (primary mammary epithelium) upon expression of TERT [GeneID=7015] off a retroviral vector.
Genes up-regulated in hepatocellular carcinoma (HCC) induced by overexpression of MYC [GeneID=4609].
Genes up-regulated by adenoviral expression of c-MYC [GeneID=4609] in HUVEC cells (umbilical vein endothelium).
Genes down-regulated during transition from L0 (non-tumor, not infected with HCV) to L1 (non-tumor, infected with HCV) in the development of hepatocellular carcinoma.
Genes up-regulated during epithelial to mesenchymal transition (EMT) induced by TGFB1 [GeneID=7040] in the EpH4 cells (mammary epithelium cell line transformed by HRAS [GeneID=3265]).
Genes up-regulated in HT1080 cells (fibrosarcoma) by treatment with interferon alpha for 6 h.
Primary up-regulated targets of TP53 [GeneID=7157] in the H1299 (lung cancer) cell line.
Genes up-regulated in BJAB cells (B-lymphoma) after glutamine [PubChem=738] deprivation.
Genes up-regulated after GATA1 [GeneID=2623] activation in G1E-ER4 cells (erythroid precursors engineered to express GATA1 upon addition of estradiol [PubChem=5757]).
Genes up-regulated in MCF-7 cells (breast cancer) by estradiol (E2) [PubChem=5757].
Genes up-regulated in hepatocellular carcinoma (HCC) tissue of MYC and TGFA [GeneID=4609;7039] double transgenic mice.
Genes downregulated in peripheral blood lymphocytes (PBL) from patients with well functioning kidneys more than 1-year post transplant compared to those from normal living kidney donors.
HOXA9 [GeneID=3205] targets up-regulated in hematopoietic stem cells.
Genes down-regulated in HT1080 (fibrosarcoma) cells by treatment with interferon beta for 6 h.
Genes up-regulated during transition from G2 (moderately differentiated tumor, infected with HCV) to G3 (poorly differentiated tumor, infected with HCV) in the development of hepatocellular carcinoma.
Down-regulated genes in lung tissue of smokers with chronic obstructive pulmonary disease (COPD) vs smokers without disease (GOLD-2 vs GOLD-0).
Genes down-regulated in AIDS-related primary effusion lymphoma (PEL) samples compared to other tumor subtypes and normal B lymphocytes.
Human orthologs of BMYB [GeneID=4605] target genes in zebra fish, identified as commonly changed in the BMYB loss of function mutant crb ('crush and burn') and after knockdown of BMYB by morpholino.
Primary down-regulated targets of TP53 [GeneID=7157] in the H1299 (lung cancer) cell line.
Genes up-regulated by POU5F1 [GeneID=5460] in bladder cancer cell lines.
Genes down-regulated by POU5F1 [GeneID=5460] in bladder cancer cell lines.
Genes down-regulated in five primary endothelial cell types (lung, aortic, iliac, dermal, and colon) by TNF [GeneID=7124].
Genes up-regulated in mature plasma cells compared with plasmablastic B lymphocytes.
Genes up-regulated in NCCIT cell line (embryonic teratocarcinoma) after stimulation with WNT3A [GeneID=89780].
Genes down-regulated in BJAB cells (B-lymphoma) after leucine [PubChem=857] deprivation.
Genes whose expression is coregulated with that of RUNX1 [GeneID=861] in hematopoietic stem cells (HSC).
Genes down-regulated in HC11 cells (mammary epithelium) by expression of constantly active CTNNB1 [GeneID=1499].
Genes specifically up-regulated in pediatric acute lymphoblastic leukemia (ALL) patients by mercaptopurine [PubChem=667490] and low-dose methotrexate (LDMTX) [PubChem=4112].
Genes up-regulated in hepatocellular carcinoma (HCC) cell lines  resistant to IFNA2 [GeneID=3440].
Best trans-regulated quantitative trait loci (QTLs) in the mouse genome which modulate transcription in brain tissue.
Genes up-regulated during transition from G1 (well differentiated tumor, infected with HCV) to G2 (moderately differentiated tumor, infected with HCV) in the development of hepatocellular carcinoma.
Genes up-regulated in a breast cancer cell line resistant to tamoxifen [PubChem=5376] compared to the parental line sensitive to the drug.
Human orthologs of genes down-regulated in the crb ('crash and burn') zebrafish mutant that represents a loss-of-function mutation in BMYB [GeneID=4605].
Genes down-regulated in germinal center T helper cells compared to other CD4+ [GeneID=920] T lymphocyte types.
Genes up-regulated in primary hepatocytes and Hep3B (hepatocyte) cells in response to IFNA [GeneID=3439].
Cell proliferation genes up-regulated by histone deacetylase (HDAC) inhibitors SAHA and depsipeptide [PubChem=5311;5352062].
Genes down-regulated in plasma cells compared with B lymphocytes.
Down-regulated genes predicting response of patients with hepatocellular carcinoma (HCC) to combination chemotherapy with 5-fluorouracil (5-FU) [PubChem=3385] and IFN1@ [GeneID=3438].
Genes up-regulated in long term hematopoietic stem cells (LT-HSC) compared to multipotent progenitor (MPP) cells.
Genes associated with clinical prognosis of pediatric AML (acute myeloid leukemia): good prognosis=no relapse 3 years; poor prognosis=relapse < 1 year or no response to therapy.
Top 50 up-regulated markers for the diffused large B-cell lymphoma (DLBCL) that distinguished between cured and fatal/refractory clinical outcomes.
Genes up-regulated in kidney biopsies from patients with acute transplant rejection compared to the biopsies from patients with well functioning kidneys more than 1-year post transplant.
Genes up-regulated in hepatocellular carcinoma of ACOX1 [GeneID=51] knockout mice.
Genes down-regulated during transition from G2 (moderately differentiated tumor, infected with HCV) to G3 (poorly differentiated tumor, infected with HCV) in the development of hepatocellular carcinoma.
Genes specifically up-regulated in pediadric acute lymphoblastic leukemia (ALL) patients by mercaptopurine [PubChem=667490].
Molecular timetable composed of 162 time-indicating genes (182 probes) in the peripheral (liver) clock.
Neurologically relevant transcripts with highest variance accounted for by mouse strain (genotype) differences.
Protein profiles associated with survival in lung adenocarcinoma.
Top up-regulated marker genes for medulloblastoma classification: desmoplastic vs classic morphology.
Genes induced in the liver during hepatitis B (HBV) viral clearance in chimpanzees.
Human orthologs of genes up-regulated in zebra fish after knockdown of BMYB [GeneID=4605] by morpholino.
Down-regulated genes highly correlated with acute lymphoblastic leukemia (ALL) vs acute myeloid leukemia (AML).
Genes that escape X inactivation.
Genes up-regulated in HT1080 (fibrosarcoma) cells by treatment with interferon beta for 6 h.
Genes down-regulated in response to both hypoxia and overexpression of an active form of HIF1A [GeneID=3091].
Neurologically relevant transcripts with highest abundance fold range in brain tissue among mouse strains.
Down-regulated genes discriminating multiple myeloma samples by type of immunoglobulin they produce: IgG vs IgA.
Genes down-regulated in hepatocellular carcinoma (HCC) from MYC and E2F1 [GeneID=4609;1869] double transgenic mice.
Genes whose expression in bone marrow samples correlated directly with increased levels of serum IL5 [GeneID=3567].
The 50 most up-regulated genes in primary invasive breast dutcal carcinoma (IDC) or lymph node metastases,  compared to normal mammary epithelium.
Neurologically relevant genes modulated in brain tissue by a trans-regulatory QTL (quantitative trait locus) near D6Mit150 marker.
Genes up-regulated in LNCaP cells (prostate cancer) in response to synthetic androgen R1881 [PubChem=13766].
Genes up-regulated by forced expression of APC [GeneID=324] in the APC-deficient SW480  cell line (colon cancer).
Genes whose expression is significantly and negatively correlated with poor breast cancer clinical outcome (defined as developing distant metastases in less than 5 years).
Genes changed in INA-6 cells (multiple myeloma, MM) by re-addition of IL6 [GeneID=3569] after its initial withdrawal for 12h.
Top down-regulated marker genes for medulloblastoma classification: desmoplastic vs classic morphology.
Genes down-regulated in MCF-7 cells (breast cancer) by estradiol (E2) [PubChem=5757].
Genes specifically down-regulated in pediatric acute lymphoblastic leukemia (ALL) patients by high-dose methotrexate (HDMTX) [PubChem=4112].
Genes essential to the development of megakaryocytes, as expressed in normal cells and essential thrombocythemic cells (ET).
Genes down-regulated in mature plasma cells compared with plasmablastic B lymphocytes.
Potential marker genes specifically up-regulated in the majority of hepatocellular carcinoma (HCC) tumors.
Genes down-regulated during epithelial to mesenchymal transition (EMT) induced by TGFB1 [GeneID=7040] in the EpH4 cells (mammary epithelium cell line transformed by HRAS [GeneID=3265]).
Top 100 probe sets for pediatric acute myeloid leukemia (AML) subtypes with chimeric MLL fusions [GeneID=4297].
Genes up-regulated in Jurkat cells (T lymphocyte) by expression of a constitutively active form of IRF3 [GeneID=3661].
Up-regulated genes predicting response of patients with hepatocellular carcinoma (HCC) to combination chemotherapy with 5-fluorouracil (5-FU) [PubChem=3385] and IFN1@ [GeneID=3438].
Genes up-regulated in hepatocellular carcinoma (HCC) from MYC and E2F1 [GeneID=4609;1869] double transgenic mice.
Genes up-regulated in the temporal cortex samples from patients with major depressive disorder.
Genes up-regulated in P14 nerves of transgenic mice having hypomorhic (reduced function) allele of EGR2 [GeneID=1959].
Genes identified by ChIP within the high-affinity group of MYC [GeneID=4609] targets.
Genes upregulated in peripheral blood lymphocytes (PBL) from patients with well functioning kidneys more than 1-year post transplant compared to those from normal living kidney donors.
Top 100 probe sets for pediatric acute myeloid leukemia (AML) subtype FAB M7 (also known as acute megakaryoblastic leukemia, AMKL).
Genes involved in oxidative phosphorylation; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.
Genes down-regulated in peripheral blood lymphocytes (PBL) from patients with acute transplant rejection compared to those from patients with well functioning kidneys more than 1-year post transplant.
Genes down-regulated in HT1080 (fibrosarcoma) cells by treatment with interferon gamma for 6 h.
Genes up-regulated in five primary endothelial cell types (lung, aortic, iliac, dermal, and colon) by IFNG [GeneID=3458].
Genes up-regulated in five primary endothelial cell types (lung, aortic, iliac, dermal, and colon) by TNF [GeneID=7124].
Top marker genes in medulloblastoma associated with good response to treatment (good outcome).
Genes up-regulated in P493-6 cells (Burkitt's lymphoma) induced to express MYC [GeneID=4609].
Genes upregulated in KRAS [GeneID=3845] knockdown vs control in a human cell line.
Genes specifically up-regulated in pediatric acute lymphoblastic leukemia (ALL) patients by high-dose methotrexate (HDMTX) [PubChem=4112].
Up-regulated genes discriminating multiple myeloma samples by type of immunoglobulin they produce: IgG vs IgA.
Genes up-regulated in mast cells (MC) after stimulation with a bacterial lipopolysaccharide (LPS).
Genes consistently down-regulated in HMEC cells (primary mammary epithelium) upon expression of TERT [GeneID=7015] off a retroviral vector.
Top 50 down-regulated markers distinguishing diffuse large B-cell lymphoma (DLBCL) from follicular lymphoma (FL) samples.
Genes down-regulated in hepatocellular carcinoma (HCC) induced by diethylnitrosamine (DENA) [PubChem=5921].
Genes down-regulated in five primary endothelial cell types (lung, aortic, iliac, dermal, and colon) by IFNG [GeneID=3458].
Genes specifically down-regulated in pediatric acute lymphoblastic leukemia (ALL) patients by mercaptopurine [PubChem=667490] and low-dose methotrexate (LDMTX) [PubChem=4112].
Genes down-regulated in hepatocellular carcinoma (HCC) induced by overexpression of MYC [GeneID=4609].
Genes up-regulated in hepatocellular carcinoma (HCC) induced by ciprofibrate [PubChem=2763].
Genes up-regulated during transition from L1 (non-tumor, infected with HCV) to G1 (well differentiated tumor, infected with HCV) in the development of hepatocellular carcinoma.
Top marker genes in medulloblastoma associated with poor response to treatment (poor outcome).
Genes up-regulated in peripheral B lymphocytes after incubation with IL4 [GeneID=3565] for 4 h.
Transcripts in hematopoietic stem cells (HSC) which are trans-regulated (i.e., modulated by a QTL (quantitative trait locus) not in a close proximity to the gene).
Genes whose expression is coregulated with that of FLI1 [GeneID=2313] in hematopoietic stem cells (HSC).
Down-regulated genes discriminating multiple myeloma samples by the ype of immunoglobulin light chain they produce: Ig lambda (IGLL) vs Ig kappa (IGLK).
Nearest neighbors of LYL1 [GeneID=4066], based on the close agreement of their expression profiles with that of LYL1 in pediatric T cell acute lymphoblastic leukemia (T-ALL).
Genes down-regulated in BJAB cells (B-lymphoma) after glucose [PubChem=206] deprivation.
Genes whose expression is significantly and positively correlated with poor breast cancer clinical outcome (defined as developing distant metastases in less than 5 years).
Genes up-regulated in 293T (transformed fetal renal cell) upon expression of MYC [GeneID=4609].
Genes up-regulated in response to both hypoxia and overexpression of an active form of HIF1A [GeneID=3091].
Genes whose promoters were bound by E2F1 and E2F4 [GeneID=1869;1874] in the primary fibroblasts WI-38, by ChIP on chip assay.
Genes down-regulated in hepatocellular carcinoma (HCC) cell lines  resistant to IFNA2 [GeneID=3440].
HOXA9 [GeneID=3205] targets down-regulated in hematopoietic stem cells.
Genes down-regulated in kidney biopsies from patients with acute transplant rejection compared to the biopsies from patients with well functioning kidneys more than 1-year post transplant.
Genes up-regulated in hepatocellular carcinoma (HCC) with intra-hepatic metastasis compared to the non-metastatic tumors.
Top 50 up-regulated markers distinguishing diffuse large B-cell lymphoma (DLBCL) from follicular lymphoma (FL) samples.
Genes down-regulated in Jurkat cells (T lymphocyte) by expression of a constitutively active form of IRF3 [GeneID=3661].
Genes down-regulated in hepatocellular carcinoma (HCC) tumors with higher risk of early intrahepatic recurrence. The single up-regulated gene (GenBank Accession=AC000063) has been excluded from the signature.
Genes down-regulated in primary hepatocytes and Hep3B (hepatocyte) cells in response to IFNA [GeneID=3439].
Genes down-regulated in a breast cancer cell line resistant to tamoxifen [PubChem=5376] compared to the parental line sensitive to the drug.
Cell proliferation genes down-regulated by histone deacetylase (HDAC) inhibitors SAHA and depsipeptide [PubChem=5311;5352062].
Up-regulated genes in lung tissue of smokers with chronic obstructive pulmonary disease (COPD) vs smokers without disease (GOLD-2 vs GOLD-0).
Genes up-regulated in AIDS-related primary effusion lymphoma (PEL) samples compared to other tumor subtypes and normal B lymphocytes.
Genes up-regulated in adult T-cell leukemia (ATL) cells compared to T lymphocytes from healthy controls.
Genes down-regulated in BJUB cells (B-lymphoma) in response to  rapamycin (sirolimus) [PubChem=6610346] treatment.
Genes down-regulated in 293T (transformed fetal renal cell) upon expression of MYC [GeneID=4609].
Genes down-regulated in hepatocellular carcinoma (HCC) induced by overexpression of E2F1 [GeneID=1869].
Genes up-regulated in hepatocellular carcinoma (HCC) induced by diethylnitrosamine (DENA) [PubChem=5921].
Genes down-regulated in kidney biopsies from patients with well functioning kidneys more than 1-year post transplant compared to the biopsies from normal living kidney donors.
Genes up-regulated in BJUB cells (B-lymphoma) in response to  rapamycin (sirolimus) [PubChem=6610346] treatment.
Genes down-regulated in BJAB cells (B-lymphoma) after glutamine [PubChem=738] deprivation.
Up-regulated genes discriminating multiple myeloma samples by the ype of immunoglobulin light chain they produce: Ig lambda (IGLL) vs Ig kappa (IGLK).
Genes up-regulated in peripheral blood lymphocytes (PBL) from patients with acute transplant rejection compared to those from patients with well functioning kidneys more than 1-year post transplant.
Genes up-regulated in kidney biopsies from patients with well functioning kidneys more than 1-year post transplant compared to the biopsies from normal living kidney donors.
'Memory genes' expressed uniquely in CD8+ [GeneID=925] memory T lymphocytes (compared with effector or naive cells)
Genes up-regulated in hepatocellular carcinoma (HCC) induced by overexpression of E2F1 [GeneID=1869].
Top 100 probe sets for pediatric acute myeloid leukemia (AML) subtype t(8;21) ; has AML1 ETO fusion [GeneID=861;862].
The 'stemnes' signature: genes up-regulated and common to 6 human embryonic stem cell lines tested.
Genes up-regulated in Hc cells (normal hepatocyte) by  TNF [GeneID=7124].
Genes up-regulated in HT1080 (fibrosarcoma) cells by treatment with interferon gamma for 6 h.
Genes changed in the B cell chronic lymphocytic leukemia (B-CLL) with deletions in the 17p13 region.
Genes up-regulated in the uteri of ovariectomized mice 6 h after progesterone [PubChem=5994] injection: HOXA10 [GeneID=3206] knockout vs wild type animals.
Top 50 up-regulated genes in cluster CD-1 of multiple myeloma samples with the characteristic expression spike of CCND1 [GeneID=595].
Genes down-regulated in AtT20 cells (pituitary cancer) after treatment with LIF [GeneID=3976].
Top genes up-regulated at day 5 of Cre-Lox induced APC [GeneID=324] knockout in the intestine.
Top 30 increased eosinophil specific transcripts.
Genes defining differentiation potential of the bipotential myeloid cell line FDB.
Genes up-regulated in adipose tissue from obese mouse strains compared to the lean ones.
Top genes down-regulated at day 5 of Cre-Lox induced APC [GeneID=324] knockout in the intestine.
Selected genes changed in K562 (immortalized erythroleukemia) cells induced by hemin [PubChem=26945] treatment to express erythroid properties.
Genes up-regulated in RD-EF cells (rhabdomyosarcoma) engineered to express EWSR1-FLI1 fusion [GeneID=2130;2313] and which are also highly expressed in Ewing's famliy tumors.
Top genes up-regulated in MM4 vs MM1 subgroup of multiple myeloma samples.
Genes up-regulated in hematopoietic stem cells (HSC) overexpressing a constitutively active form of STAT5 [GeneID=6776] off retroviral vector.
Genes up-regulated in hematopoietic progenitor cells (HPC) of T lymphocyte and NK (natural killer) lineage.
Genes down-regulated during myeloid differentiation induced by tretinoin (ATRA) [PubChem=444795] and IL3 [GeneID=3652] in the EML cell line (myeloid progenitor).
Genes up-regulated in macrophages by aerolysin-related cytotoxic enterotoxin (Act) from Aeromonas hydrophila.
Cluster 2: genes down-regulated by RB1, CDNK2A [GeneID=1029;5925], and one of the E2Fs (E2F1, E2F2, or E2F3 [GeneID=1869;1870;1871]).
Genes changed in the B cell chronic lymphocytic leukemia (B-CLL) with mutations in the variable immunoglobulin veriable heavy chain (VH) genes.
Metastatic propensity markers of head and neck squamous cell carcinoma (HNSCC): up-regulated in metastatic vs non-metastatic tumors.
Genes commonly down-regulated in CD-1 and CD-2 clusters of multiple myeloma samples and which were higher expressed in the CD-1 group.
Genes up-regulated in day 6 embryoid bodies derived from embryonic stem cells (ES) with HEX [GeneID=3087] knockout.
Down-regulated genes in myeloid progenitors immortalized by HOXA9 [GeneID=3205] vs those immortalized by HOXA9 and MEIS1 [GeneID=4211].
Genes up-regulated in acute myeloid leukemia (AML) with respect to cellular localization of NPM1 [GeneID=4869]: cytoplasmic vs. nucleolar.
Genes up-regulated in B-CLL (B-cell chronic lymphocytic leukemia) patients with mutated immunoglobulin variable heavy chain (VH) genes.
Genes up-regulated in HEL cells (erythroleukemia) upon expression of ELF4 [GeneID=2000].
Genes up-regulated synergistically in NB4 cells (acute promyelocytic leukemia, APL) by tretinoin and NSC682994 [PubChem=444795;388304].
Genes up-regulated by estradiol (E2) [PubChem=5757] in U2OS cells (osteosarcoma) expressing ESR1 or ESR2 [GeneID=2099;2100].
Genes up-regulated in B cell lymphoma tumors expressing an activated form of MYC [GeneID=4609].
Genes down-regulated in normal bone marrow plasma cells (BMPC) compared to polyclonal plasmablasts (PPC) that also distinguished multiple myeloma (MM) samples by expression of levels of TACI [GeneID=23495].
Genes up-regulated in GH3 cells (pituitary cancer) after treatment with LIF [GeneID=3976].
Genes in a cCDNA library from hematopoietic stem cells (HSC) after subtraction of lineage-specific markers.
Top 100 genes positively associated with T-cell acute lymphoblastic leukemia MLL T-ALL) expressing MLL-ENL fusion [GeneID=4297;4298].
Genes down-regulated in lymph nodes from patients with mantle cell lymphoma (MCL) compared to the non-malignant hyperplastic lymph nodes.
Genes up-regulated in CD-1 compared to CD-2 cluster of multiple myeloma samples.
Genes changed between developmental stages of Valpha14i  natural killer T lymphocyte cells (NKT).
Top 50 genes up-regulated in granulocyte/macrophage progenitors (GMP) upon expression of MLL-CBP fusion [GeneID=4297;1387].
Genes up-regulated in esophagus by the carcinogen NMBA [PubChem=13643] and brought back to normal by a diet with PEITC [PubChem=16741] or black raspberries.
Genes down-regulated in esophagus by the carcinogen NMBA [PubChem=13643] and brought back to normal by a diet with PEITC [PubChem=16741] or black raspberries.
Genes changed in the B cell chronic lymphocytic leukemia (B-CLL) with deletions in the 13q14 region.
Genes up-regulated in lymph nodes from patients with mantle cell lymphoma (MCL) compared to the non-malignant hyperplastic lymph nodes.
Genes down-regulated in day 6 embryoid bodies derived from embryonic stem cells (ES) with HEX [GeneID=3087] knockout.
Liver selective genes
Top genes down-regulated in metastatic (T24T) vs non-metastatic (T24) bladder cancer cell lines.
'Spiked' genes: genes most highly up-regulated in multiple myeloma samples; were not differentially expressed as compared to the normal plasma cells.
Genes down-regulated in multiple myeloma (MM) compared to normal plasma cells from the patient's identical twin.
Integrin signaling signature in precursor B leukemia (PBL) cells:  fibronectin (FN1) [GeneID=2335] vs control treatment with poly-L-lysine.
Top 50 up-regulated genes in cluster LB of multiple myeloma samples belonging to the low bone disease group.
Genes changed in the B cell chronic lymphocytic leukemia (B-CLL) with deletions in the 11q23 region.
Myb-regulated genes in MCF7 (breast cancer) and lung epithelial cell lines overexpressing MYBL2, MYBL1 or MYB [GeneID=4605;4603;4602].
Genes defining proliferation and self renewal potential of the bipotential myeloid cell line FDB.
Genes down-regulated in T lymphocytes overexpressing TERT [GeneID=7015] off a retrovirus vector.
Genes up-regulated in RAW 264.7 cells (macrophage) 3 hr after stimulation with bacterial lipopolysaccharide (LPS).
Genes down-regulated in Wilm's tumor samples compared to fetal  kidney.
Genes down-regulated in hematopoietic precursor cells conditionally expressing HOXA9 and MEIS1 [GeneID=3205;4211].
Genes down-regulated in H358 cells (lung cancer) by inducible expression of CEBPA [GeneID=1050] off plasmid vector.
Genes down-regulated in adipose tissue from obese mouse strains compared to the lean ones.
Top 100 genes negatively associated with T-cell acute lymphoblastic leukemia MLL T-ALL) expressing MLL-ENL fusion [GeneID=4297;4298].
Up-regulated genes in myeloid progenitors immortalized by HOXA9 [GeneID=3205] vs those immortalized by HOXA9 and MEIS1 [GeneID=4211].
Genes down-regulated in RAW 264.7 cells (macrophage) 3 hr after stimulation with bacterial lipopolysaccharide (LPS).
Genes down-regulated in acute promyelocytic leukemia (APL) patients with mutated FLT3 [GeneID=2322].
Genes commonly up-regulated in CD-1 and CD-2 clusters of multiple myeloma samples and which were higher expressed in the CD-1 group.
Genes correlated with the development of hyperglycemia in obese mice.
ES/PNET (Ewing sarcoma; primitive neuroectodermal tumors) markers up-regulated in neuroblastoma cell lines expressing ESWR1-FLI1 [GeneID=2130;2313] fusion protein.
Top 50 up-regulated genes in cluster PR of multiple myeloma samples characterized by increased expression of proliferation and cell cycle genes.
Genes up-regulated in H358 cells (lung cancer) by inducible expression of CEBPA [GeneID=1050] off plasmid vector.
Genes down-regulated in B cell lymphoma tumors expressing an activated form of MYC [GeneID=4609].
Target genes for STAT3 [GeneID=20848] in CSF3 [GeneID=12985] signaling during myeloblast differentiation to neutrophils.
Genes most significantly up-regulated in multiple myeloma samples, compared to normal bone marrow plasma cells.
Genes up-regulated during in vitro maturation of CD14+ [GeneID=929] monocytes (day 0) into immature (day 7) and mature dendritic cells (day 14).
Genes down-regulated in KCL22 cells (chronic myelogenous leukemia, CML, with BCR-ABL1 [GeneID=613;25] fusion) by expression of CEBPA [GeneID=1050].
Genes down-regulated during in vitro maturation of CD14+ [GeneID=929] monocytes (day 0) into immature (day 7) and mature dendritic cells (day 14).
Top 50 genes down-regulated in granulocyte/macrophage progenitors (GMP) upon expression of MLL-CBP fusion [GeneID=4297;1387].
Genes up-regulated in hematopoietic progenitor cells (HPC) of B lymphocyte lineage CD34+CD45RA+CD10+ [GeneID=947;5788;4311].
Genes commonly expressed in long term hematopoietic stem cells (HSC) and multipotent progenitors (MPP).
Genes down-regulated in pre-B lymphocytes upon Cre-Lox knockout of E2A [GeneID=6929].
Genes up-regulated in primary keratinocytes by expression of constantly active NOTCH1 [GeneID=4851].
Top 50 up-regulated genes in cluster CD-2 of multiple myeloma samples with the characteristic expression spike of CCND3 [GeneID=896].
Genes changed in the B cell chronic lymphocytic leukemia (B-CLL) with trisomy of chromosome 12.
Genes up-regulated in AtT20 cells (pituitary cancer) after  treatment with LIF [GeneID=3976].
Genes up-regulated in immunoglobulin light chain amyloidosis plasma cells (ALPC) compared to multiple myeloma (MM) cells.
Genes up-regulated in polymorphonuclear neutrophilic granulocytes (PMNs) attracted to skin wounds.
Genes changed in NIH 3T3 cells (embryonic fibroblast) by expression of one or more of C/EBP proteins: CEBPA, CEBPB, CEBPG,  and CEBPD [GeneID=1050;1051;1054;1052].
Genes up-regulated in acute myeloid leukemia (AML) patients with mutated NPM1 [GeneID=4869].
Up-regulated genes in the signature of adipose stromal cells (ADSC) immortalized by forced expression of telomerase (TERT) [GeneID=7015].
Gene down-regulated by CD40 [GeneID=958] signaling in Ramos cells (EBV negative Burkitt lymphoma).
Top 50 up-regulated genes in cluster MF of multiple myeloma samples with characteristic expression spike of MAF family transcription factors.
Genes down-regulated in BEC (blood endothelial cells) compared to LEC (lymphatic endothelial cells).
Genes abnormally regulated in response to CD40L and IL4 [GeneID=959;3565] stimulation of B lymphocytes from patients with a hypomorphic mutation of IKBKG [GeneID=8517].
Genes up-regulated in T lymphocytes overexpressing TERT [GeneID=7015] off a retrovirus vector.
Genes up-regulated in LEC (lymphatic endothelial cells) compared to BEC (blood endothelial cells).
Genes up-regulated in Wilm's tumor samples compared to fetal  kidney.
Genes up-regulated in Ewing family tumors (EFT) compared with normal bone marrow samples.
Genes up-regulated in acute promyelocytic leukemia (APL) patients with mutated FLT3 [GeneID=2322].
Genes up-regulated in MEF cells (embryonic fibroblast) expressing ~25% of YY1 [GeneID=7528].
Genes down-regulated in polymorphonuclear neutrophilic granulocytes (PMNs) attracted to skin wounds.
Genes down-regulated in MEF cells (embryonic fibroblast) expressing ~25% of YY1 [GeneID=7528].
Genes down-regulated in B-CLL (B-cell chronic lymphocytic leukemia) patients with mutated immunoglobulin variable heavy chain (VH) genes.
Cluster 1: genes up-regulated by RB1, CDNK2A [GeneID=1029;5925], and one of the E2Fs (E2F1, E2F2, or E2F3 [GeneID=1869;1870;1871]).
Genes down-regulated in acute myeloid leukemia (AML) with respect to cellular localization of NPM1 [GeneID=4869]: cytoplasmic vs. nucleolar.
Down-regulated genes in the signature of adipose stromal cells (ADSC) immortalized by forced expression of telomerase (TERT) [GeneID=7015].
Genes up-regulated in hematopoietic precursor cells conditionally expressing HOXA9 and MEIS1 [GeneID=3205;4211].
Genes down-regulated in the uteri of ovariectomized mice 6 h after progesterone [PubChem=5994] injection: HOXA10 [GeneID=3206] knockout vs wild type animals.
Genes down-regulated in primary keratinocytes by expression of constantly active NOTCH1 [GeneID=4851].
Up-regulated genes distinguishing in multiple myeloma (MM) samples with higher expression of TACI [GeneID=23495].
Differentially expressed genes between high vs low ZAP70 [GeneID=7535] acute lymphoblastic leukemia (ALL) cases with no known molecular aberrations.
Genes specific to BEC (blood endothelium cells) repressed in BEC by expression of PROX1 [GeneID=5629] off adenovirus vector.
Genes directly down-regulated by CD44 [GeneID=960] stimulation of B lymphocytes.
Genes significantly up-regulated in the blood mononuclear cells from patients with systemic lupus erythematosus compared to those from healthy persons.
Genes up-regulated in NB4 cells (acute promyelocytic leukemia, APL) by tretinoin [PubChem=444795] alone.
Genes down-regulated in immunoglobulin light chain amyloidosis plasma cells (ALPC) compared to multiple myeloma (MM) cells.
Hypoxia response genes up-regulated in both astrocytes and HeLa cell line.
Endoplasmic retuculum (ER) stress response (caused by  tunicamycin [PubChem=5282055]) genes dependent on CHOP [GeneID=13198].
The v2LDG set: 50 most variable late differentiation genes (LDG) with similar expression patterns in bone marrow plasma cells (BPC) and multiple myeloma (MM) samples.
Genes up-regulated by expression of GAB2 [GeneID=9846] in K562 cells (chronic myeloid leukemia (CML) cell line with p210 BCR-ABL [GeneID=613;25]).
Genes down-regulated in hematopoietic progenitor cells (HPC) of T lymphocyte and NK (natural killer) lineage.
Top 50 most-increased mast cell specific genes.
Granule constituents expressed during mouse promyelocytic cell line differentiation to neutrophils.
Top 50 up-regulated genes in cluster MS of multiple myeloma samples with characteristic expression spike of WHSC1 [GeneID=7468].
Genes up-regulated during myeloid differentiation induced by tretinoin (ATRA) [PubChem=444795] and IL3 [GeneID=3652] in the EML cell line (myeloid progenitor).
The 'Bullinger validation signature' [PMID=15084693] used to validate prediction of prognostic outcome of acute myeloid leukemia (AML) patients with a normal karyotype.
Metastatic propensity markers of head and neck squamous cell carcinoma (HNSCC): down-regulated in metastatic vs non-metastatic tumors.
Genes whose CpG islands are hyper-methylated in the NB4 cell line (APL, acute promyelocytic leukemia) compared to PBMC (normal peripheral peripheral blood mononuclear cells).
Top 50 up-regulated genes in cluster HP of multiple myeloma samples characterized by a hyperploid signature.
Genes down-regulated in NB4 cells (acute promyelocytic leukemia, APL) by tretinoin [PubChem=444795] alone.
Genes up-regulated in KCL22 cells (chronic myelogenous leukemia, CML, with BCR-ABL1 [GeneID=613;25] fusion) by expression of CEBPA [GeneID=1050].
Genes differentially expressed in pediatric AML (acute myeloid leukemia) samples from patients with good survival (>3 years without relapse) compared to those with poor survival (relapsed within one year after treatment).
Genes up-regulated in pro-B lymphocytes after knockout of CREBBP [GeneID=1387].
Genes down-regulated in acute myeloid leukemia (AML) patients with mutated NPM1 [GeneID=4869].
Neuroblastoma markers down-regulated in neuroblastoma cell lines expressing ESWR1-FLI1 [GeneID=2130;2313] fusion protein.
Genes up-regulated by imatinib [PubChem=5291] during dendritic cell differentiation.
Genes specifically expressed in FAB subtypes M2, M4, M5 and M7 of pediatric AML (acute myeloid leukemia).
Genes down-regulated in CD-1 compared to CD-2 cluster of multiple myeloma samples.
Down-regulated genes distinguishing in multiple myeloma (MM) samples with lower expression of TACI [GeneID=23495].
Genes down-regulated in GH3 cells (pituitary cancer) after treatment with LIF [GeneID=3976].
Genes down-regulated in pro-B lymphocytes after knockout of CREBBP [GeneID=1387].
Genes down-regulated in pancreatic cells from mice with double knockout of E2F1 [GeneID=1869] and E2F2 [GeneID=1870] compared to wild type.
Genes temporally up-regulated by CD44 [GeneID=960] stimulation of B lymphocytes.
Genes down-regulated in hematopoietic stem cells (HSC) overexpressing a constitutively active form of STAT5 [GeneID=6776] off retroviral vector.
Genes temporally down-regulated by CD44 [GeneID=960] stimulation of B lymphocytes.
Genes up-regulated in pancreatic cells from mice with double knockout of E2F1 [GeneID=1869] and E2F2 [GeneID=1870] compared to wild type.
Genes up-regulated in multiple myeloma (MM) compared to normal plasma cells from the patient's identical twin.
Putative targets or partners of EZH2 [GeneID=2146] in hematopoietic stem cells.
Genes most significantly down-regulated in multiple myeloma samples, compared to normal bone marrow plasma cells.
Gene up-regulated by CD40 [GeneID=958] signaling in Ramos cells (EBV negative Burkitt lymphoma).
Genes changed in the B cell chronic lymphocytic leukemia (B-CLL) with deletions in the  6q21 region.
Genes changed by expression of activated form of HRas[GeneID=3265] in MEF cells (embryonic fibroblast) with or without p65/c-Rel complex [GeneID=5970;5966].
Genes down-regulated in samples from B-CLL (B-cell chronic lymphocytic leukemia) with the immunoglobulin heavy chain VH3-21 gene.
Genes up-regulated in pre-B lymphocytes upon Cre-Lox knockout of E2A [GeneID=6929].
Genes down-regulated synergistically in NB4 cells (acute promyelocytic leukemia, APL) by tretinoin and NSC682994 [PubChem=444795;388304].
Genes whose CpG islands showed greatly increased histone H4 acetylation in NB4 cells (acute promyelocytic leukemia, APL) upon treatment with tretinoin [PubChem=444795].
Genes that are rapidly down-regulated as multipotential cells of the FDCP-mix hematopoiesis model undergo differentiation and loose their self-renewal and proliferation properties.
Genes up-regulated in normal bone marrow plasma cells (BMPC) compared to polyclonal plasmablasts (PPC) that also distinguished multiple myeloma (MM) samples by expression of levels of TACI (TNFRSF13B) [GeneID=23495].
Genes specific to LEC (lymphatic endothelium cells) induced in BEC (blood endothelium cells) by expression of PROX1 [GeneID=5629] off adenovirus vector.
Genes directly up-regulated by CD44 [GeneID=960] stimulation of B lymphocytes.
Myeloid leukemia model in mice with germ-line MLL-AF9 fusion knock-in [GeneID=4297;4300]: genes changed in comparison among the leukemic, preleukemic and wild-type animals.
Genes up-regulated in samples from B-CLL (B-cell chronic lymphocytic leukemia) with the immunoglobulin heavy chain VH3-21 gene.
Cluster 8: genes changed in primary keratinocytes by UVB irradiation.
Genes up-regulated in normal fibroblasts under hypoxia conditions.
Cluster d9: genes progressively down-regulated in WS1 cells (fibroblast) through 24 h after irradiation with high dose UV-C.
Genes up-regulated in T24 cells (bladder carcinoma) after treatment with decitabine (5-aza-2'-deoxycytidine) [PubChem=451668].
Genes in the expression cluster 'Early Progenitors Shared': up-regulated in hematopoietic progenitors from adult bone marrow and from fetal liver.
Genes down-regulated in fibroblasts from patients with Hutchinson-Gilford progeria (premature aging), compared to those from normal young individuals.
Genes down-regulated by trabectedin [PubChem=3199] and its synthetic analog phthalascidin Pt 650 in HCT116 cells (colon cancer).
Oxidative stress genes down-regulated in ARPE-19 cells (retinal pigmented epithelium) in response to tert-butyl hydroperoxide (tBH) and H2O2 [PubChem=6410;784].
Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 20 h time point that were not up-regulated at the previous time point, 18 h.
Genes up-regulated in primary tissue culture of epidermal kerationcytes after UVB irradiation.
Genes up-regulated in primary adipocytes compared to preadipocytes.
Downregulated in the neocortex of aged adult mice (30-month) vs young adult (5-month)
Genes commonly up-regulated in human alveolar rhabdomyosarcoma (ARMS) and its mouse model overexpressing PAX3-FOXO1 [GeneID=5077;2308] fusion.
Genes commonly down-regulated in human alveolar rhabdomyosarcoma (ARMS) and its mouse model overexpressing PAX3-FOXO1 [GeneID=5077;2308] fusion.
Genes up-regulated in primary fibroblasts from Rett syndrom patients who carry mutations inactivating MECP2 [GeneID=4204].
Genes up-regulated in the nucleus accumbens (a major reward center in brain) 8 weeks after induction of deltaFosB, a FOSB [GeneID=2354] splice variant.
Genes down-regulated in  FL5.12 cells (pro-B lymphocyte) in response to methotrexate [PubChem=4112].
Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 16 h time point that were not up-regulated at the previous time point, 14 h.
Genes up-regulated in hyppocampus at late postnatal stages (clusters 11 and 15).
Genes up-regulated in MCF-7 cells (breast cancer) in response to growth medium from L3T3-L1 cells (differentiated to pre-adipocytes).
Down-regulated genes distinguishing between breast cancer tumors with mutated BRCA1 [GeneID=672] from those with mutated BRCA2 [GeneID=675].
Strongly down-regulated at 8-48 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.
Genes up-regulated in HUVEC cells (endothelium) at 2 h after VEGFA [GeneID=7422] stimulation.
Genes basally silent, with hypermethylated promoters, up-regulated by the combination of TSA and decitabine [PubChem=5562;451668] in RKO cells (colorectal cancer).
Genes up-regulated in T98 cells (glioma) 48 h after treatment with interferon beta.
Genes up-regulated in patients at the incipient stage of Alzheimer's disease.
Genes in the expression cluster 'MBC Shared': up-regulated in mature blood cell populations from adult bone marrow and fetal liver.
Cluster G3: genes increasingly up-regulated in NHEK cells (normal keratinocyte) after 6 h time point upon UV-B irradiation.
Up-regulated in murine dorsal skin cells at 6 h after treatment with the phorbol ester carcinogen TPA [PubChem=4792].
Genes identified as hypermethylated in SW48 cells (colon cancer).
Genes down-regulated in atria of failing hearts (DCM and ICM) compared to healthy controls.
Genes up-regulated specifically in human pancreas.
Adipocyte abundant genes up-regulated in 3T3-L1 cells (fibroblasts induced to differentiate to adipocytes) in response to troglitazone [PubChem=5591].
Genes down-regulated by expression of HBV X protein (HBVgp3) [GeneID=944566] in primary hepatocytes.
Up-regulated in hepatocytes upon expression of NOS2 [GeneID=4843].
Up-regulated in the cerebral cortex of aged (22 months) BALB/c mice, compared to young (2 months) controls
Oxidative stress genes down-regulated in ARPE-19 cells (retinal pigmented epithelium) in response to HNE, tBH and H2O2 [PubChem=5283344;6410;784].
Genes distinguishing between sporadic breast cancer tumors and hereditary breast cancer tumors that have mutated BRCA1 and BRCA2 [GeneID=672;675].
Genes up-regulated in HEK293 cells (embryonic kidney) at 6 h, 12 h or 24 h after infection with reovirus strain T3A (known as a strong inducer of apoptosis).
Genes up-regulated in FL5.12 cells (pro-B lymphocyte) in response to cisplatin [PubChem=2767].
Genes in the expression cluster 'Late Progenitors Shared': up-regulated in hematopoietic late progenitor cells from adult bone marrow and fetal liver.
Age down-regulated genes in the human frontal cortex.
Adipocyte abundant genes up-regulated in 3T3-L1 cells (fibroblasts induced to differentiate to adipocytes) in response to TNF [GeneID=7124].
Genes up-regulated in NCI-H2170 cells (lung cancer) upon induction of resistance to cisplatin [PubChem=2767].
Up-regulated in the neocortex of aged (30-month) mice subjected to caloric restriction since young adulthood.
Genes down-regulated in H460 cells (non-small cell lung carcinoma, NSCLC) after treatment with sodium butyrate [PubChem=5222465].
Genes in the expression cluster 'LT-HSC Shared': up-regulated in long term hematopoietic stem cells (LT-HSC) from adult bone marrow and fetal liver.
Oxidative stress genes down-regulated in ARPE-19 cells (retinal pigmented epithelium) in response to HNE and H2O2 [PubChem=5283344;784].
Genes discriminating between direct (cisplatin, MMS, mitomycin C [PubChem=2767;4156;5746]) and indirect (paclitaxel, hydroxyurea, etoposide [PubChem=4666;3657;36462]) acting genotoxins at 4 h time point.
Genes up-regulated in HeLa cells (cervical carcinoma) at 4 h after stimulation with TNF [GeneID=7124].
Genes up-regulated in chondrosarcoma and ovarian carcinoma cell lines which developed resistance to trabectedin [PubChem=3199].
Selected genes up-regulated in WS1 (fibroblast) in response to irradiation with low dose UV-C.
Genes down-regulated in brain from patients with Alzheimer's disease.
Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 16 h time point that were not down-regulated at the previous time point, 14 h.
Genes up-regulated in MMEC cells (myometrial endothelium) at 6 h after VEGFA [GeneID=7422] stimulation.
Genes up-regulated in A172 cells (glioma, does not express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 24 h.
Genes depleted in embryonic, neural and hematopoietic stem cells.
Genes up-regulated in MEF cells (embryonic fibroblast) lacking TP53 and BRCA1 [GeneID=7157;672] by expression of TP53; most genes are further up-regulated by simultaneous expression of BRCA1.
Cluster d4: genes progressively down-regulated in WS1 cells (fibroblast) through 12 h after irradiation with high dose UV-C.
Genes commonly up-regulated in cancer relative to normal tissue, according to the meta-analysis of the OncoMine gene expression database.
Top 20 positive significant genes associated with malignant fibrous histiocytoma tumors.
Genes up-regulated at 6 months of age in lungs from LIPA [GeneID=3988] knockout mice, which display pulmonary pathology.
Genes down-regulated by expression of HBV X protein (HBVgp3) [GeneID=944566] in SK-Hep-1 cells (hepatocellular carcinoma).
Top 20 genes whose down-regulation correlated with gastrointestinal stromal tumors (GIST) and synovial sarcoma compared to other tumors.
Genes known to be induced by hypoxia
Adipocyte abundant genes down-regulated in 3T3-L1 cells (fibroblasts induced to differentiate to adipocytes) in response to troglitazone [PubChem=5591] and TNF [GeneID=7124].
Genes up-regulated specifically in human salivary gland tissue.
Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 10 h time point that were not down-regulated at the previous time point, 8 h.
Downregulated in the vastus lateralis muscle of middle aged rhesus monkeys subjected to caloric restriction since young adulthood vs age matched controls
Genes up-regulated in ALAB cells (breast cancer) upon reintroduction of SMARCA4 [GeneID=6597] expressed off adenoviral vector.
Down-regulated in HEK293 cells (kidney epithelium) by treatment with sodium arsenite [PubChem=26435].
Genes down-regulated in primary keratinocytes at 6 h after UVB irradiation.
Down-regulated genesin the left ventricle myocardium of patients with heart failure following implantation of LVAD (left ventricular assist device).
Genes enriched in embryonic, neural and hematopoietic stem cells.
Cluster 7: genes up-regulated in SW260 cells (colon cancer) by curcumin and sulindac [PubChem=969516;5352].
Genes up-regulated in the mouse model of acute lung injury induced by inhaling nickel sulfate [PubChem=24586].
Cluster 4: genes changed in primary keratinocytes by UVB irradiation.
Genes down-regulated in BT549 cells (breast cancer) by expression of SMARCE1 [GeneID=6605] off a retroviral vector.
Genes up-regulated specifically in human testis tissue.
Genes down-regulated in primary fibroblasts from Rett syndrom patients who carry mutations inactivating MECP2 [GeneID=4204].
Cluster 6: genes changed in primary keratinocytes by UVB irradiation.
Genes down-regulated in the nucleus accumbens (a major reward center in the brain) 8 weeks after induction of CREB1 [GeneID=1385] expression in a transgenic Tet-Off system.
Genes whose expression decreases with age in normal kidney, excluding those with higher expression in blood.
Genes up-regulated by in C3H/10T1/2 cells (embryonic pluripotent cell) in response to SSH [GeneID=6469].
Genes with some basal expression and partially methylated promoters, up-regulated by the combination of TSA and decitabine [PubChem=5562;451668] in RKO cells (colorectal cancer).
Cluster 2: genes changed in primary keratinocytes by UVB irradiation.
Genes up-regulated in the atria of healthy hearts, compared to venticles.
Genes most consistently regulated at 24 h by all six genotoxins tested: cisplatin, methyl methanesulfonate, mitomycin C, taxol, hydroxyurea and etoposide [PubChem=2767;4156;5746;4666;3657;36462].
Top 20 genes whose up-regulation correlated with gastrointestinal stromal tumors (GIST) compared to synovial sarcoma.
Genes most strongly up-regulated in kidney glomeruli isolated from TCF21 [GeneID=6943] knockout mice.
Up-regulated genes distinguishing between two groups of non-BRCA1/BRCA2 [GeneID=672;675] breast tumors (BRACx): group A vs group B.
Genes down-pregulated by dsRNA in GRE cells (glioma; no interferon system).
All significantly down-regulated genes in kidney glomeruli isolated from TCF21 [Gene ID=6943] knockout mice.
Genes down-regulated in c-JunER cells (mammary gland epithelum) by overexpression of IFRD1 [GeneID=3475] off an adenovirus vector.
Genes up-regulated in NIH-3T3 cells (fibroblast) after knockdown of PRMT5 [GeneID=10419] by RNAi.
Top genes down-regulated in liver tissue from mice with knockout of ZMPSTE24 [GeneID=10269].
50 most interesting genes up-regulated in the pancreatic cancer cell lines (AsPC1, Hs766T, MiaPaCa2, Panc1) but not in the non-neoplastic cells (HPDE) by decitabine (5-aza-2'-deoxycytidine) [PubChem=451668].
Genes up-regulated in HL-60 cells (promyeloid leukemia) by cantharidin [PubChem=6708701].
Down-regulated genes distinguishing between two groups of non-BRCA1/BRCA2 [GeneID=672;675] breast tumors (BRACx): group A vs group B.
Down-regulated in the hypothalamus of aged (22 months) BALB/c mice, compared to young (2 months) controls
Genes down-regulated in normal keratinocytes immortalized by infection with the high risk HPV31 (human papilloma virus) strain.
Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 24 h time point that were not down-regulated at the previous time point, 20 h.
Cluster 8: genes down-regulated in SW260 cells (colon cancer) by sodium butyrate, curcumin, sulindac and TSA [PubChem=5222465;969516;5352;5562].
Cancer related genes up-regulated in any of four hepatoma cell lines following 24 h treatment with TSA [PubChem=5562].
Down-regulated genes in metastatic vs primary solid tumors.
Genes highly expressed in the neonatal hippocampus (clusters 4 and 8).
Genes up-regulated in the nucleus accumbens (a major reward center in the brain) after 5 days of cocaine [PubChem=5760] treatment.
Upregulated in the vastus lateralis muscle of aged vs young adult rhesus monkeys
Genes up-regulated after heat shock in peripheral lympocytes from old donors, compared to those from the young ones.
Genes down-regulated in MCF7 cells (breast cancer) after treatment with the oxydants: hydrogen peroxyde, menadione, and t-butyl hydroperoxyde [PubChem=784;4055;6410].
Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 14 h time point that were not down-regulated at the previous time point, 12 h.
Genes down-regulated in NIH 3T3 cells (fibroblasts) 24 h after inducing MyoD [GeneID=4654] differentiation program.
Genes up-regulated in embryonic stem cells from TCEB3 [GeneID=6924] knockout mice.
Genes discriminating between direct (cisplatin, MMS, mitomycin C [PubChem=2767;4156;5746]) and indirect (paclitaxel, hydroxyurea, etoposide [PubChem=4666;3657;36462]) acting genotoxins at 24 h time point.
Genes up-regulated in 786-0 cells (renal carcinoma, RCC) upon expression of VHL [GeneID=7428] off a retroviral vector under normoxia (normal oxygen) condition.
Genes down-regulated in SW480 cells (colon cancer with mutated p53 [GeneID=7157]) upon expression of BRCA1 [GeneID=672] off an adenovirus vector.
Downregulated in the cerebellum of aged adult mice (30-month) vs young adult (5-month)
Up-regulated in B lymphocytes from patients with ICF syndrom caused by mutations in DNMT3B [GeneID=1789] compared to normals.
Genes up-regulated in primary fibroblast culture after treatment with interferon alpha for 6 h.
Genes up-regulated in the nucleus accumbens (a major reward center in brain) 2 weeks after induction of deltaFosB, a FOSB [GeneID=2354] splice variant.
Genes most strongly down-regulated in kidney glomeruli isolated from TCF21 [GeneID=6943] knockout mice.
Genes up-regulated specifically in human thymus.
Genes down-regulated in gastric cancer cell lines resistant to 5-fluorouracil [PubChem=3385].
Top 20 negative significant genes associated with liposarcomas, versus other soft-tissue tumors.
Genes up-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 8 h time point that were not up-regulated at the previous time point, 6 h.
Genes up-regulated in at least 8 of 11 sarcoma cell lines by trabectedin [PubChem=3199].
Down-regulated in ovarian epithelial cells (MCV152) 72 hours following FSH treatment, compared to untreated
Genes up-regulated in MMEC cells (myometrial endothelium) at 12 h after VEGFA [GeneID=7422] stimulation.
Up-regulated in GHOST(3)CXCR4 cells (osteosarcoma) upon ectopic expression of ILF3 [GeneID=3609].
Genes up-regulated in MCF7 cells (breast cancer) after treatment with the oxydants: hydrogen peroxyde, menadione, and t-butyl hydroperoxyde [PubChem=784;4055;6410].
Genes up-regulated in aorta biopsies from mice treated with rosiglitazone [PubChem=77999].
Genes down-regulated in T98 cells (glioma) 48 h after treatment with interferon beta.
Genes up-regulated in glomeruli of kidneys from patients with diabetic nephropathy (type 2 diabetes mellitus).
Genes up-regulated in BJ cells (foreskin fibroblasts) immortalized by expression of TERT [GeneID=7015].
Genes up-regulated by expression of HBV X protein (HBVgp3) [GeneID=944566] both in SK-Hep-1 cells (hepatocellular carcinoma) and normal primary hepatocytes.
Genes down-regulated in fibroblasts with defective XPC [GeneID=7508] in response to cisplatin [PubChem=2767].
Genes up-regulated in primary keratinocytes at 6 h after UVB irradiation.
Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 20 h time point that were not down-regulated at the previous time point, 18 h.
Genes up-regulated in MEF cells (embryonic fibroblasts) from PARP1 [GeneID=142] knockout mice.
Genes whose splicing in neocortex was most affected by knock out of NOVA2 [GeneID=4858].
Cluster 10: genes down-regulated in SW260 cells (colon cancer) by sodium butyrate and TSA [PubChem=5222465;5562] with the same kinetics with which each alters the level of histone H4 acetylation.
Genes in the expression cluster 'HSC Shared': up-regulated in hematopoietic stem cells (HSC) from adult bone marrow and fetal liver.
Genes down-regulated in C2AS12 cells (myoblast) by IGF1 [GeneID=3479] vs PDGFB [GeneID=5155].
Genes up-regulated in H1299 cells (lung cancer) by expression of SMARCA4 [GeneID=6597] off a plasmid vector.
Genes up-regulated in gastric cancer cell lines resistant to 5-fluorouracil [PubChem=3385].
Genes down-regulated in corneal fibroblasts after treatment with IL1A [GeneID=3552].
Adipocyte abundant genes down-regulated in 3T3-L1 cells (fibroblasts induced to differentiate to adipocytes) in response to TNF [GeneID=7124].
Genes up-regulated in brain from patients with Alzheimer's disease.
Genes up-regulated in NIH 3T3 cells (fibroblasts) 24 h after inducing MyoD [GeneID=4654] differentiation program.
Strongly down-regulated at 2 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.
Genes up-regulated in HK-2 cells kidney tubular epithelium) under hypoxia and down-regulated on re-oxygenation.
Downregulated in the vastus lateralis muscle of aged vs young adult rhesus monkeys
Genes up-regulated in atria of failing hearts (DCM and ICM) compared to healthy controls.
Top 20 positive significant genes associated with liposarcomas, versus other soft-tissue tumors.
Genes whose promoters contain TP53 [GeneID=7157] response elements.
Cluster 9: genes up-regulated in SW260 cells (colon cancer) by sodium butyrate and TSA [PubChem=5222465;5562] with the same kinetics with which each alters the level of histone H4 acetylation.
Genes up-regulated in hypertrophic scar fibroblasts in response to IL6 [GeneID=3569].
Genes down-regulated in BJ cells (foreskin fibroblasts) immortalized by expression of TERT [GeneID=7015].
Genes down-regulated in SCC12B2 cells (squamous cell carcinoma) by UV-B irradiation.
Genes up-regulated in more than one of several human hepatoma cell lines by TSA [PubChem=5562].
Genes whose expression decreases with age in normal kidney.
Genes in cluster 2: moderately up-regulated in HFW cells (fibroblast) upon treatment with sodium arsenite [PubChem=26435] at all time points.
Genes up-regulated in gastric cancer cell lines: doxorubicin [PubChem=31703] resistant vs sensitive.
Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 48 h time point that were not down-regulated at the previous time point, 24 h.
Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 48 h time point that were not up-regulated at the previous time point, 24 h.
Down-regulated in human fetal pituitary tissue, compared to adult pituitary tissue
Up-regulated at 48-96 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.
Genes up-regulated in MMEC cells (myometrial endothelium) by VEGFA [GeneID=7422] stimulation.
Up-regulated genesin the left ventricle myocardium of patients with heart failure following implantation of LVAD (left ventricular assist device).
Genes down-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 8 h time point that were not down-regulated at the previous time point, 6 h.
Genes down-regulated in embryonic stem cells with BRCA1 [GeneID=672] loss of function (LOF).
Cluster 2: ECM related genes up-regulated in dermal fibroblasts within 30 min after TGFB1 [GeneID=7040] addition; reached a plateau after that.
Genes up-regulated in gastric cancer patients refractory to chemotherapy treatment with 5-fluorouracil and cisplatin [PubChem=3385;2767] compared to the sensitive state.
Genes down-regulated in T98G cells (glioma, express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 24 h.
Cluster d5: genes progressively down-regulated in WS1 cells (fibroblast) through 18 h after irradiation with high dose UV-C.
Genes up-regulated in  FL5.12 cells (pro-B lymphocyte) in response to methotrexate [PubChem=4112].
Genes commonly up-regulated in undifferentiated cancer relative to well-differentiated cancer, based on the meta-analysis of the OncoMine gene expression database.
Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 14 h time point that were not up-regulated at the previous time point, 12 h.
Genes down-regulated in embryonic stem cells from TCEB3 [GeneID=6924] knockout mice.
Up-regulated in the gastrocnemius muscle of aged (30-month) mice subjected to caloric restriction diet since young adulthood.
Genes up-regulated in SW480 cells (colon cancer with mutated p53 [GeneID=7157]) upon expression of BRCA1 [GeneID=672] off an adenovirus vector.
Cluster 1: ECM related genes up-regulated in dermal fibroblasts within 30 min after TGFB1 [GeneID=7040] addition, and which kept increasing with time.
Genes down-regulated in HeLa cells (cervical carcinoma) by trabectedin [PubChem=3199].
Downregulated in the gastrocnemius muscle of aged adult mice (30-month) vs young adult (5-month)
Genes up-regulated in HDMEC cells (microvascular endothelium): proliferating vs quiescent cells.
Genes up-regulated in HeLa cells (cervical carcinoma) by trabectedin [PubChem=3199].
Cluster 5: ECM related genes up-regulated in dermal fibroblasts later than 30 min after TGFB1 [GeneID=7040] addition; decreased slowly after the peak at 120 min time point.
Selected genes down-regulated during differentiation of 3T3-L1 cells (fibroblast) into adipocytes in response to adipogenic hormones.
Age up-regulated genes in the human frontal cortex.
Strongly up-regulated at 16-24 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.
Genes up-regulated in NHEK cells (normal keratinocytes) by UV-B irradiation.
Genes up-regulated at 3 months of age in lungs from LIPA [GeneID=3988] knockout mice, which display pulmonary pathology.
Up-regulated at any timepoint following infection of primary human foreskin fibroblasts with CMV
Up-regulated in human fetal pituitary tissue, compared to adult pituitary tissue
Progressively down-regulated 8-96 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.
Genes up-regulated in HT-29 cells (colon cancer) by the combination of trichostatin A (TSA) and sodium butyrate [PubChem=5562;5222465].
Adipocyte abundant genes up-regulated in 3T3-L1 cells (fibroblasts induced to differentiate to adipocytes) in response to troglitazone [PubChem=5591] and TNF [GeneID=7124].
Strongly up-regulated at 8 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.
ECM related genes up-regulated early (within 30 min) in dermal fibroblasts after addition of TGFB1 [GeneID=7040].
Genes up-regulated in MFCF-7 cells (breast cancer) by exogenous HG1 [GeneID=2688].
Down-regulated at 8 h following infection of primary human foreskin fibroblasts with CMV
Down-regulated at 24 h following infection of primary human foreskin fibroblasts with CMV
Genes down-regulated by expression of HBV X protein (HBVgp3) [GeneID=944566] both in SK-Hep-1 cells (hepatocellular carcinoma) and normal primary hepatocytes.
Genes up-regulated specifically in human kidney tissue.
Cluster d2: genes down-regulated consistently in WS1 cells (fibroblast) between 6 h and 24 h after irradiation with high dose UV-C.
Genes down-regulated in NIH-3T3 cells (fibroblast) after knockdown of PRMT5 [GeneID=10419] by RNAi.
Genes down-regulated in peripheral lymphocytes from old individuals compared to those from young donors.
50 genes up-regulated in the pancreatic cancer cell lines (AsPC1, Hs766T, MiaPaCa2, Panc1) but not in the non-neoplastic cells (HPDE) by the combination of decitabine  and TSA [PubChem=451668;5562].
Genes down-regulated in Sertoli cells from both 4 and 10 week old ETV5 [GeneID=2119] knockout mice.
Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 18 h time point that were not down-regulated at the previous time point, 16 h.
Up-regulated in CD4+ [GeneID=920] T lymphocytes after 4 h treatment with 100 nM TSA [PubChem=5562].
Genes in the expression cluster 'ST-HSC Shared': up-regulated in short term hematopoietic stem cells (ST-HSC) from adult bone marrow and fetal liver.
Genes down-regulated in primary tissue culture of epidermal kerationcytes after UVB irradiation.
Genes in cluster 4: immediate down-regulation in HFW cells (fibroblast) by sodium arsenite [PubChem=26435].
Genes up-regulated in A549 cells (lung carcinoma) upon infection with RSV (respiratory syncytial virus) and up-regulated by further treatment with ribavirin [PubChem=5064].
Cluster 4: genes down-regulated in SW260 cells (colon cancer) by sodium butyrate and sulindac [PubChem=5222465;5352].
Up-regulated in HEK293 cells (kidney epithelium) by treatment with sodium arsenite [PubChem=26435].
Cluster G4: genes increasingly up-regulated in NHEK cells (normal keratinocyte) after 12 h time point after UV-B irradiation.
Cluster d7: genes progressively down-regulated in WS1 cells (fibroblast) through 18 h after irradiation with high dose UV-C.
Down-regulated in B lymphocytes from patients with ICF syndrom caused by mutations in DNMT3B [GeneID=1789] compared to normals.
Genes down-regulated in the ventricles of healthy hearts, compared to atria.
Cluster d6: genes progressively down-regulated in WS1 cells (fibroblast) through 18 h after irradiation with high dose UV-C.
ECM related genes up-regulated later than 30 min following addition of TGFB1 [GeneID=7040] in dermal fibroblasts.
Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 18 h time point that were not up-regulated at the previous time point, 16 h.
Upregulated in the neocortex of aged adult mice (30-month) vs young adult (5-month)
Genes down-regulated in HL-60 cells (promyeloid leukemia) by cantharidin [PubChem=6708701].
Cluster 5: genes progressively up-regulated (peak at 24 h time point) during differentiation of 3T3-L1 fibroblasts into adipocytes in response to adipogenic hormones.
Genes up-regulated in 3T3-L1 cells (adipocyte) by insulin [GeneID=3630] which continued to respond normally to insulin in the insulin resistant cells.
Genes similarly up-regulated in 3T3-L1 cells (fibroblasts able to differentiate to adipocytes) upon stimulation of INSR or IGFR1 by NTF3 [GeneID=3643;3480;4908].
Genes specifically up-regulated in FL5.12 cells (pro-B lymphocyte) by  camptothecin [PubChem=2538].
Selected genes down-regulated in WS1 (fibroblast) in response to irradiation with high dose UV-C.
Genes up-regulated in HSC (hematopoietic stem cells) compared to HPC (hematopoietic progenitor cells).
Genes down-regulated in ALAB cells (breast cancer) upon reintroduction of SMARCA4 [GeneID=6597] expressed off adenoviral vector.
Genes up-regulated in 3T3 cells (fibroblast) upon activation of JNK pathway.
Genes down-regulated in gastric cancer cell lines: doxorubicin [PubChem=31703] resistant vs sensitive.
Cluster 0: genes changed in primary keratinocytes by UVB irradiation.
Genes down-regulated in pulpal tissue extracted from carious teeth.
Cluster 2: genes maximally expressed at 2 h time point during differentiation of 3T3-L1 fibroblasts into adipocytes (cluster 2) in response to adipogenic hormones.
Up-regulated PDGF targets identified by a gene-trap screen.
Genes up-regulated in the nucleus accumbens (a major reward center in the brain) 8 weeks after induction of CREB1 [GeneID=1385] expression in a transgenic Tet-Off system.
Upregulated in the cerebellum of aged adult mice (30-month) vs young adult (5-month)
Oxidative stress genes down-regulated in ARPE-19 cells (retinal pigmented epithelium) in response to HNE and tBH [PubChem=5283344;6410].
Down-regulated in brown preadipocytes with IRS1 [GeneID=3667] knockout vs wild type controls; the knockouts have severe defects in adipocyte differentiation.
Genes whose expression increases with age in normal kidney, excluding those with higher expression in blood.
Genes whose expression increases with age in normal kidney.
Genes up-regulated in the nucleus accumbens (a major reward center in the brain) after 4 weeks of cocaine [PubChem=5760] treatment.
Genes up-regulated in HeLa cells (cervical carcinoma) at 30 min after stimulation with TNF [GeneID=7124].
Up-regulated by induction of exogenous BRCA1 in EcR-293 cells
Genes up-regulated in MEF cells (embryonic fibroblast) upon Cre-lox knockout of DNMT1 [GeneID=1786].
Genes up-regulated in normal keratinocytes immortalized by infection with the high risk HPV31 (human papilloma virus) strain.
Genes highly expressed in prenatal hippocampus (cluster 1).
Progressively up-regulated from 8-48 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.
Down-regulated at any timepoint following infection of primary human foreskin fibroblasts with CMV
Genes in the expression cluster 'Intermediate Progenitors Shared': up-regulated in hematopoietic intemediate progenitor cells from adult bone marrow and fetal liver.
Selected genes up-regulated in WS1 (fibroblast) in response to irradiation with high dose UV-C.
Genes up-regulated specifically in human liver tissue.
Cancer related genes down-regulated in any of four hepatoma cell lines following 24 h treatment with TSA [PubChem=5562].
Genes up-regulated in C2AS12 cells (myoblast) by IGF1 [GeneID=3479] vs PDGFB [GeneID=5155].
Genes down-regulated in patients at the incipient stage of Alzheimer's disease.
Genes up-regulated in LD419 cells (fibroblast) after treatment with decitabine (5-aza-2'-deoxycytidine) [PubChem=451668].
Cellular genes up-regulated in forskin fibroblasts by expression of CMV EI86 protein off an adenovirus vector.
Down-regulated in the neocortex of aged (30-month) mice subjected to caloric restriction since young adulthood.
All significantly up-regulated genes in kidney glomeruli isolated from TCF21 [Gene ID=6943] knockout mice.
Cluster 1: genes changed in primary keratinocytes by UVB irradiation.
Genes up-regulated in fibroblasts from middle-age individuals, compared to those from the young donors.
Genes up-regulated in liver from transgenic mice with reduced expression of POR [GeneID=5447] in all tissues.
Genes up-regulated by expression of HBV X protein (HBVgp3) [GeneID=944566] in SK-Hep-1 cells (hepatocellular carcinoma).
Genes up-pregulated by dsRNA in GRE cells (glioma; no interferon system).
Genes most profoundly induced in HUVEC cells (endothelium) by VEGFA [GeneID=7422].
Up-regulated at 4 hours following treatment of mouse lymphocytes (TK 3.7.2C) with a high dose of methyl methanesulfonate (MMS)
Strongly up-regulated at 2 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.
Genes down-regulated in LD419 cells (fibroblast) after treatment with decitabine (5-aza-2'-deoxycytidine) [PubChem=451668].
Down-regulated in CD4+ [GeneID=920] T lymphocytes after 4 h treatment with 100 nM TSA [PubChem=5562].
Genes down-regulated in liver from transgenic mice with reduced expression of POR [GeneID=5447] in all tissues.
Down-regulated at 48-96 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.
Genes down-regulated in aorta biopsies from mice treated with rosiglitazone [PubChem=77999].
Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 10 h time point that were not up-regulated at the previous time point, 8 h.
Genes up-regulated in SW-13 cells (kidney cancer) by transient expression of SMARCA4 [GeneID=6597] at 24 h off a plasmid vector.
Genes differentially expressed in hereditary breast cancer tumors with mutated BRCA1 [GeneID=672] compared to those with mutated BRCA2 [GeneID=675].
Cluster d1: genes down-regulated in WS1 cells (fibroblast) at 6 h after irradiation with high dose UV-C.
Genes down-regulated in HEK293 cells (embryonic kidney) at 6 h, 12 h or 24 h after infection with reovirus strain T3A (known as a strong inducer of apoptosis).
Genes up-regulated in the brain cortex of mice that were exposed to an enriched learning environment for one day.
Genes down-regulated in 3T3-L1 cells (adipocyte) by insulin [GeneID=3630] but displayed blunted response to insulin the insulin resistant cells.
Genes up-regulated in A549 cells (lung carcinoma) upon infection with RSV (respiratory syncytial virus) and down-regulated by further treatment with ribavirin [PubChem=5064].
Down-regulated in murine dorsal skin cells at 6 h after treatment with the phorbol ester carcinogen TPA [PubChem=4792].
Genes up-regulated in NIH 3T3 cells (fibroblasts) 24 h after inducing MYOD [GeneID=4654] which were down-regulated by dominant negative form of SMARCA4 [GeneID=6597].
Genes specifically down-regulated in FL5.12 cells (pro-B lymphocyte) by  camptothecin [PubChem=2538].
Genes down-regulated in NCI-H2170 cells (lung cancer) upon induction of resistance to cisplatin [PubChem=2767].
Cluster 1:  genes progressively down-regulated over 24 h (peak at 0 h timepoint) during differentiation of 3T3-L1 fibroblasts into adipocytes in response to adipogenic hormones.
Up-regulated genes distinguishing between breast cancer tumors with mutated BRCA1 [GeneID=672] from those with mutated BRCA2 [GeneID=675].
Genes down-regulated in MEF cells (embryonic fibroblast) upon Cre-lox knockout of DNMT1 [GeneID=1786].
Genes down-regulated in NHEK cells (normal keratinocytes) by UV-B irradiation.
Genes up-regulated in A172 cells (glioma, does not express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 48 h.
Genes down-regulated in CS-B cells (Cockayne syndrome fibroblast, CS) with defficient ERCC6 [GeneID=2074] in response to hydrogen peroxide [PubChem=784].
DNA replication genes up-regulated in a Rat-1a cell line (fibroblast) by expression of E2F1 [GeneID=1869].
Cluster 4: ECM related genes up-regulated in dermal fibroblasts later than 30 min after TGFB1 [GeneID=7040] addition; kept increasing with time.
Up-regulated at 24 h following infection of primary human foreskin fibroblasts with CMV
Top 20 genes whose up-regulation correlated with gastrointestinal stromal tumors (GIST) and synovial sarcoma compared to other tumors.
Strongly down-regulated at 2-96 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.
Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 12 h time point that were not up-regulated at the previous time point, 10 h.
Top 20 positive significant genes associated with schwannoma tumors.
Genes in the expression cluster 'HSC and Progenitors Shared': up-regulated in hematopoietic stem cells (HSC) and progenitors from adult bone marrow and fetal liver.
Up-regulated genes in metastatic vs primary solid tumors.
Genes up-regulated in SCC12B2 cells (squamous cell carcinoma) by UV-B irradiation.
Upregulated in the vastus lateralis muscle of middle aged rhesus monkeys subjected to caloric restriction since young adulthood vs age matched controls
Genes up-regulated in RPTEC cells (normal kidney) by hypoxia.
Genes down-regulated in A172 cells (glioma, does not express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 48 h.
Genes prefentially expressed in human inner ear tissue (cochlea and vestibule), at least 10-fold higher from a mixture of 29 other tissues.
Cluster 5: genes up-regulated in SW260 cells (colon cancer) by curcumin and sulindac [PubChem=969516;5352].
Up-regulated in brown preadipocytes with IRS1 [GeneID=3667] knockout vs wild type controls; the knockouts have severe defects in adipocyte differentiation.
Genes up-regulated in 3T3-L1 cells (adipocyte) by insulin [GeneID=3630] but displayed blunted response to insulin the insulin resistant cells.
Genes up-regulated in MFCF-7 cells (breast cancer) upon stable autocrine expression of HG1 [GeneID=2688].
Genes down-regulated in MFCF-7 cells (breast cancer) by exogenous HG1 [GeneID=2688].
Genes down-regulated in glomeruli of kidneys from patients with diabetic nephropathy (type 2 diabetes mellitus).
Genes up-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 6 h time point that were not up-regulated at the previous time point, 4 h.
Cluster G1: genes most highly up-regulated in NHEK cells (normal keratinocyte) between 6 h and 12 h after UV-B irradiation.
Genes down-regulated in fibroblasts from old individuals, compared to those from young donors.
Genes up-regulated in liver from mice with liver specific knockout of POR [GeneID=5447] vs mice with reduced expression of POR in all tissues.
Genes down-regulated in primary keratinocytes at 24 h after UVB irradiation.
Genes that are transcriptionally regulated by HIF1A [GeneID=3091].
Genes down-regulated in D-341 MED (OBR) cells (medulloblastoma) resistant to both carmustine and O6-BG [PubChem=2578;4578].
Genes up-regulated in fibroblasts with defective XPC [GeneID=7508] in response to cisplatin [PubChem=2767].
Top genes up-regulated in liver tissue from mice with knockout of ZMPSTE24 [GeneID=10269].
Genes in cluster 3: delayed up-regulation in HFW cells (fibroblast) by sodium arsenite [PubChem=26435].
50 most interesting genes up-regulated in pancreatic cancer cell lines (AsPC1, Hs766T, MiaPaCa2, Panc1) but not in the non-neoplastic cells (HPDE) by TSA [PubChem=5562].
Genes down-regulated in HPL1D cells (lung epithelium) upon exposure to nickel acetate [PubChem=9756].
Genes showing decreasing expression in brown preadipocytes with increasing ability of the cells to differentiate.
Cluster G6: genes increasingly down-regulated in NHEK cells (normal keratinocyte) after UV-B irradiation.
Top 20 positive significant genes associated with leiomyosarcoma tumors expressing muscle gene cluster with CNN1 [GeneID=1264].
Genes down-regulated in MFCF-7 cells (breast cancer) upon stable autocrine expression of HG1 [GeneID=2688].
Cluster 7: genes changed in primary keratinocytes by UVB irradiation.
Genes down-regulated in the ventricles of failing hearts (DCM and ICM) compared to the healthy controls.
Genes up-regulated in 786-0 cells  (renal carcinoma, RCC) by hypoxia and in the absensce of VHL [GeneID=7428].
Down-regulated in hepatocytes upon expression of NOS2 [GeneID=4843].
Genes in cluster 1: strongly up-regulated in HFW cells (fibroblast) upon treatment with sodium arsenite [PubChem=26435] at all time points.
Genes down-regulated in T98G cells (glioma, express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 48 h.
Cluster 3: genes maximally expressed at 8 hr time point  during differentiation of 3T3-L1 fibroblasts into adipocytes in response to adipogenic hormones.
Genes down-regulated in MEF cells (embryonic fibroblasts) from PARP1 [GeneID=142] knockout mice.
Genes up-regulated in anergic mouse T helper cells (A.E7), versus non-anergic stimulated controls
Genes up-regulated by expression of HBV X protein (HBVgp3) [GeneID=944566] in primary hepatocytes.
Cluster 5: genes changed in primary keratinocytes by UVB irradiation.
Adipocyte genes induced in 3T3-L1 cells (adipocyte) by constitutively active PPARG [GeneID=5468] or its agonist, TZD [PubChem=5437].
Top 20 positive significant genes associated with CNN1 [GeneID=1264] negative leiomyosarcoma tumors.
Genes down-regulated in fibroblasts from middle-age individuals, compared to those from the young donors.
Genes up-regulated in D-341 MED (OBR) cells (medulloblastoma) resistant to both carmustine and O6-BG [PubChem=2578;4578].
Genes up-regulated in the pancreatic cancer cell lines (AsPC1, Hs766T, MiaPaCa2, Panc1) but not in the non-neoplastic cells (HPDE) by decitabine (5-aza-2'-deoxycytidine) [PubChem=451668].
Genes up-regulated in liver from mice with liver specific knockout of POR [GeneID=5447].
Genes most consistently regulated at 4 h by all six genotoxins tested: cisplatin, methyl methanesulfonate, mitomycin C, taxol, hydroxyurea and etoposide [PubChem=2767;4156;5746;4666;3657;36462].
Genes down-regulated in the mouse model of acute lung injury induced by inhaling nickel sulfate [PubChem=24586].
Genes up-regulated in the brain cortex of mice that were exposed to an enriched learning environment for 2 or 14 days.
Cluster 6: genes down-regulated in SW260 cells (colon cancer) by sodium butyrate and sulindac [PubChem=5222465;5352].
Selected genes down-regulated in WS1 (fibroblast) in response to irradiation with low dose UV-C.
Genes down-regulated in 3T3-L1 cells (adipocyte) by insulin [GeneID=3630] which continued to respond normally to insulin in the insulin resistant cells.
Genes up-regulated in T98G cells (glioma, express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 48 h.
Cluster d8: genes progressively down-regulated in WS1 cells (fibroblast) through 18 h after irradiation with high dose UV-C.
Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 24 h time point that were not up-regulated at the previous time point, 20 h.
Genes up-regulated in BT549 cells (breast cancer) by expression of SMARCE1 [GeneID=6605] off a retroviral vector.
Cluster 3: genes changed in primary keratinocytes by UVB irradiation.
Genes down-regulated in 3T3 cells (fibroblast) upon activation of JNK pathway.
Down-regulated in GHOST(3)CXCR4 cells (osteosarcoma) upon ectopic expression of ILF3 [GeneID=3609].
Cluster d3: genes progressively down-regulated in WS1 cells (fibroblast) through 12 h irradiation with high dose UV-C.
Genes up-regulated in MCV152 cells (ovarian cancer) treated with follicle stimulating hormone (FSH).
Down-regulated in the gastrocnemius muscle of aged (30-month) mice subjected to caloric restriction diet since young adulthood.
Genes up-regulated in HUVEC cells (endothelium) at 30 min after VEGFA [GeneID=7422] stimulation.
Genes down-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 6 h time point that were not down-regulated at the previous time point, 4 h.
Upregulated in the gastrocnemius muscle of aged adult mice (30-month) vs young adult (5-month)
Down-regulated synergystically by gamma-irradiation and 3-aminobenzamine [PubChem=1645], an inhibitor of PARP1 [GeneID=142].
Genes similarly down-regulated in 3T3-L1 cells (fibroblasts able to differentiate to adipocytes) upon stimulation of INSR or IGFR1 by NTF3 [GeneID=3643;3480;4908].
Genes up-regulated in rFSH-17 cells (primary granulosa) after stimulation with FSH.
Genes down-regulated in testis from 4 week old ETV5 [GeneID=2119] knockout mice.
Up-regulated at 8 h following infection of primary human foreskin fibroblasts with CMV
Down-regulated by induction of exogenous BRCA1 in EcR-293 cells
Genes down-regulated in hypertrophic scar fibroblasts in response to IL6 [GeneID=3569].
Down-regulated in the cerebral cortex of aged (22 months) BALB/c mice, compared to young (2 months) controls
Genes down-regulated in at least 8 of 11 sarcoma cell lines by trabectedin [PubChem=3199].
Strongly down-regulated at 8-96 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.
Genes down-regulated in primary adipocytes compared to preadipocytes.
Genes down-regulated in huT78R cells (cutaneous T-cell lymphoma, CTCL) resistant to IFNA2 [GeneID=3440] compared to the IFN2A sensitive parental cell line.
Genes down-regulated after heat shock in peripheral lympocytes from old donors, compared to those from the young ones.
Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 12 h time point that were not down-regulated at the previous time point, 10 h.
Genes up-regulated in corneal fibroblasts after treatment with IL1A [GeneID=3552].
Up-regulated in the hypothalamus of aged (22 months) BALB/c mice, compared to young (2 months) controls
Genes up-regulated in response to hydrogen peroxide [PubChem=784] in CS-B cells (Cockayne syndrome fibroblast, CS) expressing ERCC6 [GeneID=2074] off a plasmid vector.
Cluster G2: genes increasingly up-regulated in NHEK cells (normal keratinocyte) and reaching maximum levels at 12 h and 24 h after UV-B irradiation.
Cluster 3: ECM related genes up-regulated in dermal fibroblasts within 30 min after TGFB1 [GeneID=7040] addition; returned rapidly to basal level after that.
Genes up-regulated in MMEC cells (myometrial endothelium) at 3 h after VEGFA [GeneID=7422] stimulation.
Genes showing increasing expression in brown preadipocytes with decreasing ability of the cells to differentiate.
Genes up-regulated in H460 cells (non-small cell lung carcinoma, NSCLC) after treatment with sodium butyrate [PubChem=5222465].
Genes up-regulated in pulpal tissue extracted from carious teeth.
Selected genes up-regulated during differentiation of 3T3-L1 cells (fibroblast) into adipocytes in response to adipogenic hormones.
Genes down-regulated in liver from mice with liver specific knockout of POR [GeneID=5447].
Genes up-regulated specifically in human placenta.
Strongly up-regulated at 96 h during differentiation of 3T3-L1 cells (fibroblast) into adipocytes.
Genes up-regulated by TSA alone [PubChem=5562], with non-hypermethylated promoters, in RKO cells (colorectal cancer).
Cluster 4: genes maximally expressed at 16 h time point during differentiation of 3T3-L1 fibroblasts into adipocytes in response to adipogenic hormones.
Genes down-regulated in chondrosarcoma and ovarian carcinoma cell lines which developed resistance to trabectedin [PubChem=3199].
Genes selected in supervised analyses to discriminate cells expressing c-Myc [GeneID=4609] from control cells expressing GFP.
Genes selected in supervised analyses to discriminate cells expressing E2F3 [GeneID=1871] from control cells expressing GFP.
Genes selected in supervised analyses to discriminate cells expressing activated HRAS [GeneID=3265] oncogene from control cells expressing GFP.
Genes selected in supervised analyses to discriminate cells expressing c-Src (CSK) [GeneID=1445] from control cells expressing GFP.
Genes selected in supervised analyses to discriminate cells expressing activated beta-catenin (CTNNB1) [GeneID=1499] oncogene from control cells expressing GFP.
Genes up-regulated in A4573 cells (Ewing's sarcoma, ESFT) after knockdown of BMI1 [GeneID=648] by RNAi.
Genes down-regulated in A4573 cells (Ewing's sarcoma, ESFT) after knockdown of BMI1 [GeneID=648] by RNAi.
The 'amino acid deprivation response' (AADR): genes up-regulated in HL-60 cells (acute promyelocytic leukemia, APL) after amino acid deprivation or treatment with the aminopeptidase inhibitor tosedostat (CHR-2797) [PubChem=15547703].
Genes up-regulated in HL-60 cells (acute promyelocytic leukemia, APL) after treatment with the aminopeptidase inhibitor tosedostat (CHR-2797) [PubChem=15547703] for 6 h.
Genes down-regulated in HL-60 cells (acute promyelocytic leukemia, APL) after treatment with the aminopeptidase inhibitor tosedostat (CHR-2797) [PubChem=15547703] for 6 h.
Genes up-regulated in HL-60 cells (acute promyelocytic leukemia, APL) after treatment with the aminopeptidase inhibitor tosedostat (CHR-2797) [PubChem=15547703] for 24 h.
Genes down-regulated in HL-60 cells (acute promyelocytic leukemia, APL) after treatment with the aminopeptidase inhibitor tosedostat (CHR-2797) [PubChem=15547703] for 24 h.
Genes up-regulated in HEP3B cells (liver cancer) overexpressing ATF5 [GeneID=22809] off a plasmid vector.
Genes down-regulated in HEP3B cells (liver cancer) overexpressing ATF5 [GeneID=22809] off a plasmid vector.
Genes up-regulated upon skin specific knockout of FOS [GeneID=2353] by cre-lox in the K5-SOS-F mice (express a constitutively active form of SOS1 [GeneID=6654] in the skin).
Genes down-regulated upon skin specific knockout of FOS [GeneID=2353] by cre-lox in the K5-SOS-F mice (express a constitutively active form of SOS1 [GeneID=6654] in the skin).
Genes whose expression in a panel of lymphoblastoid cell lines was associated with cytotoxicity of the anti-cancer analogs of cytidine, gemcitabine and cytarabine [PubChem=596;3461;6253].
The 'cytidine analog pathway': genes involved in transport and metabolism of the anti-cancer analogs of cytidine: gemcitabine and cytarabine [PubChem=596;3461;6253].
Immune response genes up-regulated in zenograft tumors formed by SNU-601 cells (gastric cancer) made to express LRRC3B [GeneID=116135].
Proteins secreted in co-culture of LKR-13 tumor cells (non-small cell lung cancer, NSCLC) and MHS stroma cells (macrophages).
Proteins secreted in co-culture of LKR-13 tumor cells (non-small cell lung cancer, NSCLC) and MEC stroma cells (endothelium).
Proteins secreted in co-culture of LKR-13 tumor cells (non-small cell lung cancer, NSCLC) and MLg stroma cells (fibroblasts).
Selected genes up-regulated during invasion of lymphatic vessels during metastasis.
Selected genes down-regulated during invasion of lymphatic vessels during metastasis.
Genes down-regulated in duodenum of 3 month old MUC2 [GeneID=4583] knockout mice.
Genes up-regulated in duodenum of 6 month old MUC2 [GeneID=4583] knockout mice.
Genes down-regulated in duodenum of 6 month old MUC2 [GeneID=4583] knockout mice.
Genes down-regulated in colon of 3 month old MUC2 [GeneID=4583] knockout mice.
The postradiation tumor escape signature: genes up-regulated in tumors from irradiated stroma vs those from non-irradiated stroma.
The postradiation tumor escape signature: genes down-regulated in tumors from irradiated stroma vs those from non-irradiated stroma.
Genes up-regulated in A549GARS cells (lung cancer) resistant to the geldanamycin and 17-AAG [PubChem=5476289;6440175].
Genes down-regulated in A549GARS cells (lung cancer) resistant to the geldanamycin and 17-AAG [PubChem=5476289;6440175].
The 'group 1 set' of genes associated with acquired endocrine therapy resistance in breast tumors expressing ESR1 and ERBB2 [GeneID=2099;2064].
The 'group 2 set' of genes associated with acquired endocrine therapy resistance in breast tumors expressing ESR1 and ERBB2 [GeneID=2099;2064].
The 'group 3 set' of genes associated with acquired endocrine therapy resistance in breast tumors expressing ESR1 and ERBB2 [GeneID=2099;2064].
The 'group 4 set' of genes associated with acquired endocrine therapy resistance in breast tumors expressing ESR1 but not ERBB2 [GeneID=2099;2064].
The 'group 5 set' of genes associated with acquired endocrine therapy resistance in breast tumors expressing ESR1 but not ERBB2 [GeneID=2099;2064].
Top genes up-regulated in colon epithelium biopsies from FAP (familial adenomatous polyposis) patients with mutated APC [GeneID=324].
Top genes down-regulated in colon epithelium biopsies from FAP (familial adenomatous polyposis) patients with mutated APC [GeneID=324].
Selected electrophile and drug detoxication genes down-regulated in A549 and H460 cells (lung cancer) upon knockdown of NFE2L2 [GeneID=4780] by RNAi.
Antigen processing and presentation genes up-regulated in JY cells (B lymphocytes) treated with TSA [PubChem=5562].
Antigen processing and presentation genes down-regulated in JY cells (B lymphocytes) treated with trichostatin A (TSA) [PubChem=5562].
Genes methylated aberrantly in HCT116 and Colo320 (colon cancer) cells.
Genes un-methylated aberrantly in HCT116 and Colo320 (colon cancer) cells.
Genes from the brain cancer stem (cancer stem cell, CSC) signature.
Genes up-regulated in small intestine tissue from transgenic mice expressing a mutant form of COL13A1 [GeneID=1305], compared to normal controls.
Genes down-regulated in small intestine tissue from transgenic mice expressing a mutant form of COL13A1 [GeneID=1305], compared to normal controls.
Genes up-regulated in NIH3T3 cells (fibroblast) engineered to stably express MUC4 [GeneID=4585].
Genes down-regulated in NIH3T3 cells (fibroblast) engineered to stably express MUC4 [GeneID=4585].
Genes up-regulated in mammary glands from the CITED1 [GeneID=4435] knockout mice: homozygotic vs. heterozygotic animals.
Genes down-regulated in mammary glands from the CITED1 [GeneID=4435] knockout mice: homozygotic vs. heterozygotic animals.
Genes up-regulated in mammary glands from the CITED1 [GeneID=4435] knockout mice: homozygotic vs wild type (WT) animals.
Genes down-regulated in mammary glands from the CITED1 [GeneID=4435] knockout mice: homozygotic vs wild type (WT) animals.
Genes changed in Rat1a cells (fibroblasts) by overexpression of  HMGA1 isoform a [GeneID=3159] off a plasmid vector.
Genes changed in Rat1a cells (fibroblasts) by overexpression of  HMGA1 isoform b [GeneID=3159] off a plasmid vector.
Common up-regulated transcripts in fibroblasts expressing either XP/CS or TDD mutant forms of ERCC3 [GeneID=2071], after UVC irradiation.
Genes enriched in neurons in the adult mouse brain identified through correlation-based searches seeded with neuron cell-type specific gene expression patterns.
Genes enriched in astrocytes in the adult mouse brain identified through correlation-based searches seeded with the astrocyte cell-type specific gene expression patterns.
Genes enriched in oligodendrocytes in the adult mouse brain identified through correlation-based searches seeded with the oligodendrocyte cell-type specific gene expression patterns.
Genes enriched in choroid plexus cells in the brain identified through correlation-based searches seeded with the choroid plexus cell-type specific gene expression patterns.
Top 100 ranked genes most specific to midbrain region of adult mouse brain.
Top 100 ranked genes most specific to  pons region (P) of the adult mouse brain.
Top 100 ranked genes most specific to  medulla (myelencephalon) hindbrain region of adult mouse brain.
Top 100 ranked genes most specific to the cerebellum region of adult mouse brain.
Transcripts showing subcellular localization to both distal and proximal dendrites in the adult mouse brain.
Transcripts showing subcellular localization only to proximal dendrites in the adult mouse brain.
Cluster T4 of genes with similar expression profiles in thymic T lymphocytes after FOXP3 [GeneID=50943] loss of function (LOF).
Cluster T7 of genes with similar expression profiles in thymic T lymphocytes after FOXP3 [GeneID=50943] loss of function (LOF).
Cluster P2 of genes with similar expression profiles in peripheral T ymphocytes after FOXP3 [GeneID=50943] loss of function (LOF).
Cluster P3 of genes with similar expression profiles in peripheral T lymphocytes after FOXP3 [GeneID=50943] loss of function (LOF).
Cluster P4 of genes with similar expression profiles in peripheral T lymphocytes after FOXP3 [GeneID=50943] loss of function (LOF).
Cluster P6 of genes with similar expression profiles in peripheral T lymphocytes after FOXP3 [GeneID=50943] loss of function (LOF).
Cluster P7 of genes with similar expression profiles in peripheral T lymphocytes after FOXP3 [GeneID=50943] loss of function (LOF).
Genes changed in peripheral regulatory T lymphocytes that depend on PDE3B [GeneID=5140].
FOXP3 [GeneID=50943] target genes up-regulated in T lymphocytes after stimulation with IL2 [GeneID=3558].
FOXP3 [GeneID=50943] target genes down-regulated in T lymphocytes after stimulation with IL2 [GeneID=3558].
Genes whose promoters are bound by FOXP3 [GeneID=50943] based an a ChIP-chip analysis.
Genes with promoters bound by FOXP3 [GeneID=50943] in hybridoma cells stimulated by PMA [PubChem=4792] and ionomycin [PubChem=3733].
Genes with promoters bound by FOXP3 [GeneID=50943] in unstimulated hybridoma cells.
Genes with promoters bound by E2F4 [GeneID=1874] in unstimulated hybridoma cells.
Genes with promoters bound by FOXP3 [GeneID=50943], dependent on it, and up-regulated in hybridoma cells stimulated by PMA [PubChem=4792] and ionomycin [PubChem=3733].
Genes with promoters bound by FOXP3 [GeneID=50943], dependent on it, and down-regulated in hybridoma cells stimulated by PMA [PubChem=4792] and ionomycin [PubChem=3733].
Direct FOXP3 [GeneID=50943] targets that exhibit consistent transcriptional behavior in hybridoma and in ex vivo T lymphocytes.
Genes with promoters bound by FOXP3 [GeneID=50943] and which are up-regulated only in developing (located in the thymus) regulatory CD4+ [GeneID=920] T lymphocytes.
Genes with promoters bound by FOXP3 [GeneID=50943] and which are down-regulated only in developing (located in the thymus) regulatory CD4+ [GeneID=920] T lymphocytes.
Genes with promoters bound by FOXP3 [GeneID=50943] and which are up-regulated only in mature (peripheral blood) regulatory CD4+ [GeneID=920] T lymphocytes.
Genes with promoters bound by FOXP3 [GeneID=50943] and which are down-regulated only in mature (peripheral blood) regulatory CD4+ [GeneID=920] T lymphocytes.
Genes with promoters bound by FOXP3 [GeneID=50943] and which are up-regulated both in developing (located in the thymus) and mature (from peripheral blood) regulatory CD4+ [GeneID=920] T lymphocytes.
Genes with promoters bound by FOXP3 [GeneID=50943] and which are down-regulated both in developing (located in the thymus) and mature (from peripheral blood) regulatory CD4+ [GeneID=920] T lymphocytes.
Genes up-regulated after Cre-lox knockout of APC [GeneID=324] in the small intestine.
Genes down-regulated after double Cre-lox knockout  of both APC and MYC [GeneID=324;4609] in small intestine.
Genes up-regulated after Cre-lox knockout of APC [GeneID=324] in the small intestine that require functional MYC [GeneID=4609].
Wnt target genes up-regulated after Cre-lox knockout of APC [GeneID=324] in the small intestine that require functional MYC [GeneID=4609].
Genes expressed in at least one prostate cancer cell line but not in normal prostate epithelial cells or stromal cells
Genes up-regulated SUM44/LCCTam cells (breast cancer) resistant to 4-hydroxytamoxifen [PubChem=63062] relative to the parental SUM44 cells sensitive to the drug.
Genes down-regulated SUM44/LCCTam cells (breast cancer) resistant to 4-hydroxytamoxifen [PubChem=63062] relative to the parental SUM44 cells sensitive to the drug.
Overconnected mutated transcription factors regulating genes within the breast cancer amplicome.
Genes up-regulated by estradiol [PubChem=5757] and up-regulated by ESRRA [GeneID=2101] in MCF-7 cells (breast cancer).
Genes down-regulated by estradiol [PubChem=5757] and down-regulated by ESRRA [GeneID=2101] in MCF-7 cells (breast cancer).
Genes up-regulated by ESRRA [GeneID=2101] only.
Genes down-regulated by ESRRA [GeneID=2101] only.
Genes up-regulated after Cre-lox knockout of LSD1 [GeneID=23028] in pituitary.
Genes down-regulated after Cre-lox knockout of LSD1 [GeneID=23028] in pituitary.
Class T (tolerizeable) genes: induced during the first LPS stimulation and either not re-induced or induced to a much lesser degree in tolerant macrophages.
Class NT (non-tolerizeable) genes: induced during the first LPS stimulation and induced at equal or greater degree in tolerant macrophages.
Genes up-regulated in EpiSC cells (mouse epiblast embryonic stem cells) after treatment with the ALK [GeneID=238] inhibitor SB-431542 [PubChem=4521392].
Genes up-regulated in EpiSC cells (epiblast stem cells) after treatment with the ALK [GeneID=238] inhibitor SB-431542 [PubChem=4521392].
Genes up-regulated in mES cells (mouse embryonic stem cells) after tratment with the ALK [GeneID=238] inhibitor SB-431542 and JAK inhibitor I [PubChem=4521392;5494425].
Genes down-regulated in mES cells (mouse embryonic stem cells) after tratment with the ALK [GeneID=238] inhibitor SB-431542 and JAK inhibitor I [PubChem=4521392;5494425].
Genes up-regulated in mES cells (mouse embryonic stem cells) after tratment with JAK inhibitor I [PubChem=5494425].
Genes down-regulated in mES cells (mouse embryonic stem cells) after tratment with JAK inhibitor I [PubChem=5494425].
Cluster B: genes down-regulated in primary lung tumors driven by KRAS [GeneID=3845] activation and loss of STK11 [GeneID=6794]; also up-regulated in human squamous cell carcinoma (SCC) vs adenocarcinoma subtype of NSCLC (non-small cell lung cancer).
Cluster A: genes up-regulated in primary lung tumors driven by KRAS [GeneID=3845] activation and loss of STK11 [GeneID=6794]; also up-regulated in human squamous cell carcinoma (SCC) vs adenocarcinoma subtype of NSCLC (non-small cell lung cancer).
Genes required for epigenetic silencing of FAS [GeneID=355] by activated KRAS [GeneID=3845] in NIH 3T3 cells, based on RNAi screen.
Genes up-regulated in neural progenitor cells (NPC) isolated from E13 cortical tissue of SMRT [GeneID=9612] knockout mice.
Genes specifically responding to 4NQO treatment of primary fibroblasts.
Genes specifically responding to gamma radiation.
UV only responding genes in primary fibroblasts from young donors.
Genes responding to 4NQO treatment and gamma irradiation.
4NQO treatment and UV irradiation responding genes.
Gamma and UV responding genes.
Human environmental etress response genes not changed in primary fibroblasts from old donors in response to 4NQO treatment.
Human environmental stress response genes not changed in primary fibroblasts from Wilmor syndrom (WS) patients in response to 4NQO treatment.
Human environmental stress response (H-ESR) genes not changed in primary fibroblasts from old donors in response to gamma radiation.
Human environmental stress response genes not changed in primary fibroblasts from Werner syndrom (WS) patients in response to gamma radiation.
Human environmental stress response genes not changed in primary fibroblasts from old donors in response to UV radiation.
Human environmental stress response genes not changed in primary fibroblasts from patients with Warner syndrom (WS) .
Genes with GO annotation and down-regulated after DNA damage in cell lines from young donors.
Genes with GO annotation and up-regulated after DNA damage in cell lines from young donors.
All common  up-regulated stress response genes (Human Environmental Stress Response, H-ESR).
All common down-regulated stress response genes (Human Environmental Stress Response, H-ESR).
Genes with high histone H3 trimethylation mark at K27 (H3K27me3) in PC3 cells (prostate cancer) by ChIP-chip assay on a 12K CpG array (high-CpG-density promoters, HCP).
Top 200 genes with high histone H3 trimethylation mark at K27 (H3K27me3) in PC3 cells (prostate cancer), by ChIP-chip assay on an 88K microarray (all promoters).
Genes with high levels of histone H3 monomethylation mark at K27 (H3K27me1) in SW48 cells (colon cancer) by ChIP-chip assay on a 12K CpG array (CpG promoters only, HCP=high-CpG-density promoters).
Genes with high histone H3 tri-methylation mark at K27 (H3K27me3) in SW48 cells (colon cancer), by ChIP-chip assay on a 12K CpG array (high-CpG-density promoters, HCP).
Genes up-regulated in PC3 cells (prostate cancer) after EZH2 [GeneID=2146] knockdown by RNAi.
Genes down-regulated in tumor compared to non-tumor liver samples from patients with hepatocellular carcinoma (HCC).
Genes up-regulated after cre-lox knockout of GATA6 [GeneID=2627] in airway epithelium.
Genes down-regulated after cre-lox knockout of GATA6 [GeneID=2627] in airway epithelium.
Genes up-regulated by hemizygotic cre-lox knockout of RSP6 [GeneID=81492] in keratinocytes.
Genes down-regulated by hemizygotic cre-lox knockout of RSP6 [GeneID=81492] in keratinocytes.
Genes up-regulated in gastric cancer cell lines resistant to cisplatin [PubChem=2767].
Genes down-regulated in gastric cancer cell lines resistant to cisplatin [PubChem=2767].
Up-regulated genes in the 'Field Effect' signature of normal lung tissue adjacent to the tumor.
Up-regulated genes classifying non-tumor lung tissues by age after incution of lung cancer by urethane injection [PubChem=5641]: early (24-26 weeks) vs late (46 weeks).
Down-regulated genes classifying non-tumor lung tissues by age after incution of lung cancer by urethane injection [PubChem=5641]: early (24-26 weeks) vs late (46 weeks).
Genes up-regulated in at least one of three multiple myeloma (MM) cell lines treated with the DNA hypomethylating agent decitabine (5-aza-2'-deoxycytidine) [PubChem=451668].
Genes down-regulated in at least one of three multiple myeloma (MM) cell lines treated with the DNA hypomethylating agent decitabine (5-aza-2'-deoxycytidine) [PubChem=451668].
Genes up-regulated in at least one of three multiple myeloma (MM) cell lines by TSA [PubChem=5562].
Genes down-regulated in at least one of three multiple myeloma (MM) cell lines by TSA [PubChem=5562].
Genes up-regulated in multiple myeloma (MM) cell lines treated with both decitabine [PubChem=451668] TSA [PubChem=5562].
Genes down-regulated in multiple myeloma (MM) cell lines treated with both decitabine [PubChem=451668] TSA [PubChem=5562].
Genes up-regulated in meningioma samples positive for PGR [GeneID=5241] compared to those without the receptor.
Genes down-regulated in meningioma samples positive for PGR [GeneID=5241] compared to those without the receptor.
Genes that comprise the mitochondria gene module
Genes that comprise the proteasome gene module
Gene predicting resistance of the NCI-60 cell lines to gamma radiation.
Genes down-regulated across the entire panel of NCI-60 cell lines in response to gamma radiation.
Genes with basal expression distinguishing NCI-60 cell lines with poor survival after 8 Gy gamma irradiation.
Genes with basal expression distinguishing NCI-60 cell lines with poor survival after 2 Gy gamma irradiation.
Up-regulated genes distinguishing between M1 (pro-inflammatory) and M2 (anti-inflammatory) macrophage subtypes.
Down-regulated genes distinguishing between M1 (pro-inflammatory) and M2 (anti-inflammatory) macrophage subtypes.
Components of RNA post-transcriptional modification machinery up-regulated in MDA-MB-435 cells (breast cancer) whose metastatic potential has been reduced by expression of NME1 [GeneID=4830].
Up-regulated genes displaying alternative splicing in MDA-MB-435 cells (breast cancer) whose metastatic potential has been reduced by expression of NME1 [GeneID=4830].
Down-regulated genes displaying alternative splicing in MDA-MB-435 cells (breast cancer) whose metastatic potential has been reduced by expression of NME1 [GeneID=4830].
Candidate genes in significant regions of chromosomal copy number gains in a panel of melanoma samples.
Candidate genes in significant regions of chromosomal copy number losses in a panel of melanoma samples.
Genes up-regulated in mice with skin specific knockout of RB1 [GeneID=5925] by Cre-lox.
Genes down-regulated in mice with skin specific knockout of RB1 [GeneID=5925] by Cre-lox.
Genes up-regulated in mice with skin specific knockout of TP53 [GeneID=7157].
Genes down-regulated in mice with skin specific knockout of TP53 [GeneID=7157].
Genes up-regulated in mice with skin specific double knockout of both RB1 and TP53 [GeneID=5925;7157] by Cre-lox.
Genes down-regulated in mice with skin specific double knockout of both RB1 and TP53 [GeneID=5925;7157] by Cre-lox.
Genes in the red cluster of protein kinases distinguishing between luminal A and basal breast cancer subtypes.
Genes in the green cluster of protein kinases distinguishing between luminal A and basal breast cancer subtypes.
Genes in the blue cluster of protein kinases distinguishing between luminal A and basal breast cancer subtypes.
Genes in the gray cluster of protein kinases distinguishing between luminal A and basal breast cancer subtypes.
Genes up-regulated in breast cancer tumors (formed by MCF-7 xenografts) resistant to tamoxifen [PubChem=5376].
Genes down-regulated in breast cancer tumors (formed by MCF-7 xenografts) resistant to tamoxifen [PubChem=5376].
Genes rapidly up-regulated in breast cancer cell cultures by estradiol [PubChem=5757].
Genes up-regulated in prostate tumor vs normal tissue samples.
Genes down-regulated in prostate tumor vs normal tissue samples.
Genes up-regulated in prostate cancer samples from African-American patients compared to those from the European-American patients.
Genes down-regulated in prostate cancer samples from African-American patients compared to those from the European-American patients.
Genes up-regulated in MCF10A cells (breast cancer) grown at low (mesenchymal phenotype) compared to those grown at high (epithelial, basal-like phenotype) confluency.
Genes down-regulated in MCF10A cells (breast cancer) grown at low (mesenchymal phenotype) compared to those grown at high (epithelial, basal-like phenotype) confluency.
Genes up-regulated in chronic lymphocytic leukemia (CLL) samples bearing deletions in the 13q14 region.
Genes down-regulated in chronic lymphocytic leukemia (CLL) samples bearing deletions in the 13q14 region.
Genes up-regulated in both colorectal cancer cells and normal testis relative to normal colon epithelium.
Genes up-regulated by IL2 [GeneID=3558] in cells derived from  CD4+ [GeneID=920] cutaneous T-cell lymphoma (CTCL).
Genes down-regulated by IL2 [GeneID=3558] in cells derived from  CD4+ [GeneID=920] cutaneous T-cell lymphoma (CTCL).
Cluster 1: genes up-regulated in lung tissue samples from mice with oncogenic form of KRAS [GeneID=3845] and inactivated PTEN [GeneID=5728].
Cluster 2: genes down-regulated in lung tissue samples from mice with oncogenic form of KRAS [GeneID=3845] and inactivated PTEN [GeneID=5728].
Cluster 3: genes up-regulated in lung tissue samples from mice with tumor-bearing genotypes (activated KRAS [GeneID=3845] alone or together with inactivated PTEN [GeneID=5728]).
Cluster 4: genes down-regulated in lung tissue samples from mice with tumor-bearing genotypes (activated KRAS [GeneID=3845] alone or together with inactivated PTEN [GeneID=5728]).
Genes down-regulated in HT1080 cells (fibrosarcoma) by treatment with interferon alpha for 6 h.
Genes from chromosomal copy number gains in a panel of 51 primary colon carcinoma samples.
Genes from chromosomal copy number losses in a panel of 51 primary colon carcinoma samples.
Genes up-regulated in three-dimentional (3D) cultures of preinvasive (S3-C) vs invasive (T4-2) breast cancer cells.
Genes down-regulated in three-dimentional (3D) cultures of preinvasive (S3-C) vs invasive (T4-2) breast cancer cells.
Genes up-regulated in monolayer (2D) cultures of preinvasive (S3-C) vs invasive (T4-2) breast cancer cells.
Genes down-regulated in monolayer (2D) cultures of preinvasive (S3-C) vs invasive (T4-2) breast cancer cells.
Genes up-regulated in MCF-7 cells (breast cancer) after knockdown of YBX1 [GeneID=4904] by RNAi.
Genes down-regulated in MCF-7 cells (breast cancer) after knockdown of YBX1 [GeneID=4904] by RNAi.
Genes up-regulated in A549 cells (lung cancer) upon expression of ASCL1 [GeneID=429] off a viral vector.
Genes down-regulated in A549 cells (lung cancer) upon expression of ASCL1 [GeneID=429] off a viral vector.
Genes whose CpG islands became hypermethylated in breast progenitor cells pre-exposed to estradiol [PubChem=5757].
Genes up-regulated in SaOS-2 cells (osteosarcoma) upon knockdown of YY1 [GeneID=7528] by RNAi.
Genes down-regulated in SaOS-2 cells (osteosarcoma) upon knockdown of YY1 [GeneID=7528] by RNAi.
Inflammatory genes down-regulated in mammary carcinoma cells after stimulation with TGFB1 [GeneID=7040] for 1 hr.
Genes whose promoters where bound by HOXC6 [GeneID=3223] in LNCaP cells (prostate cancer), according to a ChIP-chip analysis.
Genes gradually up-regulated by histamine [PubChem=774] in B16-F10 melanoma tumors.
Genes gradually down-regulated by histamine [PubChem=774] in B16-F10 melanoma tumors.
Genes corresponding to the histamine [PubChem=774] response network.
'Cancer prone response profile' (CPRP): genes changed in response to estradiol [PubChem=5757]  in epithelial cell cultures from patients at high risk of breast cancer.
'Cancer prone response profile' (CPRP): genes changed in response to bisphenol A [PubChem=6623]  in epithelial cell cultures from patients at high risk of breast cancer.
'Cancer prone response profile' (CPRP): genes common to estradiol and bisphenol A [PubChem=5757;6623]  response of epithelial cell cultures from patients at high risk of breast cancer.
Genes silenced by DNA methylation in prostate cancer cell lines.
Genes up-regulated in prostate cancer cell lines after treatment with 5-aza-2'-deoxycytidine (decitabine) [PubChem=451668].
Genes up-regulated during prostate cancer progression in mice heterozygotic for both NKX3.1 and PTEN [GeneID=4824;5728].
Genes down-regulated during prostate cancer progression in mice heterozygotic for both NKX3.1 and PTEN [GeneID=4824;5728].
Mouse orthologs of human prostate cancer tumor markers which were deregulated in mice heterozygotic for both NKX3.1 and PTEN [GeneID=4824;5728].
Genes up-regulated in mesenchymal stem cells (MSC) engineered to express EWS-FLI1 [GeneID=2130;2321] fusion protein.
Genes down-regulated in mesenchymal stem cells (MSC) engineered to express EWS-FLI1 [GeneID=2130;2321] fusion protein.
Genes down-regulated in A549 cells (lung cancer) after treatment with AZD0530 [PubChem=10302451], a SRC [GeneID=6714] kinase inhibitor.
The metastasis gene signature: genes up-regulated during metastasis of NSCLC (non-small cell lung carcinoma) tumors to bone.
Genes down-regulated by flavopiridol [PubChem=5287969] in the HCT116 cells (colon cancer) depending on their TP53 [GeneID=7157] status: wild-type vs loss of the gene's function (LOF).
Genes up-regulated in SCLC (small cell lung cancer) cells with acquired resistance to ABT-737 [PubChem=11228183], an inhibitor of the BCL2 [GeneID=596] family proteins.
Genes down-regulated in SCLC (small cell lung cancer) cells with acquired resistance to ABT-737 [PubChem=11228183], an inhibitor of the BCL2 [GeneID=596] family proteins.
Up-regulated genes in the cancer progenitor (stem) cells corresponding to side population (SP) MCF7 cells (breast cancer) positive for MUC1 [GeneID=4582].
Down-regulated genes in the cancer progenitor (stem) cells corresponding to side population (SP) MCF7 cells (breast cancer) positive for MUC1 [GeneID=4582].
Up-regulated genes defining rejection of mammary carcinoma (MMC) tumors.
Down-regulated genes defining rejection of mammary carcinoma (MMC) tumors.
Genes up-regulated in H358 cells (lung cancer) by inducible expression of FOXA2 [GeneID=3170] in a Tet-off system.
Genes down-regulated in H358 cells (lung cancer) by inducible expression of FOXA2 [GeneID=3170] in a Tet-off system.
Genes up-regulated in derivatives of MCF-7aro cells (breast cancer) that developed resistance to tamoxifen [PubChem=5376] or  inhibitors of aromatase (CYP19A1) [GeneID=1588].
Genes down-regulated in derivatives of MCF-7aro cells (breast cancer) that developed resistance to tamoxifen [PubChem=5376] or  inhibitors of aromatase (CYP19A1) [GeneID=1588].
Top genes up-regulated in mesenchyme stem cells (MSC) grown in a tumor conditioned medium, which leads to carcinoma-associated fibroblast phenotype.
Genes with promoters bound by HOXC6 [GeneID=3223] in LNCaP cells (prostate cancer) and up-regulated upon loss of function (LOF) of HOXC6.
Genes with promoters bound by HOXC6 [GeneID=3223] in LNCaP cells (prostate cancer) and down-regulated upon loss of function (LOF) of HOXC6.
Epigenetically silenced genes up-regulated in HCT116 cells (colon cancer) hypomorphic for DICER1 [GeneID=23405].
Embryonic genes targeted by LET7A1 [GeneID=406881] and which are up-regulated in many human cancers.
Genes whose promoters were bound by HOXC6 [GeneID=3223] in LNCaP cells (prostate cancer) and which were up-regulated in comparison of tumor vs normal prostate tissue samples.
Genes whose promoters were bound by HOXC6 [GeneID=3223] in LNCaP cells (prostate cancer) and which were down-regulated in comparison of tumor vs normal prostate tissue samples.
Genes commonly up-regulated in SK-N-BE cells (neuroblastoma) after RNAi knockdown of CCND1 and CDK4 [GeneID=595;1019].
Genes commonly down-regulated in SK-N-BE cells (neuroblastoma) after RNAi knockdown of CCND1 and CDK4 [GeneID=595;1019].
Genes up-regulated in normal tissue adjacent to liver tumor, compared to the normal liver samples.
Genes down-regulated in normal tissue adjacent to liver tumor, compared to the normal liver samples.
Genes up-regulated in hepatocellular carcinoma (HCC) compared to normal liver samples.
Genes down-regulated in hepatocellular carcinoma (HCC) compared to normal liver samples.
Genes up-regulated in liver tumor compared to the normal adjacent tissue.
Genes down-regulated in liver tumor compared to the normal adjacent tissue.
Genes whose promoters display higher levels of histone H3 trimethylation mark at K27 (H3K27me3) in hepatocellular carcinoma (HCC) compared to normal liver.
Genes whose promoters display lower levels of histone H3 trimethylation mark at K27 (H3K27me3) in hepatocellular carcinoma (HCC) compared to normal liver.
Genes whose promoters display higher histone H3 trimethylation mark at K9 (H3K9me3) in hepatocellular carcinoma (HCC) compared to normal liver.
Genes whose promoters display lower histone H3 trimethylation mark at K9 (H3K9me3) in hepatocellular carcinoma (HCC) compared to normal liver.
Genes whose DNA is hypo-methylated in hepatocellular carcinoma (HCC) compared to normal liver.
Genes up-regulated in the MM1S cells (multiple myeloma) after treatment with aplidin [PubChem=44152164], a marine-derived compound with potential anti-cancer properties.
Genes down-regulated in the MM1S cells (multiple myeloma) after treatment with aplidin [PubChem=44152164], a marine-derived compound with potential anti-cancer properties.
Genes whose DNA was methylated both in primary tumors and across a panel of cancer cell lines.
Epithelial and mesenchymal markers up-regulated in MEF cells (embryonic fibroblasts) after knockout of PRKAR1A [GeneID=5573].
Epithelial and mesenchymal markers down-regulated in MEF cells (embryonic fibroblasts) after knockout of PRKAR1A [GeneID=5573].
Genes up-regulated in HT29 cells (colon cancer) after knockdown of CD24 [GeneID=100133941] by both RNAi and monoclonal antibodies.
Genes down-regulated in HT29 cells (colon cancer) after knockdown of CD24 [GeneID=100133941] by both RNAi and monoclonal antibodies.
Genes up-regulated in brain relapse of breast cancer.
Genes down-regulated in brain relapse of breast cancer.
Genes up-regulated in bone relapse of breast cancer.
Genes down-regulated in bone relapse of breast cancer.
Genes up-regulated in lung relapse of breast cancer.
Genes down-regulated in lung relapse of breast cancer.
Genes up-regulated in liver relapse of breast cancer.
Genes down-regulated in liver relapse of breast cancer.
Genes up-regulated in pleura relapse of breast cancer.
Genes down-regulated in pleura relapse of breast cancer.
Genes up-regulated in the luminal B subtype of breast cancer.
Genes down-regulated in the luminal B subtype of breast cancer.
Genes up-regulated in the luminal A subtype of breast cancer.
Genes down-regulated in the luminal A subtype of breast cancer.
Genes up-regulated in the erbb2 subype of breast cancer samples, characterized by higher expression of ERBB2 [GeneID=2064].
Genes down-regulated in the erbb2 subype of breast cancer samples, characterized by higher expression of ERBB2 [GeneID=2064].
Genes up-regulated in the normal-like subtype of breast cancer.
Genes down-regulated in the normal-like subtype of breast cancer.
Genes up-regulated in basal subtype of breast cancer samles.
Genes down-regulated in basal subtype of breast cancer samles.
Genes up-regulated in response to nutlin-3a [PubChem=216345], an inhibitor of MDM2 [GeneID=4193],  in skin fibroblast cultures after knockdown of TP53 [GeneID=7157] by RNAi.
Genes down-regulated in response to nutlin-3a [PubChem=216345], an inhibitor of MDM2 [GeneID=4193],  in skin fibroblast cultures after knockdown of TP53 [GeneID=7157] by RNAi.
Genes up-regulated in HSA/c and KYSE140 cells (esophageal squamous cell carcinoma, ESCC) after knockdown of PTTG1 [GeneID=9232] by RNAi.
Genes down-regulated in HSA/c and KYSE140 cells (esophageal squamous cell carcinoma, ESCC) after knockdown of PTTG1 [GeneID=9232] by RNAi.
Selected genes implicated in metastasis and epithelial-to-mesenchymal transition (EMT) which were up-regulated in MDA-MB-231 cells (breast cancer) upon knockdown of SKI [GeneID=6497] by RNAi.
Selected genes implicated in metastasis and epithelial-to-mesenchymal transition (EMT) which were down-regulated in MDA-MB-231 cells (breast cancer) upon knockdown of SKI [GeneID=6497] by RNAi.
Top highly correlated genes positively associated with poor survival of patients with suboptimally debulked ovarian tumors.
Top highly correlated genes negatively associated with poor survival of patients with suboptimally debulked ovarian tumors.
Genes whose expression in optimally debulked ovarian tumors is associated with survival prognosis.
Genes whose expression in suboptimally debulked ovarian tumors is associated with survival prognosis.
Apoptosis genes up-regulated by TP53 [GeneID=7157] in HCT116 cells (colon cancer) treated with thymoquinone [PubChem=10281].
Apoptosis genes down-regulated by TP53 [GeneID=7157] in HCT116 cells (colon cancer) treated with thymoquinone [PubChem=10281].
Top 50 genes up-regulated in ovarian cancer progenitor cells (also known as side population, SP, cells) in response to interferon alpha (IFNA).
Genes silenced in HCT116 cells (colon cancer) by methylation of CpG islands in their promoters.
Protease genes up-regulated at tumor-bone interface compared to the tumor alone area.
Protease genes down-regulated at tumor-bone interface compared to the tumor alone area.
Methylated germline-specific genes with high-CpG-density promoters (HCP) in primary fibroblasts.
Unmethylated germline-specific genes with high-CpG-density promoters (HCP) in primary fibroblasts.
Unmethylated germline-specific genes with high-CpG-density promoters (HCP) in sperm.
Methylated germline-specific genes with high-CpG-density promoters (HCP) in sperm.
Genes up-regulated in hairy cell leukemia (HCL) compared with normal and other neoplastic B cell populations.
Genes down-regulated in hairy cell leukemia (HCL) compared with normal and other neoplastic B cell populations.
Genes down-regulated in HCT116 cells (colon cancer) upon expression of MIR34B or MIR34C [GeneID=407041;407042] microRNAs.
Genes up-regulated in adipose tissue mesenchymal stem cells (ASC) vs bone marrow mesenchymal stem cells (rBMSC)
Genes down-regulated in adipose tissue mesenchymal stem cells (ASC) vs bone marrow mesenchymal stem cells (rBMSC)
Genes up-regulated in cancer stem cells isolated from mammary tumors compared to the non-tumorigenic cells.
Genes down-regulated in cancer stem cells isolated from mammary tumors compared to the non-tumorigenic cells.
Top genes down-regulated in mesenchyme stem cells (MSC) grown in a tumor conditioned medium, which leads to carcinoma-associated fibroblast phenotype.
Genes up-regulated in ZR-75-1 cells (breast cancer, amplified 8p11-12 region) upon knockdown of PPAPDC1B [GeneID=84513] by RNAi.
Genes down-regulated in ZR-75-1 cells (breast cancer, amplified 8p11-12 region) upon knockdown of PPAPDC1B [GeneID=84513] by RNAi.
Inflammatory cytokines, chemokines and their cognate receptors up-regulated in THP-1 cells (monocyte) after treatment with PSMD4 [GeneID=5710].
Up-regulated genes in the expression signature of aneuploidy in uveal melanoma tumors: low vs high aneuploidy.
Down-regulated genes in the expression signature of aneuploidy in uveal melanoma tumors: low vs high aneuploidy.
The glioblastoma multiforme (GBM) plasticity signature: genes up-regulated in neural stem cells (NSC) with double knockout of TP53 and PTEN [GeneID=7157;5728] vs those with knockout of TP53 alone.
The glioblastoma multiforme (GBM) plasticity signature: genes down-regulated in neural stem cells (NSC) with double knockout of TP53 and PTEN [GeneID=7157;5728] vs those with knockout of TP53 alone.
Genes up-regulated in microdissected endothelial samples from ovarian cancer tumors with tumor-infiltrating lymphocytes (TIL) vs those without TILs.
Genes  down-regulated in microdissected endothelial samples from ovarian cancer tumors with tumor-infiltrating lymphocytes (TIL) vs those without TILs.
Genes up-regulated in E8.5 embryos with heterozygous knockout of TCOF1 [GeneID=6949] compared to wild type.
Genes changed in HBE cells (bronchial epithelium) after treatment with IL22 and IL17A [GeneID=50616;3605].
Genes up-regulated in ex-vivo colonic tissue after treatment with IL22 [GeneID=50616].
Genes down-regulated in ex-vivo colonic tissue after treatment with IL22 [GeneID=50616].
Direct targets of FOXA2 [GeneID=3170] in liver, according to a ChIP-chip analysis.
Genes up-regulated in MCF7-ADR cell line (breast cancer) resistant to docetaxel [PubChem=148124].
Atherosclerotic process genes whose coronary expression changed after darapladib [PubChem=9939609] treatment.
Genes important for ovulation, based on mouse models with female fertility defects.
Genes important for cumulus expansion, based on mouse models with female fertility defects.
Genes important for fertilization, based on mouse models with female fertility defects.
Maternal effect genes, based on mouse models wih female fertility defects.
Genes important for implantation and uterine, based on mouse models with female fertility defects.
Genes important for post-implantation and post-partum,  based on mouse models with female fertility defects.
Genes important for steroidogenesis, based on mouse models with female fertility defects.
Meitic and DNA repair genes important for female fertility, based on mouse models with female fertility defects.
Genes central for female fertility pathways, based on mouse models with female fertility defects.
Genes important for embryonic germ cell, based on mouse models with female fertility defects.
Genes important for early anral follicle, based on mouse models with female fertility defects.
Luteal genes, based on mouse models with female fertility defects.
Genes important for preovulatory follicle,  based on mouse models with female fertility defects.
Genes important for Sertoli, peritubular, Leydig and interstitial cells, based on mouse models with male reproductive defects.
Genes important for spermatogonia, based on mouse models with male reproductive defects.
Genes important for spermatocyte, based on mouse models with male reproductive defects.
Genes important for spermatid differentiation, based on mouse models with male reproductive defects.
Spermatozoa genes, based on mouse models with male reproductive defects.
Potential targets of MIR15A and MIR16-1 [GeneID=406948;406950] microRNAs in prostate cancer.
Genes up-regulated in blister cells from patients with adverse drug reactions (ADR).
Genes down-regulated in blister cells from patients with adverse drug reactions (ADR).
Differentially expressed genes in a panel of xenografts representing 8 common pediatric tumors compared to the normal tissues.
Down-regulated genes in colon carcinoma tumors with lymph node metastases.
Up-regulated genes in colon carcinoma tumors compared to the matched normal mucosa samples.
Down-regulated genes in colon carcinoma tumors compared to the matched normal mucosa samples.
Up-regulated genes in both rectal and colon carcinoma compared to normal mucosa samples.
Down-regulated genes in both rectal and colon carcinoma compared to normal mucosa samples.
Genes up-regulated in rectal but down-regulated in colon carcinoma compared to normal mucosa samples.
Genes down-regulated in rectal but up-regulated in colon carcinoma compared to normal mucosa samples.
Genes up-regulated in freshly isolated CD31- [GeneID=5175] (stromal stem cells from adipose tissue) versus the CD31+ (non-stem) counterparts.
Genes down-regulated in freshly isolated CD31- [GeneID=5175] (stromal stem cells from adipose tissue) versus the CD31+ (non-stem) counterparts.
Genes up-regulated in cultured stromal stem cells from adipose tissue, compared to the freshly isolated cells.
Genes down-regulated in cultured stromal stem cells from adipose tissue, compared to the freshly isolated cells.
Up-regulated genes in NMuMG cells (mammary epithelium) after stimulation with WNT3A [GeneID=89780].
Down-regulated genes in NMuMG cells (mammary epithelium) after stimulation with WNT3A [GeneID=89780].
Up-regulated genes in NMuMG cells (mammary epithelium) after stimulation with TGFB1 [GeneID=7040].
Down-regulated genes in NMuMG cells (mammary epithelium) after stimulation with TGFB1 [GeneID=7040].
Up-regulated genes in NMuMG cells (mammary epithelium) after stimulation with both TGFB1 and WNT3A [GeneID=7040;89780].
Down-regulated genes in NMuMG cells (mammary epithelium) after stimulation with both TGFB1 and WNT3A [GeneID=7040;89780].
Genes up-regulated in highly metastatic pancreatic cancer cells.
Top genes up-regulated in orthotopic tumors from highly metastatic pancreatic cancer cells.
Bottom genes down-regulated in subcutaneous tumors from highly metastatic pancreatic cancer cells.
Genes from 16q24 region up-regulated in retinoblastoma tumors with 16q24 LOH (loss of heterozygocity) compared to those without the LOH.
Up-regulated genes in pediatric adrenocortical tumors (ACT) compared to the normal tissue.
Down-regulated genes in pediatric adrenocortical tumors (ACT) compared to the normal tissue.
Up-regulated genes in pediatric adrenocortical carcinoma (ACC) compared to the adenoma (ACA) tumors.
Down-regulated genes in pediatric adrenocortical carcinoma (ACC) compared to the adenoma (ACA) tumors.
Genes involved in cell cycle regulation which were up-regulated in MCF-7 cells (breast cancer) by tretinoin (retinoic acid) [PubChem=444795].
Genes up-regulated in RKO cells (colon cancer) after treatment with the NR4A1 [GeneID=3164] agonist, DIM-C-pPhOCH3.
Up-regulated genes in MDA-MB-435 cells (breast cancer) undergoing G2/M arrest after treatment with 2-methoxyestradiol (2ME2)[PubChem=1573].
Down-regulated genes in MDA-MB-435 cells (breast cancer) undergoing G2/M arrest after treatment with 2-methoxyestradiol (2ME2) [PubChem=1573].
Genes from the most frequent genomic gains and amplifications in a panel of patients with lymph node negative breast cancer (NNBC).
Genes from the most frequent genomic losses and homozygous deletions in a panel of patients with lymph node negative breast cancer (NNBC).
Genes up-regulated in pilocytic astrocytoma (PA) samples from patients with type 1 neurofibromatosis syndrom (NF1) compared to the PA tumors from non-NF1 patients.
Genes up-regulated in pilocytic astrocytoma (PA) from supratentorial regions compared to the infratentorial PA tumors.
Genes down-regulated in pilocytic astrocytoma (PA) from supratentorial regions compared to the infratentorial PA tumors.
Protein kinase genes most significantly up-regulated in ASPS (alveolar soft part sarcoma) tumors compared to four other types of primitive sarcomas.
Up-regulated genes in breast tumors from transgenic mice overexpressing ERBB2 and CDC25A [GeneID=2064;993] compared to those from mice overexpressing ERBB2 only.
Down-regulated genes in breast tumors from transgenic mice overexpressing ERBB2 and CDC25A [GeneID=2064;993] compared to those from mice overexpressing ERBB2 only.
Up-regulated genes common to all pretumorigenic cells with acquired drug resistance.
Down-regulated genes common to all pretumorigenic cells with acquired drug resistance.
Genes up-regulated in A549 cells (lung cancer) expressing MIRLET7A3 [GeneID=406883] microRNA off a plasmid vector.
Genes down-regulated in A549 cells (lung cancer) expressing MIRLET7A3 [GeneID=406883] microRNA off a plasmid vector.
Up-regulated genes in MM1.S cells (multiple myeloma) treated with adaphostin [PubChem=387042], a tyrosine kinase inhibitor with anticancer properties.
Down-regulated genes in MM1.S cells (multiple myeloma) treated with adaphostin [PubChem=387042], a tyrosine kinase inhibitor with anticancer properties.
Genes specifically up-regulated in tumor endothelium.
Genes specifically down-regulated in tumor endothelium.
Up-regulated genes of putative pathways stimulated in tumor endothelial cells by papillary serous ovarian epithelial tumor cells.
Genes up-regulated in highly immune-resistant cancer cell line developed from a susceptible cancer using an in vivo selection strategy.
Genes up-regulated 6 h after induction of HoxA5 [GeneID=3205] expression in a breast cancer cell line.
Genes down-regulated 6 h after induction of HoxA5 [GeneID=3205] expression in a breast cancer cell line.
Genes up-regulated 9 h after induction of HoxA5 [GeneID=3205] expression in a breast cancer cell line.
Genes down-regulated 9 h after induction of HoxA5 [GeneID=3205] expression in a breast cancer cell line.
Genes up-regulated in neurons after NPAS4 [GeneID=266743] knockdown by RNAi.
Genes down-regulated in neurons after NPAS4 [GeneID=266743] knockdown by RNAi.
Genes up-regulated in Paneth cell (part of intestiinal epithelium) of mice with hypomorphic (reduced function) form of ATG16L1 [GeneID=55054].
Genes down-regulated in Paneth cell (part of intestiinal epithelium) of mice with hypomorphic (reduced function) form of ATG16L1 [GeneID=55054].
Genes up-regulated in pre B lymphocyte after induction of physiological DNA double-strand breaks (DSB) by RAG2 [GeneID=5897]; the changes are independent of ATM [GeneID=472] signaling.
Genes down-regulated in pre B lymphocyte after induction of physiological DNA double-strand breaks (DSB) by RAG2 [GeneID=5897]; the changes are independent of ATM [GeneID=472] signaling.
Genes up-regulated in pre B lymphocyte after induction of physiological DNA double-strand breaks (DSB) by RAG2 [GeneID=5897]; the changes depend on ATM [GeneID=472] but not NFKB signaling.
Genes down-regulated in pre B lymphocyte after induction of physiological DNA double-strand breaks (DSB) by RAG2 [GeneID=5897]; the changes depend on ATM [GeneID=472] but not NFKB signaling.
Supplementary Table 2. Genelist comparing microarray expression profiles of spermatogonial cells, haGSCs and hES (H1) cells. Examples of expression rates of different hES cell enriched and germ cell specific genes, surface markers for germ cell selection and signal transduction in all three cell types (spermatogonial cells = SC).
Genes enriched in pluripotent adult germline stem cells.
Genes up-regulated in a mouse model of heart disease whose expression reverted to normal by silencing of MIR21 [GeneID=406991] microRNA.
Genes down-regulated in a mouse model of heart disease whose expression reverted to normal by silencing of MIR21 [GeneID=406991] microRNA.
List of genes in the 19q13 amplicon region based on a copy number alterations study of a panel of 16 pancreatic cancer cell lines and 31 primary tumors.
Genes whose expression positively correlated with sensitivity of breast cancer cell lines to dasatinib [PubChem=3062316].
Genes whose expression negatively correlated with resistance of breast cancer cell lines to dasatinib [PubChem=3062316].
Genes up-regulated by skin tumor promoters but completely blocked by expression of TAM67, a dominan-negative form of JUN [GeneID=3725].
Known targets of AP1 that were down-regulated by overexpression of TAM67, a dominant-negative form of JUN [GeneID=3725].
Up-regulated genes that best disciminate plasmablastic plasmacytoma from plasmacytic plasmacytoma tumors.
Down-regulated genes that best disciminate plasmablastic plasmacytoma from plasmacytic plasmacytoma tumors.
Genes whose DNA methylation differed between primary ALL cells (acute lymphoblastic leukemia) and normal peripheral blood samples.
Protein biosynthesis, transport or catabolism genes up-regulated in hyperploid multiple myeloma (MM) compared to the non-hyperploid MM samples.
Protein biosynthesis, transport or catabolism genes down-regulated in hyperploid multiple myeloma (MM) compared to the non-hyperploid MM samples.
Genes up-regulated in basal mammary epithelial cells compared to the luminal ones.
Genes down-regulated in basal mammary epithelial cells compared to the luminal ones.
Up-regulated genes in A2780 cells (ovarian cancer) treated with 17AAG [PubChem=6440175], a chemical with anticancer properties.
Down-regulated genes in A2780 cells (ovarian cancer) treated with 17AAG [PubChem=6440175], a chemical with anticancer properties.
Representative genes up-regulated in MiaPaCa2 cells (pancreatic cancer) under glucose-deprived conditions.
Selected genes up-regulated in response to the Ras inhibitor salirasib [PubChem=5469318] in a panel of cancer cell lines with constantly active HRAS [GeneID=3265].
Selected genes down-regulated in response to the Ras inhibitor salirasib [PubChem=5469318] in a panel of cancer cell lines with constantly active HRAS [GeneID=3265].
Genes regulated by hypoxia, based on literature searches.
EMT (epithelial-mesenchymal transition) genes up-regulated genes in melanoma tumous that developed metastatic disease compared to primary melanoma that did not.
EMT (epithelial-mesenchymal transition) genes down-regulated genes in melanoma tumous that developed metastatic disease compared to primary melanoma that did not.
Neural-related genes up-regulated in melanoma tumors that developed metastases compared to primary melanoma that did not.
Up-regulated genes in melanoma tumous that developed metastatic disease compared to primary melanoma that did not.
Down-regulated genes in melanoma tumors that developed metastatic disease compared to primary melanoma that did not.
Tumorigenesis markers of head and neck squamous cell carcinoma (HNSCC): up-regulated in the 'early' tumors vs normal samples.
Tumorigenesis markers of head and neck squamous cell carcinoma (HNSCC): down-regulated in the 'early' tumors vs normal samples.
Genes up-regulated in naive T lymphocytes lacking FURIN [GeneID=5045]: Cre-Lox knockout of FURIN in CD4+ [GeneID=920] cells.
Genes down-regulated in naive T lymphocytes lacking FURIN [GeneID=5045]: Cre-Lox knockout of FURIN in CD4+ [GeneID=920] cells.
Genes constituting the PluriNet protein-protein network shared by the pluripotent cells (embryonic stem cells, embryonical carcinomas and induced pluripotent cells).
Genes up-regulated in mouse stroma of pancreatic adenocarcinoma zenografts after treatment with HhAntag, a hedgehog (Hh) pathway inhibitor.
Genes down-regulated in mouse stroma of pancreatic adenocarcinoma zenografts after treatment with HhAntag, a hedgehog (Hh) pathway inhibitor.
Genes required for both proliferation and CTNNB1 [GeneID=1499] activity in DLD-1 cell (colon cancer with APC [GeneID=324] deletions).
Genes required for CTNNB1 [GeneID=1499] activity in DLD-1 cell (colon cancer with APC [GeneID=324] deletions), based on shRNA screen.
Genes required for proliferation of DLD-1 cell (colon cancer with APC [GeneID=324] deletions), based on shRNA screen.
Transcription factors expressed in progenitors of exocrine pancreatic cells.
Transcription factors expressed in progenitors of endocrine pancreatic cells.
Transcription factors expressed in adult pancreatic beta cells.
Prmary innate immune response genes induced in 293T cells (embryonic kidney) by overexpression of STING (TMEM173) [GeneID=340061].
Up-regulated genes in the subpopulation of invasive PyMT cells (breast cancer) compared to the general population of PyMT cells.
Down-regulated genes in the subpopulation of invasive PyMT cells (breast cancer) compared to the general population of PyMT cells.
Up-regulated genes in HepG2 cells (liver cancer) overexpressing an oncogenic variant of tumor suppressor TIP30 [GeneID=10553] compared to its wild type form.
Down-regulated genes in HepG2 cells (liver cancer) overexpressing an oncogenic variant of tumor suppressor TIP30 [GeneID=10553] compared to its wild type form.
Genes from common genomic gains observed in a meta analyis of copy number alterations across a panel of different cancer cell lines and tumor samples.
Selected genes changed in NMuMG cells (mammary epithelium) transformed by overexpression of CCND1 [GeneID=595] vs those transformed by overexpression of CCND1 and MYC [GeneID=4609].
Genes up-regulated in response to both single dose and fractionated radiation that were common to all three cell lines studied.
Up-regulated genes in medulloblastoma tumors from heterozygotic CXCR6 [GeneID=10663] knockout mice compared to those from PTCH1 [GeneID=5727] heterozygotic knockout mice.
Down-regulated genes in medulloblastoma tumors from heterozygotic CXCR6 [GeneID=10663] knockout mice compared to those from PTCH1 [GeneID=5727] heterozygotic knockout mice.
Nuclear receptors whose expression correlated with that of aromatase (CYP19A1) [GeneID=1588] in a panel of breast cancer biopsies.
Genes up-regulated in cancer stem cells derived from glyoblastoma tumors: CD133+ [GeneID=8842]  vs. CD133- cells.
Genes down-regulated in cancer stem cells derived from glyoblastoma tumors: CD133+ [GeneID=8842]  vs. CD133- cells.
Angiogenic markers up-regulated in lymph endothelial cells upon infection with KSHV (Kaposi's sarcoma herpes virus).
Angiogenic markers down-regulated in lymph endothelial cells upon infection with KSHV (Kaposi's sarcoma herpes virus).
Mitochondrial genes; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.
Genes up-regulated in differentiating C2C12 cells (myoblasts) upon expression of PPARGC1A [GeneID=10891] off an adenoviral vector.
Tricarboxylic acid related genes; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.
Genes highly expressed in hepatocellular carcinoma with poor survival.
Genes highly expressed in hepatocellular carcinoma with good survival.
Mitochondrial genes
Reactive oxidative species (ROS) genes; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.
Genes up-regulated in multiple myeloma (MM) compared to monoclonal gammopathy of uncertain significance (MGUS).
Genes down-regulated in multiple myeloma (MM) compared to monoclonal gammopathy of uncertain significance (MGUS).
Genes from cluster 1: up-regulated in group C of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.
Genes from cluster 2: down-regulated in group C of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.
Genes from cluster 3: up-regulated in group D of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.
Genes from cluster 4: down-regulated in group D of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.
Genes up-regulated in group D of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.
Genes down-regulated in group D of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.
Genes up-regulated both in group C and D of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.
Genes down-regulated both in group C and D of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.
Genes up-regulated in group C of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.
Genes down-regulated in group C of tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609] in plasma cells.
Genes silenced by DNA methylation in bladder cancer cell lines.
Genes up-regulated in HUVEC cells (umbilical vein endothelium) by fenretinide [PubChem=1744].
Genes down-regulated in HUVEC cells (umbilical vein endothelium) by fenretinide [PubChem=1744].
Genes down-regulated in  tumor-conditioned vs quiescent endothelial cells and up-regulated upon treatment with decitabine and TSA [PubChem=451668;5562].
G1 to S phase regulators significantly changed in DanG cells (pancreatic cancer) treated with Ly294002 [PubChem=3973], a phosphoinositide 3-kinase (PI3K) inhibitor.
Integrin, VEGF, Wnt and TGFbeta signaling pathway genes up-regulated in PC-3 cells (prostate cancer) after knockdown of PDEF [GeneID=25803] by RNAi.
Integrin, VEGF, Wnt and TGFbeta signaling pathway genes down-regulated in PC-3 cells (prostate cancer) after knockdown of PDEF [GeneID=25803] by RNAi.
Up-regulated genes in Calu3 cells (non-small cell lung cancer, NSCLC) resistant to gemcitabine [PubChem=3461] which became down-regulated in response to bexarotene [PubChem=82146].
Down-regulated genes in Calu3 cells (non-small cell lung cancer, NSCLC) resistant to gemcitabine [PubChem=3461] which became up-regulated in response to bexarotene [PubChem=82146].
Genes up-regulated in B lymphocytes from patients with primary immunodefiency syndrom.
Genes down-regulated in B lymphocytes from patients with primary immunodefiency syndrom.
Up-regulated genes significantly associated with positive minimal residual disease (MRD) on day 46 after chemotherapy treatment of children with acute lymphoblastic leukemia (ALL).
Down-regulated genes significantly associated with positive minimal residual disease (MRD) on day 46 after chemotherapy treatment of children with acute lymphoblastic leukemia (ALL).
Genes up-regulated in bone marrow progenitors by constitutively active NOTCH1 [GeneID=4851].
Genes down-regulated in bone marrow progenitors by constitutively active NOTCH1 [GeneID=4851].
Up-regulated genes that distinguished smokers with and without lung cancer.
Down-regulated genes that distinguished smokers with and without lung cancer.
Genes changed in liver in response to nifedipine [PubChem=4485] treatment of iron overload.
Cytokines, growth factors, and secreted proteins that show increased expression on a protein array of samples from aged TERC [GeneID=7012] knockout mice.
Cytokines, growth factors, and secreted proteins that show decreased expression on a protein array of samples from aged TERC [GeneID=7012] knockout mice.
An assortment of osteoblast transcriptional regulators.
Genes whose expression most significantly correlated with cancer cell line sensitivity to the proapoptotic ligand APO2 [GeneID=8797].
Up-regulated genes associated with sensitivity and resistance to gamma-secretase (GSI) in T-cell acute lymphoblastic leukemia (T-ALL) cell lines.
Down-regulated genes associated with sensitivity and resistance to gamma-secretase (GSI) in T-cell acute lymphoblastic leukemia (T-ALL) cell lines.
Chemokine genes up-regulated within 2 hr of c-Myc [GeneID=4609] activation in a mouse model of Myc-induced pancreatic beta-cell tumorigenesis.
Genes up-regulated in hepatic stellar cells after stimulation with bacterial lipopolysacharide (LPS).
Genes down-regulated in hepatic stellar cells after stimulation with bacterial lipopolysacharide (LPS).
A biomarker of plasma signaling proteins that predicts clinical Alzheimer's diagnosis.
Exercise regulated genes in hyppocampus.
Genes up-regulated during later stages of renal maturation (days P14-P16) in kidney specific knockout of PKD1 [GeneID=5310].
Genes down-regulated during later stages of renal maturation (days P14-P16) in kidney specific knockout of PKD1 [GeneID=5310].
Genes up-regulated by 2-methoxyestradiol (2ME2) [PubChem=1573] in the MM.1S cell line (multiple myeloma) sensitive to dexamethasone [PubChem=5743].
Genes down-regulated by 2-methoxyestradiol (2ME2) [PubChem=1573] in the MM.1S cell line (multiple myeloma) sensitive to dexamethasone [PubChem=5743].
Genes up-regulated in MCF-7 cells (breast cancer) by selective estrogen receptor modulators (SERM) 4-hydroxytamoxifen, raloxifene, or ICI 182780 but not by estradiol [PubChem=44959;5035;3478439;5757].
Genes down-regulated in MCF-7 cells (breast cancer) by selective estrogen receptor modulators (SERM) 4-hydroxytamoxifen, raloxifene, or ICI 182780 but not by estradiol [PubChem=44959;5035;3478439;5757].
Genes up-regulated at the peak of an antigen response of naive CD8+ [GeneID=925;926] T-cells.
Hepatic graft versus host disease (GVHD), day 7: up-regulated in allogeneic vs syngeneic bone marrow transplant.
Hepatic graft versus host disease (GVHD), day 7: down-regulated in allogeneic vs syngeneic bone marrow transplant.
Hepatic graft versus host disease (GVHD), day 35: genes up-regulated in allogeneic vs syngeneic bone marrow transplant.
Hepatic graft versus host disease (GVHD), day 35: genes down-regulated in allogeneic vs syngeneic bone marrow transplant.
Maturation of monocyte-derived dendritic cells (DC) in response to inflammatory stimuli: genes up-regulated only at 8 hr after the stimulation (cluster A).
Maturation of monocyte-derived dendritic cells (DC) in response to inflammatory stimuli: genes up-regulated both at 8 hr and 48 hr after the stimulation (cluster B).
Maturation of monocyte-derived dendritic cells (DC) in response to inflammatory stimuli: genes up-regulated only at 48 hr after the stimulation (cluster C).
Genes down-regulated during the course of maturation of monocyte-derived dendritic cells (DC) in response to inflammatory stimuli (cluster D).
Genes up-regulated in the influenza-specific CD8+ [GeneID=925] T lymphocytes from bronchoalveolar lavage (BAL) compared to those from spleen.
Genes down-regulated in the influenza-specific CD8+ [GeneID=925] T lymphocytes from bronchoalveolar lavage (BAL) compared to those from spleen.
Neutrophil-specific genes up-regulated in comparison of immature with mature neutrophils.
Neutrophil-specific genes down-regulated in comparison of immature with mature neutrophils.
Genes up-regulated in neutrophils upon treatment with activated protein C (PROC) [GeneID=5624] of pulmonary inflammation induced by bacterial lipopolysaccharide (LPS).
Genes down-regulated in neutrophils upon treatment with activated protein C (PROC) [GeneID=5624] of pulmonary inflammation induced by bacterial lipopolysaccharide (LPS).
Top 50 marker genes for glioblastoma multiforme (GBM), a class of high grade glioma.
Top 50 marker genes for anaplastic oligodendroglioma (AO), a class of high grade glioma.
Genes up-regulated in U937 cells (acute promyelocytic leukemia, APL) expressing RARA [GeneID=5914] fused with either PML or PLZF [GeneID=5371;7704].
Genes down-regulated in U937 cells (acute promyelocytic leukemia, APL) expressing RARA [GeneID=5914] fused with either PML or PLZF [GeneID=5371;7704].
Genes up-regulated in U937 cells (acute promyelocytic leukemia, APL) by tretinoin (ATRA) [PubChem=444795].
Genes up-regulated by tretinoin (ATRA) [PubChem=444795] in U937 cells (acute promyelocytic leukemia, APL) made sensitive to the drug by expression of the PML-RARA fusion [GeneID=5371;5914].
Genes up-regulated by tretinoin (ATRA) [PubChem=444795] in U937 cells (acute promyelocytic leukemia, APL) made resistant to the drug by expression of the PLZF-RARA fusion [GeneID=7704, 5914].
Interferon-inducible genes up-regulated in A549 cells (lung cancer) infected with a respiratory syncytial virus (RSV) that had its NS1 [GeneID=1494468] gene knocked down by RNAi.
Genes up-regulated in brain endothelial cells from patients with Alzheimer disease.
Genes down-regulated in brain endothelial cells from patients with Alzheimer disease.
Genes up-regulated in DLD-1 cells (colon cancer) in response to hypoxia; might not be direct targets of HIF1A [GeneID=3091].
Genes down-regulated in DLD-1 cells (colon cancer) in response to hypoxia; might not be direct targets of HIF1A [GeneID=3091].
Genes up-regulated in vascular smooth muscle cells (VSMC) by MAPK8 (JNK1) [GeneID=5599].
Genes down-regulated in vascular smooth muscle cells (VSMC) by MAPK8 (JNK1) [GeneID=5599].
Genes up-regulated in spleen interferon-producing dendritic cells (IKDC) compared to plasmacytoid dendritic cells (PDC) and  conventional dendritic cells (cDC).
Genes up-regulated in gastric mucosal tissue of mice on 2% cholesterol [PubChem=5997] diet and infected with H. pylori vs those infected with H. pylori while on 0% cholesterol diet.
Genes down-regulated in gastric mucosal tissue of mice on 2% cholesterol [PubChem=5997] diet and infected with H. pylori vs those infected with H. pylori while on 0% cholesterol diet.
Genes up-regulated in HL-60 cells (acute myeloid leukemia, AML) by expression of p210 BCR-ABL [GeneID=613;25] fusion protein.
Genes down-regulated in HL-60 cells (acute myeloid leukemia, AML) by expression of p210 BCR-ABL [GeneID=613;25] fusion protein.
Genes up-regulated in T98G cells (glioblastoma) by TNC [GeneID=3371].
Genes down-regulated in T98G cells (glioblastoma) by TNC [GeneID=3371].
Genes up-regulated in peripheral blood monocytes by CSF2RB (GM-CSF) and IL4 [GeneID=1437;3565].
Genes down-regulated in peripheral blood monocytes by CSF2RB (GM-CSF) and IL4 [GeneID=1437;3565].
Genes up-regulated in peripheral blood monocytes by HGF [GeneID=3082].
Genes down-regulated in peripheral blood monocytes by HGF [GeneID=3082].
Genes up-regulated in peripheral blood mononucleocytes by HGF [GeneID=3082] compared to those regulated by CSF2RB (GM-CSF) and IL4 [GeneID=1437;3565].
Genes down-regulated in peripheral blood mononucleocytes by HGF [GeneID=3082] compared to those regulated by CSF2RB (GM-CSF) and IL4 [GeneID=1437;3565].
Genes up-regulated in fibroblasts from MLL [GeneID=4297] knockout mice.
Genes down-regulated in fibroblasts from MLL [GeneID=4297] knockout mice.
Up-regulated genes in the canonical gene expression signature of the fibroblast core serum response (CSR) defined by the Stanford group.
Down-regulated genes in the canonical gene expression signature of the fibroblast core serum response (CSR) defined by the Stanford group.
Fibroblast serum response genes showing periodic expression during the cell cycle; excluded from the core serum response signature.
Up-regulated target genes shared by acute myeloid leukemia (AML) translocation products PML RARA [GeneID=5371;5914], AML1 ETO [GeneID=861;862], and PLZF RARA [GeneID=5914;7704].
Down-regulated target genes shared by acute myeloid leukemia (AML) translocation products PML RARA [GeneID=5371;5914], AML1 ETO [GeneID=861;862], and PLZF RARA [GeneID=5914;7704].
Top 100 probe sets associated with MLL fusions [GeneID=4297] irrespective of the lineage of the pediatric acute leukemia.
Genes up-regulated in primary B lymphocytes engineered to overexpress BCL2 [GeneID=12043].
Genes down-regulated in primary B lymphocytes engineered to overexpress BCL2 [GeneID=12043].
Up-regulated genes from the optimal set of 550 markers discriminating breast cancer samples by ESR1 [GeneID=2099] expression: ER(+) vs ER(-) tumors.
Down-regulated genes from the optimal set of 550 markers discriminating breast cancer samples by ESR1 [GeneID=2099] expression: ER(+) vs ER(-) tumors.
Up-regulated genes from the optimal set of 100 markers discriminating ER(-) breast cancer tumors by  BRCA1 [GeneID=672] mutation status.
Down-regulated genes from the optimal set of 100 markers discriminating ER(-) breast cancer tumors by  BRCA1 [GeneID=672] mutation status.
Genes up-regulated more than 7-fold by expressing JAK2 [GeneID=3717] in the JAK2 null cell line.
Up-regulated genes whose expression correlates with copy number gains in pancreatic adenocarcinoma cell lines and primary tumor specimens.
Down-regulated genes whose expression correlates with copy number losses in pancreatic adenocarcinoma cell lines and primary tumor specimens.
Genes up-regulated in the Kras2LA mouse lung cancer model with mutated KRAS [GeneID=3845].
Genes down-regulated in the Kras2LA mouse lung cancer model with mutated KRAS [GeneID=3845].
Genes that contributed maximally to the GSEA score of the up-regulated gene set from the KrasLA mouse model in two human lung cancer expression data sets comparing mutant vs normal KRAS [GeneID=3845].
Genes up-regulated in primary keratinocytes by expression of p50 (NFKB1) and p65 (RELA) [GeneID=4790;5970] components of NFKB.
Genes down-regulated in primary keratinocytes by expression of p50 (NFKB1) and p65 (RELA) [GeneID=4790;5970] components of NFKB.
Genes up-regulated in primary fibroblast cells by expression of p50 (NFKB1) and p65  (RELA) [GeneID=4790;5970] components of NFKB.
Genes up-regulated during differentiation from pre-BI to large pre-BII lymphocyte.
Genes down-regulated during differentiation from pre-BI to large pre-BII lymphocyte.
Genes up-regulated during differentiation from large pre-BII to small pre-BII lymphocyte.
Genes down-regulated during differentiation from large pre-BII to small pre-BII lymphocyte.
Genes up-regulated during differentiation from small pre-BII to immature B lymphocyte.
Genes down-regulated during differentiation from small pre-BII to immature B lymphocyte.
Genes up-regulated during differentiation of immature to mature B lymphocyte.
Genes down-regulated during differentiation of immature to mature B lymphocyte.
Genes up-regulated in bone marrow hematopoietic stem cells (HSC, CD34+ [GeneID=947]) from patients with low risk of myelodysplastic syndrome (MDS) compared with healthy controls.
Genes down-regulated in bone marrow hematopoietic stem cells (HSC, CD34+ [GeneID=947]) from patients with low risk of myelodysplastic syndrome (MDS) compared with healthy controls.
Genes up-regulated in bone marrow hematopoietic stem cells (HSC, CD34+ [GeneID=947]) from patients with high risk of myelodysplastic syndrome (MDS) compared with healthy controls.
Genes down-regulated in bone marrow hematopoietic stem cells (HSC, CD34+ [GeneID=947]) from patients with high risk of myelodysplastic syndrome (MDS) compared with healthy controls.
Genes up-regulated in bone marrow hematopoietic stem cells (HSC, CD34+ [GeneID=947]) from patients with high risk of myelodysplastic syndrom (MDS) compared to the low risk patients.
Genes down-regulated in bone marrow hematopoietic stem cells (HSC, CD34+ [GeneID=947]) from patients with high risk of myelodysplastic syndrom (MDS) compared to the low risk patients.
Genes up-regulated at early stages of progenitor T lymphocyte maturation compared to the late stages.
Genes down-regulated at early stages of progenitor T lymphocyte maturation compared to the late stages.
Genes enriched in the intrathymic T progenitor (ITTP) cells compared to all other T lymphocyte differentiation stages.
Genes enriched in the double polar (DP) thymocyte compared to all other T lymphocyte differentiation stages.
Genes enriched in the single positive 4 (SP4) thymocytes compared to all other T lymphocyte differentiation stages.
Candidate genes specific for recent thymic emigrants (RTEs).
Genes enriched in the naive circulating T lymphocytes compared to the earlier differentiation stages.
Genes enriched at every T lymphocyte differentiation stage compared to the early passage fetal thymic stromal cultures (TSC).
'Wilm's tumor signature': genes highly expressed in Wilm's tumor samples compared to normal fetal kidney and a heterologous tumor, Burkit lymphoma.
Genes in the stroma-derived prognostic predictor of breast cancer disease outcome.
Cluster 6 of method A: up-regulation of these genes in patients with non-small cell lung cancer (NSCLC) predicts poor survival outcome.
Cluster 4 of method A: up-regulation of these genes in patients with non-small cell lung cancer (NSCLC) predicts good survival outcome.
Genes for which mutations result in atrial septation defects, a major class of congenital heart disease.
Cluster 5 of method A: up-regulation of these genes in patients with non-small cell lung cancer (NSCLC) predicts good survival outcome.
Genes for which mutations result in developmental defects in ventricular septation and atrioventricular cushion formation, a major class of congenital heart disease.
Genes for which mutations result in developmental defects in the great vessels formation and valvulogenesis, a major class of congenital heart disease.
Genes up-regulated in neural stem cells (NSC) at 36 h after cre-lox knockout of TLX (NR2E1) [GeneID=7101].
Genes down-regulated in neural stem cells (NSC) at 36 h after cre-lox knockout of TLX (NR2E1) [GeneID=7101].
Genes up-regulated in neural stem cells (NSC) at 60 h after cre-lox knockout of TLX (NR2E1) [GeneID=7101].
Genes down-regulated in neural stem cells (NSC) at 60 h after cre-lox knockout of TLX (NR2E1) [GeneID=7101].
Genes down-regulated in neural stem cells (NSC) at both 36 h and 60 h after cre-lox knockout of TLX (NR2E1) [GeneID=7101].
Genes up-regulated in neural stem cells (NSC) at both 36 h and 60 h after cre-lox knockout of TLX (NR2E1) [GeneID=7101].
Genes up-regulated in HEK293 cells (embryo kidney) after knockdown of TUT1 [GeneID=64852] by RNAi.
Genes down-regulated in HEK293 cells (embryo kidney) after knockdown of TUT1 [GeneID=64852] by RNAi.
Genes up-regulated in MDA-MB-231 cells (breast cancer) after knockdown of SATB1 [GeneID=6304] by RNAi.
Genes down-regulated in MDA-MB-231 cells (breast cancer) after knockdown of SATB1 [GeneID=6304] by RNAi.
Cluster 12 of method A: up-regulation of these genes in patients with non-small cell lung cancer (NSCLC) predicts good survival outcome.
Genes up-regulated in MEF cells (embryonic fibroblast) with double knockout of the translation repressors 4EBP1 [GeneID=1978] and 4EBP2 [GeneID=1979].
Genes forming the macrophage-enriched metabolic network (MEMN) claimed to have a causal relationship with the metabolic syndrom traits.
Up-regulated 'cooperation response genes': responded synergystically to the combination of mutant TP53 and HRAS [GeneID=7157;3265] in YAMC cells (colon).
Down-regulated 'cooperation response genes': responded synergystically to the combination of mutant TP53 and HRAS [GeneID=7157;3265] in YAMC cells (colon).
Genes up-regulated in the induced pluripotent cells (iPS) and embryonic stem cells (ES) compared to the parental lineage-committed and partially reprogrammed cell lines.
Genes down-regulated in the induced pluripotent cells (iPS) and embryonic stem cells (ES) compared to the parental lineage-committed and partially reprogrammed cell lines.
Genes up-regulated in partially reprogrammed and pluripotent cell populations (induced, iPS; and embryonic stem cells, ES) compared to parental lineage-commited cell lines.
Genes down-regulated in partially reprogrammed and pluripotent cell populations (induced, iPS; and embryonic stem cells, ES) compared to parental lineage-commited cell lines.
Genes up-regulated in cells that have been partially reprogrammed to pluripotency: comparison with the parental lineage-committed cell lines, fully reprogrammed stem cells, and embryonic stem cells.
Genes up-regulated in transgenic mice expressing human MYC [GeneID=4609] in prostate.
Genes down-regulated in transgenic mice expressing human MYC [GeneID=4609] in prostate.
Direct targets of IRF4 [GeneID=3662] that constitute a multiple myeloma program.
IRF4 [GeneID=3662] target genes up-regulated in primary myeloma vs. mature B lymphocytes.
IRF4 [GeneID=3662] target genes up-regulated in plasma cells compared to mature B lymphocytes.
IRF4 [GeneID=3662] target genes induced after activation of primary B lymphocytes by anti-IgM crosslinking.
IRF4 [GeneID=3662] target genes up-regulated in plasmacytoid dendritic cells compared to monocytes.
Housekeeping genes identified as expressed across 19 normal tissues.
Genes with intermediate-CpG-density promoters (ICP) bearing histone H3 trimethylation mark at K4 (H3K4me3) in ES cells (embryonic stem).
Genes with intermediate-CpG-density promoters (ICP) bearing histone trimethylation marks at K4 (H3K4me3) and K27 (H3K27me3)ES cells (embryonic stem).
Genes with high-CpG-density promoters (HCP) bearing the H3K27 tri-methylation (H3K27me3) mark in neural precursor cells (NPC).
Genes with intermediate-CpG-density promoters (ICP) bearing histone H3 trimethylation mark at K4 (H3K4me3) in neural precursor cells (NPC).
Genes with high-CpG-density promoters (HCP) bearing histone H3 trimethylation marks at k4 (H3K4me3) and K27 ((H3K27me3) in neural precursor cells (NPC).
Genes with high-CpG-density promoters (HCP) that have no histone H3 methylation marks in neural precursor cells (NPC).
Genes with intermediate-CpG-density promoters (ICP) that have no histone H3 methylation marks in neural precursor cells (NPC).
Genes with high-CpG-density promoters (HCP) bearing the H3K27 tri-methylation (H3K27me3) mark in brain.
Genes with intermediate-CpG-density promoters (ICP) bearing histone H3 trimethylation mark at K4 (H3K4me3) in brain.
Genes with high-CpG-density promoters (HCP) bearing histone H3 dimethylation at K4 (H3K4me2) and trimethylation at K27 (H3K27me3) in brain.
Genes with high-CpG-density promoters (HCP) that have no histone H3 methylation marks in brain.
Putative metastasis genes: up-regulated in metastatic cell lines LM2 (lung) and BoM2 (bone) relative to the parental MDA-MB-231 line (breast adenocarcinoma).
Cohesin targets identified by ChIP-chip which were up-regulated after knockdown of CTCF and RAD21 [GeneID=10664;5885] by RNAi.
Nearest neighbors of HOX11 [GeneID=3195], based on the close agreement of their expression profiles with that of HOX11 in pediatric T cell acute lymphoblastic leukemia (T-ALL).
Genes specifically up-regulated in pediatric acute lymphoblastic leukemia (ALL) patients by mercaptopurine [PubChem=667490] and high dose methotrexate (HDMTX) [PubChem=4112].
Genes specifically down-regulated in pediatric acute lymphoblastic leukemia (ALL) patients by mercaptopurine [PubChem=667490] and high dose methotrexate (HDMTX) [PubChem=4112].
B lymphocyte early differentiation genes (EDG): top genes up-regulated in tonsil B lymphocytes (TBC) compared to the tonsil plasma cells (TPC).
B lymphocyte early differentiation genes (EDG): top genes down-regulated in tonsil B lymphocytes (TBC) compared to the tonsil plasma cells (TPC).
Transcripts significantly enriched in pseudopodia of NIH/3T3 cells (fibroblast) in response to both chemotactic (lysophosphatidic acid, LPA [PubChem=3988]) and haptotactic (fibronectin, FN1 [GeneID=2335) migratory stimuli.
Transcripts enriched in pseudopodia of NIH/3T3 cells (fibroblast) in response to the chemotactic migration stimulus by lysophosphatidic acid (LPA) [PubChem=3988].
Transcripts depleted in pseudopodia of NIH/3T3 cells (fibroblast) in response to the chemotactic migration stimulus by lysophosphatidic acid (LPA) [PubChem=3988].
Transcripts enriched in pseudopodia of NIH/3T3 cells (fibroblast) in response to haptotactic migratory stimulus by fibronectin, FN1 [GeneID=2335].
Transcripts depleted from pseudopodia of NIH/3T3 cells (fibroblast) in response to haptotactic migratory stimulus by fibronectin, FN1 [GeneID=2335].
Selected genes up-regulated in prostate tumors developed by transgenic mice overexpressing VAV3 [GeneID=10451] in prostate epithelium.
Selected genes down-regulated in prostate tumors developed by transgenic mice overexpressing VAV3 [GeneID=10451] in prostate epithelium.
Genes up-regulated in the ANBL-6 cell line (multiple myeloma, MM) after withdrawal of IL6 [GeneID=3569].
Genes down-regulated in the ANBL-6 cell line (multiple myeloma, MM) after withdrawal of IL6 [GeneID=3569].
Genes up-regulated in ANBL-6 cell line (multiple myeloma, MM) co-cultured with bone marrow stromal cells compared to those grown in the presence of IL6 [GeneID=3569].
Genes down-regulated in ANBL-6 cell line (multiple myeloma, MM) co-cultured with bone marrow stromal cells compared to those grown in the presence of IL6 [GeneID=3569].
Genes up-regulated in ANBL-6 cell line (multiple myeloma, MM)  expressing a constantly active form of NRAS [GeneID=4893] off a plasmid vector compared to those grown in the presence of IL6 [GeneID=3569].
Genes down-regulated in ANBL-6 cell line (multiple myeloma, MM)  expressing a constantly active form of NRAS [GeneID=4893] off a plasmid vector compared to those grown in the presence of IL6 [GeneID=3569].
Genes up-regulated in ANBL-6 cell line (multiple myeloma, MM) expressing an activated form of NRAS [GeneID=4893] off a plasmid vector compared to those co-cultured with bone marrow stromal cells.
Genes down-regulated in ANBL-6 cell line (multiple myeloma, MM) expressing an activated form of NRAS [GeneID=4893] off a plasmid vector compared to those co-cultured with bone marrow stromal cells.
Genes up-regulated by overexpression of MAD1 [GeneID=4084] in primary thymocytes from RAG2 [GeneID=5897] knockout mice.
Genes down-regulated by overexpression of MAD1 [GeneID=4084] in primary thymocytes from RAG2 [GeneID=5897] knockout mice.
B lymphocyte late differentiation genes (LDG): top genes up-regulated in plasma cells from tonsils (TPC) compared to those from bone marrow (BPC).
B lymphocyte late differentiation genes (LDG): top genes down-regulated in plasma cells from tonsils (TPC) compared to those from bone marrow (BPC).
The vEDG up-regulated set: most variable early differentiation genes (EDG) with similar expression patterns in tonsil B lymphocytes (TBC) and multiple myeloma (MM) cells compared to the plasma cells from tonsil (TPC) and bone marrow (BPC).
The vEDG down-regulated set: most variable early differentiation genes (EDG) with similar expression patterns in tonsil B lymphocytes (TBC) and multiple myeloma (MM) cells compared to the plasma cells from tonsil (TPC) and bone marrow (BPC).
The v1LDG up-regulated set: most variable late differentiation genes (LDG) with similar expression patterns in tonsil plasma cells (TPC) and multiple myeloma (MM) samples.
The v1LDG down-regulated set: most variable late differentiation genes (LDG) with similar expression patterns in tonsil plasma cells (TPC) and multiple myeloma (MM) samples.
Genes up-regulated in MEF cells (embryonic fibroblast) after expression of E2F1 or E2F2 [GeneID=1869;1870].
Genes up-regulated by 3 h of euglycemic hyperinsulinemic clamp in the vastus lateralis muscle of healthy lean subjects.
Genes down-regulated by 3 h of euglycemic hyperinsulinemic clamp in the vastus lateralis muscle of healthy lean subjects.
Top 40 genes from cluster 1 of acute myeloid leukemia (AML) expression profile; 57% of the samples are FAB M1 subtype,  43% have 11q23 abnormalities, and 36% have up-regulated EVI1 [GeneID=2122] expression.
Top 40 genes from cluster 2 of acute myeloid leukemia (AML) expression profile; 71% of the samples are FAB M4 or M5 subtypes, and 82% bear internal tundem duplications in FLT3 [GeneID=2322].
Top 40 genes from cluster 3 of acute myeloid leukemia (AML) expression profile; 84% of the samples are FAB M1 or M2 subtypes, 52% bear intern tandem duplication in FLT3 [GeneID=2322].
Top 40 genes from cluster 4 of acute myeloid leukemia (AML) expression profile; 87% of the samples are FAB M1 subtype, 53% bear mutations in CEBPA [GeneID=1050].
Top 40 genes from cluster 5 of acute myeloid leukemia (AML) expression profile; 96% of the samples are FAB M4 or M5 subtype.
Top 40 genes from cluster 6 of acute myeloid leukemia (AML) expression profile; all samples are FAB M1 or M2 subtypes and all samples have internal tundem duplication of FLT3 [GeneID=2322].
Top 40 genes from cluster 7 of acute myeloid leukemia (AML) expression profile; 61% of the samples are FAB M1 or M2 subtype.
Top 40 genes from cluster 8 of aculte myeloid leukemia (AML) expression profile; 69% of the samples are FAB M2 subtype.
Top 40 genes from cluster 9 of acute myeloid leukemia (AML) expression profile; 87% of the samples are FAB M4 or M5 subtype, all have inv(16) inversion producing the CBFB-MYH11 fusion [GeneID=865;4629]; indicate good survival.
Top 40 genes from cluster 10 of acute myeloid leukemia (AML) expression profile; 41% of the samples are FAB M1 subtype, 45% have up-regulated EVI1 [GeneID=2122] expression; indicate poor survival.
Top 40 genes from cluster 11 of acute myeloid leukemia (AML) expression profile; 67% of the samples are FAB M4 or M5.
Top 40 genes from cluster 12 of acute myeloid leukemia (AML) expression profile; 89% of the samples are FAB M3 subtype, 95% bear the t(15;17) translocation, all have the PML-RARA fusion [GeneID=5371;5914]; indicate good survival.
Top 40 genes from cluster 13 of acute myeloid leukemia (AML) expression profile; 91% of the samples are FAB M2 subtype, all bear the t(8;21) translocation producing the AML1-ETO fusion [GeneID=861;862]; indicate good survival.
Top 40 genes from cluster 15 of acute myeloid leukemia (AML) expression profile; 88% of the samples are FAB M1 or M2 subtype, 63% have mutations in CEBPA [GeneID=1050].
Top 40 genes from cluster 16 of acute myeloid leukemia (AML) expression profile; 81% of the samples are FAB M5 subtype, 45% have 11q23 abnormalities.
Genes that best predicted acute myeloid leukemia (AML) with the t(8;21) translocation producing the AML1-ETO fusion [GeneID=861;862].
Genes that best predicted acute myeloid leukemia (AML) with the 11q23 rearrangements.
Genes that best predicted acute myeloid leukemia (AML) with the up-regulated expression of EVI1 [GeneID=2122].
Genes that best predicted acute myeloid leukemia (AML) with mutations in CEBPA [GeneID=1050].
Genes that best predicted acute myeloid leukemia (AML) with internal tandem duplications (IDT) in FLT3 [GeneID=2322].
Genes up-regulated in peripheral blood mononuclear cells (PBMC) from sickle cell disease patients compared to those from healthy subjects.
Genes down-regulated in peripheral blood mononuclear cells (PBMC) from sickle cell disease patients compared to those from healthy subjects.
Genes up-regulated in atypical ductal hyperplastic tissues from patients with (ADHC) breast cancer vs those without the cancer (ADH).
Genes down-regulated in atypical ductal hyperplastic tissues from patients with (ADHC) breast cancer vs those without the cancer (ADH).
The lung adenocarcinoma TSP (tumor sequencing project) genes bearing recurrent somatic mutations.
The lung adenocarcinoma TSP (tumor sequencing project) genes mutations in which show positive correlation with the  higher overall mutation rate.
Genes significantly mutated in 91 glioblastoma samples.
Cis-regulated expression quantitative loci (cis-eQTL) in the liver that contribute to metabolic quantitative traits (weight, fat mass, and plasma glucose and cholesterol levels).
Up-regulated genes in hepatocellular carcinoma (HCC) subclass G1, defined by unsupervised clustering
Down-regulated genes in hepatocellular carcinoma (HCC) subclass G1, defined by unsupervised clustering
Genes in hepatocellular carcinoma (HCC) subclass G2, defined by unsupervised clustering.
Up-regulated genes in hepatocellular carcinoma (HCC) subclass G3, defined by unsupervised clustering.
Down-regulated genes in hepatocellular carcinoma (HCC) subclass G3, defined by unsupervised clustering.
Down-regulated genes in hepatocellular carcinoma (HCC) subclass G5, defined by unsupervised clustering.
Up-regulated genes in hepatocellular carcinoma (HCC) subclass G6, defined by unsupervised clustering.
Down-regulated genes in hepatocellular carcinoma (HCC) subclass G6, defined by unsupervised clustering.
Up-regulated genes in hepatocellular carcinoma (HCC) subclass G12, defined by unsupervised clustering
Down-regulated genes in hepatocellular carcinoma (HCC) subclass G12, defined by unsupervised clustering
Up-regulated genes in hepatocellular carcinoma (HCC) subclass G23, defined by unsupervised clustering.
Down-regulated genes in hepatocellular carcinoma (HCC) subclass G23, defined by unsupervised clustering.
Up-regulated genes in hepatocellular carcinoma (HCC) subclass G56, defined by unsupervised clustering.
Down-regulated genes in hepatocellular carcinoma (HCC) subclass G56, defined by unsupervised clustering.
Up-regulated genes in hepatocellular  carcinoma (HCC) subclass G123, defined by unsupervised clustering.
Down-regulated genes in hepatocellular  carcinoma (HCC) subclass G123, defined by unsupervised clustering.
Top 200 marker genes up-regulated in the 'CTNNB1' subclass of hepatocellular carcinoma (HCC); characterized by activated CTNNB1 [GeneID=1499].
Top 200 marker genes down-regulated in the 'CTNNB1' subclass of hepatocellular carcinoma (HCC); characterized by activated CTNNB1 [GeneID=1499].
Top 200 marker genes up-regulated in the 'proliferation' subclass of hepatocellular carcinoma (HCC); characterized by increased proliferation, high levels of serum AFP [GeneID=174], and chromosomal instability.
Top 200 marker genes down-regulated in the 'proliferation' subclass of hepatocellular carcinoma (HCC); characterized by increased proliferation, high levels of serum AFP [GeneID=174], and chromosomal instability.
All marker genes up-regulated in the 'interferon' subclass of hepatocellular carcinoma (HCC).
All marker genes down-regulated in the 'interferon' subclass of hepatocellular carcinoma (HCC).
Marker genes up-regulated in the 'chromosome 7 polysomy' subclass of hepatocellular carcinoma (HCC); characterized by polysomy of chromosome 7 and by a lack of gains of chromosome 8q.
Marker genes down-regulated in the 'chromosome 7 polysomy' subclass of hepatocellular carcinoma (HCC); characterized by polysomy of chromosome 7 and by a lack of gains of chromosome 8q.
Marker genes up-regulated in the 'unannotated' subclass of hepatocellular carcinoma (HCC) samples.
Marker genes down-regulated in the 'unannotated' subclass of hepatocellular carcinoma (HCC) samples.
'Late-TGFB1 signature': genes overexpressed in primary hepatocytes at a late phase of TGFB1 [GeneID=7040] treatment; is associated with a more invasive phenotype.
'Early-TGFB1 signature': genes overexpressed in primary hepatocytes at an early phase of TGFB1 [GeneID=7040] treatment; is associated with a less invasive phenotype.
Genes whose expression correlated with higher risk of late recurrence of hepatocellular carcinoma (HCC).
Genes whose expression correlated with lower risk of late recurrence of hepatocellular carcinoma (HCC).
Survival signature genes defined in adjacent liver tissue: genes correlated with poor survival of hepatocellular carcinoma (HCC) patients.
Survival signature genes defined in adjacent liver tissue: genes correlated with good survival of hepatocellular carcinoma (HCC) patients.
Selected up-regulated MET [GeneID=4233] target genes from a classifier of hepatocellular carcinoma (HCC) cases; associated with poor survival.
Selected down-regulated MET [GeneID=4233] target genes from a classifier of hepatocellular carcinoma (HCC) cases; associated with poor survival.
Up-regulated genes distinguishing hepatocellular carcinoma (HCC) samples positive for EPCAM [GeneID=4072] from the negative ones.
Down-regulated genes distinguishing hepatocellular carcinoma (HCC) samples positive for EPCAM [GeneID=4072] from the negative ones.
Genes up-regulated in hepatocellular carcinoma (HCC) cells with hepatic stem cell properties.
Genes down-regulated in hepatocellular carcinoma (HCC) cells with hepatic stem cell properties.
Genes up-regulated in tumor-adjacent liver tissue, which is asociated with intrahepatic metastasis of hepatocellular carcinoma
Genes down-regulated in tumor-adjacent liver tissue, which is asociated with intrahepatic metastasis of hepatocellular carcinoma
Fig.5, Supplementary Fig.2 Genes overexpressed in human hepatocellular carcinoma with hepatoblast property
Genes up-regulated in samples from patients with recurrent hepatocellular carcinoma (HCC).
Genes down-regulated in samples from patients with recurrent hepatocellular carcinoma (HCC).
Genes positively correlated with recurrence free survival in patients with hepatitis B-related (HBV) hepatocellular carcinoma (HCC).
Genes negatively correlated with recurrence free survival in patients with hepatitis B-related (HBV) hepatocellular carcinoma (HCC).
Genes whose expression most strongly and consistently associated with the long term survival of patients with high grade glioma tumors.
Genes whose expression most strongly and consistently associated with the short term survival of patients with high grade glioma tumors.
Up-regulated genes predicting poor survival of patients with thyroid carcinoma.
Down-regulated genes predicting poor survival of patients with thyroid carcinoma.
Genes specifically expressed in samples from patients with pediatric AML (acute myeloid leukemia ) bearing t(8;21) translocation.
Genes specifically expressed in samples from patients with pediatric acute myeloid leukemia (AML) bearing inv(16) translocation.
Genes specifically expressed in samples from patients with pediatric acute myeloid leukemia (AML) bearing t(9;11) translocation.
Genes specifically expressed in samples from patients with pediatric acute myeloid leukemia (AML) bearing 11q23 rearrangements.
Genes with high-CpG-density promoters (HCP) bearing histone H3 dimethylation mark at K4 (H3K4me2) and trimethylation mark at K27 (H3K27me3) in neural precursor cells (NPC).
Genes with high-CpG-density promoters (HCP) bearing bivalent histone H3 dimethylation mark at K4 (H3K4me2) and trimethlation mark at K27 (H3K27me3) in brain.
Genes up-regulated in hepatocellular carcinoma (HCC) samples from patients with early recurrence (within 2 years after surgery) after resection.
Genes down-regulated in hepatocellular carcinoma (HCC) samples from patients with early recurrence (within 2 years after surgery) after resection.
Genes with high-CpG-density promoters (HCP) bearing histone H3 dimethylation mark at K4 (H3K4me2) in neural precursor cells (NPC).
Genes with high-CpG-density promoters (HCP) bearing histone H3 dimethylation mark (H3K4me2) in brain.
Genes with high-CpG-density promoters (HCP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MCV6 cells (embryonic fibroblasts trapped in a differentiated state).
Genes with intermediate-CpG-density promoters (ICP) bearing the bivalent trimethylation marks at H3K4 (H3K4me3) and H3K27 (H3K27me3) in MCV6 cells (embryonic fibroblasts trapped in a differentiated state).
Genes with intermediate-CpG-density promoters (ICP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MCV6 cells (embryonic fibroblasts trapped in a differentiated state).
Genes with low-CpG-density promoters (LCP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MCV6 cells (embryonic fibroblasts trapped in a differentiated state).
Genes with low-CpG-density promoters (LCP) bearing the tri-methylation mark at H3K4 (H3K4me3) in MCV6 cells (embryonic fibroblasts trapped in a differentiated state).
Genes with intermediate-CpG-density promoters (ICP) bearing the bivalent tri-methylation marks at H3K4 (H3K4me3) and H3K27 (H3K27me3) in MEF cells (embryonic fibroblasts).
Genes with intermediate-CpG-density promoters (ICP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MEF cells (embryonic fibroblasts).
Genes with low-CpG-density promoters (LCP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MEF cells (embryonic fibroblasts).
Genes with low-CpG-density promoters (LCP) bearing tri-methylation mark at H3K4 (H3K4me3) in MEF cells (embryonic fibroblasts).
Genes with high-CpG-density promoters (HCP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MCV8.1 (induced pluripotent cells, iPS).
Genes with high-CpG-density promoters (HCP) without H3 methylation marks at either H3K4 or H3K27 in MCV8.1 cells (induced pluripotent cells, iPS).
Genes with intermediate-CpG-density promoters (ICP) bearing the bivalent tri-methylation marks at H3K4 (H3K4me3) and H3K27 (H3K27me3) in MCV8.1 cells (induced pluripotent cells, iPS).
Genes with intermediate-CpG-density promoters (ICP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MCV8.1 cells (induced pluripotent cells, iPS).
Genes with low-CpG-density promoters (LCP) bearing the bivalent tri-methylation marks at H3K4 (H3K4me3) and H3K27 (H3K27me3) in MCV8.1 cells (induced pluripotent cells, iPS).
Genes with low-CpG-density promoters (LCP) bearing the tri-methylation mark at H3K27 (H3K27me3) in MCV8.1 cells (induced pluripotent cells, iPS).
Table 2S. Genes in MEF, MCV6, MCV8.1 and ES cells by  epigenetic mark of their promoter
Genes whose over-expression is associated with the risk of death in multiple cancer types
Genes up-regulated in hepatocellular carcinoma (HCC) with early recurrence.
Genes down-regulated in hepatocellular carcinoma (HCC) with early recurrence.
Genes up-regulated in both the patients in the multicentric hepatocellular carcinoma (HCC) group and those with multicentric recurrence.
Genes down-regulated in both the patients in the multicentric hepatocellular carcinoma (HCC) group and those with multicentric recurrence.
Genes up-regulated by FOXP3 [GeneID=50943] in both ex vivo and hybridoma cells.
Genes down-regulated by FOXP3 [GeneID=50943] in both ex vivo and hybridoma cells.
Genes up-regulated in CD4+ [GeneID=920] T lymphocytes by expression of AML1 [GeneID=861] off a viral vector.
Genes down-regulated in CD4+ [GeneID=920] T lymphocytes by expression of AML1 [GeneID=861] off a viral vector.
Genes up-regulated in CD4+ [GeneID=920] T lymphocytes transduced with FOXP3 [GeneID=50943].
Genes down-regulated in CD4+ [GeneID=920] T lymphocytes transduced with FOXP3 [GeneID=50943].
Genes up-regulated in prostate cancer samples bearing the fusion of TMPRSS2 with ERG [GeneID=7113;2078].
Genes down-regulated in prostate cancer samples bearing the fusion of TMPRSS2 with ERG [GeneID=7113;2078].
Genes down-regulated in A375 cells (melanoma) treated with KINK-1, a small molecule inhibitor of NFKB.
Genes down-regulated in S-17 cells (bone marrow stroma) after stimulation with FGF2 [GeneID=2247].
Proteins with reduced expression in mulignant glioma cell line (A172) which bears loss of heterozygosity (LOH) in the 1p region.
Genes defining a 25-signal proteomic signature associated with a high risk of cancer recurrence and poor survival of NSCLC (non-small cell lung cancer) patients.
Genes up-regulated in multiple drug resistant neuroblastoma cell lines.
The 'CLASS-11' set of pro- and anti-inflammatory cytokines whose expression identifies stage I lung adenocarcinoma patients with poor prognosis.
Genes from the 254-gene classifier which were down-regulated in melanoma patients with a reported distant metastasis within 4 years.
Genes up-regulated in CL1-5 cells (lung cancer) overexpressing DNAJB4 [GeneID=11080] off a plasmid vector.
Genes down-regulated in CL1-5 cells (lung cancer) overexpressing DNAJB4 [GeneID=11080] off a plasmid vector.
Down-regulated genes associated with poor survival prognosis of patients with metastatic neuroblastoma that lack MYCN [GeneID=4613] amplification.
Genes affected by epigenetic aberrations in prostate cancer.
Interferon cluster genes up-regulated in skin tumors treated with imiquimod [PubChem=57469].
Inflammatory cytokines and their receptors modulated in brain tumors after treatment with an oncocytic virus, a potential anticancer therapy.
Inflammatory cytokines and their receptors moduated in brain tumors in response to treatment with cyclic RGD peptide prior to the oncocytic virus therapy.
Genes up-regulated in follicular thyroid adenoma (FTA) compared to other thyroid tumors.
Genes down-regulated in follicular thyroid adenoma (FTA) compared to other thyroid tumors.
Genes up-regulated in thyroid tumors of uncertain malignancy (T-UM) compared to other thyroid tumors.
Genes down-regulated in thyroid tumors of uncertain malignancy (T-UM) compared to other thyroid tumors.
Genes up-regulated in papillary thyroid carcinoma (PTC) compared to other thyroid tumors.
Genes down-regulated in papillary thyroid carcinoma (PTC) compared to other thyroid tumors.
Genes changed in LSK cells (bone marrow) as a function of a QTL for the size of hematopoietic stem cell (HSC) population: comparison of reciprocal congenic strains D.B. Chr3 (DB), B.D. Chr3 (BD) and the parental strains B6 and D2.
Methylated germline-specific genes with low-CpG-density promoters (LCP) in primary fibroblasts.
Unmethylated germline-specific genes with low-CpG-density promoters (LCP) in primary fibroblasts.
Germline-specific genes with intermediate-CpG-density promoters (ICP) that are methylated in primary fibroblasts.
Methylated germline-specific genes with intermediate-CpG-density promoters (ICP) in sperm.
Unmethylated germline-specific genes with intermediate-CpG-density promoters (ICP) in sperm.
Methylated germline-specific genes with low-CpG-density promoters (LCP) in sperm.
Unmethylated germline-specific genes with low-CpG-density promoters (LCP) in sperm.
The XPRSS-Int network genes up-regulated in breast tumors from patients with germline mutations in BRCA1 [GeneID=672] compared to those with the wild type allele.
The XPRSS-Int network genes down-regulated in breast tumors from patients with germline mutations in BRCA1 [GeneID=672] compared to those with the wild type allele.
Genes associated with resistance to doxorubicin [PubChem=31703].
Genes associated with resistance to mitoxantrone [PubChem=4212].
Genes responsive to estradiol [PubChem=5757] both in normal and cancer ovarian cell lines.
Selected genes with immunologic function which were reciprocally changed in evasion and tolerogenic tumor models.
Selected genes with immunologic function which were reciprocally changed in evasion and tolerogenic tumor models.
Genes regulated by ESR1 [GeneID=2099] in MCF-7 cells (breast cancer).
Genes regulated by ESRRA [GeneID=2101] in MCF-7 cells (breast cancer).
Genes up-regulated by estradiol [PubChem=5757] and not modulated by ESRRA [GeneID=2101] in MCF-7 cells (breast cancer).
Selected genes up-regulated in peripheral blood monocytes (PBMC) of patients with hepatocellular carcinoma (HCC) compared to those with chronic hepatitis.
Top 20 genes expressed higher in epithelioid than in sarcomatoid mesothelioma samples.
Top genes associated with favorable overall survival of mesothelioma patients after surgery.
Top genes associated with unfavorable overall survival of mesothelioma patients after surgery.
Top genes associated with favorable survival after surgery of patients with epithelioid mesothelioma.
Top genes associated with unfavorable survival after surgery of patients with epithelioid mesothelioma.
Genes whose expression pattern in adult male germ cell tumors (GCT) correlates with POU5F1 [GeneID=5460].
Top 25 most highly expressed genes in embryonic carcinoma relative to seminoma tumors.
Top 25 most highly expressed genes in seminoma relative to embryonic carcinoma tumors.
Genes up-regulated in H1975 cells (non-small cell lung cancer, NSCLC) resistant to gefitinib [PubChem=123631] after treatment with EGFR inhibitor CL-387785 [PubChem=2776] for 24h.
Genes down-regulated in H1975 cells (non-small cell lung cancer, NSCLC) resistant to gefitinib [PubChem=123631] after treatment with EGFR inhibitor CL-387785 [PubChem=2776] for 24h.
Genes identified by method 2 as coordinately down-regulated late in HMEC cells (mammary epithelium) during acinar development in vitro.
Top up-regulated genes from principal component 1 (PCA1) which captures variation between normal plasma cells and tumors arising from aberrant expression of BCL2L1 and MYC [GeneID=598;4609].
Top down-regulated genes from principal component 1 (PCA1) which captures variation between normal plasma cells and tumors arising from aberrant expression of BCL2L1 and MYC [GeneID=598;4609].
Top up-regulated genes from principal component 3 (PCA3) which captures variation among different plasma cell tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609].
Top down-regulated genes from principal component 3 (PCA3) which captures variation among different plasma cell tumors arising from overexpression of BCL2L1 and MYC [GeneID=598;4609].
Genes from 'subtype S1' signature of hepatocellular carcinoma (HCC): aberrant activation of the WNT signaling pathway.
Genes from 'subtype S2' signature of hepatocellular carcinoma (HCC): proliferation, MYC and AKT1 [GeneID=4609;207] activation.
Genes from 'subtype S3' signature of hepatocellular carcinoma (HCC): hepatocyte differentiation.
Up-regulated genes in head and neck cancer compared to cervical carcinoma samples.
Down-regulated genes in head and neck cancer compared to cervical carcinoma samples.
Genes up-regulated in hepatoblastoma samples compared to normal liver tissue.
Genes down-regulated in hepatoblastoma samples compared to normal liver tissue.
Genes up-regulated in robust Cluster 2 (rC2) of hepatoblastoma samples compared to those in the robust Cluster 1 (rC1).
Genes down-regulated in robust Cluster 2 (rC2) of hepatoblastoma samples compared to those in the robust Cluster 1 (rC1).
Genes up-regulated at early fetal liver stage (embryonic days  E11.5 - E12.5) compared to the late fetal liver stage (embryonic days E14.5 - E16.5).
Genes down-regulated at early fetal liver stage (embryonic days  E11.5 - E12.5) compared to the late fetal liver stage (embryonic days E14.5 - E16.5).
Genes whose expression classifies hepatoblastoma tumors as belonging to either rC1 or rC2 subtypes and whose expression predicts poor survival.
Genes exclusively up-regulated in B lymphocytes from CLL (chronic lymphocytic leukemia) patients but with a similiar expression pattern in the normal cells and in the cells from WM (Waldenstroem's macroblobulinemia) patients.
Genes exclusively down-regulated in B lymphocytes from CLL (chronic lymphocytic leukemia) patients but with a similiar expression pattern in the normal cells and in the cells from WM (Waldenstroem's macroblobulinemia) patients.
Genes exclusively up-regulated in B lymphocytes from WM (Waldenstroem's macroblobulinemia) patients but with a similiar expression pattern in the normal cells and in the cells from CLL (chronic lymphocytic leukemia) patients.
Genes exclusively down-regulated in B lymphocytes from WM (Waldenstroem's macroblobulinemia) patients but with a similiar expression pattern in the normal cells and in the cells from CLL (chronic lymphocytic leukemia) patients.
Genes exclusively up-regulated in plasma cells from MM (multiple myeloma) patients but with a similiar expression pattern in the normal cells and in the cells from WM (Waldenstroem's macroblobulinemia) patients.
Genes exclusively up-regulated in B lymphocytes from WM (Waldenstroem's macroglobulinemia) but with a similar expression profile in MM (macroglobulinemia) and normal cells.
Genes from the 254-gene classifier which were up-regulated in melanoma patients with a reported distant metastasis within 4 years.
Genes showing similar expression profiles in all subtypes of cutaneous T cell lymphoma (CTCL).
Differentially expressed genes relevant to pathogenesis of cutaneous T cell lymphoma (CTCL).
Genes up-regulated in HUVEC cells (primary endothelium) after stimulation with leukotriene LTD4 [PubChem=3908] or thrombin (F2) [GeneID=2147] for 1 h.
The optimal set of 70 prognostic markers predicting poor breast cancer clinical outcome (defined as developing metastases with 5 years).
Genes up-regulated similarly  in primary fibroblast cultures from Werner syndrom patients and normal old donors compared to those from normal young donors.
Genes down-regulated similarly  in primary fibroblast cultures from Werner syndrom patients and normal old donors compared to those from normal young donors.
Genes distinctly up-regulated in primary fibroblast cultures from normal old donors compared to those from normal young donors.
Genes distinctly down-regulated in primary fibroblast cultures from normal old donors compared to those from normal young donors.
Genes distinctly up-regulated in primary fibroblast cultures from Werner syndrom patients compared to those from normal young donors.
Genes distinctly down-regulated in primary fibroblast cultures from Werner syndrom patients compared to those from normal young donors.
Genes down-regulated in T cell acute lymphocytic leukemia (T-ALL) patients refractory to chemotherapy treatment.
Genes whose expression predicted relapse in less than 2 years after chemotherapy for adult patients with T-ALL (T cell lymphoblastic leukemia).
Genes whose expression is coregulated with that of IL3RA [GeneID=3563] in hematopoietic stem cells (HSC).
Genes trans-regulated by the hematopoietic stem cell (HSC) proliferation QTL (quantitative trait locus) Scp2.
Top 50 down-regulated genes in cluster CD-1 of multiple myeloma samples with the characteristic expression spike of CCND1 [GeneID=595].
Top 50 down-regulated genes in cluster CD-2 of multiple myeloma samples with the charachteristic expression spike of CCND3 [GeneID=896].
Top 50 down-regulated genes in cluster LB of multiple myeloma samples belonging to the low bone disease group.
Top 50 down-regulated genes in cluster HP of multiple myeloma samples characterized by a hyperploid signature.
Top 50 down-regulated genes in cluster MF of multiple myeloma samples with characteristic expression spike of MAF family transcription factors.
Top 50 down-regulated genes in cluster MS of multiple myeloma samples with characteristic expression spike of WHSC1 [GeneID=7468].
Top 50 down-regulated genes in cluster PR of multiple myeloma samples characterized by increased expression of proliferation and cell cycle genes.
Genes up-regulated by MYC [GeneID=4609], according to the MYC Target Gene Database.
Genes down-regulated by MYC [GeneID=4609], according to the MYC Target Gene Database.
Genes up-regulated by MYC [GeneID=4609] and whose promoters are bound by MYC, according to MYC Target Gene Database.
Genes down-regulated by MYC [GeneID=4609] and whose promoters are bound by MYC, according to MYC Target Gene Database.
Genes whose promoters are bound by MYC [GeneID=4609], according to MYC Target Gene Database.
Genes up-regulated in HeLa cells (cervical carcinoma) 12 h after infection with adenovirus Ad12.
Genes down-regulated in HeLa cells (cervical carcinoma) 12 h after infection with adenovirus Ad12.
Genes up-regulated in HeLa cells (cervical carcinoma) 24 h after infection with adenovirus Ad12.
Genes down-regulated in HeLa cells (cervical carcinoma) 24 h after infection with adenovirus Ad12.
Genes up-regulated in HeLa cells (cervical carcinoma) 32 h after infection with adenovirus Ad12.
Genes down-regulated in HeLa cells (cervical carcinoma) 32 h after infection with adenovirus Ad12.
Genes up-regulated in HeLa cells (cervical carcinoma) 48 h after infection with adenovirus Ad12.
Genes down-regulated in HeLa cells (cervical carcinoma) 48 h after infection with adenovirus Ad12.
Genes modulated in HeLa cells (cervical carcinoma) by TNF [GeneID=7124] via NFKB pathway.
Genes modulated in HeLa cells (cervical carcinoma) by TNF [GeneID=7124] not via NFKB pathway.
The 'core ESC-like gene module': genes coordinately up-regulated in a compendium of mouse embryonic stem cells (ESC) which are shared with the human ESC-like module.
The 'adult tissue stem' module: genes coordinately up-regulated in a compendium of adult tissue stem cells.
Top 100 probe sets contrubuting to the positive side of the 1st principal component; predominantly associated with spindle cell and pleomorphic sarcoma samples.
Top 100 probe sets contrubuting to the negative side of the 1st principal component; predominantly associated with synovial sarcoma and myxoid/round cell liposarcoma samples.
Top 100 probe sets contrubuting to the positive side of the 2nd principal component; associated with adipocytic differentiation.
Top 100 probe sets contrubuting to the negative side of the 2nd principal component; associated with adipocytic differentiation.
Genes up-regulated in metastatic tumors from the whole panel of patients with prostate cancer.
Genes down-regulated in metastatic tumors from the whole panel of patients with prostate cancer.
Genes with high-CpG-density promoters (HCP) bearing histone H3 K27 trimethylation mark (H327me3) in embryonic stem cells (ES).
Genes with high-CpG-density promoters (HCP) without H3 methylation marks at K4 and K27 in embryonic stem cells (ES).
Genes with intermediate-CpG-density promoters (ICP) bearing histone H3 K27 trimethylation mark (H3K27me3) in embryonic stem cells (ES).
Genes with intermediate-CpG-density (ICP) promoters bearing histone H3 K4 trimethylation mark (H3K4me3) in embryonic stem cells (ES).
Genes with intermediate-CpG-density promoters (ICP) bearing bivalent histone H3 methylation mark (H3K4me3 and H3K27me3) in embryonic stem cells (ES).
Genes with low-CpG-density promoters bearing H3 trimethylation mark at K27 (H3K27me3) in embryonic stem cells (ES).
Genes with low-CpG-density promoters (LCP) bearing histone H3 trimethylation mark at K4 (H3K4me3) in embryonic stem cells (ES).
Genes with low-CpG-density promoters (LCP) bearing the bivalent histone H3 trimethylation mark at K4 and K27 (H3K4me3 and H3K27me3) in embryonic stem cells (ES).
Genes with high-CpG-density promoters (HCP) bearing histone H3 trimethylation mark at K27 (H3K27me3) in neural progenitor cells (NPC).
Genes with high-CpG-density promoters (HCP) bearing the bivalent histone H3 trimethylation mark at K4 and K27 (H3K4me3 and H3K27me3) in neural progenitor cells (NPC).
Genes with intermediate-CpG-density promoters (ICP) bearing histone H3 trimethylation mark at K27 (H3K27me3) in neural progenitor cells (NPC).
Genes with intermediate-CpG-density promoters (ICP) bearing histone H3 trimethylation mark at K4 (H3K4me3) in neural progenitor cells (NPC).
Genes with low-CpG-density promoters (LCP) bearing histone H3 trimethylation mark at K27 in neural progenitor cells (NPC).
Genes with low-CpG-density promoters (LCP) bearing histone H3 trimethylation mark at K4 (H3K4me3) in neural progenitor cells (NPC).
Genes with high-CpG-density promoters (HCP) bearing histone H3 trimethylation mark at K27 (H3K27me3) in MEF cells (embryonic fibroblast).
Genes with high-CpG-density promoters (HCP) with unmethylated histone H3 in MEF cells (embryonic fibroblast).
Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 0.
Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 1.
Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 2.
Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 3.
Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 4.
Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 5.
Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 6.
Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 7.
Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 8.
Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 9.
Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 10.
Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 11.
Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 12.
Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 13.
Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 14.
Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 15.
Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 16.
Genes co-regulated in uterus during a time course response to progesterone [PubChem=5994]: SOM cluster 17.
Genes whose reduced expression in nasopharyngeal carinoma (NPC) correlated most with the increased expression of EBNA1 [GeneID=3783774], a latent gene of Epstein-Barr virus (EBV).
Genes in cluster 5: slowly down-regulated in HFW cells (fibroblast) by sodium arsenite [PubChem=26435].
Genes involved in pyruvate metabolism; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.
Genes involved in free fatty acid oxidation; based on literature and sequence annotation resources and coverted to Affymetrix HG-U133A probe sets.
Genes involved in gluconeogenesis; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.
Genes involved in glycogen metabolism; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.
Genes involved in glycolysis; based on literature and sequence annotation resources and converted to Affymetrix HG-U133A probe sets.
Genes up-regulated in fibroblasts from old individuals, compared to those from young donors.
Genes up-regulated in mesenchymal stem cells during early phase of adipogenesis, defined as days 1 to 5 of culturing with adipogenic hormones.
Genes down-regulated in mesenchymal stem cells during early phase of adipogenesis, defined as days 1 to 5 of culturing with adipogenic hormones.
Genes up-regulated in mesenchymal stem cells during late phase of adipogenesis, defined as days 7 to 14 of culturing with adipogenic hormones.
Genes down-regulated in mesenchymal stem cells during late phase of adipogenesis, defined as days 7 to 14 of culturing with adipogenic hormones.
Genes down-regulated in the brain cortex of mice that were exposed to an enriched learning environment for one day.
Cluster 6: ECM related genes up-regulated in dermal fibroblasts later than 30 min after TGFB1 [GeneID=7040] addition; slowly increased up to 120 min time point, then reached a plateau.
Genes up-regulated in huT78R cells (cutaneous T-cell lymphoma, CTCL) resistant to IFNA2 [GeneID=3440] compared to the IFN2A sensitive parental cell line.
Genes up-regulated in pyloric atrium with knockout of TFF2 [GeneID=7032].
Genes down-regulated in pyloric atrium with knockout of TFF2 [GeneID=7032].
Genes down-regulated on serial passage of MEF cells (embryonic fibroblast).
Gene expression signature of vascular invasion of hepatocellular carcinoma (HCC).
Genes up-regulated in 3T3-L1 cells (fibroblast) induced to differentiate to mature adipocytes and then treated with a TZD derivative AD-5075 [PubChem=128440], a PPARG [GeneID=5468] activator.
Genes down-regulated in 3T3-L1 cells (fibroblast) induced to differentiate to mature adipocytes and then treated with a TZD derivative AD-5075 [PubChem=128440], a PPARG [GeneID=5468] activator.
Cluster 1: genes up-regulated in SW260 cells (colon cancer) by sodium butyrate, curcumin, sulindac and TSA [PubChem=5222465;969516;5352;5562].
Cluster 2: genes up-regulated in SW260 cells (colon cancer) by sodium butyrate, curcumin, sulindac and TSA [PubChem=5222465;969516;5352;5562].
Genes up-regulated in primary keratinocytes at 1 h after UVB irradiation.
Genes down-regulated in primary keratinocytes at 1 h after UVB irradiation.
Genes up-regulated in response to hydorgen peroxyde [PubChem=784] in CS-B cells (Cockaine syndrome fibroblast, CS) with defficient ERCC6 [GeneID=2074].
Genes down-regulated in response to hydorgen peroxyde [PubChem=784] in CS-B cells (Cockaine syndrome fibroblast, CS) with defficient ERCC6 [GeneID=2074].
Genes up-regulated in peripheral lymphocytes from old individuals compared to those from young donors.
Top genes associated with chemosensitivity to 5-fluorouracil [PubChem=3385] across 85 tumor xenografts.
Top genes associated with chemosensitivity to cisplatin [PubChem=2767] across 85 tumor xenografts.
Top genes associated with chemosensitivity to nimustine [PubChem=39214] across 85 tumor xenografts.
Top genes associated with chemosensitivity to doxorubicin [PubChem=31703] across 85 tumor xenografts.
Top genes associated with chemosensitivity to cyclophosphamide [PubChem=2907] across 85 tumor xenografts.
Top genes associated with chemosensitivity to mitomycin [PubChem=5746] across 85 tumor xenografts.
Top genes associated with chemosensitivity to methotrexate [PubChem=4112] across 85 tumor xenografts.
Top genes associated with chemosensitivity to vincristine [PubChem=5978] across 85 tumor xenografts.
Top genes associated with chemosensitivity to vinblastine [PubChem=13342] across 85 tumor xenografts.
Cluster G5: genes up-regulated in NHEK cells (normal keratinocyte) at 3 h and 24 h time points after UV-B irradiation.
Cluster G24: genes induced in NHEK (normal keratinocyte) but not in SCC12B2 cells (squamous cell carcinoma) by UV-B radiation.
Cluster G28: genes differentially up-regulated in NHEK (normal keratinocyte) compared to SCC12B2 cells (squamous cell carcinoma) by UV-B radiation.
Adipocyte abundant genes down-regulated in 3T3-L1 cells (fibroblasts induced to differentiate to adipocytes) in response to troglitazone [PubChem=5591].
Top 20 genes whose down-regulation correlated with gastrointestinal stromal tumors (GIST) compared to synovial sarcoma.
A cluster of genes specifically up-regulated in gastrointestinal stromal tumors (GIST).
Top 20 negative significant genes associated with leiomyosarcoma tumors expressing muscle gene cluster with CNN1 [GeneID=1264].
Top 20 negative significant genes associated with CNN1 [GeneID=1264] negative leiomyosarcoma tumors.
Top 20 positive significant genes associated with synovial sarcoma tumors.
Top 20 negative significant genes associated with synovial sarcoma tumors.
Top 20 negative significant genes associated with malignant fibrous histiocytoma tumors.
Top 20 negative significant genes associated with schwannoma tumors.
Genes up-regulated in normal fibroblasts in response to IL6 [GeneID=3569].
Genes down-regulated in normal fibroblasts in response to IL6 [GeneID=3569].
Genes down-regulated in A172 cells (glioma, does not express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 24 h.
Genes up-regulated in T98G cells (glioma, express MGMT [GeneID=4255]) by carmustine [PubChem=2578] at 24 h.
Genes up-regulated in MCF7 cells (breast cancer) upon knockdown of CLOCK [GeneID=9575] by RNAi that also belong to the highest confidence network (according to Ingenuity Pathway Analysis).
Genes down-regulated in MCF7 cells (breast cancer) upon knockdown of CLOCK [GeneID=9575] by RNAi that also belong to the highest confidence network (according to Ingenuity Pathway Analysis).
A list of known cell cycle regulated genes that was compiled from the literature by the authors.
Genes up-regulated in 786-0 cells (renal carcinoma, RCC) by the loss of VHL [GeneID=7428] and in response to hypoxia.
Genes downstream of both CDKN1A and TP53 [GeneID=1026;7157] in 2774qw1 cells (ovarian cancer).
Genes downstream of CDKN1A [GeneID=1026] in a TP53 [GeneID=7157] independent pathway in 2774qw1 cells (ovarian cancer).
Genes up-regulated in MEF cells (embryonic fibroblast) lacking TP53 and BRCA1 [GeneID=7157;672] by expression of BRCA1.
Genes down-regulated in MEF cells (embryonic fibroblast) lacking TP53 and BRCA1 [GeneID=7157;672] by expression of BRCA1.
Genes up-regulated in primary granulosa cells after stimulation with LH or FSH gonadotrophic hormones for 24 h.
Genes down-regulated in primary granulosa cells after stimulation with LH or FSH gonadotrophic hormones for 24 h.
Genes up-regulated in primary granulosa cells in response to forskolin [PubChem=47936].
Genes down-regulated in primary granulosa cells in response to forskolin [PubChem=47936].
Genes concordantly up-regulated in DU-145 and MCF-7 cells (lprostate, breast cancer) upon expression of BRCA1.
Genes concordantly down-regulated in DU-145 and MCF-7 cells (lprostate, breast cancer) upon expression of BRCA1.
Genes up-regulated in primary fibroblast cell culture at 30 min time point after infection with HCMV (AD169 strain).
Genes down-regulated in primary fibroblast cell culture at 30 min time point after infection with HCMV (AD169 strain).
Genes up-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 1 h time point that were not up-regulated at the previous time point, 30 min.
Genes down-regulated in primary fibroblast cell culture after infection with HCMV (AD169 strain) at 1 h time point that were not down-regulated at the previous time point, 30 min.
Genes up-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 2 h time point that were not up-regulated at the previous time point, 1 h.
Genes down-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 2 h time point that were not down-regulated at the previous time point, 1 h.
Genes up-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 4 h time point that were not up-regulated at the previous time point, 2 h.
Genes down-regulated in primary fibroblast cell culture point after infection with HCMV (AD169 strain) at 4 h time point that were not down-regulated at the previous time point, 2 h.
Genes periodically expressed in synchronized HeLa cells (cervical carcinoma), with peak during the G1/S phase of cell cycle.
Genes periodically expressed in synchronized HeLa cells (cervical carcinoma), with peak during the S phase of cell cycle.
Genes periodically expressed in synchronized HeLa cells (cervical carcinoma), with peak during the G2 phase of cell cycle.
Genes periodically expressed in synchronized HeLa cells (cervical carcinoma), with peak during the G2/M phase of cell cycle.
Genes periodically expressed in synchronized HeLa cells (cervical carcinoma), with peak during the M/G1 phase of cell cycle.
Genes in this set correspond to the most abuntant transcripts that are also specific to platelets.
Genes up-regulated by TGFB1 [GeneID=7040] in MEF cells (embryonic fibroblast) via TGFB1R [GeneID=7046].
Genes down-regulated by TGFB1 [GeneID=7040] in MEF cells (embryonic fibroblast) via TGFB1R [GeneID=7046].
Genes whose expression in primary ER(+) [GeneID=2099] breast cancer tumors positively correlates with developing distant metastases.
Genes whose expression in primary ER(+) [GeneID=2099] breast cancer tumors negatively correlates with developing distant metastases.
Genes whose expression in primary ER(-) [GeneID=2099] breast cancer tumors negatively correlates with developing distant metastases.
Genes up-regulated in ITNK cells (T-lymphocyte progenitors (DN3 cells) reprogrammed to natural killer (NK) cells by ablation of BCL11B [GeneID=64919] gene), compared to the parental DN3 cells.
Genes down-regulated in ITNK cells (T-lymphocyte progenitors (DN3 cells) reprogrammed to natural killer (NK) cells by ablation of BCL11B [GeneID=64919] gene), compared to the parental DN3 cells.
Genes showing significantly elevated somatic mutation frequencies in proneural G-CIMP (a CpG island methylator phenotype) GBM (glyoblastoma multiforme) tumors.
Genes with significantl germline mutation differences in proneural G-CIMP (a CpG island methylator phenotype) GBM (glyoblastoma multiforme) tumors.
Top 50 most differentially hypermethylated and down-regulated genes in proneural G-CIMP (a CpG island methylator phenotype) GBM (glyoblastoma multiforme) tumors.
Network of differentially expressed myeloid genes centered around CEBPA [GeneID=1050].
Network of differentially expressed myeloid genes centered around MN1 [GeneID=4330].
Genes with promoters occupied by PML-RARA fusion [GeneID=5371,5914] protein in acute promyelocytic leukemia(APL) cells NB4 and two APL primary blasts, based on  Chip-seq data.
Genes up-regulated in NB4 cells (acute promyelocytic leukemia, APL) in response to tretinoin [PubChem=444795]; based on Chip-seq data.
Genes down-regulated in NB4 cells (acute promyelocytic leukemia, APL) in response to tretinoin [PubChem=444795]; based on Chip-seq data.
Gene promoters preferentially bound by a mutated form of TP53 [GeneID=7157] in SKBR3 cells (breast cancer).
Genes induced in SKBR3 cells (breast cancer) by mutated TP53 [GeneID=7157].
Genes repressed in SKBR3 cells (breast cancer) by mutated TP53 [GeneID=7157].
Genes induced in SKBR3 cells (breast cancer) by 25-hydroxyvitamin D3 [PubChem=1593].
Genes repressed in SKBR3 cells (breast cancer) by 25-hydroxyvitamin D3 [PubChem=1593].
Genes whose expression was significantly and positively correlated with the number of perineuronal oligodendrocytes in the layer III of BA9 brain region.
Genes whose expression was significantly and negatively correlated with the number of perineuronal oligodendrocytes in the layer III of BA9 brain region.
Genes whose expression significantly and positively correlated with oligodendrocyte density in layer VI of BA9 brain region in patients with bipolar disorder.
Genes whose expression significantly and negatively correlated with oligodendrocyte density in layer VI of BA9 brain region in patients with bipolar disorder.
Genes whose expression significantly and positively correlated with the density of CALB1-positive [GeneID=793]  GABAergic interneurons in the BA9 brain region across all subjects with psychiatric disorders.
Genes whose expression significantly and negatively correlated with the density of CALB1-positive [GeneID=793]  GABAergic interneurons in the BA9 brain region across all subjects with psychiatric disorders.
Genes whose expression in brain significantly and positively correlated with the duration of all psychiatric disorders studied.
Genes whose expression in brain significantly and negatively correlated with the duration of all psychiatric disorders studied.
Genes correlated with proneural type of glioblastoma multiforme tumors.
Genes correlated with neural type of glioblastoma multiforme tumors.
Genes correlated with classical type of glioblastoma multiforme tumors.
Genes correlated with mesenchymal type of glioblastoma multiforme tumors.
Up-regulated genes in the cancer gene signature, representing a gene signature of cellular transformation.
Down-regulated genes in the cancer gene signature, representing a gene signature of cellular transformation.
Genes up-regulated in senescent IMR90 cells (fibroblast) after knockdown of RB1 [GeneID=5925] by RNAi.
Genes up-regulated in IMR90 cells (fibroblast) grown under low serum conditions and after knockdown of RB1 [GeneID=5925] by RNAi.
Genes up-regulated in growing IMR90 cells (fibroblast) after knockdown of RB1 [GeneID=5925] by RNAi.
Genes up-regulated in confluent IMR90 cells (fibroblast) after knockdown of RB1 [GeneID=5925] by RNAi.
Genes up-regulated in RS4;11 cells (MLL, mixed lineage leukemia) in response to SB216763 [PubChem=176158], an inhibitor of GSK3B [GeneID=2932].
Genes down-regulated in RS4;11 cells (MLL, mixed lineage leukemia) in response to SB216763 [PubChem=176158], an inhibitor of GSK3B [GeneID=2932].
Genes up-regulated by hypoxia in TRAMP-C cells (prostatic cancer).
Genes up-regulated by hypoxia in TRAMP-C cells (prostatic cancer) expressing HIF1A and FOXA2 [GeneID=3091,3170] off plasmid vectors.
Genes identified as synthetic lethal with imatinib [PubChem=5291] in RNAi screen in K562 cells (CML, chronic myelogenous leukemia).
Genes up-regulated in SKOV3ip1 cells (ovarian cancer) upon knockdown of EZH2 [GeneID=2146] by RNAi.
Genes down-regulated in SKOV3ip1 cells (ovarian cancer) upon knockdown of EZH2 [GeneID=2146] by RNAi.
Genes up-regulated in SH-SY5Y cells (neuroblastoma) after knockdown of NF1 [GeneID=4763] by RNAi.
Genes down-regulated in SH-SY5Y cells (neuroblastoma) after knockdown of NF1 [GeneID=4763] by RNAi.
Genes consistently overexpressed with age, based on meta-analysis of microarray data.
Genes consistently underexpressed with age, based on meta-analysis of microarray data.
Genes up-regulated in MCF7 cells (breast cancer) at 6 h of estradiol [PubChem=5757] treatment.
Genes down-regulated in MCF7 cells (breast cancer) at 6 h of estradiol [PubChem=5757] treatment.
Genes up-regulated in MCF7 cells (breast cancer) at 24 h of estradiol [PubChem=5757] treatment.
Genes down-regulated in MCF7 cells (breast cancer) at 24 h of estradiol [PubChem=5757] treatment.
Cluster 1 of aberrantly hypermethylated genes in blasts from AML (acute myeloid leukemia) patients.
Cluster 1 of aberrantly hypomethylated genes in blasts from AML (acute myeloid leukemia) patients.
Cluster 2 of aberrantly hypermethylated genes in blasts from AML (acute myeloid leukemia) patients.
Cluster 2 of aberrantly hypomethylated genes in blasts from AML (acute myeloid leukemia) patients.
Cluster 3 of aberrantly hypermethylated genes in blasts from AML (acute myeloid leukemia) patients.
Cluster 3 of aberrantly hypomethylated genes in blasts from AML (acute myeloid leukemia) patients.
Cluster 4 of aberrantly hypermethylated genes in blasts from AML (acute myeloid leukemia) patients.
Cluster 4 of aberrantly hypomethylated genes in blasts from AML (acute myeloid leukemia) patients.
Cluster 5 of aberrantly hypermethylated genes in blasts from AML (acute myeloid leukemia) patients.
Cluster 5 of aberrantly hypomethylated genes in blasts from AML (acute myeloid leukemia) patients.
Cluster 6 of aberrantly hypermethylated genes in blasts from AML (acute myeloid leukemia) patients.
Cluster 6 of aberrantly hypomethylated genes in blasts from AML (acute myeloid leukemia) patients.
Cluster 7 of aberrantly hypermethylated genes in blasts from AML (acute myeloid leukemia) patients.
Cluster 7 of aberrantly hypomethylated genes in blasts from AML (acute myeloid leukemia) patients.
Classic adipogenic genes (group 1) that are induced by PPARG  [GeneID=5468] during adipogenesis in 3T3-L1 preadipocytes.
Adipogenic genes (group 2) that are selectively repressed by  SIRT1 [GeneID=23411] in mature 3T3-L1 adipocytes.
Genes up-regulated in ovarian tumors from mouse models for the BMP SMAD signaling (gonad specific double knockout of SMAD1 and SMAD5 [GeneID=4086, 4090]).
Genes down-regulated in ovarian tumors from mouse models for the BMP SMAD signaling (gonad specific double knockout of SMAD1 and SMAD5 [GeneID=4086, 4090]).
Genes differentially expressed in E18.5 whole embryos upon knockout of FBXW8 [GeneID=26259].
Genes encoding mRNA transcripts specifically bound by DCP2 [GeneID=167227].
Genes up-regulated in placenta of mice with EHMT2 [GeneID=10919] knocked out.
Genes responding to progestin R5020 [PubChem=36709] treatment of T47D-MTVL cells (breast cancer).
Genes up-regulated in liver samples of liver-specific knockout of HNF4A [GeneID=3172].
Genes down-regulated in liver samples of liver-specific knockout of HNF4A [GeneID=3172].
Genes significantly de-regulated (p < 0.05) by MIR21 [GeneID=406991] in A172 cells (glioma).
Genes bound and activated by ZNF217 [GeneID=7764] in MCF7 cells (breast cancer).
Genes bound and repressed by ZNF217 [GeneID=7764] in MCF7 cells (breast cancer).
Genes up-regulated in small intestine upon loss of both APC and MBD2 [GeneID=324, 8932].
Genes down-regulated in small intestine upon loss of both APC and MBD2 [GeneID=324, 8932].
Genes up-regulated in immature bone marrow progenitor cells upon knock out of CBFA2T3 [GeneID=863].
Genes down-regulated in immature bone marrow progenitor cells upon knock out of CBFA2T3 [GeneID=863].
Genes up-regulated in RAW 264.7 cells (macrophage) upon stimulation with TNFSF11 [GeneID=8600].
Potential targets of MIR302A [GeneID=407028].
Genes up-regulated in CD34+ [GeneID=947] cells by intermediate activity levels of STAT5A [GeneID=6776]; predominant long-term growth and self-renewal phenotype.
Genes down-regulated in CD34+ [GeneID=947] cells by intermediate activity levels of STAT5A [GeneID=6776]; predominant long-term growth and self-renewal phenotype.
Genes up-regulated to their maximal levels in CD34+ [GeneID=947] cells by intermediate activity levels of STAT5A [GeneID=6776]; predominant long-term growth and self-renewal phenotype.
Genes up-regulated in a linear fashion in CD34+ [GeneID=947] cells upon increasing activity levels of STAT5A [GeneID=6776]; predominant long-term growth and self-renewal phenotype.
Proteins identified in complex with PML [GeneID=5371] in K562 cells (lymphoblast).
Genes up-regulated in K562 cells (lymphoblast) by MYC [GeneID=4609] in the presence of CKN1B [GeneID=1027].
Genes down-regulated in K562 cells (lymphoblast) by MYC [GeneID=4609] in the presence of CKN1B [GeneID=1027].
Genes up-regulated in osteoblasts from wild type male mice compared to those with AR [GeneID=367] knockout.
Genes down-regulated in osteoblasts from wild type male mice compared to those with AR [GeneID=367] knockout.
Genes up-regulated in erythroid progenitor cells from fetal livers of E13.5 embryos with KLF1 [GeneID=10661] knockout compared to those from the wild type embryos.
Genes down-regulated in erythroid progenitor cells from fetal livers of E13.5 embryos with KLF1 [GeneID=10661] knockout compared to those from the wild type embryos.
Genes bound by ESR1 [GeneID=2099] and up-regulated by estradiol [PubChem=5757] in MCF-7 cells (breast cancer).
Genes bound by ESR1 [GeneID=2099] and down-regulated by estradiol [PubChem=5757] in MCF-7 cells (breast cancer).
Genes bound by ESR1 [GeneID=2099] and up-regulated by estradiol [PubChem=5757] in MCF-7 cells (breast cancer) expressing constitutevly active form of AKT1 [GeneID=207].
Genes bound by ESR1 [GeneID=2099] and down-regulated by estradiol [PubChem=5757] in MCF-7 cells (breast cancer) expressing constitutevly active form of AKT1 [GeneID=207].
Genes up-regulated in MDA-MB-231 cells (breast cancer) upon overexpression of PARVB [GeneID=29780] under all three culture conditions.
Genes down-regulated in MDA-MB-231 cells (breast cancer) upon overexpression of PARVB [GeneID=29780] under all three culture conditions.
Genes up-regulated upon overexpression of PARVB [GeneID=29780] in MDA-MB-231 cells (breast cancer) cultured in 3D collagen I and 3D Matrigel only.
Genes down-regulated upon overexpression of PARVB [GeneID=29780] in MDA-MB-231 cells (breast cancer) cultured in 3D collagen I and 3D Matrigel only.
Genes up-regulated upon overexpression of PARVB [GeneID=29780] in MDA-MB-231 cells (breast cancer) cultured in 3D Matrigel only.
Genes down-regulated upon overexpression of PARVB [GeneID=29780] in MDA-MB-231 cells (breast cancer) cultured in 3D Matrigel only.
Category A genes: p53-dependent genes whose expression in the absence of S389 phosphorylation is similar to loss of TP53 [GeneID=7157] in MEF (embryonic fibroblast) cells in response to UV-C irradiation.
Category B genes: p53-dependent genes whose expression in the absence of S389 phosphorylation is dissimilar to loss of TP53 [GeneID=7157] in MEF (embryonic fibroblast) cells in response to UV-C irradiation.
Category C genes: p53-independent genes whose expression in the absence of S389 phosphorylation is dissimilar to loss of TP53 [GeneID=7157] in MEF (embryonic fibroblast) cells in response to UV-C irradiation.
Category D genes: p53-independent genes whose expression in the absence of S389 phosphorylation is similar to loss of TP53 [GeneID=7157] in MEF (embryonic fibroblast) cells in response to UV-C irradiation.
Late response genes: differentially expressed only 12 h after UV-C irradiation of MEF cells (embryonic fibroblast).
Early-late response genes: differentially expressed in the first 3 h and after 12 h following UV-C irradiation of MEF cells (embryonic fibroblast).
Middle response genes: differentially expressed in the period between 3 h and 12 h after UV-C irradiation of MEF cells (embryonic fibroblast).
Transcriptionally inactive genes whose promoters (regions between -2 kb to +0.5 kb relative to trascription start sites) where bound by NF-Y transcription factor.
Transcriptionally inactive genes which where bound by NF-Y transcription factor.
Genes commonly up-regulated in UET-13 cells (mesenchymal progenitor) by expression of EWSR1 [GeneID=2130] fusions with ETS transcription factors FLI1 and ERG [GeneID=2313 ,2078].
Genes commonly down-regulated in UET-13 cells (mesenchymal progenitor) by expression of EWSR1 [GeneID=2130] fusions with ETS transcription factors FLI1 and ERG [GeneID=2313 ,2078].
A consensus set of genes that were significantly down-regulated by MIR106B [GeneID=406900].
Partial list of genes up-regulated in the kidney of GLIS2 [GeneID=84662] knockout mice compared to the wild type.
Partial list of genes down-regulated in the kidney of GLIS2 [GeneID=84662] knockout mice compared to the wild type.
Proteins significantly induced by oxidative stress (hydrogen peroxide [PubChem=784] in 786-O cells (renal clear cell carcinoma, RCC) expressing VHL [GeneID=7428].
Proteins significantly repressed by oxidative stress (hydrogen peroxide [PubChem=784] in 786-O cells (renal clear cell carcinoma, RCC) expressing VHL [GeneID=7428].
Genes up-regulated during adipogenesis of 3T3-L1 cells (fibroblast).
Genes down-regulated during adipogenesis of 3T3-L1 cells (fibroblast).
Genes up-regulated in A549 cells (lung adenocarcinoma) upon SKIL [GeneID=6498] knockdown by RNAi.
Genes down-regulated in A549 cells (lung adenocarcinoma) upon SKIL [GeneID=6498] knockdown by RNAi.
Genes up-regulated in HCT116 cells (colorectal carcinoma) upon knockout of PTEN [GeneID=5728].
Genes down-regulated in HCT116 cells (colorectal carcinoma) upon knockout of PTEN [GeneID=5728].
Genes down-regulated in synovial sarcoma samples with SYT-SSX fusions resulting from translocation of SS18 [GeneID=SS18] to one of the SSX genes.
Genes down-regulated in MEF cells (embryonic fibroblast) upon knockout of ATF2 [GeneID=1386].
Genes down-regulated in HeLa cells upon knockdown of MLL2 [GeneID=8085] by RNAi.
Transcripts down-regulated by overexpression of MIR16 family of microRNA molecules in DLD-1 and HCT116 (colon cancer) cells hypomorphic for DICER1 [GeneID=23405].
Genes down-regulated in testis tissues upon knockout of TAF7L [GeneID=54457].
Genes up-regulated in liver tissue upon knockout of H2AFY [GeneID=9555].
Genes down-regulated in liver tissue upon knockout of H2AFY [GeneID=9555].
Genes up-regulated in ES (embryonic stem cells) with defficient SUZ12 [GeneID=23512].
Genes down-regulated in ES (embryonic stem cells) with defficient SUZ12 [GeneID=23512].
Genes up-regulated in I/11 erythroblast cells upon expression of an activated form of FOXO3 [GeneID=2309].
Genes down-regulated in I/11 erythroblast cells upon expression of an activated form of FOXO3 [GeneID=2309].
Genes strongly up-regulated in colon tissue upon MBD2 [GeneID=8932] knockout.
Genes up-regulated in 9.5 days post coitus (dpc) embryos with COMMD1 [GeneID=150684] knockout compared to normal 8.5 dpc and 9.5 dpc embryos.
Genes up-regulated in 9.5 days post coitus (dpc) embryos with COMMD1 [GeneID=150684] knockout compared to normal 9.5 dpc embryos.
Genes down-regulated in 9.5 days post coitus (dpc) embryos with COMMD1 [GeneID=150684] knockout compared to normal 9.5 dpc embryos.
Genes up-regulated in 9.5 days post coitus (dpc) embryos with COMMD1 [GeneID=150684] knockout and in normal 8.5 dpc embryos compared to normal 9.5 dpc embryos.
Genes down-regulated in 9.5 days post coitus (dpc) embryos with COMMD1 [GeneID=150684] knockout and in normal 8.5 dpc embryos compared to normal 9.5 dpc embryos.
Genes up-regulated in normal 9.5 days post coitus (dpc) embryos compared to normal 8.5 dpc and 9.5 dpc embryos.
Genes down-regulated in normal 9.5 days post coitus (dpc) embryos compared to normal 8.5 dpc and 9.5 dpc embryos.
Genes up-regulated in HepG2 cells (hepatocellular carcinoma, HCC) upon expression of HNF4A [GeneID=3172] and down-regulated upon knockdown of HNF4A [GeneID=3172] in these cells by RNAi.
Representative genes up-regulated in C2C12 cells (myoblast) lacking NFkB activity due to expression of a super repressor form of NFKBIA [GeneID=4792].
Representative genes up-regulated in MEF cells (embryonic fibroblast) in response to TNF [GeneID=7124].
Genes up-regulated in RWPE-1 cells (prostate cancer) upon expression of constitutively active form of STAT3 [GeneID=6774].
Genes down-regulated in RWPE-1 cells (prostate cancer) upon expression of constitutively active form of STAT3 [GeneID=6774].
Genes up-regulated in RPWE-1 cells by activated STAT3 [GeneID=6774].
Genes up-regulated in DL23 cells (colon cancer) upon expression of an activated form of FOXO3 [GeneID=2309].
Genes down-regulated in DL23 cells (colon cancer) upon expression of an activated form of FOXO3 [GeneID=2309].
Genes up-regulated in DAOY cells (medulloblastoma) upon knockdown of both BMI1 and PCGF2 [GeneID=648, 7703] by RNAi.
Genes up-regulated in DO11.10 cells (hybridoma) by expression of transciptionally activating form of HDAC7 [GeneID=51564] and down-regulated by its transcriptionally repressing form.
Genes down-regulated in DO11.10 cells (hybridoma) by expression of transciptionally activating form of HDAC7 [GeneID=51564] and up-regulated by its transcriptionally repressing form.
Genes up-regulated in DO11.10 cells (hybridoma) by expression of transciptionally activating and by transcriptionally repressive forms of HDAC7 [GeneID=51564].
Genes down-regulated in DO11.10 cells (hybridoma) by expression of transciptionally activating and by transcriptionally repressive forms of HDAC7 [GeneID=51564].
Genes down-regulated in HeLa cells upon knockdown of ELAVL1 [GeneID=1994] by RNAi.
Genes up-regulated in uterus upon knockout of BMP2 [GeneID=650].
Genes down-regulated in uterus upon knockout of BMP2 [GeneID=650].
Genes translationally regulated in MEF cells (embryonic fibroblasts) in response to serum starvation but not by rapamycin (sirolimus) [PubChem=6610346].
Genes translationally regulated in MEF cells (embryonic fibroblasts) in response to serum starvation and by rapamycin (sirolimus) [PubChem=6610346].
Genes translationally regulated in MEF cells (embryonic fibroblasts) by rapamycin (sirolimus) [PubChem=6610346] but not in response to serum deprivation.
Genes translationally repressed by rapamycin (sirolimus) [PubChem=6610346] in MEF cells (embryonic fibroblast) lacking either TSC1 or TSC2 [GeneID=7248, 7249] but not in the wild type cells.
Genes translationally up-regulated by serum in MEF cells (embryonic fibroblast) lacking TSC1 [GeneID=7248].
Genes translationally up-regulated by serum in MEF cells (embryonic fibroblast) lacking TSC2 [GeneID=7249].
Genes translationally repressed upon serum deprivation in MEF cells (embryonic fibroblast).
Top scoring genes whose transcripts bound TIAR1 [GeneID=7073] in extracts from RKO cells (colon cancer).
Direct targets of PRDM5 [GeneID=11107].
Top genes up-regulated in HEK293 cells (fibroblast) in response to trichostatin A (TSA) [PubChem=5562].
Genes up-regulated in intestinal crypt cells upon deletion of CTNNB1 [GeneID=1499].
Genes down-regulated in intestinal crypt cells upon deletion of CTNNB1 [GeneID=1499].
Genes in the hypoxia signature, based on analysis of nine neuroblastoma cell lines in hypoxia and normal oxygen conditions.
Genes in the hypoxia signature, based on analysis of 11 neuroblastoma cell lines in hypoxia and normal oxygen conditions.
Top 20 up-regulated genes in leukemic progenitor cells expressing activated fusion of ESWR1 and FLI1 [GeneID=2130, 2313] compared to normal hematopoetic progenitors.
Top 20 down-regulated genes in leukemic progenitor cells expressing activated fusion of ESWR1 and FLI1 [GeneID=2130, 2313] compared to normal hematopoetic progenitors.
Genes up-regulated in leukemic progenitor cells expressing activated fusion of ESWR1 and FLI1 [GeneID=2130, 2313] compared to normal hematopoetic progenitors.
Genes down-regulated in leukemic progenitor cells expressing activated fusion of ESWR1 and FLI1 [GeneID=2130, 2313] compared to normal hematopoetic progenitors.
Transcripts (mRNA molecules) rapidly degraded upon interaction with KHSRP [GeneID=8570].
Genes up-regulated in E12.5 hearts from mice with SP3 [GeneID=6670] knockout compared to the wild type organ.
Genes down-regulated in E12.5 hearts from mice with SP3 [GeneID=6670] knockout compared to the wild type organ.
Proteins associated with ZNF143 [GeneID=7702] in HeLa cells, based on MudPIT analysis.
Genes with promoters occupied by SMAD2 or SMAD3 [GeneID=4087, 4088] in HaCaT cells (keratinocyte) according to a ChIP-chip analysis.
Genes up-regulated in hearts of E18.5 embryos upon knockout of VEGFA [GeneID=7422].
Genes down-regulated in hearts of E18.5 embryos upon knockout of VEGFA [GeneID=7422].
Genes up-regulated in Harderian gland tissue upon knockout of AOX4 [GeneID=71872].
Genes down-regulated in Harderian gland tissue upon knockout of AOX4 [GeneID=71872].
Genes up-regulated in skin upon knockout of AOX4 [GeneID=71872].
Genes down-regulated in skin upon knockout of AOX4 [GeneID=71872].
Genes up-regulated in HEK-293 cells (fibroblast) upon knockdown of both CTBP1 and SATB1 [GeneID=1487, 6304] by RNAi.
Genes down-regulated in HEK-293 cells (fibroblast) upon knockdown of both CTBP1 and SATB1 [GeneID=1487, 6304] by RNAi.
Genes up-regulated in HEK-293 cells (fibroblast) upon knockdown of CTBP1 but not of SATB1 [GeneID=1487, 6304] by RNAi.
Genes down-regulated in HEK-293 cells (fibroblast) upon knockdown of CTBP1 but not of SATB1 [GeneID=1487, 6304] by RNAi.
Genes up-regulated during later stage of differentiation of Oli-Neu cells (oligodendroglial precursor) in response to PD174265 [PubChem=4709].
Genes down-regulated during differentiation of Oli-Neu cells (oligodendroglial precursor) in response to PD174265 [PubChem=4709].
Oligodendrocyte core differentiation genes: up-regulated in Oli-neo cells (oligodendroglial precursor) at 10 h after treatment with PD174265, dexamethasone or isotretinoin [PubChem=4709, 5743, 5282379].
Genes down-regulated by VHL [GeneID=7428] and re-expressed under hypoxia conditions in renal carcinoma cells.
Genes up-regulated in hypertrophic hearts (due to expression of constitutively active form of PPP3CA [GeneID=5530]) and predicted to be targets of miR-1 microRNA.
Genes down-regulated in hypertrophic hearts (due to expression of constitutively active form of PPP3CA [GeneID=5530]) and predicted to be targets of miR-1 microRNA.
Genes up-regulated in hypertrophic hearts (due to expression of constitutively active form of PPP3CA [GeneID=5530]) and predicted to be targets of miR-133 microRNA.
Genes down-regulated in hypertrophic hearts (due to expression of constitutively active form of PPP3CA [GeneID=5530]) and predicted to be targets of miR-133 microRNA.
Genes up-regulated in hypertrophic hearts (due to expression of constitutively active form of PPP3CA [GeneID=5530]) and predicted to be targets of miR-30 microRNA.
Genes down-regulated in hypertrophic hearts (due to expression of constitutively active form of PPP3CA [GeneID=5530]) and predicted to be targets of miR-30 microRNA.
Transcripts stabilized by NO [PubChem=145068] identified as up-regulated by NO [PubChem=145068] in the presence of actinomycin D [PubChemiD=2019] in IMR-90 and NIH 3T3 cells (fibroblast).
Genes up-regulated in U2OS cells (osteosarcoma) upon knockdown of TOPBP1 [GeneID=11073].
Genes up-regulated in E12.5 forelimb buds with POR [GeneID=5447] knockout.
Genes down-regulated in E12.5 forelimb buds with POR [GeneID=5447] knockout.
Genes up-regulated in MEF cells (embryonic fibroblast) with ELAVL1 [GeneID=1994] knocked out.
Genes down-regulated in MEF cells (embryonic fibroblast) with ELAVL1 [GeneID=1994] knocked out.
Genes up-regulated in testis tissue expressing hypomorphic allele of THOC1 [GeneID=9984].
Genes down-regulated in testis tissue expressing hypomorphic allele of THOC1 [GeneID=9984].
Genes up-regulated in 745A cells (erythroleukemia) upon knockdown of FLI1 [GeneID=2313] by RNAi and down-regulation of SPI1 [GeneID=6688] by HMBA [PubChem=3616].
Genes down-regulated in 745A cells (erythroleukemia) upon knockdown of FLI1 [GeneID=2313] by RNAi and down-regulation of SPI1 [GeneID=6688] by HMBA [PubChem=3616].
Genes up-regulated in pancreatic islets upon knockout of HNF1A [GeneID=6927].
Genes down-regulated in pancreatic islets upon knockout of HNF1A [GeneID=6927].
Genes up-regulated in liver tissue upon knockout of HNF1A [GeneID=6927].
Genes down-regulated in liver tissue upon knockout of HNF1A [GeneID=6927].
Genes differentially expressed in ES cells with DPPA4 [GeneID=55211] knockout.
Genes down-regulated in E14 ES (embryonic stem) cells upon knockdown of CYCT1 [GeneID=904] by RNAi.
Genes down-regulated in E14 ES (embryonic stem) cells upon knockdown of CYCT2 [GeneID=905] by RNAi.
Genes regulated in MCF7 cells (breast cancer) by expression of full-length and truncated (611-CTF) forms of ERBB2 [GeneID=2064] at both 15 h and 60 h time points.
Genes regulated in MCF7 cells (breast cancer) by expression of the truncated (611-CTF) form of ERBB2 [GeneID=2064] at both 15 h and 60 h time points.
Genes regulated in MCF7 cells (breast cancer) by expression of the full-length and truncated (611-CTF) forms of ERBB2 [GeneID=2064] at 60 h time point.
Genes regulated in MCF7 cells (breast cancer) by expression of the truncated (611-CTF) form of ERBB2 [GeneID=2064] at 15 h time point.
Genes regulated in MCF7 cells (breast cancer) by expression of the full-length form of ERBB2 [GeneID=2064] at 60 h time point.
Genes regulated in MCF7 cells (breast cancer) by expression of the truncated (611-CTF) form of ERBB2 [GeneID=2064] at 60 h time point.
Genes up-regulated in MCF7 cells (breast cancer) more than three-fold by the truncated form 611-CTF of ERBB2 [GeneID=2064] and less than two-fold by the full-length ERBB2 [GeneID=2064].
Genes with promoters bound by both PPARG and RXRA [GeneID=5468, 6256] at 36 h time point of adipocyte differentiation of 3T3-L1 cells (preadipocyte).
Genes with promoters bound by PPARG [GeneID=5468] at 36 h time point of adipocyte differentiation of 3T3-L1 cells (preadipocyte).
Genes with promoters bound by both PPARG and RXRA [GeneID=5468, 6256] at 8 day time point of adipocyte differentiation of 3T3-L1 cells (preadipocyte).
Genes with promoters bound by PPARG [GeneID=5468] at 8 day time point of adipocyte differentiation of 3T3-L1 cells (preadipocyte).
Genes with promoters bound by both PPARG and RXRA [GeneID=5468, 6256] at 8 (but not 0) day time point of adipocyte differentiation of 3T3-L1 cells (preadipocyte) and that were newly modified by H4K20me1.
Genes up-regulated in M2-10B4 cells (osteoblast) in response to phenylamil [PubChem=4755].
Genes down-regulated in M2-10B4 cells (osteoblast) in response to phenylamil [PubChem=4755].
Genes up-regulated in neonatal cardiac myocytes upon knockdown of BCL3 [GeneID=602] by RNAi.
Genes down-regulated in neonatal cardiac myocytes upon knockdown of BCL3 [GeneID=602] by RNAi.
Genes translationally up-regulated in HUVEC cells (endothelium) grown on FN1 [GeneID=2335] compared to those grown on laminin 1.
Genes up-regulated during adipogenic differentiation of 3T3-L1 cells (preadipocyte) and down-regulated by troglitazone [PubChem=5591].
Genes differentially expressed in liver tissue upon knockout of the 1a isoform of SREBF1 [GeneID=6720].
Transcripts dependent upon IRS1 and IRS2 [GeneID=3667, 8660] for normal expression in liver.
Genes up-regulated in G1ME cells (megakaryocyte/erythroid progenitor lacking GATA1 [GeneID=2623]) upon knockdown of GATA2 [GeneID=2624] by RNAi.
Genes down-regulated in G1ME cells (megakaryocyte/erythroid progenitor lacking GATA1 [GeneID=2623]) upon knockdown of GATA2 [GeneID=2624] by RNAi.
Genes up-regulated during neuronal differentiation of SH-SY5Y cells (neuroblastoma) in response to stimulation by tretinoin (all-trans retinoic acid, ATRA) [PubChem=444795] and BDNF [GeneID=627].
Genes down-regulated during neuronal differentiation of SH-SY5Y cells (neuroblastoma) in response to stimulation by tretinoin (all-trans retinoic acid, ATRA) [PubChem=444795] and BDNF [GeneID=627].
Major erythrocyte membrane genes.
Genes up-regulated in MEF cells (embryonic fibroblast) upon stimulation with TGFB1 [GeneID=7040] for 1 h.
Genes down-regulated in MEF cells (embryonic fibroblast) upon stimulation with TGFB1 [GeneID=7040] for 1 h.
Genes up-regulated in MEF cells (embryonic fibroblast) upon stimulation with TGFB1 [GeneID=7040] for 10 h.
Genes down-regulated in MEF cells (embryonic fibroblast) upon stimulation with TGFB1 [GeneID=7040] for 10 h.
Genes up-regulated in MEF cells (embryonic fibroblast) upon knockout of NFIC [GeneID=4782].
Genes down-regulated in MEF cells (embryonic fibroblast) upon knockout of NFIC [GeneID=4782].
Genes up-regulated after 1 h of TGFB1 [GeneID=7040] stimulation in MEF cells (embryonic fibroblast) with  NFIC [GeneID=4782] knockout vs wild type MEFs.
Genes down-regulated after 1 h of TGFB1 [GeneID=7040] stimulation in MEF cells (embryonic fibroblast) with  NFIC [GeneID=4782] knockout vs wild type MEFs.
Genes up-regulated after 10 h of TGFB1 [GeneID=7040] stimulation in MEF cells (embryonic fibroblast) with  NFIC [GeneID=4782] knockout vs wild type MEFs.
Genes down-regulated after 10 h of TGFB1 [GeneID=7040] stimulation in MEF cells (embryonic fibroblast) with  NFIC [GeneID=4782] knockout vs wild type MEFs.
Genes requiring MLL [GeneID=4297] for H3K4me3 and expression in MEF cells (embryonic fibroblast).
Hepatic genes regulated by fasting or in response to WY14643 [PubChem=5694] and which require intact PPARA [GeneID=5465].
Genes downregulated in the postnatal day 3 pancreata with impaired function of GLIS3 [GeneID=169792].
Genes with DNA sequences bound by RARG [GeneID=5916] in MEF cells (embryonic fibroblast).
Genes bound by RARG [GeneID=5916] and up-regulated by tretinoin (all-trans retinoic acid, ATRA) [PubChem=444795] in MEF cells (embryonic fibroblast).
Genes bound by RARG [GeneID=5916] and down-regulated by tretinoin (all-trans retinoic acid, ATRA) [PubChem=444795] in MEF cells (embryonic fibroblast).
Genes with DNA sequences bound by RARA and RARG [GeneID=5914, 5916] in ES cells.
Genes dependent on KDM3A [GeneID=55818] for hypoxic induction in RCC4 cells (renal carcinoma) expressing VHL [GeneID=7428].
Genes not induced under hypoxia, but dependent on KDM3A [GeneID=55818] for hypoxic expression in RCC4 cells (renal carcinoma) expressing VHL [GeneID=7428].
Genes induced under hypoxia independently of KDM3A [GeneID=55818] in RCC4 cells (renal carcinoma) expressing VHL [GeneID=7428].
Genes consistently and robustly repressed by estradiol [PubChem=5757] in MCF7 cells (breast cancer); this reperession was prevented by fulvestrant [PubChem=3478439].
Genes up-regulated in both AGS and HGC-27 cells (gastric cancer) by BHLHA15 [GeneID=168620] transfection.
Genes up-regulated in BEAS-2B cells (bronchial epithelium) stimulated with IL13 [GeneID=3596] on days 1 to 3 and then rested for the next 3 days (repeated-stimulation or memory model)
Genes down-regulated in BEAS-2B cells (bronchial epithelium) stimulated with IL13 [GeneID=3596] on days 1 to 3 and then rested for the next 3 days (repeated-stimulation or memory model)
Genes up-regulated in BEAS-2B cells (bronchial epithelium) stimulated with IL13 [GeneID=3596] on days 1 to 3, rested on days 4 and 5, and then restimulated on day 6 for 1 h before lysis (priming model).
Genes up-regulated hT-RPE cells (immortalized retinal pigment epithelium) by MYC [GeneID=4609].
Proteins identified by mass spectrometry in complexes containing ALKBH8 [GeneID=91801].
Genes up-regulated in testis tissue upon knockout of CTCFL [GeneID=140690].
Genes with known mitosis function that were down-regulated in MEF cells (embryonic fibroblast) upon knockout of LIN9 [GeneID=286826].
Genes up-regulated in the liver tissue from 10 week old male mice with KLF10 [GeneID=7071] compared to wild-type littermates.
Genes down-regulated in the liver tissue from 10 week old male mice with KLF10 [GeneID=7071] compared to wild-type littermates.
Genes up-regulated in HeLa cells (cervical carcinoma) upon knockdown of PHF8 [GeneID=23133] by RNAi.
Genes down-regulated in HeLa cells (cervical carcinoma) upon knockdown of PHF8 [GeneID=23133] by RNAi.
List of genomically imprinted genes.
Genes up-regulated in primary LEC cells (lymphatic endothelum) upon overexpression of MIR31 [GeneID=407035].
Genes down-regulated in primary LEC cells (lymphatic endothelum) upon overexpression of MIR31 [GeneID=407035].
Genes up-regulated in Calu-6 cells (lung cancer) at 1 h time point after TNF [GeneID=7124] treatment.
Genes down-regulated in Calu-6 cells (lung cancer) at 1 h time point after TNF [GeneID=7124] treatment.
Genes whose expression changes in Calu-6 cells (lung cancer) by TNF [GeneID=7124] were blocked completely by p38 inhibitor LY479754.
Genes whose expression changes in Calu-6 cells (lung cancer) by TNF [GeneID=7124] were blocked partially by p38 inhibitor LY479754.
Genes whose expression changes in Calu-6 cells (lung cancer) by TNF [GeneID=7124] were not affected by p38 inhibitor LY479754.
Transcripts bound by CELF1 [GeneID=10658] in HeLa cells (cervical carcinoma).
Hypomethylated genes in prostate tissue from mice carrying hypomorphic alleles of DNMT1 [GeneID=1786].
Major ELAVL4 [GeneID=1996] associated mRNAs encoding proteins with functions in neuronal physiology.
Genes up-regulated in C3H10T1/2 cells (mesenchyme multipotent cells) upon their differentiation to brown adipocytes in response to BMP7 [GeneID=655].
Genes up-regulated in ES cells (embryonic stem) heterozygotic for KDM1A [GeneID=23028] loss of function mutant compared to the homozygotic loss of the gene.
Genes down-regulated in ES cells (embryonic stem) heterozygotic for KDM1A [GeneID=23028] loss of function mutant compared to the homozygotic loss of the gene.
Genes deregulated in U2OS cells (osteosarcoma) upon knockdown of BAP1 [GeneID=8314] by RNAi.
Loci bound exclusively by SALL4 [GeneID=57167] isoform a in ES cells (embryonic stem).
Loci bound exclusively by SALL4 [GeneID=57167] isoform b in ES cells (embryonic stem).
Loci bound by both isoforms (a and b) of SALL4 [GeneID=57167] in ES cells (embryonic stem).
Loci bound exclusively by SIN3A [GeneID=25942] in myotubules.
Transcripts bound to IGF2BP2 [GeneID=10644] complexes and differentially regulated in myoblasts with IGF2BP2 [GeneID=10644] knockdown by RNAi.
Genes representing a co-expression network in atopic CD4 [GeneID=920] T lymphocyte responses.
Genes representing Th1 / cytotoxic module in sputum during asthma exacerbations.
Genes representing interferon-induced antiviral module in sputum during asthma exacerbations.
Genes representing epithelial differentiation module in sputum during asthma exacerbations.
The '3/3 signature': genes consistently up-regulated in all three pools of normal mammary stem cells (defined by their ability to retain the dye PKH26).
The '3/3 signature': genes consistently down-regulated in all three pools of normal mammary stem cells (defined by their ability to retain the dye PKH26).
Proteins interacting with AIRE [GeneID=326], based on massspectroscopy analysis of co-immunoprecipitates in 293T cells (embryonic kidney).
Key proteins in mammalian autophagosome formation.
Genes indentified by RNAi screen as regulating infection of THP-1 cells (macrophage) with Mycobacterium tuberculosis.
Genes defining the Mycobacterium tuberculosis strain-independent regulatory axis of the host macrophage cells.
Genes up-regulated in LSC (leukemic stem) cells compared to LPC (leukemia progenitor) cells from AML (acute myeloid leukemia) tumor samples.
Genes down-regulated in LSC (leukemic stem) cells compared to LPC (leukemia progenitor) cells from AML (acute myeloid leukemia) tumor samples.
Genes up-regulated in liver samples containing tumor thrombi in the major branches of the portal vein at surgery (PT) compared to those from metastasis-free HCC patients (PN) at the time of surgery and at follow-up.
Genes down-regulated in liver samples containing tumor thrombi in the major branches of the portal vein at surgery (PT) compared to those from metastasis-free HCC patients (PN) at the time of surgery and at follow-up.
Genes distinguishing prednisolone [PubChem=5755] resistant and sensitive B-lineage ALL; here - genes up-regulated in the drug resistant samples.
Genes distinguishing prednisolone [PubChem=5755] resistant and sensitive B-lineage ALL; here - genes down-regulated in the drug resistant samples.
Genes distinguishing vincristine [PubChem=5978] resistant and sensitive B-lineage ALL; here - genes up-regulated in the drug resistant samples.
Genes distinguishing vincristine [PubChem=5978] resistant and sensitive B-lineage ALL; here - genes down-regulated in the drug resistant samples.
Genes distinguishing asparaginase resistant and sensitive B-lineage ALL; here - genes up-regulated in the drug resistant samples.
Genes distinguishing asparaginase resistant and sensitive B-lineage ALL; here - genes down-regulated in the drug resistant samples.
Genes distinguishing daunorubicin [PubChem=30323] resistant and sensitive B-lineage ALL; here - genes up-regulated in the drug resistant samples.
Genes distinguishing daunorubicin [PubChem=30323] resistant and sensitive B-lineage ALL; here - genes down-regulated in the drug resistant samples.
Genes distinguishing prednisolone [PubChem=5755] resistant and sensitive ALL (B- and T-lineage ALL); here - genes up-regulated in the drug resistant samples.
Genes distinguishing prednisolone [PubChem=5755] resistant and sensitive ALL (B- and T-lineage ALL); here - genes down-regulated in the drug resistant samples.
Genes distinguishing vincristine [PubChem=5978] resistant and sensitive ALL (B- and T-lineage ALL); here - genes up-regulated in the drug resistant samples.
Genes distinguishing vincristine [PubChem=5978] resistant and sensitive ALL (B- and T-lineage ALL); here - genes down-regulated in the drug resistant samples.
Genes distinguishing daunorubicin [PubChem=30323] resistant and sensitive ALL (B- and T-lineage ALL); here - genes up-regulated in the drug resistant samples.
Genes distinguishing daunorubicin [PubChem=30323] resistant and sensitive ALL (B- and T-lineage ALL); here - genes down-regulated in the drug resistant samples.
Genes distinguishing asparaginase resistant and sensitive ALL (B- and T-lineage ALL); here - genes up-regulated in the drug resistant samples.
Genes distinguishing asparaginase resistant and sensitive ALL (B- and T-lineage ALL); here - genes down-regulated in the drug resistant samples.
Genes up-regulated in lung tissue upon LPS aspiration with mechanical ventilation (MV) compared to control (PBS aspiration without MV).
Genes up-regulated during prostate cancer progression in the JOCK1 model due to inducible activation of FGFR1 [GeneID=2260] gene in prostate.
Genes down-regulated during prostate cancer progression in the JOCK1 model due to inducible activation of FGFR1 [GeneID=2260] gene in prostate.
Invasiveness signature resulting from cancer cell/microenvironment interaction.
Genes consistently up-regulated in mammary stem cells both in mouse and human species.
Genes consistently down-regulated in mammary stem cells both in mouse and human species.
Genes consistently up-regulated in mammary luminal progenitor cells both in mouse and human species.
Genes consistently down-regulated in mammary luminal progenitor cells both in mouse and human species.
Genes consistently up-regulated in mature mammary luminal cells both in mouse and human species.
Genes consistently down-regulated in mature mammary luminal cells both in mouse and human species.
Genes up-regulated in the HSC supportive stromal cell lines.
Genes up-regulated in the HSC non-supportive stromal cell lines.
Genes up-regulated in B lymphocytes at 2 h after exprosure to 10 Gy dose of ionizing radiation.
Genes down-regulated in B lymphocytes at 2 h after exprosure to 10 Gy dose of ionizing radiation.
Genes up-regulated in B lymphocytes at 6 h after exprosure to 10 Gy dose of ionizing radiation.
Genes down-regulated in B lymphocytes at 6 h after exprosure to 10 Gy dose of ionizing radiation.
Genes significantly (FDR < 10%) up-regulated in IMR-90 cells (fibroblast) in response to direct irradiation.
Genes significantly (FDR < 10%) down-regulated in IMR-90 cells (fibroblast) in response to direct irradiation.
Genes significantly (FDR < 10%) up-regulated in IMR-90 cells (fibroblast) in response to bystander irradiation.
Genes significantly (FDR < 10%) down-regulated in IMR-90 cells (fibroblast) in response to bystander irradiation.
Genes displaying an ionizing radiation response in the human skin cell samples.
Genes up-regulated in the human skin cells at 4 h after exprosure to 5 Gy dose of ionizing radiation.
Cell cycle genes significantly (p =< 0.05) changed in fibroblast cells at 2 h after exposure to ionizing radiation.
Cell cycle genes significantly (p =< 0.05) changed in fibroblast cells at 6 h after exposure to ionizing radiation.
Cell cycle genes significantly (p =< 0.05) changed in fibroblast cells at 24 h after exposure to ionizing radiation.
Genes persistently induced by EGF [GeneID =1950] in 184A1 cells (mammary epithelium).
Class I of genes transiently induced by EGF [GeneID =1950] in 184A1 cells (mammary epithelium).
Class II of genes transiently induced by EGF [GeneID =1950] in 184A1 cells (mammary epithelium).
Class III of genes transiently induced by EGF [GeneID =1950] in 184A1 cells (mammary epithelium).
Genes down-regulated by second pulse of EGF [GeneID =1950] in 184A1 cells (mammary epithelium).
Genes transiently induced only by the second pulse of EGF [GeneID =1950] in 184A1 cells (mammary epithelium).
Genes transiently induced only by the first pulse of EGF [GeneID =1950] in 184A1 cells (mammary epithelium).
Genes induced in the time interval between two pulses of EGF [GeneID =1950] in 184A1 cells (mammary epithelium).
Genes repressed in the time interval between two pulses of EGF [GeneID =1950] in 184A1 cells (mammary epithelium).
Genes persistently repressed by EGF [GeneID =1950] in 184A1 cells (mammary epithelium).
Genes up-regulated in type 1 (soleus) vs type 2B (EDL) myofibers.
Genes down-regulated in type 2B (EDL) vs type 1 (soleus) myofibers.
Genes up-regulated in liver from mice transgenic for SREBF1 or SREBF2 [GeneID = 6720, 6721] and down-regulated in mice lacking SCAP [GeneID=22937].
Genes transcriptionally modulated in the blood of multiple sclerosis patients in response to subcutaneous treatment with recombinant IFNB1 [GeneID = 3456].
Genes encoding collagen proteins
Genes encoding structural ECM glycoproteins
Genes encoding enzymes and their regulators involved in the remodeling of the extracellular matrix
Genes encoding proteins affiliated structurally or functionally to extracellular matrix proteins
Genes encoding proteoglycans
Genes encoding secreted soluble factors
Ensemble of genes encoding core extracellular matrix including ECM glycoproteins, collagens and proteoglycans
Ensemble of genes encoding ECM-associated proteins including ECM-affilaited proteins, ECM regulators and secreted factors
Genes encoding structural components of basement membranes
Ensemble of genes encoding extracellular matrix and extracellular matrix-associated proteins
Cluster 6: selected luminal genes clustered together across breast cancer samples.
Cluster 5: selected 17q21_23 amplicon genes clustered together across breast cancer samples.
Cluster 4: selected stromal genes clustered together across breast cancer samples.
Cluster 3: selected apocrine, basal and hypoxia genes clustered together across breast cancer samples.
Genes up-regulated in functionally defined leukemic stem cells (LSC) from acute myeloid leukemia (AML) patients.
Genes up-regulated in human hematopoietic stem cell (HSC) enriched populations compared to committed progenitors and mature cells.
Genes up-regulated in human hematopoietic lineage committed progenitor cells versus hematopoietic stem cells (HSC) and mature cells.
Shared human hematopoietic stem cell (HSC) and acute myeloid leukemia (AML) stem cell (LSC) genes: HSC genes that are highly expressed in LSC versus other leukemic cells.
Genes up-regulated in the mouse embryonic brain or immature neurons at 2 h or 6 h, respectively after exposure to 1 Gy dose of ionizing radiation.
Genes up-regulated in human peripheral blood mononuclear cells (PBMC)  at 8 h after exposure to 0.1 and 1.0 Gy dose of ionizing radiation.
Genes directly bound and regulated by TP53[GeneID=7157].
Cell cycle genes with peak expression in G1/S check point.
Cell cycle genes with peak expression in G2/M check point.
Target genes of the DREAM complex.
Expressed genes (FPKM>1) associated with high-confidence PAX3-FOXO1 sites with enhancers in primary tumors and cell lines, restricted to those within topological domain boundaries
Expressed genes (FPKM>1) associated with super-high-confidence PAX3-FOXO1 sites with highly-recurrent enhancers in primary tumors and cell lines, restricted to those within topological domain boundaries
Expressed genes (FPKM>1) associated with high-confidence PAX3-FOXO1 sites with enhancers in primary tumors and cell lines, restricted to those within topological domain boundaries, which are downregulated by delta log2(FPKM) < -0.2
Genes overexpressed in cholangiocarcinoma class 2 associated with poor prognosis.
Genes overexpressed in cholangiocarcinoma class 1 associated with good prognosis
Genes over-expressed in stem cell-like cholangiocellular carcinoma.
Genes under-expressed in stem cell-like cholangiocellular carcinoma
Genes over-expressed in KRT19-positive [GeneID=3880] hepatocellular carcinoma (HCC).
Genes under-expressed in KRT19-positive [GeneID=3880] hepatocellular carcinoma (HCC).
Genes over-expressed in hepatocellular carcinoma (HCC) with vascular invasion.
Genes under-expressed in hepatocellular carcinoma (HCC) with vascular invasion.
Genes over-expressed in KRT19-positive [GeneID=3880] hepatocellular carcinoma.
Genes under-expressed in KRT19-positive [GeneID=3880] hepatocellular carcinoma.
Genes over-expressed in hepatocellular carcinoma (HCC) with poor survival
Genes under-expressed in hepatocellular carcinoma (HCC) with poor survival
Genes that have high expression in mammary tumors of adenomyoepithelial histology.
Genes that are highly expressed in mammary tumors of epithelial-mesenchymal transition (EMT) histology.
Genes that that have low expression in mammary tumors of epithelial-mesenchymal transition (EMT) histology.
Genes that have high expression in mammary tumors of squamous epithelium histology.
Genes that have high expression in paplillary mammary tumors.
Genes that have high expression in mammary tumors of microacinar histology.
Genes that have low expression in mammary tumors of microacinar histology.
Genes that have high expression in mammary tumors of solid nodular histology.
Genes that have low expression in mammary tumors of solid nodular histology.
Genes down-regulated in basal radial glia (bRG) relative to apical radial glia (aRG), and up-regulated in both aRG and bRG relative to neurons.
Genes up-regulated in basal radial glia (bRG) relative to apical radial glia (aRG), and up-regulated in both aRG and bRG relative to neurons.
Human-specific genes up-regulated in basal radial glia (bRG) relative to apical radial glia (aRG), and up-regulated in both aRG and bRG relative to neurons.
Genes having at least one occurence of the highly conserved motif M144 AAANWWTGC in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M77 AAAYRNCTG in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$MYOD_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$E47_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CMYB_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AP4_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M17 AACTTT in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$MEF2_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ELK1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$SP1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$EVI1_06 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ATF_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$HOX13_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$E2F_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ELK1_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$RSRFC4_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CETS1P54_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M108 AACWWCAANK in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$P300_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$NFE2_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CREB_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CREBP1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CREBP1CJUN_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$SOX5_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$E4BP4_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$E2F_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$NFKAPPAB65_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CREL_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M113 AACYNNNNTTCCS in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$NFKAPPAB_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$NMYC_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$MYOGNF1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$COMP1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$HEN1_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$YY1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$IRF1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$IRF2_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$TAL1BETAE47_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$TAL1ALPHAE47_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M63 AAGWWRNYGGC in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$HEN1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$YY1_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$TAL1BETAITF2_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$E47_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CP2_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$GATA1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$GATA2_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$GATA3_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$EVI1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$EVI1_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M103 ACAWNRNSRCGG in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$EVI1_03 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$EVI1_04 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$EVI1_05 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$MZF1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$MZF1_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ZID_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$IK1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$IK2_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$IK3_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CDP_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M142 ACAWYAAAG in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$PBX1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$PAX6_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$PAX2_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$S8_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CDP_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CDPCR1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CDPCR3_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CDPCR3HD_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$NRF2_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CEBPB_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M57 ACCTGTTG in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$CREB_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$TAXCREB_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$TAXCREB_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CEBPA_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CEBPB_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$MYCMAX_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$MAX_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$USF_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$USF_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$MYCMAX_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M4 ACTAYRNNNCCCR in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$PBX1_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$GATA1_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$GATA1_03 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$GATA1_04 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$HFH1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$FOXD3_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$HNF3B_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$HNF1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$TST1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$HNF4_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M105 ACTWSNACTNY in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$OCT1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$OCT1_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$OCT1_03 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$OCT1_04 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AHR_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$LYF1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$PAX5_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$PAX5_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$BRN2_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$HSF1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M135 AGCYRWTTC in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$HSF2_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$SRY_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$SRF_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ARP1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$RORA1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$RORA2_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$COUP_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CEBP_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$SRY_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$OCT1_05 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M65 ARGGGTTAA in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$OCT1_06 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AP1FJ_Q2 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AP1_Q2 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AP1_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AP4_Q5 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AP4_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CREB_Q2 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CREB_Q4 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CREBP1_Q2 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$MYB_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M99 ATCMNTCCGY in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$MYOD_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$NFY_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$SRF_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$USF_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AP1_Q4 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AP2_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CEBP_Q2 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ER_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$GR_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$NF1_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M102 ATGGYGGA in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$NFKB_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$OCT1_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$SP1_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AP1_C (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CEBP_C (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$GATA_C (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$GRE_C (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$HNF1_C (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$NFKB_C (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$NFY_C (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M143 CAGNWMCNNNGAC in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$OCT_C (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$SEF1_C (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$SRF_C (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$TATA_C (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$USF_C (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$SREBP1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$SREBP1_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$HAND1E47_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$STAT_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$STAT1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M160 CAGNYGKNAAA in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$STAT3_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$MEF2_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$MEF2_03 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$MEF2_04 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AHRARNT_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ARNT_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AHRARNT_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$NKX25_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$NKX25_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$PPARA_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M134 CATRRAGC in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$EGR1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$NGFIC_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$EGR3_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$EGR2_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$OCT1_07 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CHOP_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$GFI1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$XBP1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$TATA_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$NRSF_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M104 CCAATNNSNNNGCG in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$RREB1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ISRE_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$HLF_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$OLF1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AML1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$P53_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$LMO2COM_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$LMO2COM_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$MIF1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$RFX1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M45 CCANNAGRKGGC in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$RFX1_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$TCF11MAFG_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$TCF11_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$NFY_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$HFH3_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$FREAC2_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$FREAC3_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$FREAC4_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$FREAC7_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$HFH8_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M165 CCAWNWWNNNGGC in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$NFAT_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$MYCMAX_B (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$PAX3_B (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$PAX8_B (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$WHN_B (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ZF5_B (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ATF_B (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ETS1_B (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ETS2_B (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$GABP_B (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M124 CCAWYNNGAAR in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$OCT1_B (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$GATA1_05 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$PAX3_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$PAX4_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$PAX4_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$PAX4_03 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$PAX4_04 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$MSX1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$HOXA3_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$EN1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M158 CCCNNNNNNAAGWT in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$AMEF2_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$MMEF2_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$HMEF2_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$RSRFC4_Q2 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$SOX9_B1 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$HNF4_01_B (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AREB6_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AREB6_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AREB6_03 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AREB6_04 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M106 CCGNMNNTNACG in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$CART1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$TGIF_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$MEIS1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$MEIS1AHOXA9_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$MEIS1BHOXA9_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$FOXJ2_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$FOXJ2_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$NKX61_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$E2F_Q3 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$E2F_Q4 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M167 CCTNTMAGA in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$E2F_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$E2F1_Q3 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$E2F1_Q4 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$E2F1_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$TITF1_Q3 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$HMX1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$IPF1_Q4 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CHX10_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$VDR_Q3 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$SPZ1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M81 CGGAARNGGCNG in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$AR_Q2 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ZIC1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ZIC2_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ZIC3_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$NKX3A_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$IRF7_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$FAC1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$STAT5A_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$STAT5B_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$STAT5A_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M100 CRGAARNNNNCGA in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$GATA6_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$POU3F2_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$POU3F2_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$POU6F1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$HIF1_Q5 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ROAZ_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AP2REP_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AP2ALPHA_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AP2GAMMA_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$TBP_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M171 CTCNANGTGNY in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$FOXO4_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$FOXO1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$FOXO1_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$FOXO4_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$FOXO3_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CDC5_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AR_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$PITX2_Q2 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ATF6_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$NCX_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M101 CTGCAGY in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$NKX22_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$PAX2_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$NKX62_Q2 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$BACH2_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$MAZR_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$STAT1_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$STAT5A_03 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$STAT6_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$BACH1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$STAT1_03 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M153 CTGRYYYNATT in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$STAT3_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$STAT4_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$STAT5A_04 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$STAT6_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$LHX3_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ERR1_Q2 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$PPARG_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ATF3_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ATF4_Q2 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$E2F_03 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M82 CTGYNNCTYTAA in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$AP1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$PPARA_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$GNCF_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$NERF_Q2 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$RP58_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$HTF_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ARNT_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$MYCMAX_03 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AFP1_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ALX4_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M29 CTTTAAR in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$CEBPDELTA_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CEBPGAMMA_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CRX_Q4 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$DBP_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$EFC_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$FOXM1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$FXR_Q3 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$GATA4_Q3 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$GCM_Q2 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$HNF4ALPHA_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M34 CYTAGCAAY in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$HNF6_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$HOXA4_Q2 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$HSF_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$LBP1_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$LFA1_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$LXR_Q3 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$MAF_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$MAZ_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$MTF1_Q4 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$NFMUE1_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M137 GAANYNYGACNY in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$NRF1_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$PEA3_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$PTF1BETA_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$PU1_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$SP3_Q3 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$TCF1P_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$TCF4_Q5 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$TEF_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$TEL2_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ALPHACP1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M148 GATGKMRGCG in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$AP3_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ATF1_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$E12_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$E4F1_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ETF_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$HEB_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ICSBP_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$SMAD3_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$TEF1_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$TFIII_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M95 GCCNNNWTAAR in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$TFIIA_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$MYOGENIN_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ZF5_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$PAX8_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CACBINDINGPROTEIN_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CACCCBINDINGFACTOR_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$COREBINDINGFACTOR_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$HNF3ALPHA_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$HP1SITEFACTOR_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$USF2_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M48 GCGNNANTTCC in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$SF1_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CDX2_Q5 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$OSF2_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$SMAD4_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CIZ_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$E2F1DP1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$E2F1DP2_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$E2F4DP1_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$E2F4DP2_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$E2F1DP1RB_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M164 GCGSCMNTTT in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$HFH4_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$POU1F1_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$LEF1_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ELF1_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$IRF1_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$SREBP1_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$HMGIY_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AML1_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$P53_DECAMER_Q2 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$DR1_Q3 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M78 GCTNWTTGK in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$PPAR_DR1_Q2 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$HNF4_DR1_Q3 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$COUP_DR1_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$LXR_DR4_Q3 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$FXR_IR1_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AML_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CEBP_Q3 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ETS_Q4 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$IRF_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$MYB_Q3 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M21 GGAANCGGAANY in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$NFKB_Q6_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$NFY_Q6_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$SREBP_Q3 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$STAT_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AHR_Q5 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$GATA_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$HNF1_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$HNF3_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$SMAD_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$YY1_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M74 GGAMTNNNNNTCCY in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$TTF1_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$OCT_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$USF_Q6_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$HIF1_Q3 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$MYC_Q2 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AP2_Q3 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CREB_Q3 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$PIT1_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$E2F_Q2 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$E2A_Q2 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M163 GGARNTKYCCA in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$LEF1_Q2 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$NF1_Q6_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$EGR_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$PAX_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$FOX_Q2 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$SRF_Q4 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$NRF2_Q4 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CEBP_Q2_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$MYB_Q5_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ER_Q6_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M159 GGCKCATGS in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$AP2_Q6_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CREB_Q2_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CREB_Q4_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$E2F_Q3_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$E2F_Q4_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$E2F_Q6_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$GR_Q6_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$SRF_Q5_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AP1_Q2_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AP1_Q6_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M88 GGCNKCCATNK in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$AP1_Q4_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AP4_Q6_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$MYOD_Q6_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$OCT1_Q5_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$SP1_Q6_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$SP1_Q4_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$SP1_Q2_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$NFAT_Q4_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$E2F1_Q3_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$E2F1_Q4_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M123 GGCNNMSMYNTTG in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$E2F1_Q6_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$MEF2_Q6_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$CP2_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AR_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$PR_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$GR_01 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AR_03 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$PR_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$ER_Q6_02 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$PR_Q2 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the highly conserved motif M118 GGCNRNWCTTYS in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the transcription factor binding site V$VDR_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$AR_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$T3R_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$PXR_Q2 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$DR4_Q2 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$DR3_Q4 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the transcription factor binding site V$HNF4_Q6 (v7.4 TRANSFAC) in the regions spanning up to 4 kb around their transcription starting sites.
Genes having at least one occurence of the motif AGCACTT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-93, hsa-miR-302a, hsa-miR-302b, hsa-miR-302c, hsa-miR-302d, hsa-miR-372, hsa-miR-373, hsa-miR-520e, hsa-miR-520a, hsa-miR-526b*, hsa-miR-520b, hsa-miR-520c and hsa-miR-520d (v7.1 miRBase).
Genes having at least one occurence of the motif CTACCTC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-let-7a, hsa-let-7b, hsa-let-7c, hsa-let-7d, hsa-let-7e, hsa-let-7f, hsa-miR-98, hsa-let-7g and hsa-let-7i (v7.1 miRBase).
Genes having at least one occurence of the motif GCACTTT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-17-5p, hsa-miR-20a, hsa-miR-106a, hsa-miR-106b, hsa-miR-20b and hsa-miR-519d (v7.1 miRBase).
Genes having at least one occurence of the highly conserved motif M119 GGGNRMNNYCAT in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the motif TGCTGCT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-15a, hsa-miR-16, hsa-miR-15b, hsa-miR-195, hsa-miR-424 and hsa-miR-497 (v7.1 miRBase).
Genes having at least one occurence of the motif TGTTTAC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-30a-5p, hsa-miR-30c, hsa-miR-30d, hsa-miR-30b and hsa-miR-30e-5p (v7.1 miRBase).
Genes having at least one occurence of the motif GTGCAAT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-25, hsa-miR-32, hsa-miR-92, hsa-miR-363 and hsa-miR-367 (v7.1 miRBase).
Genes having at least one occurence of the motif TGAATGT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-181a, hsa-miR-181b, hsa-miR-181c and hsa-miR-181d (v7.1 miRBase).
Genes having at least one occurence of the motif GCGCTTT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-518b, hsa-miR-518c and hsa-miR-518d (v7.1 miRBase).
Genes having at least one occurence of the motif TGGTGCT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-29a, hsa-miR-29b and hsa-miR-29c (v7.1 miRBase).
Genes having at least one occurence of the motif TGCACTG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-148a, hsa-miR-152 and hsa-miR-148b (v7.1 miRBase).
Genes having at least one occurence of the motif CACTGCC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-34a, hsa-miR-34c and hsa-miR-449 (v7.1 miRBase).
Genes having at least one occurence of the motif TACGGGT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-99a, hsa-miR-100 and hsa-miR-99b (v7.1 miRBase).
Genes having at least one occurence of the motif CTCTAGA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-526c, hsa-miR-518f* and hsa-miR-526a (v7.1 miRBase).
Genes having at least one occurence of the highly conserved motif M31 GGGYGTGNY in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the motif TTGCACT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-130a, hsa-miR-301 and hsa-miR-130b (v7.1 miRBase).
Genes having at least one occurence of the motif TGCACTT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-519c, hsa-miR-519b and hsa-miR-519a (v7.1 miRBase).
Genes having at least one occurence of the motif AGCGCTT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-518f, hsa-miR-518e and hsa-miR-518a (v7.1 miRBase).
Genes having at least one occurence of the motif CAGTATT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-200b, hsa-miR-200c and hsa-miR-429 (v7.1 miRBase).
Genes having at least one occurence of the motif ACATTCC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-1 and hsa-miR-206 (v7.1 miRBase).
Genes having at least one occurence of the motif AAGTCCA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-422b and hsa-miR-422a (v7.1 miRBase).
Genes having at least one occurence of the motif AAAGGGA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-204 and hsa-miR-211 (v7.1 miRBase).
Genes having at least one occurence of the motif AATGTGA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-23a and hsa-miR-23b (v7.1 miRBase).
Genes having at least one occurence of the motif CACTGTG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-128a and hsa-miR-128b (v7.1 miRBase).
Genes having at least one occurence of the motif ACTGAAA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-30a-3p and hsa-miR-30e-3p (v7.1 miRBase).
Genes having at least one occurence of the highly conserved motif M19 GKCGCNNNNNNNTGAYG in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the motif CTCAGGG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-125b and hsa-miR-125a (v7.1 miRBase).
Genes having at least one occurence of the motif TACTTGA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-26a and hsa-miR-26b (v7.1 miRBase).
Genes having at least one occurence of the motif TCTATGA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-376a and hsa-miR-376b (v7.1 miRBase).
Genes having at least one occurence of the motif GTATGAT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-154* and hsa-miR-487 (v7.1 miRBase).
Genes having at least one occurence of the motif CAGTGTT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-141 and hsa-miR-200a (v7.1 miRBase).
Genes having at least one occurence of the motif AGTTCTC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-146a and hsa-miR-146b (v7.1 miRBase).
Genes having at least one occurence of the motif TAGGTCA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-192 and hsa-miR-215 (v7.1 miRBase).
Genes having at least one occurence of the motif ATGTAGC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-221 and hsa-miR-222 (v7.1 miRBase).
Genes having at least one occurence of the motif ACTGTGA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-27a and hsa-miR-27b (v7.1 miRBase).
Genes having at least one occurence of the motif TGCACGA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-517a and hsa-miR-517c (v7.1 miRBase).
Genes having at least one occurence of the highly conserved motif M98 GTCNYYATGR in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the motif TTTGCAC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-19a and hsa-miR-19b (v7.1 miRBase).
Genes having at least one occurence of the motif ACTACCT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-196a and hsa-miR-196b (v7.1 miRBase).
Genes having at least one occurence of the motif TTGGAGA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-515-5p and hsa-miR-519e* (v7.1 miRBase).
Genes having at least one occurence of the motif CACTTTG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-520g and hsa-miR-520h (v7.1 miRBase).
Genes having at least one occurence of the motif GGGACCA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-133a and hsa-miR-133b (v7.1 miRBase).
Genes having at least one occurence of the motif GACTGTT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-212 and hsa-miR-132 (v7.1 miRBase).
Genes having at least one occurence of the motif AAGCCAT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-135a and hsa-miR-135b (v7.1 miRBase).
Genes having at least one occurence of the motif ATGCTGC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-103 and hsa-miR-107 (v7.1 miRBase).
Genes having at least one occurence of the motif ACAGGGT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-10a and hsa-miR-10b (v7.1 miRBase).
Genes having at least one occurence of the motif CTCTGGA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-520a* and hsa-miR-525 (v7.1 miRBase).
Genes having at least one occurence of the highly conserved motif M91 GTGGGTGK in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the motif GCGCCTT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-525* and hsa-miR-524 (v7.1 miRBase).
Genes having at least one occurence of the motif ACACTGG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-199a and hsa-miR-199b (v7.1 miRBase).
Genes having at least one occurence of the motif GCACCTT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-18a and hsa-miR-18b (v7.1 miRBase).
Genes having at least one occurence of the motif GGCCAGT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNAs hsa-miR-193a and hsa-miR-193b (v7.1 miRBase).
Genes having at least one occurence of the motif CGCTGCT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-503 (v7.1 miRBase).
Genes having at least one occurence of the motif TCTGATC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-383 (v7.1 miRBase).
Genes having at least one occurence of the motif GTGCCTT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-506 (v7.1 miRBase).
Genes having at least one occurence of the motif ACAACTT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-382 (v7.1 miRBase).
Genes having at least one occurence of the motif ATGTTAA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-302c* (v7.1 miRBase).
Genes having at least one occurence of the motif GGATCCG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-127 (v7.1 miRBase).
Genes having at least one occurence of the highly conserved motif M43 GTTGNYNNRGNAAC in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the motif CATTTCA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-203 (v7.1 miRBase).
Genes having at least one occurence of the motif TCCAGAT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-516-5p (v7.1 miRBase).
Genes having at least one occurence of the motif AGTCAGC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-345 (v7.1 miRBase).
Genes having at least one occurence of the motif ACACTCC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-122a (v7.1 miRBase).
Genes having at least one occurence of the motif GTGTGAG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-342 (v7.1 miRBase).
Genes having at least one occurence of the motif CTAGGAA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-384 (v7.1 miRBase).
Genes having at least one occurence of the motif CTATGCA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-153 (v7.1 miRBase).
Genes having at least one occurence of the motif AGGGCAG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-18a* (v7.1 miRBase).
Genes having at least one occurence of the motif GTGCCAT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-183 (v7.1 miRBase).
Genes having at least one occurence of the motif ACTGCAG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-17-3p (v7.1 miRBase).
Genes having at least one occurence of the highly conserved motif M89 GTTNYYNNGGTNA in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the motif GTTTGTT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-495 (v7.1 miRBase).
Genes having at least one occurence of the motif TATTATA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-374 (v7.1 miRBase).
Genes having at least one occurence of the motif CTTGTAT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-381 (v7.1 miRBase).
Genes having at least one occurence of the motif AAAGGAT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-501 (v7.1 miRBase).
Genes having at least one occurence of the motif GGGGCCC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-296 (v7.1 miRBase).
Genes having at least one occurence of the motif CTACTGT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-199a* (v7.1 miRBase).
Genes having at least one occurence of the motif CAAGGAT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-362 (v7.1 miRBase).
Genes having at least one occurence of the motif GTGTTGA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-505 (v7.1 miRBase).
Genes having at least one occurence of the motif ATACTGT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-144 (v7.1 miRBase).
Genes having at least one occurence of the motif TGTATGA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-485-3p (v7.1 miRBase).
Genes having at least one occurence of the highly conserved motif M37 GTTRYCATRR in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the motif GTATTAT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-369-3p (v7.1 miRBase).
Genes having at least one occurence of the motif TCCCCAC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-491 (v7.1 miRBase).
Genes having at least one occurence of the motif GCTTGAA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-498 (v7.1 miRBase).
Genes having at least one occurence of the motif GTGGTGA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-197 (v7.1 miRBase).
Genes having at least one occurence of the motif GGGCATT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-365 (v7.1 miRBase).
Genes having at least one occurence of the motif TGAGATT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-216 (v7.1 miRBase).
Genes having at least one occurence of the motif GTCAACC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-380-5p (v7.1 miRBase).
Genes having at least one occurence of the motif GGTGAAG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-412 (v7.1 miRBase).
Genes having at least one occurence of the motif AGGGCCA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-328 (v7.1 miRBase).
Genes having at least one occurence of the motif GTGACTT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-224 (v7.1 miRBase).
Genes having at least one occurence of the highly conserved motif M157 KCCGNSWTTT in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the motif GAGACTG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-452* (v7.1 miRBase).
Genes having at least one occurence of the motif CAGGGTC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-504 (v7.1 miRBase).
Genes having at least one occurence of the motif GCTCTTG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-335 (v7.1 miRBase).
Genes having at least one occurence of the motif TCGATGG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-213 (v7.1 miRBase).
Genes having at least one occurence of the motif GTCTTCC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-7 (v7.1 miRBase).
Genes having at least one occurence of the motif ATAACCT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-154 (v7.1 miRBase).
Genes having at least one occurence of the motif TCTAGAG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-517* (v7.1 miRBase).
Genes having at least one occurence of the motif GGCAGAC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-346 (v7.1 miRBase).
Genes having at least one occurence of the motif AGGCACT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-515-3p (v7.1 miRBase).
Genes having at least one occurence of the motif ATAGGAA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-202* (v7.1 miRBase).
Genes having at least one occurence of the highly conserved motif M116 KMCATNNWGGA in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the motif CCAGGTT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-490 (v7.1 miRBase).
Genes having at least one occurence of the motif TTGCCAA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-182 (v7.1 miRBase).
Genes having at least one occurence of the motif CGGTGTG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-220 (v7.1 miRBase).
Genes having at least one occurence of the motif TAGCTTT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-9* (v7.1 miRBase).
Genes having at least one occurence of the motif CTGAGCC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-24 (v7.1 miRBase).
Genes having at least one occurence of the motif TTGGGAG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-150 (v7.1 miRBase).
Genes having at least one occurence of the motif AAACCAC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-140 (v7.1 miRBase).
Genes having at least one occurence of the motif CCCACAT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-299-3p (v7.1 miRBase).
Genes having at least one occurence of the motif ATGTTTC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-494 (v7.1 miRBase).
Genes having at least one occurence of the motif GTACTGT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-101 (v7.1 miRBase).
Genes having at least one occurence of the highly conserved motif M120 KRCTCNNNNMANAGC in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the motif CAGGTCC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-492 (v7.1 miRBase).
Genes having at least one occurence of the motif GAGCCTG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-484 (v7.1 miRBase).
Genes having at least one occurence of the motif GTAAGAT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-200a* (v7.1 miRBase).
Genes having at least one occurence of the motif TCCGTCC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-184 (v7.1 miRBase).
Genes having at least one occurence of the motif CACGTTT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-302a* (v7.1 miRBase).
Genes having at least one occurence of the motif TATCTGG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-488 (v7.1 miRBase).
Genes having at least one occurence of the motif AGGAAGC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-516-3p (v7.1 miRBase).
Genes having at least one occurence of the motif ACGCACA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-210 (v7.1 miRBase).
Genes having at least one occurence of the motif ATATGCA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-448 (v7.1 miRBase).
Genes having at least one occurence of the motif AATGGAG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-136 (v7.1 miRBase).
Genes having at least one occurence of the highly conserved motif M112 KTGGYRSGAA in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the motif CCTGTGA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-513 (v7.1 miRBase).
Genes having at least one occurence of the motif AACGGTT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-451 (v7.1 miRBase).
Genes having at least one occurence of the motif ATGAAGG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-205 (v7.1 miRBase).
Genes having at least one occurence of the motif CTCAAGA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-526b (v7.1 miRBase).
Genes having at least one occurence of the motif GGCAGCT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-22 (v7.1 miRBase).
Genes having at least one occurence of the motif TCTGGAC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-198 (v7.1 miRBase).
Genes having at least one occurence of the motif CAGCTTT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-320 (v7.1 miRBase).
Genes having at least one occurence of the motif CCATCCA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-432* (v7.1 miRBase).
Genes having at least one occurence of the motif CATGTAA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-496 (v7.1 miRBase).
Genes having at least one occurence of the motif AAGCACA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-218 (v7.1 miRBase).
Genes having at least one occurence of the highly conserved motif M110 MCAATNNNNNGCG in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the motif GCAAGAC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-431 (v7.1 miRBase).
Genes having at least one occurence of the motif ATGTCAC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-489 (v7.1 miRBase).
Genes having at least one occurence of the motif CCTGCTG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-214 (v7.1 miRBase).
Genes having at least one occurence of the motif GTCTACC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-379 (v7.1 miRBase).
Genes having at least one occurence of the motif CTACTAG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-325 (v7.1 miRBase).
Genes having at least one occurence of the motif CCTGAGT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-510 (v7.1 miRBase).
Genes having at least one occurence of the motif GACAGGG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-339 (v7.1 miRBase).
Genes having at least one occurence of the motif ATACCTC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-202 (v7.1 miRBase).
Genes having at least one occurence of the motif GGCAGTG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-324-3p (v7.1 miRBase).
Genes having at least one occurence of the highly conserved motif M138 MYAATNNNNNNNGGC in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the motif GAGCCAG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-149 (v7.1 miRBase).
Genes having at least one occurence of the motif TCTCTCC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-185 (v7.1 miRBase).
Genes having at least one occurence of the motif AGCATTA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-155 (v7.1 miRBase).
Genes having at least one occurence of the motif GCAAAAA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-129 (v7.1 miRBase).
Genes having at least one occurence of the motif GGCACAT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-455 (v7.1 miRBase).
Genes having at least one occurence of the motif GTCGATC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-369-5p (v7.1 miRBase).
Genes having at least one occurence of the motif GGCGGCA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-371 (v7.1 miRBase).
Genes having at least one occurence of the motif CTTTGTA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-524* (v7.1 miRBase).
Genes having at least one occurence of the motif CTGTTAC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-194 (v7.1 miRBase).
Genes having at least one occurence of the motif ATGCAGT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-217 (v7.1 miRBase).
Genes having at least one occurence of the highly conserved motif M125 RAAGNYNNCTTY in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the motif ATGCTGG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-338 (v7.1 miRBase).
Genes having at least one occurence of the motif ACATATC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-190 (v7.1 miRBase).
Genes having at least one occurence of the motif CTCCAAG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-432 (v7.1 miRBase).
Genes having at least one occurence of the motif AAGCAAT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-137 (v7.1 miRBase).
Genes having at least one occurence of the motif ACCAAAG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-9 (v7.1 miRBase).
Genes having at least one occurence of the motif TTTGTAG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-520d* (v7.1 miRBase).
Genes having at least one occurence of the motif TGCCTTA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-124a (v7.1 miRBase).
Genes having at least one occurence of the motif AACTGAC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-223 (v7.1 miRBase).
Genes having at least one occurence of the motif AAAGACA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-511 (v7.1 miRBase).
Genes having at least one occurence of the motif ATAAGCT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-21 (v7.1 miRBase).
Genes having at least one occurence of the highly conserved motif M66 RACTNNRTTTNC in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the motif TCTGATA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-361 (v7.1 miRBase).
Genes having at least one occurence of the motif TACAATC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-508 (v7.1 miRBase).
Genes having at least one occurence of the motif ACTTTAT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-142-5p (v7.1 miRBase).
Genes having at least one occurence of the motif TTTGCAG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-518a-2* (v7.1 miRBase).
Genes having at least one occurence of the motif AACATTC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-409-3p (v7.1 miRBase).
Genes having at least one occurence of the motif ACAACCT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-453 (v7.1 miRBase).
Genes having at least one occurence of the motif GTGCCAA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-96 (v7.1 miRBase).
Genes having at least one occurence of the motif TCATCTC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-143 (v7.1 miRBase).
Genes having at least one occurence of the motif GAGCTGG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-337 (v7.1 miRBase).
Genes having at least one occurence of the motif AGTCTAG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-151 (v7.1 miRBase).
Genes having at least one occurence of the highly conserved motif M154 RNCTGNYNRNCTGNY in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the motif AGTCTTA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-499 (v7.1 miRBase).
Genes having at least one occurence of the motif CCCAGAG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-326 (v7.1 miRBase).
Genes having at least one occurence of the motif GCTGAGT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-512-5p (v7.1 miRBase).
Genes having at least one occurence of the motif ACCATTT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-522 (v7.1 miRBase).
Genes having at least one occurence of the motif AGCTCCT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-28 (v7.1 miRBase).
Genes having at least one occurence of the motif AGCGCAG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-191* (v7.1 miRBase).
Genes having at least one occurence of the motif ACTGCCT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-34b (v7.1 miRBase).
Genes having at least one occurence of the motif GTTAAAG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-302b* (v7.1 miRBase).
Genes having at least one occurence of the motif GACAATC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-219 (v7.1 miRBase).
Genes having at least one occurence of the motif CGCAAAA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-450 (v7.1 miRBase).
Genes having at least one occurence of the highly conserved motif M140 RNGTGGGC in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the motif AACTGGA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-145 (v7.1 miRBase).
Genes having at least one occurence of the motif AAGCACT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-520f (v7.1 miRBase).
Genes having at least one occurence of the motif AGGAGTG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-483 (v7.1 miRBase).
Genes having at least one occurence of the motif GTGTCAA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-514 (v7.1 miRBase).
Genes having at least one occurence of the motif GCAAGGA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-502 (v7.1 miRBase).
Genes having at least one occurence of the motif AGGTGCA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-500 (v7.1 miRBase).
Genes having at least one occurence of the motif ACTGTAG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-139 (v7.1 miRBase).
Genes having at least one occurence of the motif GTGCAAA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-507 (v7.1 miRBase).
Genes having at least one occurence of the motif TGCTTTG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-330 (v7.1 miRBase).
Genes having at least one occurence of the motif TTTTGAG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-373* (v7.1 miRBase).
Genes having at least one occurence of the highly conserved motif M122 RNTCANNRNNYNATTW in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the motif TAGAACC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-182* (v7.1 miRBase).
Genes having at least one occurence of the motif GGGATGC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-324-5p (v7.1 miRBase).
Genes having at least one occurence of the motif CCAGGGG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-331 (v7.1 miRBase).
Genes having at least one occurence of the motif ACCAATC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-509 (v7.1 miRBase).
Genes having at least one occurence of the motif GGCACTT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-519e (v7.1 miRBase).
Genes having at least one occurence of the motif ATGTACA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-493 (v7.1 miRBase).
Genes having at least one occurence of the motif GCATTTG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-105 (v7.1 miRBase).
Genes having at least one occurence of the motif CAGTCAC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-134 (v7.1 miRBase).
Genes having at least one occurence of the motif TCCAGAG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-518c* (v7.1 miRBase).
Genes having at least one occurence of the motif CACCAGC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-138 (v7.1 miRBase).
Genes having at least one occurence of the highly conserved motif M129 RRAGTTGT in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the motif CAGCACT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-512-3p (v7.1 miRBase).
Genes having at least one occurence of the motif GTACAGG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-486 (v7.1 miRBase).
Genes having at least one occurence of the motif GTTATAT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-410 (v7.1 miRBase).
Genes having at least one occurence of the motif GTCAGGA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-378 (v7.1 miRBase).
Genes having at least one occurence of the motif ACACTAC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-142-3p (v7.1 miRBase).
Genes having at least one occurence of the motif ATTCTTT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-186 (v7.1 miRBase).
Genes having at least one occurence of the motif CTCTATG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-368 (v7.1 miRBase).
Genes having at least one occurence of the motif ACCGAGC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-423 (v7.1 miRBase).
Genes having at least one occurence of the motif TGTGTGA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-377 (v7.1 miRBase).
Genes having at least one occurence of the motif ATCATGA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-433 (v7.1 miRBase).
Genes having at least one occurence of the highly conserved motif M146 RRCCGTTA in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the motif CAGCAGG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-370 (v7.1 miRBase).
Genes having at least one occurence of the motif CTTTGCA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-527 (v7.1 miRBase).
Genes having at least one occurence of the motif GGTGTGT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-329 (v7.1 miRBase).
Genes having at least one occurence of the motif ATTACAT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-380-3p (v7.1 miRBase).
Genes having at least one occurence of the motif CGTCTTA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-208 (v7.1 miRBase).
Genes having at least one occurence of the motif ATCTTGC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-31 (v7.1 miRBase).
Genes having at least one occurence of the motif AAGGGAT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-188 (v7.1 miRBase).
Genes having at least one occurence of the motif TGCAAAC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-452 (v7.1 miRBase).
Genes having at least one occurence of the motif CAGCCTC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-485-5p (v7.1 miRBase).
Genes having at least one occurence of the motif GTAAACC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-299-5p (v7.1 miRBase).
Genes having at least one occurence of the highly conserved motif M107 RTTTNNNYTGGM in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the motif GGTAACC in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-409-5p (v7.1 miRBase).
Genes having at least one occurence of the motif TAATAAT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-126* (v7.1 miRBase).
Genes having at least one occurence of the motif ATGCACG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-517b (v7.1 miRBase).
Genes having at least one occurence of the motif CCACACA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-147 (v7.1 miRBase).
Genes having at least one occurence of the motif TAATGTG in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-323 (v7.1 miRBase).
Genes having at least one occurence of the motif TTCCGTT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-191 (v7.1 miRBase).
Genes having at least one occurence of the motif AGTGCGT in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-521 (v7.1 miRBase).
Genes having at least one occurence of the motif CAATGCA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-33 (v7.1 miRBase).
Genes having at least one occurence of the motif GTAGGCA in their 3' untranslated region. The motif represents putative target (that is, seed match) of human mature miRNA hsa-miR-189 (v7.1 miRBase).
Genes having at least one occurence of the highly conserved motif M151 RYAAAKNNNNNNTTGW in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M128 RYCACNNRNNRNCAG in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M133 RYTAAWNNNTGAY in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M87 RYTGCNWTGGNR in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M62 SMTTTTGT in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M80 SNACANNNYSYAGA in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M71 SYATTGTG in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M162 TAANNYSGCG in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M136 TAAYNRNNTCC in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M132 TCCATTKW in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M39 TCCCRNNRTGC in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M42 TGACATY in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M22 TGCGCANK in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M92 TGCTGAY in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M27 TGGNNNNNNKCCAR in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M117 TGTYNNNNNRGCARM in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M8 TMTCGCGANR in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M75 TNCATNTCCYR in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M64 TTANTCA in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M161 TTANWNANTGGM in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M72 TTCYRGAA in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M169 TTTNNANAGCYR in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M152 WCAANNNYCAG in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M59 WCTCNATGGY in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M155 WGTTNNNNNAAA in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M174 WTGAAAT in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M46 WTTGKCTG in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M127 WWTAAGGC in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M126 WYAAANNRNNNGCG in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M147 YAATNANRNNNCAG in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M90 YAATNRNNNYNATT in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M97 YATTNATC in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M58 YCATTAA in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M149 YGACNNYACAR in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M96 YGCANTGCR in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M30 YGCGYRCGC in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M109 YGTCCTTGR in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M145 YKACATTT in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M170 YNGTTNNNATT in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M166 YNTTTNNNANGCARM in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M156 YRCCAKNNGNCGC in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M115 YRTCANNRCGC in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M168 YTAAYNGCT in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M114 YTCCCRNNAGGY in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M150 YTTCCNNNGGAMR in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M173 YWATTWNNRGCT in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M52 YYCATTCAWW in the region spanning up to 4 kb around their transcription start sites. The motif does not match any known transcription factor binding site (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M111 RACCACAR sites. The motif matches transcription factor binding site V$AML_Q6 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M7 TGANTCA sites. The motif matches transcription factor binding site V$AP1_C (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M15 CAGCTG sites. The motif matches transcription factor binding site V$AP4_Q5 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M76 CAGGTA sites. The motif matches transcription factor binding site V$AREB6_01 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M14 TGACGTCA sites. The motif matches transcription factor binding site V$ATF3_Q6 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M9 TGAYRTCA sites. The motif matches transcription factor binding site V$ATF3_Q6 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M172 TTGCWCAAY sites. The motif matches transcription factor binding site V$CEBPB_02 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M23 TAATTA sites. The motif matches transcription factor binding site V$CHX10_01 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M12 CAGGTG sites. The motif matches transcription factor binding site V$E12_Q6 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M69 SGCGSSAAA sites. The motif matches transcription factor binding site V$E2F1DP2_01 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M26 TTAYRTAA sites. The motif matches transcription factor binding site V$E4BP4_01 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M20 GTGACGY sites. The motif matches transcription factor binding site V$E4F1_Q6 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M3 SCGGAAGY sites. The motif matches transcription factor binding site V$ELK1_02 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M25 TGACCTY sites. The motif matches transcription factor binding site V$ERR1_Q2 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M16 RYTTCCTG sites. The motif matches transcription factor binding site V$ETS2_B (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M60 TTGTTT sites. The motif matches transcription factor binding site V$FOXO4_01 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M36 RTAAACA sites. The motif matches transcription factor binding site V$FREAC2_01 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M11 MGGAAGTG sites. The motif matches transcription factor binding site V$GABP_B (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M131 GATAAGR sites. The motif matches transcription factor binding site V$GATA_C (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M94 TGATTTRY sites. The motif matches transcription factor binding site V$GFI1_01 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M139 AAAYWAACM sites. The motif matches transcription factor binding site V$HFH4_01 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M84 RGTTAMWNATT sites. The motif matches transcription factor binding site V$HNF1_01 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M83 TGTTTGY sites. The motif matches transcription factor binding site V$HNF3_Q6 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M141 TTCNRGNNNNTTC sites. The motif matches transcription factor binding site V$HSF_Q6 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M68 RGAANNTTC sites. The motif matches transcription factor binding site V$HSF1_01 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M85 STTTCRNTTT sites. The motif matches transcription factor binding site V$IRF_Q6 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M73 CTTTGA sites. The motif matches transcription factor binding site V$LEF1_Q2 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M13 CTTTGT sites. The motif matches transcription factor binding site V$LEF1_Q2 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M61 YTAATTAA sites. The motif matches transcription factor binding site V$LHX3_01 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M24 GGGAGGRR sites. The motif matches transcription factor binding site V$MAZ_Q6 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M33 YTATTTTNR sites. The motif matches transcription factor binding site V$MEF2_02 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M41 TGACAGNY sites. The motif matches transcription factor binding site V$MEIS1_01 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M53 RYTGCNNRGNAAC sites. The motif matches transcription factor binding site V$MIF1_01 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M2 CACGTG sites. The motif matches transcription factor binding site V$MYC_Q2 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M35 GCANCTGNY sites. The motif matches transcription factor binding site V$MYOD_Q6 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M47 TGCCAAR sites. The motif matches transcription factor binding site V$NF1_Q6 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M55 TGGAAA sites. The motif matches transcription factor binding site V$NFAT_Q4_01 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M32 TGASTMAGC sites. The motif matches transcription factor binding site V$NFE2_01 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M86 GGGNNTTTCC sites. The motif matches transcription factor binding site V$NFKB_Q6_01 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M5 GATTGGY sites. The motif matches transcription factor binding site V$NFY_Q6_01 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M1 RCGCANGCGY sites. The motif matches transcription factor binding site V$NRF1_Q6 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M44 YATGNWAAT sites. The motif matches transcription factor binding site V$OCT_C (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M130 CCCNNGGGAR sites. The motif matches transcription factor binding site V$OLF1_01 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M70 CGTSACG sites. The motif matches transcription factor binding site V$PAX3_B (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M56 GGGTGGRR sites. The motif matches transcription factor binding site V$PAX4_03 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M93 GGATTA sites. The motif matches transcription factor binding site V$PITX2_Q2 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M50 RGAGGAARY sites. The motif matches transcription factor binding site V$PU1_Q6 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M28 CTAWWWATA sites. The motif matches transcription factor binding site V$RSRFC4_Q2 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M54 TAAWWATAG sites. The motif matches transcription factor binding site V$RSRFC4_Q2 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M38 TGACCTTG sites. The motif matches transcription factor binding site V$SF1_Q6 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M49 CATTGTYY sites. The motif matches transcription factor binding site V$SOX9_B1 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M6 GGGCGGR sites. The motif matches transcription factor binding site V$SP1_Q6 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M18 TCANNTGAY sites. The motif matches transcription factor binding site V$SREBP1_01 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M121 CCAWWNAAGG sites. The motif matches transcription factor binding site V$SRF_Q4 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M40 TTCYNRGAA sites. The motif matches transcription factor binding site V$STAT5B_01 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M51 TATAAA sites. The motif matches transcription factor binding site V$TATA_01 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M67 TGANNYRGCA sites. The motif matches transcription factor binding site V$TCF11MAFG_01 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M79 WGGAATGY sites. The motif matches transcription factor binding site V$TEF1_Q6 (v7.4 TRANSFAC).
Genes having at least one occurence of the highly conserved motif M10 GCCATNTTG sites. The motif matches transcription factor binding site V$YY1_Q6 (v7.4 TRANSFAC).
Neighborhood of ATRX
Neighborhood of ATOX1
Neighborhood of BCL2
Neighborhood of BNIP1
Neighborhood of BAG5
Neighborhood of BCL2L11
Neighborhood of BECN1
Neighborhood of BRCA1
Neighborhood of BUB1
Neighborhood of BUB3
Neighborhood of CTBP1
Neighborhood of CCNF
Neighborhood of CCNI
Neighborhood of DNMT1
Neighborhood of ERCC2
Neighborhood of ESPL1
Neighborhood of FDXR
Neighborhood of FEN1
Neighborhood of GPX4
Neighborhood of HAT1
Neighborhood of HDAC1
Neighborhood of HDAC2
Neighborhood of MDM2
Neighborhood of MT4
Neighborhood of MSH2
Neighborhood of MSH3
Neighborhood of NF1
Neighborhood of PRDX3
Neighborhood of PCNA
Neighborhood of PSMC1
Neighborhood of PSMC2
Neighborhood of PSMF1
Neighborhood of PRKDC
Neighborhood of RAD21
Neighborhood of RAD23A
Neighborhood of RAD23B
Neighborhood of RAD51L3
Neighborhood of RAD54L
Neighborhood of RFC1
Neighborhood of RFC4
Neighborhood of RFC5
Neighborhood of RPA1
Neighborhood of RPA2
Neighborhood of RRM1
Neighborhood of STK17A
Neighborhood of SMC1L1
Neighborhood of SP3
Neighborhood of SOD1
Neighborhood of TERF1
Neighborhood of TERF2IP
Neighborhood of TFDP2
Neighborhood of UNG
Neighborhood of MYC
Neighborhood of XPC
Neighborhood of XRCC5
Neighborhood of AATF
Neighborhood of ACP1
Neighborhood of ACTG1
Neighborhood of ANP32B
Neighborhood of AP2M1
Neighborhood of AP3D1
Neighborhood of ARAF1
Neighborhood of ARL3
Neighborhood of ATF2
Neighborhood of BMI1
Neighborhood of BMPR2
Neighborhood of BUB1B
Neighborhood of CAMK4
Neighborhood of CASP10
Neighborhood of CASP2
Neighborhood of CD8A
Neighborhood of CDC10
Neighborhood of CDC16
Neighborhood of CDC2L5
Neighborhood of CDH4
Neighborhood of CDK2
Neighborhood of CNTN1
Neighborhood of CSNK1D
Neighborhood of CSNK2B
Neighborhood of CTSB
Neighborhood of CUL1
Neighborhood of DAP
Neighborhood of DAP3
Neighborhood of DCC
Neighborhood of DDB1
Neighborhood of DDX11
Neighborhood of DEAF1
Neighborhood of DEK
Neighborhood of DMPK
Neighborhood of EI24
Neighborhood of EIF3S2
Neighborhood of EIF3S6
Neighborhood of EIF4A2
Neighborhood of EIF4E
Neighborhood of EPHA7
Neighborhood of ERCC4
Neighborhood of ERH
Neighborhood of ESR1
Neighborhood of ETV3
Neighborhood of FANCG
Neighborhood of FBL
Neighborhood of FLT1
Neighborhood of FOSL1
Neighborhood of FRK
Neighborhood of FSHR
Neighborhood of G22P1
Neighborhood of GMPS
Neighborhood of GNB1
Neighborhood of GSPT1
Neighborhood of HEAB
Neighborhood of IFNA1
Neighborhood of IKBKG
Neighborhood of IL13
Neighborhood of IL16
Neighborhood of IL4
Neighborhood of IL9
Neighborhood of ITGA2
Neighborhood of JAG1
Neighborhood of JAK3
Neighborhood of JUND
Neighborhood of KDR
Neighborhood of LCAT
Neighborhood of LMO1
Neighborhood of LTK
Neighborhood of MAGEA8
Neighborhood of MAGEA9
Neighborhood of MAP2K2
Neighborhood of MAP2K7
Neighborhood of MAP3K14
Neighborhood of MBD4
Neighborhood of MLLT10
Neighborhood of MTA1
Neighborhood of MYL3
Neighborhood of MYST2
Neighborhood of NME2
Neighborhood of NOS2A
Neighborhood of NPM1
Neighborhood of ORC1L
Neighborhood of PAPSS1
Neighborhood of PAX7
Neighborhood of PDCD1
Neighborhood of PDPK1
Neighborhood of PHB
Neighborhood of PML
Neighborhood of PPP1CA
Neighborhood of PPP1CC
Neighborhood of PPP2CA
Neighborhood of PPP2R4
Neighborhood of PPP2R5B
Neighborhood of PPP2R5E
Neighborhood of PPP5C
Neighborhood of PPP6C
Neighborhood of PRKACA
Neighborhood of PRKAG1
Neighborhood of PRKAR1A
Neighborhood of PRKCA
Neighborhood of PTEN
Neighborhood of PTPN11
Neighborhood of PTPN9
Neighborhood of PTPRB
Neighborhood of PTPRR
Neighborhood of RAB11A
Neighborhood of RAB1A
Neighborhood of RAB3A
Neighborhood of RAB5A
Neighborhood of RAB6A
Neighborhood of RAC1
Neighborhood of RAF1
Neighborhood of RAGE
Neighborhood of RAN
Neighborhood of RAP1A
Neighborhood of RBBP8
Neighborhood of RBM8A
Neighborhood of REV3L
Neighborhood of RUNX1
Neighborhood of SART1
Neighborhood of SKP1A
Neighborhood of SNRP70
Neighborhood of SS18
Neighborhood of SUPT3H
Neighborhood of THPO
Neighborhood of THRA
Neighborhood of TNFRSF25
Neighborhood of TNFRSF6
Neighborhood of TPR
Neighborhood of TPT1
Neighborhood of TTN
Neighborhood of UBE2A
Neighborhood of UBE2I
Neighborhood of UBE2N
Neighborhood of USP5
Neighborhood of WNT1
Neighborhood of ZNF10
Neighborhood of ATM
Neighborhood of BNIP1
Neighborhood of BAG5
Neighborhood of BCL2L1
Neighborhood of BECN1
Neighborhood of ERBB2IP
Neighborhood of GSTA4
Neighborhood of HDAC1
Neighborhood of PSME1
Neighborhood of RAD21
Neighborhood of SIRT2
Neighborhood of TINF2
Neighborhood of ACTG1
Neighborhood of AIP
Neighborhood of ANP32B
Neighborhood of APEX1
Neighborhood of AQP4
Neighborhood of BMPR2
Neighborhood of CALM1
Neighborhood of CASP2
Neighborhood of CBFB
Neighborhood of CDH5
Neighborhood of CHUK
Neighborhood of CRKL
Neighborhood of CSNK1A1
Neighborhood of CSNK1D
Neighborhood of CSNK2B
Neighborhood of DDX11
Neighborhood of DDX5
Neighborhood of DEAF1
Neighborhood of DENR
Neighborhood of DFFA
Neighborhood of DLG1
Neighborhood of DPF2
Neighborhood of ERCC4
Neighborhood of FANCC
Neighborhood of FANCL
Neighborhood of FCGR2B
Neighborhood of GSPT1
Neighborhood of HBP1
Neighborhood of HMGA2
Neighborhood of IL6ST
Neighborhood of ING1
Neighborhood of LTK
Neighborhood of MAP1B
Neighborhood of MAP4K4
Neighborhood of MAPK10
Neighborhood of MAX
Neighborhood of MLL
Neighborhood of MSN
Neighborhood of MYCL1
Neighborhood of MYST2
Neighborhood of NCAM1
Neighborhood of NF2
Neighborhood of NPM1
Neighborhood of NUMA1
Neighborhood of PFN1
Neighborhood of PPM1D
Neighborhood of PPP1CC
Neighborhood of PRKAG1
Neighborhood of PRKCG
Neighborhood of PTK2
Neighborhood of PTPRD
Neighborhood of PTPRU
Neighborhood of RAB10
Neighborhood of RAF1
Neighborhood of RAN
Neighborhood of RAP2A
Neighborhood of RBM8A
Neighborhood of RING1
Neighborhood of SMARCC1
Neighborhood of SMARCD1
Neighborhood of SMO
Neighborhood of SUFU
Neighborhood of SUPT4H1
Neighborhood of TEC
Neighborhood of TPR
Neighborhood of TPT1
Neighborhood of UBE2N
Neighborhood of USP6
Neighborhood of VAV1
Neighborhood of ZNF198
Neighborhood of HPX
Neighborhood of IGFBP1
Neighborhood of MLANA
Neighborhood of MYST2
Neighborhood of TNFRSF25
Neighborhood of WBSCR22
Neighborhood of ATM
Neighborhood of BNIP2
Neighborhood of BNIP3L
Neighborhood of BUB1
Neighborhood of BUB3
Neighborhood of CARD15
Neighborhood of CDC20
Neighborhood of CDC2
Neighborhood of CENPE
Neighborhood of CENPF
Neighborhood of CCNA1
Neighborhood of CCNA2
Neighborhood of CCNB2
Neighborhood of ESPL1
Neighborhood of FEN1
Neighborhood of GSTM1
Neighborhood of H2AFX
Neighborhood of HPX
Neighborhood of HAT1
Neighborhood of HDAC1
Neighborhood of TDG
Neighborhood of MLH1
Neighborhood of MSH2
Neighborhood of MSH6
Neighborhood of PRDX2
Neighborhood of PCNA
Neighborhood of RAD23A
Neighborhood of RFC3
Neighborhood of RFC4
Neighborhood of RPA1
Neighborhood of RRM1
Neighborhood of RRM2
Neighborhood of SMC1L1
Neighborhood of SMC2L1
Neighborhood of SMC4L1
Neighborhood of TST
Neighborhood of XRCC5
Neighborhood of AF1Q
Neighborhood of ANK1
Neighborhood of ANP32B
Neighborhood of APEX1
Neighborhood of BUB1B
Neighborhood of CASP1
Neighborhood of CASP4
Neighborhood of CASP8
Neighborhood of CBFB
Neighborhood of CD14
Neighborhood of CD1D
Neighborhood of CD33
Neighborhood of CD48
Neighborhood of CD53
Neighborhood of CD7
Neighborhood of CD97
Neighborhood of CDC27
Neighborhood of CDH11
Neighborhood of CDH3
Neighborhood of CDKN1C
Neighborhood of CEBPA
Neighborhood of CKS1B
Neighborhood of CKS2
Neighborhood of CYP2B6
Neighborhood of DAP3
Neighborhood of DDX5
Neighborhood of DEK
Neighborhood of DENR
Neighborhood of DNM1
Neighborhood of EGFR
Neighborhood of EIF3S6
Neighborhood of ELAC2
Neighborhood of FBL
Neighborhood of FGR
Neighborhood of FOS
Neighborhood of G22P1
Neighborhood of GLTSCR2
Neighborhood of HCK
Neighborhood of HLA-C
Neighborhood of HMMR
Neighborhood of HPN
Neighborhood of ICAM3
Neighborhood of IGF1
Neighborhood of IGFBP1
Neighborhood of IL2RB
Neighborhood of INPP5D
Neighborhood of ITGAL
Neighborhood of ITGB2
Neighborhood of JAK1
Neighborhood of KISS1
Neighborhood of KPNB1
Neighborhood of LCAT
Neighborhood of LYN
Neighborhood of MAP2K3
Neighborhood of MAPT
Neighborhood of MATK
Neighborhood of MBD4
Neighborhood of MCL1
Neighborhood of MCM4
Neighborhood of MCM5
Neighborhood of MKI67
Neighborhood of MLF1
Neighborhood of MMP1
Neighborhood of MMP11
Neighborhood of MSN
Neighborhood of MYD88
Neighborhood of MYL2
Neighborhood of MYL3
Neighborhood of NPM1
Neighborhood of NS
Neighborhood of PA2G4
Neighborhood of PAK2
Neighborhood of PCAF
Neighborhood of PECAM1
Neighborhood of PPP6C
Neighborhood of PTPN4
Neighborhood of PTPN6
Neighborhood of PTPRC
Neighborhood of PTX3
Neighborhood of RAB3A
Neighborhood of RAB7L1
Neighborhood of RAN
Neighborhood of RAP1B
Neighborhood of RBBP6
Neighborhood of RTN1
Neighborhood of S100A4
Neighborhood of SELL
Neighborhood of SERPINB5
Neighborhood of SERPINI2
Neighborhood of SNRK
Neighborhood of SPI1
Neighborhood of SPINK1
Neighborhood of SPRR1B
Neighborhood of SPTA1
Neighborhood of SPTB
Neighborhood of ST13
Neighborhood of STAT6
Neighborhood of TAL1
Neighborhood of TIMP2
Neighborhood of TM4SF2
Neighborhood of TNFRSF1B
Neighborhood of TNFSF10
Neighborhood of TPT1
Neighborhood of TTK
Neighborhood of TTN
Neighborhood of TYK2
Neighborhood of UBE2I
Neighborhood of VAV1
Neighborhood of ZAP70
Ovary genes.
DRG (dorsal root ganglia) genes.
Genes in the cancer module 3.
Genes in the cancer module 4.
Lung genes.
Trachea genes.
Genes in the cancer module 7.
Genes in the cancer module 8.
Genes in the cancer module 9.
Genes in the cancer module 11.
Spinal cord (neuro-development) genes.
Genes in the cancer module 12.
Genes in the cancer module 13.
Genes in the cancer module 14.
Genes in the cancer module 15.
Genes in the cancer module 17.
Genes in the cancer module 18.
Adrenal gland - metabolic genes.
Genes in the cancer module 20.
Genes in the cancer module 21.
Genes in the cancer module 22.
Liver genes - metabolism and xenobiotics.
Fetal liver genes - metabolism and xenobiotics.
Genes in the cancer module 25.
Genes in the cancer module 26.
Genes in the cancer module 27.
Genes in the cancer module 28.
Genes in the cancer module 29.
Genes in the cancer module 32.
Immune / stress response genes.
Genes in the cancer module 35.
Genes in the cancer module 36.
Genes in the cancer module 37.
Placenta genes.
Genes in the cancer module 39.
Organic acid metabolism.
Genes in the cancer module 41.
Genes in the cancer module 42.
Energy pathways.
Thymus genes.
Whole blood genes.
Genes in the cancer module 46.
ECM and collagens.
Genes in the cancer module 48.
Genes in the cancer module 49.
Genes in the cancer module 50.
Genes in the cancer module 51.
Cell line expressed genes.
Cell line expressed genes.
Cell cycle (expression cluster).
Genes in the cancer module 55.
Cell cycle (KEGG, GenMapp).
Genes in the cancer module 57.
Genes in the cancer module 58.
Genes in the cancer module 59.
Heart genes.
Genes in the cancer module 61.
Genes in the cancer module 62.
Porins / transporters.
Membranal receptors.
Genes in the cancer module 65.
Genes in the cancer module 66.
Genes in the cancer module 67.
Genes in the cancer module 68.
Genes in the cancer module 69.
Genes in the cancer module 70.
Genes in the cancer module 71.
Testis genes.
Genes in the cancer module 73.
Immune response.
Inflammatory response.
Genes in the cancer module 77.
AA metabolism.
Genes in the cancer module 79.
Genes in the cancer module 80.
Genes in the cancer module 81.
Genes in the cancer module 82.
Genes in the cancer module 83.
Immune (humoral) and inflammatory response.
Genes in the cancer module 85.
Small monomeric GTPases.
Genes in the cancer module 87.
Heart, liver, kidney and pancreas metabolic and xenobiotic response genes.
Genes in the cancer module 89.
Genes in the cancer module 90.
Proteasome.
Secreted signaling molecules.
Oxidoreductases.
Signaling.
Genes in the cancer module 95.
Genes in the cancer module 96.
Genes in the cancer module 97.
Genes in the cancer module 98.
Genes in the cancer module 99.
Genes in the cancer module 100.
Genes in the cancer module 101.
Nucleotide (purine) biosynthesis.
Genes in the cancer module 103.
Genes in the cancer module 104.
Genes in the cancer module 105.
Cytochrome P450.
Genes in the cancer module 107.
Genes in the cancer module 108.
Serine proteases.
Genes in the cancer module 110.
Genes in the cancer module 111.
Genes in the cancer module 112.
Genes in the cancer module 113.
Protein biosynthesis and ribosomes.
Genes in the cancer module 115.
Genes in the cancer module 116.
Signaling.
cell line expressed genes.
Genes in the cancer module 119.
Genes in the cancer module 120.
Genes in the cancer module 121.
Adhesion molecules.
Genes in the cancer module 123.
Transcription.
Genes in the cancer module 125.
Lymphoma and immune response expression clusters.
Genes in the cancer module 127.
Genes in the cancer module 128.
Signaling.
Complement.
Blood coagulation factors.
Genes in the cancer module 132.
Genes in the cancer module 133.
Genes in the cancer module 134.
Genes in the cancer module 135.
Genes in the cancer module 136.
CNS genes.
Genes in the cancer module 138.
Genes in the cancer module 139.
Genes in the cancer module 141.
Genes in the cancer module 143.
Genes in the cancer module 145.
Genes in the cancer module 146.
GPCR.
Genes in the cancer module 148.
Translation factors.
Ttranslation elongation.
Genes in the cancer module 151.
Oxidative phosphorylation and ATP synthesis.
Genes in the cancer module 153.
Intermediate filaments.
Genes in the cancer module 155.
Genes in the cancer module 156.
Genes in the cancer module 157.
DNA replication.
Translation regulation.
tRNA synthesis.
Genes in the cancer module 162.
Genes in the cancer module 163.
Enzyme inhibitors (esp serine proteases).
Genes in the cancer module 165.
Genes in the cancer module 166.
Genes in the cancer module 168.
Immune response.
Immune response.
Genes in the cancer module 171.
Genes in the cancer module 172.
Genes in the cancer module 173.
Genes in the cancer module 174.
Genes in the cancer module 175.
Signaling.
Genes in the cancer module 177.
Genes in the cancer module 178.
Blood cells and cancer expression cancer.
Genes in the cancer module 180.
Genes in the cancer module 181.
Genes in the cancer module 182.
RNA splicing.
Genes in the cancer module 184.
Genes in the cancer module 186.
Genes in the cancer module 188.
Genes in the cancer module 189.
IGFBPs.
Genes in the cancer module 191.
Genes in the cancer module 192.
Genes in the cancer module 194.
Breast cancer expression clusters.
Genes in the cancer module 196.
Genes in the cancer module 197.
Genes in the cancer module 198.
Genes in the cancer module 199.
Genes in the cancer module 200.
Genes in the cancer module 201.
Genes in the cancer module 202.
Genes in the cancer module 203.
Genes in the cancer module 204.
Genes in the cancer module 205.
Genes in the cancer module 206.
Genes in the cancer module 207.
Genes in the cancer module 208.
Catabolic peptidases.
Genes in the cancer module 210.
Genes in the cancer module 211.
Catalytic activities / metabolism.
NCI cell lines expression clusters.
Ion channels.
Neurotransmitter (GABA) receptor.
Genes in the cancer module 218.
Genes in the cancer module 219.
Developmental processes.
Fatty acid metabolism.
Genes in the cancer module 222.
Immune (defense) response.
Genes in the cancer module 226.
Genes in the cancer module 227.
Genes in the cancer module 229.
Genes in the cancer module 233.
Bone remodeling.
AA and sulfur metabolism.
Genes in the cancer module 236.
Genes in the cancer module 237.
Genes in the cancer module 238.
Genes in the cancer module 239.
Genes in the cancer module 240.
Genes in the cancer module 241.
Genes in the cancer module 242.
Genes in the cancer module 243.
Response to DNA damage.
Genes in the cancer module 245.
Xenobiotic metabolism.
Genes in the cancer module 248.
Genes in the cancer module 249.
TFs and nuclear.
Intracellular transport (MT cytoskeleton and motors).
Genes in the cancer module 254.
Genes in the cancer module 255.
Genes in the cancer module 256.
Genes in the cancer module 257.
RTK signaling.
Genes in the cancer module 262.
Cell ion homeostasis / chemokines.
Chemotaxis (chemokines).
Genes in the cancer module 264.
Caner module 265: IL receptors.
Genes in the cancer module 267.
Genes in the cancer module 272.
Phosphate metabolism.
Vesicular transport / synapse genes.
Genes in the cancer module 275.
Genes in the cancer module 277.
Ubiquitin ligases.
Genes in the cancer module 279.
Metal ion (zinc) binding.
Phosphatase regulators.
Genes in the cancer module 284.
Genes in the cancer module 285.
Genes in the cancer module 286
Genes in the cancer module 287.
Genes in the cancer module 288.
Genes in the cancer module 289.
B-cell malignancies expression clusters.
Genes in the cancer module 292.
Genes in the cancer module 293.
Genes in the cancer module 294.
Genes in the cancer module 295.
Genes in the cancer module 297.
Keratin.
Genes in the cancer module 299.
Programmed cell death.
Genes in the cancer module 301.
Genes in the cancer module 303.
CoA and fatty acid metabolism.
Glycolysis and TCA cycle.
Oxidative phosphorylation (COX and ATPases).
Pol II transcription.
ROS metabolism.
Genes in the cancer module 311.
Viral anti-apoptotic evasion mechanisms.
Genes in the cancer module 313.
Spindle and kinetochore.
Ion channels.
Genes in the cancer module 317.
Genes in the cancer module 318.
Cancer module 320: M phase.
Genes in the cancer module 321.
Genes in the cancer module 322.
Genes in the cancer module 323.
Metal / Ca ion binding.
Genes in the cancer module 325.
Genes in the cancer module 326.
Genes in the cancer module 327.
AcetylCholine receptors.
Genes in the cancer module 329.
Genes in the cancer module 330.
Genes in the cancer module 331.
Genes in the cancer module 332.
Genes in the cancer module 333.
Genes in the cancer module 334.
Genes in the cancer module 335.
Nucleotide metabolism.
Genes in the cancer module 340.
Genes in the cancer module 341.
Genes in the cancer module 342.
Nitrogen metabolism.
Immune response and Ag processing and presentation.
Genes in the cancer module 346.
Genes in the cancer module 349.
Genes in the cancer module 350.
Nuclear pore complex.
AA biosynthesis.
Protein folding.
Genes in the cancer module 356.
Intermediate filaments and keratins.
B lymphoma expression clusters.
Genes in the cancer module 360.
B lymphoma expression clusters.
Angiogenesis.
Genes in the cancer module 363.
Breast cancer expression clusters.
Genes in the cancer module 367.
Peptide and AA transporters.
Genes in the cancer module 371.
Genes in the cancer module 372.
Oxidoreductases.
GPCR signaling pathways (immune and neuro).
Energy pathways and carbohydrate metabolism.
Genes in the cancer module 378.
Genes in the cancer module 379.
Genes in the cancer module 381.
Peptide hormones.
Heparin binding.
Genes in the cancer module 387.
Spliceosome.
Breast cancer expression clusters.
rRNA processing and DNA repair.
Genes in the cancer module 395.
Genes in the cancer module 396.
Genes in the cancer module 397.
Genes in the cancer module 399.
Genes in the cancer module 400.
Genes in the cancer module 401.
Genes in the cancer module 402.
DNA damage response.
Steroid hormone receptors and binding proteins.
Growth suppressors.
Genes in the cancer module 408.
Cell adhesion.
Genes in the cancer module 411.
Genes in the cancer module 412.
Genes in the cancer module 414.
Genes in the cancer module 415.
Genes in the cancer module 416.
Genes in the cancer module 417.
Genes in the cancer module 418.
Genes in the cancer module 419.
Chromatin.
Genes in the cancer module 424.
Genes in the cancer module 426.
Genes in the cancer module 427.
Genes in the cancer module 429.
Genes in the cancer module 430.
Eicosanoid metabolism.
Genes in the cancer module 432.
Cytokines and GFs.
Genes in the cancer module 436.
Intermediate filaments and MT.
Genes in the cancer module 439.
Urea cycle metabolism.
Genes in the cancer module 444.
Genes in the cancer module 445.
Genes in the cancer module 447.
Genes in the cancer module 448.
Genes in the cancer module 451.
Genes in the cancer module 453.
Genes in the cancer module 454.
Genes in the cancer module 455.
B lymphoma expression clusters.
Genes in the cancer module 457.
Genes in the cancer module 458.
Genes in the cancer module 459.
Eicosanoid metabolism (and related carboxylic acid biosynthesis).
Oxidoreductases.
Genes in the cancer module 465.
Genes in the cancer module 470.
Genes in the cancer module 471.
Genes in the cancer module 474.
Genes in the cancer module 478.
Breast cancer expression clusters.
Genes in the cancer module 481.
Genes in the cancer module 484.
Genes in the cancer module 485.
Genes in the cancer module 486.
Growth inhibitory genes.
Genes in the cancer module 489.
Genes in the cancer module 491.
Genes in the cancer module 492.
Genes in the cancer module 493.
Genes in the cancer module 495.
CNS development.
Genes in the cancer module 500.
Genes in the cancer module 501.
Genes in the cancer module 503.
Steroid hormone and heme metabolism.
Genes in the cancer module 509.
Genes in the cancer module 511.
Muscle genes.
Genes in the cancer module 514.
Genes in the cancer module 516.
Oxidoreductases.
T-cell proliferation genes.
Immune response genes.
Actin cytoskeleton binding.
Genes in the cancer module 525.
Genes in the cancer module 528.
ROS (glutathione, ox stress).
Blood cells and cancer expression clusters.
Genes in the cancer module 533.
Genes in the cancer module 534.
Anti-apoptosis.
Genes in the cancer module 539.
Iron ion homeostasis.
Annexin, MHCII, and lectins.
Genes in the cancer module 544.
IL-1 signaling.
Genes in the cancer module 547.
Chromatin and nucleosomes.
Genes in the cancer module 557.
Genes in the cancer module 560.
MMPs.
Genes in the cancer module 563.
Genes in the cancer module 567.
Genes in the cancer module 568.
Genes in the cancer module 571.
Cell cycle regulators and carbohydrate transporters.
Complement and cAMP signaling.
Genes in the cancer module 576.
Any process that activates or increases the frequency, rate or extent of viral transcription.
The progression of a cardiac chamber over time, from its formation to the mature structure. A cardiac chamber is an enclosed cavity within the heart.
A DNA metabolic process that prevents or corrects errors to ensure that DNA is replicated accurately. Errors can be corrected either by intrinsic DNA polymerase proofreading activity or via mismatch repair.
Any biological process in an organism that recurs with a regularity of approximately 24 hours.
Remodeling the acyl chains of phosphatidylserine, through sequential deacylation and re-acylation reactions, to generate phosphatidylserine containing different types of fatty acid acyl chains.
The process whose specific outcome is the progression of the spinal cord over time, from its formation to the mature structure. The spinal cord primarily conducts sensory and motor nerve impulses between the brain and the peripheral nervous tissues.
The series of molecular signals generated as a consequence of a platelet-derived growth factor receptor binding to one of its physiological ligands.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipoprotein particle stimulus.
Any process that modulates the frequency, rate or extent of NLRP3 inflammasome complex assembly.
Any process that activates or increases the frequency, rate or extent of epithelial cell differentiation.
Any process that activates or increases the frequency, rate or extent of kinase activity, the catalysis of the transfer of a phosphate group, usually from ATP, to a substrate molecule.
Any process that stops, prevents, or reduces the frequency, rate or extent of the movement of a transcription factor from the cytoplasm to the nucleus.
The directed movement of potassium ions (K+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
Any process that modulates the frequency, rate or extent of signaling pathways initiated by the cross-linking of an antigen receptor on a T cell.
The process in which cardiac muscle adapts, with consequent modifications to structural and/or functional phenotypes, in response to a stimulus. Stimuli include contractile activity, loading conditions, substrate supply, and environmental factors.
Any process that stops, prevents or reduces the rate or extent of epithelial cell proliferation.
The directed movement of an organism or motile cell on, within or near a second organism, where the two organisms are in a symbiotic interaction.
Any process that modulates the frequency, rate or extent of protein targeting to mitochondrion.
Any process in which a protein is transported to, or maintained in, apical regions of the cell.
Any process that modulates the rate, frequency or extent of the establishment of planar polarity, the coordinated organization of groups of cells in a tissue, such that they all orient to similar coordinates.
The process whose specific outcome is the progression of a neuron that resides in the forebrain, from its initial commitment to its fate, to the fully functional differentiated cell.
Any process that activates or increases the frequency, rate or extent of protein maturation.
A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a neuromuscular junction.
A cell cycle process that results in the division of the cytoplasm of a cell after mitosis, resulting in the separation of the original cell into two daughter cells.
Any process that stops, prevents or reduces the frequency, rate or extent of a response to endoplasmic reticulum stress.
The cascade of processes by which a signal interacts with a receptor, causing a change in the activity of a SMAD protein, and ultimately effecting a change in the functioning of the cell.
The chemical reactions and pathways resulting in the formation of a protein in the cytoplasm. This is a ribosome-mediated process in which the information in messenger RNA (mRNA) is used to specify the sequence of amino acids in the protein.
The process in which genetic material, in the form of chromosomes, is organized into specific structures and then physically separated and apportioned to two or more sets during M phase of the meiotic cell cycle.
Any process that activates or increases the frequency, rate or extent of the directed movement of calcium ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
Any process that modulates the frequency, rate or extent of double-strand break repair.
A DNA biosynthetic process that uses RNA as a template for RNA-dependent DNA polymerases (e.g. reverse transcriptase) that synthesize the new strand.
Any process that modulates the frequency, rate or extent of signaling pathways initiated by the cross-linking of an antigen receptor on a B cell.
Any process that modulates the frequency, rate or extent of G-protein coupled receptor protein signaling pathway activity.
The process whose specific outcome is the progression of the dendrite over time, from its formation to the mature structure. A dendrite is a freely branching protoplasmic process of a nerve cell.
Any process that modulates the rate frequency or extent of a phase of elevated metabolic activity, during which oxygen consumption increases; this leads to the production, by an NADH dependent system, of hydrogen peroxide (H2O2), superoxide anions and hydroxyl radicals.
The process that results in the uptake of a G-protein coupled receptor into an endocytic vesicle.
The activities involved in the mental information processing system that receives (registers), modifies, stores, and retrieves informational stimuli. The main stages involved in the formation and retrieval of memory are encoding (processing of received information by acquisition), storage (building a permanent record of received information as a result of consolidation) and retrieval (calling back the stored information and use it in a suitable way to execute a given task).
The process whose specific outcome is the progression of a neuron over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell.
Any process that modulates the frequency, rate or extent of Golgi organization.
The progression of an endothelial cell over time, from its formation to the mature structure.
Any process that increases the frequency, rate or extent of myotube differentiation. Myotube differentiation is the process in which a relatively unspecialized cell acquires specialized features of a myotube cell. Myotubes are multinucleated cells that are formed when proliferating myoblasts exit the cell cycle, differentiate and fuse.
Any process that modulates the frequency, rate or extent of cell activation, the change in the morphology or behavior of a cell resulting from exposure to an activating factor such as a cellular or soluble ligand.
An aging process that has as participant a whole multicellular organism. Multicellular organism aging includes loss of functions such as resistance to disease, homeostasis, and fertility, as well as wear and tear. Multicellular organisms aging includes processes like cellular senescence and organ senescence, but is more inclusive. May precede death (GO:0016265) of an organism and may succeed developmental maturation (GO:0021700).
Dynamic structural changes to eukaryotic chromatin that require energy from the hydrolysis of ATP, ranging from local changes necessary for transcriptional regulation to global changes necessary for chromosome segregation, mediated by ATP-dependent chromatin-remodelling factors.
The developmental process pertaining to the initial formation of an anatomical structure from unspecified parts. This process begins with the specific processes that contribute to the appearance of the discrete structure and ends when the structural rudiment is recognizable. An anatomical structure is any biological entity that occupies space and is distinguished from its surroundings. Anatomical structures can be macroscopic such as a carpel, or microscopic such as an acrosome.
The directed movement of charged atoms or small charged molecules into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
The covalent alteration of one or more fatty acids in a lipid, resulting in a change in the properties of the lipid.
Any process that decreases the rate, frequency or extent of kidney development. Kidney development is the process whose specific outcome is the progression of the kidney over time, from its formation to the mature structure. The kidney is an organ that filters the blood and excretes the end products of body metabolism in the form of urine.
Any process that modulates the frequency, rate or extent of hepatocyte proliferation.
Any process involved in the maintenance of an internal steady state of acylglycerol within an organism or cell.
Any process that stops or reduces the activity of a phosphoprotein phosphatase.
Any process that stops, prevents, or reduces the frequency, rate or extent of protein complex assembly.
The chemical reactions and pathways involving hemoglobin, including its uptake and utilization.
The union of male and female gametes to form a zygote.
A change in morphology and behavior of a leukocyte resulting from exposure to a specific antigen, mitogen, cytokine, cellular ligand, or soluble factor.
A process that is carried out at the cellular level that results in the assembly, arrangement of constituent parts, or disassembly of chromosomes, structures composed of a very long molecule of DNA and associated proteins that carries hereditary information. This term covers covalent modifications at the molecular level as well as spatial relationships among the major components of a chromosome.
Any process that modulates the frequency, rate or extent of the change in the membrane potential of the mitochondria from negative to positive.
Any process that stops, prevents, or reduces the frequency, rate or extent of MAP kinase activity.
Any process in which a synaptic vesicle or vesicles are transported to, and/or maintained in, a specific location.
The chemical reactions and pathways involving a phenol, any compound containing one or more hydroxyl groups directly attached to an aromatic carbon ring.
Any process that modulates the frequency, rate or extent of signaling pathways initiated by the cross-linking of an antigen receptor on a B- or T cell.
Any process that set the alignment of spindle relative to other cellular structures.
The process in which the anatomical structures of the metanephric nephron are generated and organized. A metanephric nephron is the functional unit of the metanephros.
The chemical reactions and pathways involving glyceraldehyde-3-phosphate, an important intermediate in glycolysis.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a UV-C radiation stimulus. UV-C radiation (UV-C light) spans the wavelengths 100 to 280 nm.
The chemical reactions and pathways resulting in the breakdown of carbohydrates, any of a group of organic compounds based of the general formula Cx(H2O)y.
The process whose specific outcome is the progression of the dentate gyrus over time, from its formation to the mature structure. The dentate gyrus is one of two interlocking gyri of the hippocampus. It contains granule cells, which project to the pyramidal cells and interneurons of the CA3 region of the ammon gyrus.
The directed movement of ions to establish or maintain an electrochemical gradient across a membrane by means of some agent such as a transporter or pore.
The process in which the labyrinthine layer of the placenta progresses, from its formation to its mature state.
The acetylation of the N-terminal amino acid of proteins.
A organ system process carried out by any of the organs or tissues of neurological system.
The self-renewing division of a neuronal stem cell.
The chemical reactions and pathways resulting in the breakdown of ceramides, any N-acetylated sphingoid.
The elimination by an organism of the waste products that arise as a result of metabolic activity. These products include water, carbon dioxide (CO2), and nitrogenous compounds.
The whole of the physical, chemical, and biochemical processes carried out by multicellular organisms to break down ingested nutrients into components that may be easily absorbed and directed into metabolism.
Any process that activates, maintains or increases the frequency, rate or extent of glutamatergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter glutamate.
Any process that activates or increases the frequency, rate or extent of mitosis.
The process whose specific outcome is the progression of the hindbrain over time, from its formation to the mature structure. The hindbrain is the posterior of the three primary divisions of the developing chordate brain, or the corresponding part of the adult brain (in vertebrates, includes the cerebellum, pons, and medulla oblongata and controls the autonomic functions and equilibrium).
The chemical reactions and pathways involving oligosaccharides, molecules with between two and (about) 20 monosaccharide residues connected by glycosidic linkages.
Any process that decreases the rate, frequency, or extent of dendritic spine development, the process whose specific outcome is the progression of the dendritic spine over time, from its formation to the mature structure.
Any process that modulates the frequency, rate or extent of the increase in size or mass of an organism occurring in, on or near the exterior of its host organism.
The process in which genetic material, in the form of chromosomes, is organized into specific structures and then physically separated and apportioned to two or more sets. In eukaryotes, chromosome segregation begins with the condensation of chromosomes, includes chromosome separation, and ends when chromosomes have completed movement to the spindle poles.
Any process that stops, prevents or reduces the frequency, rate or extent of cyclin-dependent protein kinase activity.
The chemical reactions and pathways involving organic ethers, any anhydride of the general formula R1-O-R2, formed between two identical or nonidentical organic hydroxy compounds.
The process in which precursor cell type acquires the specialized features of a hematopoietic progenitor cell, a class of cell types including myeloid progenitor cells and lymphoid progenitor cells.
The chemical reactions and pathways involving cytokines, any of a group of proteins or glycoproteins that function to control the survival, growth and differentiation of tissues and cells, and which have autocrine and paracrine activity.
The directed movement of organelles or molecules along microtubules from the cell body toward the cell periphery in nerve cell axons.
Any process that stops, prevents, or reduces the frequency, rate or extent of signal transduction mediated by the ERK1 and ERK2 cascade.
The chemical reactions and pathways resulting in the formation of steroids, compounds with a 1,2,cyclopentanoperhydrophenanthrene nucleus; includes de novo formation and steroid interconversion by modification.
The chemical reactions and pathways involving alditol phosphates, any phosphorylated polyhydric alcohol derived from the acyclic form of a monosaccharide by reduction of its aldehyde or keto group to an alcoholic group.
The directed, sodium-independent, movement of organic anions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
Any process that modulates the rate, frequency, or extent of protein tyrosine kinase activity.
Any process that modulates the frequency, rate, or extent of interferon-beta production.
The extension of an RNA molecule after transcription initiation and promoter clearance at a DNA-dependent RNA polymerase promoter by the addition of ribonucleotides catalyzed by an RNA polymerase.
The conversion of N-linked glycan (N = nitrogen) structures from the initially transferred oligosaccharide to a mature form, by the actions of glycosidases and glycosyltransferases. The early processing steps are conserved and play roles in glycoprotein folding and trafficking.
The directed movement of inorganic ions from outside of a cell into the cytoplasmic compartment. This may occur via transport across the plasma membrane or via endocytosis.
The directed movement of substances from endoplasmic reticulum to cytosol.
Any process that stops, prevents, or reduces the frequency, rate or extent of reproductive process.
The series of molecular signals generated as a consequence of a receptor binding to an extracellular purine or purine derivative and transmitting the signal to a heterotrimeric G-protein complex to initiate a change in cell activity.
The process in which membrane potential decreases with respect to its steady-state potential, usually from negative potential to a more positive potential. For example, the initial depolarization during the rising phase of an action potential is in the direction from the negative steady-state resting potential towards the positive membrane potential that will be the peak of the action potential.
The process in which a neuroblast acquires specialized features of an interneuron residing in the olfactory bulb.
Any process that activates or increases the frequency, rate or extent of G-protein coupled receptor protein signaling pathway activity.
The process in which spindle microtubules become physically associated with the proteins making up the kinetochore complex.
Any process that modulates the frequency, rate or extent of lyase activity, the catalysis of the cleavage of C-C, C-O, C-N and other bonds by other means than by hydrolysis or oxidation, or conversely adding a group to a double bond. They differ from other enzymes in that two substrates are involved in one reaction direction, but only one in the other direction. When acting on the single substrate, a molecule is eliminated and this generates either a new double bond or a new ring.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nitrogen compound stimulus.
Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of a solute from one side of a membrane to the other.
Any process that modulates the frequency, rate or extent of DNA recombination, a DNA metabolic process in which a new genotype is formed by reassortment of genes resulting in gene combinations different from those that were present in the parents.
Any process that modulates the frequency, rate or extent of leukocyte proliferation.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an ethanol stimulus.
The chemical reactions and pathways involving the nonmetallic element sulfur or compounds that contain sulfur, such as the amino acids methionine and cysteine or the tripeptide glutathione.
Any process that activates or increases the frequency, rate or extent of the introduction of a phosphate group to a tyrosine residue of a Stat1 protein.
Any process that modulates the frequency, rate or extent of cell cycle checkpoint.
Any process that stops, prevents or reduces the frequency, rate or extent of transcription regulatory region DNA binding.
Any process that activates or increases the frequency, rate or extent of DNA replication.
Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process in neurons.
Any process that activates or increases the frequency, rate or extent of reproductive process.
Any process that increases the rate, frequency or extent of metanephros development. Metanephros development is the process whose specific outcome is the progression of the metanephros over time, from its formation to the mature structure. The metanephros is an organ that filters the blood and excretes the end products of body metabolism in the form of urine.
Any process that activates or increases the frequency, rate or extent of lymphocyte death by apoptotic process.
The process of introducing one or more phosphate groups into a nucleotide to produce a phosphorylated nucleoside.
Any epigenetic process that activates or increases the rate of gene expression.
The controlled release of glutamate by a cell. The glutamate is the most abundant excitatory neurotransmitter in the nervous system.
Any process that modulates the frequency, rate or extent of mRNA metabolic process.
Any process that activates or increases the frequency, rate or extent of protein binding.
Any process that modulates the frequency, rate or extent of the movement of an NFAT protein from the cytoplasm to the nucleus.
Any process that modulates the frequency, rate or extent of vasculogenesis.
The process in which a relatively unspecialized cell acquires specialized features of a lens fiber cell, any of the elongated, tightly packed cells that make up the bulk of the mature lens in the camera-type eye. The cytoplasm of a lens fiber cell is devoid of most intracellular organelles including the cell nucleus, and contains primarily crystallins, a group of water-soluble proteins expressed in vary large quantities.
The series of events required for an organism to receive a sensory stimulus, convert it to a molecular signal, and recognize and characterize the signal. This is a neurological process.
The progression of the hepaticobiliary system over time, from its formation to the mature structure. The hepaticobiliary system is responsible for metabolic and catabolic processing of small molecules absorbed from the blood or gut, hormones and serum proteins, detoxification, storage of glycogen, triglycerides, metals and lipid soluble vitamins and excretion of bile. Included are the synthesis of albumin, blood coagulation factors, complement, and specific binding proteins.
The chemical reactions and pathways resulting in the breakdown of a fatty acid, any of the aliphatic monocarboxylic acids that can be liberated by hydrolysis from naturally occurring fats and oils. Fatty acids are predominantly straight-chain acids of 4 to 24 carbon atoms, which may be saturated or unsaturated; branched fatty acids and hydroxy fatty acids also occur, and very long chain acids of over 30 carbons are found in waxes.
Any process that modulates the frequency, rate or extent of vesicle fusion.
The biogenesis of a mitochondrial respiratory chain complex I, a protein complex located in the mitochondrial inner membrane that forms part of the mitochondrial respiratory chain. Includes the synthesis of constituent proteins and their aggregation, arrangement and bonding together.
Any process that modulates the rate, frequency or extent of lipid storage. Lipid storage is the accumulation and maintenance in cells or tissues of lipids, compounds soluble in organic solvents but insoluble or sparingly soluble in aqueous solvents. Lipid reserves can be accumulated during early developmental stages for mobilization and utilization at later stages of development.
The directed movement of carbohydrate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Carbohydrates are any of a group of organic compounds based of the general formula Cx(H2O)y.
Any process that modulates the rate, frequency, or extent of a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a growth factor stimulus.
The stages of blood cell formation that take place within the embryo.
The process whose specific outcome is the progression of an embryo over time, from zygote formation until the end of the embryonic life stage. The end of the embryonic life stage is organism-specific and may be somewhat arbitrary; for mammals it is usually considered to be birth, for insects the hatching of the first instar larva from the eggshell.
The process in which an antigen-presenting cell expresses antigen (peptide or polysaccharide) on its cell surface in association with an MHC class II protein complex.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a ionizing radiation stimulus. Ionizing radiation is radiation with sufficient energy to remove electrons from atoms and may arise from spontaneous decay of unstable isotopes, resulting in alpha and beta particles and gamma rays. Ionizing radiation also includes X-rays.
The directed movement of a protein from the nucleus into the cytoplasm.
The process whose specific outcome is the progression of an epithelium over time, from its formation to the mature structure. An epithelium is a tissue that covers the internal or external surfaces of an anatomical structure.
Any process that activates or increases the frequency, rate or extent of the binding or confining calcium ions such that they are separated from other components of a biological system.
The chemical reactions and pathways resulting in the formation of secondary metabolites, the compounds that are not necessarily required for growth and maintenance of cells, and are often unique to a taxon.
The orderly movement of a cell from one site to another that will contribute to the progression of the heart over time, from its initial formation, to the mature organ.
A process in which a protein is transported to, or maintained in, a location within the cytoskeleton.
The reformation of the nuclear envelope following its breakdown in the context of a normal process.
A series of molecular signals in which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The pathway is induced by the cell cycle regulator phosphoprotein p53, or an equivalent protein, in response to the detection of DNA damage, and ends when the execution phase of apoptosis is triggered.
Any process that modulates the frequency, rate or extent of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm.
The chemical reactions and pathways involving phospholipids, any lipid containing phosphoric acid as a mono- or diester.
The chemical reactions and pathways involving the ammonium ion.
Any process that modulates the frequency, rate, or extent of interleukin-4 production.
The chemical reactions and pathways resulting in the breakdown of non-coding RNA transcripts (ncRNAs). Includes the breakdown of cryptic unstable transcripts (CUTs).
Any process that modulates the frequency, rate or extent of adipocyte differentiation.
The chemical reactions and pathways resulting in the formation of amino acids of the glutamine family, comprising arginine, glutamate, glutamine and proline.
Any process that modulates the frequency, rate or extent of protein activation cascade.
Any process that modulates the frequency, rate or extent of telomerase RNA localization to Cajal body.
Any process that modulates the propensity of RNA molecules to degradation. Includes processes that both stabilize and destabilize RNAs.
The process that mediates interactions between a bundle of His cell and its surroundings that contributes to the process of the bundle of His cell communicating with a Purkinje myocyte in cardiac conduction. Encompasses interactions such as signaling or attachment between one cell and another cell, between a cell and an extracellular matrix, or between a cell and any other aspect of its environment.
Any process that modulates the frequency, rate or extent of cell maturation.
Any process that decreases the rate, frequency or extent of the progression of the cell over time, from its formation to the mature structure. Cell development does not include the steps involved in committing a cell to a specific fate.
The process in which anatomical structures of the mammary gland are generated and organized. Morphogenesis refers to the creation of shape. The mammary gland is a large compound sebaceous gland that in female mammals is modified to secrete milk.
The disaggregation of a protein complex into its constituent components, occurring at the level of an individual cell. Protein complexes may have other associated non-protein prosthetic groups, such as nucleic acids, metal ions or carbohydrate groups.
Any process that modulates the frequency, rate or extent of cytokine production involved in inflammatory response.
The process whose specific outcome is the progression of the ureter over time, from its formation to the mature structure. The ureter is a muscular tube that transports urine from the kidney to the urinary bladder or from the Malpighian tubule to the hindgut.
The process in which the anatomical structures of the soma are generated and organized.
Any process by which an organism retains a population of somatic stem cells, undifferentiated cells in the embryo or adult which can undergo unlimited division and give rise to cell types of the body other than those of the germ-line.
A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of structures formed of microtubules and associated proteins in the cytoplasm of a cell.
Any process that activates, maintains or increases the rate of the cascade of processes induced by the cell cycle regulator phosphoprotein p53, or an equivalent protein, in response to the detection of DNA damage.
A response to a stimulus that consists of a sequential series of modifications to a set of proteins where the product of one reaction acts catalytically in the following reaction. The magnitude of the response is typically amplified at each successive step in the cascade. Modifications typically include proteolysis or covalent modification, and may also include binding events.
Any process that increases the frequency, rate or extent of phospholipase activity, the hydrolysis of a phospholipid.
Any process that stops, prevents, or reduces the frequency, rate or extent of the phosphorylation of peptidyl-tyrosine.
Any process that modulates the frequency, rate or extent of collateral sprouting.
Any cellular process that results in the specification, formation or maintenance of monopolar intracellular organization or cell growth patterns. Monopolar cell organization is directional organization along an axis.
The process in which a neuronal cell in a multicellular organism interprets its surroundings.
The chemical reactions and pathways involving a nucleoside diphosphate, a compound consisting of a nucleobase linked to a deoxyribose or ribose sugar esterified with diphosphate on the sugar.
Assembly or disassembly of microtubules by the addition or removal of tubulin heterodimers from a microtubule.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an ammonium ion stimulus.
Any process that modulates the frequency, rate, or extent of interleukin-5 production.
Any process that modulates the frequency, rate or extent of the import of the hexose monosaccharide glucose into a cell or organelle.
Any process that stops, prevents, or reduces the frequency, rate or extent of the hydrolysis of a peptide bond or bonds within a protein.
An endocytosis process that results in the uptake of liquid material by cells from their external environment; literally 'cell drinking'. Liquid is enclosed in vesicles, called pinosomes, formed by invagination of the plasma membrane.
Any process that modulates the frequency, rate or extent of epithelial cell apoptotic process.
The chemical reactions and pathways involving phosphatidylethanolamine, any of a class of glycerophospholipids in which a phosphatidyl group is esterified to the hydroxyl group of ethanolamine. It is a major structural phospholipid in mammalian systems. It tends to be more abundant than phosphatidylcholine in the internal membranes of the cell and is an abundant component of prokaryotic membranes.
The chemical reactions and pathways involving phosphatidylcholines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of choline. They are important constituents of cell membranes.
The biological process whose specific outcome is the progression of the lung epithelium from an initial condition to its mature state. This process begins with the formation of lung epithelium and ends with the mature structure. The lung epithelium is the specialized epithelium that lines the inside of the lung.
The process whose specific outcome is the progression of the metencephalon over time, from its formation to the mature structure.
The series of molecular signals generated as a consequence of a receptor binding to an extracellular purine nucleotide and transmitting the signal to a heterotrimeric G-protein complex to initiate a change in cell activity.
A process that results in the assembly, arrangement of constituent parts, or disassembly of an actin filament bundle.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a virus.
The aggregation, arrangement and bonding together of proteins and RNA molecules to form a cytoplasmic mRNA processing body.
The process of gaseous exchange between an organism and its environment. In plants, microorganisms, and many small animals, air or water makes direct contact with the organism's cells or tissue fluids, and the processes of diffusion supply the organism with dioxygen (O2) and remove carbon dioxide (CO2). In larger animals the efficiency of gaseous exchange is improved by specialized respiratory organs, such as lungs and gills, which are ventilated by breathing mechanisms.
Any process that stops, prevents or reduces the frequency, rate or extent of protein modification by small protein conjugation or removal.
The modification of an amino acid to an active form, for incorporation into a peptide, protein or other macromolecule.
The process in which a precursor cell type acquires the specialized features of a dendritic cell. A dendritic cell is a leukocyte of dendritic lineage specialized in the uptake, processing, and transport of antigens to lymph nodes for the purpose of stimulating an immune response via T cell activation.
The process in which a relatively unspecialized cell acquires the specialized features of a natural killer cell.
The process of shaping a trabecula in bone. A trabecula is a tissue element in the form of a small beam, strut or rod.
Any process that modulates the frequency, rate, or extent of an inflammatory response to an antigenic stimulus.
Any process that modulates the frequency, rate or extent of the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, and mediated by the proteasome.
Any process that stops, prevents, or reduces the frequency, rate or extent of neuron differentiation.
Any process that modulates the frequency, rate or extent of skeletal muscle tissue development.
The progression of muscle tissue over time, from its initial formation to its mature state. Muscle tissue is a contractile tissue made up of actin and myosin fibers.
Any process that stops, prevents or decreases the rate of the phosphorylation by a protein of one or more of its own residues.
The controlled release of acid by a cell or a tissue.
Any process that activates or increases the frequency, rate, or extent of an adaptive immune response.
Any process that modulates the frequency, rate or extent of osteoclast differentiation.
Any process that modulates the frequency, rate or extent of protein binding.
The progression of a cardiac septum over time, from its initial formation to the mature structure.
Any process that modulates the frequency, rate or extent of the controlled release of an icosanoid from a cell.
The directed movement of L-alpha-amino acid across a membrane.
Any process that modulates the frequency, rate or extent of the covalent addition of methyl groups to histones.
Any process that increases the rate, frequency or extent of mitochondrial fission. Mitochondrial fission is the division of a mitochondrion within a cell to form two or more separate mitochondrial compartments.
An immune response against microbes mediated through a body fluid. Examples of this process are seen in the antimicrobial humoral response of Drosophila melanogaster and Mus musculus.
The process in which the anatomical structures of the epidermis are generated and organized. The epidermis is the outer epithelial layer of an animal, it may be a single layer that produces an extracellular material (e.g. the cuticle of arthropods) or a complex stratified squamous epithelium, as in the case of many vertebrate species.
Any cellular process that depends upon or alters the intermediate filament cytoskeleton, that part of the cytoskeleton comprising intermediate filaments and their associated proteins.
The operation of the mind by which an organism becomes aware of objects of thought or perception; it includes the mental activities associated with thinking, learning, and memory.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a zinc ion stimulus.
The chemical reactions and pathways involving purine deoxyribonucleotide, a compound consisting of deoxyribonucleoside (a purine base linked to a deoxyribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.
A process in which an organism has a negative effect on the functioning of the second organism's cells.
The establishment, maintenance and elaboration of a pattern along a line or around a point.
The chemical reactions and pathways involving phosphatidylinositol, any glycophospholipid in which a sn-glycerol 3-phosphate residue is esterified to the 1-hydroxyl group of 1D-myo-inositol.
The process in which the anatomical structures of a cell part are generated and organized.
Any process in which a pigment granule is transported to, and/or maintained in, a specific location within the cell.
A series of molecular signals initiated by the binding of a vascular endothelial growth factor (VEGF) to a receptor on the surface of the target cell, and ending with regulation of a downstream cellular process, e.g. transcription.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an organophosphorus stimulus. Organophosphorus is a compound containing phosphorus bound to an organic molecule; several organophosphorus compounds are used as insecticides, and they are highly toxic cholinesterase inhibitors.
The directed movement of organelles or molecules along microtubules in neuron projections.
The membrane organization process that joins two lipid bilayers to form a single membrane, involving only one organism.
Any process that modulates the frequency, rate or extent of protein ubiquitination involved in ubiquitin-dependent protein catabolic process.
The regrowth of skeletal muscle tissue to repair injured or damaged muscle fibers in the postnatal stage.
The chemical reactions and pathways resulting in the formation of a polysaccharide, a polymer of many (typically more than 10) monosaccharide residues linked glycosidically.
Any process that modulates the frequency, rate or extent of the introduction of a phosphate group to a tyrosine residue of a STAT (Signal Transducer and Activator of Transcription) protein.
The regrowth of a lost or destroyed organ.
The process in which the anatomical structures of a gland are generated and organized.
Any process that stops, prevents, or reduces the frequency, rate, or extent of an adaptive immune response.
The process in which angiotensinogen metabolites in the bloodstream modulate the force with which blood passes through the circulatory system. The process begins when renin is released and cleaves angiotensinogen.
A cellular process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of ribosome subunits; includes transport to the sites of protein synthesis.
The process of regulating the proliferation and elimination of B cells such that the total number of B cells within a whole or part of an organism is stable over time in the absence of an outside stimulus.
A series of molecular signals mediated by the endoplasmic reticulum stress sensor IRE1 (Inositol-requiring transmembrane kinase/endonuclease). Begins with activation of IRE1 in response to endoplasmic reticulum (ER) stress, and ends with regulation of a downstream cellular process, e.g. transcription. One target of activated IRE1 is the transcription factor HAC1 in yeast, or XBP1 in mammals; IRE1 cleaves an intron of a mRNA coding for HAC1/XBP1 to generate an activated HAC1/XBP1 transcription factor, which controls the up regulation of UPR-related genes. At least in mammals, IRE1 can also signal through additional intracellular pathways including JNK and NF-kappaB.
The specific behavior of a single organism in response to external or internal stimuli.
Any process that activates or increases the frequency, rate or extent of calcium ion-dependent exocytosis.
Any process that activates or increases the frequency, rate or extent of endocytosis.
Selection of a splice site by components of the assembling spliceosome.
Modulation of the frequency, rate or extent of translation as a result of a stimulus indicating the organism is under stress. The stress is usually, but not necessarily, exogenous (e.g. temperature, humidity, ionizing radiation).
Any process that decreases the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA (for protein-coding genes) and the translation of that mRNA into protein. Protein maturation is included when required to form an active form of a product from an inactive precursor form.
The chemical reactions and pathways resulting in the formation of a phenol, any compound containing one or more hydroxyl groups directly attached to an aromatic carbon ring.
Any process that activates or increases the frequency, rate or extent of erythrocyte differentiation.
The movement of a dendritic cell within or between different tissues and organs of the body.
The series of events required for an organism to receive a sensory temperature stimulus, convert it to a molecular signal, and recognize and characterize the signal. This is a neurological process.
The directed movement of substances into, out of or within a lysosome.
The chemical reactions and pathways resulting in the breakdown of substances, carried out by individual cells.
Any process that activates or increases the frequency, rate or extent of DNA biosynthetic process.
Any process that stimulates, induces or increases the rate of macrophage activation.
Any process that modulates the frequency, rate or extent of calcium-mediated signaling, the process in which a cell uses calcium ions to convert an extracellular signal into a response.
Any process that modulates the frequency, rate or extent of alpha-beta T cell activation.
The process whose specific outcome is the progression of the muscle over time, from its formation to the mature structure. The muscle is an organ consisting of a tissue made up of various elongated cells that are specialized to contract and thus to produce movement and mechanical work.
Any process that activates or increases the frequency, rate or extent of hemopoiesis.
The process in which the anatomical structures of the outflow tract septum are generated and organized. The outflow tract septum is a partition in the outflow tract.
Any process that modulates the frequency, rate or extent of mammary gland epithelial cell proliferation.
Any process that modulates the frequency, rate or extent of phosphatidylinositol 3-kinase activity, the catalysis of the transfer of a phosphate group, usually from ATP, to an inositol lipid at the 3' position of the inositol ring.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an epidermal growth factor stimulus.
The regulated exocytosis of secretory granules by a leukocyte.
The process of regulating the proliferation and elimination of myeloid cells such that the total number of myeloid cells within a whole or part of an organism is stable over time in the absence of an outside stimulus.
Any process that modulates the force with which blood travels through the circulatory system. The process is controlled by a balance of processes that increase pressure and decrease pressure.
Any process that modulates the rate, frequency, or extent of branching morphogenesis, the process in which the anatomical structures of branches are generated and organized.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an electrical stimulus.
Any process that stops, prevents, or reduces the frequency, rate or extent of the addition of telomeric repeats by telomerase.
Any process that modulates the rate, frequency or extent of T cell chemotaxis. T cell chemotaxis is the directed movement of a T cell in response to an external stimulus.
Any process that modulates the rate, frequency, or extent of the establishment of planar polarity involved in neural tube closure, the coordinated organization of groups of cells in the plane of an epithelium that contributes to the closure of the neural tube.
Any process that modulates the frequency, rate, or extent of production of a cytokine.
Any process that modulates the frequency, rate or extent of ERBB signaling pathway.
Any process that modulates the frequency, rate or extent of cholesterol homeostasis.
The developmental process in which a ventricular septum is generated and organized. A ventricular septum is an anatomical structure that separates the lower chambers (ventricles) of the heart from one another.
Any process that activates or increases the frequency, rate or extent of endothelial cell chemotaxis.
Any process that activates or increases the frequency, rate or extent of endothelial cell differentiation.
Any process that stops, prevents or reduces the rate or extent of smooth muscle cell proliferation.
A process that directly activates any of the steps required for tolerance, a physiologic state in which the immune system does not react destructively against the components of an organism that harbors it or against antigens that are introduced to it.
Any biological process involved in the maintenance of an internal steady state of a chemical.
A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a synapse, the junction between a neuron and a target (neuron, muscle, or secretory cell).
The process whose specific outcome is the progression of the metanephros over time, from its formation to the mature structure. In mammals, the metanephros is the excretory organ of the fetus, which develops into the mature kidney and is formed from the rear portion of the nephrogenic cord. The metanephros is an endocrine and metabolic organ that filters the blood and excretes the end products of body metabolism in the form of urine.
Any process that modulates the frequency, rate or extent of any cellular process that depends upon or alters the microtubule cytoskeleton.
Any process that stops or reduces the activity of a transporter.
A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of endosomes.
Any process that modulates the rate, frequency, or extent of the series of events that restore integrity to a damaged tissue, following an injury.
Any process that modulates the frequency, rate or extent of signal transduction mediated by the MAP kinase (MAPK) cascade.
The activation of endogenous cellular processes that result in the death of a cell as part of its development.
Any process that activates, maintains or increases the rate of skeletal muscle tissue development.
The movement of a myeloid leukocyte within or between different tissues and organs of the body.
Any process that determines the size and arrangement of collagen fibrils within an extracellular matrix.
Any process that activates or increases the frequency, rate or extent of neuron death.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of stimulus by estradiol, a C18 steroid hormone hydroxylated at C3 and C17 that acts as a potent estrogen.
The process whose specific outcome is the progression of the blood vessels of the heart over time, from its formation to the mature structure.
The process whose specific outcome is the progression of a cartilage element over time, from its formation to the mature structure. Cartilage elements are skeletal elements that consist of connective tissue dominated by extracellular matrix containing collagen type II and large amounts of proteoglycan, particularly chondroitin sulfate.
Any process that modulates the frequency, rate or extent of tumor necrosis factor superfamily cytokine production.
Long distance growth of a single neuron projection involved in cellular development. A neuron projection is a prolongation or process extending from a nerve cell, e.g. an axon or dendrite.
Any process that modulates the frequency, rate or extent of cardiac muscle tissue development.
Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving cyclic nucleotides.
The chemical reactions and pathways resulting in the formation of a pyrimidine nucleotide, a compound consisting of nucleoside (a pyrimidine base linked to a deoxyribose or ribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a myofibril being extended beyond its slack length.
Any process that stops, prevents, or reduces the frequency, rate or extent of oligodendrocyte differentiation.
Any process that modulates the frequency, rate or extent of signal transduction mediated by the phosphatidylinositol 3-kinase cascade.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cold stimulus, a temperature stimulus below the optimal temperature for that organism.
Any process that decreases the frequency, rate or extent of the directed movement of sodium ions (Na+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-1 stimulus.
A organ system process carried out by any of the organs or tissues of the circulatory system. The circulatory system is an organ system that moves extracellular fluids to and from tissue within a multicellular organism.
Any process that modulates the frequency, rate or extent of increases in the diameter of blood vessels.
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving triglyceride, any triester of glycerol.
Any process that decreases the rate, frequency, or extent of the chemical reactions and pathways resulting in the formation of glycoproteins, any protein that contains covalently bound glycose (i.e. monosaccharide) residues; the glycose occurs most commonly as oligosaccharide or fairly small polysaccharide but occasionally as monosaccharide.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cocaine stimulus. Cocaine is a crystalline alkaloid obtained from the leaves of the coca plant.
The directed movement of a motile cell guided by a specific chemical concentration gradient. Movement may be towards a higher concentration (positive chemotaxis) or towards a lower concentration (negative chemotaxis).
Any process that stops, prevents or reduces the frequency, rate or extent of intrinsic apoptotic signaling pathway by p53 class mediator.
The chemical reactions and pathways resulting in the breakdown of a ribonucleotide, a compound consisting of ribonucleoside (a base linked to a ribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.
Any process that activates or increases the frequency, rate or extent of mitotic sister chromatid separation.
The cellular process that completes DNA-templated transcription; the formation of phosphodiester bonds ceases, the RNA-DNA hybrid dissociates, and RNA polymerase releases the DNA.
Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-1 production.
Any process that activates or increases the frequency, rate or extent of cation channel activity.
Any process that modulates the frequency, rate or extent of the regulated release of a prostaglandin from a cell.
Any process that modulates the frequency, rate or extent of podosome assembly.
Any process that modulates the frequency, rate or extent of cellular senescence.
The process in which the left cardiac ventricle is generated and organized.
Any process that stops, prevents, or reduces the frequency, rate or extent of striated muscle cell differentiation.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an amine stimulus. An amine is a compound formally derived from ammonia by replacing one, two or three hydrogen atoms by hydrocarbyl groups.
Any process that modulates the frequency, rate or extent of the directed movement of organic acids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
Any process that modulates the rate, frequency, or extent of DNA-dependent DNA replication, the process in which new strands of DNA are synthesized, using parental DNA as a template for the DNA-dependent DNA polymerases that synthesize the new strands.
Any process that stops, prevents or reduces the frequency, rate or extent of potassium ion transmembrane transporter activity.
The formation of a protein homotetramer, a macromolecular structure consisting of four noncovalently associated identical subunits.
Any process involved in the development or functioning of the immune system, an organismal system for calibrated responses to potential internal or invasive threats.
The process of shaping a trabecula in the heart. A trabecula is a small, often microscopic, tissue element in the form of a small beam, strut or rod, which generally has a mechanical function. Trabecula are usually but not necessarily, composed of dense collagenous tissue.
The aggregation, arrangement and bonding together of a set of components to form respiratory chain complex IV (also known as cytochrome c oxidase), the terminal member of the respiratory chain of the mitochondrion and some aerobic bacteria. Cytochrome c oxidases are multi-subunit enzymes containing from 13 subunits in the mammalian mitochondrial form to 3-4 subunits in the bacterial forms.
Any process in which a vesicle or vesicles are transported to, and/or maintained in, a specific location.
The chemical reactions and pathways involving nitric oxide, nitrogen monoxide (NO), a colorless gas only slightly soluble in water.
Any process that activates or increases the frequency, rate or extent of leukocyte apoptotic process.
Any process that activates, maintains or increases the frequency or rate of cell fate commitment. Cell fate commitment is the commitment of cells to specific cell fates and their capacity to differentiate into particular kinds of cells. Positional information is established through protein signals that emanate from a localized source within a cell (the initial one-cell zygote) or within a developmental field.
The process in which the anatomical structures of the forebrain are generated and organized. The forebrain is the anterior of the three primary divisions of the developing chordate brain or the corresponding part of the adult brain (in vertebrates, includes especially the cerebral hemispheres, the thalamus, and the hypothalamus and especially in higher vertebrates is the main control center for sensory and associative information processing, visceral functions, and voluntary motor functions).
A process in which telomeres are protected from degradation and fusion, thereby ensuring chromosome stability by protecting the ends from both degradation and from being recognized as damaged DNA. May be mediated by specific single- or double-stranded telomeric DNA binding proteins.
The process in which the anatomical structures of a prostate gland are generated and organized.
Any process that stops, prevents, or reduces the frequency, rate or extent of axon outgrowth.
Any process that activates or increases the frequency, rate, or extent of type I interferon production. Type I interferons include the interferon-alpha, beta, delta, episilon, zeta, kappa, tau, and omega gene families.
Any process that modulates the frequency, rate or extent of signaling via a stress-activated protein kinase signaling cascade.
The process whose specific outcome is the progression of a myeloid cell over time, from its formation to the mature structure.
Any process that stops, prevents, or reduces the frequency, rate or extent of kinase activity, the catalysis of the transfer of a phosphate group, usually from ATP, to a substrate molecule.
Any regulation of mitochondrial membrane permeability that is involved in apoptotic process.
The directed movement of proteins in a cell, including the movement of proteins between specific compartments or structures within a cell, such as organelles of a eukaryotic cell.
Any process that modulates the frequency, rate or extent of the removal of acetyl groups from histones.
Any process that modulates the rate or frequency of phosphatase activity. Phosphatases catalyze the hydrolysis of phosphoric monoesters, releasing inorganic phosphate.
The directed movement of neurotransmitters into neurons or glial cells. This process leads to inactivation and recycling of neurotransmitters.
Any process in which a microtubule is maintained in a specific location in a cell.
The process resulting in division and partitioning of components of a cell to form more cells; may or may not be accompanied by the physical separation of a cell into distinct, individually membrane-bounded daughter cells.
Any process that modulates the rate, frequency, or extent of a mRNA catabolic process, the chemical reactions and pathways resulting in the breakdown of RNA, ribonucleic acid, one of the two main type of nucleic acid, consisting of a long, unbranched macromolecule formed from ribonucleotides joined in 3',5'-phosphodiester linkage.
Control of the spatial distribution of intermediate filaments; includes organizing filaments into meshworks, bundles, or other structures, as by cross-linking.
Any process that modulates the frequency, rate, or extent of interleukin-10 production.
The directed movement of sodium ions out of a cell or organelle.
Any process that stops, prevents, or reduces the frequency, rate or extent of cell division.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an ultraviolet radiation (UV light) stimulus. Ultraviolet radiation is electromagnetic radiation with a wavelength in the range of 10 to 380 nanometers.
Any process that modulates the frequency, rate or extent of nuclear division, the partitioning of the nucleus and its genetic information.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus by the chemical structure of the anion portion of a dissociated acid (rather than the acid acting as a proton donor). The acid chemical may be in gaseous, liquid or solid form.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a prostagladin E stimulus.
Any process that stops, prevents or reduces the frequency, rate or extent of response to reactive oxygen species.
Any process that increases the rate, frequency, or extent of epithelial to mesenchymal transition. Epithelial to mesenchymal transition is where an epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a steroid hormone stimulus.
Any process that activates or increases the frequency, rate or extent of RNA splicing.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of being rendered immobile.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-4 stimulus.
Any process that activates or increases the frequency, rate or extent of keratinocyte differentiation.
The process in which a cardiac chamber is generated and organized. A cardiac chamber is an enclosed cavity within the heart.
Any process that modulates the rate, frequency, or extent of cartilage development, the process whose specific outcome is the progression of the cartilage over time, from its formation to the mature structure. Cartilage is a connective tissue dominated by extracellular matrix containing collagen type II and large amounts of proteoglycan, particularly chondroitin sulfate.
Any process that activates or increases the frequency, rate, or extent of interleukin-8 production.
The chemical reactions and pathways involving serotonin (5-hydroxytryptamine), a monoamine neurotransmitter occurring in the peripheral and central nervous systems, also having hormonal properties.
Any process that modulates the frequency, rate or extent of the antiviral response of a cell or organism.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a peptide stimulus.
Any process that modulates the frequency, rate or extent of endothelial cell apoptotic process.
A DNA replication process that uses parental DNA as a template for the DNA-dependent DNA polymerases that synthesize the new strands.
Any process that modulates the frequency, rate or extent of skeletal muscle cell differentiation.
Any process that activates or increases the frequency, rate or extent of cellular protein catabolic process.
Any process involved in the maintenance of an internal steady state of sterol within an organism or cell.
The establishment, maintenance and elaboration of a pattern along a line or a point in an embryo.
Any process that modulates the frequency, rate or extent of leukocyte apoptotic process.
Any process that activates or increases the frequency, rate, or extent of interleukin-1 beta production.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipid stimulus.
The controlled release of a substance by a cell.
The chemical reactions and pathways involving any conjugated, water-soluble protein in which the nonprotein group consists of a lipid or lipids.
A process in which an organism has a negative effect on the functioning of the second organism's cells, where the two organisms are in a symbiotic interaction.
The directed movement of an iron coordination entity into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
The chemical reactions and pathways resulting in the formation of phosphatidylcholines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of choline.
The chemical reactions and pathways involving keratan sulfate, a glycosaminoglycan with repeat units consisting of beta-1,4-linked D-galactopyranosyl-beta-(1,4)-N-acetyl-D-glucosamine 6-sulfate and with variable amounts of fucose, sialic acid and mannose units; keratan sulfate chains are covalently linked by a glycosidic attachment through the trisaccharide galactosyl-galactosyl-xylose to peptidyl-threonine or serine residues.
Any process that modulates the frequency, rate or extent of coagulation, the process in which a fluid solution, or part of it, changes into a solid or semisolid mass.
A cellular process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of a membrane.
Any process that modulates the frequency, rate or extent of epidermis development.
The formation of the ectoderm, mesoderm and endoderm during gastrulation.
Any process that stops, prevents, or reduces the frequency, rate or extent of muscle cell differentiation.
The chemical reactions and pathways by which a cell derives energy from stored compounds such as fats or glycogen.
The chemical reactions and pathways resulting in the formation of glycolipid, a class of 1,2-di-O-acylglycerols joined at oxygen 3 by a glycosidic linkage to a carbohydrate part (usually a mono-, di- or tri-saccharide).
Any process that modulates the frequency, rate or extent of actin nucleation, the initial step in the formation of an actin filament in which actin monomers combine to form a new filament.
Any process that modulates the frequency, rate or extent of dendritic cell differentiation.
The process whose specific outcome is the progression of an epithelial cell over time, from its formation to the mature structure. An epithelial cell is a cell usually found in a two-dimensional sheet with a free surface.
The directed movement of an amide, any compound containing one, two, or three acyl groups attached to a nitrogen atom, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
Any process that modulates the frequency, rate, or extent of interferon-gamma production. Interferon-gamma is also known as type II interferon.
Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving lipids.
Any process in which a protein is transported to, or maintained at, the kinetochore.
Any process that stops, prevents, or reduces the frequency, rate or extent of adipocyte differentiation.
Any process that results in a change in state or activity of an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of detection of, or exposure to, a period of light or dark of a given length, measured relative to a particular duration known as the 'critical day length'. The critical day length varies between species.
The chemical reactions and pathways resulting in the formation of an alpha-amino acid.
A transition where a mesenchymal cell establishes apical/basolateral polarity, forms intercellular adhesive junctions, synthesizes basement membrane components and becomes an epithelial cell.
The establishment of a barrier between endothelial cell layers of the intestine to exert specific and selective control over the passage of water and solutes, thus allowing formation and maintenance of compartments that differ in fluid and solute composition.
The process whose specific outcome is the progression of the salivary gland over time, from its formation to the mature structure. Salivary glands include any of the saliva-secreting exocrine glands of the oral cavity.
The DNA-dependent DNA replication that takes place as part of the cell cycle.
Any process that stops, prevents, or reduces the frequency, rate or extent of transcription elongation, the extension of an RNA molecule after transcription initiation and promoter clearance by the addition of ribonucleotides, catalyzed by RNA polymerase II.
The progressive compaction of dispersed interphase chromatin into threadlike chromosomes prior to mitotic or meiotic nuclear division, or during apoptosis, in eukaryotic cells.
Any process that activates, maintains or increases the rate of a response to a stimulus. Response to stimulus is a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus.
Any process that modulates the activity of a monooxygenase.
The series of events required for an organism to receive a sensory mechanical stimulus, convert it to a molecular signal, and recognize and characterize the signal. This is a neurological process.
The specification and formation of anisotropic intracellular organization of an epithelial cell.
Any series of molecular signals generated as a consequence of binding to toll-like receptor 9.
The process, occurring in the embryo, by which the anatomical structures of the digit are generated and organized. A digit is one of the terminal divisions of an appendage, such as a finger or toe.
Any process that modulates the rate, frequency, or extent of the Wnt signaling pathway through beta-catenin, the series of molecular signals initiated by binding of a Wnt protein to a frizzled family receptor on the surface of the target cell, followed by propagation of the signal via beta-catenin, and ending with a change in transcription of target genes.
A nitrogen compound metabolic process that contributes to the nitrogen cycle. The nitrogen cycle is a series of metabolic pathways by which nitrogen is converted between various forms and redox states; it encompasses pathways in which nitrogen is acted upon directly, such as nitrification, denitrification, nitrogen fixation, and mineralization.
The change in morphology and behavior of a mature or immature T cell resulting from exposure to a mitogen, cytokine, chemokine, cellular ligand, or an antigen for which it is specific, leading to the initiation or perpetuation of an immune response.
Any process that stops, prevents, or reduces the frequency, rate or extent of leukocyte proliferation.
A programmed necrotic cell death process which begins when a cell receives a signal (e.g. a ligand binding to a death receptor or to a Toll-like receptor), and proceeds through a series of biochemical events (signaling pathways), characterized by activation of receptor-interacting serine/threonine-protein kinase 1 and/or 3 (RIPK1/3, also called RIP1/3) and by critical dependence on mixed lineage kinase domain-like (MLKL), and which typically lead to common morphological features of necrotic cell death. The process ends when the cell has died. The process is divided into a signaling phase, and an execution phase, which is triggered by the former.
Any process that stops, prevents, or reduces the frequency, rate or extent of gliogenesis, the formation of mature glia.
The movement of a dendritic cell in response to an external stimulus.
Any process that modulates the frequency, rate, or extent of antigen processing and presentation of peptide antigen.
A process that modulates neuronal synaptic plasticity, the ability of neuronal synapses to change as circumstances require. They may alter function, such as increasing or decreasing their sensitivity, or they may increase or decrease in actual numbers.
Any process that modulates the frequency, rate or extent of phospholipase C activity.
Any process that modulates the frequency, rate or extent of developmental growth.
The controlled breakdown of any cell membrane in the context of a normal process such as autophagy.
Any process that modulates the frequency, rate or extent of glutamatergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter glutamate.
The initiation of the activity of the inactive enzyme phospolipase C as the result of a series of molecular signals generated as a consequence of a G-protein coupled receptor binding to its physiological ligand.
Any process that stops, prevents, or reduces the frequency, rate or extent of biomineral tissue development, the formation of hard tissues that consist mainly of inorganic compounds.
Any process that stops, prevents, or reduces the frequency, rate or extent of bone resorption.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an external stimulus.
The chemical reactions and pathways involving nicotinamide-adenine dinucleotide phosphate, a coenzyme involved in many redox and biosynthetic reactions; metabolism may be of either the oxidized form, NADP, or the reduced form, NADPH.
Any process that activates or increases the frequency, rate or extent of mRNA processing.
The process in which a highly ordered sequence of patterning events generates the branched epithelial tubes of the lung, consisting of reiterated combinations of bud outgrowth, elongation, and dichotomous subdivision of terminal units.
The series of events in which a mechanical stimulus is received and converted into a molecular signal as part of sensory perception.
Any process that modulates the frequency, rate or extent of cell-cell adhesion mediated by cadherin.
The process whose specific outcome is the progression of an epithelium in the metanephros over time, from its formation to the mature structure. An epithelium is a tissue that covers the internal or external surfaces of an anatomical structure.
Any process that modulates the frequency, rate or extent of smooth muscle cell differentiation.
A fatty acid oxidation process that results in the complete oxidation of a long-chain fatty acid. Fatty acid beta-oxidation begins with the addition of coenzyme A to a fatty acid, and occurs by successive cycles of reactions during each of which the fatty acid is shortened by a two-carbon fragment removed as acetyl coenzyme A; the cycle continues until only two or three carbons remain (as acetyl-CoA or propionyl-CoA respectively).
Any cellular process that depends upon or alters the actin cytoskeleton, that part of the cytoskeleton comprising actin filaments and their associated proteins.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a fluid shear stress stimulus. Fluid shear stress is the force acting on an object in a system where the fluid is moving across a solid surface.
Any process that stops, prevents, or reduces the frequency, rate or extent of muscle contraction.
The directed movement of transition metal ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. A transition metal is an element whose atom has an incomplete d-subshell of extranuclear electrons, or which gives rise to a cation or cations with an incomplete d-subshell. Transition metals often have more than one valency state. Biologically relevant transition metals include vanadium, manganese, iron, copper, cobalt, nickel, molybdenum and silver.
Any process that activates or increases the frequency, rate or extent of muscle cell differentiation.
Any process that modulates the frequency, rate, or extent of an adaptive immune response.
The chemical reactions and pathways resulting in the formation of phosphatidylinositol, any glycophospholipid in which the sn-glycerol 3-phosphate residue is esterified to the 1-hydroxyl group of 1D-myo-inositol.
Any process that increases the frequency, rate or extent of cell communication. Cell communication is the process that mediates interactions between a cell and its surroundings. Encompasses interactions such as signaling or attachment between one cell and another cell, between a cell and an extracellular matrix, or between a cell and any other aspect of its environment.
Any process that increases the frequency, rate or extent of lipid kinase activity, the catalysis of the transfer of a phosphate group, usually from ATP, to a simple or complex lipid.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a corticosteroid hormone stimulus. A corticosteroid is a steroid hormone that is produced in the adrenal cortex. Corticosteroids are involved in a wide range of physiologic systems such as stress response, immune response and regulation of inflammation, carbohydrate metabolism, protein catabolism, blood electrolyte levels, and behavior. They include glucocorticoids and mineralocorticoids.
Any process that activates or increases the frequency, rate or extent of leukocyte degranulation.
A process in which a sodium ion is transported from one side of a membrane to the other by means of some agent such as a transporter or pore.
The process in which a ubiquitin group, or multiple groups, are covalently attached to the target protein, thereby initiating the degradation of that protein.
Any process that stops, prevents, or reduces the frequency, rate or extent of the migration of the endothelial cells of blood vessels.
Formation of a prolongation or process extending from a cell, e.g. a flagellum or axon.
Any process that modulates the vectorial transfer of a protein from the cytoplasm into the nucleus, across the nuclear membrane.
The chemical reactions and pathways involving glucocorticoids, hormonal C21 corticosteroids synthesized from cholesterol. Glucocorticoids act primarily on carbohydrate and protein metabolism, and have anti-inflammatory effects.
Any process leading to the attainment of the full functional capacity of a protein.
Any process in which skeletal muscles change their phenotypic profiles in response to altered functional demands and a variety of signals.
A protein glycosylation process in which a carbohydrate or carbohydrate derivative unit is added to a protein via the N4 atom of peptidyl-asparagine, the omega-N of arginine, or the N1' atom peptidyl-tryptophan.
The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, with ubiquitin-protein ligation catalyzed by the anaphase-promoting complex, and mediated by the proteasome.
The process in which the anatomical structures of the hindlimb are generated and organized.
Any cellular process that results in the specification, formation or maintenance of the apicobasal polarity of an epithelial cell.
The process whose specific outcome is the progression of the loop of Henle over time, from its formation to the mature structure. The loop of Henle is a nephron tubule that connects the proximal convoluted tubule to the distal convoluted tubule.
A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a vesicle.
The multiplication or reproduction of keratinocytes, resulting in the expansion of a cell population. Keratinocytes are epidermal cells which synthesize keratin and undergo a characteristic change as they move upward from the basal layers of the epidermis to the cornified (horny) layer of the skin.
A change in morphology and behavior of a macrophage resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor, leading to the initiation or perpetuation of an immune response.
The chemical reactions and pathways involving indolalkylamines, indole or indole derivatives containing a primary, secondary, or tertiary amine group.
Any process that activates or increases the rate or extent of binding, the selective interaction of a molecule with one or more specific sites on another molecule.
The process in which a relatively unspecialized cell acquires specialized features of a smooth muscle cell; smooth muscle lacks transverse striations in its constituent fibers and are almost always involuntary.
The process whose specific outcome is the progression of the male genitalia over time, from its formation to the mature structure.
Any process that modulates the frequency, rate or extent of hydrolase activity, the catalysis of the hydrolysis of various bonds, e.g. C-O, C-N, C-C, phosphoric anhydride bonds, etc. Hydrolase is the systematic name for any enzyme of EC class 3.
The progression of a cardiac cushion over time, from its initial formation to the mature structure. The endocardial cushion is a specialized region of mesenchymal cells that will give rise to the heart septa and valves.
Any process that stops, prevents or reduces the frequency, rate or extent of ERBB signaling pathway.
The physiological process in which dietary excess is sensed by the central nervous system, resulting in a reduction in food intake and increased energy expenditure.
Any process that modulates the frequency, rate or extent of meiosis, the process in which the nucleus of a diploid cell divides twice forming four haploid cells, one or more of which usually function as gametes.
The growth process in which a branch increases in length from its base to its tip.
Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving amides.
Any process that activates or increases the frequency, rate or extent of a process involved in the formation, arrangement of constituent parts, or disassembly of a vacuole.
Any process that decreases the rate or frequency of platelet activation. Platelet activation is a series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue.
The chemical reactions and pathways resulting in the breakdown of amino acids of the glutamine family, comprising arginine, glutamate, glutamine and proline.
The process, occurring during the embryonic phase, whose specific outcome is the progression of the skeleton over time, from its formation to the mature structure.
A developmental process, independent of morphogenetic (shape) change, that is required for a neuron to attain its fully functional state.
The process of T cell selection that occurs in the thymus.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a biotic stimulus, a stimulus caused or produced by a living organism.
The chemical reactions and pathways involving coenzyme A, 3'-phosphoadenosine-(5')diphospho(4')pantatheine, an acyl carrier in many acylation and acyl-transfer reactions in which the intermediate is a thiol ester.
A process in which a protein is transported to, or maintained in, a location within a cilium.
Prevention of degradation of RNA molecules.
The sliding movement of actin thin filaments and myosin thick filaments past each other.
Any process that modulates the frequency, rate or extent of cell morphogenesis contributing to cell differentiation. Cell morphogenesis involved in differentiation is the change in form (cell shape and size) that occurs when relatively unspecialized cells acquire specialized structural and/or functional features that characterize the cells, tissues, or organs of the mature organism or some other relatively stable phase of the organism's life history.
Any process that modulates the frequency, rate or extent of protein homodimerization, interacting selectively with an identical protein to form a homodimer.
Any process that modulates the frequency, rate, or extent of heterotypic cell-cell adhesion.
Any process that activates or increases the frequency, rate or extent of reactive oxygen species biosynthetic process.
The chemical reactions and pathways involving an alpha-amino acid.
The chemical reactions and pathways involving mitochondrial DNA.
The chemical reactions and pathways involving cyclic GMP, guanosine 3',5'-phosphate.
Behavior in a fully developed and mature organism.
The process in which the migration of an axon growth cone of a retinal ganglion cell (RGC) is directed to its target in the brain in response to a combination of attractive and repulsive cues.
Any process that activates or increases the frequency, rate or extent of membrane invagination.
Any process in which is the spindle is transported to, and/or maintained in, a specific location.
The chemical reactions and pathways resulting in the breakdown of hydrogen peroxide (H2O2).
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an organic cyclic compound stimulus.
Any process that activates or increases the frequency, rate, or extent of cytokine production that contributes to an immune response.
Any process that modulates the frequency, rate or extent of the addition of SUMO groups to a protein.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stress acting at the endoplasmic reticulum. ER stress usually results from the accumulation of unfolded or misfolded proteins in the ER lumen.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a light stimulus, electromagnetic radiation of wavelengths classified as infrared, visible or ultraviolet light.
Any process in which a host organism activates or increases the frequency, rate or extent of viral transcription, the synthesis of either RNA on a template of DNA or DNA on a template of RNA.
Any process that stops, prevents or reduces the frequency, rate or extent of stem cell differentiation.
Any process that stops, prevents, or reduces the frequency, rate, or extent of the production of molecular mediator of immune response.
A series of molecular signals mediated by a sphingolipid.
The directed movement of synaptic vesicles along cytoskeletal fibers such as microfilaments or microtubules within a cell, powered by molecular motors.
The process in which relatively unspecialized cells, e.g. embryonic or regenerative cells, acquire specialized structural and/or functional features of a mature cell found in the lung. Differentiation includes the processes involved in commitment of a cell to a specific fate.
A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable hemostatic plug.
A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures.
A series of molecular signals generated as a consequence of a nucleotide-binding domain, leucine rich repeat containing receptor (NLR) binding to one of its physiological ligands. NLRs are cytoplasmic receptors defined by their tripartite domain architecture that contains: a variable C-terminus, a middle nucleotide-binding domain, and a LRR domain that is variable in the repeats composition and number. The NLR signaling pathway begins with binding of a ligand to a NLR receptor and ends with regulation of a downstream cellular process.
The nucleotide-excision repair process that carries out preferential repair of DNA lesions on the actively transcribed strand of the DNA duplex. In addition, the transcription-coupled nucleotide-excision repair pathway is required for the recognition and repair of a small subset of lesions that are not recognized by the global genome nucleotide excision repair pathway.
The process in which membrane potential changes in the depolarizing direction from the negative resting potential towards the positive membrane potential that will be the peak of the action potential.
Any process involved in the maturation of a precursor Small SubUnit (SSU) ribosomal RNA (rRNA) molecule into a mature SSU-rRNA molecule.
The chemical reactions and pathways involving beta-amyloid, a glycoprotein associated with Alzheimer's disease, and its precursor, amyloid precursor protein (APP).
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating damage to the organism.
The series of molecular signals initiated by binding of a Wnt protein to a frizzled family receptor on the surface of the target cell, followed by propagation of the signal via effectors other than beta-catenin.
A slow mechanism of blood pressure regulation that responds to changes in pressure resulting from fluid and salt intake by modulating the quantity of blood in the circulatory system.
Any process that stops, prevents, or reduces the frequency, rate, or extent of leukocyte mediated immunity.
Any process that activates or increases the frequency, rate or extent of activity of the transcription factor CREB.
Any process that stops, prevents, or reduces the frequency, rate, extent or direction of cell growth.
The directed movement of modified amino acids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
The chemical reactions and pathways resulting in the formation of cyclic GMP, guanosine 3',5'-phosphate.
The controlled release of proteins from a cell.
The process of generating multiple mRNA molecules from a given set of exons by differential use of exons from the primary transcript(s) to form multiple mature mRNAs that vary in their exon composition.
Learning by associating a stimulus (the cause) with a particular outcome (the effect).
The chemical reactions and pathways involving snoRNA, small nucleolar RNA, any of a class of small RNAs that are associated with the eukaryotic nucleus as components of small nucleolar ribonucleoproteins. They participate in the processing or modifications of many RNAs, mostly ribosomal RNAs (rRNAs) though snoRNAs are also known to target other classes of RNA, including spliceosomal RNAs, tRNAs, and mRNAs via a stretch of sequence that is complementary to a sequence in the targeted RNA.
Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of substances, carried out by individual cells.
Any process that modulates the frequency, rate or extent of a response to an extracellular stimulus.
The directed movement of a cofactor into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. A cofactor is a substance that is required for the activity of an enzyme or other protein.
Any process that activates or increases the frequency, rate or extent of adipocyte differentiation.
Any process that stops, prevents, or reduces the frequency, rate or extent of the process of creating protein polymers.
The chemical reactions and pathways resulting in the breakdown of a drug that has originated externally to the cell or organism.
Any process that stops, prevents or reduces the frequency, rate or extent of reactive oxygen species metabolic process.
Any process that modulates the rate, frequency, or extent of protein deacetylation, the removal of an acetyl group from a protein amino acid. An acetyl group is CH3CO-, derived from acetic
The process whose specific outcome is the progression of the otic vesicle over time, from its formation to the mature structure. The otic vesicle is a transient embryonic structure formed during development of the vertebrate inner ear.
Any process that activates or increases the frequency, rate or extent of DNA-templated transcription initiation.
Any neuron projection extension that is involved in neuron projection guidance.
The process of removing one or more phosphate groups from a phosphorylated lipid, any member of a group of substances soluble in lipid solvents but only sparingly soluble in aqueous solvents.
Any process that stops, prevents, or reduces the frequency, rate or extent of DNA repair.
The directed movement of metal ions, any metal ion with an electric charge, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
The regulated release of proinsulin from secretory granules (B granules) in the B cells of the pancreas; accompanied by cleavage of proinsulin to form mature insulin.
Any process that activates or increases the frequency, rate or extent of multiplication or reproduction of fibroblast cells.
The stepwise addition of the components of the GPI anchor on to phosphatidylinositol lipids in the endoplasmic reticulum membrane.
A type of cell death that is morphologically characterized by an increasingly translucent cytoplasm, swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. Necrotic cells do not fragment into discrete corpses as their apoptotic counterparts do. Moreover, their nuclei remain intact and can aggregate and accumulate in necrotic tissues.
Any process that modulates the frequency, rate, or extent of mast cell activation as part of an immune response.
Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving amines.
Any process that activates or increases the frequency, rate or extent of the directed movement of proteins within cells.
Any virus-mediated process that modulates the levels of viral proteins in a cell.
Any process in which a chromosome is transported to, or maintained in, a specific location.
Any process that modulates the frequency, rate or extent of a respiratory system process, an organ system process carried out by any of the organs or tissues of the respiratory system.
Any process that activates or increases the frequency, rate or extent of adenylate cyclase activity.
Any process that activates or increases the frequency, rate or extent of neuron differentiation.
The process in which the anatomical structures of the skeleton are generated and organized during the embryonic phase.
Any process that initiates the activity of an inactive GTPase through the replacement of GDP by GTP.
The chemical reactions and pathways involving inositol phosphate, 1,2,3,4,5,6-cyclohexanehexol, with one or more phosphate groups attached.
The process of regulating the proliferation and elimination of T cells such that the total number of T cells within a whole or part of an organism is stable over time in the absence of an outside stimulus.
Any process that modulates the frequency, rate or extent of receptor activity. Receptor activity is when a molecule combines with an extracellular or intracellular messenger to initiate a change in cell activity.
The modification of histones by addition of methyl groups.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a fluid shear stress stimulus. Fluid shear stress is the force acting on an object in a system where the fluid is moving across a solid surface.
Any process that activates or increases the activity of a transporter.
Any process that activates or increases the frequency, rate or extent of the movement of a transcription factor from the cytoplasm to the nucleus.
The process in which a precursor cell type acquires the specialized features of an alpha-beta T cell. An alpha-beta T cell is a T cell that expresses an alpha-beta T cell receptor complex.
The directed movement of a protein to a specific location on a chromosome.
The formation of a covalent cross-link between or within protein chains.
The modification of peptidyl-serine.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an extracellular stimulus.
A series of molecular signals initiated by the binding of a SLIT protein to a Roundabout (ROBO) family receptor on the surface of a target cell, and ending with regulation of a downstream cellular process, e.g. transcription.
The directed movement of a protein to a specific location.
Any process that stops, prevents or reduces the frequency, rate or extent of response to DNA damage stimulus.
The chemical reactions and pathways involving glutamate, the anion of 2-aminopentanedioic acid.
The chemical reactions and pathways involving sphingomyelin, N-acyl-4-sphingenyl-1-O-phosphorylcholine, any of a class of phospholipids in which the amino group of sphingosine is in amide linkage with one of several fatty acids, while the terminal hydroxyl group of sphingosine is esterified to phosphorylcholine.
The chemical reactions and pathways involving tRNA, transfer RNA, a class of relatively small RNA molecules responsible for mediating the insertion of amino acids into the sequence of nascent polypeptide chains during protein synthesis. Transfer RNA is characterized by the presence of many unusual minor bases, the function of which has not been completely established.
Any process that stops or reduces the rate of ATP hydrolysis by an ATPase.
Any process that activates or increases the frequency, rate or extent of locomotion of a cell or organism.
Any process that modulates the frequency, rate or extent of dendrite morphogenesis.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lithium (Li+) ion stimulus.
The process whose specific outcome is the progression of the mammary gland epithelium over time, from its formation to the mature structure. The mammary gland is a large compound sebaceous gland that in female mammals is modified to secrete milk.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a prostagladin stimulus.
Any process that modulates the frequency, rate, or extent of myeloid cell apoptotic process.
Any process that stops, prevents, or reduces the frequency, rate or extent of a multi-organism process in which a virus is a participant.
Any process of regulating the production and elimination of erythrocytes within an organism.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a heat stimulus, a temperature stimulus above the optimal temperature for that organism.
The series of successive proteolytic cleavages of the Notch protein, which result in an active form of the receptor.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cadmium (Cd) ion stimulus.
Specific behavior of a newborn or infant mammal that results in the derivation of nourishment from the breast.
Any process that increases the rate, frequency or extent of kidney development. Kidney development is the process whose specific outcome is the progression of the kidney over time, from its formation to the mature structure. The kidney is an organ that filters the blood and excretes the end products of body metabolism in the form of urine.
Any process that modulates the frequency, rate or extent of mitotic spindle checkpoint.
The process in which a signal is passed on to downstream components within the cell through the I-kappaB-kinase (IKK)-dependent activation of NF-kappaB. The cascade begins with activation of a trimeric IKK complex (consisting of catalytic kinase subunits IKKalpha and/or IKKbeta, and the regulatory scaffold protein NEMO) and ends with the regulation of transcription of target genes by NF-kappaB. In a resting state, NF-kappaB dimers are bound to I-kappaB proteins, sequestering NF-kappaB in the cytoplasm. Phosphorylation of I-kappaB targets I-kappaB for ubiquitination and proteasomal degradation, thus releasing the NF-kappaB dimers, which can translocate to the nucleus to bind DNA and regulate transcription.
Any process that modulates the frequency, rate or extent of non-canonical Wnt signaling pathway.
Any process that modulates the frequency, rate or extent of kinase activity, the catalysis of the transfer of a phosphate group, usually from ATP, to a substrate molecule.
The directed movement of a chromosome to the nuclear envelope that contributes to homologous chromosome segregation and precedes synapsis.
Any process that stops, prevents, or reduces the frequency, rate or extent of DNA recombination.
Any process that activates or increases the frequency, rate or extent of lymphocyte migration.
Any process that stops, prevents or reduces the frequency, rate or extent of cellular response to insulin stimulus.
Any process that activates or increases the frequency, rate, or extent of cellular extravasation.
The process in which a relatively unspecialized myeloid precursor cell acquires the specialized features of any cell of the myeloid leukocyte lineage.
A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a peroxisome. A peroxisome is a small, membrane-bounded organelle that uses dioxygen (O2) to oxidize organic molecules.
The process in which a DNA strand is synthesized from template DNA during replication by the action of polymerases, which add nucleotides to the 3' end of the nascent DNA strand.
The chemical reactions and pathways resulting in the breakdown of compounds derived from amino acids, organic acids containing one or more amino substituents.
The attachment, via cell adhesion molecules, of a cell to either another cell of the same organism, or to an underlying substrate of the same organism such as the extracellular matrix.
The chemical reactions and pathways involving a polyol, any alcohol containing three or more hydroxyl groups attached to saturated carbon atoms.
Any process that increases the rate, frequency or extent of a process involved in starting transcription from an RNA polymerase II promoter.
The formation of an apical junction, a functional unit located near the cell apex at the points of contact between epithelial cells composed of the tight junction, the zonula adherens junction and the desmosomes, by the aggregation, arrangement and bonding together of its constituents.
The chemical reactions and pathways involving pyrimidine ribonucleoside triphosphate, a compound consisting of a pyrimidine base linked to a ribose sugar esterified with triphosphate on the sugar.
The process of regulating the proliferation and elimination of lymphocytes such that the total number of lymphocytes within a whole or part of an organism is stable over time in the absence of an outside stimulus.
The process whose specific outcome is the progression of a Sertoli cell over time, from its formation to the mature structure. Cell development does not include the steps involved in committing a cell to a Sertoli cell fate.
Any process that stops, prevents, or reduces the frequency, rate or extent of RNA splicing.
The cell cycle process by which a cell commits to entering the next cell cycle phase.
The process in which the anatomical structures of a tissue are generated and organized.
The directed movement of substances from endosomes to lysosomes.
Any process involved in the conversion of a primary mRNA transcript into one or more mature mRNA(s) prior to translation into polypeptide.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an angiotensin stimulus. Angiotensin is any of three physiologically active peptides (angiotensin II, III, or IV) processed from angiotensinogen.
The process whose specific outcome is the progression of the dendritic spine over time, from its formation to the mature structure. A dendritic spine is a protrusion from a dendrite and a specialized subcellular compartment involved in synaptic transmission.
Any process that modulates the frequency, rate or extent of protein oligomerization.
The chemical reactions and pathways involving heme, any compound of iron complexed in a porphyrin (tetrapyrrole) ring.
The chemical reactions and pathways resulting in the formation of amino acids of the serine family, comprising cysteine, glycine, homoserine, selenocysteine and serine.
The process that gives rise to the cerebellar Purkinje cell layer. This process pertains to the initial formation of a structure from unspecified parts. The Purkinje cell layer lies just underneath the molecular layer of the cerebellar cortex. It contains the neuronal cell bodies of the Purkinje cells that are arranged side by side in a single layer. Candelabrum interneurons are vertically oriented between the Purkinje cells. Purkinje neurons are inhibitory and provide the output of the cerebellar cortex through axons that project into the white matter. Extensive dendritic trees from the Purkinje cells extend upward in a single plane into the molecular layer where they synapse with parallel fibers of granule cells.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a carbohydrate stimulus.
The chemical reactions and pathways resulting in the breakdown of an inositol phosphate, 1,2,3,4,5,6-cyclohexanehexol, with one or more phosphate groups attached.
The chemical reactions and pathways involving C21-steroid hormones, steroid compounds containing 21 carbons which function as hormones.
Any process that stops, prevents, or reduces the frequency, rate or extent of glia cell differentiation.
Any process that activates, maintains or increases the frequency, rate or extent of synapse assembly, the aggregation, arrangement and bonding together of a set of components to form a synapse.
The neurological system process in which a signal is transmitted through the nervous system by a combination of action potential propagation and synaptic transmission.
Any process that activates or increases the frequency, rate or extent of vasculature development.
Any process that activates or increases the frequency, rate or extent of epidermal cell differentiation.
The membrane organization process that joins two lipid bilayers to form a single membrane.
Any process that activates or increases the frequency, rate or extent of TOR signaling.
Any process that activates or increases the frequency, rate or extent of glia cell differentiation.
The specification of male sex of an individual organism.
The process whose specific outcome is the progression of a type B pancreatic cell over time, from its formation to the mature structure. A type B pancreatic cell is a cell located towards center of the islets of Langerhans that secretes insulin.
Any process that modulates the frequency, rate or extent of enzymatic generation of superoxide by a cell.
A series of molecular signals initiated by the cross-linking of an antigen receptor on a B or T cell.
Any process that activates or increases the rate or extent of progression through the mitotic cell cycle.
The process of providing, via surface-bound receptor-ligand pairs, a second, antigen-independent, signal in addition to that provided by the B- or T cell receptor to augment B- or T cell activation.
Any process that modulates the frequency, rate or extent of serine-type peptidase activity.
Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving steroids.
The chemical reactions and pathways involving a cofactor, a substance that is required for the activity of an enzyme or other protein. Cofactors may be inorganic, such as the metal atoms zinc, iron, and copper in certain forms, or organic, in which case they are referred to as coenzymes. Cofactors may either be bound tightly to active sites or bind loosely with the substrate.
The binding of a protein or protein complex to the barbed (or plus) end of an actin filament, thus preventing the addition, exchange or removal of further actin subunits.
The orderly movement of endothelial cells into the extracellular matrix in order to form new blood vessels involved in sprouting angiogenesis.
Any process that stops, prevents, or reduces the frequency, rate or extent of the activity of an intracellular estrogen receptor signaling pathway.
Any process that modulates the frequency, rate, or extent of a type 2 immune response.
An mRNA stabilization process in which one or more RNA-binding proteins associate with the 3'-untranslated region (UTR) of an mRNA.
The chemical reactions and pathways resulting in the breakdown of a drug, a substance used in the diagnosis, treatment or prevention of a disease.
Any process that activates or increases the frequency, rate or extent of Rho protein signal transduction.
The developmental process pertaining to the initial formation of the primitive streak from unspecified parts. The primitive streak is a ridge of cells running along the midline of the embryo where the mesoderm ingresses. It defines the anterior-posterior axis.
Any process that results in a change in state or activity of a cell or organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as the result of a phenylpropanoid stimulus. The process begins with detection of the stimulus and ends with a change in state or activity or the cell or organism. A phenylpropanoid is any of secondary metabolites with structures based on a phenylpropane skeleton. The class includes phenylpropanoid esters, flavonoids, anthocyanins, coumarins and many small phenolic molecules. Phenylpropanoids are also precursors of lignin.
Any process that modulates the frequency, rate or extent of epithelial cell migration.
Any process that activates or increases the frequency, rate or extent of the Notch signaling pathway.
Any biological process that results in permanent cessation of all vital functions of a cell. A cell should be considered dead when any one of the following molecular or morphological criteria is met: (1) the cell has lost the integrity of its plasma membrane; (2) the cell, including its nucleus, has undergone complete fragmentation into discrete bodies (frequently referred to as apoptotic bodies). The cell corpse (or its fragments) may be engulfed by an adjacent cell in vivo, but engulfment of whole cells should not be considered a strict criteria to define cell death as, under some circumstances, live engulfed cells can be released from phagosomes (see PMID:18045538).
Any process involved in the maintenance of an internal steady state of iron ions at the level of a cell.
Assembly of actin filament bundles in which the filaments are loosely packed (approximately 30-60 nm apart) and arranged with opposing polarities; the loose packing allows myosin (usually myosin-II) to enter the bundle.
The removal of an acyl group, any group or radical of the form RCO- where R is an organic group, from a macromolecule.
The process preceding formation of the peptide bond between the first two amino acids of a protein. This includes the formation of a complex of the ribosome, mRNA, and an initiation complex that contains the first aminoacyl-tRNA.
The stimulation of the activity of NF-kappaB-inducing kinase through phosphorylation at specific residues.
The process of communication from a neuron to a target (neuron, muscle, or secretory cell) across a synapse using the neurotransmitter acetylcholine.
Any process that stops, prevents, or reduces the frequency, rate, or extent of cytokine production contributing to an immune response.
Any process that modulates the frequency, rate, or extent of toll-like receptor 4 signaling pathway.
Any process that activates or increases the frequency, rate or extent of cellular protein localization. Cellular protein localization is any process in which a protein is transported to, and/or maintained in, a specific location and encompasses movement within the cell, from within the cell to the cell surface, or from one location to another at the surface of a cell.
A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the plasma membrane.
Any process that modulates the frequency, rate or extent of the regulated release of a neurotransmitter from a cell.
Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of a protein by the destruction of the native, active configuration, with or without the hydrolysis of peptide bonds.
Any process that initiates the activity of the inactive enzyme adenylate cyclase.
The process in which a relatively unspecialized cell acquires specialized features of a white adipocyte, an animal connective tissue cell involved in energy storage. White adipocytes have cytoplasmic lipids arranged in a unique vacuole.
The complete process of formation and maturation of an ovum or female gamete from a primordial female germ cell. Examples of this process are found in Mus musculus and Drosophila melanogaster.
A process that modulates short-term neuronal synaptic plasticity, the ability of neuronal synapses to change in the short-term as circumstances require. Short-term neuronal synaptic plasticity generally involves increasing or decreasing synaptic sensitivity.
The chemical reactions and pathways resulting in the breakdown of aldehydes, any organic compound with the formula R-CH=O.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a type I interferon stimulus. Type I interferons include the interferon-alpha, beta, delta, episilon, zeta, kappa, tau, and omega gene families.
The aggregation, arrangement and bonding together of a set of components to form a mitochondrial respiratory chain complex.
The chemical reactions and pathways resulting in the breakdown of hyaluronan, the naturally occurring anionic form of hyaluronic acid, any member of a group of glycosaminoglycans, the repeat units of which consist of beta-1,4 linked D-glucuronyl-beta-(1,3)-N-acetyl-D-glucosamine.
The chemical reactions and pathways resulting in the formation of any of a group of substances that are released on excitation from the axon terminal of a presynaptic neuron of the central or peripheral nervous system and travel across the synaptic cleft to either excite or inhibit the target cell.
The glucose-6-phosphate catabolic process in which, coupled to NADPH synthesis, glucose-6-P is oxidized with the formation of carbon dioxide (CO2) and ribulose 5-phosphate; ribulose 5-P then enters a series of reactions interconverting sugar phosphates. The pentose phosphate pathway is a major source of reducing equivalents for biosynthesis reactions and is also important for the conversion of hexoses to pentoses.
A series of molecular signals initiated by the binding of a cytokine to a receptor on the surface of a cell, and ending with regulation of a downstream cellular process, e.g. transcription.
The process of introducing a phosphate group into ADP, adenosine diphosphate, to produce ATP.
Any process that stops, prevents, or reduces the frequency, rate or extent of locomotion of a cell or organism.
The chemical reactions and pathways involving IMP, inosine monophosphate.
Any process involved in forming the mature 3' end of a non-coding RNA molecule.
The process whose specific outcome is the progression of lymph nodes over time, from their formation to the mature structure. A lymph node is a round, oval, or bean shaped structure localized in clusters along the lymphatic vessels, with a distinct internal structure including specialized vasculature and B- and T-zones for the activation of lymphocytes.
A process that modulates the size of a cellular component.
Transport of substances into, out of or within a mitochondrion.
The chemical reactions and pathways resulting in the formation of compounds that contain sulfur, such as the amino acids methionine and cysteine or the tripeptide glutathione.
The expansion of a T cell population by cell division. Follows T cell activation.
A process carried out by the nervous system that is required for the proper control of respiratory gaseous exchange. This process occurs in the respiratory center of the brain in vertebrates.
The process of targeting specific proteins to particular regions of the cell, typically membrane-bounded subcellular organelles. Usually requires an organelle specific protein sequence motif.
Any process that increases the frequency, rate or extent of cholesterol efflux. Cholesterol efflux is the directed movement of cholesterol, cholest-5-en-3-beta-ol, out of a cell or organelle.
A biosynthetic process - chemical reactions and pathways resulting in the formation of substances - involving a single organism.
Any process that activates or increases the frequency, rate or extent of viral genome replication.
Any process that stops, prevents, or reduces the frequency, rate or extent of the innate immune response.
Any process that modulates the frequency, rate or extent of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate selective glutamate receptor activity.
Any process that modulates the frequency, rate or extent of endothelial cell differentiation.
Any process that modulates the frequency, rate or extent of the regulated release of norepinephrine.
The process aimed at the progression of a glial cell over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell.
The chemical reactions and pathways resulting in the formation of a protein in a mitochondrion. This is a ribosome-mediated process in which the information in messenger RNA (mRNA) is used to specify the sequence of amino acids in the protein; the mitochondrion has its own ribosomes and transfer RNAs, and uses a genetic code that differs from the nuclear code.
Any process that modulates the frequency, rate or extent of retinoic acid receptor signaling pathway activity.
The process in which a relatively unspecialized cell acquires specialized features of a striated muscle cell; striated muscle fibers are divided by transverse bands into striations, and cardiac and voluntary muscle are types of striated muscle.
The process that modulates the force with which blood travels through the systemic arterial circulatory system. The process is controlled by a balance of processes that increase pressure and decrease pressure.
Any process that modulates the frequency, rate or extent of smooth muscle contraction.
The chemical reactions and pathways resulting in the breakdown of a polyol, any alcohol containing three or more hydroxyl groups attached to saturated carbon atoms.
Any intracellular signal transduction in which the signal is passed on within the cell via a second messenger; a small molecule or ion that can be quickly generated or released from intracellular stores, and can diffuse within the cell. Second-messenger signaling includes production or release of the second messenger, and effectors downstream of the second messenger that further transmit the signal within the cell.
Any process that mediates the transfer of information from one cell to another.
Any process that stops, prevents, or reduces the frequency, rate or extent of B cell activation.
Any process that activates or increases the frequency, rate or extent of coagulation.
Any process that decreases the rate, frequency, or extent of protein tyrosine kinase activity.
The process in which the anatomical structures of the lung are generated and organized.
The process in which a relatively unspecialized cell acquires specialized features of a ventricular cardiac muscle cell. Cardiac muscle cells are striated muscle cells that are responsible for heart contraction. The ventricle is the part of the heart that pumps blood out of the organ.
The process of removing one or more methyl groups from a molecule, involving the oxidation (i.e. electron loss) of one or more atoms in the substrate.
Any process that modulates the frequency or rate of macrophage activation.
Any series of molecular signals initiated by the binding of an extracellular ligand to a vascular endothelial growth factor receptor (VEGFR) located on the surface of the receiving cell, and ending with regulation of a downstream cellular process, e.g. transcription.
Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the MAPK cascade.
The chemical reactions and pathways involving macromolecules, large molecules including proteins, nucleic acids and carbohydrates, in multicellular organisms occurring at the tissue, organ, or organismal level.
The chemical reactions and pathways resulting in the breakdown of carbohydrate derivative.
The directed movement of L-enantiomer amino acids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
Any process that activates or increases the frequency, rate or extent of action potential creation, propagation or termination. This typically occurs via modulation of the activity or expression of voltage-gated ion channels.
Any process that modulates the frequency, rate or extent of muscle contraction.
Any process that modulates the frequency, rate or extent of cholesterol efflux. Cholesterol efflux is the directed movement of cholesterol, cholest-5-en-3-beta-ol, out of a cell or organelle.
Any process that modulates the frequency, rate or extent of exocytosis.
Any process that stops, prevents, or reduces the frequency, rate, or extent of toll-like receptor signaling pathway.
A process in which an anion is transported from one side of a membrane to the other by means of some agent such as a transporter or pore.
Any process that activates or increases the frequency, rate or extent of protein localization to the cell surface.
A protein modification process in which one or more groups of a small protein, such as ubiquitin or a ubiquitin-like protein, are covalently attached to or removed from a target protein.
The process whose specific outcome is the progression of the renal vesicle over time, from its formation to the mature structure. An epithelium is a tissue that covers the internal or external surfaces of an anatomical structure. The renal vesicle is the primordial structure of the nephron epithelium, and is formed by the condensation of mesenchymal cells.
Any process that modulates the levels of body fluids.
Any process that modulates the levels of hormone within an organism or a tissue. A hormone is any substance formed in very small amounts in one specialized organ or group of cells and carried (sometimes in the bloodstream) to another organ or group of cells in the same organism, upon which it has a specific regulatory action.
The process whose specific outcome is the progression of a bone cell over time, from initial commitment of the cell to a specific fate, to the fully functional differentiated cell.
Any process that modulates the frequency, rate or extent of a defense response.
Any process that stops, prevents, or reduces the frequency, rate or extent of a neurophysiological process.
The chemical reactions and pathways involving pyrimidine nucleoside monophosphate, a compound consisting of a pyrimidine base linked to a ribose or deoxyribose sugar esterified with phosphate on the sugar.
Any process that increases the rate or extent of heart growth. Heart growth is the increase in size or mass of the heart.
Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids.
Any process that stops, prevents, or reduces the frequency, rate, or extent of peptide secretion.
The process in which vesicles are directed to specific destination membranes. Targeting involves coordinated interactions among cytoskeletal elements (microtubules or actin filaments), motor proteins, molecules at the vesicle membrane and target membrane surfaces, and vesicle cargo.
Any process that modulates the frequency, rate or extent of the directed movement of proteins from the nucleus to the cytoplasm.
The detachment of cells from radial glial fibers at the appropriate time when they cease to migrate and form distinct layer in the cerebral cortex.
Any process that activates or increases the frequency, rate or extent of actin cytoskeleton reorganization.
Any process that establishes and transmits the specification of sexual status of an individual organism.
The chemical reactions and pathways resulting in the breakdown of oligosaccharides, molecules with between two and (about) 20 monosaccharide residues connected by glycosidic linkages.
The expansion of a B cell population by cell division. Follows B cell activation.
Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving DNA.
The aggregation, arrangement and bonding together of a mature, active proteasome complex.
The directed movement of a protein to a specific location in the endoplasmic reticulum.
The chemical reactions and pathways resulting in the formation of pyrimidine nucleoside triphosphate, a compound consisting of a pyrimidine base linked to a ribose or deoxyribose sugar esterified with triphosphate on the sugar.
Any process that stops, prevents, or reduces the frequency, rate or extent of endocytosis.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a potassium ion stimulus.
Any process that modulates the occurrence or rate of lymphocyte death by apoptotic process.
The chemical reactions and pathways involving small molecules, any low molecular weight, monomeric, non-encoded molecule.
The process whose specific outcome is the progression of the thymus over time, from its formation to the mature structure. The thymus is a symmetric bi-lobed organ involved primarily in the differentiation of immature to mature T cells, with unique vascular, nervous, epithelial, and lymphoid cell components.
Any process that stops, prevents or reduces the frequency, rate or extent of adherens junction organization.
Any biological process involved in the maintenance of an internal steady state.
The process in which the anatomical structure of the cranial nerves are generated and organized. The cerebellar cortex is a thin mantle of gray matter that covers the surface of each cerebral hemisphere. It has a characteristic morphology with convolutions (gyri) and crevices (sulci) that have specific functions. Six layers of nerve cells and the nerve pathways that connect them comprise the cerebellar cortex. Together, these regions are responsible for the processes of conscious thought, perception, emotion and memory as well as advanced motor function.
Any process that activates or increases the frequency, rate or extent of cytoplasmic transport.
The process in which the anatomical structures of epithelia are generated and organized. An epithelium consists of closely packed cells arranged in one or more layers, that covers the outer surfaces of the body or lines any internal cavity or tube.
The process whereby a relatively unspecialized cell acquires the specialized features of an osteoblast, a mesodermal or neural crest cell that gives rise to bone.
Any process that modulates the frequency, rate or extent of striated muscle cell differentiation.
Reactions triggered in response to the presence of a virus that act to protect the cell or organism.
The series of events required for an organism to receive a sensory chemical stimulus, convert it to a molecular signal, and recognize and characterize the signal. This is a neurological process.
Any process that modulates the frequency, rate or extent of ruffle assembly.
The deposition or aggregation of coloring matter in a cell.
Any process that stops, prevents, or reduces the frequency, rate or extent of calcium ion-dependent exocytosis.
The directed movement of substances into, out of or within a vacuole.
Any process that stops, prevents or reduces the rate or extent of cell adhesion to another cell.
Any process that activates or increases the frequency, rate or extent of viral release from host cell.
The directed killing of a target cell by a leukocyte.
Any process that activates or increases the frequency, rate or extent of vacuolar transport.
Any process that activates or increases the frequency, rate or extent of lyase activity, the catalysis of the cleavage of C-C, C-O, C-N and other bonds by other means than by hydrolysis or oxidation, or conversely adding a group to a double bond.
The synchronization of a circadian rhythm to photoperiod, the intermittent cycle of light (day) and dark (night).
The chemical reactions and pathways involving superoxide, the superoxide anion O2- (superoxide free radical), or any compound containing this species.
The chemical reactions and pathways involving organic hydroxy compound.
Any process that contributes to the maintenance of proper telomeric length and structure by affecting and monitoring the activity of telomeric proteins and lengthening the telomeric DNA.
The sequence of reactions within a cell required to convert absorbed photons into a molecular signal.
Any process that modulates the frequency, rate or extent of ligase activity, the catalysis of the ligation of two substances with concomitant breaking of a diphosphate linkage, usually in a nucleoside triphosphate. Ligase is the systematic name for any enzyme of EC class 6.
Any process that modulates the frequency, rate or extent of oxidoreductase activity, the catalysis of an oxidation-reduction (redox) reaction, a reversible chemical reaction in which the oxidation state of an atom or atoms within a molecule is altered. One substrate acts as a hydrogen or electron donor and becomes oxidized, while the other acts as hydrogen or electron acceptor and becomes reduced.
The directed movement of sulfate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a food stimulus; food is anything which, when taken into the body, serves to nourish or build up the tissues or to supply body heat.
Any process that modulates the frequency, rate or extent of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway.
A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of telomeres, terminal regions of a linear chromosome that include the telomeric DNA repeats and associated proteins.
The process whose specific outcome is the progression of an organismal system whose objective is to provide calibrated responses by an organism to a potential internal or invasive threat, over time, from its formation to the mature structure. A system is a regularly interacting or interdependent group of organs or tissues that work together to carry out a given biological process.
The chemical reactions and pathways resulting in the formation of the nucleotide cAMP (cyclic AMP, adenosine 3',5'-cyclophosphate).
The chemical reactions and pathways resulting in the breakdown of an alpha-amino acid.
The organization process that preserves a cellular component in a stable functional or structural state.
Any process that modulates the frequency, rate or extent of cardiac muscle cell contraction.
A series of molecular signals initiated by the binding of the Fc portion of immunoglobulin G (IgG) to an Fc-gamma receptor on the surface of a signal-receiving cell, and ending with regulation of a downstream cellular process, e.g. transcription. The Fc portion of an immunoglobulin is its C-terminal constant region.
The chemical reactions and pathways involving rRNA, ribosomal RNA, a structural constituent of ribosomes.
A system process carried out by the organs and tissues of the respiratory system. The respiratory system is an organ system responsible for respiratory gaseous exchange.
The directed movement of a neurotransmitter into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Neurotransmitters are any chemical substance that is capable of transmitting (or inhibiting the transmission of) a nerve impulse from a neuron to another cell.
Any process that modulates the frequency, rate or extent of T-helper cell differentiation.
Any process that modulates the frequency, rate or extent of voltage-gated calcium channel activity.
Any process that reduces the internal pH of an organism, part of an organism or a cell, measured by the concentration of the hydrogen ion.
Any process that increases the activity of triglyceride lipase.
The chemical reactions and pathways resulting in the breakdown of monosaccharides, polyhydric alcohols containing either an aldehyde or a keto group and between three to ten or more carbon atoms.
Any process that activates or increases the frequency, rate or extent of mRNA metabolic process.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a fungicide stimulus. Fungicides are chemicals used to kill fungi.
Any process in which a host organism stops, prevents, or reduces the frequency, rate or extent of viral transcription.
Any process that modulates the frequency, rate or extent of EGF-activated receptor activity.
Covalent attachment of the ubiquitin-like protein NEDD8 (RUB1) to another protein.
Any process involved in the maintenance of an internal steady state of potassium ions within an organism or cell.
The directed movement of hormones into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
The chemical reactions and pathways resulting in the breakdown of a protein by the destruction of the native, active configuration, with or without the hydrolysis of peptide bonds.
Any process that activates or increases the frequency, rate or extent of the activity of any intracellular steroid hormone receptor signaling pathway.
Any process that decreases the frequency, rate or extent of myotube differentiation. Myotube differentiation is the process in which a relatively unspecialized cell acquires specialized features of a myotube cell. Myotubes are multinucleated cells that are formed when proliferating myoblasts exit the cell cycle, differentiate and fuse.
The directed movement of inorganic anions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Inorganic anions are atoms or small molecules with a negative charge which do not contain carbon in covalent linkage.
The process of introducing a phosphate group into a carbohydrate, any organic compound based on the general formula Cx(H2O)y.
The targeting and directed movement of proteins into a cell or organelle.  Not all import involves an initial targeting event.
The chemical reactions and pathways involving a nucleoside bisphosphate, a compound consisting of a nucleobase linked to a deoxyribose or ribose sugar esterified with one phosphate group attached to each of two different hydroxyl groups on the sugar.
Any process that modulates the frequency, rate or extent of the activity of any intracellular steroid hormone receptor signaling pathway.
The process in which a relatively unspecialized epithelial cell becomes a more specialized epithelial cell of the mammary gland.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a gamma radiation stimulus. Gamma radiation is a form of electromagnetic radiation (EMR) or light emission of a specific frequency produced from sub-atomic particle interaction, such as electron-positron annihilation and radioactive decay. Gamma rays are generally characterized as EMR having the highest frequency and energy, and also the shortest wavelength, within the electromagnetic radiation spectrum.
Any process that modulates the rate or extent of heat generation.
Any process that modulates the rate, frequency or extent of fibroblast cell migration. Fibroblast cell migration is accomplished by extension and retraction of a pseudopodium.
Any process that initiates the directed movement of a motile cell or organism towards a higher concentration in a concentration gradient of a specific chemical.
The regrowth of a lost or destroyed body part, such as an organ or tissue.
A series of molecular signals in which a signal is conveyed from the cell surface to trigger the apoptotic death of a cell. The pathway starts with either a ligand binding to a cell surface receptor, or a ligand being withdrawn from a cell surface receptor (e.g. in the case of signaling by dependence receptors), and ends when the execution phase of apoptosis is triggered.
Any process that modulates the frequency, rate, extent or accuracy of translational elongation.
The binding of a cell to the extracellular matrix via adhesion molecules.
The progression of the pituitary gland over time from its initial formation until its mature state. The pituitary gland is an endocrine gland that secretes hormones that regulate many other glands.
The pairwise union of individuals for the purpose of sexual reproduction, ultimately resulting in the formation of zygotes.
A developmental process involving two tissues in which one tissue (the inducer) produces a signal that directs cell fate commitment of cells in the second tissue (the responder).
Any process that modulates the frequency, rate or extent of transferase activity, the catalysis of the transfer of a group, e.g. a methyl group, glycosyl group, acyl group, phosphorus-containing, or other groups, from one compound (generally regarded as the donor) to another compound (generally regarded as the acceptor). Transferase is the systematic name for any enzyme of EC class 2.
Any process that stops, prevents or reduces the frequency, rate or extent of alcohol biosynthetic process.
The cell cycle process in which paired chromosomes are detached from each other. Chromosome separation begins with the release of cohesin complexes from chromosomes; in budding yeast, this includes the cleavage of cohesin complexes along the chromosome arms, followed by the separation of the centromeric regions. Chromosome separation also includes formation of chromatid axes mediated by condensins, and ends with the disentangling of inter-sister catenation catalyzed by topoisomerase II (topo II).
The chemical reactions and pathways involving ceramide oligosaccharides carrying in addition to other sugar residues, one or more sialic acid residues.
A homeostatic process involved in the maintenance of an internal steady state within a defined tissue of an organism, including control of cellular proliferation and death and control of metabolic function.
The process in which an antigen-presenting cell expresses antigen (peptide or lipid) on its cell surface in association with an MHC class Ib protein complex. Class Ib here refers to non-classical class I molecules, such as those of the CD1 or HLA-E gene families.
The series of molecular signals generated by the binding of gamma-aminobutyric acid (GABA, 4-aminobutyrate), an amino acid which acts as a neurotransmitter in some organisms, to a cell surface receptor.
Any process that activates or increases the frequency, rate or extent of the directed movement of sterols into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
An immune response based on directed amplification of specific receptors for antigen produced through a somatic diversification process that includes somatic recombination of germline gene segments encoding immunoglobulin superfamily domains, and allowing for enhanced responses upon subsequent exposures to the same antigen (immunological memory). Recombined receptors for antigen encoded by immunoglobulin superfamily domains include T cell receptors and immunoglobulins (antibodies). An example of this is the adaptive immune response found in Mus musculus.
A regulatory process that halts progression through the cell cycle during one of the normal phases (G1, S, G2, M).
The chemical reactions and pathways involving any of the compounds secreted by the thyroid gland, largely thyroxine and triiodothyronine.
The recognition and removal of an apoptotic cell by a neighboring cell or by a phagocyte.
The process in which an organism effects a change in the structure or processes of a second organism.
The aggregation, arrangement and bonding together of the mature ribosome and of its subunits.
Any process that stops, prevents, or reduces the frequency, rate or extent of actin depolymerization.
The re-formation of a broken phosphodiester bond in the DNA backbone, carried out by DNA ligase, that contributes to DNA repair.
Any process that modulates the frequency, rate or extent of cell junction assembly.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of detection of, or exposure to, a hyperosmotic environment, i.e. an environment with a higher concentration of solutes than the organism or cell.
Any process that modulates the rate, frequency or extent of SMAD protein import into the nucleus, i.e. the directed movement of a SMAD proteins from the cytoplasm into the nucleus. Pathway-restricted SMAD proteins and common-partner SMAD proteins are involved in the transforming growth factor beta receptor signaling pathways.
Any process that stops, prevents, or reduces the frequency, rate, or extent of natural killer cell mediated immunity.
The progression of the artery over time, from its initial formation to the mature structure. An artery is a blood vessel that carries blood away from the heart to a capillary bed.
The removal of an alkyl group from a protein amino acid. An alkyl group is any group derived from an alkane by removal of one hydrogen atom.
Any process that stops, prevents, or reduces the frequency, rate or extent of dendrite morphogenesis.
Any process that stops, prevents, or reduces the frequency, rate, or extent of type I interferon production. Type I interferons include the interferon-alpha, beta, delta, episilon, zeta, kappa, tau, and omega gene families.
The aggregation, arrangement and bonding together of the extracellular matrix.
The conversion of DNA-damage induced single-stranded gaps into large molecular weight DNA after replication. Includes pathways that remove replication-blocking lesions in conjunction with DNA replication.
The process whose specific outcome is the progression of the skeleton over time, from its formation to the mature structure. The skeleton is the bony framework of the body in vertebrates (endoskeleton) or the hard outer envelope of insects (exoskeleton or dermoskeleton).
The chemical reactions and pathways involving organophosphates, any phosphate-containing organic compound.
The process whose specific outcome is the progression of the cardiac myofibril over time, from its formation to the mature structure. A cardiac myofibril is a myofibril specific to cardiac muscle cells.
Any process that modulates the frequency, rate or extent of heart contraction. Heart contraction is the process in which the heart decreases in volume in a characteristic way to propel blood through the body.
The chemical reactions and pathways resulting in the formation of amino acids, organic acids containing one or more amino substituents.
The process in which the anatomical structure of the cranial nerves are generated and organized. The cranial nerves are composed of twelve pairs of nerves that emanate from the nervous tissue of the hindbrain. These nerves are sensory, motor, or mixed in nature, and provide the motor and general sensory innervation of the head, neck and viscera. They mediate vision, hearing, olfaction and taste and carry the parasympathetic innervation of the autonomic ganglia that control visceral functions.
The initiation of the activity of the inactive enzyme JUN kinase (JNK).
Any process that modulates the rate, frequency, or extent of brown fat cell differentiation. Brown fat cell differentiation is the process in which a relatively unspecialized cell acquires specialized features of a brown adipocyte, an animal connective tissue cell involved in adaptive thermogenesis. Brown adipocytes contain multiple small droplets of triglycerides and a high number of mitochondria.
A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of fibrils, insoluble fibrous aggregates consisting of polysaccharides and/or proteins.
The chemical reactions and pathways involving long-chain fatty acids, A long-chain fatty acid is a fatty acid with a chain length between C13 and C22.
The directed movement of inorganic cations with a valency of one into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Inorganic cations are atoms or small molecules with a positive charge which do not contain carbon in covalent linkage.
The process in which the extent of cardiac muscle contraction is reduced.
Any process that activates or increases the frequency, rate or extent of behavior, the internally coordinated responses (actions or inactions) of whole living organisms (individuals or groups) to internal or external stimuli.
A series of molecular signals in which a cell uses calcium ions released from an intracellular store to convert a signal into a response.
The process whose specific outcome is the progression of the neural tube over time, from its formation to the mature structure. The mature structure of the neural tube exists when the tube has been segmented into the forebrain, midbrain, hindbrain and spinal cord regions. In addition neural crest has budded away from the epithelium.
The chemical reactions and pathways involving a polysaccharide, a polymer of many (typically more than 10) monosaccharide residues linked glycosidically.
Any process that modulates the frequency, rate or extent of intracellular signal transduction.
The chemical reactions and pathways involving a cyclic nucleotide, a nucleotide in which the phosphate group is in diester linkage to two positions on the sugar residue.
Any process that activates or increases the rate or extent of T cell proliferation.
Any physiological process involved in changing the position of a multicellular organism or an anatomical part of a multicellular organism.
The process that results in the assembly of clathrin triskelia into the ordered structure known as a clathrin cage.
Any process that stops, prevents, or reduces the frequency, rate or extent of meiosis.
The process in which a relatively unspecialized cell acquires specialized features of a vascular smooth muscle cell.
Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of substances.
Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving nitrogen or nitrogenous compounds.
The process in which a segment of DNA is incorporated into another, usually larger, DNA molecule such as a chromosome.
A change in the morphology or behavior of a cell resulting from exposure to an activating factor such as a cellular or soluble ligand.
Any process that modulates the frequency, rate or extent of the formation of a myelin sheath around nerve axons.
Any process that stops, prevents, or reduces the frequency, rate or extent of JUN kinase activity.
Any process that modulates the frequency, rate or extent of axon guidance.
Any process that modulates the frequency, rate or extent of the regulated release of dopamine.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a copper ion stimulus.
Any process that modulates the frequency, rate or extent of the circadian sleep/wake cycle.
Any process that stops, prevents or reduces the frequency, rate or extent of cellular protein catabolic process.
Any process that modulates the frequency, rate or extent of the error-free repair of a double-strand break in DNA in which the broken DNA molecule is repaired using homologous sequences.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an axon injury stimulus.
Any process that modulates the frequency, rate or extent of a process involved in the formation, arrangement of constituent parts, or disassembly of a vacuole.
Any process that modulates the frequency, rate or extent of gene expression such that an expression pattern recurs with a regularity of approximately 24 hours.
The chemical reactions and pathways involving retinol, one of the three compounds that makes up vitamin A.
The chemical reactions and pathways involving oxaloacetate, the anion of oxobutanedioic acid, an important intermediate in metabolism, especially as a component of the TCA cycle.
Any process that decreases the rate or extent of the tumor necrosis factor-mediated signaling pathway. The tumor necrosis factor-mediated signaling pathway is the series of molecular signals generated as a consequence of tumor necrosis factor binding to a cell surface receptor.
Any process that stops, prevents, or reduces the frequency, rate or extent of exocytosis.
A series of molecular signals generated as a consequence of a intracellular steroid hormone receptor binding to one of its physiological ligands.
Any process that modulates the frequency, rate or extent of the activity of the Wnt signal transduction pathway.
Any process that stops, prevents or reduces the frequency, rate or extent of cell junction assembly.
The process in which an antigen-presenting cell expresses peptide antigen in association with an MHC protein complex on its cell surface, including proteolysis and transport steps for the peptide antigen both prior to and following assembly with the MHC protein complex. The peptide antigen is typically, but not always, processed from an endogenous or exogenous protein.
The series of molecular signals mediated by the serine/threonine kinase Hippo or one of its orthologs. In Drosophila, Hippo in complex with the scaffold protein Salvador (Sav), phosphorylates and activates Warts (Wts), which in turn phosphorylates and inactivates the Yorkie (Yki) transcriptional activator. The core fly components hippo, sav, wts and mats are conserved in mammals as STK4/3 (MST1/2), SAV1/WW45, LATS1/2 and MOB1.
Any process that decreases the rate, frequency, or extent of epithelial to mesenchymal transition. Epithelial to mesenchymal transition where an epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell.
Any process that modulates the rate, frequency or extent of membrane depolarization. Membrane depolarization is the process in which membrane potential changes in the depolarizing direction from the resting potential, usually from negative to positive.
The chemical reactions and pathways resulting in the formation of any amino sugar, sugars containing an amino group in place of a hydroxyl group.
Any process that modulates the frequency, rate or extent of nervous system development, the origin and formation of nervous tissue.
Any process that modulates the frequency, rate or extent of the directed movement of a protein to a specific location on a chromosome.
Any process that modulates the frequency, rate or extent of cardiac muscle cell differentiation.
Any process that increases the frequency, rate or extent of a digestive system process, a physical, chemical, or biochemical process carried out by living organisms to break down ingested nutrients into components that may be easily absorbed and directed into metabolism.
A series of molecular signals in which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The pathway is induced by the detection of DNA damage, and ends when the execution phase of apoptosis is triggered.
The chemical reactions and pathways leading to the formation of tetrapyrroles, natural pigments containing four pyrrole rings joined by one-carbon units linking position 2 of one pyrrole ring to position 5 of the next.
The chemical reactions and pathways resulting in the formation of a nucleoside phosphate.
The aggregation, arrangement and bonding together of proteins and lipids to form a protein-lipid complex.
Any process that increases the frequency, rate or extent of the directed movement of sodium ions (Na+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
The series of events in which a stimulus from another organism is received and converted into a molecular signal.
The directed movement of a substance or cellular entity, such as a protein complex or organelle, to a specific location within, or in the membrane of, a cell.
A series of molecular signals initiated by glutamate binding to a glutamate receptor on the surface of the target cell, and proceeding with the activated receptor promoting the exchange of GDP for GTP on the alpha-subunit of an associated heterotrimeric G-protein complex. Ends with regulation of a downstream cellular process, e.g. transcription.
The progression of the neural retina over time from its initial formation to the mature structure. The neural retina is the part of the retina that contains neurons and photoreceptor cells.
Any phosphodiester bond hydrolysis involved in the conversion of a primary ribosomal RNA (rRNA) transcript into a mature rRNA molecule.
Any process involved in the progression from anaphase/telophase to G1 that is associated with a conversion from high to low mitotic CDK activity.
The process in which the anatomical structures of the forelimb are generated and organized. The forelimbs are the front limbs of an animal, e.g. the arms of a human.
The chemical reactions and pathways resulting in the formation of amino acids of the aspartate family, comprising asparagine, aspartate, lysine, methionine and threonine.
The directed movement of manganese (Mn) ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
Any process that activates or increases the frequency, rate or extent of the covalent addition of a methyl group to the lysine at position 4 of histone H3.
The process whose specific outcome is the progression of a neuron projection over time, from its formation to the mature structure. A neuron projection is any process extending from a neural cell, such as axons or dendrites (collectively called neurites).
Generation of the male gamete; specialised haploid cells produced by meiosis and along with a female gamete takes part in sexual reproduction.
Any process that increases the rate, frequency or extent of fibroblast cell migration. Fibroblast cell migration is accomplished by extension and retraction of a pseudopodium.
Any process that stops, prevents or reduces the frequency, rate or extent of response to oxidative stress.
The aggregation, arrangement and bonding together of a set of components to form a protein complex, mediated by chaperone molecules that do not form part of the finished complex.
The directed movement of an organelle along a microtubule, mediated by motor proteins. This process begins with the attachment of an organelle to a microtubule, and ends when the organelle reaches its final destination.
The process whose specific outcome is the progression of a chondrocyte over time, from its commitment to its mature state. Chondrocyte development does not include the steps involved in committing a chondroblast to a chondrocyte fate.
A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of membrane rafts, small (10-200 nm), heterogeneous, highly dynamic, sterol- and sphingolipid-enriched membrane domains that compartmentalize cellular processes.
The cell cycle process in which replicated homologous chromosomes are organized and then physically separated and apportioned to two sets during the mitotic cell cycle. Each replicated chromosome, composed of two sister chromatids, aligns at the cell equator, paired with its homologous partner. One homolog of each morphologic type goes into each of the resulting chromosome sets.
The process in which tubulin alpha-beta heterodimers begin aggregation to form an oligomeric tubulin structure (a microtubule seed). Microtubule nucleation is the initiating step in the formation of a microtubule in the absence of any existing microtubules ('de novo' microtubule formation).
The directed movement of a protein to a specific location on or in an organelle. Encompasses establishment of localization in the membrane or lumen of a membrane-bounded organelle.
Any process that stops, prevents, or reduces the frequency, rate, or extent of an acute inflammatory response.
Any process that modulates the frequency, rate or extent of the binding or confining calcium ions such that they are separated from other components of a biological system.
Any process that modulates the frequency, rate or extent of membrane lipid metabolic process.
The macroautophagy process in which a region of cytoplasm containing an intracellular pathogen or some part of an intracellular pathogen (e.g. viral capsid) is enclosed in a double membrane bound autophagosome, which then fuses with the lysosome leading to degradation of the contents.
The process in which a drug is transported from one side of a membrane to the other by means of some agent such as a transporter or pore.
Any process that activates or increases the frequency, rate or extent of membrane depolarization.
Any series of molecular signals generated as a consequence of binding to a toll-like receptor where the MyD88 adaptor molecule mediates transduction of the signal. Toll-like receptors directly bind pattern motifs from a variety of microbial sources to initiate innate immune response.
Any process that modulates the frequency, rate or extent of the process of creating protein polymers.
Any process that modulates the frequency, rate or extent of the process of directing proteins towards a membrane, usually using signals contained within the protein.
The process whose specific outcome is the progression of an epithelium in the kidney over time, from its formation to the mature structure. An epithelium is a tissue that covers the internal or external surfaces of an anatomical structure.
The modification of histone H2A by addition of one or more ubiquitin groups.
The process in which calcium salts are deposited into calcareous tooth structures such as dental enamel, dentin and cementum.
Any process that modulates the frequency, rate or extent of the cyclical phases of growth (anagen), regression (catagen), quiescence (telogen), and shedding (exogen) in the life of a hair.
Any process that stops, prevents, or reduces the frequency, rate or extent of bone remodeling.
Any process that activates or increases the frequency, rate or extent of receptor mediated endocytosis, the uptake of external materials by cells, utilizing receptors to ensure specificity of transport.
A cell cycle process that sets the alignment of mitotic spindle relative to other cellular structures.
Any process that activates or increases the frequency, rate or extent of protein oligomerization.
A cell cycle checkpoint that originates from the mitotic or meiotic spindle.
Any process that activates or increases the frequency, rate or extent of STAT cascade.
The chemical reactions and pathways resulting in the formation of leukotriene, a pharmacologically active substance derived from a polyunsaturated fatty acid, such as arachidonic acid.
Any process that activates or increases the frequency, rate or extent of substrate adhesion-dependent cell spreading.
Any process that activates or increases the frequency, rate or extent of thymocyte aggregation.
The chemical reactions and pathways involving any of a group of physiologically important biogenic amines that possess a catechol (3,4-dihydroxyphenyl) nucleus and are derivatives of 3,4-dihydroxyphenylethylamine.
Any process that activates or increases the frequency, rate or extent of protein complex disassembly, the disaggregation of a protein complex into its constituent components.
The initial formation of a blastocyst from a solid ball of cells known as a morula.
A process that modulates the rate or extent of water loss from an organism via the skin.
Any process that stops, prevents or reduces the frequency, rate or extent of regulated secretory pathway.
The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the cells of the metanephros as it progresses from its formation to the mature state.
Any process that activates or increases the frequency, rate or extent of alcohol biosynthetic process.
Any process that modulates the frequency, rate or extent of epithelial cell differentiation involved in kidney development.
The directed movement of magnesium (Mg) ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
The chemical reactions and pathways involving any ribonucleoside, a nucleoside in which pyrimidine base is linked to a ribose (beta-D-ribofuranose) molecule.
A process in which a protein is transported to, or maintained at, the centrosome.
Any process that activates or increases the rate or extent of B cell proliferation.
Any process that increases the frequency, rate or extent of a process involved in the formation, arrangement of constituent parts, or disassembly of an organelle.
The expansion of a muscle cell population by cell division.
The process in which a cell becomes capable of differentiating autonomously into a ventral spinal cord interneuron in an environment that is neutral with respect to the developmental pathway.
The directed movement of amino acids, organic acids containing one or more amino substituents across a membrane by means of some agent such as a transporter or pore.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus by the chemical structure of the anion portion of the dissociated acid (rather than the acid acting as a proton donor). The acid chemical may be in gaseous, liquid or solid form.
The internalization of bacteria, immune complexes and other particulate matter or of an apoptotic cell by phagocytosis, including the membrane and cytoskeletal processes required, which involves one of three mechanisms: zippering of pseudopods around a target via repeated receptor-ligand interactions, sinking of the target directly into plasma membrane of the phagocytosing cell, or induced uptake via an enhanced membrane ruffling of the phagocytosing cell similar to macropinocytosis.
Any process that modulates the frequency, rate, or extent of tolerance induction.
Any process that modulates the frequency, rate or extent of corticosteroid hormone secretion.
A cell aging process stimulated in response to cellular stress, whereby normal cells lose the ability to divide through irreversible cell cycle arrest.
The addition of a sulfate group to a molecule.
Any process that modulates the rate or extent of progression through the meiotic cell cycle.
The removal of an alkyl group from one or more nucleotides within an DNA molecule.
Movement of organelles or other particles along actin filaments, or sliding of actin filaments past each other, mediated by motor proteins.
Any process that activates or increases the rate or extent of epithelial cell proliferation.
The myofibril assembly process that results in the organization of muscle actomyosin into sarcomeres. The sarcomere is the repeating unit of a myofibril in a muscle cell, composed of an array of overlapping thick and thin filaments between two adjacent Z discs.
Any process that activates or increases the frequency, rate, or extent of B cell mediated immunity.
The type of sexual cycle seen in females, often with physiologic changes in the endometrium that recur at regular intervals during the reproductive years.
Any process that stops, prevents or reduces the frequency, rate or extent of nitric oxide metabolic process.
The process whose specific outcome is the progression of the brain ventricular system over time, from its formation to the mature structure. The brain ventricular system consists of four communicating cavities within the brain that are continuous with the central canal of the spinal cord. These cavities include two lateral ventricles, the third ventricle and the fourth ventricle. Cerebrospinal fluid fills the ventricles and is produced by the choroid plexus.
Locomotory behavior in a fully developed and mature organism.
Any process that modulates the frequency, rate or extent of activated T cell proliferation.
Any process that activates or increases the frequency, rate, or extent of a homeostatic process.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a gravitational stimulus.
Any process that modulates the frequency, rate or extent of the regulated release of immunoglobulins from a cell.
The chemical reactions and pathways involving acetyl-CoA, a derivative of coenzyme A in which the sulfhydryl group is acetylated; it is a metabolite derived from several pathways (e.g. glycolysis, fatty acid oxidation, amino-acid catabolism) and is further metabolized by the tricarboxylic acid cycle. It is a key intermediate in lipid and terpenoid biosynthesis.
The chemical reactions and pathways involving creatine (N-(aminoiminomethyl)-N-methylglycine), a compound synthesized from the amino acids arginine, glycine, and methionine that occurs in muscle.
Any process that modulates the frequency, rate or extent of cellular component biogenesis, a process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of a cellular component.
Any process that increases the rate, frequency or extent of macrophage derived foam cell differentiation. Macrophage derived foam cell differentiation is the process in which a macrophage acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions.
The directed movement of iron (Fe) ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
Any process that modulates the frequency, rate or extent of a protein or other molecule binding to a receptor.
Any process that activates or increases the frequency, rate or extent of the directed movement of potassium ions (K+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
Any process that activates, maintains or increases the frequency, rate or extent of nervous system development, the origin and formation of nervous tissue.
Any process that modulates the frequency, rate or extent of cardiac muscle cell proliferation.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an oxygen-containing compound stimulus.
Any process that modulates the frequency, rate or extent of interleukin-10 secretion.
Any process that modulates the rate, frequency or extent of the formation of a lamellipodium, a thin sheetlike extension of the surface of a migrating cell.
The chemical reactions and pathways involving any of a class of organic compounds that contain the carbonyl group, CO, and in which the carbonyl group is bonded only to carbon atoms, as carried out by individual cells. The general formula for a ketone is RCOR, where R and R are alkyl or aryl groups.
The process whose specific outcome is the progression of the cranial nerves over time, from its formation to the mature structure. The cranial nerves are composed of twelve pairs of nerves that emanate from the nervous tissue of the hindbrain. These nerves are sensory, motor, or mixed in nature, and provide the motor and general sensory innervation of the head, neck and viscera. They mediate vision, hearing, olfaction and taste and carry the parasympathetic innervation of the autonomic ganglia that control visceral functions.
The series of molecular signals initiated by binding of a Wnt protein to a receptor on the surface of the target cell where activated receptors leads to an increase in intracellular calcium and activation of protein kinase C (PKC).
A series of molecular signals initiated by binding of a ligand to the tyrosine kinase receptor EGFR (ERBB1) on the surface of a cell. The pathway ends with regulation of a downstream cellular process, e.g. transcription.
The creation of greater cell numbers in the forebrain due to cell division of progenitor cells.
Any process that results in a change in state or activity of an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a muramyl dipeptide stimulus. Muramyl dipeptide is derived from peptidoglycan.
Any process that modulates the frequency, rate or extent of the directed movement of a motile cell or organism towards a higher concentration in a concentration gradient of a specific chemical.
Any process that modulates the frequency, rate or extent of the immune response, the immunological reaction of an organism to an immunogenic stimulus.
Any process that stops, prevents, or reduces the frequency, rate or extent of the Notch signaling pathway.
The chemical reactions and pathways resulting in the breakdown of membrane lipids, any lipid found in or associated with a biological membrane.
Any process that activates or increases the rate of neuroblast proliferation.
The process in which the anatomical structures of cartilage are generated and organized.
The controlled release of a peptide from a cell or a tissue.
The chemical reactions and pathways involving a thioester, a compound of general formula RC(=O)SR' in which the linking oxygen in an ester is replaced by a sulfur atom. They are the product of esterification between a carboxylic acid and a thiol.
Any process that stops, prevents or reduces the frequency, rate or extent of intrinsic apoptotic signaling pathway in response to DNA damage.
Any process that modulates the frequency, rate or extent of T-helper 2 cell differentiation.
Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving amides.
The chemical reactions and pathways involving a purine ribonucleoside bisphosphate, a compound consisting of a purine base linked to a ribose sugar esterified with one phosphate group attached to each of two different hydroxyl groups on the sugar.
The modification of peptidyl-cysteine.
The process in which a relatively unspecialized hemopoietic precursor cell acquires the specialized features of a leukocyte. A leukocyte is an achromatic cell of the myeloid or lymphoid lineages capable of ameboid movement, found in blood or other tissue.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an exogenous double-stranded RNA stimulus.
The process in which the anatomical structures of embryonic epithelia are generated and organized.
A process in which force is generated within skeletal muscle tissue, resulting in a change in muscle geometry. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. In the skeletal muscle, the muscle contraction takes advantage of an ordered sarcomeric structure and in most cases it is under voluntary control.
Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving any hormone.
The process whose specific outcome is the progression of the tongue over time, from its formation to the mature structure. The tongue is the movable, muscular organ on the floor of the mouth of most vertebrates, in many other mammals is the principal organ of taste, aids in the prehension of food, in swallowing, and in modifying the voice as in speech.
The increase in size or mass of a bone that contributes to the shaping of that bone.
Assembly or disassembly of actin filaments by the addition or removal of actin monomers from a filament.
Any process in which an organism or cell protects itself from ultraviolet radiation (UV), which may also result in resistance to repeated exposure to UV.
A protein modification process in which one or more covalently attached groups of a small protein, such as ubiquitin or a ubiquitin-like protein, are removed from a target protein.
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of nitric oxide.
The chemical reactions and pathways involving phosphatidylglycerols, any of a class of phospholipids in which the phosphatidyl group is esterified to the hydroxyl group of glycerol. They are important constituents of cell membranes.
The chemical reactions and pathways resulting in the formation of one of a family of organic molecules consisting of a pyrimidine base covalently bonded to a sugar ribose (a ribonucleoside) or deoxyribose (a deoxyribonucleoside).
The process resulting in the release of a polypeptide chain from the ribosome, usually in response to a termination codon (UAA, UAG, or UGA in the universal genetic code).
A cellular process that is involved in cytokinesis (the division of the cytoplasm of a cell and its separation into two daughter cells).
The process in which the anatomical structure of the endocardial cushion is generated and organized. The endocardial cushion is a specialized region of mesenchymal cells that will give rise to the heart septa and valves.
Any process that modulates the frequency, rate or extent of the innate immune response, the organism's first line of defense against infection.
A cellular transport process in which transported substances are moved in membrane-bounded vesicles; transported substances are enclosed in the vesicle lumen or located in the vesicle membrane. The process begins with a step that directs a substance to the forming vesicle, and includes vesicle budding and coating. Vesicles are then targeted to, and fuse with, an acceptor membrane.
The appearance of interleukin-1 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.
A process in which a host organism modulates the frequency, rate or extent of any of a process being mediated by a virus with which it is infected.
Any process that modulates the frequency, rate or extent of DNA repair.
Any process that modulates the proportions or spatial arrangement of lipids in a cellular membrane.
An automatic response to a stimulus beginning with a nerve impulse from a receptor and ending with the action of an effector such as a gland or a muscle. Signaling never reaches a level of consciousness.
Any process involved in the carrying out of an immune response by a leukocyte.
The chemical reactions and pathways resulting in the biosynthesis of deoxyribose phosphate, the phosphorylated sugar 2-deoxy-erythro-pentose.
Any process that stops, prevents or reduces the frequency, rate or extent of serine-type peptidase activity.
A process in which a protein is transported to, or maintained in, the cell periphery.
Any process that modulates the frequency, rate or extent of protein glycosylation. Protein glycosylation is the addition of a carbohydrate or carbohydrate derivative unit to a protein amino acid, e.g. the addition of glycan chains to proteins.
Any process that stops, prevents, or reduces the frequency, rate or extent of multiplication or reproduction of fibroblast cells.
Any process that modulates the frequency, rate or extent of muscle tissue development.
The chemical reactions and pathways resulting in the formation of organic acids, any acidic compound containing carbon in covalent linkage.
Any process that stops, prevents, or reduces the frequency, rate or extent of DNA-dependent DNA replication.
Any process that modulates the frequency, rate, or extent of leukocyte migration.
A developmental process, independent of morphogenetic (shape) change, that is required for an organ to attain its fully functional state. An organ is a tissue or set of tissues that work together to perform a specific function or functions.
Any process that modulates the frequency, rate or extent of cellular response to heat.
Any process that activates or increases the frequency, rate, or extent of an acute inflammatory response.
A gastrulation process in which the initial invagination becomes the anus and the mouth forms second.
The process whose specific outcome is the progression of the endocardium over time, from its formation to the mature structure. The endocardium is an anatomical structure comprised of an endothelium and an extracellular matrix that forms the innermost layer of tissue of the heart, and lines the heart chambers.
The process in which a mesodermal, bone marrow or neural crest cell acquires specialized features of an endothelial cell, a thin flattened cell. A layer of such cells lines the inside surfaces of body cavities, blood vessels, and lymph vessels, making up the endothelium.
Any process that stops, prevents or reduces the frequency, rate or extent of cellular protein localization. Cellular protein localization is any process in which a protein is transported to, and/or maintained in, a specific location and encompasses movement within the cell, from within the cell to the cell surface, or from one location to another at the surface of a cell.
The introduction of semen or sperm into the genital tract of a female.
Any process that modulates the frequency, rate or extent of the directed movement of nucleobases, nucleosides, nucleotides and nucleic acids, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
The chemical reactions and pathways resulting in the formation of phosphatidylinositol-3-phosphate, a phosphatidylinositol monophosphate carrying the phosphate group at the 3-position.
The chemical reactions and pathways resulting in the breakdown of a cyclic nucleotide, a nucleotide in which the phosphate group is in diester linkage to two positions on the sugar residue.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an epidermal growth factor stimulus.
Any process that activates or increases the frequency, rate or extent of the directed movement of a solute from one side of a membrane to the other.
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of nucleotides.
Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving carbohydrate.
The series of molecular signals initiated by binding of a Wnt protein to a frizzled family receptor on the surface of the target cell and ending with a change in cell state.
Any process that modulates levels of neurotransmitter.
Any process that activates or increases the frequency, rate or extent of signaling via the stress-activated protein kinase signaling cascade.
The modification of peptidyl-arginine.
The regionalization process in which the identity of an organ primordium is specified. Identity is considered to be the aggregate of characteristics by which a structure is recognized.
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways by which individual cells transform amines.
The synthesis of ribosomal RNA (rRNA), any RNA that forms part of the ribosomal structure, from a DNA template.
Any process that activates or increases the frequency, rate or extent of the directed movement of lipids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
The process that gives rise to the configuration of the constituent parts of an anatomical structure. This process pertains to the physical shaping of a rudimentary structure. Anatomical structures can be macroscopic such as a carpel, or microscopic such as an acrosome.
A transition where an epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell.
The process of introducing a phosphate group on to a pathway restricted SMAD protein. A pathway restricted SMAD protein is an effector protein that acts directly downstream of the transforming growth factor family receptor.
A membrane budding which involves only one organism.
Any process that stops, prevents, or reduces the frequency, rate or extent of signal transduction mediated by the MAPKKK cascade.
The process in which the spongiotrophoblast layer of the placenta progresses from its formation to its mature state.
Any process that stops, prevents, or reduces the frequency, rate or extent of nervous system development, the origin and formation of nervous tissue.
The modification of histone H2A by addition of a single ubiquitin group.
Any process that modulates the frequency, rate or extent of extracellular matrix organization.
The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the cells of the spinal cord. Differentiation includes the processes involved in commitment of a cell to a specific fate.
A cell cycle checkpoint that detects and negatively regulates progression from G2 to M phase as part of a mitotic cell cycle.
Any process that activates or increases the frequency, rate or extent of interleukin-8 secretion.
The chemical reactions and pathways involving pyrimidine nucleobases, 1,3-diazine, organic nitrogenous bases.
Posttranscriptional addition of a methyl group to either a nucleotide or 2'-O ribose in a polyribonucleotide. Usually uses S-adenosylmethionine as a cofactor.
Any process that generates a purine-containing compound, any nucleobase, nucleoside, nucleotide or nucleic acid that contains a purine base, from derivatives of them without de novo synthesis.
A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a stereocilium. A stereocilium is an actin-based protrusion from the apical surface of inner ear receptor cells.
Any process that stops, prevents or reduces the frequency, rate or extent of cation transmembrane transport.
Any process that modulates the frequency, rate or extent of phospholipid metabolic process.
Any process that stops, prevents or reduces the frequency, rate or extent of cytoplasmic transport.
Any process that activates or increases the frequency, rate or extent of cellular response to transforming growth factor beta stimulus.
The regrowth of axons following their loss or damage.
Any cellular process that depends upon or alters the microtubule cytoskeleton, that part of the cytoskeleton comprising microtubules and their associated proteins.
Any intracellular signal transduction in which the signal is passed on within the cell via calcium ions.
The process in which a low-density lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts degraded.
Any process involved in the controlled movement of a sperm cell.
Any process that stops, prevents, or reduces the frequency, rate or extent of the activity of a transcription factor, any factor involved in the initiation or regulation of transcription.
Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of a protein by the destruction of the native, active configuration, with or without the hydrolysis of peptide bonds.
The chemical reactions and pathways involving amino acids, carboxylic acids containing one or more amino groups, as carried out by individual cells.
Any process that increases the frequency, rate or extent of DNA binding. DNA binding is any process in which a gene product interacts selectively with DNA (deoxyribonucleic acid).
The directed movement of a nucleotide, any compound consisting of a nucleoside that is esterified with (ortho)phosphate, into, out of or within a cell.
Any process that modulates the frequency, rate or extent of hair follicle development.
The assembly of cristae, the inwards folds of the inner mitochondrial membrane.
The trafficking of synaptic vesicles from the pre-synaptic membrane so the vesicle can dock and prime for another round of exocytosis and neurotransmitter release. Recycling occurs after synaptic vesicle exocytosis, and is necessary to replenish presynaptic vesicle pools, sustain transmitter release and preserve the structural integrity of the presynaptic membrane.
Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving nucleosides.
The regionalization process in which the areas along the dorsal/ventral axis are established that will lead to differences in cell differentiation. The dorsal/ventral axis is defined by a line that runs orthogonal to both the anterior/posterior and left/right axes. The dorsal end is defined by the upper or back side of an organism. The ventral end is defined by the lower or front side of an organism.
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving a vitamin, one of a number of unrelated organic substances that occur in many foods in small amounts and that are necessary in trace amounts for the normal metabolic functioning of the body.
The enzymatic release of energy from inorganic and organic compounds (especially carbohydrates and fats) which requires oxygen as the terminal electron acceptor.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an insulin stimulus. Insulin is a polypeptide hormone produced by the islets of Langerhans of the pancreas in mammals, and by the homologous organs of other organisms.
The process of binding or confining metal ions such that they are separated from other components of a biological system.
The directed movement of copper (Cu) ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
The aggregation, arrangement and bonding together of a set of components to form a membrane.
Any process that modulates the frequency, rate or extent of the cascade of processes induced by the cell cycle regulator phosphoprotein p53, or an equivalent protein, in response to the detection of DNA damage.
The whole of the physical, chemical, and biochemical processes carried out by living organisms to break down ingested lipids into components that may be easily absorbed and directed into metabolism.
Any process that activates or increases the frequency, rate or extent of a process involved in the formation, arrangement of constituent parts, or disassembly of cell structures, including the plasma membrane and any external encapsulating structures such as the cell wall and cell envelope.
Any cell cycle regulatory process that promotes the commitment of a cell from G1 to S phase of the mitotic cell cycle.
Any process that increases the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA (for protein-coding genes) and the translation of that mRNA into protein. Protein maturation is included when required to form an active form of a product from an inactive precursor form.
Any process that an organism uses to control its balance, the orientation of the organism (or the head of the organism) in relation to the source of gravity. In humans and animals, balance is perceived through visual cues, the labyrinth system of the inner ears and information from skin pressure receptors and muscle and joint receptors.
An immune response taking place in an organ or tissues such as the liver, brain, mucosa, or nervous system tissues.
Any process that modulates the frequency, rate or extent of cardiac muscle contraction via the regulation of the release of sequestered calcium ion by sarcoplasmic reticulum into cytosol. The sarcoplasmic reticulum is the endoplasmic reticulum of striated muscle, specialised for the sequestration of calcium ions that are released upon receipt of a signal relayed by the T tubules from the neuromuscular junction.
Any process that stops, prevents or reduces the frequency, rate or extent of organelle assembly.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interferon-beta stimulus. Interferon-beta is a type I interferon.
Any process that modulates the rate, frequency or extent of organ formation. Organ formation is the process pertaining to the initial formation of an organ from unspecified parts. The process begins with the specific processes that contribute to the appearance of the discrete structure, such as inductive events, and ends when the structural rudiment of the organ is recognizable, such as a condensation of mesenchymal cells into the organ rudiment.
The process whose specific outcome is the progression of the forebrain over time, from its formation to the mature structure. The forebrain is the anterior of the three primary divisions of the developing chordate brain or the corresponding part of the adult brain (in vertebrates, includes especially the cerebral hemispheres, the thalamus, and the hypothalamus and especially in higher vertebrates is the main control center for sensory and associative information processing, visceral functions, and voluntary motor functions).
The series of molecular signals generated as a consequence of excitation of rhodopsin by a photon and the events that convert the absorbed photons into a cellular response.
Any process that initiates the activity of the inactive enzyme cysteine-type endopeptidase.
Any process that modulates the rate, frequency or extent of mesonephros development. Mesonephros development is the process whose specific outcome is the progression of the mesonephros over time, from its formation to the mature structure. The mesonephros is an endocrine and metabolic organ that filters the blood and excretes the end products of body metabolism in the form of urine.
The chemical reactions and pathways involving carbohydrate derivative.
Any process that modulates the frequency, rate or extent of chromatin binding. Chromatin binding is the selective interaction with chromatin, the network of fibers of DNA, protein, and sometimes RNA, that make up the chromosomes of the eukaryotic nucleus during interphase.
The multiplication or reproduction of stem cells, resulting in the expansion of a stem cell population. A stem cell is a cell that retains the ability to divide and proliferate throughout life to provide progenitor cells that can differentiate into specialized cells.
The chemical reactions and pathways involving nicotinamide adenine dinucleotide (NAD), a coenzyme present in most living cells and derived from the B vitamin nicotinic acid.
Any process that modulates the frequency, rate or extent of extracellular matrix assembly.
A process in which a protein is transported to, or maintained in, a location within a lysosome.
The covalent alteration of one or more nucleotides within an mRNA molecule to produce an mRNA molecule with a sequence that differs from that coded genetically.
The somatic process that results in the generation of sequence diversity of immunoglobulins.
A series of molecular signals initiated by binding of a ligand to a member of the ERBB family of receptors on the surface of a cell, where the signal is transmitted by ERBB2. The pathway ends with regulation of a downstream cellular process, e.g. transcription. ERBB2 receptors are themselves unable to bind to ligands, but act as a signal-amplifying tyrosine kinase within a heterodimeric pair.
Cell migration that is accomplished by extension and retraction of a pseudopodium.
The process in which a relatively unspecialized cell acquires specialized features of a hematopoietic stem cell. A stem cell is a cell that retains the ability to divide and proliferate throughout life to provide progenitor cells that can differentiate into specialized cells.
The process in which neuroepithelial cells in the ventral neural tube acquire specialized structural and/or functional features of motor neurons. Motor neurons innervate an effector (muscle or glandular) tissue and are responsible for transmission of motor impulses from the brain to the periphery. Differentiation includes the processes involved in commitment of a cell to a specific fate.
The chemical reactions and pathways involving monocarboxylic acids, any organic acid containing one carboxyl (COOH) group or anion (COO-).
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a protein that is not folded in its correct three-dimensional structure.
The chemical reactions and pathways resulting in the formation of aminoglycans, any polymer containing amino groups that consists of more than about 10 monosaccharide residues joined to each other by glycosidic linkages.
The chemical reactions and pathways involving dicarboxylic acids, any organic acid containing two carboxyl (COOH) groups or anions (COO-).
Any process that stops, prevents, or reduces the frequency, rate or extent of astrocyte differentiation.
Any process that activates or increases the frequency, rate or extent of proteasomal protein catabolic process.
Any process that modulates the frequency, rate or extent of energy homeostasis.
Any process that modulates the establishment or extent of a membrane potential, the electric potential existing across any membrane arising from charges in the membrane itself and from the charges present in the media on either side of the membrane.
Any process that increases the rate, frequency or extent of release of cytochrome c from mitochondria, the process in which cytochrome c is enabled to move from the mitochondrial intermembrane space into the cytosol, which is an early step in apoptosis and leads to caspase activation.
The hydroxylation of peptidyl-proline to form peptidyl-hydroxyproline.
Any process that results in a change in state or activity of a multicellular organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating the organism is under stress. The stress is usually, but not necessarily, exogenous (e.g. temperature, humidity, ionizing radiation).
Any process that stops, prevents, or reduces the frequency, rate or extent of small GTPase mediated signal transduction.
The movement of organelles or other particles from one location in the cell to another along microtubules.
The directed movement of betaine, the N-trimethyl derivative of an amino acid, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
The directed movement of ammonium across a membrane by means of some agent such as a transporter or pore. Ammonium is the cation NH4+.
Any process that modulates the frequency, rate or extent of the growth of all or part of an organism so that it occurs at its proper speed, either globally or in a specific part of the organism's development.
The directed movement of cations, atoms or small molecules with a net positive charge, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
The process in which a neuroblast acquires the specialized structural and functional features of a GABAergic neuron.
The major inducible pathway for the general turnover of cytoplasmic constituents in eukaryotic cells, it is also responsible for the degradation of active cytoplasmic enzymes and organelles during nutrient starvation. Macroautophagy involves the formation of double-membrane-bounded autophagosomes which enclose the cytoplasmic constituent targeted for degradation in a membrane-bounded structure.  Autophagosomes then fuse with a lysosome (or vacuole) releasing single-membrane-bounded autophagic bodies that are then degraded within the lysosome (or vacuole). Though once thought to be a purely non-selective process, it appears that some types of macroautophagy, e.g. macropexophagy, macromitophagy, may involve selective targeting of the targets to be degraded.
A fatty acid beta-oxidation pathway in which the initial step of each oxidation cycle, which converts an acyl-CoA to a trans-2-enoyl-CoA, is catalyzed by acyl-CoA dehydrogenase; the electrons removed by oxidation pass through the respiratory chain to oxygen and leave H2O as the product. Fatty acid beta-oxidation begins with the addition of coenzyme A to a fatty acid, and ends when only two or three carbons remain (as acetyl-CoA or propionyl-CoA respectively).
The initial attachment of a membrane or protein to a target membrane. Docking requires only that the proteins come close enough to interact and adhere.
A process that leads to a temporary increase in postsynaptic potential due to the flow of positively charged ions into the postsynaptic cell. The flow of ions that causes an EPSP is an excitatory postsynaptic current (EPSC) and makes it easier for the neuron to fire an action potential.
The chemical reactions and pathways involving amino acids of the glutamine family, comprising arginine, glutamate, glutamine and proline.
Any process that modulates the frequency, rate or extent of nuclease activity, the hydrolysis of ester linkages within nucleic acids.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an inorganic substance stimulus.
Any process that stops, prevents, or reduces the frequency, rate or extent of the addition of an acetyl group to a histone protein.
The process that results in the fusion of a phagosome, a vesicle formed by phagocytosis, with a lysosome.
Any process in which a symbiont organism modulates the frequency, rate or extent of a cellular process, any process that is carried out at the cellular level, but not necessarily restricted to a single cell, in its host organism.
Any process that modulates the rate, frequency, or extent of vesicle-mediated transport, the directed movement of substances, either within a vesicle or in the vesicle membrane, into, out of or within a cell.
The chemical reactions and pathways resulting in the breakdown of organonitrogen compound.
Any process that modulates the frequency, rate or extent of astrocyte differentiation.
Any process that modulates the frequency, rate or extent of hydrogen peroxide-induced cell death.
The chemical reactions and pathways involving ADP, adenosine 5'-diphosphate.
Any process that activates or increases the rate or extent of cell proliferation.
Any process that modulates the frequency, rate or extent of the directed movement of sodium ions (Na+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
Any process that activates or increases the frequency, rate or extent of tumor necrosis factor superfamily cytokine production.
Any process that stops, prevents, or reduces the frequency, rate or extent of G-protein coupled receptor protein signaling pathway activity.
The modification of histones by removal of ubiquitin groups.
The chemical reactions and pathways involving glucosamine-containing compounds (glucosamines).
The directed movement of organic acids, any acidic compound containing carbon in covalent linkage, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
The regionalization process resulting in the creation of areas within the forebrain that will direct the behavior of cell migration in differentiation as the forebrain develops.
The process in which nerve cells are generated in the forebrain. This includes the production of neuroblasts from and their differentiation into neurons.
The attachment of one cell to another cell via adhesion molecules that require the presence of calcium for the interaction.
The process whose specific outcome is the progression of the pancreas over time, from its formation to the mature structure. The pancreas is an endoderm derived structure that produces precursors of digestive enzymes and blood glucose regulating enzymes.
The movement of a leukocyte in response to an external stimulus.
The chemical reactions and pathways involving glucose 6-phosphate, a monophosphorylated derivative of glucose with the phosphate group attached to C-6.
The process in which a solute is transported from one side of a membrane to the other into, out of or within a mitochondrion.
A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the nuclear pore.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nitric oxide stimulus.
A mitotic cell cycle checkpoint that slows DNA synthesis in response to DNA damage by the prevention of new origin firing and the stabilization of slow replication fork progression.
Any process that modulates the physical form or the activity of a synapse, the junction between a neuron and a target (neuron, muscle, or secretory cell).
The modification of histone H3 at a lysine in position 9 of the histone.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interferon-alpha stimulus. Interferon-alpha is a type I interferon.
Any process that stops, prevents, or reduces the frequency, rate or extent of translational initiation.
Any process that modulates the frequency, rate, or extent of toll-like receptor signaling pathway.
The process whose specific outcome is the progression of the cardiac conduction system over time, from its formation to the mature structure. The cardiac conduction system consists of specialized cardiomyocytes that regulate the frequency of heart beat.
Any process that modulates the frequency, rate or extent of glomerular filtration. Glomerular filtration is the process in which blood is filtered by the glomerulus into the renal tubule.
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving fatty acids.
The aggregation, arrangement and bonding together of a cytochrome complex. A cytochrome complex is a protein complex in which at least one of the proteins is a cytochrome, i.e. a heme-containing protein involved in catalysis of redox reactions.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a metal ion stimulus.
The attachment of a cell to the underlying substrate via adhesion molecules.
Any process that stops, prevents, or reduces the frequency, rate or extent of developmental growth.
Any process that stops, prevents or reduces the frequency, rate or extent of intracellular signal transduction.
The developmental process pertaining to the initial formation of an endocardial cushion. The endocardial cushion is a specialized region of mesenchymal cells that will give rise to the heart septa and valves.
Any process that modulates the frequency, rate or extent of The DNA-dependent DNA replication that occurs in the nucleus of eukaryotic organisms as part of the cell cycle.
The directed movement of an organic hydroxy compound (organic alcohol) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. An organic hydroxy compound is an organic compound having at least one hydroxy group attached to a carbon atom.
Any process involved in the maintenance of an internal steady state of calcium ions within the cytoplasm of a cell or between mitochondria and their surroundings.
Ossification that requires the replacement of a preexisting tissue prior to bone tissue formation.
Any process that modulates the frequency, rate or extent of any cellular process that depends upon or alters the actin cytoskeleton.
The series of events that restore integrity to a damaged tissue, following an injury.
The process in which the mitotic cell cycle is halted during one of the normal phases (G1, S, G2, M).
The chemical reactions and pathways resulting in the breakdown of hexose, any monosaccharide with a chain of six carbon atoms in the molecule.
The chemical reactions and pathways involving glutamine, 2-amino-4-carbamoylbutanoic acid.
A process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nerve growth factor stimulus.
Any process that stops or reduces the activity of the enzyme telomerase, which catalyzes of the reaction: deoxynucleoside triphosphate + DNA(n) = diphosphate + DNA(n+1).
Any process involved in the conversion of one or more primary RNA transcripts into one or more mature RNA molecules.
Any process that modulates the frequency, rate or extent of the IRE1-mediated unfolded protein response.
Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of fatty acids.
A biological process in which synaptic vesicles are loaded with neurotransmitters, move to the active zone, exocytose and are then recycled via endocytosis, ultimately leading to reloading with neurotransmitters.
The cellular chemical reactions and pathways involving a nucleobase-containing small molecule: a nucleobase, a nucleoside, or a nucleotide.
Any process that activates or increases the frequency, rate or extent of the regulated release of interleukin-1 from a cell.
Any process that modulates the frequency, rate, or extent of cytokine production that contributes to an immune response.
Any process that activates or increases the frequency, rate or extent of leukocyte proliferation.
The intramolecular conversion of uridine to pseudouridine within an RNA molecule. This posttranscriptional base modification occurs in tRNA, rRNA, and snRNAs.
The aggregation, arrangement and bonding together of a set of components to form a protein complex, occurring at the level of an individual cell.
Reactions, triggered in response to the presence of a foreign body or the occurrence of an injury, which result in restriction of damage to the organism attacked or prevention/recovery from the infection caused by the attack.
The directed movement of poly(A)+ mRNA out of the nucleus into the cytoplasm.
The chemical reactions and pathways resulting in the formation of phospholipids, any lipid containing phosphoric acid as a mono- or diester.
Any process that stops, prevents, or reduces the frequency, rate or extent of leukocyte apoptotic process.
Any process that activates or increases the frequency, rate or extent of hydrolase activity, the catalysis of the hydrolysis of various bonds.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-4 stimulus.
The chemical reactions and pathways involving any member of a large group of derivatives or analogs of porphyrin. Porphyrins consists of a ring of four pyrrole nuclei linked each to the next at their alpha positions through a methine group.
A process required for sperm to reach fertilization competence. Sperm undergo an incompletely understood series of morphological and molecular maturational processes, termed capacitation, involving, among other processes, protein tyrosine phosphorylation and increased intracellular calcium.
Any process that activates or increases the frequency, rate or extent of telomerase activity, the catalysis of the reaction: deoxynucleoside triphosphate + DNA(n) = diphosphate + DNA(n+1).
Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-6 production.
Any process involved in the maintenance of an internal steady state of monovalent inorganic cations at the level of a cell.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a methylmercury stimulus.
Any process that modulates the frequency, rate or extent of the formation of a daughter centriole of an existing centriole.
Any process that activates or increases frequency, rate or extent of chemical reactions and pathways in multicellular organisms that occur at the tissue, organ, or organismal level.
Any process that modulates the frequency, rate, or extent of an acute inflammatory response.
The appearance of a cytokine due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.
Any series of molecular signals generated as a consequence of binding to a toll-like receptor. Toll-like receptors directly bind pattern motifs from a variety of microbial sources to initiate innate immune response.
Any process that activates or increases the frequency, rate or extent of the directed movement of substances within cells.
The orderly movement of a cell from one site to another at least one of which is located in the forebrain.
The process of removing one or more methyl groups from a molecule.
Any process involved in the controlled self-propelled movement of a cell that results in translocation of the cell from one place to another.
Any process that increases the rate, frequency, or extent of the orderly movement of an endothelial cell into the extracellular matrix to form an endothelium.
The cellular and vascular changes occurring in the endometrium of the pregnant uterus just after the onset of blastocyst implantation. This process involves the proliferation and differentiation of the fibroblast-like endometrial stromal cells into large, polyploid decidual cells that eventually form the maternal component of the placenta.
Any process that modulates the rate, frequency or extent of mononuclear cell migration. Mononuclear cell migration is the movement of a mononuclear cell within or between different tissues and organs of the body.
The chemical reactions and pathways resulting in the formation of ceramides, any N-acylated sphingoid.
Any process that stops, prevents, or reduces the frequency, rate or extent of growth of an organ of an organism.
Any process that stops, prevents, or reduces the frequency, rate, or extent of a response to biotic stimulus.
The directed movement of organophosphate esters into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Organophosphate esters are small organic molecules containing phosphate ester bonds.
A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures comprising microtubules and their associated proteins.
The modification of histones by addition of a single ubiquitin group.
Any process that modulates the frequency, rate or extent of cell cycle G2/M phase transition.
The process in which the anatomical structures of the viscerocranium are generated and organized during the embryonic phase. The viscerocranium is the part of the skull comprising the facial bones.
Recombination occurring within or between DNA molecules in somatic cells.
The accumulation of pigment in an organism, tissue or cell, either by increased deposition or by increased number of cells.
Any process that activates or increases the frequency, rate or extent of protein localization to cell periphery.
Any process that activates or increases the frequency, rate or extent of translational initiation.
Any process that decreases the rate, frequency, or extent of cell aging. Cell aging is the progression of the cell from its inception to the end of its lifespan.
Any process involved with the carrying out of an immune response by a B cell, through, for instance, the production of antibodies or cytokines, or antigen presentation to T cells.
The progression of the aorta over time, from its initial formation to the mature structure. An aorta is an artery that carries blood from the heart to other parts of the body.
The process in which a relatively unspecialized cell acquires specialized features of the embryonic placenta.
The asymmetric division of cells to produce two daughter cells with different developmental potentials. It is of fundamental significance for the generation of cell diversity.
The establishment of an organism's body plan or part of an organism such that a similar arrangement in form and relationship of parts around a common axis, or around each side of a plane is created.
A process in which a protein is transported to, or maintained in, a location within the endoplasmic reticulum.
The chemical reactions and pathways resulting in the formation of bile acids, any of a group of steroid carboxylic acids occurring in bile.
Any process that stops, prevents, or reduces the frequency, rate or extent of coagulation.
The replacement, within chromatin, of resident histones or histone subunits with alternative, sometimes variant, histones or subunits.
Any process involved in the maintenance of an internal steady state of lipid within an organism or cell.
The enzymatic release of energy from inorganic and organic compounds (especially carbohydrates and fats) which either requires oxygen (aerobic respiration) or does not (anaerobic respiration).
The identification of lesions in DNA, such as pyrimidine-dimers, intrastrand cross-links, and bulky adducts. The wide range of substrate specificity suggests the repair complex recognizes distortions in the DNA helix.
Any process that modulates the frequency, rate or extent of endothelial cell development.
The process in which a precursor cell type acquires the specialized features of a B cell. A B cell is a lymphocyte of B lineage with the phenotype CD19-positive and capable of B cell mediated immunity.
The multiplication or reproduction of neural precursor cells, resulting in the expansion of a cell population. A neural precursor cell is either a nervous system stem cell or a nervous system progenitor cell.
The directed movement of substances into, out of, or within the nucleus.
The chemical reactions and pathways involving peptides, compounds of two or more amino acids where the alpha carboxyl group of one is bound to the alpha amino group of another.
Any process that decreases the frequency, rate or extent of cell-substrate adhesion. Cell-substrate adhesion is the attachment of a cell to the underlying substrate via adhesion molecules.
Any process that modulates the frequency, rate or extent of epithelial cell differentiation.
The orderly movement of an endothelial cell into the extracellular matrix to form an endothelium.
The chemical reactions and pathways resulting in the breakdown of organic hydroxy compound.
The chemical reactions and pathways involving glycerolipids, any lipid with a glycerol backbone. Diacylglycerol and phosphatidate are key lipid intermediates of glycerolipid biosynthesis.
The alteration of an amino acid residue in a peptide.
The controlled release of a substance by a cell or a tissue.
Any process that modulates the rate, frequency or extent of sequestering of triglyceride. Triglyceride sequestration is the process of binding or confining any triester of glycerol such that it is separated from other components of a biological system.
Any process that stops, prevents, or reduces the frequency, rate or extent of fibroblast growth factor receptor signaling pathway activity.
Any process that stops, prevents, or reduces the frequency, rate or extent of protein oligomerization.
A change in the morphology or behavior of a cell resulting from exposure to an activating factor such as a cellular or soluble ligand, leading to the initiation or perpetuation of an immune response.
Any process that activates or increases the frequency, rate or extent of vasodilation.
The chemical reactions and pathways involving homocysteine, the amino acid alpha-amino-gamma-mercaptobutanoic acid. Homocysteine is an important intermediate in the metabolic reactions of its S-methyl derivative, methionine.
Any process that stops, prevents, or reduces the frequency, rate or extent of the covalent alteration of a histone.
The chemical reactions and pathways resulting in the breakdown of a cofactor, a substance that is required for the activity of an enzyme or other protein.
The chemical reactions and pathways resulting in the breakdown of a pyrimidine-containing compound, i.e. any compound that contains pyrimidine or a formal derivative thereof.
Any process that stops or reduces the frequency, rate or extent of DNA binding. DNA binding is any process in which a gene product interacts selectively with DNA (deoxyribonucleic acid).
The process whose specific outcome is the progression of the ventral region of the spinal cord over time, from its formation to the mature structure. The neurons of the ventral region of the mature spinal cord participate in motor output.
Any process that modulates the frequency, rate or extent of a circadian rhythm. A circadian rhythm is a biological process in an organism that recurs with a regularity of approximately 24 hours.
The directed movement of anions, atoms or small molecules with a net negative charge, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
The attachment of one cell to another cell via adhesion molecules.
The process in which the anatomical structure of an endothelium is generated and organized. Endothelium refers to the layer of cells lining blood vessels, lymphatics, the heart, and serous cavities, and is derived from bone marrow or mesoderm. Corneal endothelium is a special case, derived from neural crest cells.
The chemical reactions and pathways involving guanosine-containing compounds (guanosines).
Any process that activates or increases the frequency, rate or extent of the release into the cytosolic compartment of calcium ions sequestered in the endoplasmic reticulum or mitochondria.
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving cyclic nucleotides.
The chemical reactions and pathways resulting in the formation of chondroitin sulfate proteoglycan, any glycoprotein whose glycosaminoglycan units are chondroitin sulfate. Chondroitin sulfates are a group of 10-60 kDa glycosaminoglycans, widely distributed in cartilage and other mammalian connective tissues; the repeat units consist of beta-(1,4)-linked D-glucuronyl beta-(1,3)-N-acetyl-D-galactosamine sulfate.
The process whose specific outcome is the progression of a glandular epithelial cell over time, from its formation to the mature structure. A glandular epithelial cell is a columnar/cuboidal epithelial cell is a cell found in a two dimensional sheet with a free surface exposed to the lumen of a gland.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a magnesium ion stimulus.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an ATP (adenosine 5'-triphosphate) stimulus.
The directed movement of cholesterol, cholest-5-en-3-beta-ol, out of a cell or organelle.
The process of creating protein oligomers, compounds composed of a small number, usually between three and ten, of component monomers; protein oligomers may be composed of different or identical monomers. Oligomers may be formed by the polymerization of a number of monomers or the depolymerization of a large protein polymer.
The disaggregation of a beta-catenin destruction complex into its constituent components.
The aggregation, arrangement and bonding together of a set of components to form an axonemal dynein inner arm, an inner arm structure present on the outer doublet microtubules of ciliary and flagellar axonemes.
Any process that modulates the frequency, rate or extent of epithelial cell proliferation.
The formation or destruction of chromatin structures.
Any process that modulates the activity of the enzyme nitric-oxide synthase.
Any process that modulates the rate, frequency, or extent of the androgen receptor signaling pathway.
The pattern specification process that results in the subdivision of the left/right axis in space to define an area or volume in which specific patterns of cell differentiation will take place or in which cells interpret a specific environment.
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a xenobiotic compound stimulus. Xenobiotic compounds are compounds foreign to living organisms.
Any process that modulates the rate, frequency or extent of macrophage derived foam cell differentiation. Macrophage derived foam cell differentiation is the process in which a macrophage acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions.
The process in which the anatomical structures of the digestive tract are generated and organized during embryonic development. The digestive tract is the anatomical structure through which food passes and is processed.
The process whose specific outcome is the progression of a blood vessel of the placenta over time, from its formation to the mature structure.
Any process that activates or increases the frequency, rate or extent of guanylate cyclase activity.
The chemical reactions and pathways involving melanins, pigments largely of animal origin. High molecular weight polymers of indole quinone, they are irregular polymeric structures and are divided into three groups: allomelanins in the plant kingdom and eumelanins and phaeomelanins in the animal kingdom.
Any process that activates, maintains or increases the rate of a response to an external stimulus.
Any process that activates or increases the frequency, rate or extent of cell cycle G2/M phase transition.
Any process that modulates the frequency, rate or extent of removal of superoxide radicals.
Any process that stops, prevents or reduces the frequency, rate or extent of stem cell proliferation.
A developmental process that is a deterioration and loss of function over time. Aging includes loss of functions such as resistance to disease, homeostasis, and fertility, as well as wear and tear. Aging includes cellular senescence, but is more inclusive. May precede death and may succeed developmental maturation (GO:0021700).
Any process that modulates the frequency, rate or extent of vacuolar transport.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an electrical stimulus.
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the phosphorylation of ADP to ATP that accompanies the oxidation of a metabolite through the operation of the respiratory chain. Oxidation of compounds establishes a proton gradient across the membrane, providing the energy for ATP synthesis.
Any process that stops, prevents, or reduces the frequency, rate or extent of chromosome segregation, the process in which genetic material, in the form of chromosomes, is organized and then physically separated and apportioned to two or more sets.
Any process that stops, prevents or reduces the frequency, rate or extent of extrinsic apoptotic signaling pathway.
Any process that modulates the frequency, rate or extent of bone development.
Any process that activates or increases the frequency, rate or extent of T cell mediated cytotoxicity.
Any process that modulates the frequency, rate, or extent of leukocyte mediated cytotoxicity.
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of cholesterol.
The chemical reactions and pathways resulting in the breakdown of a polysaccharide, a polymer of many (typically more than 10) monosaccharide residues linked glycosidically.
Any process that stops, prevents, or reduces the frequency, rate or extent of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm.
The proliferation of cells in the inner cell mass.
Any process that activates or increases the rate or extent of mRNA splicing via a spliceosomal mechanism.
Any process that modulates the frequency, rate or extent of gene expression after the production of an RNA transcript.
Any process that activates or increases the frequency, rate or extent of DNA-dependent DNA replication.
An action or movement due to the application of a sudden unexpected stimulus.
The process in which the migration of an axon growth cone of a motor neuron is directed to a specific target site in response to a combination of attractive and repulsive cues.
The synthesis of RNA from a DNA template by RNA polymerase II, originating at an RNA polymerase II promoter. Includes transcription of messenger RNA (mRNA) and certain small nuclear RNAs (snRNAs).
The chemical reactions and pathways resulting in the breakdown of any ribonucleoside, a nucleoside in which a pyrimidine base is linked to a ribose (beta-D-ribofuranose) molecule.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus arising within the organism.
The progression of the hypothalamus region of the forebrain, from its initial formation to its mature state.
Any series of molecular signals generated as a consequence of a pattern recognition receptor (PRR) binding to one of its physiological ligands. PRRs bind pathogen-associated molecular pattern (PAMPs), structures conserved among microbial species, or damage-associated molecular pattern (DAMPs), endogenous molecules released from damaged cells.
Any process that activates or increases the frequency, rate or extent of progression through the meiotic cell cycle.
The process whose specific outcome is the progression of the lateral mesoderm over time, from its formation to the mature structure.
Any process that activates or increases the rate or extent of cell adhesion to an extracellular matrix.
The process whose specific outcome is the progression of an embryo from its formation until the end of its embryonic life stage. The end of the embryonic stage is organism-specific. For example, for mammals, the process would begin with zygote formation and end with birth. For insects, the process would begin at zygote formation and end with larval hatching. For plant zygotic embryos, this would be from zygote formation to the end of seed dormancy. For plant vegetative embryos, this would be from the initial determination of the cell or group of cells to form an embryo until the point when the embryo becomes independent of the parent plant.
Any process that modulates the frequency, rate or extent of striated muscle contraction.
Any process that modulates the frequency, rate or extent of leukocyte differentiation.
Any process that modulates the frequency, rate or extent of transcription elongation, the extension of an RNA molecule after transcription initiation and promoter clearance by the addition of ribonucleotides, catalyzed by RNA polymerase II.
The directed movement of water (H2O) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
The specification and formation of anisotropic intracellular organization or cell growth patterns.
The chemical reactions and pathways involving biotin, cis-tetrahydro-2-oxothieno(3,4-d)imidazoline-4-valeric acid; the (+) enantiomer is very widely distributed in cells and serves as a carrier in a number of enzymatic beta-carboxylation reactions.
The self-renewing division of a stem cell. A stem cell is an undifferentiated cell, in the embryo or adult, that can undergo unlimited division and give rise to one or several different cell types.
The chemical reactions and pathways resulting in the formation of reactive oxygen species, any molecules or ions formed by the incomplete one-electron reduction of oxygen.
Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of a nitric oxide synthase enzyme.
The process whose specific outcome is the progression of the digestive system over time, from its formation to the mature structure. The digestive system is the entire structure in which digestion takes place. Digestion is all of the physical, chemical, and biochemical processes carried out by multicellular organisms to break down ingested nutrients into components that may be easily absorbed and directed into metabolism.
Any process that increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of steroids, compounds with a 1,2,cyclopentanoperhydrophenanthrene nucleus.
A cellular process that results in a change in the spatial configuration of a DNA molecule. A conformation change can bend DNA, or alter the, twist, writhe, or linking number of a DNA molecule.
The series of events by which a mechanical stimulus is received and converted into a molecular signal.
A reproduction process that creates a new organism by combining the genetic material of two organisms. It occurs both in eukaryotes and prokaryotes: in multicellular eukaryotic organisms, an individual is created anew; in prokaryotes, the initial cell has additional or transformed genetic material. In a process called genetic recombination, genetic material (DNA) originating from two different individuals (parents) join up so that homologous sequences are aligned with each other, and this is followed by exchange of genetic information. After the new recombinant chromosome is formed, it is passed on to progeny.
The process in which a relatively unspecialized cell acquires specialized features of an epidermal cell, any of the cells making up the epidermis.
A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a synaptonemal complex. A synaptonemal complex is a proteinaceous scaffold formed between homologous chromosomes during meiosis.
In base excision repair, an altered base is removed by a DNA glycosylase enzyme, followed by excision of the resulting sugar phosphate. The small gap left in the DNA helix is filled in by the sequential action of DNA polymerase and DNA ligase.
The chemical reactions and pathways resulting in the breakdown of carbohydrates, any of a group of organic compounds based of the general formula Cx(H2O)y, as carried out by individual cells.
Any process that stops, prevents, or reduces the frequency, rate, or extent of a type 2 immune response.
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving nucleosides.
The directed movement of a motile cell or organism in response to an external stimulus.
The chemical reactions and pathways involving citrulline, N5-carbamoyl-L-ornithine, an alpha amino acid not found in proteins.
Any process that stops, prevents or reduces the frequency, rate or extent of axon guidance.
The process pertaining to the initial formation of an organ from unspecified parts. The process begins with the specific processes that contribute to the appearance of the discrete structure, such as inductive events, and ends when the structural rudiment of the organ is recognizable, such as a condensation of mesenchymal cells into the organ rudiment. Organs are a natural part or structure in an animal or a plant, capable of performing some special action (termed its function), which is essential to the life or well-being of the whole. The heart and lungs are organs of animals, and the petal and leaf are organs of plants. In animals the organs are generally made up of several tissues, one of which usually predominates, and determines the principal function of the organ.
Any process that decreases the rate of the directed movement of calcium ions into the cytosol of a cell. The cytosol is that part of the cytoplasm that does not contain membranous or particulate subcellular components.
Any process that modulates the establishment or extent of a change in membrane potential in the polarizing direction towards the resting potential in a cardiomyocyte.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a glucagon stimulus.
Any process that stops, prevents, or reduces the frequency, rate, or extent of tissue remodeling.
A modification in a plasma membrane resulting in formation of a tubular invagination.
The embryonically driven process whose specific outcome is the progression of the placenta over time, from its formation to the mature structure. The placenta is an organ of metabolic interchange between fetus and mother, partly of embryonic origin and partly of maternal origin.
The chemical reactions and pathways resulting in the formation of small molecules, any low molecular weight, monomeric, non-encoded molecule.
A developmental process, independent of morphogenetic (shape) change, that is required for an anatomical structure to attain its fully functional state.
Any process that modulates the frequency, rate or extent of amyloid precursor protein catabolic process.
The migration of a leukocyte from the blood vessels into the surrounding tissue.
Any process that modulates the frequency, rate or extent of a process that affects and monitors the activity of telomeric proteins and the length of telomeric DNA.
Any process that modulates the frequency, rate or extent of extrinsic apoptotic signaling pathway via death domain receptors.
Any process that decreases the rate, frequency, or extent of the series of events that restore integrity to a damaged tissue, following an injury.
Any process that modulates the frequency, rate, or extent of immunoglobulin production.
The chemical reactions and pathways involving a fatty-acyl-CoA, any derivative of coenzyme A in which the sulfhydryl group is in thiolester linkage with a fatty-acyl group.
Any process that decreases the rate or frequency of muscle cell apoptotic process, a form of programmed cell death induced by external or internal signals that trigger the activity of proteolytic caspases whose actions dismantle a muscle cell and result in its death.
The chemical reactions and pathways involving glycosylphosphatidylinositol anchors, molecular mechanisms for attaching membrane proteins to the lipid bilayer of cell membranes. Structurally they consist of a molecule of phosphatidylinositol to which is linked, via the C-6 hydroxyl of the inositol, a carbohydrate chain. This chain is in turn linked to the protein through an ethanolamine phosphate group, the amino group of which is in amide linkage with the C-terminal carboxyl of the protein chain, the phosphate group being esterified to the C-6 hydroxyl of the terminal mannose of the core carbohydrate chain.
Any process that activates or increases the frequency, rate or extent of the removal of acetyl groups from histones.
A protein activation cascade that contributes to blood coagulation and consists of the cascade of enzymatic reactions initiated by physical damage to the wall of a blood vessel, leading to the formation of a formation of a fibrin clot at the site of the injury. The process also includes numerous positive and negative regulatory events.
Any process that activates or increases the frequency, rate or extent of the regulated release of insulin.
Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of a neurotransmitter into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
The chemical reactions and pathways involving amyloid precursor protein (APP), the precursor of beta-amyloid, a glycoprotein associated with Alzheimer's disease.
The nucleic acid metabolic process in which the phosphodiester bonds between nucleotides are cleaved by hydrolysis.
Any process involved in the maintenance of the internal steady state of the amount of a chemical at the level of the tissue.
Any process that modulates the frequency, rate or extent of myeloid cell differentiation.
Any process that modulates the frequency, rate or extent of a response to an external stimulus.
Any process that modulates the frequency, rate or extent of RNA polymerase II transcriptional preinitiation complex assembly.
The directed movement of unfolded or misfolded proteins from the endoplasmic reticulum to the cytosol through the translocon.
The attachment of an epithelial cell to another epithelial cell via adhesion molecules.
Any process that modulates the frequency, rate or extent of a process involved in the formation, arrangement of constituent parts, or disassembly of a mitochondrion.
The chemical reactions and pathways involving polyamines, any organic compound containing two or more amino groups.
Any process that activates or increases the frequency, rate or extent of muscle contraction.
Any process that stops, prevents, or reduces the frequency, rate or extent of signaling pathways initiated by the cross-linking of an antigen receptor on a T cell.
The chemical reactions and pathways resulting in the formation of any compound containing pteridine (pyrazino(2,3-dipyrimidine)), e.g. pteroic acid, xanthopterin and folic acid.
The orderly movement of an endothelial cell into the extracellular matrix in order to form new blood vessels during angiogenesis.
Any process that activates or increases the frequency, rate or extent of protein localization to nucleus.
Any process that activates or increases the frequency, rate or extent of BMP signaling pathway activity.
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of interferon-gamma.
The regionalization process in which specific areas of cell differentiation are determined along a proximal/distal axis. The proximal/distal axis is defined by a line that runs from main body (proximal end) of an organism outward (distal end).
A process in which force is generated within striated muscle tissue, resulting in the shortening of the muscle. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. Striated muscle is a type of muscle in which the repeating units (sarcomeres) of the contractile myofibrils are arranged in registry throughout the cell, resulting in transverse or oblique striations observable at the level of the light microscope.
Any process that stops, prevents or reduces the frequency, rate or extent of anion transport.
Any process that stops, prevents, or reduces the frequency, rate, or extent of CD4-positive, alpha-beta T cell differentiation.
The process whose specific outcome is the progression of the ectoderm over time, from its formation to the mature structure. In animal embryos, the ectoderm is the outer germ layer of the embryo, formed during gastrulation.
The chemical reactions and pathways involving hyaluronan, the naturally occurring anionic form of hyaluronic acid, any member of a group of glycosaminoglycans, the repeat units of which consist of beta-1,4 linked D-glucuronyl-beta-(1,3)-N-acetyl-D-glucosamine.
The movement of a leukocyte within or between different tissues and organs of the body.
Any process that decreases the frequency, rate or extent of the directed movement of proteins within cells.
The first meiotic nuclear division in which homologous chromosomes are paired and segregated from each other, producing two haploid daughter nuclei.
The series of events required for an organism to receive a painful stimulus, convert it to a molecular signal, and recognize and characterize the signal. Pain is medically defined as the physical sensation of discomfort or distress caused by injury or illness, so can hence be described as a harmful stimulus which signals current (or impending) tissue damage. Pain may come from extremes of temperature, mechanical damage, electricity or from noxious chemical substances. This is a neurological process.
Any epigenetic process that stops, prevents or reduces the rate of gene expression.
The chemical reactions and pathways involving alditols, any polyhydric alcohol derived from the acyclic form of a monosaccharide by reduction of its aldehyde or keto group to an alcoholic group.
The transfer of electrons from ubiquinol to cytochrome c that occurs during oxidative phosphorylation, mediated by the multisubunit enzyme known as complex III.
Any process that modulates the size of an anatomical structure.
Any process that modulates the frequency, rate or extent of cell proliferation involved in kidney development.
Any process that increases the frequency, rate or extent of a process involved in the formation, arrangement of constituent parts, or disassembly of a mitochondrion.
Any process that activates or increases the activity of an enzyme.
Any process that activates or increases the frequency, rate or extent of signal transduction by p53 class mediator.
The modification of peptidyl-lysine.
Repression of transcription by methylation of DNA, leading to the formation of heterochromatin.
Any process that modulates the activity of the enzyme lipoprotein lipase.
A series of molecular signals mediated by the detection of a hormone.
The chemical reactions and pathways resulting in the formation of androgens, C19 steroid hormones that can stimulate the development of male sexual characteristics.
Any process that stops, prevents, or reduces the frequency, rate or extent of protein binding.
Any process that activates or increases the frequency, rate or extent of oligodendrocyte differentiation.
The aggregation, arrangement and bonding together of a set of components to form an axonemal dynein complex, a dynein complex found in eukaryotic cilia and flagella, in which the motor domain heads interact with adjacent microtubules to generate a sliding force which is converted to a bending motion.
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving lipids.
Assembly of hemidesmosomes, integrin-containing protein complexes that bind to laminin in the basal lamina. Hemidesmosomes form the contact between the basal surface of epithelial cells and the underlying basal lamina.
The change in morphology and behavior of a mast cell resulting from exposure to a cytokine, chemokine, soluble factor, or to (at least in mammals) an antigen which the mast cell has specifically bound via IgE bound to Fc-epsilonRI receptors.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an external stimulus.
A protein transport process that contributes to protein import into the nucleus, and that results in the vectorial transfer of a cargo-carrier protein complex through the nuclear pore complex from the cytoplasmic side to the nucleoplasmic side of the nuclear envelope.
Any process that modulates the frequency, rate or extent of adenylate cyclase activity.
Any process that activates or increases the frequency, rate or extent of leukocyte differentiation.
A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a mitochondrial membrane, either of the lipid bilayer surrounding a mitochondrion.
Any process that activates or increases the frequency, rate or extent of neutrophil migration.
The directed movement of substances within the Golgi, mediated by small transport vesicles. These either fuse with the cis-Golgi or with each other to form the membrane stacks known as the cis-Golgi reticulum (network).
Any process that modulates the rate, frequency, or extent of the spindle checkpoint, a cell cycle checkpoint that delays the metaphase/anaphase transition until the spindle is correctly assembled and oriented, and chromosomes are attached to the spindle.
Any process that activates or increases the frequency, rate or extent of striated muscle contraction.
The developmental process in which an anatomical stucture is destroyed as a part of its normal progression.
The process in which a relatively unspecialized cell acquires specialized features of a neuron residing in the cerebral cortex.
The process whose specific outcome is the progression of the ovarian follicle over time, from its formation to the mature structure.
Any process that modulates the frequency, rate or extent of action potential creation, propagation or termination in a ventricular cardiac muscle cell contributing to the regulation of its contraction.  This typically occurs via modulation of the activity or expression of voltage-gated ion channels.
Any process that modulates the frequency, rate or extent of myoblast differentiation. A myoblast is a mononucleate cell type that, by fusion with other myoblasts, gives rise to the myotubes that eventually develop into skeletal muscle fibers.
The chemical reactions and pathways involving glucans, polysaccharides consisting only of glucose residues.
The process whose specific outcome is the progression of a cardiac atrium over time, from its formation to the mature structure. A cardiac atrium receives blood from a vein and pumps it to a cardiac ventricle.
Any process that decreases the rate, frequency, or extent of a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a growth factor stimulus.
Any process involved in the maintenance of an internal steady state of fatty acid within an organism or cell.
The cellular chemical reactions and pathways involving nucleotide-sugars, any nucleotide-carbohydrate in which the distal phosphoric residue of a nucleoside 5'-diphosphate is in glycosidic linkage with a monosaccharide or monosaccharide derivative.
The chemical reactions and pathways by which a cell derives energy from organic compounds; results in the oxidation of the compounds from which energy is released.
Any process that modulates the rate, frequency or extent of platelet aggregation. Platelet aggregation is the adhesion of one platelet to one or more other platelets via adhesion molecules.
Any process that activates or increases the vectorial transfer of a protein from the cytoplasm into the nucleus, across the nuclear membrane.
Any process that increases the frequency, rate or extent of cardiac muscle contraction.
Any process that modulates the frequency, rate or extent of substrate adhesion-dependent cell spreading.
The process whose specific outcome is the progression of a nephric duct over time, from its initial formation to a mature structure. A nephric duct is a tube that drains a primitive kidney.
The directed movement of substances from the Golgi to other parts of the cell, including organelles and the plasma membrane, mediated by small transport vesicles.
The conversion of DNA-damage induced single-stranded gaps into large molecular weight DNA after replication by using a specialized DNA polymerase or replication complex to insert a defined nucleotide across the lesion. This process does not remove the replication-blocking lesions but does not causes an increase in the endogenous mutation level. For S. cerevisiae, RAD30 encodes DNA polymerase eta, which incorporates two adenines. When incorporated across a thymine-thymine dimer, it does not increase the endogenous mutation level.
The process in which a relatively unspecialized cell acquires the specialized features of a photoreceptor cell, as found in the eye, the primary visual organ of most organisms.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a testosterone stimulus.
A cellular process that results in the assembly of one or more centrioles.
Any process that modulates the frequency, rate or extent of hemopoiesis.
The progression of the atrial septum over time, from its initial formation to the mature structure.
The series of events in which a temperature stimulus (hot or cold) is received and converted into a molecular signal.
A process in which an ion is transported from one side of a membrane to the other by means of some agent such as a transporter or pore.
The process in which calcium salts, mainly carbonated hydroxyapatite, are deposited in tooth enamel.
Any process that activates or increases the frequency, rate or extent of calcium-mediated signaling.
The characteristic movement of cells from the dorsal ridge of the neural tube to a variety of locations in a vertebrate embryo.
The process in which a cell becomes capable of differentiating autonomously into a motor neuron in an environment that is neutral with respect to the developmental pathway.
Any process that modulates the frequency, rate or extent of glycoprotein metabolic process.
The process in which a signal is passed on to downstream components within the cell, which become activated themselves to further propagate the signal and finally trigger a change in the function or state of the cell.
Any process that modulates the frequency, rate or extent of behavior, the internally coordinated responses (actions or inactions) of whole living organisms (individuals or groups) to internal or external stimuli.
The chemical reactions and pathways involving a pyrimidine nucleotide, a compound consisting of nucleoside (a pyrimidine base linked to a deoxyribose or ribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.
The chemical reactions and pathways resulting in the breakdown of glycolipid, a class of 1,2-di-O-acylglycerols joined at oxygen 3 by a glycosidic linkage to a carbohydrate part (usually a mono-, di- or tri-saccharide).
Clathrin-mediated endocytosis of presynaptic membrane that recycles synaptic vesicle membrane and its components following synaptic vesicle exocytosis. This process starts with coating of the membrane with adaptor proteins and clathrin prior to invagination and ends when uncoating has finished.
Any process that increases the rate, frequency, or extent of protein tyrosine kinase activity.
Any process that activates or increases the frequency or rate of heart contraction.
The biological process whose specific outcome is the progression of the palate from an initial condition to its mature state. This process begins with the formation of the structure and ends with the mature structure. The palate is the partition that separates the nasal and oral cavities.
Any series of molecular signals leading to activation of the innate immune response generated as a consequence of binding to a cell surface receptor.
The process that regulates the coordinated growth and sprouting of blood vessels giving rise to the organized vascular system.
Any process that modulates the frequency, rate, or extent of a homeostatic process.
A fatty acid beta-oxidation pathway in which the initial step, which converts an acyl-CoA to a trans-2-enoyl-CoA, is catalyzed by acyl-CoA oxidase; the electrons removed by oxidation pass directly to oxygen and produce hydrogen peroxide, which is cleaved by peroxisomal catalases. Fatty acid beta-oxidation begins with the addition of coenzyme A to a fatty acid, and ends when only two or three carbons remain (as acetyl-CoA or propionyl-CoA respectively).
Any process that activates or increases the frequency, rate or extent of vasoconstriction.
The directed movement of substances from the Golgi to the plasma membrane in transport vesicles that move from the trans-Golgi network to the plasma membrane, where they fuse and release their contents by exocytosis.
The process of directing proteins towards a membrane, usually using signals contained within the protein.
Progression through the phases of the mitotic cell cycle, the most common eukaryotic cell cycle, which canonically comprises four successive phases called G1, S, G2, and M and includes replication of the genome and the subsequent segregation of chromosomes into daughter cells. In some variant cell cycles nuclear replication or nuclear division may not be followed by cell division, or G1 and G2 phases may be absent.
Any process that modulates the rate, frequency or extent of the behavior associated with the intake of food.
Any process that modulates the frequency, rate or extent of thymocyte aggregation.
A cellular process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of a protein complex. Includes the synthesis of non-protein components, and those protein modifications that are involved in synthesis or assembly of the complex.
Any process that modulates the frequency, rate or extent of growth of the body of an organism so that it reaches its usual body size.
Any process that modulates the rate, frequency or extent of kidney development. Kidney development is the process whose specific outcome is the progression of the kidney over time, from its formation to the mature structure. The kidney is an organ that filters the blood and excretes the end products of body metabolism in the form of urine.
The disaggregation of a macromolecular complex into its constituent components.
Any process that activates or increases the frequency, rate or extent of cellular component biogenesis, a process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of a cellular component.
Any process that increases the frequency, rate or extent of the passage or uptake of molecules by the mitochondrial membrane.
Any process involved in the activation of any of the steps of the complement cascade, which allows for the direct killing of microbes, the disposal of immune complexes, and the regulation of other immune processes; the initial steps of complement activation involve one of three pathways, the classical pathway, the alternative pathway, and the lectin pathway, all of which lead to the terminal complement pathway.
Any process that modulates the frequency, rate or extent of the regulated release of catecholamines.
The process whose specific outcome is the progression of bone over time, from its formation to the mature structure. Bone is the hard skeletal connective tissue consisting of both mineral and cellular components.
Any process that stops, prevents, or reduces the frequency, rate or extent of the activity of any intracellular steroid hormone receptor signaling pathway.
The chemical reactions and pathways involving dermatan sulfate proteoglycan, any glycoprotein whose glycosaminoglycan units are dermatan sulfate (chondroitin sulfate B). Dermatan sulfate is a glycosaminoglycan with repeats consisting of beta-(1,4)-linked L-iduronyl-beta-(1,3)-N-acetyl-D-galactosamine 4-sulfate units.
Any process that modulates the frequency, rate or extent of biomineral tissue development, the formation of hard tissues that consist mainly of inorganic compounds.
Any process that modulates the frequency, rate or extent of the directed movement of amines into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
The process whose specific outcome is the progression of smooth muscle over time, from its formation to the mature structure.
Any process that stops, prevents or reduces the frequency, rate or extent of hematopoietic progenitor cell differentiation.
Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving nucleosides.
Any process that stops, prevents or reduces the frequency, rate or extent of cation channel activity.
Any process that results in the conversion of one or more primary non-coding RNA (ncRNA) transcripts into one or more mature ncRNA molecules.
Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of substances (such as macromolecules, small molecules, ions) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
The adhesion of one thymocyte (an immature T cell) to one or more other thymocytes via adhesion molecules.
The process in which a relatively unspecialized cell acquires specialized structural and/or functional features of a Leydig cell. A Leydig cell is a testosterone-secreting cell in the interstitial area, between the seminiferous tubules, in the testis.
The chemical reactions and pathways involving any organic compound that is weakly basic in character and contains an amino or a substituted amino group, as carried out by individual cells. Amines are called primary, secondary, or tertiary according to whether one, two, or three carbon atoms are attached to the nitrogen atom.
The covalent alteration of one or more nucleotide sites in DNA, resulting in a change in its properties.
A process in which a protein is transported to, or maintained in, a specific location in a membrane.
The set of processes involved in identifying and degrading defective or aberrant RNAs.
The aggregation, arrangement and bonding together of a set of components to form the spindle that contributes to the process of mitosis.
Any process that modulates the frequency, rate or extent of granulocyte differentiation.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an alkaloid stimulus. Alkaloids are a large group of nitrogenous substances found in naturally in plants, many of which have extracts that are pharmacologically active.
Any process that modulates the frequency, rate or extent of mesenchymal cell proliferation. A mesenchymal cell is a cell that normally gives rise to other cells that are organized as three-dimensional masses, rather than sheets.
The morphogenetic process in which an epithelial sheet bends along a linear axis.
The process in which cells digest parts of their own cytoplasm; allows for both recycling of macromolecular constituents under conditions of cellular stress and remodeling the intracellular structure for cell differentiation.
Any process that modulates the frequency, rate or extent of a process involved in the formation, arrangement of constituent parts, or disassembly of cell projections.
Any process that controls the length of actin filaments in a cell.
Any process that modulates the activity of a transporter.
The specific behavior of an organism relating to the intake of food, any substance (usually solid) that can be metabolized by an organism to give energy and build tissue.
The chemical reactions and pathways involving glutathione derivative.
A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a cell junction. A cell junction is a specialized region of connection between two cells or between a cell and the extracellular matrix.
The chemical reactions and pathways resulting in the formation of folic acid and its derivatives.
The process whose specific outcome is the progression of the embryonic heart tube over time, from its formation to the mature structure. The heart tube forms as the heart rudiment from the heart field.
The chemical reactions and pathways involving sphingoids, any of a class of compounds comprising sphinganine and its homologues and stereoisomers, and derivatives of these compounds.
Any process that decreases the stability of a protein, making it more vulnerable to degradative processes or aggregation.
Any process that stops, prevents, or reduces the frequency, rate or extent of a response to a food stimulus.
The directed movement of L-enantiomer amino acids into a cell or organelle.
The process whose specific outcome is the progression of the ear over time, from its formation to the mature structure. The ear is the sense organ in vertebrates that is specialized for the detection of sound, and the maintenance of balance. Includes the outer ear and middle ear, which collect and transmit sound waves; and the inner ear, which contains the organs of balance and (except in fish) hearing. Also includes the pinna, the visible part of the outer ear, present in some mammals.
Any process that stops, prevents, or reduces the rate or extent of cell adhesion to the extracellular matrix.
Any process that modulates the rate, frequency or extent of macrophage chemotaxis. Macrophage chemotaxis is the movement of a macrophage in response to an external stimulus.
The synthesis of DNA from a template strand in a net 3' to 5' direction. Lagging strand DNA elongation proceeds by discontinuous synthesis of short stretches of DNA, known as Okazaki fragments, from RNA primers; these fragments are then joined by DNA ligase. Although each segment of nascent DNA is synthesized in the 5' to 3' direction, the overall direction of lagging strand synthesis is 3' to 5', mirroring the progress of the replication fork.
Any process that activates or increases the rate or extent of smooth muscle cell proliferation.
The evagination of a membrane, resulting in formation of a vesicle.
A process that modulates synaptic plasticity, the ability of synapses to change as circumstances require. They may alter function, such as increasing or decreasing their sensitivity, or they may increase or decrease in actual numbers.
A process that modulates synaptic plasticity such that synapses are changed resulting in the decrease in the rate, or frequency of synaptic transmission at the synapse.
The chemical reactions and pathways involving glycosylceramides, any compound formed by the replacement of the glycosidic hydroxyl group of a cyclic form of a monosaccharide (or derivative) by a ceramide group.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a retinoic acid stimulus.
The transcription of non (protein) coding RNA from a DNA template.
Any process that modulates the frequency, rate, or extent of interleukin-1 beta production.
Any process that stops, prevents, or reduces the frequency, rate or extent of smooth muscle cell migration.
Any process that stops, prevents or reduces the frequency, rate or extent of intrinsic apoptotic signaling pathway.
The chemical reactions and pathways by which an unsaturated fatty acid (such as arachidonic acid or linolenic acid) is converted to other compounds, and in which the first step is hydroperoxide formation catalyzed by lipoxygenase.
Any process that stops, prevents or reduces the frequency, rate or extent of epithelial cell apoptotic process.
The initial attachment of a vesicle membrane to a target membrane, mediated by proteins protruding from the membrane of the vesicle and the target membrane, that contributes to exocytosis.
The change in morphology and behavior of a CD4-positive, alpha-beta T cell resulting from exposure to a mitogen, cytokine, chemokine, cellular ligand, or an antigen for which it is specific.
The process in which the anatomical structures of arterial blood vessels are generated and organized. Arteries are blood vessels that transport blood from the heart to the body and its organs.
Any process that stops, prevents or reduces the rate or extent of antiviral mechanisms, thereby facilitating viral replication.
Any process that activates or increases the rate or extent of a molecular function, an elemental biological activity occurring at the molecular level, such as catalysis or binding.
Any process that activates or increases the frequency, rate or extent of regulated secretory pathway.
The extension of new blood vessels from existing capillaries into avascular tissues resulting from the proliferation of blood vessel endothelial cells.
A change in morphology and behavior of a lymphocyte resulting from exposure to a specific antigen, mitogen, cytokine, chemokine, cellular ligand, or soluble factor.
The incorporation of a metal and exogenous sulfur into a metallo-sulfur cluster.
Any process that stops, prevents, or reduces the frequency, rate or extent of retinoic acid receptor signaling pathway activity.
The formation of a tri-snRNP complex containing U4 and U6 (or U4atac and U6atac) snRNAs and U5 snRNAs and associated proteins. This includes reannealing of U4 and U6 (or U4atac and U6atac) snRNAs released from previous rounds of splicing to reform the U4/U6 snRNP (or U4atac/U6atac snRNP) as well as the subsequent association of the U5 snRNP with the U4/U6 snRNP (or U4atac/U6atac snRNP) to form a tri-snRNP that is ready to reassemble into another spliceosome complex.
Any process that modulates the frequency, rate, or extent of T cell tolerance induction.
Any process that activates or increases the frequency, rate or extent of response to oxidative stress.
The formation of a protein trimer, a macromolecular structure consisting of three noncovalently associated identical or nonidentical subunits.
Any process that modulates the frequency, rate or extent of the phosphorylation of peptidyl-serine.
The chemical reactions and pathways involving proteoglycans, any glycoprotein in which the carbohydrate units are glycosaminoglycans.
The directed movement of nitrogen-containing compounds into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
The chemical reactions and pathways involving dopamine, a catecholamine neurotransmitter and a metabolic precursor of noradrenaline and adrenaline.
Reactions triggered in response to the presence of another organism that act to protect the cell or organism from damage caused by that organism.
Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways involving glycogen.
The expansion of a leukocyte population by cell division.
Any process that activates or increases the frequency, rate or extent of microtubule polymerization or depolymerization.
The chemical reactions and pathways involving L-ascorbic acid, (2R)-2-[(1S)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2,5-dihydrofuran-3-olate; L-ascorbic acid is vitamin C and has co-factor and anti-oxidant activities in many species.
The process whose specific outcome is the progression of the cerebellar granule layer over time, from its formation to the mature structure. The granular layer is the innermost layer of the cerebellar cortex. This layer contains densely packed small neurons, mostly granule cells. Some Golgi cells are found at the outer border. Granule neurons send parallel fibers to the upper molecular layer, where they synapse with Purkinje cell dendrites. Mossy fibers from the pontine nuclei in the white matter synapse with granule cell axons, Golgi cell axons and unipolar brush interneuron axons at cerebellar glomeruli in the granule cell layer.
Heritable alterations in the activity of a gene that depend on whether it passed through the paternal or the maternal germline, but that are not encoded by DNA itself.
The aggregation, arrangement and bonding together of a set of components to form an adherens junction. An adherens junction is a cell junction at which the cytoplasmic face of the plasma membrane is attached to actin filaments.
A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a secretory granule. A secretory granule is a small subcellular vesicle, surrounded by a membrane, that is formed from the Golgi apparatus and contains a highly concentrated protein destined for secretion.
Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of potassium ions (K+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
Any process that activates or increases the frequency, rate, or extent of interleukin-12 production.
Any process that modulates the occurrence or rate of T cell death by apoptotic process.
Fusion of the membrane of a vesicle with the plasma membrane, thereby releasing its contents into the extracellular space.
The process whose specific outcome is the progression of ventricular cardiac muscle over time, from its formation to the mature structure.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interferon-gamma stimulus. Interferon gamma is the only member of the type II interferon found so far.
Any process that stops, prevents, or reduces the frequency, rate or extent of the covalent addition of methyl groups to histones.
Any process that modulates the frequency, rate or extent of glial cell proliferation.
The process whose specific outcome is the progression of the embryo in the uterus over time, from formation of the zygote in the oviduct, to birth. An example of this process is found in Mus musculus.
Any process that stops, prevents or reduces the frequency, rate or extent of blood circulation.
Any series of molecular signals that conveys information from the endoplasmic reticulum to the nucleus, usually resulting in a change in transcriptional regulation.
The chemical reactions and pathways involving ethanol, CH3-CH2-OH, a colorless, water-miscible, flammable liquid produced by alcoholic fermentation.
The chemical reactions and pathways resulting in the formation of dicarboxylic acids, any organic acid containing two carboxyl (-COOH) groups.
The formation of a protein heterotrimer, a macromolecular structure consisting of three noncovalently associated subunits, of which not all are identical.
The directed movement of a vesicle along a cytoskeletal fiber such as a microtubule or and actin filament, mediated by motor proteins.
Any process that modulates the frequency, rate or extent of the movement of a transcription factor from the cytoplasm to the nucleus.
The directed, self-propelled movement of a cilium of an epithelial cell. This movement is usually coordinated between many epithelial cells, and serves to move fluid.
Any process that stops, prevents or reduces the rate or extent of progression through the meiotic cell cycle.
The process in which a relatively unspecialized cell acquires specialized features of a mesenchymal cell. A mesenchymal cell is a loosely associated cell that is part of the connective tissue in an organism. Mesenchymal cells give rise to more mature connective tissue cell types.
Any process that stops, prevents or reduces the frequency, rate or extent of DNA biosynthetic process.
The chemical reactions and pathways involving fatty acids with a chain length of less than C6.
The developmental process in which atrial septum is generated and organized. The atrial septum separates the upper chambers (the atria) of the heart from one another.
Any process that modulates the frequency, rate or extent of small GTPase mediated signal transduction.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a growth hormone stimulus. Growth hormone is a peptide hormone that binds to the growth hormone receptor and stimulates growth.
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of interleukin-2.
The covalent alteration of one or more nucleotides within an RNA molecule to produce an RNA molecule with a sequence that differs from that coded genetically.
The cellular component assembly that is part of the initial shaping of the component during its developmental progression.
The creation of two or more organelles by division of one organelle.
The process, occurring in the embryo, by which the anatomical structures of the forelimb are generated and organized. The forelimbs are the front limbs of an animal, e.g. the arms of a human.
Any process that modulates the frequency, rate or extent of fibroblast apoptotic process.
The process whose specific outcome is the progression of the nose over time, from its formation to the mature structure. The nose is the specialized structure of the face that serves as the organ of the sense of smell and as part of the respiratory system. Includes the nasi externus (external nose) and cavitas nasi (nasal cavity).
The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the cells of the kidney as it progresses from its formation to the mature state.
Any process that modulates the frequency, rate or extent of transcription from an RNA ploymerase III promoter.
The progression of a muscle structure over time, from its formation to its mature state. Muscle structures are contractile cells, tissues or organs that are found in multicellular organisms.
Any process that decreases the rate, frequency or extent of a cellular process that is involved in the progression of biochemical and morphological phases and events that occur in a cell during successive cell replication or nuclear replication events.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus reflecting an increase in the level of oxygen.
Any process that affects the rate, extent or location of chromatin silencing.
The acquisition, loss, or modification of macromolecules within a complex, resulting in the alteration of an existing complex.
The aggregation, arrangement and bonding together of constituent RNAs and proteins to form the large ribosomal subunit.
Any process in which a substance or cellular entity, such as a protein complex or organelle, is maintained in a specific location within, or in the membrane of, a cell, and is prevented from moving elsewhere.
The process whose specific outcome is the progression of the cerebellar cortex over time, from its formation to the mature structure. The cerebellar cortex is a thin mantle of gray matter that covers the surface of each cerebral hemisphere. It has a characteristic morphology with convolutions (gyri) and crevices (sulci) that have specific functions. Six layers of nerve cells and the nerve pathways that connect them comprise the cerebellar cortex. Together, these regions are responsible for the processes of conscious thought, perception, emotion and memory as well as advanced motor function.
Any process that modulates the frequency, rate or extent of microtubule polymerization.
Any process that modulates the frequency, rate or extent of mesoderm development.
An immune response which is associated with resistance to intracellular bacteria, fungi, and protozoa, and pathological conditions such as arthritis, and which is typically orchestrated by the production of particular cytokines by T-helper 1 cells, most notably interferon-gamma, IL-2, and lymphotoxin.
Any process that activates or increases the frequency, rate, or extent of a type 2 immune response.
The process in which a lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts degraded.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus reflecting the presence, absence, or concentration of oxygen.
The cellular DNA metabolic process resulting in the breakdown of DNA, deoxyribonucleic acid, one of the two main types of nucleic acid, consisting of a long unbranched macromolecule formed from one or two strands of linked deoxyribonucleotides, the 3'-phosphate group of each constituent deoxyribonucleotide being joined in 3',5'-phosphodiester linkage to the 5'-hydroxyl group of the deoxyribose moiety of the next one.
Any process that modulates the frequency, rate or extent of the activity of an intracellular estrogen receptor signaling pathway.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hormone stimulus.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a prostagladin stimulus.
The commitment of cells to specific cell fates of the endoderm, ectoderm, or mesoderm as a part of gastrulation.
The process of restoring DNA after damage. Genomes are subject to damage by chemical and physical agents in the environment (e.g. UV and ionizing radiations, chemical mutagens, fungal and bacterial toxins, etc.) and by free radicals or alkylating agents endogenously generated in metabolism. DNA is also damaged because of errors during its replication. A variety of different DNA repair pathways have been reported that include direct reversal, base excision repair, nucleotide excision repair, photoreactivation, bypass, double-strand break repair pathway, and mismatch repair pathway.
The process in which an antigenically naive T cell acquires the specialized features of an effector, regulatory, or memory T cell as part of an immune response. Effector T cells include cells which provide T cell help or exhibit cytotoxicity towards other cells.
The series of molecular signals generated as a consequence of the insulin-like growth factor receptor binding to one of its physiological ligands.
The formation of a protein heterotetramer, a macromolecular structure consisting of four noncovalently associated subunits, of which not all are identical.
Any process that stops, prevents, or reduces the frequency, rate or extent of heart contraction.
The process where neuronal precursors migrate tangentially in the telencephalon, primarily guided by interactions that do not require cell-cell contact.
The chemical reactions and pathways resulting in the breakdown of compounds that contain sulfur, such as the amino acids methionine and cysteine or the tripeptide glutathione.
The directed movement of chloride into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
The removal of tubulin heterodimers from one or both ends of a microtubule.
The process of creating protein polymers, compounds composed of a large number of component monomers; polymeric proteins may be made up of different or identical monomers. Polymerization occurs by the addition of extra monomers to an existing poly- or oligomeric protein.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a corticosteroid hormone stimulus. A corticosteroid is a steroid hormone that is produced in the adrenal cortex. Corticosteroids are involved in a wide range of physiologic systems such as stress response, immune response and regulation of inflammation, carbohydrate metabolism, protein catabolism, blood electrolyte levels, and behavior. They include glucocorticoids and mineralocorticoids.
A cascade of processes induced by the detection of DNA damage within a cell.
The chemical reactions and pathways involving cobalamin (vitamin B12), a water-soluble vitamin characterized by possession of a corrin nucleus containing a cobalt atom.
The process that reduces the force with which blood travels through the systemic arterial circulatory system.
A process in which force is generated within muscle tissue, resulting in a change in muscle geometry. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis.
Any process in which a telomere is transported to, and/or maintained in, a specific location.
Any process involved in the maintenance of an internal steady state of transition metal ions within an organism or cell. A transition metal is an element whose atom has an incomplete d-subshell of extranuclear electrons, or which gives rise to a cation or cations with an incomplete d-subshell. Transition metals often have more than one valency state. Biologically relevant transition metals include vanadium, manganese, iron, copper, cobalt, nickel, molybdenum and silver.
Any process that modulates the frequency, rate or extent of adherens junction organization.
Any series of molecular signals initiated by the binding of an extracellular ligand to a receptor on the surface of the target cell, where the receptor possesses catalytic activity or is closely associated with an enzyme such as a protein kinase, and ending with regulation of a downstream cellular process, e.g. transcription.
The chemical reactions and pathways resulting in the breakdown of a pyrimidine nucleotide, a compound consisting of nucleoside (a pyrimidine base linked to a deoxyribose or ribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.
The series of molecular signals generated as a consequence of a G-protein coupled receptor binding to its physiological ligand, where the pathway proceeds with activation of protein kinase C (PKC). PKC is activated by second messengers including diacylglycerol (DAG).
Any viral process that modulates the frequency, rate, or extent of the antiviral response of the host cell or organism.
Any process that modulates the frequency, rate or extent of receptor internalization.
Any process that modulates the frequency, rate or extent of calcium ion transmembrane transport.
Any process in which a protein is transported to, or maintained at, the centromeric region of a chromosome.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a bacterium.
Any process that modulates the frequency, rate, or extent of antigen processing and presentation.
A decrease in the diameter of blood vessels, especially arteries, usually causing an increase in blood pressure.
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of proteins by the translation of mRNA in a mitochondrion.
Any process that activates or increases the frequency, rate, or extent of leukocyte migration.
The directed movement of calcium ions into a cell or organelle.
A developmental process, independent of morphogenetic (shape) change, that is required for a cell to attain its fully functional state.
Any process that results in a change in the behavior of an organism as a result of a pain stimulus. Pain stimuli cause activation of nociceptors, peripheral receptors for pain, include receptors which are sensitive to painful mechanical stimuli, extreme heat or cold, and chemical stimuli.
Any process that modulates the frequency, rate or extent of the controlled release of a substance from a cell or a tissue.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a toxic stimulus.
Any process in which an organism modulates the frequency, rate or extent of transcription in a second organism, where the two organisms are in a symbiotic interaction.
A series of molecular signals which triggers the apoptotic death of a cell. The pathway starts with reception of a signal, and ends when the execution phase of apoptosis is triggered.
The biological process whose specific outcome is the progression of a neural nucleus from its initial condition to its mature state. A neural nucleus is an anatomical structure consisting of a discrete aggregate of neuronal soma.
Any process involved in the carrying out of an immune response by a lymphocyte.
Any process that modulates the frequency, rate or extent of heart morphogenesis.
The chemical reactions and pathways involving S-adenosylmethionine, S-(5'-adenosyl)-L-methionine, an important intermediate in one-carbon metabolism.
A series of molecular signals initiated by the binding of the Fc portion of immunoglobulin E (IgE) to an Fc-epsilon receptor on the surface of a signal-receiving cell, and ending with regulation of a downstream cellular process, e.g. transcription. The Fc portion of an immunoglobulin is its C-terminal constant region.
The progression of the hippocampus over time from its initial formation until its mature state.
Any process that modulates the frequency, rate or extent of protein localization to the cell surface.
The chemical reactions and pathways resulting in the formation of a ribonucleoside triphosphate, a compound consisting of a nucleobase linked to a ribose sugar esterified with triphosphate on the sugar.
The chemical reactions and pathways involving primary amino compound.
Any process that activates or increases the frequency, rate or extent of telomere capping.
Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of amines into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
Any process that modulates the frequency, rate or extent of chromosome segregation, the process in which genetic material, in the form of chromosomes, is organized and then physically separated and apportioned to two or more sets.
Any process that increases the frequency, rate or extent of insulin receptor signaling.
The process whose specific outcome is the progression of the pons over time, from its formation to the mature structure. The pons lies above the medulla and next to the cerebellum. The pons conveys information about movement from the cerebral hemisphere to the cerebellum.
A protein ubiquitination process in which ubiquitin monomers are attached to a protein, and then ubiquitin polymers are formed by linkages between lysine residues at position 11 of the ubiquitin monomers. K11-linked polyubiquitination targets the substrate protein for degradation. The anaphase-promoting complex promotes the degradation of mitotic regulators by assembling K11-linked polyubiquitin chains.
The series of events involved in the perception of taste in which a gustatory chemical stimulus is received and converted into a molecular signal.
Any process that modulates the frequency, rate or extent of mesenchymal cell apoptotic process.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an inactivity stimulus.
The chemical reactions and pathways involving sphingolipids, any of a class of lipids containing the long-chain amine diol sphingosine or a closely related base (a sphingoid).
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a pain stimulus. Pain stimuli cause activation of nociceptors, peripheral receptors for pain, include receptors which are sensitive to painful mechanical stimuli, extreme heat or cold, and chemical stimuli.
The addition of an acetyl group to a protein amino acid. An acetyl group is CH3CO-, derived from acetic
Any process that activates or increases the frequency, rate or extent of transcription elongation, the extension of an RNA molecule after transcription initiation and promoter clearance by the addition of ribonucleotides, catalyzed by RNA polymerase II.
Any process that modulates the frequency, rate or extent of the directed movement of substances between the nucleus and the cytoplasm.
Any process that decreases the rate, frequency, or extent of the directed movement of calcium ions into a cell or organelle.
The chemical reactions and pathways involving any hormone, naturally occurring substances secreted by specialized cells that affects the metabolism or behavior of other cells possessing functional receptors for the hormone, as carried out by individual cells.
The chemical reactions and pathways involving any compound containing pteridine (pyrazino(2,3-dipyrimidine)), e.g. pteroic acid, xanthopterin and folic acid.
The continuous turnover of bone matrix and mineral that involves first, an increase in resorption (osteoclastic activity) and later, reactive bone formation (osteoblastic activity). The process of bone remodeling takes place in the adult skeleton at discrete foci. The process ensures the mechanical integrity of the skeleton throughout life and plays an important role in calcium homeostasis. An imbalance in the regulation of bone resorption and bone formation results in many of the metabolic bone diseases, such as osteoporosis.
The process in which the anatomical structures of the eye are generated and organized during embryonic development.
The joining of the small ribosomal subunit, ternary complex, and mRNA.
A series of molecular signals initiated by the binding of a chemokine to a receptor on the surface of a cell, and ending with regulation of a downstream cellular process, e.g. transcription.
Any process that activates or increases the frequency, rate, or extent of interferon-beta production.
Any process that stops, prevents, or reduces the frequency, rate, or extent of leukocyte migration.
Any process that modulates the frequency, rate or extent of the controlled release of a protein from a cell.
Any process that modulates the frequency, rate or extent of the phosphorylation of peptidyl-tyrosine.
Any process that modulates the frequency, rate or extent of natural killer cell activation.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an insulin stimulus. Insulin is a polypeptide hormone produced by the islets of Langerhans of the pancreas in mammals, and by the homologous organs of other organisms.
Any process that activates or increases the frequency, rate or extent of the assembly of a filopodium, a thin, stiff protrusion extended by the leading edge of a motile cell such as a crawling fibroblast or amoeba, or an axonal growth cone.
Any process that modulates the rate or frequency of muscle cell apoptotic process, a form of programmed cell death induced by external or internal signals that trigger the activity of proteolytic caspases whose actions dismantle a muscle cell and result in its death.
Any process that activates or increases the frequency, rate or extent of NIK/NF-kappaB signaling.
Any process that modulates the frequency, rate, or extent of the chemical reactions and pathways resulting in the breakdown of substances.
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving carbohydrates.
Any process that stops, prevents, or reduces the frequency, rate or extent of synaptic transmission, the process of communication from a neuron to a target (neuron, muscle, or secretory cell) across a synapse.
Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of cytokines.
The process in which the neural tube is divided into specific regions along the rostrocaudal axis.
The change in morphology and behavior of a mature or immature B cell resulting from exposure to a mitogen, cytokine, chemokine, cellular ligand, or an antigen for which it is specific.
Any biological process that results in permanent cessation of all vital functions of a cell upon exposure to an oxidative stress stimulus.
Any process that modulates the frequency, rate or extent of neuron differentiation.
Any process that stops, prevents, or reduces the frequency, rate, or extent of interferon-gamma production. Interferon-gamma is also known as type II interferon.
Any process that modulates the frequency, rate or extent of fibrinolysis, an ongoing process that solubilizes fibrin, resulting in the removal of small blood clots.
Any process that stops, prevents, or reduces the frequency, rate or extent of the activity of the transcription factor NF-kappaB.
Addition of multiple ubiquitin groups to a protein, forming a ubiquitin chain.
Any process in which a ribonucleoprotein complex is transported to, or maintained in, a specific location within a cell.
Any process that modulates the frequency, rate or extent of mRNA 3'-end processing, any process involved in forming the mature 3' end of an mRNA molecule.
Any process that modulates the frequency, rate or extent of the directed movement of peptides, compounds of two or more amino acids where the alpha carboxyl group of one is bound to the alpha amino group of another, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
Any process that activates or increases the frequency, rate or extent of the directed movement of charged atoms or small charged molecules into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
The chemical reactions and pathways resulting in the formation of ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.
The series of molecular signals initiated by binding of a Wnt protein to a frizzled family receptor on the surface of the target cell, followed by propagation of the signal via beta-catenin, and ending with a change in transcription of target genes. In this pathway, the activated receptor signals via downstream effectors that result in the inhibition of beta-catenin phosphorylation, thereby preventing degradation of beta-catenin. Stabilized beta-catenin can then accumulate and travel to the nucleus to trigger changes in transcription of target genes.
Inflammation which comprises a rapid, short-lived, relatively uniform response to acute injury or antigenic challenge and is characterized by accumulations of fluid, plasma proteins, and granulocytic leukocytes. An acute inflammatory response occurs within a matter of minutes or hours, and either resolves within a few days or becomes a chronic inflammatory response.
The chemical reactions and pathways involving a nucleobase, a nitrogenous base that is a constituent of a nucleic acid, e.g. the purines: adenine, guanine, hypoxanthine, xanthine and the pyrimidines: cytosine, uracil, thymine.
An immune response mediated through a body fluid.
Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-10 production.
A process that is carried out at the cellular level which results in the arrangement of constituent parts of a phagosome within a cell. Phagosome maturation begins with endocytosis and formation of the early phagosome and ends with the formation of the hybrid organelle, the phagolysosome.
Any process that modulates the frequency, rate or extent of cellular response to hypoxia.
Any process that modulates the frequency, rate or extent of female gonad development.
Any process that modulates the occurrence or rate of thymocyte death by apoptotic process.
The alteration of DNA, protein, or sometimes RNA, in chromatin, which may result in changing the chromatin structure.
A change in the morphology or behavior of a myeloid leukocyte resulting from exposure to an activating factor such as a cellular or soluble ligand.
The chemical reactions and pathways involving a reactive nitrogen species.
The regionalization process in which specific areas of cell differentiation are determined along the anterior-posterior axis. The anterior-posterior axis is defined by a line that runs from the head or mouth of an organism to the tail or opposite end of the organism.
Any process that activates or increases the frequency, rate or extent of cell division.
The progression of the eyelid in a camera-type eye from its formation to the mature state. The eyelid is a membranous cover that helps protect and lubricate the eye.
The chemical reactions and pathways resulting in the formation of a pigment, any general or particular coloring matter in living organisms, e.g. melanin.
A series of molecular signals initiated by binding of a ligand to a member of the ERBB family of receptor tyrosine kinases on the surface of a cell, and ending with regulation of a downstream cellular process, e.g. transcription.
Morphogenesis, during the embryonic phase, of a tissue or tissues that work together to perform a specific function or functions. Morphogenesis is the process in which anatomical structures are generated and organized. Organs are commonly observed as visibly distinct structures, but may also exist as loosely associated clusters of cells that work together to perform a specific function or functions.
The progression of the reproductive system over time from its formation to the mature structure. The reproductive system consists of the organs that function in reproduction.
The directed movement of calcium ions (Ca2+) into, out of or within the cytosol.
Any process that modulates the rate, frequency or extent of the assembly, arrangement of constituent parts, or disassembly of the microtubule spindle.
Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of substances.
The movement of a population of phospholipid molecules from one leaflet of the plasma membrane bilayer to the opposite leaflet, resulting in loss of lipid asymmetry and surface exposure of phosphatidylserine (PS) and phosphatidylethanolamine (PE).
The process that results in the generation of glial cells. This includes the production of glial progenitors and their differentiation into mature glia.
The modification of peptidyl-threonine.
The division of a mitochondrion within a cell to form two or more separate mitochondrial compartments.
Any process involved in the maturation of an rRNA molecule originally produced as part of a tricistronic rRNA transcript that contained the Small SubUnit (SSU) rRNA, the 5.8S rRNA, and the Large SubUnit (LSU) rRNA, in that order, from 5' to 3' along the primary transcript.
Any process that stops, prevents or reduces the frequency, rate or extent of sprouting angiogenesis.
The directed movement of polyols, any polyhydric alcohol, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
Any process that modulates the frequency, rate or extent of cardiac muscle contraction by changing the calcium ion signals that trigger contraction.
The process in which an antigen-presenting cell expresses antigen (peptide or lipid) on its cell surface in association with an MHC protein complex.
The chemical reactions and pathways resulting in the breakdown of amino acids, organic acids containing one or more amino substituents.
The orderly movement of glial cells through the telencephalon.
Any process in which a cell, substance or cellular entity, such as a protein complex or organelle, is maintained in a location and prevented from moving elsewhere.
The process whose specific outcome is the progression of the nephron epithelium over time, from its formation to the mature structure. An epithelium is a tissue that covers the internal or external surfaces of an anatomical structure. The nephron epithelium is a tissue that covers the surface of a nephron.
Any process that stops, prevents or reduces the frequency, rate or extent of receptor activity.
The process in which a relatively unspecialized cell acquires specialized features of a keratinocyte.
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of a nitric-oxide synthase enzyme.
Any process that activates or increases the frequency, rate or extent of calcium ion transmembrane transport.
Any process that stops, prevents, or reduces the frequency, rate or extent of epithelial cell migration.
Any process that increases the extent of synapse maturation, the process that organizes a synapse so that it attains its fully functional state.
The process in which a relatively unspecialized cell acquires specialized features of a neuron whose cell body resides in the peripheral nervous system.
Any process that maintains the redox environment of a cell or compartment within a cell.
Any process that activates or increases the frequency, rate or extent of smooth muscle contraction.
Any process that stops or decreases the rate or extent of glial cell proliferation.
Any process that activates or increases the frequency, rate or extent of the controlled release of a protein from a cell.
Any process that activates or increases the frequency, rate or extent of the formation, arrangement of constituent parts, or disassembly of cytoskeletal structures.
Any process that modulates the frequency, rate or extent of steroid hormone secretion.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a ketone stimulus.
Any process that stops, prevents, or reduces the frequency, rate or extent of protein kinase B signaling, a series of reactions mediated by the intracellular serine/threonine kinase protein kinase B.
Lymph vessel formation when new vessels emerge from the proliferation of pre-existing vessels.
Any process that modulates the potential difference across a post-synaptic membrane.
Any process that activates or increases the frequency, rate, or extent of toll-like receptor signaling pathway.
The series of events required for an organism to receive a gustatory stimulus, convert it to a molecular signal, and recognize and characterize the signal. Gustation involves the direct detection of chemical composition, usually through contact with chemoreceptor cells. This is a neurological process.
The response of an organism to a perceived external threat.
Any process that modulates the frequency, rate or extent of clathrin-mediated endocytosis.
Any process that modulates the rate, frequency, or extent of the orderly movement of an endothelial cell into the extracellular matrix to form an endothelium.
The process whose specific outcome is the progression of a blood vessel of the labyrinthine layer of the placenta over time, from its formation to the mature structure. The embryonic vessels grow through the layer to come in close contact with the maternal blood supply.
The process of communication from a neuron to another neuron across a synapse.
A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the mitochondrial inner membrane.
A process that is carried out at the cellular level and in which the structure of a cilium is organized.
The transport of protons across a membrane to generate an electrochemical gradient (proton-motive force) that provides energy for the synthesis of ATP or GTP.
Any process that activates or increases the activity of a phosphoprotein phosphatase.
The chemical reactions and pathways resulting in the formation of compounds derived from amino acids, organic acids containing one or more amino substituents.
A process in which a protein is transported to, or maintained at, a location in a vacuole.
The process in which the anatomical structures of the metanephric renal vesicle are generated and organized. The renal vesicle is the primordial structure of the metanephric nephron epithelium, and is formed by the condensation of mesenchymal cells.
Any process that stops, prevents, or reduces the frequency, rate or extent of Rho protein signal transduction.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hydrogen peroxide (H2O2) stimulus.
Any process that modulates the frequency, rate or extent of growth of an organ of an organism.
Any process that modulates the frequency, rate or extent of synapse assembly, the aggregation, arrangement and bonding together of a set of components to form a synapse.
Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of a neurotransmitter.
Any process that activates or increases the frequency, rate, extent or direction of cell growth.
Any process that stops or reduces the rate of oxidoreductase activity, the catalysis of an oxidation-reduction (redox) reaction, a reversible chemical reaction in which the oxidation state of an atom or atoms within a molecule is altered.
The process whose specific outcome is the progression of the gut over time, from its formation to the mature structure during embryonic development. The gut is the region of the digestive tract extending from the beginning of the intestines to the anus.
The transfer of mannose from dolichyl activated mannose to the hydroxyl group of a seryl or threonyl residue of a protein acceptor molecule, to form an O-linked protein-sugar linkage.
The chemical reactions and pathways resulting in the formation of guanosine-containing compounds (guanosines).
The deposition of hydroxyapatite, a form of calcium phosphate with the formula Ca10(PO4)6(OH)2, in bone tissue.
Any process that modulates the rate, frequency, or extent of the series of molecular signals generated as a consequence of a transmembrane receptor serine/threonine kinase binding to its physiological ligand.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an organic substance stimulus.
A process involved in the sexual cycle seen in females, often with physiologic changes in the endometrium that recur at regular intervals during the reproductive years.
Any process that activates or increases the frequency, rate or extent of cell adhesion.
Any process in which a protein is transported to, or maintained at, a part of a chromosome that is organized into chromatin.
The process of transferring a fucosyl group to a serine or threonine residues in a protein acceptor molecule, to form an O-linked protein-sugar linkage.
The progression of the cerebral cortex over time from its initial formation until its mature state. The cerebral cortex is the outer layered region of the telencephalon.
The process whose specific outcome is the progression of the endocrine pancreas over time, from its formation to the mature structure. The endocrine pancreas is made up of islet cells that produce insulin, glucagon and somatostatin.
Any process that modulates the frequency, rate, or extent of interleukin-8 production.
The RNA metabolic process in which the phosphodiester bonds between ribonucleotides are cleaved by hydrolysis.
The chemical reactions and pathways involving organic acids, any acidic compound containing carbon in covalent linkage.
Any process that modulates the frequency, rate, or extent of excretion, the elimination by an organism of the waste products that arise as a result of metabolic activity.
The chemical reactions and pathways involving aromatic amino acid family, amino acids with aromatic ring (phenylalanine, tyrosine, tryptophan).
Any intracellular signal transduction in which the signal is passed on within the cell via a cyclic nucleotide. Includes production or release of the cyclic nucleotide, and downstream effectors that further transmit the signal within the cell.
Any process that activates or increases the frequency, rate or extent of phospholipid metabolic process.
Any process that modulates the frequency, rate or extent of an endocrine process, a process involving the secretion of or response to endocrine hormones. An endocrine hormone is a hormone released into the circulatory system.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an insecticide stimulus. Insecticides are chemicals used to kill insects.
Any process that modulates the frequency, rate or extent of poly(A) tail shortening of a nuclear-transcribed mRNA. Poly(A) tail shortening is the decrease in length of the poly(A) tail of an mRNA from full length to an oligo(A) length.
The directed movement into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore of quaternary ammonium compounds, any compound that can be regarded as derived from ammonium hydroxide or an ammonium salt by replacement of all four hydrogen atoms of the NH4+ ion by organic groups.
The cell cycle transition where a cell leaves M phase and enters a new G1 phase. M phase is the part of the mitotic cell cycle during which mitosis and cytokinesis take place.
Any process that modulates the frequency, rate or extent of symbiosis, an interaction between two organisms living together in more or less intimate association.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a growth hormone stimulus. Growth hormone is a peptide hormone that binds to the growth hormone receptor and stimulates growth.
The removal of one or more mannose residues from a mannosylated protein.
A cell cycle checkpoint that detects and negatively regulates progression from G1 to S phase in the cell cycle in response to DNA damage.
Any process that activates or increases the frequency, rate or extent of pri-miRNA transcription from RNA polymerase II promoter.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus reflecting the presence, absence, or concentration of oxygen.
Any process that activates or increases the frequency, rate, or extent of an immune system process.
The sequence of reactions within a cell required to convert absorbed photons from visible light into a molecular signal. A visible light stimulus is electromagnetic radiation that can be perceived visually by an organism; for organisms lacking a visual system, this can be defined as light with a wavelength within the range 380 to 780 nm.
Any process that mediates interactions between a cell and its surroundings that contributes to the process of cardiac conduction. Encompasses interactions such as signaling or attachment between one cell and another cell, between a cell and an extracellular matrix, or between a cell and any other aspect of its environment.
Any process in which a protein is transported to, or maintained at, the telomeric region of a chromosome.
Any process that activates or increases the frequency, rate or extent of calcium ion transmembrane transporter activity.
Any process that modulates the frequency, rate or extent of receptor mediated endocytosis, the uptake of external materials by cells, utilizing receptors to ensure specificity of transport.
Any process that activates or increases the frequency, rate, or extent of lymphocyte mediated immunity.
Any process that activates or increases the frequency, rate or extent of biomineral tissue development, the formation of hard tissues that consist mainly of inorganic compounds.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a transforming growth factor beta stimulus.
The chemical reactions and pathways involving N-acetylglucosamine. The D isomer is a common structural unit of glycoproteins in plants, bacteria and animals; it is often the terminal sugar of an oligosaccharide group of a glycoprotein.
The extension of an RNA molecule after transcription initiation and promoter clearance at an RNA polymerase II promoter by the addition of ribonucleotides catalyzed by RNA polymerase II.
The phosphorylation of ADP to ATP that accompanies the oxidation of a metabolite through the operation of the respiratory chain. Oxidation of compounds establishes a proton gradient across the membrane, providing the energy for ATP synthesis.
Alterations undergone by nuclei at the molecular and morphological level as part of the execution phase of apoptosis.
Any process that modulates the frequency, rate or extent of Rac protein signal transduction.
The chemical reactions and pathways involving an amide, any derivative of an oxoacid in which an acidic hydroxy group has been replaced by an amino or substituted amino group, as carried out by individual cells.
A reproductive behavior in which a parent cares for and rears offspring.
Any process that modulates the frequency, rate or extent of DNA binding. DNA binding is any process in which a gene product interacts selectively with DNA (deoxyribonucleic acid).
The appearance of immunoglobulin due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.
Any process that modulates the frequency, rate, or extent of production of transforming growth factor-beta.
The process in which the population of cells that make up a tissue undergo directed movement.
The directed movement of one-carbon compounds into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
The establishment, maintenance and elaboration of the left/right axis. The left/right axis is defined by a line that runs orthogonal to both the anterior/posterior and dorsal/ventral axes. Each side is defined from the viewpoint of the organism rather of the observer (as per anatomical axes).
Any process that results in a change in state or activity of an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a inadequate blood supply.
The process in which glial cells envelop neuronal cell bodies and/or axons to form an insulating layer. This can take the form of myelinating or non-myelinating ensheathment.
Any process that activates or increases the frequency, rate, or extent of mast cell activation as part of an immune response.
Any process that increases the frequency, rate or extent of the chemical reactions and pathways involving phosphorus or compounds containing phosphorus.
The controlled breakdown of chromatin from a higher order structure into its simpler subcomponents, DNA, histones, other proteins, and sometimes RNA.
Generation and organization of a platelet, a non-nucleated disk-shaped cell formed by extrusion from megakaryocytes, found in the blood of all mammals, and mainly involved in blood coagulation.
The process in which the anatomical structures of a dendrite are generated and organized. A dendrite is a freely branching protoplasmic process of a nerve cell.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an amphetamine stimulus. Amphetamines consist of a group of compounds related to alpha-methylphenethylamine.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cAMP (cyclic AMP, adenosine 3',5'-cyclophosphate) stimulus.
The process in which a relatively unspecialized cell acquires specialized features of a myoblast. A myoblast is a mononucleate cell type that, by fusion with other myoblasts, gives rise to the myotubes that eventually develop into striated muscle fibers.
Any process that activates or increases the frequency, rate or extent of actin nucleation, the initial step in the formation of an actin filament in which actin monomers combine to form a new filament.
Any process that modulates the frequency, rate or extent of megakaryocyte differentiation.
Any process that stops, prevents or reduces the frequency, rate or extent of hemopoiesis.
Any process that modulates the frequency, rate or extent of muscle cell differentiation.
Any process of the innate immune response that takes place in the mucosal tissues.
Any process that modulates the rate, frequency or extent of chemokine secretion, the regulated release of chemokines from a cell.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a sterol stimulus.
Any process that modulates the frequency, rate or extent of an endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway.
A cellular process that results in the biosynthesis of constituent macromolecules, assembly, and arrangement of constituent parts of a small ribosomal subunit; includes transport to the sites of protein synthesis.
The process of shaping a trabecula in an organ. A trabecula is a small, often microscopic, tissue element in the form of a small beam, strut or rod, which generally has a mechanical function. Trabecula are usually but not necessarily, composed of dense collagenous tissue.
Any process preventing the degeneration of the photoreceptor, a specialized cell type that is sensitive to light.
Any process that modulates the rate, frequency, or extent of the directed movement of calcium ions into a cell or organelle.
The chemical reactions and pathways involving any proteoglycan containing heparan sulfate, any member of a group of glycosaminoglycans that have repeat units consisting of alternating alpha-(1->4)-linked hexuronic acid and glucosamine residues, the former being a mixture of sulfated and nonsulfated D-glucuronic and L-iduronic acids, and the latter being either sulfated or acetylated on its amino group as well as sulfated on one of its hydroxyl groups.
The process whose specific outcome is the progression of a columnar/cuboidal epithelial cell of the intestine over time, from its formation to the mature structure.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a glucagon stimulus.
Any process that modulates the frequency, rate, or extent of metal ion transport. Metal ion transport is the directed movement of metal ions, any metal ion with an electric charge, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
Any process that activates or increases the frequency, rate, or extent of a T-helper 1 type immune response.
The process in which a symbiont organism effects a change in the structure or processes of its host organism.
The cell cycle process in which sister chromatids are organized and then physically separated and apportioned to two or more sets.
Any process that modulates the frequency, rate or extent of cell migration involved in sprouting angiogenesis. Cell migration involved in sprouting angiogenesis is the orderly movement of endothelial cells into the extracellular matrix in order to form new blood vessels contributing to the process of sprouting angiogenesis.
A process in which force is generated within phasic smooth muscle tissue, resulting in a change in muscle geometry. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. In the phasic smooth muscle, the muscle contraction occurs without an ordered sarcomeric structure. Phasic smooth muscle contraction occurs in a series of discrete contractions and relaxations.
The process in which a glial cell membrane closes around an axon in the central nervous system. This can be a myelinating or a non-myelinating neuron-glial interaction.
The chemical reactions and pathways resulting in the formation of monosaccharides, polyhydric alcohols containing either an aldehyde or a keto group and between three to ten or more carbon atoms.
The joining of two lipid bilayers to form a single organelle membrane.
Any process that modulates the frequency, rate or extent of signal transduction mediated by the ERK1 and ERK2 cascade.
Any process that modulates the frequency, rate, or extent of T cell mediated cytotoxicity.
The chemical reactions and pathways resulting in the formation of carbohydrate derivative.
Any process that stops, prevents, or reduces the frequency, rate or extent of the assembly of actin filament bundles.
Any process that activates or increases the frequency, rate or extent of cell junction assembly.
The biosynthetic process in which peptide bond formation occurs in the absence of the translational machinery. Examples include the synthesis of antibiotic peptides, and glutathione.
The developmental process in which the heart is generated and organized. The heart is a hollow, muscular organ, which, by contracting rhythmically, keeps up the circulation of the blood.
A series of molecular signals within the cell that are mediated by a member of the Ras superfamily of proteins switching to a GTP-bound active state.
Any process that stops, prevents, or reduces the frequency, rate or extent of dendrite development.
Any process that modulates the frequency, rate or extent of the regulated release of a hormone from a cell.
Any process that modulates the frequency, rate or extent of the directed movement of calcium ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
The series of events required for an organism to receive a sensory light stimulus, convert it to a molecular signal, and recognize and characterize the signal. This is a neurological process.
The chemical reactions and pathways involving terpenoids, any member of a class of compounds characterized by an isoprenoid chemical structure and including derivatives with various functional groups.
The multiplication or reproduction of cells, resulting in the expansion of a cell population.
Any process that modulates the frequency, rate or extent of lipid kinase activity, the catalysis of the transfer of a phosphate group, usually from ATP, to a simple or complex lipid.
Any process that activates or increases the frequency, rate or extent of osteoclast differentiation.
Any process in which a lysosome is transported to, and/or maintained in, a specific location.
The chemical reactions and pathways involving vitamin D, any of a group of related, fat-soluble compounds that are derived from delta-5,7 steroids and play a central role in calcium metabolism. Specific forms of vitamin D include calciferol (ergocalciferol; vitamin D2) and cholecalciferol (calciol; vitamin D3).
Any process that modulates the frequency, rate or extent of multiplication or reproduction of fibroblast cells.
The clustering together and adhesion of initially separate cells to form an aggregate.  Examples include the clustering of unicellular organisms or blood cells in suspension and the condensation of mesenchymal cells during cartilage formation.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hormone stimulus.
Any process that modulates the frequency, rate or extent of the formation of a syncytium, a mass of cytoplasm containing several nuclei enclosed within a single plasma membrane, by the fusion of the plasma membranes of two or more individual cells.
Any process that modulates the frequency, rate or extent of hexokinase activity.
Any process that activates or increases the frequency, rate or extent of extrinsic apoptotic signaling pathway in absence of ligand.
The chemical reactions and pathways resulting in the formation of any of a group of physiologically important biogenic amines that possess a catechol (3,4-dihydroxyphenyl) nucleus and are derivatives of 3,4-dihydroxyphenylethylamine.
Any process that activates or increases the frequency, rate or extent of muscle hypertrophy.
The process that results in the patterns of cell differentiation that will arise in an embryo.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a protozoan.
A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a multivesicular body. A multivesicular body is a type of late endosome in which regions of the limiting endosomal membrane invaginate to form internal vesicles; membrane proteins that enter the internal vesicles are sequestered from the cytoplasm.
Any process that modulates the frequency, rate, extent or direction of cell growth.
The cell cycle process in which centrosome duplication and separation takes place. The centrosome cycle can operate with a considerable degree of independence from other processes of the cell cycle.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a fibroblast growth factor stimulus.
The addition of a carboxy group to a protein amino acid.
Any process that stops, prevents or reduces the frequency, rate or extent of telomere maintenance via telomere lengthening.
The chemical reactions and pathways involving a deoxyribonucleoside triphosphate, a compound consisting of a nucleobase linked to a deoxyribose sugar esterified with triphosphate on the sugar.
The aggregation, arrangement and bonding together of proteins on DNA to form the multiprotein complex involved in damage recognition, DNA helix unwinding, and endonucleolytic cleavage at the site of DNA damage. This assembly occurs before the phosphodiester backbone of the damaged strand is cleaved 3' and 5' of the site of DNA damage.
Any process that activates or increases the frequency, rate or extent of extracellular matrix organization.
Any process in an organism in which a relatively long-lasting adaptive behavioral change occurs as the result of experience.
A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a cilium, a specialized eukaryotic organelle that consists of a filiform extrusion of the cell surface. Each cilium is bounded by an extrusion of the cytoplasmic membrane, and contains a regular longitudinal array of microtubules, anchored basally in a centriole.
Any process that modulates the frequency, rate or extent of phospholipase activity, the hydrolysis of a phospholipid.
Any process that modulates the frequency, rate or extent of a response to a food stimulus.
The process in which a chondroblast acquires specialized structural and/or functional features of a chondrocyte. A chondrocyte is a polymorphic cell that forms cartilage.
Any process that modulates the frequency, rate or extent of a process in which a cell, a substance, or a cellular entity is transported to, or maintained in a specific location within or in the membrane of a cell.
A series of molecular signals generated as a consequence of an adrenergic receptor binding to one of its physiological ligands.
The release of a mature ovum/oocyte from an ovary.
Any process that stops, prevents, or reduces the frequency, rate or extent of TOR signaling.
The progression of the substantia nigra over time from its initial formation until its mature state. The substantia nigra is the layer of gray substance that separates the posterior parts of the cerebral peduncles (tegmentum mesencephali) from the anterior parts; it normally includes a posterior compact part with many pigmented cells (pars compacta) and an anterior reticular part whose cells contain little pigment (pars reticularis).
Any process involved in the maturation of a precursor Small SubUnit (SSU) ribosomal RNA (rRNA) molecule into a mature SSU-rRNA molecule from the pre-rRNA molecule originally produced as a tricistronic rRNA transcript that contains the Small Subunit (SSU) rRNA, 5.8S rRNA, and the Large Subunit (LSU) in that order from 5' to 3' along the primary transcript.
The synthesis or release of any molecular mediator of the inflammatory response following an inflammatory stimulus, resulting in an increase in its intracellular or extracellular levels.
The process in which a startle magnitude is reduced when the startling stimulus is preceded by a low-intensity prepulse.
Any process that modulates the frequency, rate or extent of early endosome to late endosome transport.
The process in which the anatomical structures of the middle ear are generated and organized. The middle ear is the air-filled cavity within the skull of vertebrates that lies between the outer ear and the inner ear. It is linked to the pharynx (and therefore to outside air) via the Eustachian tube and in mammals contains the three ear ossicles, which transmit auditory vibrations from the outer ear (via the tympanum) to the inner ear (via the oval window).
Any process that modulates the frequency or rate of receptor biosynthesis. Receptor biosynthesis is the collection of chemical reactions and pathways resulting in the formation of a receptor molecule, a macromolecule that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function.
An intracellular protein kinase cascade containing at least a JNK (a MAPK), a JNKK (a MAPKK) and a JUN3K (a MAP3K). The cascade can also contain two additional tiers: the upstream MAP4K and the downstream MAP Kinase-activated kinase (MAPKAPK). The kinases in each tier phosphorylate and activate the kinases in the downstream tier to transmit a signal within a cell.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating an increase or decrease in the concentration of salt (particularly but not exclusively sodium and chloride ions) in the environment.
The process in which a relatively unspecialized cell acquires the specialized features of an endoderm cell, a cell of the inner of the three germ layers of the embryo.
A series of reactions, mediated by the intracellular serine/threonine kinase protein kinase B (also called AKT), which occurs as a result of a single trigger reaction or compound.
The formation of mesodermal clusters that are arranged segmentally along the anterior posterior axis of an embryo.
Any process that modulates the frequency, rate or extent of multicellular organismal development.
Any process that modulates the rate, frequency, or extent of dendritic spine development, the process whose specific outcome is the progression of the dendritic spine over time, from its formation to the mature structure.
Any process that stops, prevents or reduces the frequency, rate or extent of protein activation cascade.
The chemical reactions and pathways involving dicarboxylic acids, any organic acid containing three carboxyl (COOH) groups or anions (COO-).
Any process that modulates the frequency, rate, or extent of the chemical reactions and pathways resulting in the breakdown of triglyceride.
Any process that stops, prevents, or reduces the frequency, rate or extent of a response to an extracellular stimulus.
The expansion of a hematopoietic stem cell population by cell division. A hematopoietic stem cell is a stem cell from which all cells of the lymphoid and myeloid lineages develop.
Any process that stops, prevents or reduces the frequency, rate or extent of establishment of protein localization.
The progression of the renal tubule over time from its formation to the mature form. A renal tubule is a tube that filters, re-absorbs and secretes substances to rid an organism of waste and to play a role in fluid homeostasis.
The process in which the cardiac ventricle is generated and organized. A cardiac ventricle receives blood from a cardiac atrium and pumps it out of the heart.
The process in which an antigen-presenting cell expresses a peptide antigen on its cell surface in association with an MHC class I protein complex. Class I here refers to classical class I molecules.
Any process that modulates the extent of heart contraction, changing the force with which blood is propelled.
Any process that activates or increases the frequency, rate or extent of epithelial cell apoptotic process.
The aggregation, arrangement and bonding together of a set of macromolecules to form a complex.
Any process involved in maintaining the structure and integrity of a protein and preventing it from degradation or aggregation.
Any process that activates or increases the frequency, rate or extent of interleukin-6 secretion.
The chemical reactions and pathways resulting in the breakdown of amino acids of the aspartate family, comprising asparagine, aspartate, lysine, methionine and threonine.
Any process that stops, prevents, or reduces the frequency, rate or extent of the controlled release of a protein from a cell.
Any process that decreases the frequency, rate or extent of lipase activity, the hydrolysis of a lipid or phospholipid.
Any process that modulates the chemical reactions and pathways involving any of a class of organic compounds that contain the carbonyl group, CO, and in which the carbonyl group is bonded only to carbon atoms. The general formula for a ketone is RCOR, where R and R are alkyl or aryl groups.
Any process involved in the maturation of a precursor Large SubUnit (LSU) ribosomal RNA (rRNA) molecule into a mature LSU-rRNA molecule.
Splicing of RNA via recognition of the folded RNA structure that brings the 5' and 3' splice sites into proximity and cleavage of the RNA at both the 3' and 5' splice sites by an endonucleolytic mechanism, followed by ligation of the exons.
Any process that modulates the physical form of a synapse, the junction between a neuron and a target (neuron, muscle, or secretory cell).
A process in which muscle adapts, with consequent modifications to structural and/or functional phenotypes, in response to a stimulus. Stimuli include contractile activity, loading conditions, substrate supply, and environmental factors. These adaptive events occur in both muscle fibers and associated structures (motoneurons and capillaries), and they involve alterations in regulatory mechanisms, contractile properties and metabolic capacities.
The appearance of interferon-gamma due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. Interferon-gamma is also known as type II interferon.
The process whose specific outcome is the progression of the optic nerve over time, from its formation to the mature structure. The sensory optic nerve originates from the bipolar cells of the retina and conducts visual information to the brainstem. The optic nerve exits the back of the eye in the orbit, enters the optic canal, and enters the central nervous system at the optic chiasm (crossing) where the nerve fibers become the optic tract just prior to entering the hindbrain.
The series of molecular signals generated as a consequence of a G-protein coupled receptor binding to its physiological ligand, where the pathway proceeds with activation of phospholipase C (PLC) and a subsequent increase in the concentration of inositol trisphosphate (IP3) and diacylglycerol (DAG).
Any process that modulates the rate, frequency or extent of keratinocyte proliferation. Keratinocyte proliferation is the multiplication or reproduction of keratinocytes, resulting in the expansion of a cell population.
The directed movement of substances that are gaseous in normal living conditions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
Any process that modulates the frequency, rate or extent of fibroblast growth factor receptor signaling pathway activity.
Any process that modulates the frequency, rate, or extent of mast cell activation.
The process whose specific outcome is the progression of the midbrain over time, from its formation to the mature structure. The midbrain is the middle division of the three primary divisions of the developing chordate brain or the corresponding part of the adult brain (in vertebrates, includes a ventral part containing the cerebral peduncles and a dorsal tectum containing the corpora quadrigemina and that surrounds the aqueduct of Sylvius connecting the third and fourth ventricles).
The process in which a cell becomes capable of differentiating autonomously into a neuron in an environment that is neutral with respect to the developmental pathway. Upon specification, the cell fate can be reversed.
The chemical reactions and pathways resulting in the breakdown of organic acids, any acidic compound containing carbon in covalent linkage.
The specific behavior of an organism that is associated with reproduction.
Coordinated organization of groups of cells in a tissue, such that they all orient to similar coordinates.
Any process that modulates the occurrence or rate of cell death by apoptotic process in neurons.
The process of physically separating progeny cells after cytokinesis; this may involve enzymatic digestion of septum or cell wall components.
Any process that modulates the frequency, rate or extent of glucose import in response to insulin stimulus.
The chemical reactions and pathways resulting in the formation of an amide, any derivative of an oxoacid in which an acidic hydroxy group has been replaced by an amino or substituted amino group.
Any process that activates or increases the frequency, rate or extent of exocytosis.
The process in which the anatomical structures of an epithelial sheet are generated and organized. An epithelial sheet is a flat surface consisting of closely packed epithelial cells.
Behavior that is dependent upon the sensation of chemicals.
A series of reactions, mediated by the intracellular serine/threonine kinase protein kinase C, which occurs as a result of a single trigger reaction or compound.
The directed movement of the hexose monosaccharide glucose into a cell or organelle.
The cell cycle process in which the sister chromatids of a replicated chromosome are associated with each other.
Any process that modulates I-kappaB kinase/NF-kappaB signaling.
Any process that modulates the rate, frequency, or extent of protein kinase A signaling. PKA signaling is the series of reactions, mediated by the intracellular serine/threonine kinase protein kinase A, which occurs as a result of a single trigger reaction or compound.
Any apoptotic process in a hepatocyte, the main structural component of the liver.
The chemical reactions and pathways involving tetrahydrofolate, 5,6,7,8-tetrahydrofolic acid, a folate derivative bearing additional hydrogens on the pterin group.
Morphogenesis of an organ. An organ is defined as a tissue or set of tissues that work together to perform a specific function or functions. Morphogenesis is the process in which anatomical structures are generated and organized. Organs are commonly observed as visibly distinct structures, but may also exist as loosely associated clusters of cells that work together to perform a specific function or functions.
Any process that activates or increases the frequency, rate or extent of an organismal process, any of the processes pertinent to the function of an organism above the cellular level; includes the integrated processes of tissues and organs.
Any process that modulates the rate, frequency or extent of necrotic cell death. Necrotic cell death is a cell death process that is morphologically characterized by a gain in cell volume (oncosis), swelling of organelles, plasma membrane rupture and subsequent loss of intracellular contents.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cAMP (cyclic AMP, adenosine 3',5'-cyclophosphate) stimulus.
Any process in which a protein is transported to, or maintained at, a specific location on a chromosome.
A process which results in the assembly, arrangement of constituent parts, or disassembly of a postsynaptic membrane, the specialized area of membrane facing the presynaptic membrane on the tip of the nerve ending and separated from it by a minute cleft (the synaptic cleft).
The chemical reactions and pathways involving carnitine (hydroxy-trimethyl aminobutyric acid), a compound that participates in the transfer of acyl groups across the inner mitochondrial membrane.
The process preceding formation of the peptide bond between the first two amino acids of a protein in the cytoplasm. This includes the formation of a complex of the ribosome, mRNA, and an initiation complex that contains the first aminoacyl-tRNA.
Any process involved in the activation of any of the steps of the alternative pathway of the complement cascade which allows for the direct killing of microbes and the regulation of other immune processes.
The process in which a cardiac muscle precursor cell acquires specialized features of a cardiac muscle cell. Cardiac muscle cells are striated muscle cells that are responsible for heart contraction.
The chemical reactions and pathways involving a nucleoside triphosphate, a compound consisting of a nucleobase linked to a deoxyribose or ribose sugar esterified with triphosphate on the sugar.
The directed, self-propelled movement of a cilium.
The process in which the branching structure of the ureteric bud is generated and organized. The ureteric bud is an epithelial tube that grows out from the metanephric duct. The bud elongates and branches to give rise to the ureter and kidney collecting tubules.
A process, occurring in the vascular tissue, whereby actin/myosin complex activity generates force through ATP hydrolysis resulting in a change in smooth muscle geometry. This process is always coupled to chemo-mechanical energy conversion.
Any process that modulates the frequency, rate or extent of response to wounding.
The process of sparing immature T cells which react with self-MHC protein complexes with low affinity levels from apoptotic death.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an arsenic stimulus from compounds containing arsenic, including arsenates, arsenites, and arsenides.
Any process that increases the frequency or rate of receptor biosynthesis. Receptor biosynthesis is the collection of chemical reactions and pathways resulting in the formation of a receptor molecule, a macromolecule that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function.
Any process that activates or increases the frequency, rate or extent of stem cell differentiation.
Any process that modulates the frequency or rate of heart contraction.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a platelet-derived growth factor stimulus.
Any process that modulates the frequency, rate or extent of extrinsic apoptotic signaling pathway.
Any process in which an organism has an effect on an organism of the same species.
Any process that modulates the frequency, rate or extent of extrinsic apoptotic signaling pathway in absence of ligand.
The chemical reactions and pathways involving a pyrimidine ribonucleotide, a compound consisting of nucleoside (a pyrimidine base linked to a ribose sugar) esterified with a phosphate group at either the 3' or 5'-hydroxyl group of the sugar.
Any process that modulates the frequency, rate or extent of B cell differentiation.
The synthesis of RNA from a mitochondrial DNA template, usually by a specific mitochondrial RNA polymerase.
Any process in which a protein is maintained in a specific location a specific location on or in an organelle, and is prevented from moving elsewhere. Encompasses establishment of localization in the membrane or lumen of a membrane-bounded organelle.
Any process involved in forming the mature 3' end of an mRNA molecule.
Any process that increases the frequency, rate or extent of transcription from an RNA polymerase II promoter as a result of a stimulus indicating the organism is under stress. The stress is usually, but not necessarily, exogenous (e.g. temperature, humidity, ionizing radiation).
Any process that modulates the frequency, rate or extent of a ceramide biosynthetic process.
Any process that modulates the frequency, rate or extent of lipase activity, the hydrolysis of a lipid or phospholipid.
The process in which a relatively unspecialized cell acquires specialized features of a polarized epithelial cell. The polarized epithelial cell can be any of the cells within an epithelium where the epithelial sheet is oriented with respect to the planar axis.
Innate immune responses are defense responses mediated by germline encoded components that directly recognize components of potential pathogens.
The process in which the right cardiac ventricle is generated and organized.
A series of molecular signals that proceeds with an activated receptor promoting the exchange of GDP for GTP on the alpha-subunit of an associated heterotrimeric G-protein complex. The GTP-bound activated alpha-G-protein then dissociates from the beta- and gamma-subunits to further transmit the signal within the cell. The pathway begins with receptor-ligand interaction, or for basal GPCR signaling the pathway begins with the receptor activating its G protein in the absence of an agonist, and ends with regulation of a downstream cellular process, e.g. transcription.  The pathway can start from the plasma membrane, Golgi or nuclear membrane (PMID:24568158 and PMID:16902576).
The process in which the anatomical structures of the digestive tract are generated and organized. The digestive tract is the anatomical structure through which food passes and is processed.
The initial contact step made between the sperm plasma membrane and outer layer of the egg during fertilization.
The chemical reactions and pathways involving galactose, the aldohexose galacto-hexose. D-galactose is widely distributed in combined form in plants, animals and microorganisms as a constituent of oligo- and polysaccharides; it also occurs in galactolipids and as its glucoside in lactose and melibiose.
The nucleotide-excision repair process in which DNA lesions are removed from nontranscribed strands and from transcriptionally silent regions over the entire genome.
Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of acyl-CoA.
Any process that modulates the frequency, rate or extent of vascular endothelial growth factor receptor signaling pathway activity.
Any process that stops, prevents or reduces the frequency, rate or extent of mRNA metabolic process.
Any process that modulates the frequency, rate or extent of transcription from an RNA polymerase I promoter.
Any process that modulates the frequency, rate or extent of DNA-templated transcription initiation.
Any process that modulates the frequency, rate, or extent of cell adhesion mediated by integrin.
The chemical reactions and pathways resulting in the formation of a nucleoside triphosphate, a compound consisting of a nucleobase linked to a deoxyribose or ribose sugar esterified with triphosphate on the sugar.
The chemical reactions and pathways involving glyoxylate, the anion of glyoxylic acid, HOC-COOH.
A process in which the extent of muscle contraction is reduced. Muscle relaxation can involve a number of processes including the removal of calcium from the cytoplasm to the sarcoplasmic reticulum lumen through the action of Ca2+ ATPases. In some muscles, calcium-independent pathways also play a role in muscle relaxation by decreasing the phosphorylation state of myosin light chain.
Any process that modulates the frequency, rate or extent of protein modification by small protein conjugation or removal.
Any process involved in the maintenance of an internal steady state of anions at the level of a cell.
The chemical reactions and pathways involving a toxin, a poisonous compound (typically a protein) that is produced by cells or organisms and that can cause disease when introduced into the body or tissues of an organism.
The alteration of DNA or protein in chromatin by the covalent addition or removal of chemical groups.
Any process that modulates the frequency, rate or extent of N-methyl-D-aspartate selective glutamate receptor activity.
The chemical reactions and pathways resulting in the formation of a purine-containing compound, i.e. any compound that contains purine or a formal derivative thereof.
Any process that decreases the rate, frequency, or extent of cell cycle arrest, the process in which the cell cycle is halted during one of the normal phases.
The removal of a methyl group from one or more nucleotides within an DNA molecule.
The process, occurring after embryonic development, by which anatomical structures are generated and organized.
The progression of a skeletal muscle organ over time from its initial formation to its mature state. A skeletal muscle organ includes the skeletal muscle tissue and its associated connective tissue.
Any process that activates or increases the frequency, rate or extent of receptor activity.
A series of molecular signals initiated by the binding of the Fc portion of an immunoglobulin to an Fc receptor on the surface of a signal-receiving cell, and ending with regulation of a downstream cellular process, e.g. transcription. The Fc portion of an immunoglobulin is its C-terminal constant region.
Any process that stops, prevents, or reduces the frequency, rate, or extent of a homeostatic process.
The process whose specific outcome is the progression of an appendage over time, from its formation to the mature structure. An appendage is an organ or part that is attached to the trunk of an organism, such as a limb or a branch.
Any process that modulates the frequency, rate, or extent of B cell mediated immunity.
Any process that modulates the rate, frequency or extent of mitochondrial fission. Mitochondrial fission is the division of a mitochondrion within a cell to form two or more separate mitochondrial compartments.
The chemical reactions and pathways resulting in the breakdown of neutral lipids, lipids only soluble in solvents of very low polarity.
Any process that activates or increases the frequency, rate or extent of the regulated release of a catecholamine.
Any process that decreases the frequency, rate or extent of peptidyl-threonine phosphorylation. Peptidyl-threonine phosphorylation is the phosphorylation of peptidyl-threonine to form peptidyl-O-phospho-L-threonine.
Any process that modulates the frequency, rate, or extent of chemokine production.
The ubiquitination by a protein of one or more of its own amino acid residues, or residues on an identical protein. Ubiquitination occurs on the lysine residue by formation of an isopeptide crosslink.
The aggregation, arrangement and bonding together of a set of components to form a pore complex. A pore complex is a small opening in a membrane that allows the passage of liquids and/or gases.
Any process in which macromolecules aggregate, disaggregate, or are modified, resulting in the formation, disassembly, or alteration of a protein-lipid complex.
Any process that stops, prevents, or reduces the frequency, rate or extent of T cell death by apoptotic process.
Any process that decreases the frequency, rate or extent of the chemical reactions and pathways involving phosphorus or compounds containing phosphorus.
The chemical reactions and pathways involving 4-hydroxyproline, C5H9NO3, a derivative of the amino acid proline. The presence of hydroxyproline is essential to produce stable triple helical tropocollagen, hence the problems caused by ascorbate deficiency in scurvy. This unusual amino acid is also present in considerable amounts in the major glycoprotein of primary plant cell walls.
Any process that modulates the frequency, rate or extent of cell cycle G1/S phase transition.
Any process involved in the maintenance of an internal steady state of anions within an organism or cell.
The chemical reactions and pathways resulting in the formation of any conjugated, water-soluble protein in which the nonprotein group consists of a lipid or lipids.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a follicle-stimulating hormone stimulus.
Any process involved in the maintenance of an internal steady state of potassium ions at the level of a cell.
The addition of a mannose residue to a protein acceptor molecule.
Any process that modulates the frequency, rate or extent of fatty acid transport.
The chemical reactions and pathways resulting in the formation of any hormone, naturally occurring substances secreted by specialized cells that affects the metabolism or behavior of other cells possessing functional receptors for the hormone.
A process in which a series of electron carriers operate together to transfer electrons from donors to any of several different terminal electron acceptors to generate a transmembrane electrochemical gradient.
Any process that modulates the frequency, rate or extent of non-rapid eye movement sleep.
Any process that modulates the rate, frequency or extent of pathway-restricted SMAD protein phosphorylation. Pathway-restricted SMAD proteins and common-partner SMAD proteins are involved in the transforming growth factor beta receptor signaling pathways.
Any regulation of signal transduction that takes place in the extracellular region.
Repair of the gap in the DNA helix by DNA polymerase and DNA ligase after the portion of the strand containing the lesion has been removed by pyrimidine-dimer repair enzymes.
The chemical reactions and pathways resulting in the formation of glycosphingolipid, a compound with residues of sphingoid and at least one monosaccharide.
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an organic cyclic compound stimulus.
The process that mediates signaling interactions between one cell and another cell by transfer of current between their adjacent cytoplasms via intercellular protein channels.
The chemical reactions and pathways involving the transfer of one-carbon units in various oxidation states.
The directed movement of a substance from one side of an epithelium to the other.
Any process that reduces the pH of the vacuole, measured by the concentration of the hydrogen ion.
The process in which relatively unspecialized cells acquire specialized structural and/or functional features that characterize the mature cells of the hindbrain. Differentiation includes the processes involved in commitment of a cell to a specific fate.
Any process that modulates the frequency, rate, or extent of interleukin-1 production.
Any process that activates or increases the frequency, rate, or extent of antigen processing and presentation.
Any process that decreases the frequency, rate or extent of cell morphogenesis contributing to cell differentiation. Cell morphogenesis involved in differentiation is the change in form (cell shape and size) that occurs when relatively unspecialized cells acquire specialized structural and/or functional features that characterize the cells, tissues, or organs of the mature organism or some other relatively stable phase of the organism's life history.
Any process that modulates the frequency, rate or extent of the peroxisome proliferator activated receptor signaling pathway.
Any process that activates or increases the frequency, rate or extent of CD4-positive, alpha-beta T cell activation.
The chemical reactions and pathways resulting in the breakdown of glycoproteins, any protein that contains covalently bound glycose (i.e. monosaccharide) residues; the glycose occurs most commonly as oligosaccharide or fairly small polysaccharide but occasionally as monosaccharide.
Any process that modulates the frequency, rate or extent of lymphocyte chemotaxis.
Renal process involved in the maintenance of an internal steady state of water in the body.
Any process that modulates the frequency, rate or extent of the covalent transfer of a methyl group to either N-6 of adenine or C-5 or N-4 of cytosine.
The developmental process pertaining to the initial formation of a heart valve from unspecified parts. This process begins with the specific processes that contribute to the appearance of the discrete structure and ends when the structural rudiment is recognizable.
A cell cycle process comprising the steps by which the nucleus of a eukaryotic cell divides; the process involves condensation of chromosomal DNA into a highly compacted form. Canonically, mitosis produces two daughter nuclei whose chromosome complement is identical to that of the mother cell.
Any process that stops, prevents, or reduces the frequency, rate, or extent of myeloid leukocyte differentiation.
The chemical reactions and pathways involving of any of a diverse group of vitamins that are soluble in organic solvents and relatively insoluble in water.
A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures containing both actin and myosin or paramyosin. The myosin may be organized into filaments.
The directed movement of nucleotide across a membrane.
Any process that increases the rate, frequency or extent of a cellular process that is involved in the progression of biochemical and morphological phases and events that occur in a cell during successive cell replication or nuclear replication events.
Any process that modulates the frequency, rate or extent of chondrocyte differentiation.
Any process that modulates the frequency, rate or extent of the assembly of pseudopodia.
The process whose specific outcome is the progression of the pallium over time, from its formation to the mature structure. The pallium is the roof region of the telencephalon.
Any process that modulates the frequency, rate or extent of a response to stress. Response to stress is a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a disturbance in organismal or cellular homeostasis, usually, but not necessarily, exogenous (e.g. temperature, humidity, ionizing radiation).
The commitment of cells to specific cardiac cell fates and their capacity to differentiate into cardiac cells. Cardiac cells are cells that comprise the organ which pumps blood through the circulatory system.
Any process that activates or increases the frequency, rate, or extent of interleukin-1 production.
Formation of myofibrils, the repeating units of striated muscle.
Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of a motile cell or organism in response to a specific chemical concentration gradient.
A protein activation cascade that contributes to blood coagulation and consists of the interactions among high molecular weight kininogen, prekallikrein, and factor XII that lead to the activation of clotting factor X.
The progression of the glomerulus over time from its initial formation until its mature state. The glomerulus is a capillary tuft which forms a close network with the visceral epithelium (podocytes) and the mesangium to form the filtration barrier and is surrounded by Bowman's capsule in nephrons of the vertebrate kidney. The glomerulus is part of the nephron and is restricted to one body segment.
Any recombinational process that contributes to the maintenance of proper telomeric length.
Any process that modulates the rate, frequency or extent of release of cytochrome c from mitochondria, the process in which cytochrome c is enabled to move from the mitochondrial intermembrane space into the cytosol, which is an early step in apoptosis and leads to caspase activation.
Any process that mediates the transfer of information from one cell to another and contributes to the heart process that regulates cardiac muscle contraction; beginning with the generation of an action potential in the sinoatrial node and ending with regulation of contraction of the myocardium.
A change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a thyroid hormone stimulus.
The chemical reactions and pathways involving the phosphate group, the anion or salt of any phosphoric acid.
Any process that activates or increases the frequency, rate or extent of activity of the transcription factor NF-kappaB.
The conversion of a primary RNA molecule transcribed from a mitochondrial genome into one or more mature RNA molecules; occurs in the mitochondrion.
The chemical reactions and pathways resulting in the breakdown of lipids, as carried out by individual cells.
Any process that modulates the frequency, rate or extent of action potential creation, propagation or termination in a cardiac muscle cell. This typically occurs via modulation of the activity or expression of voltage-gated ion channels.
Any process that activates or increases the frequency, rate or extent of the cyclical phases of growth (anagen), regression (catagen), quiescence (telogen), and shedding (exogen) in the life of a hair.
The process whose specific outcome is the progression of the sympathetic nervous system over time, from its formation to the mature structure. The sympathetic nervous system is one of the two divisions of the vertebrate autonomic nervous system (the other being the parasympathetic nervous system). The sympathetic preganglionic neurons have their cell bodies in the thoracic and lumbar regions of the spinal cord and connect to the paravertebral chain of sympathetic ganglia. Innervate heart and blood vessels, sweat glands, viscera and the adrenal medulla. Most sympathetic neurons, but not all, use noradrenaline as a post-ganglionic neurotransmitter.
Any process that modulates the frequency, rate or extent of alpha-beta T cell differentiation.
The increase in size or mass of an entire multicellular organism, as opposed to cell growth.
The movement of a granulocyte within or between different tissues and organs of the body.
Any process that activates or increases the frequency, rate or extent of signaling pathways initiated by the cross-linking of an antigen receptor on a B- or T cell.
The chemical reactions and pathways involving non-coding RNA transcripts (ncRNAs).
The directed movement of phosphate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
Any process that stops, prevents, or reduces the frequency, rate or extent of the BMP signaling pathway.
Any process that activates or increases the frequency, rate or extent of neural precursor cell proliferation.
Any process that modulates the frequency, rate, or extent of cellular extravasation.
The process in which the anatomical structures of cardiac muscle tissue are generated and organized.
The change in morphology and behavior of a granulocyte resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor.
Any process that modulates the rate, frequency or extent of macrophage cytokine production. Macrophage cytokine production is the appearance of a chemokine due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.
The chemical reactions and pathways resulting in the formation of purine nucleobases, one of the two classes of nitrogen-containing ring compounds found in DNA and RNA, which include adenine and guanine.
A mitotic cell cycle checkpoint that detects and negatively regulates progression through the G2/M transition of the cell cycle in response to DNA damage.
Any process that activates or increases the frequency, rate or extent of the phosphorylation by a protein of one or more of its own residues.
Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of substances between the cytoplasm and the nucleus.
Any process that activates or increases the frequency, rate or extent of activation.
The chemical reactions and pathways resulting in the formation of carbohydrates, any of a group of organic compounds based of the general formula Cx(H2O)y.
The chemical reactions and pathways involving any amino sugar, sugars containing an amino group in place of a hydroxyl group.
Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of nucleotides.
Any process that modulates the frequency, rate or extent of the division of the cytoplasm of a cell and its separation into two daughter cells.
The chemical reactions and pathways resulting in the formation of a vitamin, one of a number of unrelated organic substances that occur in many foods in small amounts and that are necessary in trace amounts for the normal metabolic functioning of the body.
Any process that activates or increases the frequency, rate or extent of non-canonical Wnt-activated signaling pathway.
The process in which the anatomical structures of muscle are generated and organized.
The directed movement of amino acids, organic acids containing one or more amino substituents, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an epinephrine stimulus. Epinephrine is a catecholamine that has the formula C9H13NO3; it is secreted by the adrenal medulla to act as a hormone, and released by certain neurons to act as a neurotransmitter active in the central nervous system.
Any process that activates or increases the frequency, rate, or extent of cell adhesion mediated by integrin.
Any process that modulates the rate, frequency, or extent of microtubule-based movement, the movement of organelles, other microtubules and other particles along microtubules, mediated by motor proteins.
Progression of the exocrine system over time, from its formation to a mature structure. The exocrine system is a system of hormones and glands, where the glands secrete straight to a target site via ducts or tubes. The human exocrine system includes the salivary glands, sweat glands and many glands of the digestive system.
The chemical reactions and pathways involving aminoglycans, any polymer containing amino groups that consists of more than about 10 monosaccharide residues joined to each other by glycosidic linkages.
Any process that stops, prevents, or reduces the frequency, rate or extent of myoblast differentiation. A myoblast is a mononucleate cell type that, by fusion with other myoblasts, gives rise to the myotubes that eventually develop into skeletal muscle fibers.
Any process that modulates the rate or extent of fever generation.
The aggregation, arrangement and bonding together of proteins on promoter DNA to form the transcriptional preinitiation complex (PIC), the formation of which is a prerequisite for transcription.
A change in morphology and behavior of a macrophage resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor.
The process in which a relatively unspecialized mesodermal cell acquires the specialized structural and/or functional features of a cardioblast. A cardioblast is a cardiac precursor cell. It is a cell that has been committed to a cardiac fate, but will undergo more cell division rather than terminally differentiating.
The cell cycle process by which a cell in G1 phase commits to S phase.
Splicing of RNA via a series of two transesterification reactions.
The process in which the anatomical structures of blood vessels are generated and organized. The blood vessel is the vasculature carrying blood.
Any process that modulates the amount of urine excreted from the body over a unit of time.
Development of a photoreceptor, a cell that responds to incident electromagnetic radiation, particularly visible light.
The process of communication from a neuron to another neuron across a synapse using the neurotransmitter dopamine.
The process of introducing a phosphate group on to a protein.
The process in which a relatively unspecialized cell acquires specialized features of a neuron whose cell body resides in the central nervous system.
Any process that modulates the frequency, rate or extent of cell differentiation, the process in which relatively unspecialized cells acquire specialized structural and functional features.
Protection of epithelial surfaces of the gastrointestinal tract from proteolytic and caustic digestive agents.
The process whose specific outcome is the progression of an endothelium over time, from its formation to the mature structure. Endothelium refers to the layer of cells lining blood vessels, lymphatics, the heart, and serous cavities, and is derived from bone marrow or mesoderm. Corneal endothelium is a special case, derived from neural crest cells.
The repair of double-strand breaks in DNA via homologous and nonhomologous mechanisms to reform a continuous DNA helix.
The directed movement of nucleobases, nucleosides, nucleotides and nucleic acids, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.